{
  "filename": "2022 ESC_ERS Guidelines for the diagnosis and treatment of pulmonary hypertension _ European Heart Journal _ Oxford Academic.pdf",
  "title": "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension",
  "type": "pulmonary_hypertension",
  "year": 2022,
  "total_pages": 114,
  "extracted_at": "2026-01-15T00:24:37.266406",
  "chapters": [
    {
      "number": "1",
      "title": "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension",
      "start_page": 1,
      "end_page": 5,
      "content": "2022 ESC/ERS Guidelines for the diagnosis and\ntreatment of pulmonary hypertension\nDeveloped by the task force for the diagnosis and treatment of\npulmonary hypertension of the European Society of Cardiology\n(ESC) and the European Respiratory Society (ERS).\nEndorsed by the International Society for Heart and Lung\nTransplantation (ISHLT) and the European Reference Network\non rare respiratory diseases (ERN-LUNG).\nAuthors/Task Force Members: Marc Humbert\n(France), Gabor Kovacs (Austria),\nMarius M. Hoeper (Germany), Roberto Badagliacca (Italy), Rolf M.F. Berger\n(Netherlands), Margarita Brida (Croatia), Jørn Carlsen (Denmark),\nAndrew J.S. Coats (United Kingdom), Pilar Escribano-Subias (Spain),\nPisana Ferrari (Italy), Diogenes S. Ferreira (Brazil), Hossein Ardeschir Ghofrani\n(Germany), George Giannakoulas (Greece), David G. Kiely (United Kingdom),\nEckhard Mayer (Germany), Gergely Meszaros (Hungary), Blin Nagavci (Germany),\nKaren M. Olsson (Germany), Joanna Pepke-Zaba (United Kingdom),\nJennifer K. Quint (United Kingdom), Göran Rådegran (Sweden),\nGerald Simonneau (France), Olivier Sitbon (France), Thomy Tonia (Switzerland),\nMark Toshner (United Kingdom), Jean-Luc Vachiery (Belgium),\nAnton Vonk Noordegraaf (Netherlands), Marion Delcroix\n*† (ERS Chairperson)\n(Belgium), Stephan Rosenkranz\n*† (ESC Chairperson) (Germany), and ESC/ERS\nScientiﬁc Document Group\n* Corresponding authors: Stephan Rosenkranz, Clinic III for Internal Medicine (Department of Cardiology, Pulmonology and Intensive Care Medicine), and Cologne Cardiovascular\nResearch Center (CCRC), Heart Center at the University Hospital Cologne, Kerpener Str. 62, 50937 Köln, Germany. Tel.: +49-221-478-32356. Email: stephan.rosenkranz@uk-\nkoeln.de; and\nMarion Delcroix, Clinical Department of Respiratory Diseases, Centre of Pulmonary Vascular Diseases, University Hospitals of Leuven, Herestraat 49, 3000 Leuven, Belgium. Tel.: +32 16\n346813. Email: marion.delcroix@uzleuven.be\n† The two chairpersons contributed equally to the document and are joint corresponding authors.\nAuthor/Task Force Member afﬁliations are listed in author information.\n1 Representing the Association for European Paediatric and Congenital Cardiology (AEPC)\nESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.\nESC subspecialty communities having participated in the development of this document:\nAssociations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), and Heart Failure Association (HFA).\nCouncils: Council on Cardiovascular Genomics.\nWorking Groups: Adult Congenital Heart Disease, Pulmonary Circulation and Right Ventricular Function, Thrombosis.\nPatient Forum\nThe content of these European Society of Cardiology (ESC)/European Respiratory Society (ERS) Guidelines has been published for personal and educational use only. No commercial use\nis authorized. No part of the ESC/ERS Guidelines may be translated or reproduced in any form without written permission from the ESC and the ERS. Permission can be obtained upon\nsubmission of a written request to Oxford University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.\npermissions@oup.com).\nEuropean Heart Journal (2022) 43, 3618–3731\nhttps://doi.org/10.1093/eurheartj/ehac237\nESC/ERS GUIDELINES\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nDocument Reviewers: Markus Schwerzmann (ESC Review Coordinator) (Switzerland), Anh-Tuan Dinh-Xuan\n(ERS Review Coordinator) (France), Andy Bush (United Kingdom), Magdy Abdelhamid (Egypt), Victor Aboyans\n(France), Eloisa Arbustini (Italy), Riccardo Asteggiano (Italy), Joan-Albert Barberà (Spain), Maurice Beghetti\n(Switzerland), Jelena Čelutkienė (Lithuania), Maja Cikes (Croatia), Robin Condliffe (United Kingdom),\nFrances de Man (Netherlands), Volkmar Falk (Germany), Laurent Fauchier (France), Sean Gaine (Ireland),\nNazzareno Galié (Italy), Wendy Gin-Sing (United Kingdom), John Granton (Canada), Ekkehard Grünig\n(Germany), Paul M. Hassoun (United States of America), Merel Hellemons (Netherlands), Tiny Jaarsma\n(Sweden), Barbro Kjellström (Sweden), Frederikus A. Klok (Netherlands), Aleksandra Konradi (Russian\nFederation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Irene Lang (Austria),\nBasil S. Lewis (Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip (United Kingdom), Maja-Lisa Løchen\n(Norway), Alexander G. Mathioudakis (United Kingdom), Richard Mindham (United Kingdom),\nShahin Moledina1 (United Kingdom), Robert Naeije (Belgium), Jens Cosedis Nielsen (Denmark),\nHorst Olschewski (Austria), Isabelle Opitz (Switzerland), Steffen E. Petersen (United Kingdom),\nEva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Abilio Reis (Portugal), Arsen D. Ristić (Serbia),\nNicolas Roche (France), Rita Rodrigues (Portugal), Christine Selton-Suty (France), Rogerio Souza (Brazil),\nAndrew J. Swift (United Kingdom), Rhian M. Touyz (Canada/United Kingdom), Silvia Ulrich (Switzerland),\nMartin R. Wilkins (United Kingdom), and Stephen John Wort (United Kingdom)\nAll experts involved in the development of these guidelines have submitted declarations of interest. These have\nbeen compiled in a report and simultaneously published in a supplementary document to the guidelines. The\nreport is also available on the ESC website www.escardio.org/Guidelines\nSee the European Heart Journal online for supplementary data that includes background information and\ndetailed discussion of the data that have provided the basis of the guidelines.\nKeywords\nGuidelines • Pulmonary hypertension • Pulmonary arterial hypertension • Chronic thrombo-embolic pulmonary\nhypertension • Left heart disease • Congenital heart disease • Lung disease • Connective tissue disease • Endothelin\nreceptor antagonists • Phosphodiesterase type 5 inhibitors • Soluble guanylate cyclase stimulators • Prostacyclin\nanalogues • Prostacyclin receptor agonists • Pulmonary endarterectomy • Balloon pulmonary angioplasty • Lung\ntransplantation\nTable of contents\n1. Preamble .............................................................................................................\n3624\n2. Introduction ......................................................................................................\n3625\n2.1. What is new ............................................................................................\n3625\n2.2. Methods ....................................................................................................\n3635\n3. Deﬁnitions and classiﬁcations ....................................................................\n3636\n3.1. Deﬁnitions ................................................................................................\n3636\n3.2. Classiﬁcations ..........................................................................................\n3637\n4. Epidemiology and risk factors ....................................................................\n3638\n4.1. Group 1, pulmonary arterial hypertension ................................\n3638\n4.2. Group 2, pulmonary hypertension associated with left heart\ndisease .................................................................................................................\n3640\n4.3. Group 3, pulmonary hypertension associated with lung\ndiseases and/or hypoxia ..............................................................................\n3640\n4.4. Group 4, pulmonary hypertension associated with chronic\npulmonary artery obstruction ..................................................................\n3640\n4.5. Group 5, pulmonary hypertension with unclear and/or\nmultifactorial mechanisms ..........................................................................\n3640\n5. Pulmonary hypertension diagnosis ..........................................................\n3640\n5.1. Diagnosis ...................................................................................................\n3640\n5.1.1. Clinical presentation ..................................................................... 3640\n5.1.2. Electrocardiogram ......................................................................... 3640\n5.1.3. Chest radiography ......................................................................... 3641\n5.1.4. Pulmonary function tests and arterial blood gases ......... 3641\n5.1.5. Echocardiography .......................................................................... 3642\nDisclaimer: The ESC/ERS Guidelines represent the views of the ESC and the ERS and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence\navailable at the time of their publication. The ESC and the ERS are not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC/ERS Guidelines and any\nother ofﬁcial recommendations or guidelines issued by the relevant public health authorities, particularly in relation to good use of health care or therapeutic strategies. Health profes-\nsionals are encouraged to take the ESC/ERS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and implementation of preventive, diag-\nnostic, or therapeutic medical strategies; however, the ESC/ERS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make\nappropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s care-\ngiver. The ESC/ERS Guidelines do not exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the\ncompetent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is\nalso the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.\nThis article has been co-published with permission in the European Heart Journal and European Respiratory Journal. © the European Society of Cardiology and the European Respiratory\nSociety 2022. All rights reserved. The articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this\narticle. For permissions please e-mail: journals.permissions@oup.com.\nESC/ERS Guidelines\n3619\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n5.1.6. Ventilation/perfusion lung scan ................................................ 3643\n5.1.7. Non-contrast and contrast-enhanced chest computed\ntomography examinations, and digital subtraction\nangiography ................................................................................................... 3644\n5.1.8. Cardiac magnetic resonance imaging .................................... 3645\n5.1.9. Blood tests and immunology .................................................... 3646\n5.1.10. Abdominal ultrasound ............................................................... 3646\n5.1.11. Cardiopulmonary exercise testing ....................................... 3646\n5.1.12. Right heart catheterization, vasoreactivity, exercise, and\nﬂuid challenge .............................................................................................. 3646\n5.1.12.1. Right heart catheterization ............................................. 3646\n5.1.12.2. Vasoreactivity testing ........................................................ 3647\n5.1.12.3. Exercise right heart catheterization ........................... 3647\n5.1.12.4. Fluid challenge ...................................................................... 3647\n5.1.13. Genetic counselling and testing ............................................ 3648\n5.2. Diagnostic algorithm ............................................................................\n3648\n5.2.1 Step 1 (suspicion) ........................................................................... 3648\n5.2.2. Step 2 (detection) ......................................................................... 3648\n5.2.3. Step 3 (conﬁrmation) ................................................................... 3650\n5.3. Screening and early detection ..........................................................\n3652\n5.3.1. Systemic sclerosis .......................................................................... 3653\n5.3.2. BMPR2 mutation carriers ........................................................... 3653\n5.3.3. Portal hypertension ...................................................................... 3653\n5.3.4. Pulmonary embolism ................................................................... 3653\n6. Pulmonary arterial hypertension (group 1) .........................................\n3655\n6.1. Clinical characteristics .........................................................................\n3655\n6.2. Severity and risk assessment ............................................................\n3655\n6.2.1. Clinical parameters ....................................................................... 3655\n6.2.2. Imaging ................................................................................................ 3656\n6.2.2.1. Echocardiography .................................................................. 3656\n6.2.2.2. Cardiac magnetic resonance imaging ........................... 3656\n6.2.3. Haemodynamics ............................................................................. 3656\n6.2.4. Exercise capacity ............................................................................ 3657\n6.2.5. Biochemical markers .................................................................... 3658\n6.2.6. Patient-reported outcome measures ................................... 3658\n6.2.7. Comprehensive prognostic evaluation, risk assessment,\nand treatment goals .................................................................................. 3659\n6.3. Therapy .....................................................................................................\n3660\n6.3.1. General measures .......................................................................... 3660\n6.3.1.1. Physical activity and supervised rehabilitation .......... 3660\n6.3.1.2. Anticoagulation ...................................................................... 3660\n6.3.1.3. Diuretics .................................................................................... 3661\n6.3.1.4. Oxygen ...................................................................................... 3661\n6.3.1.5. Cardiovascular drugs ........................................................... 3661\n6.3.1.6. Anaemia and iron status .................................................... 3661\n6.3.1.7. Vaccination ............................................................................... 3661\n6.3.1.8. Psychosocial support ........................................................... 3661\n6.3.1.9. Adherence to treatments .................................................. 3661\n6.3.2. Special circumstances ................................................................... 3662\n6.3.2.1. Pregnancy and birth control ............................................. 3662\n6.3.2.1.1. Pregnancy ......................................................................... 3662\n6.3.2.1.2. Contraception ................................................................ 3662\n6.3.2.2. Surgical procedures .............................................................. 3662\n6.3.2.3. Travel and altitude ................................................................ 3662\n6.3.3. Pulmonary arterial hypertension therapies ........................ 3663\n6.3.3.1. Calcium channel blockers .................................................. 3663\n6.3.3.2. Endothelin receptor antagonists .................................... 3664\n6.3.3.2.1. Ambrisentan ................................................................... 3665\n6.3.3.2.2. Bosentan ........................................................................... 3665\n6.3.3.2.3. Macitentan ....................................................................... 3666\n6.3.3.3. Phosphodiesterase 5 inhibitors and guanylate cyclase\nstimulators ............................................................................................... 3666\n6.3.3.3.1. Sildenaﬁl ............................................................................ 3667\n6.3.3.3.2. Tadalaﬁl ............................................................................. 3667\n6.3.3.3.3. Riociguat ........................................................................... 3667\n6.3.3.4. Prostacyclin analogues and prostacyclin receptor\nagonists ...................................................................................................... 3667\n6.3.3.4.1. Epoprostenol .................................................................. 3667\n6.3.3.4.2. Iloprost .............................................................................. 3667\n6.3.3.4.3. Treprostinil ...................................................................... 3667\n6.3.3.4.4. Beraprost ......................................................................... 3667\n6.3.3.4.5. Selexipag ........................................................................... 3667\n6.3.4. Treatment strategies for patients with idiopathic,\nheritable, drug-associated, or connective tissue disease-\nassociated pulmonary arterial hypertension .................................. 3667\n6.3.4.1. Initial treatment decision in patients without\ncardiopulmonary comorbidities ...................................................... 3668\n6.3.4.2. Treatment decisions during follow-up in patients\nwithout cardiopulmonary comorbidities .................................... 3669\n6.3.4.3. Pulmonary arterial hypertension with\ncardiopulmonary comorbidities ...................................................... 3670\n6.3.5. Drug interactions ........................................................................... 3671\n6.3.6. Interventional therapy ................................................................. 3671\n6.3.6.1. Balloon atrial septostomy and Potts shunt ................ 3671\n6.3.6.2. Pulmonary artery denervation ........................................ 3671\n6.3.7. Advanced right ventricular failure .......................................... 3672\n6.3.7.1. Intensive care unit management ..................................... 3672\n6.3.7.2. Mechanical circulatory support ....................................... 3672\n6.3.8. Lung and heart–lung transplantation ..................................... 3672\n6.3.9. Evidence-based treatment algorithm .................................... 3673\n6.3.10. Diagnosis and treatment of pulmonary arterial\nhypertension complications ................................................................... 3673\n6.3.10.1. Arrhythmias .......................................................................... 3673\n6.3.10.2. Haemoptysis ......................................................................... 3673\n6.3.10.3. Mechanical complications ................................................ 3673\n6.3.11. End-of-life care and ethical issues ........................................ 3674\n6.3.12. New drugs in advanced clinical development (phase 3\nstudies) ........................................................................................................... 3674\n7. Speciﬁc pulmonary arterial hypertension subsets ............................\n3674\n7.1. Pulmonary arterial hypertension associated with drugs and\ntoxins ...................................................................................................................\n3674\n7.2. Pulmonary arterial hypertension associated with connective\ntissue disease ....................................................................................................\n3675\n7.2.1. Epidemiology and diagnosis ....................................................... 3675\n7.2.2. Therapy .............................................................................................. 3675\n7.3. Pulmonary arterial hypertension associated with human\nimmunodeﬁciency virus infection ............................................................\n3676\n7.3.1. Diagnosis ........................................................................................... 3676\n7.3.2. Therapy .............................................................................................. 3676\n7.4. Pulmonary arterial hypertension associated with portal\nhypertension ....................................................................................................\n3677\n7.4.1. Diagnosis ........................................................................................... 3677\n7.4.2. Therapy .............................................................................................. 3677\n7.4.2.1. Liver transplantation ............................................................ 3677\n7.5. Pulmonary arterial hypertension associated with adult\ncongenital heart disease ..............................................................................\n3678\n7.5.1. Diagnosis and risk assessment ................................................. 3678\n7.5.2. Therapy .............................................................................................. 3679\n7.6. Pulmonary arterial hypertension associated with\nschistosomiasis ................................................................................................\n3680\n3620\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n7.7. Pulmonary arterial hypertension with signs of venous/\ncapillary involvement ....................................................................................\n3680\n7.7.1. Diagnosis ........................................................................................... 3681\n7.7.2. Therapy .............................................................................................. 3681\n7.8. Paediatric pulmonary hypertension ...............................................\n3681\n7.8.1. Epidemiology and classiﬁcation ................................................ 3681\n7.8.2. Diagnosis and risk assessment ................................................. 3683\n7.8.3. Therapy .............................................................................................. 3683\n8. Pulmonary hypertension associated with left heart disease\n(group 2) ..................................................................................................................\n3685\n8.1. Deﬁnition, prognosis, and pathophysiology ...............................\n3685\n8.2. Diagnosis ...................................................................................................\n3687\n8.2.1. Diagnosis and control of the underlying left\nheart disease ................................................................................................ 3687\n8.2.2. Evaluation of pulmonary hypertension and patient\nphenotyping .................................................................................................. 3687\n8.2.3. Invasive assessment of haemodynamics ............................... 3687\n8.3. Therapy .....................................................................................................\n3688\n8.3.1. Pulmonary hypertension associated with left-sided heart\nfailure ............................................................................................................... 3688\n8.3.1.1. Heart failure with reduced ejection fraction ............. 3688\n8.3.1.2. Heart failure with preserved ejection fraction ......... 3688\n8.3.1.3. Interatrial shunt devices ..................................................... 3689\n8.3.1.4. Remote pulmonary arterial pressure monitoring in\nheart failure ............................................................................................. 3689\n8.3.2. Pulmonary hypertension associated with valvular heart\ndisease ............................................................................................................. 3689\n8.3.2.1. Mitral valve disease ............................................................... 3689\n8.3.2.2. Aortic stenosis ....................................................................... 3689\n8.3.2.3. Tricuspid regurgitation ........................................................ 3689\n8.3.3. Recommendations on the use of drugs approved for\nPAH in PH-LHD ......................................................................................... 3689\n9. Pulmonary hypertension associated with lung diseases and/or\nhypoxia (group 3) ................................................................................................\n3690\n9.1. Diagnosis ...................................................................................................\n3692\n9.2. Therapy .....................................................................................................\n3692\n9.2.1. Pulmonary hypertension associated with chronic\nobstructive pulmonary disease or emphysema ............................ 3692\n9.2.2. Pulmonary hypertension associated with interstitial lung\ndisease ............................................................................................................. 3692\n9.2.3. Recommendations on the use of drugs approved for\nPAH in PH associated with lung disease .......................................... 3693\n10. Chronic thrombo-embolic pulmonary hypertension (group 4)\n3693\n10.1. Diagnosis ................................................................................................\n3694\n10.2. Therapy ...................................................................................................\n3695\n10.2.1. Surgical treatment ....................................................................... 3695\n10.2.2. Medical therapy ............................................................................ 3695\n10.2.3. Interventional treatment .......................................................... 3696\n10.2.4. Multimodal treatment ............................................................... 3697\n10.2.5. Follow-up ........................................................................................ 3698\n10.3. Chronic thrombo-embolic pulmonary hypertension team\nand experience criteria ................................................................................\n3698\n11. Pulmonary hypertension with unclear and/or multifactorial\nmechanisms (group 5) .......................................................................................\n3699\n11.1. Haematological disorders ................................................................\n3699\n11.2. Systemic disorders .............................................................................\n3700\n11.3. Metabolic disorders ...........................................................................\n3700\n11.4. Chronic kidney failure ......................................................................\n3700\n11.5. Pulmonary tumour thrombotic microangiopathy ................\n3700\n11.6. Fibrosing mediastinitis .......................................................................\n3700\n12. Deﬁnition of a pulmonary hypertension centre .............................\n3701\n12.1. Facilities and skills required for a pulmonary hypertension\ncentre ..................................................................................................................\n3702\n12.2. European Reference Network .....................................................\n3702\n12.3. Patient associations and patient empowerment ...................\n3702\n13. Key messages .................................................................................................\n3703\n14. Gaps in evidence ...........................................................................................\n3703\n14.1. Pulmonary arterial hypertension (group 1) .............................\n3703\n14.2. Pulmonary hypertension associated with left heart disease\n(group 2) ............................................................................................................\n3703\n14.3. Pulmonary hypertension associated with lung diseases and/\nor hypoxia (group 3) ....................................................................................\n3704\n14.4. Chronic thrombo-embolic pulmonary hypertension\n(group 4) ............................................................................................................\n3704\n14.5. Pulmonary hypertension with unclear and/or multifactorial\nmechanisms (group 5) .................................................................................\n3704\n15. ‘What to do’ and ‘What not to do’ messages from\nthe Guidelines .......................................................................................................\n3704\n16. Quality indicators .........................................................................................\n3710\n17. Supplementary data .....................................................................................\n3711\n18. Data availability statement .......................................................................\n3711\n19. Author information .....................................................................................\n3711\n20. Appendix ..........................................................................................................\n3711\n21. References .......................................................................................................\n3712\nTables of Recommendations\nRecommendation Table 1 — Recommendations for right heart\ncatheterization and vasoreactivity testing ............................................\n3648\nRecommendation Table 2 — Recommendations for diagnostic\nstrategy ................................................................................................................\n3652\nRecommendation Table 3 — Recommendations for screening\nand improved detection of pulmonary arterial hypertension and\nchronic thrombo-embolic pulmonary hypertension .......................\n3654\nRecommendation Table 4 — Recommendations for evaluating\nthe disease severity and risk of death in patients with pulmonary\narterial hypertension .....................................................................................\n3660\nRecommendation Table 5 — Recommendations for general\nmeasures and special circumstances .......................................................\n3662\nRecommendation Table 6 — Recommendations for women of\nchildbearing potential ....................................................................................\n3663\nRecommendation Table 7 — Recommendations for the\ntreatment of vasoreactive patients with idiopathic, heritable, or\ndrug-associated pulmonary arterial hypertension ............................\n3664\nRecommendation Table 8 — Recommendations for the treatment\nof non-vasoreactive patients with idiopathic, heritable, or\ndrug-associated pulmonary arterial hypertension who present\nwithout cardiopulmonary comorbiditiesa ...................................................\n3668\nRecommendation Table 9 — Recommendations for initial oral\ndrug combination therapy for patients with idiopathic, heritable,\nor drug-associated pulmonary arterial hypertension without\ncardiopulmonary comorbidities ................................................................\n3669\nRecommendation Table 10 — Recommendations for sequential\ndrug combination therapy for patients with idiopathic, heritable,\nor drug-associated pulmonary arterial hypertension ......................\n3670\nRecommendation Table 11 — Recommendations for the\ntreatment of non-vasoreactive patients with idiopathic, heritable,\nor drug-associated pulmonary arterial hypertension who present\nwith cardiopulmonary comorbiditiesa ....................................................\n3671\nESC/ERS Guidelines\n3621\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nRecommendation Table 12 — Recommendations for intensive\ncare management for pulmonary arterial hypertension ..................... 3672\nRecommendation Table 13 — Recommendations for lung\ntransplantation .................................................................................................\n3673\nRecommendation Table 14 — Recommendations for pulmonary\narterial hypertension associated with drugs or toxins ...................\n3674\nRecommendation Table 15 — Recommendations for pulmonary\narterial hypertension associated with connective tissue disease\n3675\nRecommendation Table 16 — Recommendations for pulmonary\narterial hypertension associated with human immunodeﬁciency\nvirus infection ...................................................................................................\n3676\nRecommendation Table 17 — Recommendations for pulmonary\narterial hypertension associated with portal hypertension ..........\n3677\nRecommendation Table 18 — Recommendations for shunt\nclosure in patients with pulmonary–systemic ﬂow ratio .1.5:1\nbased on calculated pulmonary vascular resistance .........................\n3680\nRecommendation Table 19 — Recommendations for pulmonary\narterial hypertension associated with adult congenital heart disease\n3680\nRecommendation Table 20 — Recommendations for pulmonary\narterial hypertension with signs of venous/capillary involvement\n3681\nRecommendation Table 21 — Recommendations for paediatric\npulmonary hypertension ..............................................................................\n3685\nRecommendation Table 22 — Recommendations for pulmonary\nhypertension associated with left heart disease ................................\n3690\nRecommendation Table 23 — Recommendations for pulmonary\nhypertension associated with lung disease and/or hypoxia ..........\n3693\nRecommendation Table 24 — Recommendations for chronic\nthrombo-embolic pulmonary hypertension and chronic thrombo-\nembolic pulmonary disease without pulmonary hypertension ........\n3698\nRecommendation Table 25 — Recommendations for pulmonary\nhypertension centres .....................................................................................\n3702\nList of tables\nTable 1 Strength of the recommendations according to GRADE\n3635\nTable 2 Quality of evidence grades and their deﬁnitions ..............\n3635\nTable 3 Classes of recommendations ....................................................\n3636\nTable 4 Levels of evidence ..........................................................................\n3636\nTable 5 Haemodynamic deﬁnitions of pulmonary hypertension\n3637\nTable 6 Clinical classiﬁcation of pulmonary hypertension ............\n3638\nTable 7 Drugs and toxins associated with pulmonary arterial\nhypertension .....................................................................................................\n3640\nTable 8 Electrocardiogram abnormalities in patients with\npulmonary hypertension ..............................................................................\n3643\nTable 9 Radiographic signs of pulmonary hypertension and\nconcomitant abnormalities .........................................................................\n3643\nTable 10 Additional echocardiographic signs suggestive of\npulmonary hypertension ..............................................................................\n3645\nTable 11 Haemodynamic measures obtained during right heart\ncatheterization ..................................................................................................\n3646\nTable 12 Route of administration, half-life, dosages, and duration\nof administration of the recommended test compounds for\nvasoreactivity testing in pulmonary arterial hypertension .............\n3647\nTable 13 Phenotypic features associated with pulmonary arterial\nhypertension mutations ...............................................................................\n3649\nTable 14 Characteristic diagnostic features of patients with\ndifferent forms of pulmonary hypertension ........................................\n3651\nTable 15 World Health Organization classiﬁcation of functional\nstatus of patients with pulmonary hypertension ...............................\n3656\nTable 16 Comprehensive risk assessment in pulmonary arterial\nhypertension (three-strata model) ..........................................................\n3657\nTable 17 Suggested assessment and timing for the follow-up of\npatients with pulmonary arterial hypertension ..................................\n3658\nTable 18 Variables used to calculate the simpliﬁed four-strata\nrisk-assessment tool .......................................................................................\n3659\nTable 19 Dosing of pulmonary arterial hypertension medication\nin adults ...............................................................................................................\n3664\nTable 20 Criteria for lung transplantation and listing in patients\nwith pulmonary arterial hypertension ...................................................\n3672\nTable 21 Clinical classiﬁcation of pulmonary arterial hypertension\nassociated with congenital heart disease ..............................................\n3678\nTable 22 Use of pulmonary arterial hypertension therapies in\nchildren ................................................................................................................\n3684\nTable 23 Patient phenotyping and likelihood for left heart disease\nas cause of pulmonary hypertension ......................................................\n3688\nTable 24 Pulmonary hypertension with unclear and/or\nmultifactorial mechanisms ...........................................................................\n3699\nList of ﬁgures\nFigure 1 Central illustration ........................................................................\n3639\nFigure 2 Symptoms in patients with pulmonary hypertension ...\n3641\nFigure 3 Clinical signs in patients with pulmonary hypertension\n3642\nFigure 4 Transthoracic echocardiographic parameters in the\nassessment of pulmonary hypertension ................................................\n3644\nFigure 5 Echocardiographic probability of pulmonary\nhypertension and recommendations for further assessment ......\n3645\nFigure 6 Diagnostic algorithm of patients with unexplained\ndyspnoea and/or suspected pulmonary hypertension ....................\n3650\nFigure 7 Pathophysiology and current therapeutic targets of\npulmonary arterial hypertension (group 1) .........................................\n3655\nFigure 8 Vasoreactivity testing algorithm of patients with\npresumed diagnosis of idiopathic, heritable, or drug-associated\npulmonary arterial hypertension ..............................................................\n3665\nFigure 9 Evidence-based pulmonary arterial hypertension\ntreatment algorithm for patients with idiopathic, heritable,\ndrug-associated, and connective tissue disease-associated\npulmonary arterial hypertension ..............................................................\n3666\nFigure 10 Neonatal and paediatric vs. adult pulmonary\nhypertension .....................................................................................................\n3682\nFigure 11 Pathophysiology of pulmonary hypertension associated\nwith left heart disease (group 2) ..............................................................\n3686\nFigure 12 Pathophysiology of pulmonary hypertension associated\nwith lung disease (group 3) ........................................................................\n3691\nFigure 13 Diagnostic strategy in chronic thrombo-embolic\npulmonary hypertension ..............................................................................\n3694\nFigure 14 Management strategy in chronic thrombo-embolic\npulmonary hypertension ..............................................................................\n3696\nFigure 15 Overlap in treatments/multimodality approaches in\nchronic thrombo-embolic pulmonary hypertension .......................\n3697\nFigure 16 Pulmonary hypertension centre schematic .....................\n3701\nAbbreviations and acronyms\n6MWD\n6-minute walking distance\n6MWT\n6-minute walking test\nABG\nArterial blood gas analysis\nACEi\nAngiotensin-converting enzyme inhibitor\n3622\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 2",
          "page": 2,
          "content": " |  | m/eurheartj/article/43/38\n | Keywords Guidelines • Pulmonary hypertension • Pulmonary arterial hypertension • Chronic thrombo-embolic pulmonary\nhypertension • Left heart disease • Congenital heart disease • Lung disease • Connective tissue disease • Endothelin\nreceptor antagonists • Phosphodiesterase type 5 inhibitors • Soluble guanylate cyclase stimulators • Prostacyclin\nanalogues • Prostacyclin receptor agonists • Pulmonary endarterectomy • Balloon pulmonary angioplasty • Lung\ntransplantation | \n |  | ",
          "rows": 3,
          "cols": 3
        }
      ],
      "keywords": [
        "ct",
        "hypertension",
        "heart failure",
        "pulmonary hypertension",
        "guidelines",
        "pulmonary",
        "treatment",
        "imaging",
        "diagnosis"
      ]
    },
    {
      "number": "2",
      "title": "Abbreviations and acronyms",
      "start_page": 5,
      "end_page": 7,
      "content": "Recommendation Table 12 — Recommendations for intensive\ncare management for pulmonary arterial hypertension ..................... 3672\nRecommendation Table 13 — Recommendations for lung\ntransplantation .................................................................................................\n3673\nRecommendation Table 14 — Recommendations for pulmonary\narterial hypertension associated with drugs or toxins ...................\n3674\nRecommendation Table 15 — Recommendations for pulmonary\narterial hypertension associated with connective tissue disease\n3675\nRecommendation Table 16 — Recommendations for pulmonary\narterial hypertension associated with human immunodeﬁciency\nvirus infection ...................................................................................................\n3676\nRecommendation Table 17 — Recommendations for pulmonary\narterial hypertension associated with portal hypertension ..........\n3677\nRecommendation Table 18 — Recommendations for shunt\nclosure in patients with pulmonary–systemic ﬂow ratio .1.5:1\nbased on calculated pulmonary vascular resistance .........................\n3680\nRecommendation Table 19 — Recommendations for pulmonary\narterial hypertension associated with adult congenital heart disease\n3680\nRecommendation Table 20 — Recommendations for pulmonary\narterial hypertension with signs of venous/capillary involvement\n3681\nRecommendation Table 21 — Recommendations for paediatric\npulmonary hypertension ..............................................................................\n3685\nRecommendation Table 22 — Recommendations for pulmonary\nhypertension associated with left heart disease ................................\n3690\nRecommendation Table 23 — Recommendations for pulmonary\nhypertension associated with lung disease and/or hypoxia ..........\n3693\nRecommendation Table 24 — Recommendations for chronic\nthrombo-embolic pulmonary hypertension and chronic thrombo-\nembolic pulmonary disease without pulmonary hypertension ........\n3698\nRecommendation Table 25 — Recommendations for pulmonary\nhypertension centres .....................................................................................\n3702\nList of tables\nTable 1 Strength of the recommendations according to GRADE\n3635\nTable 2 Quality of evidence grades and their deﬁnitions ..............\n3635\nTable 3 Classes of recommendations ....................................................\n3636\nTable 4 Levels of evidence ..........................................................................\n3636\nTable 5 Haemodynamic deﬁnitions of pulmonary hypertension\n3637\nTable 6 Clinical classiﬁcation of pulmonary hypertension ............\n3638\nTable 7 Drugs and toxins associated with pulmonary arterial\nhypertension .....................................................................................................\n3640\nTable 8 Electrocardiogram abnormalities in patients with\npulmonary hypertension ..............................................................................\n3643\nTable 9 Radiographic signs of pulmonary hypertension and\nconcomitant abnormalities .........................................................................\n3643\nTable 10 Additional echocardiographic signs suggestive of\npulmonary hypertension ..............................................................................\n3645\nTable 11 Haemodynamic measures obtained during right heart\ncatheterization ..................................................................................................\n3646\nTable 12 Route of administration, half-life, dosages, and duration\nof administration of the recommended test compounds for\nvasoreactivity testing in pulmonary arterial hypertension .............\n3647\nTable 13 Phenotypic features associated with pulmonary arterial\nhypertension mutations ...............................................................................\n3649\nTable 14 Characteristic diagnostic features of patients with\ndifferent forms of pulmonary hypertension ........................................\n3651\nTable 15 World Health Organization classiﬁcation of functional\nstatus of patients with pulmonary hypertension ...............................\n3656\nTable 16 Comprehensive risk assessment in pulmonary arterial\nhypertension (three-strata model) ..........................................................\n3657\nTable 17 Suggested assessment and timing for the follow-up of\npatients with pulmonary arterial hypertension ..................................\n3658\nTable 18 Variables used to calculate the simpliﬁed four-strata\nrisk-assessment tool .......................................................................................\n3659\nTable 19 Dosing of pulmonary arterial hypertension medication\nin adults ...............................................................................................................\n3664\nTable 20 Criteria for lung transplantation and listing in patients\nwith pulmonary arterial hypertension ...................................................\n3672\nTable 21 Clinical classiﬁcation of pulmonary arterial hypertension\nassociated with congenital heart disease ..............................................\n3678\nTable 22 Use of pulmonary arterial hypertension therapies in\nchildren ................................................................................................................\n3684\nTable 23 Patient phenotyping and likelihood for left heart disease\nas cause of pulmonary hypertension ......................................................\n3688\nTable 24 Pulmonary hypertension with unclear and/or\nmultifactorial mechanisms ...........................................................................\n3699\nList of ﬁgures\nFigure 1 Central illustration ........................................................................\n3639\nFigure 2 Symptoms in patients with pulmonary hypertension ...\n3641\nFigure 3 Clinical signs in patients with pulmonary hypertension\n3642\nFigure 4 Transthoracic echocardiographic parameters in the\nassessment of pulmonary hypertension ................................................\n3644\nFigure 5 Echocardiographic probability of pulmonary\nhypertension and recommendations for further assessment ......\n3645\nFigure 6 Diagnostic algorithm of patients with unexplained\ndyspnoea and/or suspected pulmonary hypertension ....................\n3650\nFigure 7 Pathophysiology and current therapeutic targets of\npulmonary arterial hypertension (group 1) .........................................\n3655\nFigure 8 Vasoreactivity testing algorithm of patients with\npresumed diagnosis of idiopathic, heritable, or drug-associated\npulmonary arterial hypertension ..............................................................\n3665\nFigure 9 Evidence-based pulmonary arterial hypertension\ntreatment algorithm for patients with idiopathic, heritable,\ndrug-associated, and connective tissue disease-associated\npulmonary arterial hypertension ..............................................................\n3666\nFigure 10 Neonatal and paediatric vs. adult pulmonary\nhypertension .....................................................................................................\n3682\nFigure 11 Pathophysiology of pulmonary hypertension associated\nwith left heart disease (group 2) ..............................................................\n3686\nFigure 12 Pathophysiology of pulmonary hypertension associated\nwith lung disease (group 3) ........................................................................\n3691\nFigure 13 Diagnostic strategy in chronic thrombo-embolic\npulmonary hypertension ..............................................................................\n3694\nFigure 14 Management strategy in chronic thrombo-embolic\npulmonary hypertension ..............................................................................\n3696\nFigure 15 Overlap in treatments/multimodality approaches in\nchronic thrombo-embolic pulmonary hypertension .......................\n3697\nFigure 16 Pulmonary hypertension centre schematic .....................\n3701\nAbbreviations and acronyms\n6MWD\n6-minute walking distance\n6MWT\n6-minute walking test\nABG\nArterial blood gas analysis\nACEi\nAngiotensin-converting enzyme inhibitor\n3622\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nALAT\nAlanine aminotransferase\nARB\nAngiotensin receptor blocker\nARNI\nAngiotensin receptor–neprilysin inhibitor\nASAT\nAspartate aminotransferase\nASIG\nAustralian Scleroderma Interest Group\nBNP\nBrain natriuretic peptide\nBPA\nBalloon pulmonary angioplasty\nBPD\nBronchopulmonary dysplasia\nCAMPHOR\nCambridge Pulmonary Hypertension Outcome\nReview\nCCB\nCalcium channel blocker\nCDH\nCongenital diaphragmatic hernia\ncGMP\nCyclic guanosine monophosphate\nCHD\nCongenital heart disease\nCI\nCardiac index; Conﬁdence interval\ncMRI\nCardiac magnetic resonance imaging\nCO\nCardiac output\nCOMPERA\nComparative, Prospective Registry of Newly\nInitiated Therapies for PH\nCOPD\nChronic obstructive pulmonary disease\nCpcPH\nCombined post- and pre-capillary pulmonary\nhypertension\nCPET\nCardiopulmonary exercise testing\nCPFE\nCombined pulmonary ﬁbrosis and emphysema\nCT\nComputed tomography\nCTD\nConnective tissue disease\nCTEPD\nChronic thrombo-embolic pulmonary disease\nCTEPH\nChronic thrombo-embolic pulmonary\nhypertension\nCTPA\nComputed tomography pulmonary angiography\nDECT\nDual-energy computed tomography\nDLCO\nLung diffusion capacity for carbon monoxide\nDPAH\nDrug- or toxin-associated pulmonary arterial\nhypertension\ndPAP\nDiastolic pulmonary arterial pressure\nDPG\nDiastolic pressure gradient\nDSA\nDigital subtraction angiography\nECG\nElectrocardiogram\nECMO\nExtracorporeal membrane oxygenation\nEHJ\nEuropean Heart Journal\nEMA\nEuropean Medicines Agency\nEOV\nExercise oscillatory ventilation\nERA\nEndothelin receptor antagonist\nERJ\nEuropean Respiratory Journal\nERN\nEuropean Reference Network\nERN-LUNG\nEuropean Reference Network on rare\nrespiratory diseases\nERS\nEuropean Respiratory Society\nESC\nEuropean Society of Cardiology\nEtD\nEvidence to Decision\nFPHR\nFrench Pulmonary Hypertension Registry\nFVC\nForced vital capacity\nGRADE\nGrading of Recommendations, Assessment,\nDevelopment, and Evaluations\nHAART\nHighly active antiretroviral therapy\nHb\nHaemoglobin\nHF\nHeart failure\nHFpEF\nHeart failure with preserved ejection fraction\nHIV\nHuman immunodeﬁciency virus\nHPAH\nHeritable pulmonary arterial hypertension\nHPS\nHepatopulmonary syndrome\nHR\nHazard ratio\nHR-QoL\nHealth-related quality of life\nICU\nIntensive care unit\nIgG4\nImmunogolobulin G4\nILD\nInterstitial lung disease\nIPAH\nIdiopathic pulmonary arterial hypertension\nIpcPH\nIsolated post-capillary pulmonary hypertension\nIP receptor\nProstacyclin I2 receptor\nISWT\nIncremental shuttle walking test\ni.v.\nIntravenous\nLA\nLeft atrium/left atrial\nLAS\nLung allocation score\nLHD\nLeft heart disease\nLTx\nLung transplantation\nLV\nLeft ventricle/left ventricular\nLVAD\nLeft ventricular assist device\nmPAP\nMean pulmonary arterial pressure\nMR\nMagnetic resonance\nMRI\nMagnetic resonance imaging\nNOAC\nNovel oral anticoagulant\nNT-proBNP\nN-terminal pro-brain natriuretic peptide\nOR\nOdds ratio\nPA\nPulmonary artery\nPAC\nPulmonary arterial compliance\nPaCO2\nPartial pressure of arterial carbon dioxide\nPADN\nPulmonary artery denervation\nPAH\nPulmonary arterial hypertension\nPAH-CTD\nPulmonary arterial hypertension associated with\nconnective tissue disease\nPAH-SSc\nPulmonary arterial hypertension associated with\nsystemic sclerosis\nPAH-SYMPACT\nPulmonary Arterial Hypertension-Symptoms\nand Impact\nPaO2\nPartial pressure of arterial oxygen\nPAP\nPulmonary arterial pressure\nPAVM\nPulmonary arteriovenous malformation\nPAWP\nPulmonary arterial wedge pressure\nPCH\nPulmonary capillary haemangiomatosis\nPDE5i\nPhosphodiesterase 5 inhibitor\nPE\nPulmonary embolism\nPEA\nPulmonary endarterectomy\nPET\nPositron emission tomography\nPETCO2\nEnd-tidal partial pressure of carbon dioxide\nPFT\nPulmonary function test\nPH\nPulmonary hypertension\nPH-LHD\nPulmonary hypertension associated with left\nheart disease\nPICO\nPopulation, Intervention, Comparator, Outcome\nPoPH\nPorto-pulmonary hypertension\nPPHN\nPersistent pulmonary hypertension of the\nnewborn\nPROM\nPatient-reported outcome measure\nPVD\nPulmonary vascular disease\nESC/ERS Guidelines\n3623\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nPVOD\nPulmonary veno-occlusive disease\nPVR\nPulmonary vascular resistance\nPVRI\nPulmonary vascular resistance index\nQI\nQuality indicator\nQp/Qs\nPulmonary blood ﬂow/systemic blood ﬂow\nRA\nRight atrium/right atrial\nRAP\nRight atrial pressure\nRCT\nRandomized controlled trial\nREVEAL\nRegistry to Evaluate Early and Long-Term PAH\nDisease Management\nRHC\nRight heart catheterization\nRR\nRelative risk\nRV\nRight ventricle/right ventricular\nRVEF\nRight ventricular ejection fraction\nRV-FAC\nRight ventricular fractional area change\nRVOT AT\nRight ventricular outﬂow tract acceleration time\nSaO2\nArterial oxygen saturation\ns.c.\nSubcutaneous\nSCD\nSickle cell disease\nsGC\nSoluble guanylate cyclase\nSGLT-2i\nSodium–glucose cotransporter-2 inhibitor\nSLE\nSystemic lupus erythematosus\nSPAHR\nSwedish Pulmonary Arterial Hypertension Registry\nsPAP\nSystolic pulmonary arterial pressure\nSPECT\nSingle-photon emission computed tomography\nSSc\nSystemic sclerosis\nSV\nStroke volume\nSVI\nStroke volume index\nSvO2\nMixed venous oxygen saturation\nTAPSE\nTricuspid annular plane systolic excursion\nTGF-β\nTransforming growth factor-β\nTPR\nTotal pulmonary resistance\nTR\nTricuspid regurgitation\nTRPG\nTricuspid regurgitation pressure gradient\nTRV\nTricuspid regurgitation velocity\nTSH\nThyroid-stimulating hormone\nV/Q\nVentilation perfusion\nVE/VCO2\nVentilatory equivalent for carbon dioxide\nVKA\nVitamin K antagonist\nVO2\nOxygen uptake\nVO2/HR\nOxygen pulse\nVTE\nVenous thrombo-embolism\nWHO-FC\nWorld Health Organization functional class\nWSPH\nWorld Symposium on Pulmonary Hypertension\nWU\nWood units\n1. Preamble\nGuidelines summarize and evaluate available evidence, with the aim of\nassisting health professionals in proposing the best management strat-\negies for an individual patient with a given condition. Guidelines and\ntheir recommendations should facilitate decision-making of health\nprofessionals in their daily practice. However, guidelines are not a\nsubstitute for the patient’s relationship with their practitioner. The ﬁ-\nnal decisions concerning an individual patient must be made by the re-\nsponsible health professional(s), based on what they consider to be\nthe most appropriate in the circumstances. These decisions are\nmade in consultation with the patient and caregiver as appropriate.\nGuidelines are intended for use by health professionals. To ensure that\nall physicians have access to the most recent recommendations, both the\nEuropean Society of Cardiology (ESC) and European Respiratory Society\n(ERS) make their guidelines freely available in their own journals. The ESC\nand ERS warn non-medical readers that the technical language may be\nmisinterpreted and decline any responsibility in this respect.\nMany Guidelines have been issued in recent years by the ESC and\nERS. Because of their impact on clinical practice, quality criteria for\nthe development of guidelines have been established in order to\nmake all decisions transparent to the user. The ERS and ESC guid-\nance and procedure to formulate and issue clinical practice recom-\nmendations can be found on the societies’ relevant website or\njournal (https://www.escardio.org/Guidelines and https://openres.\nersjournals.com/content/8/1/00655-2021).\nThe\nESC\nand\nERS\nGuidelines represent the ofﬁcial position of the ESC and ERS on a gi-\nven topic and are regularly updated.\nThe panel of experts of these speciﬁc guidelines comprised an\nequal number of ERS and ESC members, including representatives\nfrom relevant subspecialty groups involved in the medical care of pa-\ntients with this pathology.\nThe experts of the writing and reviewing panels provided declar-\nation of interest forms for all relationships that might be perceived\nas real or potential sources of conﬂicts of interest. Their declarations\nof interest were reviewed according to the ESC declaration of interest\nrules and can be found on the ESC website (http://www.escardio.org/\nGuidelines). They have been compiled in a report and co-published in a\nsupplementary document of the guidelines. This process ensures\ntransparency and prevents potential biases in the development and re-\nview processes. Any changes in declarations of interest that arose dur-\ning the writing period were notiﬁed to the ESC and updated. The Task\nForce received its entire ﬁnancial support from the ESC and ERS with-\nout any involvement from the health care industry.\nThe ESC Clinical Practice Guidelines (CPG) Committee and the ERS\nGuidelines Director reporting to the ERS Science Council supervise\nand co-ordinate the preparation of new guidelines. These Guidelines\nunderwent extensive review by the ESC CPG Committee, the ERS\nGuidelines Working Group, and external experts. The guidelines\nwere developed after careful consideration of the scientiﬁc and medical\nknowledge and the evidence available at the time of drafting. After ap-\npropriate revisions, the guidelines were signed off by all the experts in\nthe Task Force. The ﬁnalized document was signed off by the ESC CPG\nCommittee and endorsed by the ERS Executive Committee before\nbeing simultaneously published in the European Heart Journal (EHJ)\nand the European Respiratory Journal (ERJ). The decision to publish the\nguidelines in both journals was made to ensure adequate dissemination\nof the recommendations in both the cardiology and respiratory ﬁelds.\nThe task of developing the ESC/ERS Guidelines also included creat-\ning educational tools and implementation programmes for the recom-\nmendations, including condensed pocket guidelines versions, summary\nslides, a lay summary, and an electronic version for digital applications\n(smartphones, etc.). These versions are abridged and thus, for more\ndetailed information, the user should always access the full-text version\nof the guidelines, which is freely available via the ESC and ERS websites,\nand hosted on the EHJ and ERJ websites. The National Cardiac\nSocieties of the ESC are encouraged to endorse, adopt, translate,\n3624\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "acronyms",
        "pulmonary hypertension",
        "abbreviations",
        "recommendation"
      ]
    },
    {
      "number": "3",
      "title": "1. Preamble",
      "start_page": 7,
      "end_page": 8,
      "content": "PVOD\nPulmonary veno-occlusive disease\nPVR\nPulmonary vascular resistance\nPVRI\nPulmonary vascular resistance index\nQI\nQuality indicator\nQp/Qs\nPulmonary blood ﬂow/systemic blood ﬂow\nRA\nRight atrium/right atrial\nRAP\nRight atrial pressure\nRCT\nRandomized controlled trial\nREVEAL\nRegistry to Evaluate Early and Long-Term PAH\nDisease Management\nRHC\nRight heart catheterization\nRR\nRelative risk\nRV\nRight ventricle/right ventricular\nRVEF\nRight ventricular ejection fraction\nRV-FAC\nRight ventricular fractional area change\nRVOT AT\nRight ventricular outﬂow tract acceleration time\nSaO2\nArterial oxygen saturation\ns.c.\nSubcutaneous\nSCD\nSickle cell disease\nsGC\nSoluble guanylate cyclase\nSGLT-2i\nSodium–glucose cotransporter-2 inhibitor\nSLE\nSystemic lupus erythematosus\nSPAHR\nSwedish Pulmonary Arterial Hypertension Registry\nsPAP\nSystolic pulmonary arterial pressure\nSPECT\nSingle-photon emission computed tomography\nSSc\nSystemic sclerosis\nSV\nStroke volume\nSVI\nStroke volume index\nSvO2\nMixed venous oxygen saturation\nTAPSE\nTricuspid annular plane systolic excursion\nTGF-β\nTransforming growth factor-β\nTPR\nTotal pulmonary resistance\nTR\nTricuspid regurgitation\nTRPG\nTricuspid regurgitation pressure gradient\nTRV\nTricuspid regurgitation velocity\nTSH\nThyroid-stimulating hormone\nV/Q\nVentilation perfusion\nVE/VCO2\nVentilatory equivalent for carbon dioxide\nVKA\nVitamin K antagonist\nVO2\nOxygen uptake\nVO2/HR\nOxygen pulse\nVTE\nVenous thrombo-embolism\nWHO-FC\nWorld Health Organization functional class\nWSPH\nWorld Symposium on Pulmonary Hypertension\nWU\nWood units\n1. Preamble\nGuidelines summarize and evaluate available evidence, with the aim of\nassisting health professionals in proposing the best management strat-\negies for an individual patient with a given condition. Guidelines and\ntheir recommendations should facilitate decision-making of health\nprofessionals in their daily practice. However, guidelines are not a\nsubstitute for the patient’s relationship with their practitioner. The ﬁ-\nnal decisions concerning an individual patient must be made by the re-\nsponsible health professional(s), based on what they consider to be\nthe most appropriate in the circumstances. These decisions are\nmade in consultation with the patient and caregiver as appropriate.\nGuidelines are intended for use by health professionals. To ensure that\nall physicians have access to the most recent recommendations, both the\nEuropean Society of Cardiology (ESC) and European Respiratory Society\n(ERS) make their guidelines freely available in their own journals. The ESC\nand ERS warn non-medical readers that the technical language may be\nmisinterpreted and decline any responsibility in this respect.\nMany Guidelines have been issued in recent years by the ESC and\nERS. Because of their impact on clinical practice, quality criteria for\nthe development of guidelines have been established in order to\nmake all decisions transparent to the user. The ERS and ESC guid-\nance and procedure to formulate and issue clinical practice recom-\nmendations can be found on the societies’ relevant website or\njournal (https://www.escardio.org/Guidelines and https://openres.\nersjournals.com/content/8/1/00655-2021).\nThe\nESC\nand\nERS\nGuidelines represent the ofﬁcial position of the ESC and ERS on a gi-\nven topic and are regularly updated.\nThe panel of experts of these speciﬁc guidelines comprised an\nequal number of ERS and ESC members, including representatives\nfrom relevant subspecialty groups involved in the medical care of pa-\ntients with this pathology.\nThe experts of the writing and reviewing panels provided declar-\nation of interest forms for all relationships that might be perceived\nas real or potential sources of conﬂicts of interest. Their declarations\nof interest were reviewed according to the ESC declaration of interest\nrules and can be found on the ESC website (http://www.escardio.org/\nGuidelines). They have been compiled in a report and co-published in a\nsupplementary document of the guidelines. This process ensures\ntransparency and prevents potential biases in the development and re-\nview processes. Any changes in declarations of interest that arose dur-\ning the writing period were notiﬁed to the ESC and updated. The Task\nForce received its entire ﬁnancial support from the ESC and ERS with-\nout any involvement from the health care industry.\nThe ESC Clinical Practice Guidelines (CPG) Committee and the ERS\nGuidelines Director reporting to the ERS Science Council supervise\nand co-ordinate the preparation of new guidelines. These Guidelines\nunderwent extensive review by the ESC CPG Committee, the ERS\nGuidelines Working Group, and external experts. The guidelines\nwere developed after careful consideration of the scientiﬁc and medical\nknowledge and the evidence available at the time of drafting. After ap-\npropriate revisions, the guidelines were signed off by all the experts in\nthe Task Force. The ﬁnalized document was signed off by the ESC CPG\nCommittee and endorsed by the ERS Executive Committee before\nbeing simultaneously published in the European Heart Journal (EHJ)\nand the European Respiratory Journal (ERJ). The decision to publish the\nguidelines in both journals was made to ensure adequate dissemination\nof the recommendations in both the cardiology and respiratory ﬁelds.\nThe task of developing the ESC/ERS Guidelines also included creat-\ning educational tools and implementation programmes for the recom-\nmendations, including condensed pocket guidelines versions, summary\nslides, a lay summary, and an electronic version for digital applications\n(smartphones, etc.). These versions are abridged and thus, for more\ndetailed information, the user should always access the full-text version\nof the guidelines, which is freely available via the ESC and ERS websites,\nand hosted on the EHJ and ERJ websites. The National Cardiac\nSocieties of the ESC are encouraged to endorse, adopt, translate,\n3624\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nand implement all ESC Guidelines. Pulmonary national societies are\nalso encouraged to share these guidelines with their members and de-\nvelop a summary or editorials in their own language, if appropriate.\nImplementation programmes are needed because it has been shown\nthat the outcome of disease may be favourably inﬂuenced by the thor-\nough application of clinical recommendations.\nHealth professionals are encouraged to take the ESC/ERS Guidelines\nfully into account when exercising their clinical judgement, as well as in\ndetermining and implementing preventive, diagnostic, or therapeutic\nmedical strategies. However, the ESC/ERS Guidelines do not override,\nin any way, the individual responsibility of health professionals to make\nappropriate and accurate decisions in considering each patient’s health\ncondition and in consulting with that patient or the patient’s caregiver\nwhere appropriate and/or necessary. It is also the health professional’s\nresponsibility to verify the rules and regulations applicable to drugs and\ndevices at the time of prescription and, where appropriate, to respect\nthe ethical rules of their profession in each country.\nOff-label use of medication may be presented in these guidelines if\na sufﬁcient level of evidence shows that it can be considered medic-\nally appropriate to a given condition and if patients could beneﬁt\nfrom the recommended therapy. However, the ﬁnal decisions con-\ncerning an individual patient must be made by the responsible health\nprofessional, giving special consideration to:\n• The speciﬁc situation of the patient. In this respect, it is speciﬁed\nthat, unless otherwise provided for by national regulations, off-\nlabel use of medication should be limited to situations where it\nis in the patient’s interest to do so, with regards to the quality,\nsafety, and efﬁcacy of care, and only after the patient has been fully\ninformed and provided consent.\n• Country-speciﬁc health regulations, indications by governmental\ndrug regulatory agencies, and the ethical rules to which health pro-\nfessionals are subject, where applicable.\n2. Introduction\nPulmonary hypertension (PH) is a pathophysiological disorder that\nmay involve multiple clinical conditions and may be associated with a\nvariety of cardiovascular and respiratory diseases. The complexity of\nmanaging PH requires a multifaceted, holistic, and multidisciplinary ap-\nproach, with active involvement of patients with PH in partnership\nwith clinicians. Streamlining the care of patients with PH in daily clinical\npractice is a challenging but essential requirement for effectively man-\naging PH. In recent years, substantial progress has been made in detect-\ning and managing PH, and new evidence has been timeously integrated\nin this fourth edition of the ESC/ERS Guidelines for the diagnosis and\ntreatment of pulmonary hypertension. Reﬂecting the multidisciplinary\ninput into managing patients with PH and interpreting new evidence,\nthe Task Force included cardiologists and pneumologists, a thoracic\nsurgeon, methodologists, and patients. These comprehensive clinical\npractice guidelines cover the whole spectrum of PH, with an emphasis\non diagnosing and treating pulmonary arterial hypertension (PAH) and\nchronic thrombo-embolic pulmonary hypertension (CTEPH).\n2.1. What is new\nOne of the most important proposals from the 6th World\nSymposium on Pulmonary Hypertension (WSPH) was to reconsider\nthe haemodynamic deﬁnition of PH.1 After careful evaluation, the\nnew deﬁnitions of PH have been endorsed and expanded in these\nguidelines, including a revised cut-off level for pulmonary vascular re-\nsistance (PVR) and a deﬁnition of exercise PH.\nThe classiﬁcation of PH has been updated, including repositioning\nof vasoreactive patients with idiopathic pulmonary arterial hyperten-\nsion (IPAH) and a revision of group 5 PH, including repositioning of\nPH in lymphangioleiomyomatosis in group 3.\nConcerning the diagnosis of PH, a new algorithm has been devel-\noped aiming at earlier detection of PH in the community. In addition,\nexpedited referral is recommended for high-risk or complex pa-\ntients. Screening strategies are also proposed.\nThe risk-stratiﬁcation table has been expanded to include additional\nechocardiographic and cardiac magnetic resonance imaging (cMRI)\nprognostic indicators. The recommendations for initial drug therapies\nhave been simpliﬁed, building on this revised, three-strata, multipara-\nmetric risk model to replace functional classiﬁcation. At follow-up, a\nfour-strata risk-assessment tool is now proposed based on reﬁned\ncut-off levels for World Health Organization functional class\n(WHO-FC), 6-minute walking distance (6MWD), and N-terminal\npro-brain natriuretic peptide (NT-proBNP), categorizing patients as\nlow, intermediate–low, intermediate–high, or high risk.\nThe PAH treatment algorithm has been modiﬁed, highlighting the im-\nportance of cardiopulmonary comorbidities, risk assessment both at\ndiagnosis and follow-up, and the importance of combination therapies.\nTreatment strategies during follow-up have been based on the four-\nstrata model intended to facilitate more granular decision-making.\nThe recommendations for managing PH associated with left heart dis-\nease (PH-LHD) and lung disease have been updated, including a new\nhaemodynamic deﬁnition of severe PH in patients with lung disease.\nIn group 4 PH, the term chronic thrombo-embolic pulmonary dis-\nease (CTEPD) with or without PH has been introduced, acknow-\nledging the presence of similar symptoms, perfusion defects, and\norganized ﬁbrotic obstructions in patients with or without PH at\nrest. Interventional treatment by balloon pulmonary angioplasty\n(BPA) in combination with medical therapy has been upgraded in\nthe therapeutic algorithm of CTEPH.\nNew standards for PH centres have been presented and, for the\nﬁrst time, patient representatives were actively involved in develop-\ning these guidelines.\nQuestions with direct consequences for clinical practitioners regard-\ning each PH classiﬁcation subgroup were selected and addressed, name-\nly guidance on: initial treatment strategy for group 1 PH (Population,\nIntervention, Control, Outcome [PICO] I); use of oral phosphodiester-\nase 5 inhibitors (PDE5is) for the treatment of group 2 PH (PICO II); use\nof oral PDE5is for the treatment of group 3 PH (PICO III); and use of PH\ndrugs prior to BPA for the treatment of group 4 PH (PICO IV). These\nquestions were considered to be important because: most contempor-\nary PH registries describe variable use of initial oral monotherapy and\ncombination therapy; large case series show widespread use of\nPDE5is in group 2 PH, despite a class III recommendation in the 2015\nESC/ERS Guidelines for the diagnosis and treatment of pulmonary\nhypertension; large case series show widespread use of PDE5is in group\n3 PH, despite a class III recommendation in the 2015 ESC/ERS\nGuidelines for the diagnosis and treatment of pulmonary hypertension;\nand there is no clear guidance for therapy with PH drugs in patients with\ninoperable CTEPH prior to BPA.\nESC/ERS Guidelines\n3625\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "preamble",
        "tricuspid regurgitation",
        "arb",
        "catheterization",
        "risk",
        "pulmonary hypertension",
        "recommendation"
      ]
    },
    {
      "number": "4",
      "title": "2. Introduction",
      "start_page": 8,
      "end_page": 19,
      "content": "and implement all ESC Guidelines. Pulmonary national societies are\nalso encouraged to share these guidelines with their members and de-\nvelop a summary or editorials in their own language, if appropriate.\nImplementation programmes are needed because it has been shown\nthat the outcome of disease may be favourably inﬂuenced by the thor-\nough application of clinical recommendations.\nHealth professionals are encouraged to take the ESC/ERS Guidelines\nfully into account when exercising their clinical judgement, as well as in\ndetermining and implementing preventive, diagnostic, or therapeutic\nmedical strategies. However, the ESC/ERS Guidelines do not override,\nin any way, the individual responsibility of health professionals to make\nappropriate and accurate decisions in considering each patient’s health\ncondition and in consulting with that patient or the patient’s caregiver\nwhere appropriate and/or necessary. It is also the health professional’s\nresponsibility to verify the rules and regulations applicable to drugs and\ndevices at the time of prescription and, where appropriate, to respect\nthe ethical rules of their profession in each country.\nOff-label use of medication may be presented in these guidelines if\na sufﬁcient level of evidence shows that it can be considered medic-\nally appropriate to a given condition and if patients could beneﬁt\nfrom the recommended therapy. However, the ﬁnal decisions con-\ncerning an individual patient must be made by the responsible health\nprofessional, giving special consideration to:\n• The speciﬁc situation of the patient. In this respect, it is speciﬁed\nthat, unless otherwise provided for by national regulations, off-\nlabel use of medication should be limited to situations where it\nis in the patient’s interest to do so, with regards to the quality,\nsafety, and efﬁcacy of care, and only after the patient has been fully\ninformed and provided consent.\n• Country-speciﬁc health regulations, indications by governmental\ndrug regulatory agencies, and the ethical rules to which health pro-\nfessionals are subject, where applicable.\n2. Introduction\nPulmonary hypertension (PH) is a pathophysiological disorder that\nmay involve multiple clinical conditions and may be associated with a\nvariety of cardiovascular and respiratory diseases. The complexity of\nmanaging PH requires a multifaceted, holistic, and multidisciplinary ap-\nproach, with active involvement of patients with PH in partnership\nwith clinicians. Streamlining the care of patients with PH in daily clinical\npractice is a challenging but essential requirement for effectively man-\naging PH. In recent years, substantial progress has been made in detect-\ning and managing PH, and new evidence has been timeously integrated\nin this fourth edition of the ESC/ERS Guidelines for the diagnosis and\ntreatment of pulmonary hypertension. Reﬂecting the multidisciplinary\ninput into managing patients with PH and interpreting new evidence,\nthe Task Force included cardiologists and pneumologists, a thoracic\nsurgeon, methodologists, and patients. These comprehensive clinical\npractice guidelines cover the whole spectrum of PH, with an emphasis\non diagnosing and treating pulmonary arterial hypertension (PAH) and\nchronic thrombo-embolic pulmonary hypertension (CTEPH).\n2.1. What is new\nOne of the most important proposals from the 6th World\nSymposium on Pulmonary Hypertension (WSPH) was to reconsider\nthe haemodynamic deﬁnition of PH.1 After careful evaluation, the\nnew deﬁnitions of PH have been endorsed and expanded in these\nguidelines, including a revised cut-off level for pulmonary vascular re-\nsistance (PVR) and a deﬁnition of exercise PH.\nThe classiﬁcation of PH has been updated, including repositioning\nof vasoreactive patients with idiopathic pulmonary arterial hyperten-\nsion (IPAH) and a revision of group 5 PH, including repositioning of\nPH in lymphangioleiomyomatosis in group 3.\nConcerning the diagnosis of PH, a new algorithm has been devel-\noped aiming at earlier detection of PH in the community. In addition,\nexpedited referral is recommended for high-risk or complex pa-\ntients. Screening strategies are also proposed.\nThe risk-stratiﬁcation table has been expanded to include additional\nechocardiographic and cardiac magnetic resonance imaging (cMRI)\nprognostic indicators. The recommendations for initial drug therapies\nhave been simpliﬁed, building on this revised, three-strata, multipara-\nmetric risk model to replace functional classiﬁcation. At follow-up, a\nfour-strata risk-assessment tool is now proposed based on reﬁned\ncut-off levels for World Health Organization functional class\n(WHO-FC), 6-minute walking distance (6MWD), and N-terminal\npro-brain natriuretic peptide (NT-proBNP), categorizing patients as\nlow, intermediate–low, intermediate–high, or high risk.\nThe PAH treatment algorithm has been modiﬁed, highlighting the im-\nportance of cardiopulmonary comorbidities, risk assessment both at\ndiagnosis and follow-up, and the importance of combination therapies.\nTreatment strategies during follow-up have been based on the four-\nstrata model intended to facilitate more granular decision-making.\nThe recommendations for managing PH associated with left heart dis-\nease (PH-LHD) and lung disease have been updated, including a new\nhaemodynamic deﬁnition of severe PH in patients with lung disease.\nIn group 4 PH, the term chronic thrombo-embolic pulmonary dis-\nease (CTEPD) with or without PH has been introduced, acknow-\nledging the presence of similar symptoms, perfusion defects, and\norganized ﬁbrotic obstructions in patients with or without PH at\nrest. Interventional treatment by balloon pulmonary angioplasty\n(BPA) in combination with medical therapy has been upgraded in\nthe therapeutic algorithm of CTEPH.\nNew standards for PH centres have been presented and, for the\nﬁrst time, patient representatives were actively involved in develop-\ning these guidelines.\nQuestions with direct consequences for clinical practitioners regard-\ning each PH classiﬁcation subgroup were selected and addressed, name-\nly guidance on: initial treatment strategy for group 1 PH (Population,\nIntervention, Control, Outcome [PICO] I); use of oral phosphodiester-\nase 5 inhibitors (PDE5is) for the treatment of group 2 PH (PICO II); use\nof oral PDE5is for the treatment of group 3 PH (PICO III); and use of PH\ndrugs prior to BPA for the treatment of group 4 PH (PICO IV). These\nquestions were considered to be important because: most contempor-\nary PH registries describe variable use of initial oral monotherapy and\ncombination therapy; large case series show widespread use of\nPDE5is in group 2 PH, despite a class III recommendation in the 2015\nESC/ERS Guidelines for the diagnosis and treatment of pulmonary\nhypertension; large case series show widespread use of PDE5is in group\n3 PH, despite a class III recommendation in the 2015 ESC/ERS\nGuidelines for the diagnosis and treatment of pulmonary hypertension;\nand there is no clear guidance for therapy with PH drugs in patients with\ninoperable CTEPH prior to BPA.\nESC/ERS Guidelines\n3625\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nSelected revised recommendations (R) and new recommendations (N)\nNew or\nrevised\nRecommendation in 2015 version\nClassa\nRecommendation in 2022 version\nClassa\nRight heart catheterization and vasoreactivity testing – Recommendation Table 1\nN\nIt is recommended that RHC comprises a complete set of\nhaemodynamics and is performed following standardized\nprotocols\nI\nR\nAdenosine should be considered for performing\nvasoreactivity testing as an alternative\nInhaled iloprost may be considered for performing\nvasoreactivity testing as an alternative\nIIa\nInhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol\nare recommended for performing vasoreactivity testing\nI\nDiagnostic strategy – Recommendation Table 2\nN\nIt is recommended to assign an echocardiographic\nprobability of PH, based on an abnormal TRV and the\npresence of other echocardiographic signs suggestive of\nPH (see Table 10)\nI\nN\nIt is recommended to maintain the current threshold for\nTRV (.2.8 m/s) for echocardiographic probability of PH\naccording to the updated haemodynamic deﬁnition\nI\nN\nBased on the probability of PH by echocardiography,\nfurther testing should be considered in the clinical\ncontext (i.e. symptoms and risk factors or associated\nconditions for PAH/CTEPH)\nIIa\nN\nIn symptomatic patients with intermediate\nechocardiographic probability of PH, CPET may be\nconsidered to further determine the likelihood of PH\nIIb\nScreening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension –\nRecommendation Table 3\nN\nIn patients with SSc, an annual evaluation of the risk of\nhaving PAH is recommended\nI\nR\nResting echocardiography is recommended as a screening\ntest in asymptomatic patients with SSc, followed by annual\nscreening with echocardiography, DLCO, and biomarkers\nI\nIn adult patients with SSc of .3 years’ disease duration,\nan FVC ≥40%, and a DLCO ,60%, the DETECT\nalgorithm is recommended to identify asymptomatic\npatients with PAH\nI\nN\nIn patients with SSc, where breathlessness remains\nunexplained following non-invasive assessment, RHC is\nrecommended to exclude PAH\nI\nN\nAssessing the risk of having PAH, based on an evaluation\nof breathlessness, in combination with echocardiogram\nor PFTs and BNP/NT-proBNP, should be considered in\npatients with SSc\nIIa\nN\nPolicies to evaluate the risk of having PAH should be\nconsidered in hospitals managing patients with SSc\nIIa\nR\nRHC is recommended in all cases of suspected PAH\nassociated with CTD\nI\nIn symptomatic patients with SSc, exercise\nechocardiography or CPET, or CMR may be considered\nto aid decisions to perform RHC\nIIb\nN\nIn patients with CTD with overlap features of SSc, an\nannual evaluation of the risk of PAH may be considered\nIIb\nR\nIn PE survivors with exercise dyspnoea, CTEPH should be\nconsidered\nIIa\nIn patients with persistent or new-onset dyspnoea or\nexercise limitation following PE, further diagnostic\nevaluation to assess for CTEPH/CTEPD is recommended\nI\nContinued\n3626\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nN\nFor symptomatic patients with mismatched perfusion\nlung defects beyond 3 months of anticoagulation for\nacute PE, referral to a PH/CTEPH centre is\nrecommended after considering the results of\nechocardiography, BNP/NT-proBNP, and/or CPET\nI\nN\nCounselling regarding the risk of PAH, and annual\nscreening is recommended for individuals who test\npositive for PAH-causing mutations and in ﬁrst-degree\nrelatives of patients with HPAH\nI\nN\nIn patients referred for liver transplantation,\nechocardiography is recommended as a screening test for\nPH\nI\nN\nFurther tests (echocardiography, BNP/NT-proBNP,\nPFTs, and/or CPET) should be considered in symptomatic\npatients with CTD, portal hypertension, or HIV to screen\nfor PAH\nIIa\nEvaluating the disease severity and risk of death in patients with pulmonary arterial hypertension – Recommendation Table 4\nN\nFor risk stratiﬁcation at the time of diagnosis, the use of a\nthree-strata model (low, intermediate, and high risk) is\nrecommended, taking into account all available data\nincluding haemodynamics\nI\nN\nFor risk stratiﬁcation during follow-up, the use of a\nfour-strata model (low, intermediate–low, intermediate–\nhigh, and high risk) based on WHO-FC, 6MWD, and\nBNP/NT-proBNP is recommended, with additional\nvariables taken into account as necessary\nI\nR\nAchievement/maintenance of an intermediate-risk proﬁle\nshould be considered an inadequate treatment response\nfor most patients with PAH\nIIa\nIn some PAH aetiologies and in patients with\ncomorbidities, optimization of therapy should be\nconsidered on an individual basis while acknowledging\nthat a low-risk proﬁle is not always achievable\nIIa\nGeneral measures and special circumstances – Recommendation Table 5\nR\nSupervised exercise training should be considered in\nphysically deconditioned PAH patients under medical\ntherapy\nIIa\nSupervised exercise training is recommended in patients\nwith PAH under medical therapy\nI\nR\nImmunization of PAH patients against inﬂuenza and\npneumococcal infection is recommended\nI\nImmunization of patients with PAH against SARS-CoV-2,\ninﬂuenza, and Streptococcus pneumoniae is recommended\nI\nR\nCorrection of anaemia and/or iron status may be\nconsidered in PAH patients\nIIb\nIn the presence of iron-deﬁciency anaemia, correction of\niron status is recommended in patients with PAH\nI\nN\nIn the absence of anaemia, iron repletion may be\nconsidered in patients with PAH with iron deﬁciency\nIIb\nR\nOral anticoagulant treatment may be considered in\npatients with IPAH, HPAH, and PAH due to use of\nanorexigens\nIIb\nAnticoagulation is not generally recommended in patients\nwith PAH but may be considered on an individual basis\nIIb\nR\nThe use of angiotensin-converting enzyme inhibitors,\nangiotensin-2 receptor antagonists, beta-blockers, and\nivabradine is not recommended in patients with PAH\nunless required by comorbidities (i.e. high blood pressure,\ncoronary artery disease, or left HF)\nIII\nThe use of ACEis, ARBs, ARNIs, SGLT-2is, beta-blockers,\nor ivabradine is not recommended in patients with PAH\nunless required by comorbidities (i.e. high blood pressure,\ncoronary artery disease, left HF, or arrhythmias)\nIII\nR\nIn-ﬂight O2 administration should be considered for\npatients in WHO-FC III and IV and those with arterial\nblood O2 pressure consistently ,8 kPa (60 mmHg)\nIIa\nIn-ﬂight O2 administration is recommended for patients\nusing oxygen or whose arterial blood oxygen pressure is\n,8 kPa (60 mmHg) at sea level\nI\nR\nIn elective surgery, epidural rather than general\nanaesthesia should be preferred whenever possible\nIIa\nFor interventions requiring anaesthesia, multidisciplinary\nconsultation at a PH centre to assess risk and beneﬁt\nshould be considered\nIIa\nContinued\nESC/ERS Guidelines\n3627\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nWomen of childbearing potential – Recommendation Table 6\nR\nIt is recommended that PAH patients avoid pregnancy\nI\nIt is recommended that women of childbearing potential\nwith PAH are counselled at the time of diagnosis about\nthe risks and uncertainties associated with becoming\npregnant; this should include advice against becoming\npregnant, and referral for psychological support where\nneeded\nI\nN\nIt is recommended that women of childbearing potential\nwith PAH be provided with clear contraceptive advice,\nconsidering the individual needs of the woman but\nrecognizing that the implications of contraceptive failure\nare signiﬁcant in PAH\nI\nN\nIt is recommended that women with PAH who consider\npregnancy or who become pregnant receive prompt\ncounselling in an experienced PH centre to facilitate\ngenetic counselling and shared decision-making, and to\nprovide psychological support to the patients and their\nfamilies where needed\nI\nN\nFor women with PAH having termination of pregnancy, it\nis recommended that this be performed in PH centres,\nwith psychological support provided to the patient and\nher family\nI\nN\nFor women with PAH who desire to have children, where\navailable, adoption and surrogacy with pre-conception\ngenetic counselling may be considered\nIIb\nN\nAs teratogenic potential has been reported in preclinical\nmodels for endothelin receptor antagonists and riociguat,\nthese drugs are not recommended during pregnancy\nIII\nTreatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension –\nRecommendation Table 7\nR\nContinuation of high doses of CCBs is recommended in\npatients with IPAH, HPAH, and DPAH in WHO-FC I or II\nwith marked haemodynamic improvement (near\nnormalization)\nI\nContinuing high doses of CCBs is recommended in\npatients with IPAH, HPAH, or DPAH in WHO-FC I or II\nwith marked haemodynamic improvement (mPAP\n,30 mmHg and PVR ,4 WU)\nI\nN\nIn patients with a positive vasoreactivity test but\ninsufﬁcient long-term response to CCBs who require\nadditional PAH therapy, continuation of CCB therapy\nshould be considered\nIIa\nTreatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present\nwithout cardiopulmonary comorbiditiesb – Recommendation Table 8\nN\nIn patients with IPAH/HPAH/DPAH who present at high\nrisk of death, initial combination therapy with a PDE5i, an\nERA, and i.v./s.c. prostacyclin analogues should be\nconsideredc\nIIa\nN\nIn patients with IPAH/HPAH/DPAH who present at\nintermediate–low risk of death while receiving ERA/\nPDE5i therapy, the addition of selexipag should be\nconsidered\nIIa\nN\nIn patients with IPAH/HPAH/DPAH who present at\nintermediate–high or high risk of death while receiving\nERA/PDE5i therapy, the addition of i.v./s.c. prostacyclin\nanalogues and referral for lung transplantation (LTx)\nevaluation should be considered\nIIa\nContinued\n3628\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nN\nIn patients with IPAH/HPAH/DPAH who present at\nintermediate–low risk of death while receiving ERA/\nPDE5i therapy, switching from PDE5i to riociguat may be\nconsidered\nIIb\nInitial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension\nwithout cardiopulmonary comorbidities – Recommendation Table 9\nR\nAmbrisentan + tadalaﬁl\nI\nInitial combination therapy with ambrisentan and tadalaﬁl\nis recommended\nI\nN\nInitial combination therapy with macitentan and tadalaﬁl\nis recommended\nI\nR\nOther ERA + PDE-5i\nIIa\nInitial combination therapy with other ERAs and PDE5is\nshould be considered\nIIa\nN\nInitial combination therapy with macitentan, tadalaﬁl, and\nselexipag is not recommended\nIII\nSequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension –\nRecommendation Table 10\nN\nIt is recommended to base treatment escalations on risk\nassessment and general treatment strategies (see\ntreatment algorithm)\nI\nR\nMacitentan added to sildenaﬁl\nI\nThe addition of macitentan to PDE5is or oral/inhaled\nprostacyclin analogues is recommended to reduce the\nrisk of morbidity/mortality events\nI\nN\nThe addition of oral treprostinil to ERA or PDE5i/\nriociguat monotherapy is recommended to reduce the\nrisk of morbidity/mortality events\nI\nR\nBosentan added to sildenaﬁl\nIIb\nThe addition of bosentan to sildenaﬁl is not\nrecommended to reduce the risk of morbidity/mortality\nevents\nIII\nR\nRiociguat added to bosentan\nI\nThe addition of riociguat to bosentan should be\nconsidered to improve exercise capacity\nIIa\nTreatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present\nwith cardiopulmonary comorbiditiesb – Recommendation Table 11\nN\nIn patients with IPAH/HPAH/DPAH and\ncardiopulmonary comorbidities, initial monotherapy with\na PDE5i or an ERA should be considered\nIIa\nN\nIn patients with IPAH/HPAH/DPAH with\ncardiopulmonary comorbidities who present at\nintermediate or high risk of death while receiving PDE5i\nor ERA monotherapy, additional PAH medication may be\nconsidered on an individual basis\nIIb\nEfﬁcacy of intensive care management for pulmonary arterial hypertension – Recommendation Table 12\nN\nWhen managing patients with right HF in the ICU, it is\nrecommended to involve physicians with expertise, treat\ncausative factors, and use supportive measures including\ninotropes and vasopressors, ﬂuid management, and PAH\ndrugs as appropriate\nI\nN\nMechanical circulatory support may be an option for\nselected patients as a bridge to transplantation or to\nrecovery, and interhospital transfer should be considered\nif such resources are unavailable on site\nIIa\nContinued\nESC/ERS Guidelines\n3629\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nLung transplantation – Recommendation Table 13\nR\nLung transplantation is recommended soon after\ninadequate clinical response on maximal medical therapy\nI\nIt is recommended that potentially eligible candidates are\nreferred for LTx evaluation when they have an\ninadequate response to oral combination therapy,\nindicated by an intermediate–high or high risk or by a\nREVEAL risk score .7\nI\nN\nIt is recommended to list patients for LTx who present\nwith a high risk of death or with a REVEAL risk score ≥10\ndespite receiving optimized medical therapy, including s.c.\nor i.v. prostacyclin analogues\nI\nPulmonary arterial hypertension associated with drugs or toxins – Recommendation Table 14\nN\nIt is recommended to make a diagnosis of drug- or\ntoxin-associated PAH in patients who had relevant\nexposure and in whom other causes of PH have been\nexcluded\nI\nN\nIn patients with suspected drug- or toxin-associated PAH,\nit is recommended to discontinue the causative agent\nimmediately whenever possible\nI\nN\nImmediate PAH therapy should be considered in patients\nwho present with intermediate/high-risk PAH at\ndiagnosis\nIIa\nN\nPatients with low-risk PAH should be re-evaluated 3–4\nmonths after discontinuing the suspected drug or toxin,\nand PAH therapy may be considered when the\nhaemodynamics have not normalized\nIIb\nPulmonary arterial hypertension associated with connective tissue disease – Recommendation Table 15\nN\nIn patients with PAH associated with CTD, treatment of\nthe underlying condition according to current guidelines\nis recommended\nI\nPulmonary arterial hypertension associated with human immunodeﬁciency virus infection – Recommendation Table 16\nN\nIn patients with PAH associated with HIV infection,\nantiretroviral treatment according to current guidelines is\nrecommended\nI\nN\nIn patients with PAH associated with HIV infection, initial\nmonotherapy should be considered, followed by\nsequential combination if necessary, taking into\nconsideration comorbidities and drug–drug interactions\nIIa\nPulmonary arterial hypertension associated with portal hypertension – Recommendation Table 17\nR\nEchocardiographic assessment for signs of PH is\nrecommended in symptomatic patients with liver disease\nor portal hypertension and in all candidates for liver\ntransplantation\nI\nEchocardiography is recommended in patients with liver\ndisease or portal hypertension with signs or symptoms\nsuggestive of PH, and as a screening tool in patients\nevaluated for liver transplantation or transjugular\nportosystemic shunt\nI\nR\nIt is recommended that the treatment algorithm for\npatients with other forms of PAH should be applied to\npatients with PAH associated with portal hypertension,\ntaking into account the severity of liver disease\nI\nIn patients with PAH associated with portal hypertension,\ninitial monotherapy should be considered, followed by\nsequential combination if necessary, taking into\nconsideration the underlying liver disease and indication\nfor liver transplantation\nIIa\nR\nLiver transplantation may be considered in selected\npatients responding well to PAH therapy\nIIb\nLiver transplantation should be considered on an\nindividual basis in patients with PAH associated with\nportal hypertension, as long as PVR is normal or near\nnormal with PAH therapy\nIIa\nContinued\n3630\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nN\nDrugs approved for PAH are not recommended for\npatients with portal hypertension and unclassiﬁed PH (i.e.\nelevated mPAP, high CO, and a normal PVR)\nIII\nShunt closure in patients with pulmonary–systemic ﬂow ratio .1.5:1 based on calculated pulmonary vascular resistance–\nRecommendation Table 18\nN\nIn patients with ASD, VSD, or PDA and a PVR ,3 WU,\nshunt closure is recommended\nI\nN\nIn patients with ASD, VSD, or PDA and a PVR of 3–5\nWU, shunt closure should be considered\nIIa\nN\nIn patients with ASD and a PVR .5 WU that declines to\n,5 WU with PAH treatment, shunt closure may be\nconsidered\nIIb\nN\nIn patients with VSD or PDA and a PVR .5 WU, shunt\nclosure may be considered after careful evaluation in\nspecialized centres\nIIb\nN\nIn patients with ASD and a PVR .5 WU despite PAH\ntreatment, shunt closure is not recommended\nIII\nPulmonary arterial hypertension associated with adult congenital heart disease – Recommendation Table 19\nN\nRisk assessment is recommended for patients with\npersistent PAH after defect closure\nI\nN\nRisk assessment should be considered in patients with\nEisenmenger syndrome\nIIa\nR\nBosentan is recommended in WHO-FC III patients with\nEisenmenger syndrome\nI\nBosentan is recommended in symptomatic patients with\nEisenmenger syndrome to improve exercise capacity\nI\nR\nThe use of supplemental iron treatment may be\nconsidered in patients with low ferritin plasma levels\nIIb\nSupplemental iron treatment should be considered in\npatients with iron deﬁciency\nIIa\nR\nCombination drug therapy may be considered in patients\nwith Eisenmenger syndrome\nIIb\nIn patients with PAH after corrected adult CHD, initial\noral combination therapy with drugs approved for PAH\nshould be considered for patients at low and intermediate\nrisk, while initial combination therapy including i.v./s.c.\nprostacyclin analogues should be considered for patients\nat high risk\nIIa\nR\nCombination drug therapy may be considered in patients\nwith Eisenmenger syndrome\nIIb\nIn patients with adult CHD, including Eisenmenger\nsyndrome, sequential combination therapy should be\nconsidered if patients do not meet treatment goals\nIIa\nN\nIn women with Eisenmenger syndrome, pregnancy is not\nrecommended\nIII\nR\nIf symptoms of hyperviscosity are present, phlebotomy\nwith isovolumic replacement should be considered, usually\nwhen the haematocrit is .65%\nIIa\nIn patients with Eisenmenger syndrome, routine\nphlebotomy to lower elevated haematocrit is not\nrecommended\nIII\nPulmonary arterial hypertension with signs of venous/capillary involvement – Recommendation Table 20\nR\nA combination of clinical ﬁndings, physical examination,\nbronchoscopy, and radiological ﬁndings is recommended\nto diagnose PVOD/PCH\nI\nA combination of clinical and radiological ﬁndings, ABG,\nPFTs, and genetic testing is recommended to diagnose\nPAH with signs of venous and/or capillary involvement\n(PVOD/PCH)\nI\nN\nIn patients with PVOD/PCH, the use of drugs approved\nfor PAH may be considered with careful monitoring of\nclinical symptoms and gas exchange\nIIb\nN\nLung biopsy is not recommended to conﬁrm a diagnosis\nof PVOD/PCH\nIII\nPaediatric pulmonary hypertension – Recommendation Table 21\nN\nIt is recommended to perform the diagnostic work-up,\nincluding RHC and acute vasoreactivity testing, and treat\nchildren with PH at centres with speciﬁc expertise in\npaediatric PH\nI\nContinued\nESC/ERS Guidelines\n3631\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nR\nA PH diagnostic algorithm work-up is recommended for\ndiagnosis and deﬁnition of the speciﬁc aetiology group in\npaediatric PH patients\nI\nIn children with PH, a comprehensive work-up for\nconﬁrming diagnosis and speciﬁc aetiology is\nrecommended (similar to that in adults, but adapted for\nage)\nI\nN\nFor conﬁrming PH diagnosis, RHC is recommended,\npreferably before initiating any PAH therapy\nI\nN\nIn children with IPAH/HPAH, acute vasoreactivity testing\nis recommended to detect those who may beneﬁt from\ncalcium channel blocker therapy\nI\nN\nIt is recommended to deﬁne a positive response to acute\nvasoreactivity testing in children similar to adults by a\nreduction of mPAP ≥10 mmHg to reach an absolute\nvalue of mPAP ≤40 mmHg, with an increased or\nunchanged CO\nI\nR\nA PAH-speciﬁc therapeutic algorithm is recommended in\npaediatric PH patients\nI\nIn children with PAH, a therapeutic strategy based on risk\nstratiﬁcation and treatment response is recommended,\nextrapolated from that in adults but adapted for age\nI\nR\nSpeciﬁc paediatric determinants of risk should be\nconsidered\nIIa\nIt is recommended to monitor the treatment response in\nchildren with PAH by serially assessing a panel of data\nderived from clinical assessment, echocardiographic\nevaluation, biochemical markers, and exercise tolerance\ntests\nI\nN\nAchieving and maintaining a low-risk proﬁle should be\nconsidered as an adequate treatment response for\nchildren with PAH\nIIa\nN\nIt is recommended to screen infants with\nbronchopulmonary dysplasia for PH\nI\nN\nIn infants with (or at risk of) bronchopulmonary dysplasia\nand PH, treating lung disease, including hypoxia,\naspiration, and structural airway disease, and optimizing\nrespiratory support is recommended before initiating\nPAH therapy\nI\nN\nIn neonates and infants, a diagnostic and therapeutic\napproach to PH distinct from that in older children and\nadults should be considered, given the frequent\nassociation with developmental vascular and parenchymal\nlung disease\nIIa\nPulmonary hypertension associated with left heart disease – Recommendation Table 22\nN\nRHC is recommended for suspected PH in patients with\nLHD, if it aids management decisions\nI\nN\nRHC is recommended in patients with severe tricuspid\nregurgitation with or without LHD prior to surgical or\ninterventional valve repair\nI\nR\nPatients with PH-LHD and a severe pre-capillary\ncomponent as indicated by a high DPG and/or high PVR\nshould be referred to an expert PH centre for a complete\ndiagnostic work-up and an individual treatment decision\nIIa\nFor patients with LHD and suspected PH with features of\na severe pre-capillary component and/or markers of RV\ndysfunction, referral to a PH centre for a complete\ndiagnostic work-up is recommended\nI\nN\nIn patients with LHD and CpcPH with a severe\npre-capillary component (e.g. PVR .5 WU), an\nindividualized approach to treatment is recommended\nI\nN\nWhen patients with PH and multiple risk factors for LHD,\nwho have a normal PAWP at rest but an abnormal\nresponse to exercise or ﬂuid challenge, are treated with\nPAH drugs, close monitoring is recommended\nI\nContinued\n3632\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nN\nIn patients with PH at RHC, a borderline PAWP (13–\n15 mmHg) and features of HFpEF, additional testing with\nexercise or ﬂuid challenge may be considered to uncover\npost-capillary PH\nIIb\nPulmonary hypertension associated with lung disease and/or hypoxia – Recommendation Table 23\nR\nEchocardiography is recommended for the non-invasive\ndiagnostic assessment of suspected PH in patients with\nlung disease\nI\nIf PH is suspected in patients with lung disease, it is\nrecommended that echocardiographyd be performed\nand the results interpreted in conjunction with ABG,\nPFTs including DLCO, and CT imaging\nI\nR\nOptimal treatment of the underlying lung disease, including\nlong-term O2 therapy in patients with chronic\nhypoxaemia, is recommended in patients with PH due to\nlung diseases\nI\nIn patients with lung disease and suspected PH, it is\nrecommended to optimize treatment of the underlying\nlung disease and, where indicated, hypoxaemia,\nsleep-disordered breathing, and/or alveolar\nhypoventilation\nI\nR\nReferral to an expert centre is recommended in patients\nwith echocardiographic signs of severe PH and/or severe\nright ventricular dysfunction\nI\nIn patients with lung disease and suspected severe PH, or\nwhere there is uncertainty regarding the treatment of PH,\nreferral to a PH centre is recommendede\nI\nN\nIn patients with lung disease and severe PH, an\nindividualized approach to treatment is recommended\nI\nN\nIt is recommended to refer eligible patients with lung\ndisease and PH for LTx evaluation\nI\nR\nRHC is not recommended for suspected PH in patients\nwith lung disease, unless therapeutic consequences are to\nbe expected (e.g. LTx, alternative diagnoses such as PAH\nor CTEPH, and potential enrolment in a clinical trial)\nIII\nIn patients with lung disease and suspected PH, RHC is\nrecommended if the results are expected to aid\nmanagement decisions\nI\nN\nInhaled treprostinil may be considered in patients with\nPH associated with ILD\nIIb\nN\nThe use of ambrisentan is not recommended in patients\nwith PH associated with IPF\nIII\nN\nThe use of riociguat is not recommended in patients with\nPH associated with IIP\nIII\nChronic thrombo-embolic pulmonary hypertension and chronic thrombo-embolic pulmonary disease without pulmonary\nhypertension – Recommendation Table 24\nR\nLifelong anticoagulation is recommended in all patients\nwith CTEPH\nI\nLifelong therapeutic doses of anticoagulation are\nrecommended in all patients with CTEPH\nI\nN\nAntiphospholipid syndrome testing is recommended in\npatients with CTEPH\nI\nN\nIn patients with CTEPH and antiphospholipid syndrome,\nanticoagulation with VKAs is recommended\nI\nR\nIt is recommended that all patients with CTEPH receive\nassessment of operability and decisions regarding other\ntreatment strategies made by a multidisciplinary team of\nexperts\nI\nIt is recommended that all patients with CTEPH are\nreviewed by a CTEPH team for the assessment of\nmultimodality management\nI\nR\nSurgical PEA in deep hypothermia circulatory arrest is\nrecommended for patients with CTEPH\nI\nPEA is recommended as the treatment of choice for\npatients with CTEPH and ﬁbrotic obstructions within\npulmonary arteries accessible by surgery\nI\nR\nInterventional BPA may be considered in patients who are\ntechnically inoperable or carry an unfavourable risk:beneﬁt\nratio for PEA\nIIb\nBPA is recommended in patients who are technically\ninoperable or have residual PH after PEA and distal\nobstructions amenable to BPA\nI\nR\nRiociguat is recommended in symptomatic patients who\nhave been classiﬁed as having persistent/recurrent CTEPH\nafter surgical treatment or inoperable CTEPH by a CTEPH\nteam including at least one experienced PEA surgeon\nI\nRiociguat is recommended for symptomatic patients with\ninoperable CTEPH or persistent/recurrent PH after PEA\nI\nContinued\nESC/ERS Guidelines\n3633\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nN\nLong-term follow-up is recommended after PEA and\nBPA, as well as for patients with CTEPH established on\nmedical therapy\nI\nN\nA multimodality approach should be considered for\npatients with persistent PH after PEA and for patients\nwith inoperable CTEPH\nIIa\nN\nIn patients with CTEPD without PH, long-term\nanticoagulant therapy should be considered on an\nindividual basisf\nIIa\nN\nPEA or BPA should be considered in selected\nsymptomatic patients with CTEPD without PH\nIIa\nN\nTreprostinil s.c. may be considered in patients in\nWHO-FC III–IV who have inoperable CTEPH or\npersistent/recurrent PH after PEA\nIIb\nR\nOff-label use of drugs approved for PAH may be\nconsidered in symptomatic patients who have been\nclassiﬁed as having inoperable CTEPH by a CTEPH team\nincluding at least one experienced PEA surgeon\nIIb\nOff-label use of drugs approved for PAH may be\nconsidered in symptomatic patients who have inoperable\nCTEPH\nIIb\nN\nIn patients with inoperable CTEPH, a combination of\nsGC stimulator/PDE5i, ERA, or parenteral prostacyclin\nanalogues may be considered\nIIb\nN\nBPA may be considered for technically operable patients\nwith a high proportion of distal disease and an\nunfavourable risk:beneﬁt ratio for PEA\nIIb\nPulmonary hypertension centres – Recommendation Table 25\nN\nIt is recommended that PH centres maintain a patient\nregistry\nI\nN\nIt is recommended that PH centres collaborate with\npatient associations\nI\nN\nAccreditation of the PH centres should be considered\n(e.g. https://ec.europa.eu/health/ern/assessment_en)\nIIa\nR\nIt should be considered that a referral centre follow at\nleast 50 patients with PAH or CTEPH and should receive\nat least two new referrals per month with documented\nPAH or CTEPH\nIIa\nPH centres should follow-up a sufﬁcient number of\npatients to maintain expertise (at least 50 patients with\nPAH or CTEPH and at least two new referrals per month\nwith documented PAH or CTEPH) and consider\nestablishing collaborations with high-volume centres\nIIa\n© ESC/ERS 2022\n6MWD, 6-minute walking distance; ABG, arterial blood gas analysis; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–\nneprilysin inhibitor; ASD, atrial septal defect; BNP, brain natriuretic peptide; BPA, balloon pulmonary angioplasty; CCB, calcium channel blocker; CHD, congenital heart disease; CI,\ncardiac index; CMR, cardiac magnetic resonance; CO, cardiac output; CpcPH, combined post- and pre-capillary pulmonary hypertension; CPET, cardiopulmonary exercise testing;\nCT, computed tomography; CTD, connective tissue disease; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension;\nDLCO, Lung diffusion capacity for carbon monoxide; DPAH, drug-associated pulmonary arterial hypertension; DPG, diastolic pressure gradient; ERA, endothelin receptor\nantagonist; FVC, forced vital capacity; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HIV, human immunodeﬁciency virus; HPAH, heritable pulmonary\narterial hypertension; ICU, intensive care unit; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic\npulmonary ﬁbrosis; i.v., intravenous; LHD, left heart disease; LTx, lung transplantation; mPAP, mean pulmonary arterial pressure; NT-proBNP, N-terminal pro-brain natriuretic\npeptide; PAH, pulmonary arterial hypertension; PAP, pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PCH, pulmonary capillary haemangiomatosis; PDA,\npatent ductus arteriosus; PDE5i, phosphodiesterase 5 inhibitor; PE, pulmonary embolism; PEA, pulmonary endarterectomy; PFTs, pulmonary function tests; PH, pulmonary\nhypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVOD, pulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; RAP, mean right\natrial pressure; RHC, right heart catheterization; RV, right ventricle; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2; s.c., subcutaneous; sGC, soluble guanylate\ncyclase; SGLT-2i, sodium–glucose cotransporter-2 inhibitor; SSc, systemic sclerosis; SVI, stroke volume index; TRV, tricuspid regurgitation velocity; VKA, vitamin K antagonist; VSD,\nventricular septal defect; VTE, venous thrombo-embolism; WHO-FC, World Health Organization functional class; WU, Wood units.\naClass of recommendation.\nbCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF, such as obesity, diabetes, coronary heart disease, a history of\nhypertension, and/or a low DLCO.\ncInitial triple-combination therapy including i.v./s.c. prostacyclin analogues may also be considered in patients presenting at intermediate risk but severe haemodynamic impairment (e.g.\nRAP ≥20 mmHg, CI ,2.0 L/min/m2, SVI ,31 mL/m2, and/or PVR ≥12 WU).\ndAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise PAP.\neThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.\nfLong-term anticoagulant therapy is recommended when the risk of PE recurrence is intermediate or high, or when there is no history of VTE.\n3634\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n2.2. Methods\nThree main methodological approaches were used in these\nguidelines, depending on the type of questions addressed:\n(i) Four questions that were considered highly important were for-\nmulated in the PICO format, and assessed with full systematic\nreviews and application of the Grading of Recommendations,\nAssessment, Development, and Evaluations (GRADE) ap-\nproach2 and the Evidence to Decision (EtD) framework3 (see\nSupplementary\nData,\nSection\n2.1\nfor\nfull\nmethodology\ndescription and supportive material). The resulting recommen-\ndations were rated as strong or conditional, based on four po-\ntential levels of evidence (high, moderate, low, or very low;\nTables 1 and 2). All Task Force members approved the recom-\nmendations. In addition, these recommendations were also pre-\nsented and voted following the usual ESC approach.\n(ii) Eight questions that were considered of key importance (key\nnarrative questions) were assessed with systematic literature\nsearches and application of the EtD framework.6 The evi-\ndence grading was performed following the usual ESC\napproach.\n(iii) The remaining topics of interest were assessed using the process\ncommonly followed in ESC Guidelines. Structured literature\nsearches were undertaken and grading tables, as outlined in\nTables 3 and 4, were created to describe level of conﬁdence in\nNew recommendations developed with GRADE Evidence to Decision framework\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nIn patients with IPAH/HPAH/DPAH who present at low or intermediate risk of\ndeath, initial combination therapy with a PDE5i and an ERA is recommended\nLow\nConditional\nI\nB\nThe use of PDE5i in patients with HFpEF and isolated post-capillary PH is not\nrecommended\nLow\nConditional\nIII\nC\nPDE5i may be considered in patients with severe PH associated with ILD (individual\ndecision-making in PH centres)\nVery low\nConditional\nIIb\nC\nThe use of PDE5i in patients with ILD and non-severe PH is not recommended\nVery low\nConditional\nIII\nC\nIn patients with CTEPH who are candidates for BPA, medical therapy should be\nconsidered prior to the intervention\nVery low\nConditional\nIIa\nB\n© ESC/ERS 2022\nBPA, balloon pulmonary angioplasty; CTEPH, chronic thrombo-embolic pulmonary hypertension; DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor\nantagonist; HPAH, heritable pulmonary arterial hypertension; HFpEF, heart failure with preserved ejection fraction; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial\nhypertension; PDE5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension.\naClass of recommendation.\nbLevel of evidence.\nTable 1\nStrength of the recommendations according\nto GRADE\nRecommendation\nstrength\nRationale\nStrong recommendation\nfor\nThe panel is certain that the desirable\noutweigh the undesirable effects\nConditional\nrecommendation for\nThe panel is less conﬁdent that the\ndesirable outweigh the undesirable\neffects\nConditional\nrecommendation against\nThe panel is less conﬁdent that the\nundesirable outweigh the desirable\neffects\nStrong recommendation\nagainst\nThe panel is certain that the undesirable\noutweigh the desirable effects\nNo recommendation\nThe conﬁdence in the results might be\nvery low to make a recommendation, or\nthe trade-offs between desirable and\nundesirable effects are ﬁnely balanced, or\nno data are available.\n© ESC/ERS 2022\nAdapted from the ERS Handbook for Clinical Practice Guidelines.4\nTable\n2\nQuality\nof\nevidence\ngrades\nand\ntheir\ndeﬁnitions5\nQuality\nDeﬁnition\nHigh\nWe are very conﬁdent that the true effect lies close to that\nof the estimate of the effect\nModerate\nWe are moderately conﬁdent in the effect estimate: the\ntrue effect is likely to be close to the estimate of the effect,\nbut there is a possibility that it is substantially different\nLow\nOur conﬁdence in the effect estimate is limited: the true\neffect may be substantially different from the estimate of\nthe effect\nVery low\nWe have very little conﬁdence in the effect estimate: the\ntrue effect is likely to be substantially different from the\nestimate of effect\n© ESC/ERS 2022\nESC/ERS Guidelines\n3635\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nthe recommendation provided and the quality of evidence sup-\nporting the recommendation. The Task Force discussed each\ndraft recommendation during web-based conference calls dedi-\ncated to speciﬁc sections, followed by consensus modiﬁcations\nand an online vote on each recommendation. Only recommen-\ndations that were supported by at least 75% of the Task Force\nmembers were included in the guidelines. The recommendation\ntables were colour-coded for ease of interpretation.\n3. Deﬁnitions and classiﬁcations\n3.1. Deﬁnitions\nThe deﬁnitions for PH are based on haemodynamic assessment by\nright heart catheterization (RHC). Although haemodynamics re-\npresent the central element of characterizing PH, the ﬁnal diagnosis\nand classiﬁcation should reﬂect the whole clinical context and con-\nsider the results of all investigations.\nTable 3\nClasses of recommendations\n©ESC/ERS 2022\nClasses of recommendations\nClass I \nEvidence and/or general agreement\nthat a given treatment or procedure is\nbeneficial, useful, effective.\nefficacy of the given treatment or procedure.\nfavour of usefulness/efficacy.\nUsefulness/efficacy is less well\nuseful/effective, and in some cases\nConﬂicting evidence and/or a divergence of opinion about the usefulness/ \n \nIs recommended or is indicated\nWording to use\nDeﬁnition\nClass III \nEvidence or general agreement that the\ngiven treatment or procedure is not\nmay be harmful. \nIs not recommended\n     Class IIb\nestablished by evidence/opinion.\nMay be considered\n \n   Class IIa\nWeight of evidence/opinion is in\nShould be considered\nClass II \n© ESC/ERS 2022\nTable 4\nLevels of evidence\nLevel of\nevidence A\nLevel of\nevidence B\nLevel of\nevidence C\nData derived from multiple randomized clinical trials\nor meta-analyses.\nData derived from a single randomized clinical trial\nor large non-randomized studies.\nConsensus of opinion of the experts and/or small studies,\nretrospective studies, registries.\n©ESC/ERS 2022\n© ESC/ERS 2022\n3636\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 9",
          "page": 9,
          "content": "New or\nrevised |  | Recommendation in 2015 version | Classa | Recommendation in 2022 version | Classa | \n | Right heart catheterization and vasoreactivity testing – Recommendation Table 1 |  |  |  |  | \nN |  |  |  | It is recommended that RHC comprises a complete set of\nhaemodynamics and is performed following standardized\nprotocols | I | \nR |  | Adenosine should be considered for performing\nvasoreactivity testing as an alternative\nInhaled iloprost may be considered for performing\nvasoreactivity testing as an alternative | IIa | Inhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol\nare recommended for performing vasoreactivity testing | I | \n | Diagnostic strategy – Recommendation Table 2 |  |  |  |  | \nN |  |  |  | It is recommended to assign an echocardiographic\nprobability of PH, based on an abnormal TRV and the\npresence of other echocardiographic signs suggestive of\nPH (see Table 10) | I | \nN |  |  |  | It is recommended to maintain the current threshold for\nTRV (.2.8 m/s) for echocardiographic probability of PH\naccording to the updated haemodynamic definition | I | \nN |  |  |  | Based on the probability of PH by echocardiography,\nfurther testing should be considered in the clinical\ncontext (i.e. symptoms and risk factors or associated\nconditions for PAH/CTEPH) | IIa | \nN |  |  |  | In symptomatic patients with intermediate\nechocardiographic probability of PH, CPET may be\nconsidered to further determine the likelihood of PH | IIb | \n | Screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic pulmonary hypertension –\nRecommendation Table 3 |  |  |  |  | \nN |  |  |  | In patients with SSc, an annual evaluation of the risk of\nhaving PAH is recommended | I | \nR |  | Resting echocardiography is recommended as a screening\ntest in asymptomatic patients with SSc, followed by annual\nscreening with echocardiography, DLCO, and biomarkers | I | In adult patients with SSc of .3 years’ disease duration,\nan FVC ≥40%, and a DLCO ,60%, the DETECT\nalgorithm is recommended to identify asymptomatic\npatients with PAH | I | \nN |  |  |  | In patients with SSc, where breathlessness remains\nunexplained following non-invasive assessment, RHC is\nrecommended to exclude PAH | I | \nN |  |  |  | Assessing the risk of having PAH, based on an evaluation\nof breathlessness, in combination with echocardiogram\nor PFTs and BNP/NT-proBNP, should be considered in\npatients with SSc | IIa | \nN |  |  |  | Policies to evaluate the risk of having PAH should be\nconsidered in hospitals managing patients with SSc | IIa | \nR |  | RHC is recommended in all cases of suspected PAH\nassociated with CTD | I | In symptomatic patients with SSc, exercise\nechocardiography or CPET, or CMR may be considered\nto aid decisions to perform RHC | IIb | \nN |  |  |  | In patients with CTD with overlap features of SSc, an\nannual evaluation of the risk of PAH may be considered | IIb | \nR |  | In PE survivors with exercise dyspnoea, CTEPH should be\nconsidered | IIa | In patients with persistent or new-onset dyspnoea or\nexercise limitation following PE, further diagnostic\nevaluation to assess for CTEPH/CTEPD is recommended | I | ",
          "rows": 18,
          "cols": 7
        },
        {
          "title": "Table on page 10",
          "page": 10,
          "content": "N |  |  |  | For symptomatic patients with mismatched perfusion\nlung defects beyond 3 months of anticoagulation for\nacute PE, referral to a PH/CTEPH centre is\nrecommended after considering the results of\nechocardiography, BNP/NT-proBNP, and/or CPET | I | \nN |  |  |  | Counselling regarding the risk of PAH, and annual\nscreening is recommended for individuals who test\npositive for PAH-causing mutations and in first-degree\nrelatives of patients with HPAH | I | \nN |  |  |  | In patients referred for liver transplantation,\nechocardiography is recommended as a screening test for\nPH | I | \nN |  |  |  | Further tests (echocardiography, BNP/NT-proBNP,\nPFTs, and/or CPET) should be considered in symptomatic\npatients with CTD, portal hypertension, or HIV to screen\nfor PAH | IIa | \n | Evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension – Recommendation Table 4 |  |  |  |  | \nN |  |  |  | For risk stratification at the time of diagnosis, the use of a\nthree-strata model (low, intermediate, and high risk) is\nrecommended, taking into account all available data\nincluding haemodynamics | I | \nN |  |  |  | For risk stratification during follow-up, the use of a\nfour-strata model (low, intermediate–low, intermediate–\nhigh, and high risk) based on WHO-FC, 6MWD, and\nBNP/NT-proBNP is recommended, with additional\nvariables taken into account as necessary | I | \nR |  | Achievement/maintenance of an intermediate-risk profile\nshould be considered an inadequate treatment response\nfor most patients with PAH | IIa | In some PAH aetiologies and in patients with\ncomorbidities, optimization of therapy should be\nconsidered on an individual basis while acknowledging\nthat a low-risk profile is not always achievable | IIa | \n | General measures and special circumstances – Recommendation Table 5 |  |  |  |  | \nR |  | Supervised exercise training should be considered in\nphysically deconditioned PAH patients under medical\ntherapy | IIa | Supervised exercise training is recommended in patients\nwith PAH under medical therapy | I | \nR |  | Immunization of PAH patients against influenza and\npneumococcal infection is recommended | I | Immunization of patients with PAH against SARS-CoV-2,\ninfluenza, and Streptococcus pneumoniae is recommended | I | \nR |  | Correction of anaemia and/or iron status may be\nconsidered in PAH patients | IIb | In the presence of iron-deficiency anaemia, correction of\niron status is recommended in patients with PAH | I | \nN |  |  |  | In the absence of anaemia, iron repletion may be\nconsidered in patients with PAH with iron deficiency | IIb | \nR |  | Oral anticoagulant treatment may be considered in\npatients with IPAH, HPAH, and PAH due to use of\nanorexigens | IIb | Anticoagulation is not generally recommended in patients\nwith PAH but may be considered on an individual basis | IIb | \nR |  | The use of angiotensin-converting enzyme inhibitors,\nangiotensin-2 receptor antagonists, beta-blockers, and\nivabradine is not recommended in patients with PAH\nunless required by comorbidities (i.e. high blood pressure,\ncoronary artery disease, or left HF) | III | The use of ACEis, ARBs, ARNIs, SGLT-2is, beta-blockers,\nor ivabradine is not recommended in patients with PAH\nunless required by comorbidities (i.e. high blood pressure,\ncoronary artery disease, left HF, or arrhythmias) | III | \nR |  | In-flight O administration should be considered for\n2\npatients in WHO-FC III and IV and those with arterial\nblood O pressure consistently ,8 kPa (60 mmHg)\n2 | IIa | In-flight O administration is recommended for patients\n2\nusing oxygen or whose arterial blood oxygen pressure is\n,8 kPa (60 mmHg) at sea level | I | \nR |  | In elective surgery, epidural rather than general\nanaesthesia should be preferred whenever possible | IIa | For interventions requiring anaesthesia, multidisciplinary\nconsultation at a PH centre to assess risk and benefit\nshould be considered | IIa | ",
          "rows": 17,
          "cols": 7
        },
        {
          "title": "Table on page 11",
          "page": 11,
          "content": " | Women of childbearing potential – Recommendation Table 6 |  |  |  |  | \nR |  | It is recommended that PAH patients avoid pregnancy | I | It is recommended that women of childbearing potential\nwith PAH are counselled at the time of diagnosis about\nthe risks and uncertainties associated with becoming\npregnant; this should include advice against becoming\npregnant, and referral for psychological support where\nneeded | I | \nN |  |  |  | It is recommended that women of childbearing potential\nwith PAH be provided with clear contraceptive advice,\nconsidering the individual needs of the woman but\nrecognizing that the implications of contraceptive failure\nare significant in PAH | I | \nN |  |  |  | It is recommended that women with PAH who consider\npregnancy or who become pregnant receive prompt\ncounselling in an experienced PH centre to facilitate\ngenetic counselling and shared decision-making, and to\nprovide psychological support to the patients and their\nfamilies where needed | I | \nN |  |  |  | For women with PAH having termination of pregnancy, it\nis recommended that this be performed in PH centres,\nwith psychological support provided to the patient and\nher family | I | \nN |  |  |  | For women with PAH who desire to have children, where\navailable, adoption and surrogacy with pre-conception\ngenetic counselling may be considered | IIb | \nN |  |  |  | As teratogenic potential has been reported in preclinical\nmodels for endothelin receptor antagonists and riociguat,\nthese drugs are not recommended during pregnancy | III | \n | Treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension –\nRecommendation Table 7 |  |  |  |  | \nR |  | Continuation of high doses of CCBs is recommended in\npatients with IPAH, HPAH, and DPAH in WHO-FC I or II\nwith marked haemodynamic improvement (near\nnormalization) | I | Continuing high doses of CCBs is recommended in\npatients with IPAH, HPAH, or DPAH in WHO-FC I or II\nwith marked haemodynamic improvement (mPAP\n,30 mmHg and PVR ,4 WU) | I | \nN |  |  |  | In patients with a positive vasoreactivity test but\ninsufficient long-term response to CCBs who require\nadditional PAH therapy, continuation of CCB therapy\nshould be considered | IIa | \n | Treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present\nwithout cardiopulmonary comorbiditiesb – Recommendation Table 8 |  |  |  |  | \nN |  |  |  | In patients with IPAH/HPAH/DPAH who present at high\nrisk of death, initial combination therapy with a PDE5i, an\nERA, and i.v./s.c. prostacyclin analogues should be\nconsideredc | IIa | \nN |  |  |  | In patients with IPAH/HPAH/DPAH who present at\nintermediate–low risk of death while receiving ERA/\nPDE5i therapy, the addition of selexipag should be\nconsidered | IIa | \nN |  |  |  | In patients with IPAH/HPAH/DPAH who present at\nintermediate–high or high risk of death while receiving\nERA/PDE5i therapy, the addition of i.v./s.c. prostacyclin\nanalogues and referral for lung transplantation (LTx)\nevaluation should be considered | IIa | ",
          "rows": 14,
          "cols": 7
        },
        {
          "title": "Table on page 12",
          "page": 12,
          "content": "N |  |  |  | In patients with IPAH/HPAH/DPAH who present at\nintermediate–low risk of death while receiving ERA/\nPDE5i therapy, switching from PDE5i to riociguat may be\nconsidered | IIb | \n | Initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension\nwithout cardiopulmonary comorbidities – Recommendation Table 9 |  |  |  |  | \nR |  | Ambrisentan + tadalafil | I | Initial combination therapy with ambrisentan and tadalafil\nis recommended | I | \nN |  |  |  | Initial combination therapy with macitentan and tadalafil\nis recommended | I | \nR |  | Other ERA + PDE-5i | IIa | Initial combination therapy with other ERAs and PDE5is\nshould be considered | IIa | \nN |  |  |  | Initial combination therapy with macitentan, tadalafil, and\nselexipag is not recommended | III | \n | Sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension –\nRecommendation Table 10 |  |  |  |  | \nN |  |  |  | It is recommended to base treatment escalations on risk\nassessment and general treatment strategies (see\ntreatment algorithm) | I | \nR |  | Macitentan added to sildenafil | I | The addition of macitentan to PDE5is or oral/inhaled\nprostacyclin analogues is recommended to reduce the\nrisk of morbidity/mortality events | I | \nN |  |  |  | The addition of oral treprostinil to ERA or PDE5i/\nriociguat monotherapy is recommended to reduce the\nrisk of morbidity/mortality events | I | \nR |  | Bosentan added to sildenafil | IIb | The addition of bosentan to sildenafil is not\nrecommended to reduce the risk of morbidity/mortality\nevents | III | \nR |  | Riociguat added to bosentan | I | The addition of riociguat to bosentan should be\nconsidered to improve exercise capacity | IIa | \n | Treatment of non-vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial hypertension who present\nwith cardiopulmonary comorbiditiesb – Recommendation Table 11 |  |  |  |  | \nN |  |  |  | In patients with IPAH/HPAH/DPAH and\ncardiopulmonary comorbidities, initial monotherapy with\na PDE5i or an ERA should be considered | IIa | \nN |  |  |  | In patients with IPAH/HPAH/DPAH with\ncardiopulmonary comorbidities who present at\nintermediate or high risk of death while receiving PDE5i\nor ERA monotherapy, additional PAH medication may be\nconsidered on an individual basis | IIb | \n | Efficacy of intensive care management for pulmonary arterial hypertension – Recommendation Table 12 |  |  |  |  | \nN |  |  |  | When managing patients with right HF in the ICU, it is\nrecommended to involve physicians with expertise, treat\ncausative factors, and use supportive measures including\ninotropes and vasopressors, fluid management, and PAH\ndrugs as appropriate | I | \nN |  |  |  | Mechanical circulatory support may be an option for\nselected patients as a bridge to transplantation or to\nrecovery, and interhospital transfer should be considered\nif such resources are unavailable on site | IIa | ",
          "rows": 18,
          "cols": 7
        },
        {
          "title": "Table on page 13",
          "page": 13,
          "content": " | Lung transplantation – Recommendation Table 13 |  |  |  |  | \nR |  | Lung transplantation is recommended soon after\ninadequate clinical response on maximal medical therapy | I | It is recommended that potentially eligible candidates are\nreferred for LTx evaluation when they have an\ninadequate response to oral combination therapy,\nindicated by an intermediate–high or high risk or by a\nREVEAL risk score .7 | I | \nN |  |  |  | It is recommended to list patients for LTx who present\nwith a high risk of death or with a REVEAL risk score ≥10\ndespite receiving optimized medical therapy, including s.c.\nor i.v. prostacyclin analogues | I | \n | Pulmonary arterial hypertension associated with drugs or toxins – Recommendation Table 14 |  |  |  |  | \nN |  |  |  | It is recommended to make a diagnosis of drug- or\ntoxin-associated PAH in patients who had relevant\nexposure and in whom other causes of PH have been\nexcluded | I | \nN |  |  |  | In patients with suspected drug- or toxin-associated PAH,\nit is recommended to discontinue the causative agent\nimmediately whenever possible | I | \nN |  |  |  | Immediate PAH therapy should be considered in patients\nwho present with intermediate/high-risk PAH at\ndiagnosis | IIa | \nN |  |  |  | Patients with low-risk PAH should be re-evaluated 3–4\nmonths after discontinuing the suspected drug or toxin,\nand PAH therapy may be considered when the\nhaemodynamics have not normalized | IIb | \n | Pulmonary arterial hypertension associated with connective tissue disease – Recommendation Table 15 |  |  |  |  | \nN |  |  |  | In patients with PAH associated with CTD, treatment of\nthe underlying condition according to current guidelines\nis recommended | I | \n | Pulmonary arterial hypertension associated with human immunodeficiency virus infection – Recommendation Table 16 |  |  |  |  | \nN |  |  |  | In patients with PAH associated with HIV infection,\nantiretroviral treatment according to current guidelines is\nrecommended | I | \nN |  |  |  | In patients with PAH associated with HIV infection, initial\nmonotherapy should be considered, followed by\nsequential combination if necessary, taking into\nconsideration comorbidities and drug–drug interactions | IIa | \n | Pulmonary arterial hypertension associated with portal hypertension – Recommendation Table 17 |  |  |  |  | \nR |  | Echocardiographic assessment for signs of PH is\nrecommended in symptomatic patients with liver disease\nor portal hypertension and in all candidates for liver\ntransplantation | I | Echocardiography is recommended in patients with liver\ndisease or portal hypertension with signs or symptoms\nsuggestive of PH, and as a screening tool in patients\nevaluated for liver transplantation or transjugular\nportosystemic shunt | I | \nR |  | It is recommended that the treatment algorithm for\npatients with other forms of PAH should be applied to\npatients with PAH associated with portal hypertension,\ntaking into account the severity of liver disease | I | In patients with PAH associated with portal hypertension,\ninitial monotherapy should be considered, followed by\nsequential combination if necessary, taking into\nconsideration the underlying liver disease and indication\nfor liver transplantation | IIa | \nR |  | Liver transplantation may be considered in selected\npatients responding well to PAH therapy | IIb | Liver transplantation should be considered on an\nindividual basis in patients with PAH associated with\nportal hypertension, as long as PVR is normal or near\nnormal with PAH therapy | IIa | ",
          "rows": 17,
          "cols": 7
        },
        {
          "title": "Table on page 14",
          "page": 14,
          "content": "N |  |  |  | Drugs approved for PAH are not recommended for\npatients with portal hypertension and unclassified PH (i.e.\nelevated mPAP, high CO, and a normal PVR) | III | \n | Shunt closure in patients with pulmonary–systemic flow ratio .1.5:1 based on calculated pulmonary vascular resistance–\nRecommendation Table 18 |  |  |  |  | \nN |  |  |  | In patients with ASD, VSD, or PDA and a PVR ,3 WU,\nshunt closure is recommended | I | \nN |  |  |  | In patients with ASD, VSD, or PDA and a PVR of 3–5\nWU, shunt closure should be considered | IIa | \nN |  |  |  | In patients with ASD and a PVR .5 WU that declines to\n,5 WU with PAH treatment, shunt closure may be\nconsidered | IIb | \nN |  |  |  | In patients with VSD or PDA and a PVR .5 WU, shunt\nclosure may be considered after careful evaluation in\nspecialized centres | IIb | \nN |  |  |  | In patients with ASD and a PVR .5 WU despite PAH\ntreatment, shunt closure is not recommended | III | \n | Pulmonary arterial hypertension associated with adult congenital heart disease – Recommendation Table 19 |  |  |  |  | \nN |  |  |  | Risk assessment is recommended for patients with\npersistent PAH after defect closure | I | \nN |  |  |  | Risk assessment should be considered in patients with\nEisenmenger syndrome | IIa | \nR |  | Bosentan is recommended in WHO-FC III patients with\nEisenmenger syndrome | I | Bosentan is recommended in symptomatic patients with\nEisenmenger syndrome to improve exercise capacity | I | \nR |  | The use of supplemental iron treatment may be\nconsidered in patients with low ferritin plasma levels | IIb | Supplemental iron treatment should be considered in\npatients with iron deficiency | IIa | \nR |  | Combination drug therapy may be considered in patients\nwith Eisenmenger syndrome | IIb | In patients with PAH after corrected adult CHD, initial\noral combination therapy with drugs approved for PAH\nshould be considered for patients at low and intermediate\nrisk, while initial combination therapy including i.v./s.c.\nprostacyclin analogues should be considered for patients\nat high risk | IIa | \nR |  | Combination drug therapy may be considered in patients\nwith Eisenmenger syndrome | IIb | In patients with adult CHD, including Eisenmenger\nsyndrome, sequential combination therapy should be\nconsidered if patients do not meet treatment goals | IIa | \nN |  |  |  | In women with Eisenmenger syndrome, pregnancy is not\nrecommended | III | \nR |  | If symptoms of hyperviscosity are present, phlebotomy\nwith isovolumic replacement should be considered, usually\nwhen the haematocrit is .65% | IIa | In patients with Eisenmenger syndrome, routine\nphlebotomy to lower elevated haematocrit is not\nrecommended | III | \n | Pulmonary arterial hypertension with signs of venous/capillary involvement – Recommendation Table 20 |  |  |  |  | \nR |  | A combination of clinical findings, physical examination,\nbronchoscopy, and radiological findings is recommended\nto diagnose PVOD/PCH | I | A combination of clinical and radiological findings, ABG,\nPFTs, and genetic testing is recommended to diagnose\nPAH with signs of venous and/or capillary involvement\n(PVOD/PCH) | I | \nN |  |  |  | In patients with PVOD/PCH, the use of drugs approved\nfor PAH may be considered with careful monitoring of\nclinical symptoms and gas exchange | IIb | \nN |  |  |  | Lung biopsy is not recommended to confirm a diagnosis\nof PVOD/PCH | III | \n | Paediatric pulmonary hypertension – Recommendation Table 21 |  |  |  |  | \nN |  |  |  | It is recommended to perform the diagnostic work-up,\nincluding RHC and acute vasoreactivity testing, and treat\nchildren with PH at centres with specific expertise in\npaediatric PH | I | ",
          "rows": 22,
          "cols": 7
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "R |  | A PH diagnostic algorithm work-up is recommended for\ndiagnosis and definition of the specific aetiology group in\npaediatric PH patients | I | In children with PH, a comprehensive work-up for\nconfirming diagnosis and specific aetiology is\nrecommended (similar to that in adults, but adapted for\nage) | I | \nN |  |  |  | For confirming PH diagnosis, RHC is recommended,\npreferably before initiating any PAH therapy | I | \nN |  |  |  | In children with IPAH/HPAH, acute vasoreactivity testing\nis recommended to detect those who may benefit from\ncalcium channel blocker therapy | I | \nN |  |  |  | It is recommended to define a positive response to acute\nvasoreactivity testing in children similar to adults by a\nreduction of mPAP ≥10 mmHg to reach an absolute\nvalue of mPAP ≤40 mmHg, with an increased or\nunchanged CO | I | \nR |  | A PAH-specific therapeutic algorithm is recommended in\npaediatric PH patients | I | In children with PAH, a therapeutic strategy based on risk\nstratification and treatment response is recommended,\nextrapolated from that in adults but adapted for age | I | \nR |  | Specific paediatric determinants of risk should be\nconsidered | IIa | It is recommended to monitor the treatment response in\nchildren with PAH by serially assessing a panel of data\nderived from clinical assessment, echocardiographic\nevaluation, biochemical markers, and exercise tolerance\ntests | I | \nN |  |  |  | Achieving and maintaining a low-risk profile should be\nconsidered as an adequate treatment response for\nchildren with PAH | IIa | \nN |  |  |  | It is recommended to screen infants with\nbronchopulmonary dysplasia for PH | I | \nN |  |  |  | In infants with (or at risk of) bronchopulmonary dysplasia\nand PH, treating lung disease, including hypoxia,\naspiration, and structural airway disease, and optimizing\nrespiratory support is recommended before initiating\nPAH therapy | I | \nN |  |  |  | In neonates and infants, a diagnostic and therapeutic\napproach to PH distinct from that in older children and\nadults should be considered, given the frequent\nassociation with developmental vascular and parenchymal\nlung disease | IIa | \n | Pulmonary hypertension associated with left heart disease – Recommendation Table 22 |  |  |  |  | \nN |  |  |  | RHC is recommended for suspected PH in patients with\nLHD, if it aids management decisions | I | \nN |  |  |  | RHC is recommended in patients with severe tricuspid\nregurgitation with or without LHD prior to surgical or\ninterventional valve repair | I | \nR |  | Patients with PH-LHD and a severe pre-capillary\ncomponent as indicated by a high DPG and/or high PVR\nshould be referred to an expert PH centre for a complete\ndiagnostic work-up and an individual treatment decision | IIa | For patients with LHD and suspected PH with features of\na severe pre-capillary component and/or markers of RV\ndysfunction, referral to a PH centre for a complete\ndiagnostic work-up is recommended | I | \nN |  |  |  | In patients with LHD and CpcPH with a severe\npre-capillary component (e.g. PVR .5 WU), an\nindividualized approach to treatment is recommended | I | \nN |  |  |  | When patients with PH and multiple risk factors for LHD,\nwho have a normal PAWP at rest but an abnormal\nresponse to exercise or fluid challenge, are treated with\nPAH drugs, close monitoring is recommended | I | ",
          "rows": 16,
          "cols": 7
        },
        {
          "title": "Table on page 16",
          "page": 16,
          "content": "N |  |  |  | In patients with PH at RHC, a borderline PAWP (13–\n15 mmHg) and features of HFpEF, additional testing with\nexercise or fluid challenge may be considered to uncover\npost-capillary PH | IIb | \n | Pulmonary hypertension associated with lung disease and/or hypoxia – Recommendation Table 23 |  |  |  |  | \nR |  | Echocardiography is recommended for the non-invasive\ndiagnostic assessment of suspected PH in patients with\nlung disease | I | If PH is suspected in patients with lung disease, it is\nrecommended that echocardiographyd be performed\nand the results interpreted in conjunction with ABG,\nPFTs including DLCO, and CT imaging | I | \nR |  | Optimal treatment of the underlying lung disease, including\nlong-term O therapy in patients with chronic\n2\nhypoxaemia, is recommended in patients with PH due to\nlung diseases | I | In patients with lung disease and suspected PH, it is\nrecommended to optimize treatment of the underlying\nlung disease and, where indicated, hypoxaemia,\nsleep-disordered breathing, and/or alveolar\nhypoventilation | I | \nR |  | Referral to an expert centre is recommended in patients\nwith echocardiographic signs of severe PH and/or severe\nright ventricular dysfunction | I | In patients with lung disease and suspected severe PH, or\nwhere there is uncertainty regarding the treatment of PH,\nreferral to a PH centre is recommendede | I | \nN |  |  |  | In patients with lung disease and severe PH, an\nindividualized approach to treatment is recommended | I | \nN |  |  |  | It is recommended to refer eligible patients with lung\ndisease and PH for LTx evaluation | I | \nR |  | RHC is not recommended for suspected PH in patients\nwith lung disease, unless therapeutic consequences are to\nbe expected (e.g. LTx, alternative diagnoses such as PAH\nor CTEPH, and potential enrolment in a clinical trial) | III | In patients with lung disease and suspected PH, RHC is\nrecommended if the results are expected to aid\nmanagement decisions | I | \nN |  |  |  | Inhaled treprostinil may be considered in patients with\nPH associated with ILD | IIb | \nN |  |  |  | The use of ambrisentan is not recommended in patients\nwith PH associated with IPF | III | \nN |  |  |  | The use of riociguat is not recommended in patients with\nPH associated with IIP | III | \n | Chronic thrombo-embolic pulmonary hypertension and chronic thrombo-embolic pulmonary disease without pulmonary\nhypertension – Recommendation Table 24 |  |  |  |  | \nR |  | Lifelong anticoagulation is recommended in all patients\nwith CTEPH | I | Lifelong therapeutic doses of anticoagulation are\nrecommended in all patients with CTEPH | I | \nN |  |  |  | Antiphospholipid syndrome testing is recommended in\npatients with CTEPH | I | \nN |  |  |  | In patients with CTEPH and antiphospholipid syndrome,\nanticoagulation with VKAs is recommended | I | \nR |  | It is recommended that all patients with CTEPH receive\nassessment of operability and decisions regarding other\ntreatment strategies made by a multidisciplinary team of\nexperts | I | It is recommended that all patients with CTEPH are\nreviewed by a CTEPH team for the assessment of\nmultimodality management | I | \nR |  | Surgical PEA in deep hypothermia circulatory arrest is\nrecommended for patients with CTEPH | I | PEA is recommended as the treatment of choice for\npatients with CTEPH and fibrotic obstructions within\npulmonary arteries accessible by surgery | I | \nR |  | Interventional BPA may be considered in patients who are\ntechnically inoperable or carry an unfavourable risk:benefit\nratio for PEA | IIb | BPA is recommended in patients who are technically\ninoperable or have residual PH after PEA and distal\nobstructions amenable to BPA | I | \nR |  | Riociguat is recommended in symptomatic patients who\nhave been classified as having persistent/recurrent CTEPH\nafter surgical treatment or inoperable CTEPH by a CTEPH\nteam including at least one experienced PEA surgeon | I | Riociguat is recommended for symptomatic patients with\ninoperable CTEPH or persistent/recurrent PH after PEA | I | ",
          "rows": 19,
          "cols": 7
        },
        {
          "title": "Table on page 17",
          "page": 17,
          "content": "N |  |  |  | Long-term follow-up is recommended after PEA and\nBPA, as well as for patients with CTEPH established on\nmedical therapy | I | \nN |  |  |  | A multimodality approach should be considered for\npatients with persistent PH after PEA and for patients\nwith inoperable CTEPH | IIa | \nN |  |  |  | In patients with CTEPD without PH, long-term\nanticoagulant therapy should be considered on an\nindividual basisf | IIa | \nN |  |  |  | PEA or BPA should be considered in selected\nsymptomatic patients with CTEPD without PH | IIa | \nN |  |  |  | Treprostinil s.c. may be considered in patients in\nWHO-FC III–IV who have inoperable CTEPH or\npersistent/recurrent PH after PEA | IIb | \nR |  | Off-label use of drugs approved for PAH may be\nconsidered in symptomatic patients who have been\nclassified as having inoperable CTEPH by a CTEPH team\nincluding at least one experienced PEA surgeon | IIb | Off-label use of drugs approved for PAH may be\nconsidered in symptomatic patients who have inoperable\nCTEPH | IIb | \nN |  |  |  | In patients with inoperable CTEPH, a combination of\nsGC stimulator/PDE5i, ERA, or parenteral prostacyclin\nanalogues may be considered | IIb | \nN |  |  |  | BPA may be considered for technically operable patients\nwith a high proportion of distal disease and an\nunfavourable risk:benefit ratio for PEA | IIb | \n | Pulmonary hypertension centres – Recommendation Table 25 |  |  |  |  | \nN |  |  |  | It is recommended that PH centres maintain a patient\nregistry | I | \nN |  |  |  | It is recommended that PH centres collaborate with\npatient associations | I | \nN |  |  |  | Accreditation of the PH centres should be considered\n(e.g. https://ec.europa.eu/health/ern/assessment en)\n_ | IIa | \nR |  | It should be considered that a referral centre follow at\nleast 50 patients with PAH or CTEPH and should receive\nat least two new referrals per month with documented\nPAH or CTEPH | IIa | PH centres should follow-up a sufficient number of\npatients to maintain expertise (at least 50 patients with\nPAH or CTEPH and at least two new referrals per month\nwith documented PAH or CTEPH) and consider\nestablishing collaborations with high-volume centres | IIa | ",
          "rows": 13,
          "cols": 7
        },
        {
          "title": "Table on page 18",
          "page": 18,
          "content": "GRADE |  |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nIn patients with IPAH/HPAH/DPAH who present at low or intermediate risk of\ndeath, initial combination therapy with a PDE5i and an ERA is recommended | Low | Conditional | I | B\nThe use of PDE5i in patients with HFpEF and isolated post-capillary PH is not\nrecommended | Low | Conditional | III | C\nPDE5i may be considered in patients with severe PH associated with ILD (individual\ndecision-making in PH centres) | Very low | Conditional | IIb | C\nThe use of PDE5i in patients with ILD and non-severe PH is not recommended | Very low | Conditional | III | C\nIn patients with CTEPH who are candidates for BPA, medical therapy should be\nconsidered prior to the intervention | Very low | Conditional | IIa | B",
          "rows": 7,
          "cols": 5
        },
        {
          "title": "Table on page 18",
          "page": 18,
          "content": "Recommendation\nstrength | Rationale\nStrong recommendation\nfor | The panel is certain that the desirable\noutweigh the undesirable effects\nConditional\nrecommendation for | The panel is less confident that the\ndesirable outweigh the undesirable\neffects\nConditional\nrecommendation against | The panel is less confident that the\nundesirable outweigh the desirable\neffects\nStrong recommendation\nagainst | The panel is certain that the undesirable\noutweigh the desirable effects\nNo recommendation | The confidence in the results might be\nvery low to make a recommendation, or\nthe trade-offs between desirable and\nundesirable effects are finely balanced, or\nno data are available.",
          "rows": 6,
          "cols": 2
        },
        {
          "title": "Table on page 18",
          "page": 18,
          "content": "Quality | Definition\nHigh | We are very confident that the true effect lies close to that\nof the estimate of the effect\nModerate | We are moderately confident in the effect estimate: the\ntrue effect is likely to be close to the estimate of the effect,\nbut there is a possibility that it is substantially different\nLow | Our confidence in the effect estimate is limited: the true\neffect may be substantially different from the estimate of\nthe effect\nVery low | We have very little confidence in the effect estimate: the\ntrue effect is likely to be substantially different from the\nestimate of effect",
          "rows": 5,
          "cols": 2
        },
        {
          "title": "Table on page 19",
          "page": 19,
          "content": "Class II | Conflicting evidence and/or a divergence of opinion about the usefulness/\nefficacy of the given treatment or procedure. |  |  | \n |  |  |  | \nClass IIa |  | Weight of evidence/opinion is in\nfavour of usefulness/efficacy. | Should be considered | \n |  |  |  | \nClass IIb |  | Usefulness/efficacy is less well\nestablished by evidence/opinion. | May be considered | ",
          "rows": 5,
          "cols": 5
        }
      ],
      "keywords": [
        "introduction",
        "ct",
        "pulmonary hypertension",
        "treatment",
        "indication",
        "diagnosis",
        "recommendation"
      ]
    },
    {
      "number": "5",
      "title": "3. Definitions and classifications",
      "start_page": 19,
      "end_page": 21,
      "content": "the recommendation provided and the quality of evidence sup-\nporting the recommendation. The Task Force discussed each\ndraft recommendation during web-based conference calls dedi-\ncated to speciﬁc sections, followed by consensus modiﬁcations\nand an online vote on each recommendation. Only recommen-\ndations that were supported by at least 75% of the Task Force\nmembers were included in the guidelines. The recommendation\ntables were colour-coded for ease of interpretation.\n3. Deﬁnitions and classiﬁcations\n3.1. Deﬁnitions\nThe deﬁnitions for PH are based on haemodynamic assessment by\nright heart catheterization (RHC). Although haemodynamics re-\npresent the central element of characterizing PH, the ﬁnal diagnosis\nand classiﬁcation should reﬂect the whole clinical context and con-\nsider the results of all investigations.\nTable 3\nClasses of recommendations\n©ESC/ERS 2022\nClasses of recommendations\nClass I \nEvidence and/or general agreement\nthat a given treatment or procedure is\nbeneficial, useful, effective.\nefficacy of the given treatment or procedure.\nfavour of usefulness/efficacy.\nUsefulness/efficacy is less well\nuseful/effective, and in some cases\nConﬂicting evidence and/or a divergence of opinion about the usefulness/ \n \nIs recommended or is indicated\nWording to use\nDeﬁnition\nClass III \nEvidence or general agreement that the\ngiven treatment or procedure is not\nmay be harmful. \nIs not recommended\n     Class IIb\nestablished by evidence/opinion.\nMay be considered\n \n   Class IIa\nWeight of evidence/opinion is in\nShould be considered\nClass II \n© ESC/ERS 2022\nTable 4\nLevels of evidence\nLevel of\nevidence A\nLevel of\nevidence B\nLevel of\nevidence C\nData derived from multiple randomized clinical trials\nor meta-analyses.\nData derived from a single randomized clinical trial\nor large non-randomized studies.\nConsensus of opinion of the experts and/or small studies,\nretrospective studies, registries.\n©ESC/ERS 2022\n© ESC/ERS 2022\n3636\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nPulmonary hypertension is deﬁned by a mean pulmonary arterial\npressure (mPAP) .20 mmHg at rest (Table 5). This is supported\nby studies assessing the upper limit of normal pulmonary arterial\npressure (PAP) in healthy subjects,7–9 and by studies investigating\nthe prognostic relevance of increased PAP (key narrative question\n1, Supplementary Data, Section 3.1).10–12\nIt is essential to include PVR and pulmonary arterial wedge pres-\nsure (PAWP) in the deﬁnition of pre-capillary PH, in order to dis-\ncriminate elevated PAP due to pulmonary vascular disease (PVD)\nfrom that due to left heart disease (LHD), elevated pulmonary blood\nﬂow, or increased intrathoracic pressure (Table 5). Based on the\navailable data, the upper limit of normal PVR and the lowest prognos-\ntically relevant threshold of PVR is ≏2 Wood units (WU).7,8,13,14\nPulmonary vascular resistance depends on body surface area and\nage, with elderly healthy subjects having higher values. The available\ndata on the best threshold for PAWP discriminating pre- and post-\ncapillary PH are contradictory. Although the upper limit of normal\nPAWP is considered to be 12 mmHg,15 previous ESC/ERS\nGuidelines for the diagnosis and treatment of PH, as well as the re-\ncent consensus recommendation of the ESC Heart Failure\nAssociation,16 suggest a higher threshold for the invasive diagnosis\nof heart failure (HF) with preserved ejection fraction (HFpEF)\n(PAWP ≥15 mmHg). In addition, almost all therapeutic studies of\nPAH have used the PAWP ≤15 mmHg threshold. Therefore, it is re-\ncommended keeping PAWP ≤15 mmHg as the threshold for pre-\ncapillary PH, while acknowledging that any PAWP threshold is arbi-\ntrary and that the patient phenotype, risk factors, and echocardio-\ngraphic ﬁndings, including left atrial (LA) volume, need to be\nconsidered when distinguishing pre- from post-capillary PH.\nPatients with PAH are haemodynamically characterized by pre-\ncapillary PH in the absence of other causes of pre-capillary PH,\nsuch as CTEPH and PH associated with lung diseases. All PH groups\nmay comprise both pre- and post-capillary components contributing\nto PAP elevation. In particular, older patients may present with sev-\neral conditions predisposing them to PH. The primary classiﬁcation\nshould be based on the presumed predominant cause of the pulmon-\nary pressure increase.\nPost-capillary\nPH\nis\nhaemodynamically\ndeﬁned\nas\nmPAP\n.20 mmHg and PAWP .15 mmHg. Pulmonary vascular resistance\nis used to differentiate between patients with post-capillary PH who\nhave a signiﬁcant pre-capillary component (PVR .2 WU—com-\nbined post- and pre-capillary PH [CpcPH]) and those who do not\n(PVR ≤2 WU—isolated post-capillary PH [IpcPH]).\nThere are patients with elevated mPAP (.20 mmHg) but low\nPVR (≤2 WU) and low PAWP (≤15 mmHg). These patients are fre-\nquently characterized by elevated pulmonary blood ﬂow and, al-\nthough they have PH, they do not fulﬁl the criteria of pre- or\npost-capillary PH. This haemodynamic condition may be described\nby the term ‘unclassiﬁed PH’. Patients with unclassiﬁed PH may pre-\nsent with congenital heart disease (CHD), liver disease, airway dis-\nease, lung disease, or hyperthyroidism explaining their mPAP\nelevation. Clinical follow-up of these patients is generally recom-\nmended. In the case of elevated pulmonary blood ﬂow, its aetiology\nshould be explored.\nAs the groups of PH according to clinical classiﬁcation represent\ndifferent clinical conditions, there may be additional clinically relevant\nhaemodynamic thresholds (e.g. for PVR) for the individual PH groups\nbesides the general thresholds of the haemodynamic deﬁnition of\nPH, which are discussed in the corresponding sections.\nExercise PH, deﬁned by an mPAP/cardiac output (CO) slope\n.3 mmHg/L/min between rest and exercise,17 has been re-\nintroduced. The mPAP/CO slope is strongly age dependent and its\nupper limit of normal ranges from 1.6–3.3 mmHg/L/min in the supine\nposition.17 An mPAP/CO slope .3 mmHg/L/min is not physiological\nin subjects aged ,60 years and may rarely be present in healthy sub-\njects aged .60 years.17 A pathological increase in pulmonary pres-\nsure during exercise is associated with impaired prognosis in\npatients with exercise dyspnoea18 and in several cardiovascular con-\nditions.19–22 Although an increased mPAP/CO slope deﬁnes an ab-\nnormal haemodynamic response to exercise, it does not allow for\ndifferentiation between pre- and post-capillary causes. The PAWP/\nCO slope with a threshold .2 mmHg/L/min may best differentiate\nbetween pre- and post-capillary causes of exercise PH.23,24\n3.2. Classiﬁcations\nThe basic structure of the classiﬁcation from the 2015 ESC/ERS\nGuidelines for the diagnosis and treatment of PH25,26 and the\nProceedings of the 6th WSPH1 has been kept (Table 6). The general\npurpose of the clinical classiﬁcation of PH remains to categorize clin-\nical conditions associated with PH, based on similar pathophysio-\nlogical\nmechanisms,\nclinical\npresentation,\nhaemodynamic\ncharacteristics, and therapeutic management (Figure 1). The main\nchanges are as follows:\n(i) The subgroups ‘non-responders at vasoreactivity testing’ and\n‘acute responders at vasoreactivity testing’ have been added\nto IPAH as compared with the 2015 ESC/ERS Guidelines for\nthe diagnosis and treatment of PH.25,26 In addition to patients\nwith IPAH, some patients with heritable PAH (HPAH) or\nTable 5\nHaemodynamic deﬁnitions of pulmonary\nhypertension\nDeﬁnition\nHaemodynamic characteristics\nPH\nmPAP .20 mmHg\nPre-capillary PH\nmPAP .20 mmHg\nPAWP ≤15 mmHg\nPVR .2 WU\nIpcPH\nmPAP .20 mmHg\nPAWP .15 mmHg\nPVR ≤2 WU\nCpcPH\nmPAP .20 mmHg\nPAWP .15 mmHg\nPVR .2 WU\nExercise PH\nmPAP/CO slope between rest and exercise\n.3 mmHg/L/min\n© ESC/ERS 2022\nCO, cardiac output; CpcPH, combined post- and pre-capillary pulmonary hypertension;\nIpcPH, isolated post-capillary pulmonary hypertension; mPAP, mean pulmonary arterial\npressure; PAWP, pulmonary arterial wedge pressure; PH, pulmonary hypertension;\nPVR, pulmonary vascular resistance; WU, Wood units.\nSome patients present with elevated mPAP (.20 mmHg) but low PVR (≤2 WU) and\nlow PAWP (≤15 mmHg); this haemodynamic condition may be described by the term\n‘unclassiﬁed PH’ (see text for further details).\nESC/ERS Guidelines\n3637\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\ndrug- or toxin-associated PAH (DPAH) might be acute\nresponders.\n(ii) The groups ‘PAH with features of venous/capillary (pulmonary\nveno-occlusive disease/pulmonary capillary haemangiomatosis\n[PVOD/PCH]) involvement’ and ‘persistent PH of the new-\nborn (PPHN)’ have been included in group 1 (PAH) as com-\npared with the 2015 ESC/ERS Guidelines for the diagnosis\nand treatment of PH and in line with the Proceedings of the\n6th WSPH.1\n(iii) Instead of the general term ‘sleep-disordered breathing’, the\nterm ‘hypoventilation syndromes’ should be used within group\n3 to describe conditions with increased risk of PH. Sole noctur-\nnal obstructive sleep apnoea is generally not a cause of PH, but\nPH is frequent in patients with hypoventilation syndromes caus-\ning daytime hypercapnia.\n4. Epidemiology and risk factors\nPulmonary hypertension is a major global health issue. All age groups\nare affected. Present estimates suggest a PH prevalence of ≏1% of\nthe global population. Due to the presence of cardiac and pulmonary\ncauses of PH, prevalence is higher in individuals aged .65 years.29\nGlobally, LHD is the leading cause of PH.29 Lung disease, especially\nchronic obstructive pulmonary disease (COPD), is the second\nmost common cause.29 In the UK, the observed PH prevalence\nhas doubled in the last 10 years and is currently 125 cases/million in-\nhabitants.30 Irrespective of the underlying condition, developing PH\nis associated with worsening symptoms and increased mortality.29\nIn developing countries, CHD, some infectious diseases (schistosom-\niasis, human immunodeﬁciency virus [HIV]), and high altitude re-\npresent important but under-studied causes of PH.29\n4.1. Group 1, pulmonary arterial\nhypertension\nRecent registry data from economically developed countries indicate\na PAH incidence and prevalence of ≏6 and 48–55 cases/million\nadults, respectively.31 It has been thought to predominantly affect\nyounger individuals, mostly females;32,33 this is currently true for\nHPAH, which affects twice as many females as males. However, re-\ncent data from the USA and Europe suggest that PAH is now fre-\nquently diagnosed in older patients (i.e. those aged ≥65 years,\nwho often present with cardiovascular comorbidities, resulting in a\nmore equal distribution between sexes).32 In most PAH registries,\nIPAH was the most common subtype (50–60% of all cases), followed\nby PAH associated with connective tissue disease (CTD), CHD, and\nportal hypertension (porto-pulmonary hypertension [PoPH]).32\nA number of drugs and toxins are associated with the develop-\nment of PAH.1,34–45 The association between exposure to drugs\nand toxins and PAH is classiﬁed as deﬁnite or possible, as proposed\nat the 6th WSPH (Table 7).1 There is a deﬁnite association with\ndrugs, with available data based on outbreaks, epidemiological case-\ncontrol studies, or large multicentre series. A possible association is\nsuggested by multiple case series or cases with drugs with similar me-\nchanisms of action.1\nTable\n6\nClinical\nclassiﬁcation\nof\npulmonary\nhypertension\nGROUP 1 Pulmonary arterial hypertension (PAH)\n1.1 Idiopathic\n1.1.1 Non-responders at vasoreactivity testing\n1.1.2 Acute responders at vasoreactivity testing\n1.2 Heritablea\n1.3 Associated with drugs and toxinsa\n1.4 Associated with:\n1.4.1 Connective tissue disease\n1.4.2 HIV infection\n1.4.3 Portal hypertension\n1.4.4 Congenital heart disease\n1.4.5 Schistosomiasis\n1.5 PAH with features of venous/capillary (PVOD/PCH) involvement\n1.6 Persistent PH of the newborn\nGROUP 2 PH associated with left heart disease\n2.1 Heart failure:\n2.1.1 with preserved ejection fraction\n2.1.2 with reduced or mildly reduced ejection fractionb\n2.2 Valvular heart disease\n2.3 Congenital/acquired cardiovascular conditions leading to\npost-capillary PH\nGROUP 3 PH associated with lung diseases and/or hypoxia\n3.1 Obstructive lung disease or emphysema\n3.2 Restrictive lung disease\n3.3 Lung disease with mixed restrictive/obstructive pattern\n3.4 Hypoventilation syndromes\n3.5 Hypoxia without lung disease (e.g. high altitude)\n3.6 Developmental lung disorders\nGROUP 4 PH associated with pulmonary artery obstructions\n4.1 Chronic thrombo-embolic PH\n4.2 Other pulmonary artery obstructionsc\nGROUP 5 PH with unclear and/or multifactorial mechanisms\n5.1 Haematological disordersd\n5.2 Systemic disorderse\n5.3 Metabolic disordersf\n5.4 Chronic renal failure with or without haemodialysis\n5.5 Pulmonary tumour thrombotic microangiopathy\n5.6 Fibrosing mediastinitis\n© ESC/ERS 2022\nHF, heart failure; HIV, human immunodeﬁciency virus; PAH, pulmonary arterial\nhypertension;\nPCH,\npulmonary\ncapillary\nhaemangiomatosis;\nPH,\npulmonary\nhypertension; PVOD, pulmonary veno-occlusive disease.\naPatients with heritable PAH or PAH associated with drugs and toxins might be acute\nresponders.\nbLeft ventricular ejection fraction for HF with reduced ejection fraction: ≤40%; for HF\nwith mildly reduced ejection fraction: 41–49%.\ncOther causes of pulmonary artery obstructions include: sarcomas (high or\nintermediate grade or angiosarcoma), other malignant tumours (e.g. renal carcinoma,\nuterine carcinoma, germ-cell tumours of the testis), non-malignant tumours (e.g.\nuterine leiomyoma), arteritis without connective tissue disease, congenital pulmonary\narterial stenoses, and hydatidosis.\ndIncluding\ninherited\nand\nacquired\nchronic\nhaemolytic\nanaemia\nand\nchronic\nmyeloproliferative disorders.\neIncluding sarcoidosis, pulmonary Langerhans’s cell histiocytosis, and neuroﬁbromatosis\ntype 1.\nfIncluding glycogen storage diseases and Gaucher disease.\n3638\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 19",
          "page": 19,
          "content": "Class II | Conflicting evidence and/or a divergence of opinion about the usefulness/\nefficacy of the given treatment or procedure. |  |  | \n |  |  |  | \nClass IIa |  | Weight of evidence/opinion is in\nfavour of usefulness/efficacy. | Should be considered | \n |  |  |  | \nClass IIb |  | Usefulness/efficacy is less well\nestablished by evidence/opinion. | May be considered | ",
          "rows": 5,
          "cols": 5
        },
        {
          "title": "Table on page 20",
          "page": 20,
          "content": "Definition | Haemodynamic characteristics\nPH | mPAP .20 mmHg\nPre-capillary PH | mPAP .20 mmHg\nPAWP ≤15 mmHg\nPVR .2 WU\nIpcPH | mPAP .20 mmHg\nPAWP .15 mmHg\nPVR ≤2 WU\nCpcPH | mPAP .20 mmHg\nPAWP .15 mmHg\nPVR .2 WU\nExercise PH | mPAP/CO slope between rest and exercise\n.3 mmHg/L/min",
          "rows": 6,
          "cols": 2
        }
      ],
      "keywords": [
        "ct",
        "class iii",
        "definitions",
        "class ii",
        "catheterization",
        "class i",
        "classifications",
        "pulmonary hypertension",
        "treatment",
        "diagnosis",
        "recommendation"
      ]
    },
    {
      "number": "6",
      "title": "4. Epidemiology and risk factors",
      "start_page": 21,
      "end_page": 23,
      "content": "drug- or toxin-associated PAH (DPAH) might be acute\nresponders.\n(ii) The groups ‘PAH with features of venous/capillary (pulmonary\nveno-occlusive disease/pulmonary capillary haemangiomatosis\n[PVOD/PCH]) involvement’ and ‘persistent PH of the new-\nborn (PPHN)’ have been included in group 1 (PAH) as com-\npared with the 2015 ESC/ERS Guidelines for the diagnosis\nand treatment of PH and in line with the Proceedings of the\n6th WSPH.1\n(iii) Instead of the general term ‘sleep-disordered breathing’, the\nterm ‘hypoventilation syndromes’ should be used within group\n3 to describe conditions with increased risk of PH. Sole noctur-\nnal obstructive sleep apnoea is generally not a cause of PH, but\nPH is frequent in patients with hypoventilation syndromes caus-\ning daytime hypercapnia.\n4. Epidemiology and risk factors\nPulmonary hypertension is a major global health issue. All age groups\nare affected. Present estimates suggest a PH prevalence of ≏1% of\nthe global population. Due to the presence of cardiac and pulmonary\ncauses of PH, prevalence is higher in individuals aged .65 years.29\nGlobally, LHD is the leading cause of PH.29 Lung disease, especially\nchronic obstructive pulmonary disease (COPD), is the second\nmost common cause.29 In the UK, the observed PH prevalence\nhas doubled in the last 10 years and is currently 125 cases/million in-\nhabitants.30 Irrespective of the underlying condition, developing PH\nis associated with worsening symptoms and increased mortality.29\nIn developing countries, CHD, some infectious diseases (schistosom-\niasis, human immunodeﬁciency virus [HIV]), and high altitude re-\npresent important but under-studied causes of PH.29\n4.1. Group 1, pulmonary arterial\nhypertension\nRecent registry data from economically developed countries indicate\na PAH incidence and prevalence of ≏6 and 48–55 cases/million\nadults, respectively.31 It has been thought to predominantly affect\nyounger individuals, mostly females;32,33 this is currently true for\nHPAH, which affects twice as many females as males. However, re-\ncent data from the USA and Europe suggest that PAH is now fre-\nquently diagnosed in older patients (i.e. those aged ≥65 years,\nwho often present with cardiovascular comorbidities, resulting in a\nmore equal distribution between sexes).32 In most PAH registries,\nIPAH was the most common subtype (50–60% of all cases), followed\nby PAH associated with connective tissue disease (CTD), CHD, and\nportal hypertension (porto-pulmonary hypertension [PoPH]).32\nA number of drugs and toxins are associated with the develop-\nment of PAH.1,34–45 The association between exposure to drugs\nand toxins and PAH is classiﬁed as deﬁnite or possible, as proposed\nat the 6th WSPH (Table 7).1 There is a deﬁnite association with\ndrugs, with available data based on outbreaks, epidemiological case-\ncontrol studies, or large multicentre series. A possible association is\nsuggested by multiple case series or cases with drugs with similar me-\nchanisms of action.1\nTable\n6\nClinical\nclassiﬁcation\nof\npulmonary\nhypertension\nGROUP 1 Pulmonary arterial hypertension (PAH)\n1.1 Idiopathic\n1.1.1 Non-responders at vasoreactivity testing\n1.1.2 Acute responders at vasoreactivity testing\n1.2 Heritablea\n1.3 Associated with drugs and toxinsa\n1.4 Associated with:\n1.4.1 Connective tissue disease\n1.4.2 HIV infection\n1.4.3 Portal hypertension\n1.4.4 Congenital heart disease\n1.4.5 Schistosomiasis\n1.5 PAH with features of venous/capillary (PVOD/PCH) involvement\n1.6 Persistent PH of the newborn\nGROUP 2 PH associated with left heart disease\n2.1 Heart failure:\n2.1.1 with preserved ejection fraction\n2.1.2 with reduced or mildly reduced ejection fractionb\n2.2 Valvular heart disease\n2.3 Congenital/acquired cardiovascular conditions leading to\npost-capillary PH\nGROUP 3 PH associated with lung diseases and/or hypoxia\n3.1 Obstructive lung disease or emphysema\n3.2 Restrictive lung disease\n3.3 Lung disease with mixed restrictive/obstructive pattern\n3.4 Hypoventilation syndromes\n3.5 Hypoxia without lung disease (e.g. high altitude)\n3.6 Developmental lung disorders\nGROUP 4 PH associated with pulmonary artery obstructions\n4.1 Chronic thrombo-embolic PH\n4.2 Other pulmonary artery obstructionsc\nGROUP 5 PH with unclear and/or multifactorial mechanisms\n5.1 Haematological disordersd\n5.2 Systemic disorderse\n5.3 Metabolic disordersf\n5.4 Chronic renal failure with or without haemodialysis\n5.5 Pulmonary tumour thrombotic microangiopathy\n5.6 Fibrosing mediastinitis\n© ESC/ERS 2022\nHF, heart failure; HIV, human immunodeﬁciency virus; PAH, pulmonary arterial\nhypertension;\nPCH,\npulmonary\ncapillary\nhaemangiomatosis;\nPH,\npulmonary\nhypertension; PVOD, pulmonary veno-occlusive disease.\naPatients with heritable PAH or PAH associated with drugs and toxins might be acute\nresponders.\nbLeft ventricular ejection fraction for HF with reduced ejection fraction: ≤40%; for HF\nwith mildly reduced ejection fraction: 41–49%.\ncOther causes of pulmonary artery obstructions include: sarcomas (high or\nintermediate grade or angiosarcoma), other malignant tumours (e.g. renal carcinoma,\nuterine carcinoma, germ-cell tumours of the testis), non-malignant tumours (e.g.\nuterine leiomyoma), arteritis without connective tissue disease, congenital pulmonary\narterial stenoses, and hydatidosis.\ndIncluding\ninherited\nand\nacquired\nchronic\nhaemolytic\nanaemia\nand\nchronic\nmyeloproliferative disorders.\neIncluding sarcoidosis, pulmonary Langerhans’s cell histiocytosis, and neuroﬁbromatosis\ntype 1.\nfIncluding glycogen storage diseases and Gaucher disease.\n3638\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n1%\n1%\nGlobal\npopulation\nRare\nPulmonary arterial\nhypertension (PAH)\nPH associated with\nleft heart disease\nPH associated with\nlung disease\nPH associated with\npulmonary\nartery obstructions\nPH with unclear\nand/or multifactorial\nmechanisms\nVery common\nCommon\nRare\nRare\nMedical therapy \nIdiopathic/heritable\nAssociated \nconditions\nCpcPH\nIpcPH\nNon-severe PH\nSevere PH\nCTEPH\nOther pulmonary \nobstructions\nHaematological\ndisorders\nSystemic disorders\nPAH drugs\nCCB in \nresponders\nPotentially: PAH\ndrugs (trials)\nLung\ntransplantation \nIpcPH:\nTreatment of LHDa\nCpcPH:\nTreatment of LHDa\nPH-lung disease:\nOptimized care of\nunderlying lung \ndisease\nSevere PH:\nPotentially: PAH \ndrugs (trials)\nSurgical therapy:\nPEA\nInterventional:\nBPA\nMedical therapy:\nPH drugs\nOptimized\ntreatment of\nunderlying disease\nPulmonary congestion in\npost-capillary PH\nPulmonary vascular disease /\nobstruction in pre-capillary PH\nMortality Hazard Ratio\nmPAP (mmHg)\nMortality Hazard Ratio\nPVR (Wood units)\nRight heart\nfailure\nPrevalence\nPotentially: PAH\ndrugs (trials)\n6\n5\n4\n3\n1\n2\n10\n20\n30\n40\n50\n60\n5\n4\n3\n1\n2\n0\n2\n3\n4\n5\n6\n0\n1\nCLINICAL CLASSIFICATION\nPULMONARY HYPERTENSION\nPREVALENCE\nTHERAPEUTIC STRATEGIES\nFigure 1 Central illustration. BPA, balloon pulmonary angioplasty; CCB, calcium channel blocker; CTEPH, chronic thrombo-embolic pulmonary hyper-\ntension; CpCPH, combined post- and pre-capillary pulmonary hypertension; IpcPH, isolated post-capillary pulmonary hypertension; LHD, left heart dis-\nease; PAH, pulmonary arterial hypertension; PEA, pulmonary endarterectomy; PH, pulmonary hypertension. aTreatment of heart failure according to the\nESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.27 Treatment of left-sided valvular heart disease according to the 2021\nESC/EACTS Guidelines for the management of valvular heart disease.28\nESC/ERS Guidelines\n3639\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n4.2. Group 2, pulmonary hypertension\nassociated with left heart disease\nIn 2013, the Global Burden of Disease Study reported 61.7 million\ncases of HF worldwide, which represented almost a doubling since\n1990.46 In Europe and the USA, .80% of patients with HF are\naged ≥65 years. Post-capillary PH, either isolated or combined\nwith a pre-capillary component, is a frequent complication mainly\nin HFpEF, affecting at least 50% of these patients.47,48 The prevalence\nof PH increases with severity of left-sided valvular diseases, and PH\ncan be found in 60–70% of patients with severe and symptomatic mi-\ntral valve disease49 and in up to 50% of those with symptomatic aor-\ntic stenosis.50\n4.3. Group 3, pulmonary hypertension\nassociated with lung diseases and/or\nhypoxia\nMild PH is common in advanced parenchymal and interstitial lung dis-\nease. Studies have reported that ≏1–5% of patients with advanced\nCOPD with chronic respiratory failure or candidates for lung volume\nreduction surgery or lung transplantation (LTx) have an mPAP .35–\n40 mmHg.51,52\nIn\nidiopathic\npulmonary\nﬁbrosis,\nan\nmPAP\n≥25 mmHg has been reported in 8–15% of patients upon initial\nwork-up, with greater prevalence in advanced (30–50%) and end-\nstage (.60%) disease.52 Hypoxia is a public health problem for the\nestimated 120 million people living at altitudes .2500 m. Altitude\ndwellers are at risk of developing PH and chronic mountain sickness.\nHowever, it remains unclear to what extent PH and right HF are\npublic health problems in high-altitude communities; this should be\naddressed with updated methodology and large-scale population\nstudies.53\n4.4. Group 4, pulmonary hypertension\nassociated with chronic pulmonary\nartery obstruction\nThe number of patients diagnosed with CTEPH is increasing, probably\ndue to a deeper understanding of the disease and more active screening\nfor this condition in patients who remain dyspnoeic after pulmonary\nembolism (PE) or who have risk factors for developing CTEPH.\nRegistry data indicate a CTEPH incidence and prevalence of 2–6 and\n26–38 cases/million adults, respectively.31,54,55 Patients with chronic\nthrombo-embolic pulmonary disease (CTEPD) without PH still re-\npresent a small proportion of the patients referred to CTEPH centres.56\n4.5. Group 5, pulmonary hypertension\nwith unclear and/or multifactorial\nmechanisms\nGroup 5 PH consists of a complex group of disorders that are asso-\nciated with PH.57 The cause is often multifactorial and can be secondary\nto increased pre- and post-capillary pressure, as well as direct effects on\npulmonary vasculature. The incidence and prevalence of PH in most of\nthese disorders are unknown. However, high-quality registries have re-\ncently enabled estimation of PH prevalence in adult patients with sar-\ncoidosis.58,59 Studies suggest that PH can be common and its presence\nis often associated with increased morbidity and mortality.58,59\n5. Pulmonary hypertension\ndiagnosis\n5.1. Diagnosis\nThe diagnostic approach to PH is mainly focused on two tasks. The\nprimary goal is to raise early suspicion of PH and ensure fast-track\nreferral to PH centres in patients with a high likelihood of PAH,\nCTEPH, or other forms of severe PH. The second objective is to\nidentify underlying diseases, especially LHD (group 2 PH) and lung\ndisease (group 3 PH), as well as comorbidities, to ensure proper clas-\nsiﬁcation, risk assessment, and treatment.\n5.1.1. Clinical presentation\nSymptoms of PH are mainly linked to right ventricle (RV) dysfunc-\ntion, and typically associated with exercise in the earlier course of\nthe disease.25,26 The cardinal symptom is dyspnoea on progressively\nminor exertion. Other common symptoms are related to the stages\nand severity of the disease, and are listed in Figure 2.60–62 Potential\nclinical signs and physical ﬁndings are summarized in Figure 3.60,61\nImportantly, the physical examination may also be the key to identi-\nfying the underlying cause of PH (see Figure 3).\n5.1.2. Electrocardiogram\nElectrocardiogram (ECG) abnormalities (Table 8) may raise suspicion\nof PH, deliver prognostic information, and detect arrhythmias and\nsigns of LHD. In adults with clinical suspicion of PH (e.g. unexplained\ndyspnoea on exertion), right axis deviation has a high predictive value\nfor PH.63 A normal ECG does not exclude the presence of PH, but a\nnormal ECG in combination with normal biomarkers (BNP/\nNT-proBNP) is associated with a low likelihood of PH in patients re-\nferred for suspected PH or at risk of PH (i.e. after acute PE).64,65\nTable 7\nDrugs and toxins associated with pulmonary\narterial hypertension\nDeﬁnite\nassociation\nPossible association\nAminorex\nBenﬂuorex\nDasatinib\nDexfenﬂuramine\nFenﬂuramine\nMethamphetamines\nToxic rapeseed oil\nAlkylating agents (cyclophosphamide,\nmitomycin C)a\nAmphetamines\nBosutinib\nCocaine\nDiazoxide\nDirect-acting antiviral agents against hepatitis\nC virus (sofosbuvir)\nIndirubin (Chinese herb Qing-Dai)\nInterferon alpha and beta\nLeﬂunomide\nL-tryptophan\nPhenylpropanolamine\nPonatinib\nSelective proteasome inhibitors (carﬁlzomib)\nSolvents (trichloroethylene)a\nSt John’s Wort\n© ESC/ERS 2022\naPulmonary veno-occlusive disease.\n3640\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 23",
          "page": 23,
          "content": "Definite\nassociation | Possible association\nAminorex\nBenfluorex\nDasatinib\nDexfenfluramine\nFenfluramine\nMethamphetamines\nToxic rapeseed oil | Alkylating agents (cyclophosphamide,\nmitomycin C)a\nAmphetamines\nBosutinib\nCocaine\nDiazoxide\nDirect-acting antiviral agents against hepatitis\nC virus (sofosbuvir)\nIndirubin (Chinese herb Qing-Dai)\nInterferon alpha and beta\nLeflunomide\nL-tryptophan\nPhenylpropanolamine\nPonatinib\nSelective proteasome inhibitors (carfilzomib)\nSolvents (trichloroethylene)a\nSt John’s Wort",
          "rows": 2,
          "cols": 2
        }
      ],
      "keywords": [
        "ct",
        "factors",
        "epidemiology",
        "risk",
        "pulmonary hypertension",
        "treatment",
        "diagnosis"
      ]
    },
    {
      "number": "7",
      "title": "5. Pulmonary hypertension diagnosis",
      "start_page": 23,
      "end_page": 37,
      "content": "4.2. Group 2, pulmonary hypertension\nassociated with left heart disease\nIn 2013, the Global Burden of Disease Study reported 61.7 million\ncases of HF worldwide, which represented almost a doubling since\n1990.46 In Europe and the USA, .80% of patients with HF are\naged ≥65 years. Post-capillary PH, either isolated or combined\nwith a pre-capillary component, is a frequent complication mainly\nin HFpEF, affecting at least 50% of these patients.47,48 The prevalence\nof PH increases with severity of left-sided valvular diseases, and PH\ncan be found in 60–70% of patients with severe and symptomatic mi-\ntral valve disease49 and in up to 50% of those with symptomatic aor-\ntic stenosis.50\n4.3. Group 3, pulmonary hypertension\nassociated with lung diseases and/or\nhypoxia\nMild PH is common in advanced parenchymal and interstitial lung dis-\nease. Studies have reported that ≏1–5% of patients with advanced\nCOPD with chronic respiratory failure or candidates for lung volume\nreduction surgery or lung transplantation (LTx) have an mPAP .35–\n40 mmHg.51,52\nIn\nidiopathic\npulmonary\nﬁbrosis,\nan\nmPAP\n≥25 mmHg has been reported in 8–15% of patients upon initial\nwork-up, with greater prevalence in advanced (30–50%) and end-\nstage (.60%) disease.52 Hypoxia is a public health problem for the\nestimated 120 million people living at altitudes .2500 m. Altitude\ndwellers are at risk of developing PH and chronic mountain sickness.\nHowever, it remains unclear to what extent PH and right HF are\npublic health problems in high-altitude communities; this should be\naddressed with updated methodology and large-scale population\nstudies.53\n4.4. Group 4, pulmonary hypertension\nassociated with chronic pulmonary\nartery obstruction\nThe number of patients diagnosed with CTEPH is increasing, probably\ndue to a deeper understanding of the disease and more active screening\nfor this condition in patients who remain dyspnoeic after pulmonary\nembolism (PE) or who have risk factors for developing CTEPH.\nRegistry data indicate a CTEPH incidence and prevalence of 2–6 and\n26–38 cases/million adults, respectively.31,54,55 Patients with chronic\nthrombo-embolic pulmonary disease (CTEPD) without PH still re-\npresent a small proportion of the patients referred to CTEPH centres.56\n4.5. Group 5, pulmonary hypertension\nwith unclear and/or multifactorial\nmechanisms\nGroup 5 PH consists of a complex group of disorders that are asso-\nciated with PH.57 The cause is often multifactorial and can be secondary\nto increased pre- and post-capillary pressure, as well as direct effects on\npulmonary vasculature. The incidence and prevalence of PH in most of\nthese disorders are unknown. However, high-quality registries have re-\ncently enabled estimation of PH prevalence in adult patients with sar-\ncoidosis.58,59 Studies suggest that PH can be common and its presence\nis often associated with increased morbidity and mortality.58,59\n5. Pulmonary hypertension\ndiagnosis\n5.1. Diagnosis\nThe diagnostic approach to PH is mainly focused on two tasks. The\nprimary goal is to raise early suspicion of PH and ensure fast-track\nreferral to PH centres in patients with a high likelihood of PAH,\nCTEPH, or other forms of severe PH. The second objective is to\nidentify underlying diseases, especially LHD (group 2 PH) and lung\ndisease (group 3 PH), as well as comorbidities, to ensure proper clas-\nsiﬁcation, risk assessment, and treatment.\n5.1.1. Clinical presentation\nSymptoms of PH are mainly linked to right ventricle (RV) dysfunc-\ntion, and typically associated with exercise in the earlier course of\nthe disease.25,26 The cardinal symptom is dyspnoea on progressively\nminor exertion. Other common symptoms are related to the stages\nand severity of the disease, and are listed in Figure 2.60–62 Potential\nclinical signs and physical ﬁndings are summarized in Figure 3.60,61\nImportantly, the physical examination may also be the key to identi-\nfying the underlying cause of PH (see Figure 3).\n5.1.2. Electrocardiogram\nElectrocardiogram (ECG) abnormalities (Table 8) may raise suspicion\nof PH, deliver prognostic information, and detect arrhythmias and\nsigns of LHD. In adults with clinical suspicion of PH (e.g. unexplained\ndyspnoea on exertion), right axis deviation has a high predictive value\nfor PH.63 A normal ECG does not exclude the presence of PH, but a\nnormal ECG in combination with normal biomarkers (BNP/\nNT-proBNP) is associated with a low likelihood of PH in patients re-\nferred for suspected PH or at risk of PH (i.e. after acute PE).64,65\nTable 7\nDrugs and toxins associated with pulmonary\narterial hypertension\nDeﬁnite\nassociation\nPossible association\nAminorex\nBenﬂuorex\nDasatinib\nDexfenﬂuramine\nFenﬂuramine\nMethamphetamines\nToxic rapeseed oil\nAlkylating agents (cyclophosphamide,\nmitomycin C)a\nAmphetamines\nBosutinib\nCocaine\nDiazoxide\nDirect-acting antiviral agents against hepatitis\nC virus (sofosbuvir)\nIndirubin (Chinese herb Qing-Dai)\nInterferon alpha and beta\nLeﬂunomide\nL-tryptophan\nPhenylpropanolamine\nPonatinib\nSelective proteasome inhibitors (carﬁlzomib)\nSolvents (trichloroethylene)a\nSt John’s Wort\n© ESC/ERS 2022\naPulmonary veno-occlusive disease.\n3640\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n5.1.3. Chest radiography\nChest radiography presents abnormal ﬁndings in most patients with\nPH; however, a normal chest X-ray does not exclude PH.68\nRadiographic signs of PH include a characteristic conﬁguration of\nthe cardiac silhouette due to right heart (right atrium [RA]/RV)\nand PA enlargement, sometimes with pruning of the peripheral ves-\nsels. In addition, signs of the underlying cause of PH, such as LHD or\nlung disease, may be found (Table 9).25,26,60,69,70\n5.1.4. Pulmonary function tests and arterial blood\ngases\nPulmonary function tests (PFTs) and analysis of arterial blood gas\n(ABG) or arterialized capillary blood are necessary to distinguish be-\ntween PH groups, assess comorbidities and the need for supplemen-\ntary oxygen, and determine disease severity. The initial work-up of\npatients with suspected PH should comprise forced spirometry,\nbody plethysmography, lung diffusion capacity for carbon monoxide\n(DLCO), and ABG.\nIn patients with PAH, PFTs are usually normal or may show mild\nrestrictive, obstructive, or combined abnormalities.71,72 More severe\nPFT abnormalities are occasionally found in patients with PAH asso-\nciated with CHD,73 and those with group 3 PH. The DLCO may be\nnormal in patients with PAH, although it is usually mildly reduced.71 A\nseverely reduced DLCO (,45% of the predicted value) in the pres-\nence of otherwise normal PFTs can be found in PAH associated with\nsystemic sclerosis (SSc), PVOD, in PH group 3—associated with em-\nphysema, interstitial lung disease (ILD), or combined pulmonary ﬁ-\nbrosis and emphysema—and in some PAH phenotypes.74 A low\nDLCO is associated with a poor prognosis in several forms of\nPH.75–78\nPatients with PAH usually have normal or slightly reduced partial\npressure of arterial oxygen (PaO2). Severe reduction of PaO2 might\nraise suspicion for patent foramen ovale, hepatic disease, other ab-\nnormalities\nwith\nright-to-left\nshunt\n(e.g.\nseptal\ndefect),\nor\nlow-DLCO-associated conditions.\nPartial pressure of arterial carbon dioxide (PaCO2) is typically\nlower than normal due to alveolar hyperventilation.79 Low PaCO2\nSymptoms\nDyspnoea on exertion (WHO-FC)\nFatigue and rapid exhaustion\nDyspnoea when bending forward (bendopnoea)\nPalpitations\nHaemoptysis\nExercise-induced abdominal distension and nausea\nWeight gain due to fluid retention\nSyncope (during or shortly after physical exertion)\nRare symptoms due to pulmonary artery dilationa\nExertional chest pain:\ndynamic compression of the left main coronary artery\nEarly\nLate\nHoarseness (dysphonia):\ncompression of the left laryngeal recurrent nerve\n(cardiovocal or Ortner´s syndrome)\nShortness of breath, wheezing, cough, lower respiratory\ntract infection, atelectasis:\ncompression of the bronchi\nFigure 2 Symptoms in patients with pulmonary hypertension. WHO-FC, World Health Organization functional class. aThoracic compression syn-\ndromes are found in a minority of patients with PAH with pronounced dilation of the pulmonary artery, and may occur at any disease stage and\neven in patients with otherwise mild functional impairment.\nESC/ERS Guidelines\n3641\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nat diagnosis and follow-up is common in PAH and associated with\nunfavourable outcomes.80 Elevated PaCO2 is very unusual in PAH\nand reﬂects alveolar hypoventilation, which in itself may be a cause\nof PH. Overnight oximetry or polysomnography should be per-\nformed if there is suspicion of sleep-disordered breathing or\nhypoventilation.81\n5.1.5. Echocardiography\nIndependent of the underlying aetiology, PH leads to RV pressure\noverload and dysfunction, which can be detected by echocardiog-\nraphy.82–84 When performed accurately, echocardiography provides\ncomprehensive information on right and left heart morphology, RV\nand LV function, and valvular abnormalities, and gives estimates of\nhaemodynamic parameters. Echocardiography is also a valuable\ntool with which to detect the cause of suspected or conﬁrmed\nPH, particularly with respect to PH associated with LHD or CHD.\nYet, echocardiography alone is insufﬁcient to conﬁrm a diagnosis\nof PH, which requires RHC.\nGiven the heterogeneous nature of PH and the peculiar geom-\netry of the RV, there is no single echocardiographic parameter\nthat reliably informs about PH status and underlying aetiology.\nTherefore, a comprehensive echocardiographic evaluation for sus-\npected PH includes estimating the systolic pulmonary arterial\npressure (sPAP) and detecting additional signs suggestive of PH,\naiming at assigning an echocardiographic level of probability of\nPH. Echocardiographic ﬁndings of PH, including estimating pres-\nsure and signs of RV overload and/or dysfunction, are summarized\nin Figure 4.\nSigns of PH\nCentral, peripheral, or mixed cyanosis\nAccentuated pulmonary component of the\nsecond heart sound\nRV third heart sound\nSystolic murmur of tricuspid regurgitation\nDiastolic murmur of pulmonary regurgitation\nSigns pointing towards\nunderlying cause of PH\nDigital clubbing: Cyanotic CHD, fibrotic lung\ndisease, bronchiectasis, PVOD, or liver disease\nDifferential clubbing/cyanosis:\nPDA/Eisenmenger’s syndrome\nAuscultatory findings (crackles or wheezing,\nmurmurs): lung or heart disease\nSequelae of DVT, venous insufficiency: CTEPH\nTelangiectasia: HHT or SSc \nSclerodactyly, Raynaud’s phenomenon, digital\nulceration, GORD: SSc\nSigns of RV backward failure\nSigns of RV forward failure\nDistended and pulsating jugular veins\nAbdominal distension\nHepatomegaly\nAscites\nPeripheral oedema\nPeripheral cyanosis (blue lips and tips)\nDizziness\nPallor\nCool extremities \nProlonged capillary refill\nthe\non\ntation\nlung\ndisease\nezing,\nCTEPH\ndigital\nSig\nS\nDis\nAb\nHe\nAsc\nPer\nPer\nDiz\nPal\nCo\nPro\nFigure 3 Clinical signs in patients with pulmonary hypertension. CHD, congenital heart disease; CTEPH, chronic thrombo-embolic pulmonary hyper-\ntension; DVT, deep venous thrombosis; GORD, gastro-oesophageal reﬂux disease; HHT, hereditary haemorrhagic telangiectasia; PDA, patent ductus\narteriosus; PH, pulmonary hypertension; PVOD, pulmonary veno-occlusive disease; RV, right ventricle; SSc, systemic sclerosis.\n3642\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nEstimates of sPAP are based on the peak tricuspid regurgitation\nvelocity (TRV) and the TRV-derived tricuspid regurgitation pressure\ngradient (TRPG)—after excluding pulmonary stenosis—taking into\naccount non-invasive estimates of RA pressure (RAP). Considering\nthe inaccuracies in estimating RAP and the ampliﬁcation of measure-\nment errors by using derived variables,85–87 these guidelines\nrecommend using the peak TRV (and not the estimated sPAP) as\nthe key variable for assigning the echocardiographic probability of\nPH. A peak TRV .2.8 m/s may suggest PH; however, the presence\nor absence of PH cannot be reliably determined by TRV alone.88\nLowering the TRV threshold in view of the revised haemodynamic\ndeﬁnition of PH is not supported by available data (key narrative\nquestion 2, Supplementary Data, Section 5.1).89–92 Tricuspid regurgi-\ntation (TR) velocity may underestimate (e.g. in patients with severe\nTR)28 or overestimate (e.g. in patients with high CO in liver disease\nor sickle cell disease [SCD],93,94 misinterpretation of tricuspid valve\nclosure artefact for the TR jet, or incorrect assignment of a peak TRV\nin the case of maximum velocity boundary artefacts) pressure gradi-\nents. Hence, additional variables related to RV morphology and func-\ntion are used to deﬁne the echocardiographic probability of PH\n(Table 10),82–84,95 which may then be determined as low, intermedi-\nate, or high. When interpreted in a clinical context, this probability\ncan be used to decide the need for further investigation, including\ncardiac catheterization in individual patients (Figure 5).\nEchocardiographic measures of RV function include the tricuspid\nannular plane systolic excursion (TAPSE), RV fractional area change\n(RV-FAC), RV free-wall strain, and tricuspid annulus velocity (S′\nwave) derived from tissue Doppler imaging, and potentially RV ejec-\ntion\nfraction\n(RVEF)\nderived\nfrom\n3D\nechocardiography.\nFurthermore, the TAPSE/sPAP ratio—representing a non-invasive\nmeasure of RV–PA coupling96—may aid in diagnosing PH.90,97,98\nThe pattern of RV outﬂow tract (RVOT) blood ﬂow (mid-systolic\n‘notching’) may suggest pre-capillary PH.99,100\nTo separate between group 2 PH and other forms of PH, and to\nassess the likelihood of left ventricle (LV) diastolic dysfunction, LA\nsize and signs of LV hypertrophy should always be measured, and\nDoppler echocardiographic signs (e.g. E/A ratio, E/E′) should be as-\nsessed even if the reliability of the latter is considered low.16 To iden-\ntify CHD, 2D Doppler and contrast examinations are helpful, but\ntransoesophageal contrast echocardiography or other imaging tech-\nniques (e.g. computer tomography [CT] angiography, cMRI) are\nneeded in some cases to detect or exclude sinus venosus atrial septal\ndefects, patent ductus arteriosus, and/or anomalous pulmonary ven-\nous return.101 The clinical value of exercise Doppler echocardiog-\nraphy in identifying exercise PH remains uncertain because of the\nlack of validated criteria and prospective conﬁrmatory data. In\nmost cases, increases in sPAP during exercise are caused by diastolic\nLV dysfunction.16\n5.1.6. Ventilation/perfusion lung scan\nA ventilation/perfusion (V/Q) lung scan (planar or single-photon\nemission computed tomography [SPECT]) is recommended in the\ndiagnostic work-up of patients with suspected or newly diagnosed\nPH, to rule out or detect signs of CTEPH.102,103 The V/Q SPECT\nis superior to planar imaging and is the methodology of choice; how-\never, SPECT has been widely evaluated in assessing PE, but not to the\nsame degree in CTEPH.68 In the absence of parenchymal lung dis-\nease, a normal perfusion scan excludes CTEPH with a negative pre-\ndicted value of 98%.104,105 In most patients with PAH, V/Q\nscintigraphy is normal or shows a speckled pattern but no typical\nperfusion defects characteristic of PE or CTEPH, whereas matched\nV/Q defects may be found in patients with lung disease (i.e. group\n3 PH). Non-matched perfusion defects similar to those seen in\nTable 9\nRadiographic signs of pulmonary hyperten-\nsion and concomitant abnormalities\nSigns of PH and\nconcomitant\nabnormalities\nSigns of left heart\ndisease/\npulmonary\ncongestion\nSigns of lung\ndisease\nRight heart\nenlargement\nCentral air space\nopaciﬁcation\nFlattening of\ndiaphragm (COPD/\nemphysema)\nPA enlargement\n(including aneurysmal\ndilatation)\nInterlobular septal\nthickening ‘Kerley B’\nlines\nHyperlucency\n(COPD/\nemphysema)\nPruning of the\nperipheral vessels\nPleural effusions\nLung volume loss\n(ﬁbrotic lung\ndisease)\n‘Water-bottle’ shape\nof cardiac silhouettea\nLeft atrial\nenlargement\n(including splayed\ncarina)\nLeft ventricular\ndilation\nReticular\nopaciﬁcation\n(ﬁbrotic lung\ndisease)\n© ESC/ERS 2022\nCOPD, chronic obstructive pulmonary disease; PA, pulmonary artery; PH, pulmonary\nhypertension.\naMay be present in patients with PH with advanced right ventricular failure and\nmoderate pericardial effusion.\nTable 8\nElectrocardiogram abnormalities in patients\nwith pulmonary hypertension\nTypical ECG abnormalities in PH66\n• P pulmonale (P .0.25 mV in lead II)\n• Right or sagittal axis deviation (QRS axis .90° or indeterminable)\n• RV hypertrophy (R/S .1, with R .0.5 mV in V1; R in V1 + S in lead V5\n. 1 mV)\n• Right bundle branch block—complete or incomplete (qR or rSR\npatterns in V1)\n• RV strain patterna (ST depression/T-wave inversion in the right\npre-cordial V1–4 and inferior II, III, aVF leads)\n• Prolonged QTc interval (unspeciﬁc)b\n© ESC/ERS 2022\nECG, electrocardiogram; PH, pulmonary hypertension; QTc, corrected QT interval;\nRV, right ventricular.\naPresent in advanced PH.\nbPatients with pulmonary arterial hypertension can present with a prolonged QTc\ninterval (although non-speciﬁc), which may reﬂect RV dysfunction and delayed\nmyocardial repolarization, and is an independent predictor of mortality.67\nESC/ERS Guidelines\n3643\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nCTEPH may be present in 7–10% of patients with PVOD/PCH or\nPAH.106,107 Deposition of the perfusion agent in extrapulmonary or-\ngans may hint to cardiac or pulmonary right-to-left shunting and has\nbeen reported in CHD, hepato-pulmonary syndrome, and pulmon-\nary arteriovenous malformations (PAVMs).68\n5.1.7. Non-contrast and contrast-enhanced chest\ncomputed tomography examinations, and digital\nsubtraction angiography\nComputed tomography (CT) imaging may provide important infor-\nmation for patients with unexplained dyspnoea or suspected/con-\nﬁrmed PH. The CT signs suggesting the presence of PH include an\nenlarged PA diameter, a PA-to-aorta ratio .0.9, and enlarged right\nheart chambers.68 A combination of three parameters (PA diameter\n≥30 mm, RVOT wall thickness ≥6 mm, and septal deviation ≥140°\n[or RV:LV ratio ≥1]) is highly predictive of PH.108 Non-contrast\nchest CT can help determine the cause of PH when there are\nfeatures of parenchymal lung disease, and may also point towards\nthe presence of PVOD/PCH by showing centrilobular ground-glass\nopacities (which may also be found in PAH), septal lines, and\nlymphadenopathy.68\nComputed tomography pulmonary angiography (CTPA) is mainly\nused to detect direct or indirect signs of CTEPH, such as ﬁlling de-\nfects (including thrombus adhering to the vascular wall), webs or\nbands in the PAs, PA retraction/dilatation, mosaic perfusion, and en-\nlarged bronchial arteries. Importantly, the diagnostic accuracy of\nCTPA for CTEPH is limited (at the patient level, sensitivity and spe-\nciﬁcity are 76% and 96%, respectively),109 but was reported to be\nhigher when modern, high-quality multi-detector CT scanners\nwere used and when interpreted by experienced readers.109,110\nComputed tomography pulmonary angiography may also be used\nto detect other cardiovascular abnormalities, including intracardiac\nshunts, abnormal pulmonary venous return, patent ductus arterio-\nsus, and PAVMs.\nRV\nAo\nLA\nLV\nEnlarged right ventricle;\nparasternal long-axis view\nA\nRV\nRA\nLV\nDilated RV with basal RV/LV \nratio >1.0;\nfour-chamber view\nB\nRV\nLV\nFlattened interventricular septum\n(arrows) leading to ‘D-shaped’ LV;\ndecreased LV eccentricity index;\nparasternal short-axis view\nC\nRA\nIVC\nDistended inferior vena cava \nwith diminished inspiratory\ncollapsibility; subcostal view \nD\nRVOT acceleration time of\npulmonary ejection <105 ms\nmid-systolic ‘notch’ indicative of\npre-capillary PH\nE\nReduced right ventricular\nfractional area change (<35%);\nfour-chamber view\nF\nRV\nRA\nRVOT AT <105 ms\n‘notch’\nDiastole\nSystole\nRV\nRA\nLV\nTAPSE \n<18 mm\nM-Mode\nDecreased tricuspid annular\nplane systolic excursion (TAPSE)\nmeasured with M-Mode (<18 mm)\nG\nDecreased peak systolic (S’)\nvelocity of tricuspid annulus \n(<9.5 cm/s) measured with\ntissue Doppler\nH\nEnlarged right atrial area \n(>18 cm2);\nfour-chamber view\nI\nE’\nS’\nS’ <9.5 cm/s\nRV\nRA\nA’\nRV\nIncreased systolic peak tricuspid\nregurgitation velocity (peak TRV);\nmeasured with continuous\nwave Doppler\nJ\nEstimation of systolic pulmonary\nartery pressure (sPAP);\nsPAP = TR pressure gradient + \nestimated RAP\nK\nPresence of pericardial effusion;\nfour-chamber view;\nparasternal short-axis view;\nother views (e.g. subcostal view)\nL\nRV\nRA\nEstimated RAP\nRV\nRA\nIVC\nIVC\nCollapsea\neRAP\n<2.1 cm >50%\n3 (0-5)\nPeak TRV\n>2.8 m/s\n>2.1 cm >50%\n8 (5-10)\n>2.1 cm <50% 15 (10-20)\nRV\nLV\nPeak TRV\n>2.8 m/s\nEnd-systolic\nRA >18 cm2\nFigure 4 Transthoracic echocardiographic parameters in the assessment of pulmonary hypertension. Ao, aorta; IVC, inferior vena cava; LA, left atrium;\nLV, left ventricle; PH, pulmonary hypertension; RA, right atrium; RAP, right atrial pressure; RV, right ventricle; RVOT AT, right ventricular outﬂow tract\nacceleration time; sPAP, systolic pulmonary artery pressure; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation; TRV, tricuspid\nregurgitation velocity. aRefers to collapse on inspiration.\n3644\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nIn patients presenting with a clinical picture of acute PE, chest CT\nmay be helpful in detecting signs of hitherto undetected CTEPH,\nwhich may include the presence of the above CTEPH signs, and\nRV hypertrophy as a sign for chronicity.111,112 Detecting ‘acute on\nchronic’ PE is important, as it may impact the management of pa-\ntients with presumed acute PE.\nDual-energy CT (DECT) angiography and iodine subtraction map-\nping may provide additional diagnostic information by creating iodine\nmaps,113 which reﬂect lung perfusion, thereby possibly increasing the\ndiagnostic accuracy for CTEPH.114 Although increasingly used, the\ndiagnostic value of DECT in the work-up of patients with PH has\nnot been established.\nDigital subtraction angiography (DSA) is mainly used to conﬁrm\nthe diagnosis of CTEPH and to assess treatment options (i.e. oper-\nability or accessibility for BPA). Most centres use conventional\ntwo- or three-planar DSA. However, C-arm CT imaging may pro-\nvide a higher spatial resolution, potentially identifying more target\nvessels for BPA and providing procedural guidance.115,116\n5.1.8. Cardiac magnetic resonance imaging\nCardiac magnetic resonance imaging accurately and reproducibly as-\nsesses atrial and ventricular size, morphology, and function.\nAdditional information on RV/LV myocardial strain can be obtained\nby applying tagging or by post-processing feature tracking. In add-\nition, cMRI can be used to measure blood ﬂow in the PA, aorta,\nand vena cava, allowing for quantifying stroke volume (SV),\nTable 10\nAdditional echocardiographic signs sug-\ngestive of pulmonary hypertension\nA: The ventricles\nB: Pulmonary\nartery\nC: Inferior vena\ncava and RA\nRV/LV basal diameter/\narea ratio .1.0\nRVOT AT\n,105 ms and/or\nmid-systolic\nnotching\nIVC diameter\n.21 mm with\ndecreased inspiratory\ncollapse (,50% with\na sniff or ,20% with\nquiet inspiration)\nFlattening of the\ninterventricular\nseptum (LVEI .1.1 in\nsystole and/or diastole)\nEarly diastolic\npulmonary\nregurgitation\nvelocity .2.2 m/s\nRA area (end-systole)\n.18 cm2\nTAPSE/sPAP ratio\n,0.55 mm/mmHg\nPA diameter .AR\ndiameter\nPA diameter\n.25 mm\n© ESC/ERS 2022\nAR, aortic root; IVC, inferior vena cava; LV, left ventricle; LVEI, left ventricle eccentricity\nindex; PA, pulmonary artery; RA, right atrium; RV, right ventricle; RVOT AT, right\nventricular outﬂow tract acceleration time; sPAP, systolic pulmonary arterial\npressure;\nTAPSE,\ntricuspid\nannular\nplane\nsystolic\nexcursion;\nTRV,\ntricuspid\nregurgitation velocity.\naSigns contributing to assessing the probability of PH in addition to TRV (see Figure 5).\nSigns from at least two categories (A/B/C) must be present to alter the level of\nechocardiographic probability of PH.\nPeak tricuspid regurgitation velocity (m/s)\nPresence of other echo PH signsb (see Table 10)\nT\nN\nN\n≤2.8a\n2.9–3.4\nPH PRO\nR BABILITY\nINTERMEDIATE\nA\nPH PRO\nR BABILITY\nHIGH\nPH PRO\nR BABILITY\nLOW\n>3.4\nY\nY\nYes/No\nY\nRisk factors or associated conditions\no\nfor \nf\nPAH or CTEPH\nP\nN\nN\nEcho foll\nf\now-up\n(Class IIa)\nFurther interventionc/\nRHC (if indicatedd)\n(Class I) \nAlternative diagnosis\n(Class IIa)\nY\nY\nYes/No\nY\nFigure 5 Echocardiographic probability of pulmonary hypertension and recommendations for further assessment. CPET, cardiopulmonary exercise\ntesting; CTEPH, chronic thrombo-embolic pulmonary hypertension; echo, echocardiography; LHD, left heart disease; N, no; PAH, pulmonary arterial\nhypertension; PH, pulmonary hypertension; RHC, right heart catheterization; TRV, tricuspid regurgitation velocity; Y, yes. aOr unmeasurable. The\nTRV threshold of 2.8 m/s was not changed according to the updated haemodynamic deﬁnition of PH. bSigns from at least two categories in Table 10\n(A/B/C) must be present to alter the level of echocardiographic probability of PH. cFurther testing may be necessary (e.g. imaging, CPET). dRHC should\nbe performed if useful information/a therapeutic consequence is anticipated (e.g. suspected PAH or CTEPH), and may not be indicated in patients without\nrisk factors or associated conditions for PAH or CTEPH (e.g. when mild PH and predominant LHD or lung disease are present).\nESC/ERS Guidelines\n3645\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nintracardiac shunt, and retrograde ﬂow. By combining contrast mag-\nnetic resonance (MR) angiography and pulmonary perfusion imaging\nwith late gadolinium-enhancement imaging of the myocardium, a\ncomplete picture of the heart and pulmonary vasculature can be ob-\ntained (see Supplementary Data, Table S2 for cMRI indices and nor-\nmal values). A limitation is that there is no established method with\nwhich to estimate PAP. Even though the cost and availability of the\ntechnique precludes its use in the early diagnosis of PAH, it is sensi-\ntive in detecting early signs of PH and diagnosing CHD.117\n5.1.9. Blood tests and immunology\nThe initial diagnostic assessment of patients with newly diagnosed\nPH/PAH aims to identify comorbidities and possible causes or com-\nplications of PH. Laboratory tests that should be obtained at the time\nof PH diagnosis include: blood counts (including haemoglobin [Hb]);\nserum electrolytes (sodium, potassium); kidney function (creatinine,\ncalculation of estimated glomerular ﬁltration rate, and urea); uric\nacid; liver parameters (alanine aminotransferase, aspartate amino-\ntransferase, and alkaline phosphatase, γ-glutamyl transpeptidase, bili-\nrubin); iron status (serum iron, transferrin saturation, and ferritin);\nand BNP or NT-proBNP. In addition, serological studies should in-\nclude testing for hepatitis viruses and HIV. Basic immunology labora-\ntory work-up is recommended, including screening tests for\nanti-nuclear antibodies, anti-centromere antibodies, and anti-Ro.\nScreening for biological markers of antiphospholipid syndrome is re-\ncommended in patients with CTEPH. Additional thrombophilia\nscreening is not generally recommended, unless therapeutic conse-\nquences are to be expected.118 Pulmonary arterial hypertension\nand other forms of severe PH can be associated with thyroid func-\ntion disorders; hence, laboratory screening should include at least\nthyroid-stimulating hormone.\n5.1.10. Abdominal ultrasound\nAn abdominal ultrasound examination should be part of the compre-\nhensive diagnostic work-up of patients with newly diagnosed PH,\nparticularly if liver disease is suspected. A major objective is to search\nfor liver disease and/or portal hypertension, or portocaval shunt\n(Abernethy malformation). During the course of the disease, pa-\ntients with PH may develop secondary organ dysfunction mainly af-\nfecting the liver and kidneys.119 In these patients, abdominal\nultrasound is needed for differential diagnostic reasons and to assess\nthe extent of organ damage.\n5.1.11. Cardiopulmonary exercise testing\nCardiopulmonary exercise testing (CPET) is a useful tool to assess\nthe underlying pathophysiologic mechanisms leading to exercise in-\ntolerance. Patients with PAH show a typical pattern, with a low end-\ntidal partial pressure of carbon dioxide (PETCO2), high ventilatory\nequivalent for carbon dioxide (VE/VCO2), low oxygen pulse (VO2/\nHR), and low peak oxygen uptake (VO2).120 These ﬁndings should\nprompt consideration of PVD. In patients with LHD or COPD,\nsuch a pattern may indicate an additional pulmonary vascular limita-\ntion.121,122 In populations at risk of PAH, such as those with SSc, a\nnormal peak VO2 seems to exclude the diagnosis of PAH.123\n5.1.12. Right heart catheterization, vasoreactivity,\nexercise, and ﬂuid challenge\n5.1.12.1. Right heart catheterization\nRight heart catheterization is the gold standard for diagnosing and\nclassifying PH. Performing RHC requires expertise and meticulous\nmethodology following standardized protocols. In addition to diag-\nnosing and classifying PH, clinical indications include haemodynamic\nassessment of heart or LTx candidates124 and evaluating congenital\ncardiac shunts. Interpreting invasive haemodynamics should be\ndone in the context of the clinical picture and other diagnostic inves-\ntigations. When performed in PH centres, the frequencies of serious\nadverse events (1.1%) and procedure-related mortality (0.055%) are\nlow.125 A known thrombus or tumour in the RV or RA, recently im-\nplanted (,1 month) pacemaker, mechanical right heart valve,\nTriClip, and an acute infection are contraindications to RHC; the\nrisk:beneﬁt ratio should be individually assessed before each examin-\nation and discussed with the patient. The most feared complication\nof RHC is perforation of a PA.\nThe adequate preparation of patients for RHC is of major rele-\nvance. Pre-existing medical conditions should be optimally controlled\nat the time of the examination (particularly blood pressure and vol-\nume control). In the supine position, the mid-thoracic level is recom-\nmended as the zero reference level, which is at the level of the LA in\nmost patients.126\nFor a complete assessment of cardiopulmonary haemodynamics,\nall measures listed in Table 11 must be measured or calculated.\nTable 11\nHaemodynamic measures obtained during\nright heart catheterization\nMeasured variables\nNormal value\nRight atrial pressure, mean (RAP)\n2–6 mmHg\nPulmonary artery pressure, systolic (sPAP)\n15–30 mmHg\nPulmonary artery pressure, diastolic (dPAP)\n4–12 mmHg\nPulmonary artery pressure, mean (mPAP)\n8–20 mmHg\nPulmonary arterial wedge pressure, mean (PAWP)\n≤15 mmHg\nCardiac output (CO)\n4–8 L/min\nMixed venous oxygen saturation (SvO2)a\n65–80%\nArterial oxygen saturation (SaO2)\n95–100%\nSystemic blood pressure\n120/80 mmHg\nCalculated parameters\nPulmonary vascular resistance (PVR)b\n0.3–2.0 WU\nPulmonary vascular resistance index (PVRI)\n3–3.5 WU·m2\nTotal pulmonary resistance (TPR)c\n,3 WU\nCardiac index (CI)\n2.5–4.0 L/min·m2\nStroke volume (SV)\n60–100 mL\nStroke volume index (SVI)\n33–47 mL/m2\nPulmonary arterial compliance (PAC)d\n.2.3 mL/mmHg\n© ESC/ERS 2022\nWU, Wood units.\naDerived from blood sample taken from the pulmonary artery; compartmental\noximetry to exclude an intracardiac shunt is recommended when SvO2 .75%.\nbPVR, (mPAP−PAWP)/CO.\ncTPR, mPAP/CO.\ndPAC, SV/(sPAP−dPAP).\n3646\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nIncomplete assessments must be avoided, as this may lead to mis-\ndiagnosis. As a minimum, mixed venous oxygen saturation (SvO2)\nand arterial oxygen saturation (SaO2) should be determined. A step-\nwise assessment of oxygen saturation should be performed in pa-\ntients with SvO2 .75% and whenever a left-to-right shunt is\nsuspected. Cardiac output (CO) should be assessed by the direct\nFick method or thermodilution (mean values of at least three mea-\nsurements). The indirect Fick method is considered to be less reliable\nthan thermodilution;127 however, thermodilution should not be used\nin\nthe\npresence\nof\nshunts.\nPulmonary\nvascular\nresistance\n([mPAP−PAWP]/CO) should be calculated for each patient. All\npressure measurements, including PAWP, should be performed at\nend expiration (without breath-holding manoeuvre). In patients\nwith large intrathoracic pressure changes during the respiratory cy-\ncle (i.e. COPD, obesity, during exercise), it is appropriate to average\nover at least three to four respiratory cycles. If no reliable PAWP\ncurve can be obtained, or if the PAWP values are implausible, add-\nitional measurement of LV end-diastolic pressure should be consid-\nered to avoid misclassiﬁcation. Saturations taken with the catheter in\nthe wedged position can conﬁrm an accurate PAWP.128\n5.1.12.2. Vasoreactivity testing\nThe purpose of vasoreactivity testing in PAH is to identify acute vasor-\nesponders who may be candidates for treatment with high-dose cal-\ncium channel blockers (CCBs). Pulmonary vasoreactivity testing is\nonly recommended in patients with IPAH, HPAH, or DPAH.\nInhaled nitric oxide129 or inhaled iloprost130,131 are the recommended\ntest compounds for vasoreactivity testing (Table 12). There is similar\nevidence for intravenous (i.v.) epoprostenol, but due to incremental\ndose increases and repetitive measurements, testing takes much long-\ner and is therefore less feasible.129 Adenosine i.v. is no longer recom-\nmended due to frequent side effects.132 A positive acute response is\ndeﬁned as a reduction in mPAP by ≥10 mmHg to reach an absolute\nvalue ≤40 mmHg, with increased or unchanged CO.129 In patients\nwith PH-LHD, vasoreactivity testing is restricted to evaluating heart\ntransplantation candidacy (see Section 8.1), and in patients with PH\nin the context of CHD with initial systemic-to-pulmonary shunting, va-\nsoreactivity testing can be performed to evaluate the possibility of de-\nfect closure (see Section 7.5).101\n5.1.12.3. Exercise right heart catheterization\nRight heart catheterization is the gold standard method to assess car-\ndiopulmonary haemodynamics during exercise and to deﬁne\nexercise PH.133 The main reason to perform exercise RHC is to in-\nvestigate patients with unexplained dyspnoea and normal resting\nhaemodynamics in order to detect early PVD or left heart dysfunc-\ntion. In addition, exercise haemodynamics may reveal important\nprognostic and functional information in patients at risk of PAH\nand CTEPH.22,134,135 To maximize the amount of information, exer-\ncise RHC may be combined with CPET. According to the available\ndata and experience, exercise RHC is not associated with an add-\nitional risk of complications compared with resting RHC and\nCPET.133\nIncremental exercise tests (step or ramp protocol) with repeated\nhaemodynamic measurements provide the most clinical information\non pulmonary circulation. The minimally required haemodynamic\nvariables measured at each exercise level include mPAP, sPAP, dia-\nstolic PAP (dPAP), PAWP, CO, heart rate, and systemic blood pres-\nsure. In addition, RAP, SvO2, and SaO2 should at least be measured at\nrest and peak exercise. Total pulmonary resistance (TPR), PVR, and\ncardiac index (CI) should be calculated at each exercise level, as well\nas arteriovenous difference in oxygen at peak exercise. The mPAP/\nCO and PAWP/CO slopes should also be calculated.136,137 In pa-\ntients with early PVD, PVR may be normal or mildly elevated at\nrest, but may change during exercise with a steep increase in\nmPAP, reﬂected by an mPAP/CO slope .3 mmHg/L/min, while\nthe PAWP/CO slope usually remains ,2 mmHg/L/min. Patients\nwith left heart dysfunction, such as those with HFpEF23 and/or dy-\nnamic mitral regurgitation,138 and a normal PAWP at rest, usually\nshow a steep increase in mPAP and PAWP (and mPAP/CO,\nPAWP/CO slope) during exercise.\nAccording to recent studies, a PAWP/CO slope .2 mmHg/L/min\nmay be helpful in recognizing an abnormal PAWP increase and,\ntherefore, a cardiac exercise limitation, especially in patients with\nPAWP\n12–15 mmHg\nat\nrest.23,24,139\nA\nPAWP\ncut-off\nof\n.25 mmHg during supine exercise has been recommended for diag-\nnosing HFpEF.16 In patients with lung disease, increased intrathoracic\npressure may contribute to mPAP elevation; this is exaggerated dur-\ning exercise and can be recognized by a concomitant increase in\nRAP.140 Some exercise haemodynamics are age dependent, with\nhealthy elderly subjects presenting with steeper mPAP/CO and\nPAWP/CO slopes than healthy young individuals.9,141\n5.1.12.4. Fluid challenge\nFluid challenge may reveal LV diastolic dysfunction in patients with\nPAWP ≤15 mmHg, but a clinical phenotype suggestive of LHD.\nTable 12\nRoute of administration, half-life, dosages, and duration of administration of the recommended test com-\npounds for vasoreactivity testing in pulmonary arterial hypertension\nCompound\nRoute\nHalf-life\nDosage\nDuration\nNitric oxide129\ninh\n15–30 s\n10–20 p.p.m.\n5–10 mina\nIloprost130,131\ninh\n30 min\n5–10 µgb\n10–15 minc\nEpoprostenol129\ni.v.\n3 min\n2–12 ng/kg/min\n10 mind\n© ESC/ERS 2022\nInh, inhaled; i.v., intravenous.\naMeasurement as a single step within the dose range.\nbAt mouth piece.\ncMeasurement as a single step, temporize full effect.\ndIncremental increase in 2 ng/kg/min intervals, duration of 10 min at each step.\nESC/ERS Guidelines\n3647\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nMost available data are derived from studies aiming to uncover\nHFpEF (increase in PAWP) rather than identify group 2 PH (increase\nin PAP; see Section 8.1). It is generally accepted that rapid infusion\n(over 5–10 min) of ≏500 mL (7–10 mL/kg) of saline would be sufﬁ-\ncient to detect an abnormal increase in PAWP to ≥18 mmHg (sug-\ngestive of HFpEF),142 although validation and long-term evaluation of\nthese data are needed.143 There are insufﬁcient data on the haemo-\ndynamic response to ﬂuid challenge in patients with PAH. Recent\ndata suggest that passive leg raise during RHC may also help to un-\ncover occult HFpEF.144\n5.1.13. Genetic counselling and testing\nMutations in PAH genes have been identiﬁed in familial PAH, IPAH,\nPVOD/PCH, and anorexigen-associated PAH (Table 13).148 The\nscreening recommendations herein speciﬁcally relate to patients\nwith an a priori diagnosis of PAH and not ‘at-risk’ populations being\nscreened for PAH (see Section 5.3). All patients with these conditions\nshould be informed about the possibility of a genetic condition and\nthat family members could carry a mutation that increases the risk\nof PAH, allowing for screening and early diagnosis.33,148 Even if gen-\netic testing is not performed, family members should be made aware\nof early signs and symptoms, to ensure that a timely and appropriate\ndiagnosis is made.148\nGenetic counselling by appropriately trained PAH providers or ge-\nneticists should be performed prior to genetic testing, to address the\ncomplex questions related to penetrance, genetically at-risk family\nmembers, reproduction, genetic discrimination, and psychosocial is-\nsues. Careful genetic counselling with genetic counsellors or medical\ngeneticists is critical prior to genetic testing for asymptomatic family\nmembers.148\nIf the familial mutation is known and an unaffected family member\ntests negative for that mutation, the risk of PAH for that person is the\nsame as for the general population.148\nMany of the less common mutations outlined have a potential add-\nitional set of syndromic features. These are summarized in Table 13\nwhere speciﬁc clinical history, examination, and investigations are\nsuggested. In particular, clinicians should undertake a thorough his-\ntory and examination, as syndromic PAH diagnoses may be missed\nif not interrogated. For example, in one of the largest studies to\ndate, TBX4, ALK1, and ENG mutations were represented in the top\nsix most common genetic ﬁndings in adults with previously diagnosed\nIPAH.149 These ﬁndings have been conﬁrmed and extended in inter-\nnational genetics consortia in 4241 patients with PAH.150 It is there-\nfore apparent that there is either phenotypic heterogeneity of these\nsyndromes or missed diagnostic features. As more genes associated\nwith PAH are discovered, it will become increasingly difﬁcult to indi-\nvidually test for each. Next-generation sequencing has enabled the\ndevelopment of gene panels to simultaneously interrogate several\ngenes.151 It is, however, important to check the genes included in\nthe panel at the time of testing, since the composition changes as\ngenetic discoveries advance.\n5.2. Diagnostic algorithm\nA multistep, pragmatic approach to diagnosis should be considered\nin patients with unexplained dyspnoea or symptoms/signs raising sus-\npicion of PH. This strategy is depicted in detail in Figure 6 and\nTable 14. The diagnostic algorithm does not address screening for\nspeciﬁc groups at risk of PH.\n5.2.1 Step 1 (suspicion)\nPatients with PH are likely to be seen by ﬁrst-line physicians, mainly\ngeneral practitioners, for non-speciﬁc symptoms. Initial evaluation\nshould include a comprehensive medical (including familial) history,\nthorough physical examination (including measurement of blood\npressure, heart rate, and pulse oximetry), blood test to determine\nBNP/NT-proBNP, and resting ECG. This ﬁrst step may raise a suspi-\ncion of a cardiac or respiratory disorder causing the symptoms.\n5.2.2. Step 2 (detection)\nThe second step includes classical, non-invasive lung and cardiac test-\ning. Among those tests, echocardiography is an important step in the\nRecommendation Table 1 — Recommendations for\nright heart catheterization and vasoreactivity testing\nRecommendations\nClassa\nLevelb\nRight heart catheterization\nIt is recommended that RHC is performed to\nconﬁrm the diagnosis of PH (especially PAH or\nCTEPH) and to support treatment decisions25,26\nI\nB\nIn patients with suspected or known PH, it is\nrecommended that RHC is performed in\nexperienced centres125\nI\nC\nIt is recommended that RHC comprises a\ncomplete set of haemodynamics and is performed\nfollowing standardized protocols25,26,145\nI\nC\nVasoreactivity testing\nVasoreactivity testing is recommended in patients\nwith I/H/DPAH to detect those who can be\ntreated with high doses of a CCB129,146\nI\nB\nIt is recommended that vasoreactivity testing is\nperformed at PH centres\nI\nC\nIt is recommended to consider a positive response\nto vasoreactivity testing by a reduction in mPAP\n≥10 mmHg to reach an absolute value of mPAP\n≤40 mmHg with an increased or unchanged\nCOc129\nI\nC\nInhaled nitric oxide, inhaled iloprost, or i.v.\nepoprostenol are recommended for performing\nvasoreactivity testing129–132\nI\nC\nVasoreactivity testing, for identifying candidates\nfor CCB therapy, is not recommended in patients\nwith PAH other than I/H/DPAH, and in PH groups\n2, 3, 4, and 5124,129\nIII\nC\n© ESC/ERS 2022\nCCB, calcium channel blocker; CO, cardiac output; CTEPH, chronic thrombo-embolic\npulmonary hypertension; I/H/DPAH, idiopathic, heritable, drug-associated pulmonary\narterial hypertension; i.v., intravenous; mPAP, mean pulmonary arterial pressure;\nPAH, pulmonary arterial hypertension; PH, pulmonary hypertension; RHC, right\nheart catheterization.\naClass of recommendation.\nbLevel of evidence.\ncTesting should also be performed in patients with a baseline mPAP ≤40 mmHg, in\nwhom the same responder criteria apply.\n3648\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nTable 13\nPhenotypic features associated with pulmonary arterial hypertension mutations\nGene\nPulmonary hypertension\nphenotypic association\nPutative\nmolecular\nmechanism\nInheritance\npattern\nPotential distinguishing\nclinical and examination\nfeatures\nInvestigations\nPopulations\nReference\nBMPR2\nHeritable and idiopathic PAH\nHaploinsufﬁciency\nAutosomal\ndominant\nNo speciﬁc or diagnostic clinical\nfeatures described\nNo discriminative investigations described\nPaediatric and adult\n152\nATP13A3\nUnknown\nAutosomal\ndominant\nAdult\n149\nAQP1\nUnknown\nAutosomal\ndominant\nAdult\n149\nABCC8\nHaploinsufﬁciency\nAutosomal\ndominant\nAdult\n153\nKCNK3\nHaploinsufﬁciency\nAutosomal\ndominant\nAdult\n154\nSMAD9\nHaploinsufﬁciency\nAutosomal\ndominant\nAdult\n155\nSox17\nHeritable and idiopathic PAH\nCongenital heart disease\nUnknown\nAutosomal\ndominant\nPaediatric and adult\n149\nCAV1\nHeritable and idiopathic PAH\nLipodystrophy\nGain of function;\ndominant negative\nAutosomal\ndominant\nDeﬁciency of subcutaneous\nadipose tissue\nFasting triglyceride and leptin levels\nPaediatric and adult\n156\nTBX4\nHeritable and idiopathic PAH\nSmall patella syndrome\n(ischiopatellar dysplasia)\nParenchymal lung disease\nBronchopulmonary dysplasia\nPersistent pulmonary\nhypertension of the neonate\nUnknown\nAutosomal\ndominant\nPatellar aplasia\nSkeletal abnormalities,\nparticularly pelvis, knees, and\nfeet\nSkeletal X-rays: pelvis, knees, and feet\nCT chest: diffuse parenchymal lung disease\nPaediatric and (less\ncommonly) adult\n149,157\nEIF2AK4\nPulmonary veno-occlusive\ndisease/pulmonary capillary\nhaemangiomatosis\nLoss of function\nAutosomal\nrecessive\nDistal phalangeal clubbing\nReduced DLCO\nCT chest: interlobular septal thickening and\nmediastinal lymphadenopathy, and\ncentrilobular ground-glass nodular opacities\nAdult\n158\nKDR\nHeritable and idiopathic PAH\nLoss of function\nAutosomal\ndominant\nNo speciﬁc or diagnostic clinical\nfeatures described\nPossible reduced DLCO\nOlder-onset adult\n159\nENG\nHeritable and idiopathic PAH\nHereditary haemorrhagic\ntelangiectasia\nUnknown\nAutosomal\ndominant\nTelangiectasia\nAbnormal blood vessel\nformation\nVisceral arteriovenous\nmalformations\nBleeding diathesis\nIron-deﬁciency anaemia\nPresence on imaging of pulmonary, hepatic,\ncerebral, or spinal arteriovenous\nmalformations\nInvasive endoscopic assessment of\ngastrointestinal telangiectasia\nAdult and paediatric\n160\nACVRL1\nHaploinsufﬁciency\nAutosomal\ndominant\nAdult and paediatric\n160\nGDF2\nHaploinsufﬁciency\nAutosomal\ndominant\nAdult and paediatric\n149\n© ESC/ERS 2022\nCT, computed tomography; DLCO, Lung diffusion capacity for carbon monoxide; PAH, pulmonary arterial hypertension.\nESC/ERS Guidelines\n3649\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\ndiagnostic algorithm (Figure 6), as it assigns a level of probability of\nPH, irrespective of the cause. In addition, it is an important step in\nidentifying other cardiac disorders. Based on this initial assessment,\nif causes other than PH are identiﬁed and/or in case of low probabil-\nity of PH, patients should be managed accordingly.\n5.2.3. Step 3 (conﬁrmation)\nPatients should be referred to a PH centre for further evaluation in\nthe following situations: (1) when an intermediate/high probability of\nPH is established; (2) in the presence of risk factors for PAH, or a his-\ntory of PE. A comprehensive work-up should be performed, with the\ngoal of establishing the differential diagnoses and distinguishing be-\ntween the various causes of PH according to the current clinical clas-\nsiﬁcation. The PH centre is responsible for performing an invasive\nassessment according to the clinical scenario.\nAt any time, warning signs must be recognized, as they are asso-\nciated with worse outcomes and warrant immediate intervention.\nSuch warning signs include: rapidly evolving or severe symptoms\nDiagnostic algorithm of patients with unexplained exertional dyspnoea and/or suspected PH\nSuspected cause\nPH probability\nCauses other than\nPH identified\nMedical history\nPhysical exam\nECG\nBNP/NT-p\nT roBNP\nO2 saturation\nGene\nG\nral practitioner\nN\nPFT\nABG\nChest X-ray\na\nChest CTc\nCPET\nLung assessmentb\nEchocardiography\n(see Figures 4–5,\nTable 10)\nT\nCPET\nHeartr  assessmentb\nY\nLung disease\nLow\nPH or cardiac disease\nIntermediate/High\nFast-track refef rral at\nany time in case of\ni\nwarning signs\ng\na,\nor when\ne PAH\nP\nor CTEPH\nT\ne\nare suspected\ns\nRefer to PH cent\nf\nre\n(Class I)\nComprehensive PH\nwork-up (Table 14\nT\nand ReCo Table 2)\nT\nInvasive assessment\nas needed\n(ReCo Table 2)\nT\nRapid\ncross-refef rral\nas needed\nFurther\ndiagnostic work-up\nRisk factors for \nf\nPAH\nP\nd\nor CTEPHe\nManage\naccordingly\nFigure 6 Diagnostic algorithm of patients with unexplained dyspnoea and/or suspected pulmonary hypertension. ABG, arterial blood gas analysis; BNP,\nbrain natriuretic peptide; CPET, cardiopulmonary exercise testing; CT, computed tomography; CTEPH, chronic thrombo-embolic pulmonary hyperten-\nsion; ECG, electrocardiogram; HIV, human immunodeﬁciency virus; N, no; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary ar-\nterial hypertension; PE, pulmonary embolism; PFT, pulmonary function tests; PH, pulmonary hypertension; ReCo, recommendation; Y, yes. aWarning\nsigns include rapid progression of symptoms, severely reduced exercise capacity, pre-syncope or syncope on mild exertion, signs of right heart failure.\nbLung and heart assessment by specialist as per local practice. cAs indicated; CT pulmonary angiography recommended if PH suspected. dIncludes con-\nnective tissue disease (especially systemic sclerosis), portal hypertension, HIV infection, and family history of PAH. eHistory of PE, permanent intravascular\ndevices, inﬂammatory bowel diseases, essential thrombocythaemia, splenectomy, high-dose thyroid hormone replacement, and malignancy.\n3650\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nTable 14\nCharacteristic diagnostic features of patients with different forms of pulmonary hypertension\nDiagnostic tool\nCharacteristic\nﬁndings/\nfeatures\nGroup 1 (PAH)\nGroup 2 (PH\nassociated with left\nheart disease)\nGroup 3 (PH\nassociated with\nlung disease)\nGroup 4 (PH\nassociated with\npulmonary artery\nobstructions)\n5.1.1 Clinical\npresentation\nClinical features\nVariable age, but young,\nfemale patients may be\npredominantly\naffected.a161 Clinical\npresentation depends on\nassociated conditions and\nphenotype\nSee Section 5.1.1\nMostly elderly patients,\nfemale predominance in\ncase of HFpEF.161\nHistory and clinical\nﬁndings suggestive of\nLHD\nMostly elderly patients,\nmale predominance.161\nHistory and clinical\nﬁndings suggestive of\nlung disease. Smoking\nhistory common\nVariable age, but elderly\nmale and female equally\naffected.\nHistory of VTE (CTEPH\nmay occur in the\nabsence of a VTE\nhistory).\nRisk factors for CTEPH\nSee Section 10.1\nOxygen\nrequirement for\nhypoxaemia\nUncommon, except for\nconditions with low\nDLCO or right-to-left\nshunting\nUncommon\nCommon, often\nprofound hypoxaemia\nin severe PH\nUncommon; common\nin severe cases with\npredominantly distal\npulmonary artery\nocclusions\n5.1.3 Chest\nradiography\nRA/RV/PA size ↑\nPruning of peripheral\nvessels\nLA/LV size ↑\nCardiomegaly\nOccasional signs of\ncongestion (interstitial\noedema/Kerley lines,\nalveolar oedema,\npleural effusion)\nSigns of parenchymal\nlung disease\nRA/RV/PA size ↑\nNumber and size of\nperipheral vessels ↓\nOccasional signs of\npulmonary infarction\n5.1.4 Pulmonary\nfunction tests and\nABG\nSpirometry/PFT\nimpairment\nNormal or mildly impaired\nNormal or mildly\nimpaired\nAbnormal as\ndetermined by the\nunderlying lung disease\nNormal or mildly\nimpaired\nDLCO\nNormal or\nmild-to-moderately\nreduced (low DLCO in\nSSc-PAH, PVOD, and\nsome IPAH phenotypes)\nNormal or\nmild-to-moderately\nreduced, especially in\nHFpEF\nOften very low (,45%\npredicted)\nNormal or\nmild-to-moderately\nreduced\nArterial blood gas\nPaO2\nPaCO2\nNormal or reduced\nReduced\nNormal or reduced\nUsually normal\nReduced\nReduced, normal, or\nincreased\nNormal or reduced\nNormal or reduced\n5.1.5\nEchocardiography\nSigns of PH (increased\nsPAP, enlarged RA/RV)\nCongenital heart defects\nmay be present\nSee Section 5.1.5\nSigns of LHD (HFrEF,\nHFpEF, valvular) and PH\n(increased sPAP,\nenlarged RA/RV)\nSee Section 8\nSigns of PH (increased\nsPAP, enlarged RA/RV)\nSee Section 5.1.5\nSigns of PH (increased\nsPAP, enlarged RA/RV)\nSee Section 5.1.5\n5.1.6 Lung\nscintigraphy\nPlanar –\nSPECT V/Q\nNormal or matched\nNormal or matched\nNormal or matched\nMismatched perfusion\ndefect\n5.1.7 Chest CT\nSigns of PH or PVOD\nSee Section 5.1.7\nSigns of LHD\nPulmonary oedema\nSigns of PH\nSigns of parenchymal\nlung disease\nSigns of PH\nIntravascular ﬁlling\ndefects, mosaic\nperfusion, enlarged\nbronchial arteries\nSigns of PH\n5.1.11\nCardiopulmonary\nexercise testing\nHigh VE/VCO2 slope\nLow PETCO2, decreasing\nduring exercise\nNo EOV\nMildly elevated VE/\nVCO2 slope\nNormal PETCO2,\nincreasing during\nMildly elevated VE/\nVCO2 slope\nNormal PETCO2,\nHigh VE/VCO2 slope\nLow PETCO2,\ndecreasing during\nContinued\nESC/ERS Guidelines\n3651\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n(WHO-FC III/IV), clinical signs of RV failure, syncope, signs of low CO\nstate, poorly tolerated arrhythmias, and compromised or deterio-\nrated haemodynamic status (hypotension, tachycardia). Such cases\nmust be immediately managed as inpatients for initial work-up at a\nnearby hospital or PH centre. The presence of RV dysfunction by\nechocardiography, elevated levels of cardiac biomarkers, and/or\nhaemodynamic instability must prompt referral to a PH centre for\nimmediate assessment.\nThis diagnostic process emphasizes the importance of sufﬁcient\nawareness and collaboration between ﬁrst-line, specialized medicine\nand PH centres. Effective and rapid collaboration between each part-\nner permits earlier diagnosis and management, and improves\noutcomes.\n5.3. Screening and early detection\nDespite the advent of PAH therapies that prevent clinical worsen-\ning166–168 and effective interventions for CTEPH,102 the time from\nsymptom onset to PH diagnosis remains at .2 years,169,170 with\nmost patients presenting with advanced disease. Decreasing the\ntime to diagnosis may reduce emotional uncertainty in patients,171\nreduce the use of health care resources, and enable treatment at\nan earlier stage when therapies may be more effective.172\nA proposed multifaceted approach172 to facilitate an earlier diag-\nnosis includes: (1) screening asymptomatic, high-risk groups (with\nexercise\nEOV\nincreasing during\nexercise\nexercise\nNo EOV\n5.1.12 Right heart\ncatheterization\nPre-capillary PH\nPost-capillary PH\nPre-capillary PH\nPre- (or post-) capillary\nPH\n© ESC/ERS 2022\nABG, arterial blood gas analysis; CT, computed tomography; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon monoxide; EOV,\nexercise oscillatory ventilation; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IPAH, idiopathic pulmonary arterial hypertension;\nLA, left atrium; LHD, left heart disease; LV, left ventricle; PA, pulmonary artery; PaCO2, partial pressure of arterial carbon dioxide; PAH, pulmonary arterial hypertension; PaO2, partial\npressure of arterial oxygen; PETCO2, end-tidal partial pressure of carbon dioxide; PFT, pulmonary function test; PH, pulmonary hypertension; PVOD, pulmonary veno-occlusive disease;\nRA, right atrium; RV, right ventricle; sPAP, systolic pulmonary arterial pressure; SPECT, single-photon emission computed tomography; SSc-PAH, systemic sclerosis-associated pulmonary\narterial hypertension; VE/VCO2, ventilatory equivalent for carbon dioxide; V/Q, ventilation perfusion scintigraphy; VTE, venous thrombo-embolism.\n↓, reduced; ↑, increased.\naHowever, it may affect individuals of all ages and sexes; diagnosis in males should not be delayed.\nRecommendation Table 2 — Recommendations for\ndiagnostic strategy\nRecommendation\nClassa\nLevelb\nEchocardiography\nEchocardiography is recommended as the\nﬁrst-line, non-invasive, diagnostic investigation in\nsuspected PH82,84,91\nI\nB\nIt is recommended to assign an echocardiographic\nprobability of PH, based on an abnormal TRV and\nthe presence of other echocardiographic signs\nsuggestive of PH (see Table 10)91,92,162\nI\nB\nIt is recommended to maintain the current\nthreshold for TRV (.2.8 m/s) for\nechocardiographic probability of PH according to\nthe updated haemodynamic deﬁnition88\nI\nC\nBased on the probability of PH by\nechocardiography, further testing should be\nconsidered in the clinical context (i.e. symptoms\nand risk factors or associated conditions for PAH/\nCTEPH)92\nIIa\nB\nIn symptomatic patients with intermediate\nechocardiographic probability of PH, CPET may\nbe considered to further determine the likelihood\nof PH123,163\nIIb\nC\nContinued\nImaging\nVentilation/perfusion or perfusion lung scan is\nrecommended in patients with unexplained PH to\nassess for CTEPH105\nI\nC\nCT pulmonary angiography is recommended in\nthe work-up of patients with suspected\nCTEPH104\nI\nC\nRoutine biochemistry, haematology, immunology,\nHIV testing, and thyroid function tests are\nrecommended in all patients with PAH, to identify\nassociated conditions\nI\nC\nAbdominal ultrasound is recommended for the\nscreening of portal hypertension164\nI\nC\nChest CT should be considered in all patients\nwith PH\nIIa\nC\nDigital subtraction angiography should be\nconsidered in the work-up of patients with\nCTEPH\nIIa\nC\nOther diagnostic tests\nPulmonary function tests with DLCO are\nrecommended in the initial evaluation of patients\nwith PH78\nI\nC\nOpen or thoracoscopic lung biopsy is not\nrecommended in patients with PAH\nIII\nC\n© ESC/ERS 2022\nCPET, cardiopulmonary exercise testing; CT, computed tomography; CTEPH, chronic\nthrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon\nmonoxide; HIV, human immunodeﬁciency virus; PAH, pulmonary arterial hypertension;\nPH, pulmonary hypertension; TRV, tricuspid regurgitation velocity.\naClass of recommendation.\nbLevel of evidence.\n3652\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nhigh prevalence or where the diagnosis signiﬁcantly impacts the pro-\nposed intervention), including individuals with SSc (prevalence: 5–\n19%),173,174 BMPR2 mutation carriers (14–42%),33 ﬁrst-degree rela-\ntives of patients with HPAH,148 and patients undergoing assessment\nfor liver transplantation (2–9%);175 (2) early detection of symptom-\natic patients in at-risk groups with conditions such as portal hyperten-\nsion,176 HIV infection (0.5%),177 and non-SSc CTD, where the lower\nprevalence rates do not support asymptomatic screening; and (3) ap-\nplying population-based strategies by deploying early detection ap-\nproaches in PE follow-up clinics,178,179 breathlessness clinics,172 or\nin at-risk patients identiﬁed from their health care behaviour and/\nor previous investigations.180\nScreening can be deﬁned as the systematic application of a test or\ntests to identify at-risk, asymptomatic individuals. Screening ap-\nproaches can also be extended to individuals who would not other-\nwise have sought medical attention on account of their symptoms, to\nfacilitate early detection. Tools used to screen for PH have primarily\nbeen assessed, but not exclusively, in SSc,172,174 and include blood\nbiomarkers (NT-proBNP), ECG, echocardiography (primarily using\nestimates of sPAP at rest, but also exercise studies),182 PFTs\n(DLCO and forced vital capacity [FVC]/DLCO ratio), and exercise\ntesting including CPET (which has been used in combination with\nscreening algorithms to reduce the need for RHC).123,163\n5.3.1. Systemic sclerosis\nIn SSc, the prevalence of PAH is 5–19%,174 with an annual incidence\nof developing PAH of 0.7–1.5%.183–185 Evidence for the clinical value\nof detecting PAH early in SSc was provided by a screening pro-\ngramme,186 which showed less severe haemodynamic impairment\nand better survival in screened patients compared with a contem-\nporaneous, non-screened cohort,187 providing a strong rationale\nfor screening for PAH in patients with SSc.\nThe diagnostic accuracy of echocardiography or other tests alone in\ndetecting PAH is suboptimal.173 Several screening algorithms have been\nstudied using a combination of clinicalfeatures, echocardiography, PFTs,\nand NT-proBNP to select patients with SSc for RHC (DETECT;173\nAustralian Scleroderma Interest Group [ASIG]188). Such combined ap-\nproaches have improved diagnostic accuracy compared with the use of\nechocardiography, NT-proBNP, or PFTs alone, and are able to prevent\nunnecessary RHC and identify patients with mPAP 21–24 mmHg.189\nTherefore, a multimodal approach is warranted when screening pa-\ntients with SSc for PAH; the echocardiographic assessment should fol-\nlow the strategy described in Section 5.1.5.\nBeyond initial screening, the frequency with which screening\nshould be undertaken in asymptomatic subjects with SSc is unclear.\nA study from the Australian Scleroderma Study Cohort, where an-\nnual screening was recommended (some patients were screened\nup to 10 times), noted that most patients were diagnosed with\nPAH at their ﬁrst screening; however, those diagnosed on subse-\nquent screening had a lower mPAP, PVR, and WHO-FC, and better\nsurvival than those diagnosed at ﬁrst screening.190 Based on current\nevidence, annual screening for PAH in patients with SSc is sufﬁcient.\nGiven the ﬁnancial and emotional cost associated with regular\nscreening, stratifying subjects with SSc into those at highest and low-\nest risk of PAH would be desirable. Risk factors for PAH include: (1)\nclinical and demographic factors (i.e. breathlessness, longer disease\nduration, sicca symptoms, digital ulceration, older age, and male\nsex);\nand\n(2)\nthe\nresults\nof\ninvestigations\n(e.g.\npositive\nanti-centromere antibody proﬁle, mild ILD, low DLCO, elevated\nFVC/DLCO ratio, or elevated NT-proBNP).174,191 A recent\nmeta-analysis showed that reduced digital capillary density, as as-\nsessed by video-capillaroscopy, or progression to a severe active/\nlate pattern of vascular involvement is also a risk factor for\nPAH.192 In addition to identifying patients at increased risk of PAH,\na simple prediction model integrating symptoms, DLCO, and\nNT-proBNP identiﬁed subjects at very low probability of PAH\nwho could potentially avoid further speciﬁc testing for PH.183\nFurthermore, CPET may help to identify patients with SSc with a\nlow risk of having PAH and thus to avoid unnecessary RHC.123\nThe recommendations on screening for PAH in SSc have been es-\ntablished based on key narrative question 3 (Supplementary Data,\nSection 5.2).\n5.3.2. BMPR2 mutation carriers\nIn the evolving list of genes known to be associated with PAH, experi-\nence is largely restricted to BMPR2 mutation carriers who carry a life-\ntime risk of developing PAH of ≏20%, with penetrance higher in female\ncarriers (42%) compared with male carriers (14%).33,148,193 There is\ncurrently no accepted screening strategy for evaluating PAH in\nBMPR2 mutation carriers. At present, based on expert consensus,\nasymptomatic relatives who screen positive for PAH-causing mutations\nare often offered yearly screening echocardiography.25,26 The\nDELPHI-2 study, which prospectively screened carriers and relatives,\nrecently demonstrated a 9.1% pick up over 47+ 27 months of\nPAH, with 2/55 diagnosed at baseline and 3/55 at follow-up; this\nequates to an incidence of 2.3%/year.33 The screening schedule in-\ncluded ECG, NT-proBNP, DLCO, echocardiography, CPET, and op-\ntional RHC; however, none of the cases would have been picked up\nby echocardiography alone. Screening programmes should adopt a\nmultimodal approach, although the optimal strategy and screening per-\niod remains undeﬁned and will require multinational, multicentre study.\n5.3.3. Portal hypertension\nAn estimated 1–2% of patients with liver disease and portal hyperten-\nsion develop PoPH,176,194 which is of particular relevance in patients\nconsidered for transjugular portosystemic shunting or liver transplant-\nation. In such patients, echocardiography is recommended to screen\nfor PAH, even in the absence of symptoms. By using echocardiography,\nsPAP can be measured in ≏80% of patients with portal hypertension,\nwhich aids decisions to perform RHC. In patients assessed for liver\ntransplantation, one study showed that an sPAP of .50 mmHg had\n97% sensitivity and 77% speciﬁcity for detecting moderate-to-severe\nPAH.195 Other investigators have recommended RHC when sPAP is\n.38 mmHg.196 When screening for PoPH, it is advised to assess the\nechocardiographic probability of PH (see Section 5.1.5). In agreement\nwith the International Liver Transplant Society, for patients awaiting li-\nver transplantation, it is recommended to reassess for PAH annually,\nalthough the optimal interval remains unclear.175\n5.3.4. Pulmonary embolism\nChronic thrombo-embolic pulmonary hypertension is an uncommon\nand under-diagnosed complication of acute PE.112 The reported cu-\nmulative incidence of CTEPH after acute, symptomatic PE ranges\n0.1–11.8%, depending on the collective investigated.112,178,197–199 A\nESC/ERS Guidelines\n3653\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nsystematic review and meta-analysis reported a CTEPH incidence of\n0.6% in all patients with acute PE, 3.2% in survivors, and 2.8% in\nsurvivors without major comorbidities.178 A multicentre, observa-\ntional, screening study reported a CTEPH incidence of 3.7/1000\npatient-years and a 2 year cumulative incidence of 0.79% following\nacute PE.200 A recent prospective observational study (FOCUS,\nFollow-up After Acute Pulmonary Embolism) showed a cumulative\n2 year incidence of 2.3% and 16.0% for CTEPH and post-PE impair-\nment, respectively, which were both associated with a higher risk of\nrehospitalization and death.201 Due to insufﬁcient awareness, some\npatients may have a delayed diagnosis of CTEPH because they may\ninitially be misclassiﬁed as acute PE.112 In this context, the current\nguidelines do not recommend routine follow-up of patients with PE\nby imaging methods of the pulmonary vascular tree, but suggest evalu-\nating the index imaging test used to diagnose acute PE for signs of\nCTEPH. Echocardiography is the preferred ﬁrst-line diagnostic test\nin patients with suspected CTEPH.103\nUp to 50% of patients have persistent perfusion defects after an\nacute PE; however, the clinical relevance is unclear.202–204 All patients\nin whom symptoms can be attributed to post-thrombotic deposits\nwithin PAs are considered to have CTEPD, with or without PH.54\nWhile persistent dyspnoea is common after acute PE,205 the preva-\nlence of CTEPD without PH is unknown and requires further study\n(see Section 10.1). A study exploring screening for CTEPH following\nacute PE identiﬁed, using echocardiography, a low yield of additional\nCTEPH diagnoses in asymptomatic patients.206 Current PE guide-\nlines recommend that further diagnostic evaluation may be consid-\nered in asymptomatic patients with risk factors for CTEPH at 3–6\nmonths’ follow-up.103,207 Approaches to early detection of CTEPH\nfollowing acute PE are based on identifying patients at increased\nrisk.208 In patients with persistent or new-onset dyspnoea after PE,\nnon-invasive approaches use echocardiography to assess for PH\nand cross-sectional imaging to assess for persistent perfusion defects.\nLimited data exist on strategies using DECT, CT lung subtraction iod-\nine mapping, or 3D MR perfusion imaging. Scoring systems, including\nthe Leiden CTEPH rule-out criteria206,209 can be used to inform diag-\nnostic strategies. Cardiopulmonary exercise testing may identify\ncharacteristic features of exercise limitation due to PVD, or suggest\nan alternative diagnosis. The optimal timing for assessing symptoms\nto aid early detection of CTEPH may be 3–6 months after acute\nPE, coinciding with the routine evaluation of anticoagulant treatment,\nbut earlier assessment may be necessary in highly symptomatic or\ndeteriorating patients.54,103\nRecommendation Table 3 — Recommendations for\nscreening and improved detection of pulmonary ar-\nterial hypertension and chronic thrombo-embolic pul-\nmonary hypertension\nRecommendations\nClassa\nLevelb\nSystemic sclerosis\nIn patients with SSc, an annual evaluation of the\nrisk of having PAH is recommended183,186\nI\nB\nContinued\nIn adult patients with SSc with .3 years’\ndisease duration, an FVC ≥40%, and a DLCO\n,60%, the DETECT algorithm is recommended\nto identify asymptomatic patients with PAH173,186\nI\nB\nIn patients with SSc, where breathlessness remains\nunexplained following non-invasive assessment,\nRHC is recommended to exclude PAH185–187\nI\nC\nAssessing the risk of having PAH based on an\nevaluation of breathlessness, in combination with\nechocardiogram or PFTs and BNP/NT-proBNP,\nshould be considered in patients with\nSSc172,173,186,188,190\nIIa\nB\nPolicies to evaluate the risk of having PAH\nshould be considered in hospitals managing\npatients with SSc\nIIa\nC\nIn symptomatic patients with SSc, exercise\nechocardiography or CPET, or CMR may be\nconsidered to aid decisions to perform RHC\nIIb\nC\nIn patients with CTD with overlap features of SSc,\nan annual evaluation of the risk of PAH may be\nconsidered\nIIb\nC\nCTEPH/CTEPD\nIn patients with persistent or new-onset dyspnoea\nor exercise limitation following PE, further\ndiagnostic evaluation to assess for CTEPH/\nCTEPD is recommended103\nI\nC\nFor symptomatic patients with mismatched\nperfusion lung defects beyond 3 months of\nanticoagulation for acute PE, referral to a PH/\nCTEPH centre is recommended after considering\nthe results of echocardiography, BNP/\nNT-proBNP, and/or CPET203,206\nI\nC\nOther\nCounselling regarding the risk of PAH and annual\nscreening are recommended in individuals who\ntest positive for PAH-causing mutations and in\nﬁrst-degree relatives of patients with HPAH33\nI\nB\nIn patients referred for liver transplantation,\nechocardiography is recommended as a screening\ntest for PH\nI\nC\nFurther tests (echocardiography, BNP/\nNT-proBNP, PFTs, and/or CPET) should be\nconsidered in symptomatic patients with CTD,\nportal hypertension, or HIV to screen for PAH172\nIIa\nB\n© ESC/ERS 2022\nBNP,\nbrain\nnatriuretic\npeptide;\nCMR,\ncardiac\nmagnetic\nresonance;\nCPET,\ncardiopulmonary exercise testing; CTD, connective tissue disease; CTEPD, chronic\nthrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary\nhypertension; DLCO, Lung diffusion capacity for carbon monoxide; FVC, forced vital\ncapacity; HIV, human immunodeﬁciency virus; HPAH, heritable pulmonary arterial\nhypertension;\nNT-proBNP,\nN-terminal\npro-brain\nnatriuretic\npeptide;\nPAH,\npulmonary arterial hypertension; PE, pulmonary embolism; PFT, pulmonary function\ntest; PH, pulmonary hypertension; RHC, right heart catheterization; SSc, systemic\nsclerosis.\naClass of recommendation.\nbLevel of evidence.\n3654\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 23",
          "page": 23,
          "content": "Definite\nassociation | Possible association\nAminorex\nBenfluorex\nDasatinib\nDexfenfluramine\nFenfluramine\nMethamphetamines\nToxic rapeseed oil | Alkylating agents (cyclophosphamide,\nmitomycin C)a\nAmphetamines\nBosutinib\nCocaine\nDiazoxide\nDirect-acting antiviral agents against hepatitis\nC virus (sofosbuvir)\nIndirubin (Chinese herb Qing-Dai)\nInterferon alpha and beta\nLeflunomide\nL-tryptophan\nPhenylpropanolamine\nPonatinib\nSelective proteasome inhibitors (carfilzomib)\nSolvents (trichloroethylene)a\nSt John’s Wort",
          "rows": 2,
          "cols": 2
        },
        {
          "title": "Table on page 26",
          "page": 26,
          "content": "Signs of PH and\nconcomitant\nabnormalities | Signs of left heart\ndisease/\npulmonary\ncongestion | Signs of lung\ndisease\nRight heart\nenlargement | Central air space\nopacification | Flattening of\ndiaphragm (COPD/\nemphysema)\nPA enlargement\n(including aneurysmal\ndilatation) | Interlobular septal\nthickening ‘Kerley B’\nlines | Hyperlucency\n(COPD/\nemphysema)\nPruning of the\nperipheral vessels | Pleural effusions | Lung volume loss\n(fibrotic lung\ndisease)\n‘Water-bottle’ shape\nof cardiac silhouettea | Left atrial\nenlargement\n(including splayed\ncarina)\nLeft ventricular\ndilation | Reticular\nopacification\n(fibrotic lung\ndisease)",
          "rows": 5,
          "cols": 3
        },
        {
          "title": "Table on page 28",
          "page": 28,
          "content": "A: The ventricles | B: Pulmonary\nartery | C: Inferior vena\ncava and RA\nRV/LV basal diameter/\narea ratio .1.0 | RVOT AT\n,105 ms and/or\nmid-systolic\nnotching | IVC diameter\n.21 mm with\ndecreased inspiratory\ncollapse (,50% with\na sniff or ,20% with\nquiet inspiration)\nFlattening of the\ninterventricular\nseptum (LVEI .1.1 in\nsystole and/or diastole) | Early diastolic\npulmonary\nregurgitation\nvelocity .2.2 m/s | RA area (end-systole)\n.18 cm2\nTAPSE/sPAP ratio\n,0.55 mm/mmHg | PA diameter .AR\ndiameter\nPA diameter\n.25 mm | ",
          "rows": 4,
          "cols": 3
        },
        {
          "title": "Table on page 29",
          "page": 29,
          "content": "Measured variables |  | Normal value | \nRight atrial pressure, mean (RAP) |  | 2–6 mmHg | \nPulmonary artery pressure, systolic (sPAP) |  | 15–30 mmHg | \nPulmonary artery pressure, diastolic (dPAP) |  | 4–12 mmHg | \nPulmonary artery pressure, mean (mPAP) |  | 8–20 mmHg | \nPulmonary arterial wedge pressure, mean (PAWP) |  | ≤15 mmHg | \nCardiac output (CO) |  | 4–8 L/min | \nMixed venous oxygen saturation (SvO)a\n2 |  | 65–80% | \nArterial oxygen saturation (SaO)\n2 |  | 95–100% | \nSystemic blood pressure |  | 120/80 mmHg | \n | Calculated parameters |  | \nPulmonary vascular resistance (PVR)b |  | 0.3–2.0 WU | \nPulmonary vascular resistance index (PVRI) |  | 3–3.5 WU·m2 | \nTotal pulmonary resistance (TPR)c |  | ,3 WU | \nCardiac index (CI) |  | 2.5–4.0 L/min·m2 | \nStroke volume (SV) |  | 60–100 mL | \nStroke volume index (SVI) |  | 33–47 mL/m2 | \nPulmonary arterial compliance (PAC)d |  | .2.3 mL/mmHg | ",
          "rows": 18,
          "cols": 4
        },
        {
          "title": "Table on page 30",
          "page": 30,
          "content": "Compound | Route | Half-life | Dosage | Duration\nNitric oxide129 | inh | 15–30 s | 10–20 p.p.m. | 5–10 mina\nIloprost130,131 | inh | 30 min | 5–10 µgb | 10–15 minc\nEpoprostenol129 | i.v. | 3 min | 2–12 ng/kg/min | 10 mind",
          "rows": 4,
          "cols": 5
        },
        {
          "title": "Table on page 31",
          "page": 31,
          "content": "Recommendations |  | Classa | Levelb | \n | Right heart catheterization |  |  | \nIt is recommended that RHC is performed to\nconfirm the diagnosis of PH (especially PAH or\nCTEPH) and to support treatment decisions25,26 |  | I | B | \nIn patients with suspected or known PH, it is\nrecommended that RHC is performed in\nexperienced centres125 |  | I | C | \nIt is recommended that RHC comprises a\ncomplete set of haemodynamics and is performed\nfollowing standardized protocols25,26,145 |  | I | C | \n | Vasoreactivity testing |  |  | \nVasoreactivity testing is recommended in patients\nwith I/H/DPAH to detect those who can be\ntreated with high doses of a CCB129,146 |  | I | B | \nIt is recommended that vasoreactivity testing is\nperformed at PH centres |  | I | C | \nIt is recommended to consider a positive response\nto vasoreactivity testing by a reduction in mPAP\n≥10 mmHg to reach an absolute value of mPAP\n≤40 mmHg with an increased or unchanged\nCOc129 |  | I | C | \nInhaled nitric oxide, inhaled iloprost, or i.v.\nepoprostenol are recommended for performing\nvasoreactivity testing129–132 |  | I | C | \nVasoreactivity testing, for identifying candidates\nfor CCB therapy, is not recommended in patients\nwith PAH other than I/H/DPAH, and in PH groups\n2, 3, 4, and 5124,129 |  | III | C | ",
          "rows": 11,
          "cols": 5
        },
        {
          "title": "Table on page 32",
          "page": 32,
          "content": "Reference | 152 | 149 | 149 | 153 | 154 | 155 | 149 | 156 | 149,157 | 158 | 159 | 160 | 160 | 149\nPopulations | Paediatric and adult | Adult | Adult | Adult | Adult | Adult | Paediatric and adult | Paediatric and adult | Paediatric and (less commonly) adult | Adult | Older-onset adult | Adult and paediatric | Adult and paediatric | Adult and paediatric\nInvestigations | No discriminative investigations described |  |  |  |  |  |  | Fasting triglyceride and leptin levels | Skeletal X-rays: pelvis, knees, and feet CT chest: diffuse parenchymal lung disease | Reduced DLCO CT chest: interlobular septal thickening and mediastinal lymphadenopathy, and centrilobular ground-glass nodular opacities | Possible reduced DLCO | Iron-deficiency anaemia Presence on imaging of pulmonary, hepatic, cerebral, or spinal arteriovenous malformations Invasive endoscopic assessment of gastrointestinal telangiectasia |  | \nPotential distinguishing clinical and examination features | No specific or diagnostic clinical features described |  |  |  |  |  |  | Deficiency of subcutaneous adipose tissue | Patellar aplasia Skeletal abnormalities, particularly pelvis, knees, and feet | Distal phalangeal clubbing | No specific or diagnostic clinical features described | Telangiectasia Abnormal blood vessel formation Visceral arteriovenous malformations Bleeding diathesis |  | \nInheritance pattern | Autosomal dominant | Autosomal dominant | Autosomal dominant | Autosomal dominant | Autosomal dominant | Autosomal dominant | Autosomal dominant | Autosomal dominant | Autosomal dominant | Autosomal recessive | Autosomal dominant | Autosomal dominant | Autosomal dominant | Autosomal dominant\nPutative molecular mechanism | Haploinsufficiency | Unknown | Unknown | Haploinsufficiency | Haploinsufficiency | Haploinsufficiency | Unknown | Gain of function; dominant negative | Unknown | Loss of function | Loss of function | Unknown | Haploinsufficiency | Haploinsufficiency\nPulmonary hypertension phenotypic association | Heritable and idiopathic PAH |  |  |  |  |  | Heritable and idiopathic PAH Congenital heart disease | Heritable and idiopathic PAH Lipodystrophy | Heritable and idiopathic PAH Small patella syndrome (ischiopatellar dysplasia) Parenchymal lung disease Bronchopulmonary dysplasia Persistent pulmonary hypertension of the neonate | Pulmonary veno-occlusive disease/pulmonary capillary haemangiomatosis | Heritable and idiopathic PAH | Heritable and idiopathic PAH Hereditary haemorrhagic telangiectasia |  | \nGene | BMPR2 | ATP13A3 | AQP1 | ABCC8 | KCNK3 | SMAD9 | Sox17 | CAV1 | TBX4 | EIF2AK4 | KDR | ENG | ACVRL1 | GDF2",
          "rows": 8,
          "cols": 15
        },
        {
          "title": "Table on page 34",
          "page": 34,
          "content": "Diagnostic tool | Characteristic\nfindings/\nfeatures | Group 1 (PAH) | Group 2 (PH\nassociated with left\nheart disease) | Group 3 (PH\nassociated with\nlung disease) | Group 4 (PH\nassociated with\npulmonary artery\nobstructions)\n5.1.1 Clinical\npresentation | Clinical features | Variable age, but young,\nfemale patients may be\npredominantly\naffected.a161 Clinical\npresentation depends on\nassociated conditions and\nphenotype\nSee Section 5.1.1 | Mostly elderly patients,\nfemale predominance in\ncase of HFpEF.161\nHistory and clinical\nfindings suggestive of\nLHD | Mostly elderly patients,\nmale predominance.161\nHistory and clinical\nfindings suggestive of\nlung disease. Smoking\nhistory common | Variable age, but elderly\nmale and female equally\naffected.\nHistory of VTE (CTEPH\nmay occur in the\nabsence of a VTE\nhistory).\nRisk factors for CTEPH\nSee Section 10.1\n | Oxygen\nrequirement for\nhypoxaemia | Uncommon, except for\nconditions with low\nDLCO or right-to-left\nshunting | Uncommon | Common, often\nprofound hypoxaemia\nin severe PH | Uncommon; common\nin severe cases with\npredominantly distal\npulmonary artery\nocclusions\n5.1.3 Chest\nradiography |  | RA/RV/PA size ↑\nPruning of peripheral\nvessels | LA/LV size ↑\nCardiomegaly\nOccasional signs of\ncongestion (interstitial\noedema/Kerley lines,\nalveolar oedema,\npleural effusion) | Signs of parenchymal\nlung disease | RA/RV/PA size ↑\nNumber and size of\nperipheral vessels ↓\nOccasional signs of\npulmonary infarction\n5.1.4 Pulmonary\nfunction tests and\nABG | Spirometry/PFT\nimpairment | Normal or mildly impaired | Normal or mildly\nimpaired | Abnormal as\ndetermined by the\nunderlying lung disease | Normal or mildly\nimpaired\n | DLCO | Normal or\nmild-to-moderately\nreduced (low DLCO in\nSSc-PAH, PVOD, and\nsome IPAH phenotypes) | Normal or\nmild-to-moderately\nreduced, especially in\nHFpEF | Often very low (,45%\npredicted) | Normal or\nmild-to-moderately\nreduced\n | Arterial blood gas\nPaO\n2\nPaCO\n2 | Normal or reduced\nReduced | Normal or reduced\nUsually normal | Reduced\nReduced, normal, or\nincreased | Normal or reduced\nNormal or reduced\n5.1.5\nEchocardiography |  | Signs of PH (increased\nsPAP, enlarged RA/RV)\nCongenital heart defects\nmay be present\nSee Section 5.1.5 | Signs of LHD (HFrEF,\nHFpEF, valvular) and PH\n(increased sPAP,\nenlarged RA/RV)\nSee Section 8 | Signs of PH (increased\nsPAP, enlarged RA/RV)\nSee Section 5.1.5 | Signs of PH (increased\nsPAP, enlarged RA/RV)\nSee Section 5.1.5\n5.1.6 Lung\nscintigraphy | Planar –\nSPECT V/Q | Normal or matched | Normal or matched | Normal or matched | Mismatched perfusion\ndefect\n5.1.7 Chest CT |  | Signs of PH or PVOD\nSee Section 5.1.7 | Signs of LHD\nPulmonary oedema\nSigns of PH | Signs of parenchymal\nlung disease\nSigns of PH | Intravascular filling\ndefects, mosaic\nperfusion, enlarged\nbronchial arteries\nSigns of PH\n5.1.11\nCardiopulmonary\nexercise testing |  | High VE/VCO slope\n2\nLow P CO , decreasing\nET 2\nduring exercise\nNo EOV | Mildly elevated VE/\nVCO slope\n2\nNormal P CO ,\nET 2\nincreasing during | Mildly elevated VE/\nVCO slope\n2\nNormal P CO,\nET 2 | High VE/VCO slope\n2\nLow P CO ,\nET 2\ndecreasing during",
          "rows": 11,
          "cols": 6
        },
        {
          "title": "Table on page 35",
          "page": 35,
          "content": " |  |  | exercise\nEOV | increasing during\nexercise | exercise\nNo EOV\n5.1.12 Right heart\ncatheterization |  | Pre-capillary PH | Post-capillary PH | Pre-capillary PH | Pre- (or post-) capillary\nPH",
          "rows": 2,
          "cols": 6
        },
        {
          "title": "Table on page 35",
          "page": 35,
          "content": "(WHO-FC III/IV), clinical signs of RV failure, syncope, signs of low CO\nImaging\nstate, poorly tolerated arrhythmias, and compromised or deterio-\nVentilation/perfusion or perfusion lung scan is\nrated haemodynamic status (hypotension, tachycardia). Such cases\nrecommended in patients with unexplained PH to I C\nmust be immediately managed as inpatients for initial work-up at a\nassess for CTEPH105\nnearby hospital or PH centre. The presence of RV dysfunction by\nCT pulmonary angiography is recommended in\nechocardiography, elevated levels of cardiac biomarkers, and/or\nthe work-up of patients with suspected I C\nhaemodynamic instability must prompt referral to a PH centre for\nCTEPH104\nimmediate assessment.\nThis diagnostic process emphasizes the importance of sufficient Routine biochemistry, haematology, immunology,\nawareness and collaboration between first-line, specialized medicine HIV testing, and thyroid function tests are I C\nand PH centres. Effective and rapid collaboration between each part- recommended in all patients with PAH, to identify\nner permits earlier diagnosis and management, and improves associated conditions\noutcomes. Abdominal ultrasound is recommended for the I C\nscreening of portal hypertension164\nChest CT should be considered in all patients\nIIa C\nRecommendation Table 2 — Recommendations for with PH\ndiagnostic strategy Digital subtraction angiography should be\nconsidered in the work-up of patients with IIa C\nRecommendation Classa Levelb CTEPH\nEchocardiography Other diagnostic tests\nEchocardiography is recommended as the Pulmonary function tests with DLCO are\nfirst-line, non-invasive, diagnostic investigation in I B recommended in the initial evaluation of patients I C\nsuspected PH82,84,91 with PH78\nIt is recommended to assign an echocardiographic Open or thoracoscopic lung biopsy is not III C\nprobability of PH, based on an abnormal TRV and recommended in patients with PAH\nI B\nthe presence of other echocardiographic signs CPET, cardiopulmonary exercise testing; CT, computed tomography; CTEPH, chronic\nsuggestive of PH (see Table 10)91,92,162 thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon\nmonoxide; HIV, human immunodeficiency virus; PAH, pulmonary arterial hypertension;\nIt is recommended to maintain the current\nPH, pulmonary hypertension; TRV, tricuspid regurgitation velocity.\nthreshold for TRV (.2.8 m/s) for I C aClass of recommendation.\nechocardiographic probability of PH according to bLevel of evidence.\nthe updated haemodynamic definition88\nBased on the probability of PH by 5.3. Screening and early detection\nechocardiography, further testing should be Despite the advent of PAH therapies that prevent clinical worsen-\nconsidered in the clinical context (i.e. symptoms IIa B ing166–168 and effective interventions for CTEPH,102 the time from\nand risk factors or associated conditions for PAH/ symptom onset to PH diagnosis remains at .2 years,169,170 with\nCTEPH)92\nmost patients presenting with advanced disease. Decreasing the\nIn symptomatic patients with intermediate time to diagnosis may reduce emotional uncertainty in patients,171\nechocardiographic probability of PH, CPET may reduce the use of health care resources, and enable treatment at\nIIb C\nbe considered to further determine the likelihood an earlier stage when therapies may be more effective.172\nof PH123,163 A proposed multifaceted approach172 to facilitate an earlier diag-\nContinued nosis includes: (1) screening asymptomatic, high-risk groups (with |  |  |  |  |  | \n |  |  | Imaging |  |  | \n |  | Ventilation/perfusion or perfusion lung scan is\nrecommended in patients with unexplained PH to\nassess for CTEPH105 |  | I | C | \n |  | CT pulmonary angiography is recommended in\nthe work-up of patients with suspected\nCTEPH104 |  | I | C | \n |  | Routine biochemistry, haematology, immunology,\nHIV testing, and thyroid function tests are\nrecommended in all patients with PAH, to identify\nassociated conditions |  | I | C | \n |  | Abdominal ultrasound is recommended for the\nscreening of portal hypertension164 |  | I | C | \n |  | Chest CT should be considered in all patients\nwith PH |  | IIa | C | \n |  | Digital subtraction angiography should be\nconsidered in the work-up of patients with\nCTEPH |  | IIa | C | \n |  | Other diagnostic tests |  |  |  | \n |  | Pulmonary function tests with DLCO are\nrecommended in the initial evaluation of patients\nwith PH78 |  | I | C | \n |  | Open or thoracoscopic lung biopsy is not\nrecommended in patients with PAH |  | III | C | ",
          "rows": 11,
          "cols": 7
        },
        {
          "title": "Table on page 35",
          "page": 35,
          "content": "Recommendation | Classa | Levelb\nEchocardiography |  | \nEchocardiography is recommended as the\nfirst-line, non-invasive, diagnostic investigation in\nsuspected PH82,84,91 | I | B\nIt is recommended to assign an echocardiographic\nprobability of PH, based on an abnormal TRV and\nthe presence of other echocardiographic signs\nsuggestive of PH (see Table 10)91,92,162 | I | B\nIt is recommended to maintain the current\nthreshold for TRV (.2.8 m/s) for\nechocardiographic probability of PH according to\nthe updated haemodynamic definition88 | I | C\nBased on the probability of PH by\nechocardiography, further testing should be\nconsidered in the clinical context (i.e. symptoms\nand risk factors or associated conditions for PAH/\nCTEPH)92 | IIa | B\nIn symptomatic patients with intermediate\nechocardiographic probability of PH, CPET may\nbe considered to further determine the likelihood\nof PH123,163 | IIb | C",
          "rows": 7,
          "cols": 3
        },
        {
          "title": "Table on page 37",
          "page": 37,
          "content": "In adult patients with SSc with .3 years’\ndisease duration, an FVC ≥40%, and a DLCO\n,60%, the DETECT algorithm is recommended\nto identify asymptomatic patients with PAH173,186 |  | I | B | \nIn patients with SSc, where breathlessness remains\nunexplained following non-invasive assessment,\nRHC is recommended to exclude PAH185–187 |  | I | C | \nAssessing the risk of having PAH based on an\nevaluation of breathlessness, in combination with\nechocardiogram or PFTs and BNP/NT-proBNP,\nshould be considered in patients with\nSSc172,173,186,188,190 |  | IIa | B | \nPolicies to evaluate the risk of having PAH\nshould be considered in hospitals managing\npatients with SSc |  | IIa | C | \nIn symptomatic patients with SSc, exercise\nechocardiography or CPET, or CMR may be\nconsidered to aid decisions to perform RHC |  | IIb | C | \nIn patients with CTD with overlap features of SSc,\nan annual evaluation of the risk of PAH may be\nconsidered |  | IIb | C | \n | CTEPH/CTEPD |  |  | \nIn patients with persistent or new-onset dyspnoea\nor exercise limitation following PE, further\ndiagnostic evaluation to assess for CTEPH/\nCTEPD is recommended103 |  | I | C | \nFor symptomatic patients with mismatched\nperfusion lung defects beyond 3 months of\nanticoagulation for acute PE, referral to a PH/\nCTEPH centre is recommended after considering\nthe results of echocardiography, BNP/\nNT-proBNP, and/or CPET203,206 |  | I | C | \n | Other |  |  | \nCounselling regarding the risk of PAH and annual\nscreening are recommended in individuals who\ntest positive for PAH-causing mutations and in\nfirst-degree relatives of patients with HPAH33 |  | I | B | \nIn patients referred for liver transplantation,\nechocardiography is recommended as a screening\ntest for PH |  | I | C | \nFurther tests (echocardiography, BNP/\nNT-proBNP, PFTs, and/or CPET) should be\nconsidered in symptomatic patients with CTD,\nportal hypertension, or HIV to screen for PAH172 |  | IIa | B | ",
          "rows": 13,
          "cols": 5
        },
        {
          "title": "Table on page 37",
          "page": 37,
          "content": "Recommendations |  | Classa | Levelb | \n | Systemic sclerosis |  |  | \nIn patients with SSc, an annual evaluation of the\nrisk of having PAH is recommended183,186 |  | I | B | ",
          "rows": 3,
          "cols": 5
        }
      ],
      "keywords": [
        "ct",
        "hypertension",
        "mild",
        "surgery",
        "risk",
        "severe",
        "pulmonary hypertension",
        "symptomatic",
        "pulmonary",
        "diagnosis"
      ]
    },
    {
      "number": "8",
      "title": "6. Pulmonary arterial hypertension (group 1)",
      "start_page": 38,
      "end_page": 52,
      "content": "6. Pulmonary arterial\nhypertension (group 1)\n6.1. Clinical characteristics\nThe symptoms of PAH are non-speciﬁc and mainly related to pro-\ngressive RV dysfunction (see Section 5.1.1) as a consequence of pro-\ngressive pulmonary vasculopathy (Figure 7). The presentation of PAH\nmay be modiﬁed by diseases that are associated with PAH, as well as\ncomorbidities. More detailed descriptions of the individual PAH sub-\nsets are reported in Section 7.\n6.2. Severity and risk assessment\n6.2.1. Clinical parameters\nClinical assessment is a key part of evaluating patients with PAH, as it\nprovides valuable information for determining disease severity, im-\nprovement, deterioration, or stability. At follow-up, changes in\nWHO-FC (Table 15), episodes of chest pain, arrhythmias, haemop-\ntysis, syncope, and signs of right HF provide important information.\nPhysical examination should assess heart rate, rhythm, blood pres-\nsure, cyanosis, enlarged jugular veins, oedema, ascites, and pleural ef-\nfusions. The WHO-FC is one of the strongest predictors of survival,\nIntimal proliferation, fibrosis\nPulmonary vasculopathy\nRight heart failure\nMedial hypertrophy\nVascular remodelling\nPlexiform lesion\nThrombosis\nVasoconstriction\nPulmonary\nartery\nVascular\nobstruction\nRight ventricular\nremodelling /\ndysfunction\nCurrent therapeutic targets\nMedial\nhyperplasia\nIntimal\nproliferation\nPlexiform\nlesions\nNO-sGC-cGMP pathway\nEndothelin pathway\nProstacyclin pathway\nL-arginine\nNitric oxide\n(Vasodilatation and\nantiproliferation)\nsGC\nPDE5\nGTP\ncGMP\nGMP\nArachidonic acid\nProstacyclin\n(Vasodilatation and\nantiproliferation)\ncAMP\nIP receptor\nPro-endothelin-1\nEndothelin-1\n(Vasoconstriction\nand proliferation)\nEndothelin\nreceptor A\nEndothelin\nreceptor B\nP\nP\nMP\nG\nMP\nFigure 7 Pathophysiology and current therapeutic targets of pulmonary arterial hypertension (group 1). cAMP, cyclic adenosine monophosphate; (c)\nGMP, (cyclic) guanosine monophosphate; GTP, guanosine-5′-triphosphate; IP receptor, prostacyclin I2 receptor; NO, nitric oxide; PDE5, phospho-\ndiesterase 5; sGC, soluble guanylate cyclase.\nESC/ERS Guidelines\n3655\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nboth at diagnosis and follow-up,210–212 and worsening WHO-FC is\none of the most alarming indicators of disease progression, which\nshould trigger further investigations to identify the cause(s) of clinical\ndeterioration.210,213,214\n6.2.2. Imaging\nImaging of the heart plays an essential role in the follow-up of pa-\ntients with PAH. Several echocardiographic and cMRI parameters\nhave been proposed to monitor RV function during the course of\nPAH. Table S2 provides a list of imaging parameters and relative cut-\noff values associated with increased and decreased risk of adverse\nevents.\n6.2.2.1. Echocardiography\nEchocardiography is a widely available imaging modality and is readily\nperformed at the patient’s bedside. It is crucial that a high-quality\nechocardiographic assessment by PH specialists is undertaken to re-\nduce intraobserver and interobserver variability. Of note, estimated\nsPAP at rest is not prognostic and irrelevant to therapeutic decision-\nmaking.212,215,216 An increase in sPAP does not necessarily reﬂect\ndisease progression and a decrease in sPAP does not necessarily re-\nﬂect improvement.\nDespite the complex geometry of the right heart, echocardio-\ngraphic surrogates of the true right heart dimensions, which in-\nclude a description of RV and RA areas, and the LV eccentricity\nindex, provide useful clinical information in PAH.217,218 Right ven-\ntricular dysfunction can be evaluated measuring fractional area\nchange, TAPSE, tissue Doppler, and 2D speckle tracking myocar-\ndial strain recording of RV free-wall motion, all of which represent\nisovolumetric and ejection-phase indices of load-induced RV\npump failure.219–224 The rationale for the reported measure-\nments is strong, as RV systolic function metrics assess the adap-\ntation of RV contractility to increased afterload, and increased\nright heart dimension and inferior vena cava dilation reﬂect\nfailure of this mechanism, hence maladaptation.225 Pericardial\neffusion and tricuspid regurgitation (TR) grading further explore\nRV overload and are of prognostic relevance in these pa-\ntients.218,226–228 All of these variables are physiologically inter-\ndependent\nand\ntheir\ncombination\nprovides\nadditional\nprognostic information over single measurements.223\nEchocardiography also enables combined parameters to be mea-\nsured, such as the TAPSE/sPAP ratio, which is tightly linked to RV–\nPA coupling and predicts outcome.96,97 Echocardiographic measure-\nments of RV and RA sizes combined with LV eccentricity index are\ncrucial for assessing RV reverse remodelling as an emerging marker\nof treatment efﬁcacy.220,229 Three-dimensional echocardiography\nmay achieve better estimation than standard 2D assessment, but un-\nderestimations of volumes and ejection fraction have been reported,\nand technical issues are, as yet, unresolved.230\n6.2.2.2. Cardiac magnetic resonance imaging\nThe role of cMRI in evaluating patients with PAH has been addressed\nin several studies, and RV volumes, RVEF, and SV are essential prog-\nnostic determinants in PAH.225,231–236 In patients with PAH, initial\ncMRI measurements added prognostic value to current risk\nscores.231,232 In addition, risk assessment at 1 year of follow-up based\non cMRI was at least equal to risk assessment based on RHC.237 The\ncMRI risk-assessment variables based on the current literature are in-\ncluded in Table 16.117,225,231–235,237 The stroke volume index (SVI)\ncut-off levels are based on the consensus of the literature;238 a\nchange of 10 mL in SV (LV end-diastolic volume−LV end-systolic vol-\nume) during follow-up is considered clinically signiﬁcant.239 The value\nof cMRI in the follow-up of patients has been shown in several stud-\nies, and cMRI enables treatment effects to be monitored and treat-\nment strategies adapted in time to prevent clinical failure.240–242\n6.2.3. Haemodynamics\nCardiopulmonary haemodynamics assessed by RHC provide import-\nant prognostic information, both at the time of diagnosis and at\nfollow-up.129,212,213,216,238,243–245,247,248 Currently available risk-\nstratiﬁcation tools include haemodynamic variables for prognostica-\ntion: RAP and PVR in REVEAL risk scores,213,249,250 and RAP, CI, and\nSvO2 in the ESC/ERS risk-stratiﬁcation table.25,26 The mPAP pro-\nvides little prognostic information, except in acute vasodilator re-\nsponders.129 A recent study from France, which combined clinical\nand haemodynamic parameters, found that WHO-FC, 6MWD,\nRAP, and SVI (but not SV and SvO2) were independent predictors\nof outcome.238\nTo reﬁne the risk-stratiﬁcation table (Table 16), SVI criteria are\nnow added with the cut-off values of .38 mL/m2 and ,31 mL/m2\nto determine low-risk and high-risk status, respectively.238\nThe optimal timing of follow-up RHC has not been determined.\nWhile some centres regularly perform invasive follow-up assess-\nments, others perform them as clinically indicated, and there is no\nevidence that any of these strategies is associated with better out-\ncomes (Table 17).\nTable 15\nWorld Health Organization classiﬁcation of\nfunctional\nstatus\nof\npatients\nwith\npulmonary\nhypertension\nClass\nDescriptiona\nWHO-FC I\nPatients with PH but without resulting limitation of\nphysical activity. Ordinary physical activity does not\ncause undue dyspnoea or fatigue, chest pain, or near\nsyncope\nWHO-FC II\nPatients with PH resulting in slight limitation of physical\nactivity. They are comfortable at rest. Ordinary physical\nactivity causes undue dyspnoea or fatigue, chest pain, or\nnear syncope\nWHO-FC III\nPatients with PH resulting in marked limitation of\nphysical activity. They are comfortable at rest. Less than\nordinary activity causes undue dyspnoea or fatigue,\nchest pain, or near syncope\nWHO-FC IV\nPatients with PH with an inability to carry out any\nphysical activity without symptoms. These patients\nmanifest signs of right HF. Dyspnoea and/or fatigue may\neven be present at rest. Discomfort is increased by any\nphysical activity\n© ESC/ERS 2022\nPH, pulmonary hypertension; WHO-FC, World Health Organization functional class.\naFunctional classiﬁcation of PH modiﬁed after the New York Heart Association\nfunctional classiﬁcation according to the World Health Organization 1998.147\n3656\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n6.2.4. Exercise capacity\nThe 6-minute walking test (6MWT) is the most widely used measure\nof exercise capacity in PH centres. The 6MWT is easy to perform,\ninexpensive, and widely accepted by patients, health professionals,\nand medicines agencies as an important and validated variable in\nPH. As with all PH assessments, 6MWT results must always be inter-\npreted in the clinical context. The 6MWD is inﬂuenced by factors\nsuch as sex, age, height, weight, comorbidities, need for oxygen,\nlearning curve, and motivation. Test results are usually given in abso-\nlute distance (metres) rather than the percentage of predicted va-\nlues. Change in 6MWD is one of the most commonly used\nparameters in PAH clinical trials as a primary endpoint, key second-\nary endpoint, or component of clinical worsening.251 A recent inves-\ntigation showed that the best absolute-threshold values for 1 year\nmortality and 1 year survival, respectively, were 165 m and 440 m,\nrespectively.252 Improvements in 6MWD have had less predictive\nvalue than deterioration on key clinical outcomes (mortality and sur-\nvival).250,252,253 These results are consistent with observations from\nclinical trials and registries;254,255 however, there is no single thresh-\nold that would apply to all patients.256 Some studies have also sug-\ngested that adding SaO2 measured by pulse oximetry and heart rate\nresponses may improve prognostic relevance.246,257 Hypoxaemia ob-\nserved during the 6MWT is associated with worse survival, but these\nﬁndings still await conﬁrmation in large multicentre studies.\nThe incremental shuttle walking test (ISWT) is an alternative max-\nimal test for assessing patients with PAH. The ISWT has a potential\nadvantage over the 6MWT in that it does not have a ceiling effect;\nfurthermore, it keeps the simplicity of a simple-to-perform ﬁeld\ntest, in contrast to CPET. However, the ISWT experience in PAH\nis currently limited.258\nCardiopulmonary exercise testing is a non-invasive method for as-\nsessing functional capacity and exercise limitation. It is usually\nTable 16\nComprehensive risk assessment in pulmonary arterial hypertension (three-strata model)\nDeterminants of prognosis (estimated\n1-year mortality)\nLow risk\n(,5%)\nIntermediate risk\n(5–20%)\nHigh risk\n(.20%)\nClinical observations and modiﬁable variables\nSigns of right HF\nAbsent\nAbsent\nPresent\nProgression of symptoms and clinical\nmanifestations\nNo\nSlow\nRapid\nSyncope\nNo\nOccasional syncopea\nRepeated syncopeb\nWHO-FC\nI, II\nIII\nIV\n6MWDc\n.440 m\n165–440 m\n,165 m\nCPET\nPeak VO2 .15 mL/min/kg\n(.65% pred.)\nVE/VCO2 slope ,36\nPeak VO2 11–15 mL/min/kg\n(35–65% pred.)\nVE/VCO2 slope 36–44\nPeak VO2 ,11 mL/min/kg\n(,35% pred.)\nVE/VCO2 slope .44\nBiomarkers: BNP or NT-proBNPd\nBNP ,50 ng/L\nNT-proBNP ,300 ng/L\nBNP 50–800 ng/L\nNT-proBNP 300–1100 ng/L\nBNP .800 ng/L\nNT-proBNP .1100 ng/L\nEchocardiography\nRA area ,18 cm2\nTAPSE/sPAP .0.32 mm/mmHg\nNo pericardial effusion\nRA area 18–26 cm2\nTAPSE/sPAP 0.19–0.32 mm/\nmmHg\nMinimal pericardial effusion\nRA area .26 cm2\nTAPSE/sPAP ,0.19 mm/mmHg\nModerate or large pericardial\neffusion\ncMRIe\nRVEF .54%\nSVI .40 mL/m2\nRVESVI ,42 mL/m2\nRVEF 37–54%\nSVI 26–40 mL/m2\nRVESVI\n42–54 mL/m2\nRVEF ,37%\nSVI ,26 mL/m2\nRVESVI .54 mL/m2\nHaemodynamics\nRAP ,8 mmHg\nCI ≥2.5 L/min/m2\nSVI .38 mL/m2\nSvO2 .65%\nRAP 8–14 mmHg\nCI 2.0–2.4 L/min/m2\nSVI 31–38 mL/m2\nSvO2 60–65%\nRAP .14 mmHg\nCI ,2.0 L/min/m2\nSVI ,31 mL/m2\nSvO2 ,60%\n© ESC/ERS 2022\n6MWD, 6-minute walking distance; BNP, brain natriuretic peptide; CI, cardiac index; cMRI, cardiac magnetic resonance imaging; CPET, cardiopulmonary exercise testing; HF, heart failure;\nNT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; pred., predicted; RA, right atrium; RAP, right atrial pressure; sPAP, systolic pulmonary\narterial pressure; SvO2, mixed venous oxygen saturation; RVESVI, right ventricular end-systolic volume index; RVEF, right ventricular ejection fraction; SVI, stroke volume index;\nTAPSE, tricuspid annular plane systolic excursion; VE/VCO2, ventilatory equivalents for carbon dioxide; VO2, oxygen uptake; WHO-FC, World Health Organization functional class.\naOccasional syncope during heavy exercise or occasional orthostatic syncope in a stable patient.\nbRepeated episodes of syncope even with little or regular physical activity.\ncObserve that 6MWD is dependent upon age, height, and burden of comorbidities.\ndTo harmonize with the four-strata model shown in Table 18, the BNP and NT-proBNP cut-off levels have been updated from the 2015 version based on data from the REVEAL registry,\nacknowledging that the European validation studies have used the original cut-off levels.274,292,293,295,296,302\necMRI parameters adapted from Section 6.2.2.2.\nESC/ERS Guidelines\n3657\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nperformed as a maximal exercise test, and is safe even in patients\nwith severe exercise limitation.259,260 Most PH centres use an incre-\nmental ramp protocol, although the test has not yet been standar-\ndized for this patient population. Robust prognostic evidence for\npeak VO2 and VE/VCO2 has been found in three studies, all powered\nfor multivariable analysis.261–263 When associated with SVI, peak\nVO2 provided useful information to further stratify patients with\nPAH at intermediate risk.264 However, the added value of CPET\non top of common clinical and haemodynamic variables remains\nlargely unexplored.\n6.2.5. Biochemical markers\nConsiderable efforts have been made to identify additional biomar-\nkers of PVD, addressing prognosis,265–272 diagnosis, and differenti-\nation of PH subtypes,270,273–276 as well as PAH treatment\nresponse.266 Emerging proteins related to PAH and vascular remod-\nelling include bone morphogenetic proteins 9 and 10 and translation-\nally controlled tumour protein.270,277,278 Proteome-wide screening\nin IPAH and HPAH identiﬁed a multimarker panel with prognostic\ninformation in addition to the REVEAL risk score.271 Another study\nfound that early development of SSc-associated PAH (PAH-SSc) was\npredicted by high circulating levels of C-X-C motif chemokine 4 in\npatients with SSc.276 However, none of these biomarkers have\nbeen introduced in clinical practice.\nThus, BNP and NT-proBNP remain the only biomarkers routinely\nused in clinical practice at PH centres, correlating with myocardial\nstress and providing prognostic information.279 Brain natriuretic\npeptide and NT-proBNP are not speciﬁc for PH, as they can be ele-\nvated in other forms of heart disease, exhibiting great variability. The\npreviously proposed cut-off levels of BNP (,50, 50–300, and\n.300 ng/L) and NT-proBNP (,300, 300–1400, and .1400 ng/L)\nfor low, intermediate, and high risk, respectively, in the ESC/ERS\nrisk-assessment model at baseline and during follow-up are prognos-\ntic for long-term outcomes and can be used to predict response to\ntreatment.266 Reﬁned cut-off values for BNP (,50, 50–199, 200–\n800, and .800 ng/L) and NT-pro-BNP (,300, 300–649, 650–\n1100, and .1100 ng/L) for low, intermediate–low, intermediate–\nhigh, and high risk, respectively, have recently been introduced as\npart of a four-strata risk-assessment strategy (see Section 6.2.7).280\n6.2.6. Patient-reported outcome measures\nA patient-reported outcome measure (PROM) is a term for health\noutcomes that are ‘self-reported’ by the patient. It is the patient’s ex-\nperience of living with PH and its impact on them and their care-\ngivers, including symptomatic, intellectual, psychosocial, spiritual,\nand goal-orientated dimensions of the disease and its treatment.\nDespite treatment advances improving survival, patients with PAH\npresent with a range of non-speciﬁc yet debilitating symptoms, which\naffect health-related quality of life (HR-QoL).281,282\nPatient-reported outcome measures remain an underused out-\ncome measure. Tools validated in patients with PAH should be\nused to assess HR-QoL282,283 in individual patients. There has\nbeen a reliance on generic PROMs, which have been studied in pa-\ntients with PAH but may lack sensitivity to detect changes in\nPAH.284,285 To address this, a number of PH-speciﬁc HR-QoL instru-\nments\nhave been\ndeveloped and\nvalidated (e.g.\nCambridge\nPulmonary\nHypertension\nOutcome\nReview\n[CAMPHOR],286\nemPHasis-10,282,287 Living with Pulmonary Hypertension,288 and\nPulmonary\nArterial\nHypertension-Symptoms\nand\nImpact\n[PAH-SYMPACT]).289\nThese\ndisease-speciﬁc\nPROMs\ntrack\nTable 17\nSuggested assessment and timing for the follow-up of patients with pulmonary arterial hypertension\nAt\nbaseline\n3–6 months after changes in\ntherapya\nEvery 3–6 months in stable\npatientsa\nIn case of clinical\nworsening\nMedical assessment (including\nWHO-FC)\n6MWT\nBlood test (including\nNT-proBNP)b,c\nECG\nEchocardiography or cMRI\nABG or pulse oximetryd\nDisease-speciﬁc HR-QoL\nCPET\nRHC\n© ESC/ERS 2022\n6MWT, 6-minute walking test; ABG, arterial blood gas analysis; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; BNP, brain natriuretic peptide; cMRI, cardiac magnetic\nresonance imaging; CPET, cardiopulmonary exercise testing; ECG, electrocardiogram; HR-QoL, health-related quality of life; INR, international normalized ratio; NT-proBNP, N-terminal\npro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; RHC, right heart catheterization; TSH, thyroid-stimulating hormone; WHO-FC, World Health Organization\nfunctional class.\nGreen: is indicated; yellow: should be considered; orange: may be considered.\naIntervals to be adjusted according to patient needs, PAH aetiology, risk category, demographics, and comorbidities.\nbBasic laboratory tests include blood count, INR (in patients receiving vitamin K antagonists), serum creatinine, sodium, potassium, ASAT/ALAT, bilirubin, and BNP/NT-proBNP.\ncExtended laboratory tests (e.g. TSH, troponin, uric acid, iron status, etc.) according to clinical circumstances.\ndABG should be performed at baseline but may be replaced by pulse oximetry in stable patients at follow-up.\n3658\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nfunctional status, clinical deterioration, and prognosis in PAH, and are\nmore sensitive to the differences in the risk status than generic\nPROMs.290,291 In addition, HR-QoL scores provide independent\nprognostic information.287\n6.2.7. Comprehensive prognostic evaluation, risk\nassessment, and treatment goals\nIn the 2015 ESC/ERS Guidelines for the diagnosis and treatment of\nPH, risk assessment was based on a multiparametric approach using\na three-strata model to classify patients at low, intermediate, or high\nrisk of death. Originally, these strata were based on estimated 1 year\nmortality rates of ,5%, 5–10%, and .10%, respectively.25,26 Since\nthen, registry data have shown that observed 1 year mortality rates\nin the intermediate- and high-risk groups were sometimes higher\nthan predicted (i.e. up to 20% in the intermediate-risk group and\n.20% in the high-risk group). These numbers have been updated ac-\ncordingly in the revised three-strata risk model (Table 16).292–294\nSeveral abbreviated approaches of the 2015 ESC/ERS risk-\nstratiﬁcation tool have been introduced and independently validated\nusing the Swedish Pulmonary Arterial Hypertension Registry\n(SPAHR),292 the Comparative, Prospective Registry of Newly\nInitiated Therapies for PH (COMPERA),293 and the French PH\nRegistry (FPHR).295 Other risk-stratiﬁcation tools have been devel-\noped from the US REVEAL, including the REVEAL 2.0 risk score cal-\nculator, and an abridged version (REVEAL Lite 2).249,296 In all these\nstudies, WHO-FC, 6MWD, and BNP/NT-proBNP emerged as the\nvariables with the highest predictive value.\nThe\nmain\nlimitation\nof\nthe\n2015\nESC/ERS\nthree-strata,\nrisk-assessment tool is that 60–70% of the patients are classiﬁed as\nintermediate risk.292–295,297–303 An initial attempt to substratify the\nintermediate-risk group has been proposed, using a modiﬁed mean\nscore in the SPAHR equation (with low–intermediate, 1.5–1.99\nand high–intermediate, 2.0–2.49 as cut-offs), where the high–inter-\nmediate group was associated with worse survival.302 There have\nalso been attempts to further improve risk stratiﬁcation by exploring\nthe additional value of new biomarkers,304 or by measuring RV struc-\nture and function by echocardiography and cMRI.231,305,306 Other\nstrategies have included incorporating renal function307 or combin-\ning 6MWD with TAPSE/sPAP ratio;96,97 however, all of these strat-\negies have to be further validated.\nTwo recent registry studies have evaluated a four-strata,\nrisk-assessment tool based on reﬁned cut-off levels for WHO-FC,\n6MWD, and NT-proBNP (Table 18).280,308 Patients were categorized\nas low, intermediate–low, intermediate–high, or high risk. Together,\nthese studies included .4000 patients with PAH and showed that\nthe four-strata model performed at least as well as the three-strata\nmodel in predicting mortality. The four-strata model predicted sur-\nvival in patients with IPAH, HPAH, DPAH, and PAH associated\nwith CTD (including the SSc subgroup), and in patients with PoPH.\nThe observed 1-year mortality rates in the four risk strata were 0–\n3%, 2–7%, 9–19%, and .20%, respectively. Compared with the\nthree-strata model, the four-strata model was more sensitive to\nchanges in risk from baseline to follow-up, and these changes were\nassociated with changes in the long-term mortality risk. The main ad-\nvantage of the four-strata model over the three-strata model is better\ndiscrimination within the intermediate-risk group, which helps guide\ntherapeutic decision-making (see Section 6.3.4). For these reasons,\nthe four-strata model is included in the updated treatment algorithm\n(see Figure 9). However, the three-strata model is maintained for ini-\ntial assessment, which should be comprehensive and include echocar-\ndiographic and haemodynamic variables, for which cut-off values for\nthe four-strata model have yet to be established.\nSeveral studies have identiﬁed WHO-FC, 6MWD, and BNP/\nNT-proBNP as the strongest prognostic predictors.293,295,296 With\nthe abbreviated risk-assessment tools, missing values become an im-\nportant limitation. REVEAL Lite 2 provides accurate prediction when\none key variable (WHO-FC, 6MWD, or BNP/NT-proBNP) is un-\navailable, but is no longer accurate when two of these variables are\nmissing.293,296 The original three-strata SPAHR/COMPERA risk\ntool was developed with at least two variables available, while the\nfour-strata model was developed and validated in patients for\nwhom all three variables were available. It is therefore recommended\nto use at least these three variables for risk stratiﬁcation. However,\ntwo components may be used when variables are missing, especially\nwhen a functional criterion (WHO-FC or 6MWD) is combined with\nBNP or NT-proBNP.296\nCollectively,\nthe\navailable\nstudies\nsupport\na\nrisk-based,\ngoal-orientated treatment approach in patients with PAH, where\nachieving and/or maintaining a low-risk status is favourable and re-\ncommended (key narrative question 4, Supplementary Data,\nSection 6.1).298,300,303,309,310 For risk stratiﬁcation at diagnosis, use\nof the three-strata model is recommended taking into account as\nmany factors as possible (Table 16), with a strong emphasis on disease\ntype, WHO-FC, 6MWD, BNP/NT-proBNP, and haemodynamics.\nTable 18\nVariables used to calculate the simpliﬁed four-strata risk-assessment tool\nDeterminants of prognosis\nLow risk\nIntermediate–low risk\nIntermediate–high risk\nHigh risk\nPoints assigned\n1\n2\n3\n4\nWHO-FC\nI or IIa\n-\nIII\nIV\n6MWD, m\n.440\n320–440\n165–319\n,165\nBNP or\nNT-proBNP,a ng/L\n,50\n,300\n50–199\n300–649\n200–800\n650–1100\n.800\n.1100\n© ESC/ERS 2022\n6MWD, 6-minute walking distance; BNP, brain natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; WHO-FC, World Health Organization functional class.\nRisk is calculated by dividing the sum of all grades by the number of variables and rounding to the next integer.\naWHO-FC I and II are assigned 1 point as both are associated with good long-term survival.\nESC/ERS Guidelines\n3659\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nAt follow-up, the four-strata model (Table 18) is recommended\nas a basic risk-stratiﬁcation tool, but additional variables should\nbe considered as needed, especially right heart imaging and\nhaemodynamics. At any stage, individual factors such as age,\nsex, disease type, comorbidities, and kidney function should also\nbe considered.\n6.3. Therapy\nAccording to the revised haemodynamic deﬁnition, PAH may be di-\nagnosed in patients with mPAP .20 mmHg and PVR .2 WU. Yet,\nthe efﬁcacy of drugs approved for PAH has only been demonstrated\nin patients with mPAP ≥25 mmHg and PVR .3 WU (see\nSupplementary Data, Table S1). No data are available for the efﬁcacy\nof drugs approved for PAH in patients whose mPAP is ,25 mmHg\nand whose PVR is ,3 WU. Hence, for such patients, the efﬁcacy of\ndrugs approved for PAH has not been established. The same is true\nfor patients with exercise PH, who, by deﬁnition, do not fulﬁl the\ndiagnostic criteria for PAH. Patients at high risk of developing\nPAH, for instance patients with SSc or family members of patients\nwith HPAH, should be referred to a PH centre for individual\ndecision-making.\n6.3.1. General measures\nManaging patients with PAH requires a comprehensive treatment\nstrategy and multidisciplinary care. In addition to applying PAH drugs,\ngeneral measures and care in special situations represent integral\ncomponents of optimized patient care. In this context, the systemic\nconsequences of PH and right-sided HF, often contributing to dis-\nease burden, should be appropriately managed.119\n6.3.1.1. Physical activity and supervised rehabilitation\nThe 2015 ESC/ERS Guidelines for the diagnosis and treatment of PH\nsuggested that patients with PAH should be encouraged to be active\nwithin symptom limits.25,26 Since then, additional studies have shown\nthe beneﬁcial impact of exercise training on exercise capacity\n(6MWD) and quality of life.312–316 A large, randomized controlled\ntrial (RCT) in 11 centres across 10 European countries, including\n116 patients with PAH/CTEPH on PAH drugs, showed a signiﬁcant\nimprovement in 6MWD of 34.1 + 8.3 m, quality of life, WHO-FC,\nand peak VO2 compared with standard of care.315 Since most of\nthe studies included patients who were stable on medical treatment,\npatients with PAH should be treated with the best standard of\npharmacological treatment and be in a stable clinical condition before\nembarking on a supervised rehabilitation programme. Establishing\nspecialized rehabilitation programmes for patients with PH would\nfurther enhance patient access to this intervention.317\n6.3.1.2. Anticoagulation\nThere are several reasons to consider anticoagulation in patients with\nPAH. Histopathological specimens from PAH patients’ lungs have\nshown in situ thrombosis of pulmonary vessels. Patients with CHD\nor PA aneurysms may develop thrombosis of the central PAs.\nAbnormalities in the coagulation and ﬁbrinolytic system indicating a\npro-coagulant state have been reported in patients with PAH.318\nData from RCTs on anticoagulation in PAH are lacking, and regis-\ntry data have yielded conﬂicting results. The largest registry analysis\nso far suggested a potential survival beneﬁt associated with anticoa-\ngulation in patients with IPAH,319 but this ﬁnding was not conﬁrmed\nby others.320 Two recent meta-analyses also concluded that using\nanticoagulants may improve survival in patients with IPAH;321,322\nhowever, none of the included studies were methodologically ro-\nbust. Despite the lack of evidence, registry data obtained between\n2007 and 2016 showed that anticoagulation was used in 43% of pa-\ntients with IPAH.293 In PAH associated with SSc, registry data and\nmeta-analyses uniformly indicated that anticoagulation may be harm-\nful.320–322 In CHD, there are also no RCTs on anticoagulation. There\nis also no consensus about the use of anticoagulants in patients who\nhave permanent i.v. lines for therapy with prostacyclin analogues; this\nis left to local centre practice.\nAs anticoagulation is associated with an increased bleeding risk,\nand in the absence of robust data, no general recommendation has\nbeen made for or against the use of anticoagulants in patients with\nPAH.; therefore, individual decision-making is required.\nRecommendation Table 4 — Recommendations for\nevaluating the disease severity and risk of death in pa-\ntients with pulmonary arterial hypertension\nRecommendations\nClassa\nLevelb\nIt is recommended to evaluate disease severity in\npatients with PAH with a panel of data derived\nfrom clinical assessment, exercise tests,\nbiochemical markers, echocardiography, and\nhaemodynamic\nevaluations212,213,216,249,292,293,295,296,302,307\nI\nB\nAchieving and maintaining a low-risk proﬁle on\noptimized medical therapy is recommended as a\ntreatment goal in patients with\nPAH210,212,213,216,298,300,303,309,310\nI\nB\nFor risk stratiﬁcation at the time of diagnosis, the\nuse of a three-strata model (low, intermediate,\nand high risk) is recommended, taking into\naccount all available data, including\nhaemodynamics292,293,295\nI\nB\nFor risk stratiﬁcation during follow-up, the use of a\nfour-strata model (low, intermediate–low,\nintermediate–high, and high risk) based on\nWHO-FC, 6MWD, and BNP/NT-proBNP is\nrecommended, with additional variables taken\ninto account as necessary280,308\nI\nB\nIn some PAH aetiologies and patients with\ncomorbidities, optimization of therapy should be\nconsidered on an individual basis, while\nacknowledging that a low-risk proﬁle is not always\nachievable293,294,299,311\nIIa\nB\n© ESC/ERS 2022\n6MWD, 6-minute walking distance; BNP, brain natriuretic peptide; NT-proBNP,\nN-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension;\nWHO-FC, World Health Organization functional class.\naClass of recommendation.\nbLevel of evidence.\n3660\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n6.3.1.3. Diuretics\nRight HF is associated with systemic ﬂuid retention, reduced renal\nblood ﬂow, and activation of the renin–angiotensin–aldosterone sys-\ntem. Increased right-sided ﬁlling pressures are transmitted to the re-\nnal veins, increasing interstitial and tubular hydrostatic pressure\nwithin the encapsulated kidney, which decreases net glomerular ﬁl-\ntration rate and oxygen delivery.119\nAvoiding ﬂuid retention is one of the key objectives in managing pa-\ntients with PH. Once these patients develop signs of right-sided HF and\noedema, restricting ﬂuid intake and using diuretics is recommended.\nThe three main classes of diuretics—loop diuretics, thiazides, and min-\neralocorticoid receptor antagonists—are used as monotherapy or in\ncombination, as determined by the patient’s clinical need and kidney\nfunction. Patients requiring diuretic therapy should be advised to regu-\nlarly monitor their body weight and to seek medical advice in case of\nweight gain. Close collaboration between patients, PH centres, especial-\nly PH nurses, and primary care physicians plays a vital role. Kidney func-\ntion and serum electrolytes should be regularly monitored, and\nintravascular volume depletion must be avoided as it may cause a fur-\nther decline in CO and systemic blood pressure. Physicians should\nbear in mind that ﬂuid retention and oedema may not necessarily signal\nright-sided HF, but may also be a side effect of PAH therapy.323\n6.3.1.4. Oxygen\nAlthough oxygen administration reduces PVR and improves exercise\ntolerance in patients with PAH, there are no data to suggest that long-\nterm oxygen therapy has sustained beneﬁts on the course of the dis-\nease. Most patients with PAH, except those with CHD and\npulmonary-to-systemic shunts, have minor degrees of arterial hypox-\naemia at rest, unless they have a patent foramen ovale. Data show that\nnocturnal oxygen therapy does not modify the natural history of ad-\nvanced Eisenmenger syndrome.324 In the absence of robust data on\nthe use of oxygen in patients with PAH, guidance is based on evidence\nin patients with COPD;325 when PaO2 is ,8 kPa (60 mmHg; alterna-\ntively, SaO2 ,92%) on at least two occasions, patients are advised to\ntake oxygen to achieve a PaO2 .8 kPa. Ambulatory oxygen may be\nconsidered when there is evidence of symptomatic beneﬁt and cor-\nrectable desaturation on exercise.326,327 Nocturnal oxygen therapy\nshould be considered in case of sleep-related desaturation.328\n6.3.1.5. Cardiovascular drugs\nNo data from rigorous clinical trials are available on the usefulness\nand safety of drugs that are effective in systemic hypertension or left-\nsided HF, such as angiotensin-converting enzyme inhibitors, angio-\ntensin receptor blockers (ARBs), angiotensin receptor–neprilysin in-\nhibitors\n(ARNIs),\nsodium–glucose\ncotransporter-2\ninhibitors\n(SGLT-2is), beta-blockers, or ivabradine in patients with PAH. In\nthis group of patients, these drugs may lead to potentially dangerous\ndrops in blood pressure, heart rate, or both. Likewise, the efﬁcacy of\ndigoxin/digitoxin has not been documented in PAH, although these\ndrugs may be administered to slow ventricular rate in patients with\nPAH who develop atrial tachyarrhythmias.\n6.3.1.6. Anaemia and iron status\nIron deﬁciency is common in patients with PAH and is deﬁned by ser-\num ferritin ,100 µg/L, or serum ferritin 100–299 µg/L and\ntransferrin saturation ,20%.329 The underlying pathological me-\nchanisms are complex.330–333 In patients with PAH, iron deﬁciency\nis associated with impaired myocardial function, aggravated symp-\ntoms, and increased mortality risk.333,334 Based on these data, regular\nmonitoring of iron status (serum iron, ferritin, transferrin saturation,\nsoluble transferrin receptors) is recommended in patients with PAH.\nIn patients with severe iron deﬁciency anaemia (Hb ,7–8 g/dL),\ni.v. supplementation is recommended.335–337 Oral iron formulations\ncontaining ferrous (Fe2+) sulfate, ferrous gluconate, and ferrous fu-\nmarate are often poorly tolerated, and drug efﬁcacy may be impaired\nin patients with PAH.330,331 Ferric maltol is a new, orally available for-\nmulation of ferric (Fe3+) iron and maltol. One small, open-label study\nsuggested good tolerability and efﬁcacy in patients with severe PH\nwith mild-to-moderate iron deﬁciency and anaemia.338 In contrast,\ntwo small, 12 week, randomized, cross-over trials studying iron sup-\nplementation in PAH patients without anaemia provided no signiﬁ-\ncant clinical beneﬁt.339 Randomized controlled trials comparing\noral and i.v. iron supplementation in patients with PAH are lacking.\n6.3.1.7. Vaccination\nAs a general health care measure, it is recommended that patients\nwith PAH be vaccinated at least against inﬂuenza, Streptococcus pneu-\nmoniae, and SARS-CoV-2.\n6.3.1.8. Psychosocial support\nReceiving a diagnosis of PH—often after a substantial delay—and ex-\nperiencing the physical limitations have a substantial impact on psy-\nchological, emotional, and social aspects of patients and their\nfamilies. Symptoms of depression and anxiety, as well as adjustment\ndisorders, have a high prevalence in patients with PAH. Pulmonary\narterial hypertension also has grave repercussions on ability to\nwork and income.281,340–344\nEmpathic and hopeful communication is essential for physicians\ncaring for patients with PAH. Awareness and knowledge about the\ndisease and its treatment options empower patients to engage in\nshared decision-making. Adequate diagnostic screening tools are\nthe key to identifying patients in need of referral for psychological/\npsychiatric support, including psychopharmacological medication,345\nor social assistance. Patient support groups may play an important\nrole, and patients should be advised to join such groups. Given the\nlife-limiting character of PAH, advanced care planning with referral\nto specialist palliative care services should be supported at the right\ntime.346\n6.3.1.9. Adherence to treatments\nAdhering to medical therapy is key to successfully managing PAH. In\ngeneral, factors that affect adherence are patient related (e.g. demo-\ngraphics, cognitive impairment, polypharmacy, adverse reactions/\nside effects, psychological health, health literacy, patient understand-\ning of the treatment rationale, and comorbidities), physician related\n(expertise, awareness of guidelines, and multidisciplinary team ap-\nproach), and health care system related (work setting, access to\ntreatments, and cost).347\nRecent studies have indicated that adherence to drug therapy in\npatients with PAH may be suboptimal.348,349 Given the complexity\nof PAH treatment, potential side effects, and risks associated with\ntreatment\ninterruptions,\nadherence\nshould\nbe\nperiodically\nESC/ERS Guidelines\n3661\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nmonitored by a member of the multidisciplinary team, to identify\nnon-adherence and any changes to the treatment regimen spontan-\neously triggered by patients or non-expert physicians. To promote\nadherence, it is important to ensure that patients are involved in\ncare decisions and appropriately informed about treatment options\nand rationale, expectations, side effects, and potential consequences\nof non-adherence. Patients should be advised that any changes in\ntreatment should be made in cooperation with the PH centre.\n6.3.2. Special circumstances\n6.3.2.1. Pregnancy and birth control\n6.3.2.1.1. Pregnancy. Historically, pregnancy in women with PAH\nand other forms of severe PH has been associated with maternal\nmortality rates of up to 56% and neonatal mortality rates of up to\n13%.350 With improved treatment of PAH and new approaches to\nmanaging women during pregnancy and the peri-partum period, ma-\nternal mortality has declined but remains high, ranging 11–25%.351–355\nFor these reasons, previous ESC/ERS Guidelines for the diagnosis and\ntreatment of PH have recommended that patients with PAH should\navoid pregnancy.25,26 However, there are reports of favourable preg-\nnancy outcomes in women with PH, including, but not limited to, wo-\nmen with IPAH who respond to CCB therapy.353,354,356,357\nNonetheless, pregnancy remains associated with unforeseeable risks,\nand may accelerate PH progression.358 Women with PH can deteri-\norate at any time during or after pregnancy. Therefore, physicians\nhave a responsibility to inform patients about the risks of pregnancy,\nso that women and their families can make informed decisions.\nWomen with poorly controlled disease, indicated by an\nintermediate- or high-risk proﬁle and signs of RV dysfunction, are\nat high risk of adverse outcomes; in the event of pregnancy, they\nshould be carefully counselled and early termination should be ad-\nvised. For patients with well-controlled disease, a low-risk proﬁle,\nand normal or near-normal resting haemodynamics who consider\nbecoming pregnant, individual counselling and shared decision-\nmaking are recommended. In such cases, alternatives such as adop-\ntion and surrogacy may also be explored. Pre-conception genetic\ncounselling should also be considered in HPAH.\nWomen with PH who become pregnant or present during preg-\nnancy with newly diagnosed PAH should be treated, whenever pos-\nsible, in centres with a multidisciplinary team experienced in\nmanaging PH in pregnancy. If pregnancy is continued, PAH therapy\nmay have to be adjusted. It is recommended to stop endothelin re-\nceptor antagonists (ERAs), riociguat, and selexipag because of poten-\ntial or unknown teratogenicity.359 Despite limited evidence, CCBs,\nPDE5is, and inhaled/i.v./subcutaneous (s.c.) prostacyclin analogues\nare considered safe during pregnancy.356,360\nPregnancy in PH is a very sensitive topic and requires empathic\ncommunication. Psychological support should be offered whenever\nneeded.\n6.3.2.1.2. Contraception. Women with PH of childbearing poten-\ntial should be provided with clear contraceptive advice, considering\nthe individual needs of the woman but recognizing that the implica-\ntions of contraceptive failure are signiﬁcant in PH. With appropriate\nuse, many forms of contraception, including oral contraceptives, are\nhighly effective. In patients treated with bosentan, reduced efﬁcacy of\nhormonal contraceptives should be carefully considered.361 Using\nhormonal implants or an intrauterine device are alternative options\nwith low failure rates. Surgical sterilization may be considered but is\nassociated with peri-operative risks. Emergency post-coital hormo-\nnal contraception is safe in PH.\n6.3.2.2. Surgical procedures\nSurgical procedures in patients with PH are associated with an ele-\nvated risk of right HF and death. In a prospective, multinational regis-\ntry including 114 patients with PAH who underwent non-cardiac and\nnon-obstetric surgery, the peri-operative mortality rate was 2% in\nelective procedures and 15% in emergency procedures.362 The mor-\ntality risk was associated with the severity of PH. The decision to per-\nform surgery should be made by a multidisciplinary team involving a\nPH physician, and must be based on an individual risk:beneﬁt assess-\nment considering various factors, including indication, urgency, PH\nseverity, and patient preferences. Risk scores to predict the peri-\noperative mortality risk have been developed but require further val-\nidation.363 General recommendations cannot be made. The same is\ntrue regarding the preferred mode of anaesthesia. Pre-operative op-\ntimization of PAH therapy should be attempted whenever possible\n(see also the 2022 ESC Guidelines on cardiovascular assessment\nand management of patients undergoing non-cardiac surgery).364\n6.3.2.3. Travel and altitude\nHypobaric hypoxia may induce arterial hypoxaemia, additional hyp-\noxic pulmonary vasoconstriction, and increased RV load in\nPAH.365,366 Cabin aircraft pressures are equivalent to altitudes up\nto 2438 m,367 at which the PaO2 decreases to that of an inspired\nO2 fraction of 15.1% at sea level.365 However, evidence suggests\nthat short-term (less than 1 day) normobaric hypoxia is generally\nwell tolerated in clinically stable patients with PAH.365,368–372\nIn-ﬂight oxygen administration is advised for patients using oxygen\nat sea level and for those with PaO2 ,8 kPa (60 mmHg) or SaO2\n,92%.25,26,325,369,372 An oxygen ﬂow rate of 2 L/min will raise in-\nspired oxygen pressure to values as at sea level, and patients already\nusing oxygen at sea level should increase their oxygen ﬂow\nrate.25,26,373\nAs the effects of moderate to long-term (hours–days) hypoxia ex-\nposure in PAH remain largely unexplored,374,375 patients should\navoid altitudes .1500 m without supplemental oxygen.25,26,369\nHowever, patients with PAH who are not hypoxaemic at sea level\nhave tolerated day trips to 2500 m reasonably well.376 Patients\nshould travel with written information about their disease, including\na medication list, bring extra doses of their medication, and be in-\nformed about local PH centres near their travel destination.25,26\nRecommendation Table 5 — Recommendations for\ngeneral measures and special circumstances\nRecommendations\nClassa\nLevelb\nGeneral measures\nSupervised exercise training is recommended in\npatients with PAH under medical\ntherapy314,315,317\nI\nA\nContinued\n3662\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n6.3.3. Pulmonary arterial hypertension therapies\n6.3.3.1. Calcium channel blockers\nPatients with PAH who respond favourably to acute vasoreactivity\ntesting (Figure 8) may respond favourably to treatment with\nCCBs.129,146 Less than 10% of patients with IPAH, HPAH, or DPAH\nare responders, while an acute vasodilator response does not predict\na favourable long-term response to CCBs in patients with other forms\nof PAH.129,146,378 The CCBs that have predominantly been used in\nPAH are nifedipine, diltiazem, and amlodipine.129,146 Amlodipine and\nfelodipine are increasingly being used in clinical practice due to their\nlong half-life and good tolerability. The daily doses that have shown ef-\nﬁcacy in PAH are relatively high and they must be reached progressive-\nly (Table 19). The most common adverse events are systemic\nhypotension and peripheral oedema.\nPatients who meet the criteria for a positive acute vasodilator re-\nsponse and treated with CCBs should be closely followed for safety\nand efﬁcacy, with a complete reassessment after 3–6 months of ther-\napy, including RHC. Additional acute vasoreactivity testing should be\nperformed at re-evaluation to detect persistent vasodilator re-\nsponse, supporting possible increases in CCB dosage. Patients with\na satisfactory chronic response present with WHO-FC I/II and\nmarked haemodynamic improvement (ideally, mPAP ,30 mmHg\nand PVR ,4 WU) while on CCB therapy. In the absence of a satis-\nfactory response, additional PAH therapy should be instituted. In\nsome cases, a combination of CCBs with approved PAH drugs is re-\nquired because of clinical deterioration with CCB withdrawal\nPsychosocial support is recommended in patients\nwith PAH\nI\nC\nImmunization of patients with PAH against\nSARS-CoV-2, inﬂuenza, and Streptococcus\npneumoniae is recommended\nI\nC\nDiuretic treatment is recommended in patients\nwith PAH with signs of RV failure and ﬂuid\nretention\nI\nC\nLong-term oxygen therapy is recommended in\npatients with PAH whose arterial blood oxygen\npressure is ,8 kPa (60 mmHg)c\nI\nC\nIn the presence of iron-deﬁciency anaemia,\ncorrection of iron status is recommended in\npatients with PAH\nI\nC\nIn the absence of anaemia, iron repletion may be\nconsidered in patients with PAH with iron\ndeﬁciency\nIIb\nC\nAnticoagulation is not generally recommended in\npatients with PAH but may be considered on an\nindividual basis\nIIb\nC\nThe use of ACEis, ARBs, ARNIs, SGLT-2is,\nbeta-blockers, or ivabradine is not recommended\nin patients with PAH unless required by\ncomorbidities (i.e. high blood pressure, coronary\nartery disease, left HF, or arrhythmias)\nIII\nC\nSpecial circumstances\nIn-ﬂight oxygen administration is recommended\nfor patients using oxygen or whose arterial blood\noxygen pressure is ,8 kPa (60 mmHg) at sea level\nI\nC\nFor interventions requiring anaesthesia,\nmultidisciplinary consultation at a PH centre to\nassess risk and beneﬁt should be considered\nIIa\nC\n© ESC/ERS 2022\nACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker;\nARNI, angiotensin receptor–neprilysin inhibitor; HF, heart failure; PAH, pulmonary\narterial hypertension; PH, pulmonary hypertension; RV, right ventricle; SARS-CoV-2,\nsevere\nacute\nrespiratory\nsyndrome\ncoronavirus-2;\nSGLT-2i,\nsodium–glucose\ncotransporter-2 inhibitor.\naClass of recommendation.\nbLevel of evidence.\ncMeasured on at least two occasions.\nRecommendation Table 6 — Recommendations for\nwomen of childbearing potential\nRecommendations\nClassa\nLevelb\nIt is recommended that women of childbearing\npotential with PAH are counselled at the time of\ndiagnosis about the risks and uncertainties\nassociated with becoming pregnant; this should\ninclude advice against becoming pregnant, and\nreferral for psychological support where needed\nI\nC\nContinued\nIt is recommended to provide women of\nchildbearing potential with PAH with clear\ncontraceptive advice, considering the individual needs\nof the woman but recognizing that the implications of\ncontraceptive failure are signiﬁcant in PAH\nI\nC\nIt is recommended that women with PAH who\nconsider pregnancy or who become pregnant\nreceive prompt counselling in an experienced PH\ncentre, to facilitate genetic counselling and shared\ndecision-making, and to provide psychological\nsupport to the patients and their families where\nneeded\nI\nC\nFor women with PAH having a termination of\npregnancy, it is recommended that this be\nperformed in PH centres, with psychological\nsupport provided to the patients and their families\nI\nC\nFor women with PAH who desire to have children,\nwhere available, adoption and surrogacy with pre-\nconception genetic counselling may be considered\nIIb\nC\nAs teratogenic potential has been reported in\npre-clinical models for endothelin receptor\nantagonists and riociguat, these drugs are not\nrecommended during pregnancy359,377\nIII\nB\n© ESC/ERS 2022\nPAH, pulmonary arterial hypertension; PH, pulmonary hypertension.\naClass of recommendation.\nbLevel of evidence.\nESC/ERS Guidelines\n3663\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nattempts. Patients who have not undergone a vasoreactivity study or\nthose with a negative test should not be started on CCBs because of\npotentially severe side effects (e.g. severe hypotension, syncope, and\nRV failure), unless prescribed at standard doses for other\nindications.379\n6.3.3.2. Endothelin receptor antagonists\nBinding of endothelin-1 to endothelin receptors A and B on PA\nsmooth-muscle cells promotes vasoconstriction and proliferation\n(Figure 7).380 Endothelin B receptors are mostly expressed on\nRecommendation Table 7 — Recommendations for\nthe treatment of vasoreactive patients with idiopath-\nic, heritable, or drug-associated pulmonary arterial\nhypertension\nRecommendations\nClassa\nLevelb\nHigh doses of CCBs are recommended in patients\nwith IPAH, HPAH, or DPAH who are responders\nto acute vasoreactivity testing\nI\nC\nClose follow-up with complete reassessment\nafter 3–4 months of therapy (including RHC) is\nrecommended in patients with IPAH, HPAH, or\nDPAH treated with high doses of CCBs\nI\nC\nContinuing high doses of CCBs is recommended\nin patients with IPAH, HPAH, or DPAH in\nWHO-FC I or II with marked haemodynamic\nimprovement (mPAP ,30 mmHg and PVR ,4\nWU)\nI\nC\nInitiating PAH therapy is recommended in patients\nwho remain in WHO-FC III or IV or those without\nmarked haemodynamic improvement after high\ndoses of CCBs\nI\nC\nIn patients with a positive vasoreactivity test but\ninsufﬁcient long-term response to CCBs who\nrequire additional PAH therapy, continuation of\nCCB therapy should be considered\nIIa\nC\nCCBs are not recommended in patients without a\nvasoreactivity study or non-responders, unless\nprescribed for other indications (e.g. Raynaud’s\nphenomenon)\nIII\nC\n© ESC/ERS 2022\nCCB, calcium channel blocker; DPAH, drug-associated pulmonary arterial hypertension;\nHPAH, heritable pulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial\nhypertension; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial\nhypertension; PVR, pulmonary vascular resistance; RHC, right heart catheterization;\nWHO-FC, World Health Organization functional class; WU, Wood units.\naClass of recommendation.\nbLevel of evidence.\nTable 19\nDosing of pulmonary arterial hypertension\nmedication in adults\nStarting\ndose\nTarget dose\nCalcium channel blockers\nAmlodipine\n5 mg o.d.\n15–30 mg o.d.a\nDiltiazem\n60 mg b.i.d.b\n120–360 mg b.i.d.b\nFelodipine\n5 mg o.d.\n15–30 mg o.d.a\nContinued\nNifedipine\n10 mg t.i.d.\n20–60 mg b.i.d. or t.i.d.\nEndothelin receptor antagonists (oral administration)\nAmbrisentan\n5 mg o.d.\n10 mg o.d.\nBosentan\n62.5 mg b.i.d.\n125 mg b.i.d.\nMacitentan\n10 mg o.d.\n10 mg o.d.\nPhosphodiesterase 5 inhibitors (oral administration)\nSildenaﬁl\n20 mg t.i.d.\n20 mg t.i.d.c\nTadalaﬁl\n20 or 40 mg\no.d.\n40 mg o.d.\nProstacyclin analogues (oral administration)\nBeraprost sodium\n20 µg t.i.d.\nMaximum tolerated dose up to\n40 µg t.i.d.\nBeraprost\nextended release\n60 µg b.i.d.\nMaximum tolerated dose up to\n180 µg b.i.d.\nTreprostinil\n0.25 mg b.i.d.\nor\n0.125 mg t.i.d.\nMaximum tolerated dose\nProstacyclin receptor agonist (oral administration)\nSelexipag\n200 µg b.i.d.\nMaximum tolerated dose up to\n1600 µg b.i.d.\nSoluble guanylate cyclase stimulator (oral administration)\nRiociguatd\n1 mg t.i.d.\n2.5 mg t.i.d.\nProstacyclin analogues (inhaled administration)\nIloproste\n2.5 µg 6–9\ntimes per day\n5.0 µg 6–9 times per day\nTreprostinile\n18 µg 4 times\nper day\n54–72 µg 4 times per day\nProstacyclin analogues (i.v. or s.c. administration)\nEpoprostenol i.v.\n2 ng/kg/min\nDetermined by tolerability and\neffectiveness; typical dose range\nat 1 year is 16–30 ng/kg/min,\nwith wide individual variability\nTreprostinil s.c. or\ni.v.\n1.25 ng/kg/\nmin\nDetermined by tolerability and\neffectiveness; typical dose range\nat 1 year is 25–60 ng/kg/min,\nwith wide individual variability\n© ESC/ERS 2022\nb.i.d., twice daily; i.v., intravenous; o.d., once daily; s.c., subcutaneous; t.i.d., three times\ndaily.\nDosages are those commonly used in clinical practice. This does not exclude the use of\nalternative dosages.\naThe daily dosages of amlodipine and felodipine can be administered in a single dose or\ndivided into two doses.\nbThere are different release formulations of diltiazem, some of which should be\nadministered o.d. or t.i.d.\ncSildenaﬁl is approved at a dose of 20 mg t.i.d. but doses used in practice vary widely and\nare sometimes higher.\ndIn patients at risk of systemic hypotension, riociguat may be started at 0.5 mg t.i.d.\neDoses provided are for nebulizers and may differ with the use of other formulations\nand other inhalation devices.\n3664\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\npulmonary endothelial cells, promoting vasodilation through acceler-\nated production of prostacyclin and nitric oxide, and clearance of\nendothelin-1.380 Nevertheless, selective blocking of endothelin A re-\nceptors alone or non-selective blocking of both A and B receptors\nhas shown similar effectiveness in PAH.380 Endothelial receptor an-\ntagonists have teratogenic effects and should not be used during\npregnancy.381\n6.3.3.2.1. Ambrisentan. Ambrisentan is an oral ERA that preferen-\ntially blocks the endothelin A receptors. The approved dosages in\nadults are 5 mg and 10 mg o.d. In patients with PAH, it has demon-\nstrated efﬁcacy for symptoms, exercise capacity, haemodynamics,\nand time to clinical worsening.382 An increased incidence of\nperipheral oedema was reported with ambrisentan use, while there\nwas no increased incidence of abnormal liver function.\n6.3.3.2.2. Bosentan. Bosentan is an oral, dual ERA that improves\nexercise capacity, WHO-FC, haemodynamics, and time to clinical\nworsening in patients with PAH.383 The approved target dose in\nadults is 125 mg b.i.d. Dose-dependent increases in liver transami-\nnases can occur in ≏10% of treated patients (reversible after dose\nreduction or discontinuation).384 Thus, liver function testing should\nbe performed monthly in patients receiving bosentan.384 Due to\npharmacokinetic interactions, bosentan may render hormonal con-\ntraceptives unreliable and lower serum levels of warfarin, sildenaﬁl,\nand tadalaﬁl.361,385–387\nY\nVaso\nV\nreactivity testing algorithm in patients with presumed diagnosis of I/H/D-PAH and t\nP\nreatment of responders\nRefer to PH cent\nf\nre\nReassess after 3–6 months\nContinue therapy and\np\nreassess every 6–12 months\nRight heart catheterization\nwith pulmonary vasoreactivity testinga\n(Class I)\nInitiate therapy with calcium channel bloc\np\nkers\nk\nand titrate to optimized individual doseb\n(Class I)\n≥10 mmHg mPAP d\nP\nrop from baseline\nto ≤40 mmHg with increased or unchanged cardiac output\nY\nWHO-FC I/II, BNP <50 ng/L or NT-p\nT\nroBNP <300 ng/L,\nnormal or near-normal resting haemodynamicsc\nTreat according\nto Figure 9\nN\nN\nFigure 8 Vasoreactivity testing algorithm of patients with presumed diagnosis of idiopathic, heritable, or drug-associated pulmonary arterial hyperten-\nsion. BNP, brain natriuretic peptide; I/H/D-PAH, idiopathic, heritable, drug-associated pulmonary arterial hypertension; mPAP, mean pulmonary arterial\npressure; N, no; NT-proBNP, N-terminal pro-brain natriuretic peptide; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; WHO-FC,\nWorld Health Organization functional class; WU, Wood units; Y, yes. aInhaled nitric oxide and inhaled iloprost are recommended; intravenous epopros-\ntenol can be used if inhaled nitric oxide or inhaled iloprost are unavailable. bSee text for details. cmPAP ≤30 mmHg and PVR ≤4 WU.\nESC/ERS Guidelines\n3665\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n6.3.3.2.3. Macitentan. Macitentan is an oral, dual ERA that has\nbeen found to increase exercise capacity and reduce a composite\nendpoint of clinical worsening in patients with PAH.167 While no liver\ntoxicity has been shown, a reduction in Hb to ≤8 g/dL was observed\nin 4.3% of patients receiving 10 mg of macitentan.167\n6.3.3.3. Phosphodiesterase 5 inhibitors and guanylate cyclase\nstimulators\nStimulating soluble guanylate cyclase (sGC) by nitric oxide results in\nproduction of the intracellular second messenger cyclic guanosine\nmonophosphate (cGMP) (Figure 7). This pathway is controlled by a\nRisk (3 strata)\n(Table 16)\nT\nInitial ERA\nR\n+ PDE5i therapy\np\n(Class I)\nInitial ERA + PDE5i\nand i.v.v/s.c. P\n. CAb\n(Class IIa)\nInitial oral monotherapy\np\nwith PDE5i or ERA\nR\n(Class IIa)\nAdd i.v.v o\n. r s\nr .c. P\n. CA and/or\nevaluate\na\nfof r lung transplantati\na on\n(Class IIa)\nRegular fof llow-up assessment\nand individualized therapy\np\nRegular fof llow-up assessment\n(Tab\nT le 17)\nLow or intermediate\nHigh\nRisk (4 strata) \n(Table 18)\nT\nContinue initial therapy\np\n(Class I)\nLow\nIntermediate-low\nIntermediate-high\nor high\nOR\nAdd PRA\nR\n(Class IIa)\nSwitch from\nPDE5i to sGCs\n(Class IIb)\nTr\nT eatment of patients with I/H/D-PAH or \nP\nPAH-CTD\nP\nDiagnosis confirmed at PH centre, vaso\n,\nreactivity testing negative\nGeneral measures throughout\nthe course of the disease\n(ReCo Table 5)\nT\n(Class I)\nPatient without\ncardiopulmonary comorbiditiesa\nPatient with\ncardiopulmonary comorbiditiesa\nAll risk categories\nFigure 9 Evidence-based pulmonary arterial hypertension treatment algorithm for patients with idiopathic, heritable, drug-associated, and connective\ntissue disease-associated pulmonary arterial hypertension. DLCO, Lung diffusion capacity for carbon monoxide; ERA, endothelin receptor antagonist; I/\nH/D-PAH, idiopathic, heritable, or drug-associated pulmonary arterial hypertension; i.v., intravenous; PAH-CTD, PAH associated with connective tissue\ndisease; PCA, prostacyclin analogue; PDE5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension; PRA, prostacyclin receptor agonist; ReCo, rec-\nommendation; s.c., subcutaneous; sGCs, soluble guanylate cyclase stimulator. aCardiopulmonary comorbidities are conditions associated with an in-\ncreased risk of left ventricular diastolic dysfunction, and include obesity, hypertension, diabetes mellitus, and coronary heart disease; pulmonary\ncomorbidities may include signs of mild parenchymal lung disease and are often associated with a low DLCO (,45% of the predicted value).\nbIntravenous epoprostenol or i.v./s.c. treprostinil.\n3666\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nnegative feedback loop through degradation of cGMP via different\nphosphodiesterases, among which subtype 5 (PDE5) is abundantly\nexpressed in the pulmonary vasculature.388 Phosphodiesterase 5 in-\nhibitors and sGC stimulators must not be combined with each other\nand with nitrates, as this can result in systemic hypotension.389\n6.3.3.3.1. Sildenaﬁl. Sildenaﬁl is an orally active, potent, and select-\nive inhibitor of PDE5. Several RCTs of patients with PAH treated\nwith sildenaﬁl (with or without background therapy) have conﬁrmed\nfavourable results on exercise capacity, symptoms, and/or haemo-\ndynamics.390–392 The approved dose of sildenaﬁl is 20 mg t.i.d.\nMost side effects of sildenaﬁl are mild to moderate and mainly related\nto vasodilation (headache, ﬂushing, and epistaxis).\n6.3.3.3.2. Tadalaﬁl. Tadalaﬁl is a once-daily administered PDE5i. An\nRCT of 406 patients with PAH (53% on background bosentan ther-\napy) treated with tadalaﬁl at doses up to 40 mg o.d. showed favour-\nable results on exercise capacity, symptoms, haemodynamics, and\ntime to clinical worsening.393 The side effect proﬁle was similar to\nthat of sildenaﬁl.\n6.3.3.3.3. Riociguat. While PDE5is augment the nitric oxide–cGMP\npathway by slowing cGMP degradation, sGC stimulators enhance\ncGMP production by directly stimulating the enzyme, both in the\npresence and absence of endogenous nitric oxide.394 An RCT of\n443 patients with PAH (44% and 6% on background therapy with\nERAs or prostacyclin analogues, respectively) treated with riociguat\nup to 2.5 mg t.i.d. showed favourable results on exercise capacity,\nhaemodynamics, WHO-FC, and time to clinical worsening.395 The\nside effect proﬁle was similar to that of PDE5is.\n6.3.3.4. Prostacyclin analogues and prostacyclin receptor agonists\nThe prostacyclin metabolic pathway (Figure 7) is dysregulated in pa-\ntients with PAH, with less prostacyclin synthase expressed in PAs\nand reduced prostacyclin urinary metabolites.396 Prostacyclin analo-\ngues and prostacyclin receptor agonists induce potent vasodilation,\ninhibit platelet aggregation, and also have both cytoprotective and\nanti-proliferative activities.397 The most common adverse events ob-\nserved with these compounds are related to systemic vasodilation\nand include headache, ﬂushing, jaw pain, and diarrhoea.\n6.3.3.4.1. Epoprostenol. Epoprostenol has a short half-life (3–\n5 min) and needs continuous i.v. administration via an infusion\npump and a permanent tunnelled catheter. A thermo-stable formu-\nlation is available to maintain stability up to 48 h.398 Its efﬁcacy has\nbeen demonstrated in three unblinded RCTs in patients with IPAH\n(WHO-FC\nIII\nand\nIV)399,400\nand\nSSc-associated\nPAH.401\nEpoprostenol improved symptoms, exercise capacity, haemodynam-\nics, and mortality.399 Long-term, persistent efﬁcacy has also been\nshown in IPAH,212,245 as well as in other associated PAH condi-\ntions.402–404 Serious adverse events related to the delivery system in-\nclude pump malfunction, local site infection, catheter obstruction,\nand sepsis. Recommendations for preventing central venous cath-\neter bloodstream infections have been proposed.405,406\n6.3.3.4.2. Iloprost. Iloprost is a prostacyclin analogue approved for\ninhaled administration. Inhaled iloprost has been evaluated in one\nRCT, in which six to nine repetitive iloprost inhalations were com-\npared with placebo in treatment-naïve patients with PAH or\nCTEPH.407 The study showed an increase in exercise capacity and\nimprovement in symptoms, PVR, and clinical events in the iloprost\ngroup compared with the placebo group.\n6.3.3.4.3. Treprostinil. Treprostinil is available for s.c., i.v., inhaled,\nand oral administration. Treprostinil s.c. improved exercise capacity,\nhaemodynamics, and symptoms in PAH.408 Infusion-site pain was the\nmost common adverse effect, which led to treatment discontinu-\nation in 8% of cases.408 Based on its chemical stability, i.v. treprostinil\nmay also be administered via implantable pumps, improving conveni-\nence and likely decreasing the occurrence of line infections.409,410\nInhaled treprostinil improved the 6MWD, NT-proBNP, and qual-\nity of life measures in patients with PAH on background therapy with\neither bosentan or sildenaﬁl.411 Inhaled treprostinil is not approved\nin Europe.\nOral treprostinil has been evaluated in two RCTs of patients with\nPAH on background therapy with bosentan and/or sildenaﬁl. In both\ntrials, the primary endpoint—6MWD—did not reach statistical sig-\nniﬁcance.412,413 An additional RCT in treatment-naïve patients with\nPAH showed improved 6MWD.414 An event-driven RCT that en-\nrolled 690 patients with PAH demonstrated that oral treprostinil re-\nduced the risk of clinical worsening events in patients who were\nreceiving oral monotherapy with ERAs or PDE5is.415 Oral treprosti-\nnil is not approved in Europe.\n6.3.3.4.4. Beraprost. Beraprost is a chemically stable and orally ac-\ntive prostacyclin analogue. Two RCTs have shown a modest, short-\nterm improvement in exercise capacity in patients with PAH;416,417\nhowever, there were no haemodynamic improvements or long-term\noutcome beneﬁts. Beraprost is not approved in Europe.\n6.3.3.4.5. Selexipag. Selexipag is an orally available, selective, pros-\ntacyclin receptor agonist that is chemically distinct from prostacyclin,\nwith different pharmacology. In a pilot RCT in patients with PAH (re-\nceiving stable ERA and/or PDE5i therapy), selexipag reduced PVR\nafter 17 weeks.418 An event-driven, phase 3 RCT that enrolled\n1156 patients419 showed that selexipag alone or on top of mono\nor double therapy with an ERA and/or a PDE5i reduced the relative\nrisk of composite morbidity/mortality events by 40%. The most com-\nmon side effects were headache, diarrhoea, nausea, and jaw pain.\n6.3.4. Treatment strategies for patients with\nidiopathic, heritable, drug-associated, or\nconnective tissue disease-associated pulmonary\narterial hypertension\nPulmonary arterial hypertension is a rare and life-threatening disease\nand should be managed, where possible, at PH centres in close col-\nlaboration with the patient’s local physicians.\nThis section describes drug treatment and is focused on non-\nvasoreactive patients with IPAH/HPAH/DPAH and on patients\nwith PAH associated with connective tissue disease (PAH-CTD).\nInformation on the dosing of PAH medication is summarized in\nTable 19. For other forms of PAH, treatment strategies have to be\nmodiﬁed (see Section 7). The approach to vasoreactive patients\nwith IPAH/HPAH/DPAH is described in Section 6.3.3.1.\nESC/ERS Guidelines\n3667\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nIn addition to targeted drug treatment, the comprehensive man-\nagement of patients with PAH includes general measures that may\ninclude supplementary oxygen, diuretics to optimize volume status,\npsychosocial support, and standardized exercise training (Section\n6.3.1).315 Prior to the treatment decisions, patients and their next\nof kin should be provided with appropriate and timely information\nabout the risks and beneﬁts of the treatment options so they can\nmake the ﬁnal, informed, and joint decision about the treatment\nwith the medical team. Treatment decisions in patients with IPAH/\nHPAH/DPAH or PAH-CTD should be stratiﬁed according to the\npresence or absence of cardiopulmonary comorbidities (Section\n6.3.4.3) and according to disease severity assessed by risk stratiﬁca-\ntion (Section 6.2.7).\n6.3.4.1. Initial treatment decision in patients without\ncardiopulmonary comorbidities\nThe initial treatment of patients with PAH should be based on a com-\nprehensive, multiparameter risk assessment, considering disease\ntype and severity, comorbidities, access to therapies, economic as-\npects, and patient preference.\nThe following considerations predominantly apply to patients with\nIPAH/HPAH/DPAH or PAH-CTD without cardiopulmonary co-\nmorbidities, as patients with comorbidities were under-represented\nin the clinical studies addressing treatment strategies and combin-\nation therapy in patients with PAH. Treatment considerations for pa-\ntients with PAH and cardiopulmonary comorbidities are summarized\nin Section 6.3.4.3.\nFor patients presenting at low or intermediate risk, initial combin-\nation therapy with an ERA and a PDE5i is recommended. This ap-\nproach was assessed in the AMBITION study, which compared\ninitial combination therapy using ambrisentan at a target dose of\n10 mg o.d. and tadalaﬁl at a target dose of 40 mg o.d. with initial\nmonotherapy with either drug.166 AMBITION predominantly in-\ncluded patients with IPAH/HPAH/DPAH or PAH-CTD. The primary\nendpoint was the time to ﬁrst clinical failure event (a composite of\ndeath, hospitalization for worsening PAH, disease progression, or\nunsatisfactory long-term clinical response). The hazard ratio (HR)\nfor the primary endpoint in the combination-therapy group vs. the\npooled monotherapy group was 0.50 (95% conﬁdence interval\n[CI], 0.35–0.72; P , 0.001) and there were signiﬁcant improvements\nin 6MWD and NT-proBNP with initial combination therapy. At the\nend of the study, 10% of the patients assigned to initial combination\ntherapy had died compared with 14% of the patients assigned to ini-\ntial monotherapy (HR 0.67; 95% CI, 0.42–1.08).420\nIn the TRITON study, treatment-naïve patients with PAH were\nassigned to initial dual-combination therapy with macitentan and\ntadalaﬁl, or initial triple-combination therapy with macitentan\n10 mg o.d., tadalaﬁl at a target dose of 40 mg o.d., and selexipag\nup to 1600 µg o.d.421 TRITON predominantly included patients\nwith IPAH/HPAH/DPAH or PAH-CTD. At week 26, PVR was re-\nduced by 52% and 54%, with double- or triple-combination ther-\napy, respectively, and 6MWD had increased by 55 m and 56 m,\nrespectively. The geometric means of the NT-proBNP ratio\nfrom baseline to week 26 were 0.25 and 0.26, respectively.\nHence, TRITON did not show a beneﬁt of oral triple- vs. oral\ndouble-combination therapy but conﬁrmed that substantial im-\nprovements in haemodynamics and exercise capacity can be\nobtained with initial ERA/PDE5i combination therapy. Further\nstudies are needed to determine whether oral triple-combination\ntherapy impacts long-term outcomes.\nBased on the evidence generated by these and other stud-\nies,303,422–424 initial dual-combination therapy with an ERA and a\nPDE5i is recommended for newly diagnosed patients who present\nat low or intermediate risk. Initial oral triple-combination therapy\nis not recommended, given the current lack of evidence supporting\nthis strategy. In patients presenting at high risk, initial triple-\ncombination therapy including an i.v./s.c. prostacyclin analogue\nshould be considered.426,427 While it is acknowledged that the evi-\ndence for this approach is limited to case series, there is consensus\nthat this strategy has the highest likelihood of success, especially in\nview of registry data from France showing that initial triple-\ncombination therapy including an i.v./s.c. prostacyclin analogue was\nassociated with better long-term survival than monotherapy or dual-\ncombination therapy.428 Initial triple-combination therapy including\nan i.v./s.c. prostacyclin analogue should also be considered in patients\nat intermediate risk presenting with severe haemodynamic impair-\nment (e.g. RAP ≥20 mmHg, CI ,2.0 L/min/m2, SVI ,31 mL/m2,\nand/or PVR ≥12 WU).238,426\nThe recommendations for initial oral double-combination therapy\nare based on PICO question I (Supplementary Data, Section 6.2).\nAlthough the quality of evidence is low, initial oral combination ther-\napy with an ERA and a PDE5i achieves important targets in symptom\nimprovement (functional class), exercise capacity, cardiac biomar-\nkers, and reduction of hospitalizations.\nRecommendation Table 8 — Recommendations for\nthe treatment of non-vasoreactive patients with idio-\npathic, heritable, or drug-associated pulmonary arterial\nhypertension who present without cardiopulmonary\ncomorbiditiesa\nRecommendation Table 8A\nRecommendations\nClassb\nLevelc\nRecommendations for initial therapy\nIn patients with IPAH/HPAH/DPAH who present\nat high risk of death, initial combination therapy\nwith a PDE5i, an ERA, and i.v./s.c. prostacyclin\nanalogues should be consideredd\nIIa\nC\nRecommendations for treatment decisions during follow-up\nIn patients with IPAH/HPAH/DPAH who present\nat intermediate–low risk of death while receiving\nERA/PDE5i therapy, the addition of selexipag\nshould be considered419\nIIa\nB\nIn patients with IPAH/HPAH/DPAH who present\nat intermediate–high or high risk of death while\nreceiving ERA/PDE5i therapy, the addition of i.v./\ns.c. prostacyclin analogues and referral for LTx\nevaluation should be considered\nIIa\nC\nIn patients with IPAH/HPAH/DPAH who present\nat intermediate–low risk of death while receiving\nERA/PDE5i therapy, switching from PDE5i to\nriociguat may be considered429\nIIb\nB\n© ESC/ERS 2022\n3668\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n6.3.4.2. Treatment decisions during follow-up in patients without\ncardiopulmonary comorbidities\nPatients with PAH require regular follow-up, including risk strati-\nﬁcation and an assessment of patient concordance with therapy.\nPatients who achieve a low-risk status have a much superior\nlong-term survival compared with patients with intermediate-\nor high-risk status.292,295,296 Achieving and maintaining a low-\nrisk proﬁle is therefore a key objective in managing patients\nwith PAH.\nSeveral clinical trials have assessed the safety and efﬁcacy of se-\nquential combination therapy in patients with PAH. SERAPHIN en-\nrolled 742 patients with PAH, mostly with IPAH/HPAH/DPAH and\nPAH-CTD, of whom 63.7% were receiving other PAH medication\nat the time of enrolment, mostly sildenaﬁl.167 In the subgroup of pa-\ntients with background PAH therapy, macitentan at a daily dose of\n10 mg reduced the risk of clinical worsening events compared with\nplacebo (HR 0.62; 95% CI, 0.43–0.89).167\nGRIPHON assessed the safety and efﬁcacy of selexipag.419 This\nstudy enrolled 1156 patients with PAH, also mostly with IPAH/\nHPAH/DPAH or PAH-CTD, who were treatment naïve or receiv-\ning background therapy with an ERA, PDE5i, or a combination of\nboth. Selexipag at a dose of up to 1600 µg b.i.d. was associated\nwith a reduced risk of clinical worsening events independent of\nthe background medication. In patients receiving ERA/PDE5i com-\nbination therapy (n = 376), the risk of clinical worsening events was\nlower with selexipag than with placebo (HR 0.63; 95% CI, 0.44–\n0.90).431\nThe effects of combination therapy on long-term survival in pa-\ntients with PAH remain unclear. A 2016 meta-analysis demonstrated\nthat combination therapy (initial and sequential) was associated with\na signiﬁcant risk reduction for clinical worsening (relative risk [RR]\n0.65; 95% CI, 0.58–0.72; P , 0.0001);432 however, all-cause mortality\nwas not improved (RR 0.86; 95% CI, 0.72–1.03; P = 0.09) and a sub-\nstantial proportion of patients had clinical worsening events or died\ndespite receiving combination therapy. In addition, registry data\nshowed that the use of combination therapy increased since 2015\nbut\nthere\nwas\nno\nclear\nimprovement\nin\noverall\nsurvival\nrates.428,433,434 These data were corroborated by a study showing\nthat less than half of patients receiving initial combination therapy\nwith an ERA and a PDE5i achieved and maintained a low-risk\nproﬁle.422\nSwitching from PDE5is to riociguat has also been investigated as\na treatment-escalation strategy.429,435 REPLACE was a rando-\nmized, controlled, open-label study that enrolled patients on a\nPDE5i-based therapy who were in WHO-FC III and had a\n6MWD of 165–440 m.429 The study predominantly included pa-\ntients with IPAH/HPAH/DPAH or PAH-CTD who were rando-\nmized to continue their PDE5i or to switch from a PDE5i to\nriociguat up to 2.5 mg t.i.d. The study met its primary endpoint,\ntermed ‘clinical improvement’, which was a composite of pre-\nspeciﬁed improvements in 6MWD, WHO-FC, and NT-proBNP\nat week 24. Clinical improvement at week 24 was demonstrated\nin 41% of the patients who switched to riociguat and in 20% of\nthe patients who maintained their PDE5i (odds ratio [OR] 2.78;\n95% CI, 1.53–5.06; P = 0.0007). In addition, fewer patients in the\nriociguat group experienced a clinical worsening event (OR 0.10;\n95% CI, 0.01–0.73; P = 0.0047).\nBased on the evidence summarized above, the following recom-\nmendations for treatment decisions during follow-up are:\nRecommendation Table 8B\nGRADE\nRecommendations\nQuality\nof\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nRecommendations for initial therapy\nIn patients with IPAH/\nHPAH/DPAH who\npresent at low or\nintermediate risk of\ndeath, initial\ncombination therapy\nwith a PDE5i and an\nERA is\nrecommended166\nLow\nConditional\nI\nB\n© ESC/ERS 2022\nCI, cardiac index; DLCO, Lung diffusion capacity for carbon monoxide; DPAH,\ndrug-associated\npulmonary\narterial\nhypertension;\nERA,\nendothelin\nreceptor\nantagonist; HFpEF, heart failure with preserved ejection fraction; HPAH, heritable\npulmonary arterial hypertension; IPAH, idiopathic pulmonary arterial hypertension;\ni.v., intravenous; LTx, lung transplantation; PAH, pulmonary arterial hypertension;\nPDE5i, phosphodiesterase 5 inhibitor; PVR, pulmonary vascular resistance; RAP, right\natrial pressure; s.c., subcutaneous; SVI, stroke volume index; WU, Wood units.\naCardiopulmonary comorbidities are predominantly encountered in elderly patients\nand include risk factors for HFpEF such as obesity, diabetes, coronary heart disease, a\nhistory of hypertension, and/or a low DLCO.\nbClass of recommendation.\ncLevel of evidence.\ndInitial triple-combination therapy including i.v./s.c. prostacyclin analogues may also be\nconsidered in patients presenting at intermediate risk but severe haemodynamic\nimpairment (e.g. RAP ≥20 mmHg, CI ,2.0 L/min/m2, SVI ,31 mL/m2, and/or PVR\n≥12 WU).\nRecommendation Table 9 — Recommendations for\ninitial oral drug combination therapy for patients\nwith idiopathic, heritable, or drug-associated pulmon-\nary arterial hypertension without cardiopulmonary\ncomorbidities\nRecommendations\nClassa\nLevelb\nInitial combination therapy with ambrisentan and\ntadalaﬁl is recommended166,420,423\nI\nB\nInitial combination therapy with macitentan and\ntadalaﬁl is recommended421,430\nI\nB\nInitial combination therapy with other ERAs and\nPDE5is should be considered430\nIIa\nB\nInitial combination therapy with macitentan,\ntadalaﬁl, and selexipag is not recommended421\nIII\nB\n© ESC/ERS 2022\nERA, endothelin receptor antagonist; PDE5i, phosphodiesterase 5 inhibitor.\naClass of recommendation.\nbLevel of evidence.\nESC/ERS Guidelines\n3669\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 38",
          "page": 38,
          "content": "Pulmonary vasculopathy Right heart failure\nPulmonary Vascular\nIntimal proliferation, fibrosis\nartery obstruction\nVascular remodelling\nMedial hypertrophy\nRight ventricular\nremodelling /\nThrombosis\ndysfunction\nPlexiform lesion\nVasoconstriction\nMedial Intimal Plexiform\nhyperplasia proliferation lesions\nCurrent therapeutic targets\nEndothelin pathway NO-sGC-cGMP pathway Prostacyclin pathway\nPro-endothelin-1 L-arginine Arachidonic acid\nEndothelin-1 Nitric oxide Prostacyclin\n(Vasoconstriction (Vasodilatation and (Vasodilatation and\nand proliferation) antiproliferation) antiproliferation)\nIP receptor\nsGC PDE5\nEndothelin Endothelin\nreceptor A receptor B\nGTP cGMP GMP cAMP |  | \n |  | \n |  | ",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 39",
          "page": 39,
          "content": "Class | Descriptiona\nWHO-FC I | Patients with PH but without resulting limitation of\nphysical activity. Ordinary physical activity does not\ncause undue dyspnoea or fatigue, chest pain, or near\nsyncope\nWHO-FC II | Patients with PH resulting in slight limitation of physical\nactivity. They are comfortable at rest. Ordinary physical\nactivity causes undue dyspnoea or fatigue, chest pain, or\nnear syncope\nWHO-FC III | Patients with PH resulting in marked limitation of\nphysical activity. They are comfortable at rest. Less than\nordinary activity causes undue dyspnoea or fatigue,\nchest pain, or near syncope\nWHO-FC IV | Patients with PH with an inability to carry out any\nphysical activity without symptoms. These patients\nmanifest signs of right HF. Dyspnoea and/or fatigue may\neven be present at rest. Discomfort is increased by any\nphysical activity",
          "rows": 5,
          "cols": 2
        },
        {
          "title": "Table on page 40",
          "page": 40,
          "content": "Determinants of prognosis (estimated\n1-year mortality) |  | Low risk\n(,5%) | Intermediate risk\n(5–20%) | High risk\n(.20%) | \n | Clinical observations and modifiable variables |  |  |  | \nSigns of right HF |  | Absent | Absent | Present | \nProgression of symptoms and clinical\nmanifestations |  | No | Slow | Rapid | \nSyncope |  | No | Occasional syncopea | Repeated syncopeb | \nWHO-FC |  | I, II | III | IV | \n6MWDc |  | .440 m | 165–440 m | ,165 m | \nCPET |  | Peak VO .15 mL/min/kg\n2\n(.65% pred.)\nVE/VCO slope ,36\n2 | Peak VO 11–15 mL/min/kg\n2\n(35–65% pred.)\nVE/VCO slope 36–44\n2 | Peak VO ,11 mL/min/kg\n2\n(,35% pred.)\nVE/VCO slope .44\n2 | \nBiomarkers: BNP or NT-proBNPd |  | BNP ,50 ng/L\nNT-proBNP ,300 ng/L | BNP 50–800 ng/L\nNT-proBNP 300–1100 ng/L | BNP .800 ng/L\nNT-proBNP .1100 ng/L | \nEchocardiography |  | RA area ,18 cm2\nTAPSE/sPAP .0.32 mm/mmHg\nNo pericardial effusion | RA area 18–26 cm2\nTAPSE/sPAP 0.19–0.32 mm/\nmmHg\nMinimal pericardial effusion | RA area .26 cm2\nTAPSE/sPAP ,0.19 mm/mmHg\nModerate or large pericardial\neffusion | \ncMRIe |  | RVEF .54%\nSVI .40 mL/m2\nRVESVI ,42 mL/m2 | RVEF 37–54%\nSVI 26–40 mL/m2\nRVESVI\n42–54 mL/m2 | RVEF ,37%\nSVI ,26 mL/m2\nRVESVI .54 mL/m2 | \nHaemodynamics |  | RAP ,8 mmHg\nCI ≥2.5 L/min/m2\nSVI .38 mL/m2\nSvO .65%\n2 | RAP 8–14 mmHg\nCI 2.0–2.4 L/min/m2\nSVI 31–38 mL/m2\nSvO 60–65%\n2 | RAP .14 mmHg\nCI ,2.0 L/min/m2\nSVI ,31 mL/m2\nSvO ,60%\n2 | ",
          "rows": 12,
          "cols": 6
        },
        {
          "title": "Table on page 41",
          "page": 41,
          "content": " | At\nbaseline | 3–6 months after changes in\ntherapya | Every 3–6 months in stable\npatientsa | In case of clinical\nworsening\nMedical assessment (including\nWHO-FC) |  |  |  | \n6MWT |  |  |  | \nBlood test (including\nNT-proBNP)b,c |  |  |  | \nECG |  |  |  | \nEchocardiography or cMRI |  |  |  | \nABG or pulse oximetryd |  |  |  | \nDisease-specific HR-QoL |  |  |  | \nCPET |  |  |  | \nRHC |  |  |  | ",
          "rows": 10,
          "cols": 5
        },
        {
          "title": "Table on page 42",
          "page": 42,
          "content": "Determinants of prognosis | Low risk | Intermediate–low risk | Intermediate–high risk | High risk\nPoints assigned | 1 | 2 | 3 | 4\nWHO-FC | I or IIa | - | III | IV\n6MWD, m | .440 | 320–440 | 165–319 | ,165\nBNP or\nNT-proBNP,a ng/L | ,50\n,300 | 50–199\n300–649 | 200–800\n650–1100 | .800\n.1100",
          "rows": 5,
          "cols": 5
        },
        {
          "title": "Table on page 43",
          "page": 43,
          "content": "Recommendations | Classa | Levelb\nIt is recommended to evaluate disease severity in\npatients with PAH with a panel of data derived\nfrom clinical assessment, exercise tests,\nbiochemical markers, echocardiography, and\nhaemodynamic\nevaluations212,213,216,249,292,293,295,296,302,307 | I | B\nAchieving and maintaining a low-risk profile on\noptimized medical therapy is recommended as a\ntreatment goal in patients with\nPAH210,212,213,216,298,300,303,309,310 | I | B\nFor risk stratification at the time of diagnosis, the\nuse of a three-strata model (low, intermediate,\nand high risk) is recommended, taking into\naccount all available data, including\nhaemodynamics292,293,295 | I | B\nFor risk stratification during follow-up, the use of a\nfour-strata model (low, intermediate–low,\nintermediate–high, and high risk) based on\nWHO-FC, 6MWD, and BNP/NT-proBNP is\nrecommended, with additional variables taken\ninto account as necessary280,308 | I | B\nIn some PAH aetiologies and patients with\ncomorbidities, optimization of therapy should be\nconsidered on an individual basis, while\nacknowledging that a low-risk profile is not always\nachievable293,294,299,311 | IIa | B",
          "rows": 6,
          "cols": 3
        },
        {
          "title": "Table on page 45",
          "page": 45,
          "content": "Recommendations |  | Classa | Levelb | \n | General measures |  |  | \nSupervised exercise training is recommended in\npatients with PAH under medical\ntherapy314,315,317 |  | I | A | ",
          "rows": 3,
          "cols": 5
        },
        {
          "title": "Table on page 46",
          "page": 46,
          "content": "Psychosocial support is recommended in patients\nwith PAH |  | I | C | \nImmunization of patients with PAH against\nSARS-CoV-2, influenza, and Streptococcus\npneumoniae is recommended |  | I | C | \nDiuretic treatment is recommended in patients\nwith PAH with signs of RV failure and fluid\nretention |  | I | C | \nLong-term oxygen therapy is recommended in\npatients with PAH whose arterial blood oxygen\npressure is ,8 kPa (60 mmHg)c |  | I | C | \nIn the presence of iron-deficiency anaemia,\ncorrection of iron status is recommended in\npatients with PAH |  | I | C | \nIn the absence of anaemia, iron repletion may be\nconsidered in patients with PAH with iron\ndeficiency |  | IIb | C | \nAnticoagulation is not generally recommended in\npatients with PAH but may be considered on an\nindividual basis |  | IIb | C | \nThe use of ACEis, ARBs, ARNIs, SGLT-2is,\nbeta-blockers, or ivabradine is not recommended\nin patients with PAH unless required by\ncomorbidities (i.e. high blood pressure, coronary\nartery disease, left HF, or arrhythmias) |  | III | C | \n | Special circumstances |  |  | \nIn-flight oxygen administration is recommended\nfor patients using oxygen or whose arterial blood\noxygen pressure is ,8 kPa (60 mmHg) at sea level |  | I | C | \nFor interventions requiring anaesthesia,\nmultidisciplinary consultation at a PH centre to\nassess risk and benefit should be considered |  | IIa | C | ",
          "rows": 11,
          "cols": 5
        },
        {
          "title": "Table on page 46",
          "page": 46,
          "content": "It is recommended to provide women of\nchildbearing potential with PAH with clear\ncontraceptive advice, considering the individual needs\nof the woman but recognizing that the implications of\ncontraceptive failure are significant in PAH | I | C\nIt is recommended that women with PAH who\nconsider pregnancy or who become pregnant\nreceive prompt counselling in an experienced PH\ncentre, to facilitate genetic counselling and shared\ndecision-making, and to provide psychological\nsupport to the patients and their families where\nneeded | I | C\nFor women with PAH having a termination of\npregnancy, it is recommended that this be\nperformed in PH centres, with psychological\nsupport provided to the patients and their families | I | C\nFor women with PAH who desire to have children,\nwhere available, adoption and surrogacy with pre-\nconception genetic counselling may be considered | IIb | C\nAs teratogenic potential has been reported in\npre-clinical models for endothelin receptor\nantagonists and riociguat, these drugs are not\nrecommended during pregnancy359,377 | III | B",
          "rows": 5,
          "cols": 3
        },
        {
          "title": "Table on page 46",
          "page": 46,
          "content": "Recommendations | Classa | Levelb\nIt is recommended that women of childbearing\npotential with PAH are counselled at the time of\ndiagnosis about the risks and uncertainties\nassociated with becoming pregnant; this should\ninclude advice against becoming pregnant, and\nreferral for psychological support where needed | I | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 47",
          "page": 47,
          "content": "Nifedipine |  | 10 mg t.i.d. | 20–60 mg b.i.d. or t.i.d. | \n | Endothelin receptor antagonists (oral administration) |  |  | \nAmbrisentan |  | 5 mg o.d. | 10 mg o.d. | \nBosentan |  | 62.5 mg b.i.d. | 125 mg b.i.d. | \nMacitentan |  | 10 mg o.d. | 10 mg o.d. | \n | Phosphodiesterase 5 inhibitors (oral administration) |  |  | \nSildenafil |  | 20 mg t.i.d. | 20 mg t.i.d.c | \nTadalafil |  | 20 or 40 mg\no.d. | 40 mg o.d. | \n | Prostacyclin analogues (oral administration) |  |  | \nBeraprost sodium |  | 20 µg t.i.d. | Maximum tolerated dose up to\n40 µg t.i.d. | \nBeraprost\nextended release |  | 60 µg b.i.d. | Maximum tolerated dose up to\n180 µg b.i.d. | \nTreprostinil |  | 0.25 mg b.i.d.\nor\n0.125 mg t.i.d. | Maximum tolerated dose | \n | Prostacyclin receptor agonist (oral administration) |  |  | \nSelexipag 200 µg b.i.d. Maximum tolerated dose up to\n1600 µg b.i.d. |  |  |  | \n | Soluble guanylate cyclase stimulator (oral administration) |  |  | \nRiociguatd |  | 1 mg t.i.d. | 2.5 mg t.i.d. | \n | Prostacyclin analogues (inhaled administration) |  |  | \nIloproste |  | 2.5 µg 6–9\ntimes per day | 5.0 µg 6–9 times per day | \nTreprostinile |  | 18 µg 4 times\nper day | 54–72 µg 4 times per day | \n | Prostacyclin analogues (i.v. or s.c. administration) |  |  | \nEpoprostenol i.v. |  | 2 ng/kg/min | Determined by tolerability and\neffectiveness; typical dose range\nat 1 year is 16–30 ng/kg/min,\nwith wide individual variability | \nTreprostinil s.c. or\ni.v. |  | 1.25 ng/kg/\nmin | Determined by tolerability and\neffectiveness; typical dose range\nat 1 year is 25–60 ng/kg/min,\nwith wide individual variability | ",
          "rows": 22,
          "cols": 5
        },
        {
          "title": "Table on page 47",
          "page": 47,
          "content": "Recommendations | Classa | Levelb\nHigh doses of CCBs are recommended in patients\nwith IPAH, HPAH, or DPAH who are responders\nto acute vasoreactivity testing | I | C\nClose follow-up with complete reassessment\nafter 3–4 months of therapy (including RHC) is\nrecommended in patients with IPAH, HPAH, or\nDPAH treated with high doses of CCBs | I | C\nContinuing high doses of CCBs is recommended\nin patients with IPAH, HPAH, or DPAH in\nWHO-FC I or II with marked haemodynamic\nimprovement (mPAP ,30 mmHg and PVR ,4\nWU) | I | C\nInitiating PAH therapy is recommended in patients\nwho remain in WHO-FC III or IV or those without\nmarked haemodynamic improvement after high\ndoses of CCBs | I | C\nIn patients with a positive vasoreactivity test but\ninsufficient long-term response to CCBs who\nrequire additional PAH therapy, continuation of\nCCB therapy should be considered | IIa | C\nCCBs are not recommended in patients without a\nvasoreactivity study or non-responders, unless\nprescribed for other indications (e.g. Raynaud’s\nphenomenon) | III | C",
          "rows": 7,
          "cols": 3
        },
        {
          "title": "Table on page 47",
          "page": 47,
          "content": " |  | Starting\ndose | Target dose | \n | Calcium channel blockers |  |  | \nAmlodipine |  | 5 mg o.d. | 15–30 mg o.d.a | \nDiltiazem |  | 60 mg b.i.d.b | 120–360 mg b.i.d.b | \nFelodipine |  | 5 mg o.d. | 15–30 mg o.d.a | ",
          "rows": 5,
          "cols": 5
        },
        {
          "title": "Table on page 51",
          "page": 51,
          "content": "Recommendations |  | Classb | Levelc | \n | Recommendations for initial therapy |  |  | \nIn patients with IPAH/HPAH/DPAH who present\nat high risk of death, initial combination therapy\nwith a PDE5i, an ERA, and i.v./s.c. prostacyclin\nanalogues should be consideredd |  | IIa | C | \n | Recommendations for treatment decisions during follow-up |  |  | \nIn patients with IPAH/HPAH/DPAH who present\nat intermediate–low risk of death while receiving\nERA/PDE5i therapy, the addition of selexipag\nshould be considered419 |  | IIa | B | \nIn patients with IPAH/HPAH/DPAH who present\nat intermediate–high or high risk of death while\nreceiving ERA/PDE5i therapy, the addition of i.v./\ns.c. prostacyclin analogues and referral for LTx\nevaluation should be considered |  | IIa | C | \nIn patients with IPAH/HPAH/DPAH who present\nat intermediate–low risk of death while receiving\nERA/PDE5i therapy, switching from PDE5i to\nriociguat may be considered429 |  | IIb | B | ",
          "rows": 7,
          "cols": 5
        },
        {
          "title": "Table on page 52",
          "page": 52,
          "content": " |  | GRADE |  |  |  | \nRecommendations |  | Quality\nof\nevidence | Strength of\nrecommendation | Classa | Levelb | \n | Recommendations for initial therapy |  |  |  |  | \nIn patients with IPAH/\nHPAH/DPAH who\npresent at low or\nintermediate risk of\ndeath, initial\ncombination therapy\nwith a PDE5i and an\nERA is\nrecommended166 |  | Low | Conditional | I | B | ",
          "rows": 4,
          "cols": 7
        },
        {
          "title": "Table on page 52",
          "page": 52,
          "content": "Recommendations | Classa | Levelb\nInitial combination therapy with ambrisentan and\ntadalafil is recommended166,420,423 | I | B\nInitial combination therapy with macitentan and\ntadalafil is recommended421,430 | I | B\nInitial combination therapy with other ERAs and\nPDE5is should be considered430 | IIa | B\nInitial combination therapy with macitentan,\ntadalafil, and selexipag is not recommended421 | III | B",
          "rows": 5,
          "cols": 3
        }
      ],
      "keywords": [
        "echocardiography",
        "ct",
        "echo",
        "group",
        "follow-up",
        "hypertension",
        "heart failure",
        "arterial",
        "risk",
        "mri",
        "pulmonary",
        "imaging",
        "diagnosis"
      ]
    },
    {
      "number": "9",
      "title": "7. Specific pulmonary arterial hypertension subsets",
      "start_page": 57,
      "end_page": 68,
      "content": "For patients with left main coronary artery compression syn-\ndrome, percutaneous coronary stenting is an effective and safe treat-\nment.62 For patients with asymptomatic left main coronary artery\ncompression or non-severe compromise of its anatomy, evaluation\nwith intravascular ultrasound or coronary pressure wire may help\nto avoid unnecessary interventions.494\n6.3.11. End-of-life care and ethical issues\nThe clinical course of PAH may be characterized by progressive de-\nterioration and occasional episodes of acute decompensation. Life\nexpectancy is difﬁcult to predict, as patients may either die slowly be-\ncause of progressive right HF or experience sudden death.\nPatient-orientated care is essential in managing PAH. Information\nabout disease severity and possible prognosis should be provided at\ninitial diagnosis but empathic and hopeful communication, as well as\nyielding hope, is essential, in line with Section 6.3.1.8. At the right\ntime, open and sensitive communication will enable advanced plan-\nning and discussion of a patient’s fears, concerns, and wishes, and\nwill ultimately contribute to making the ﬁnal, well-informed, and joint\ndecision about treatment with the medical team.\nPatients approaching end of life require frequent assessment of\ntheir full needs by a multidisciplinary team. In advanced stages, recog-\nnizing that cardiopulmonary resuscitation in severe PAH has a poor\noutcome may enable a do not resuscitate order; this may facilitate\npatients being in their preferred place of care at end of life.\nAttention should be given to controlling distressing symptoms and\nprescribing appropriate drugs while withdrawing medication that is\nno\nlonger\nneeded,\nwhich\nmay\ninclude\nPAH\nmedication.\nWell-informed psychological, social, and spiritual support is also vital.\nSpecialist palliative care should be consulted for patients whose\nneeds are beyond the expertise of the PH team.346\n6.3.12. New drugs in advanced clinical development\n(phase 3 studies)\nPulmonary arterial hypertension remains an incurable condition with\na high mortality rate, despite use of PAH drugs mainly targeting im-\nbalance of vasoactive factors. Novel agents, which are currently in\nphase 3 development, are ralinepag and sotatercept. Ralinepag is\nan orally available prostacyclin receptor agonist, which, in a phase\n2 RCT that included 61 patients with PAH, improved PVR compared\nwith placebo after 22 weeks of therapy.495 Sotatercept—a fusion\nprotein comprising the extracellular domain of the human activin re-\nceptor type IIA linked to the Fc domain of human immunoglobulin\nG1—acts as a ligand trap for members of the transforming growth\nfactor (TGF)-β superfamily, thus restoring balance between growth-\npromoting and growth-inhibiting pathways.496 In a phase 2 RCT that\nincluded 106 patients with PAH treated over 24 weeks, s.c. sotater-\ncept reduced PVR in patients receiving background PAH therapy;496\nimprovements were also observed in 6MWD and NT-proBNP.496\n7. Speciﬁc pulmonary arterial\nhypertension subsets\n7.1. Pulmonary arterial hypertension\nassociated with drugs and toxins\nSeveral drugs and toxins are associated with developing PAH or\nPVOD/PCH. Historically, certain appetite suppressants and toxic\nrapeseed oil were the most prominent examples, whereas metham-\nphetamines, interferons, and some tyrosine kinase inhibitors are\nmore common causes nowadays (Table 7). Pulmonary arterial hyper-\ntension is a rare complication in patients exposed to these drugs, and\nmany of these drugs have also been linked to other pulmonary com-\nplications such as parenchymal lung disease or pleural effusions.\nThese pulmonary complications may occur concurrently.\nMethamphetamine-associated PAH has mainly been reported\nfrom the USA, where some centres have found that 20–29% of their\notherwise idiopathic cases of PAH were associated with metham-\nphetamine use.497,498 Compared with patients with IPAH, those\nwith methamphetamine-associated PAH had more severe haemo-\ndynamic impairment and a higher mortality risk.498 Alpha and beta\ninterferons have also been associated with developing PAH.499 The\nsame is true of some tyrosine kinase inhibitors, especially dasatinib,\nbut also bosutinib and ponatinib.40,500\nDrug- or toxin-induced PAH should always be considered in pa-\ntients presenting with unexplained exertional dyspnoea or other\nwarning signs. The diagnostic approach should be the same as in\nother forms of PH, and the diagnosis is usually made by excluding\nother forms of PH in patients who have been exposed to drugs as-\nsociated with developing PAH.\nTreatment of DPAH follows the same basic principles as treating\nother forms of PAH. Importantly, partial or full reversal of PAH has\nbeen reported after discontinuing the causative agent, at least for in-\nterferons and dasatinib.499,500 Hence, multidisciplinary management\nof the patient should include discontinuing the presumed causative\nagents once PAH is diagnosed (also see the 2022 ESC Guidelines\non Cardio-Oncology).501 In patients with mild PH and a low-risk pro-\nﬁle, discontinuing the trigger alone may be sufﬁcient, and it is recom-\nmended that these patients be observed over 3–4 months before\nconsidering PAH therapy. Pulmonary arterial hypertension therapy\nshould be initiated in patients who do not normalize their haemo-\ndynamics after withdrawing or in patients presenting with more ad-\nvanced PAH at diagnosis. Unlike in other forms of PAH, de-escalation\nof PAH therapy is often possible during the course of the disease.500\nPhysicians should bear in mind that DPAH may have features of\nPVOD/PCH, especially in patients treated with alkylating agents\nsuch as mitomycin C or cyclophosphamide. Health professional\nawareness is essential in identifying cases of DPAH and reporting ad-\nverse effects of pharmaceutical products.\nRecommendation Table 14 — Recommendations for\npulmonary\narterial\nhypertension\nassociated\nwith\ndrugs or toxins\nRecommendations\nClassa\nLevelb\nIt is recommended to make a diagnosis of drug- or\ntoxin-associated PAH in patients who had\nrelevant exposure and in whom other causes of\nPH have been excluded\nI\nC\nIn patients with suspected drug- or\ntoxin-associated PAH, it is recommended to\nimmediately discontinue the causative agent\nwhenever possible\nI\nC\nContinued\n3674\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n7.2. Pulmonary arterial hypertension\nassociated with connective tissue disease\nPulmonary arterial hypertension is a well-known pulmonary vascular\ncomplication\nof\nSSc,173,502–504\nsystemic\nlupus\nerythematosus\n(SLE),505–507 mixed CTD,506 and, rarely, dermatomyositis508 and\nSjögren’s syndrome.509 Conversely, the relationship between rheuma-\ntoid arthritis and PAH is not established.510 After IPAH, PAH-CTD is\nthe second most prevalent type of PAH in western countries.511\nSystemic sclerosis, particularly in its limited variant, represents the\nmain cause of PAH-CTD in Europe and the USA (SLE being more\ncommon in Asia).173,502,506 The prevalence of pre-capillary PH in large\ncohorts of patients with SSc is 5–19%.173,502 In these patients, PH may\noccur in association with ILD504,512 or as a result of PAH,173,502–504,506\nsometimes with features of venous/capillary involvement.504,513\nMoreover, group 2 PH-LHD is also common due to myocardial SSc\ninvolvement.504,514 Of note, patients with SLE may also present\nwith PAH, LHD, ILD, and CTEPH (mostly in the setting of antipho-\nspholipid syndrome). It is therefore essential to carefully determine\nwhich mechanism is operative in a given patient, since this will dictate\ntreatment in the context of a multifaceted disease.\nCluster analysis performed in patients with SSc has shown that\npre-capillary PH can be characterized into distinct clusters that differ\nin prognosis.503 One cluster, characterized by the presence of exten-\nsive ILD, and another by severely impaired haemodynamics carried a\ndismal prognosis, while the two others showed either the absence of\nILD or the presence of limited ILD, with mild-to-moderate risk PAH\nand a relatively favourable overall prognosis.503\n7.2.1. Epidemiology and diagnosis\nThere is a strong female predominance in PAH-CTD (female/male\nratio 4:1), and mean age at diagnosis is commonly .50 years, espe-\ncially in SSc.173,502–511,513,515,516 In the setting of a CTD, patients may\npresent with concomitant disorders such as ILD, and have shorter\nsurvival compared with patients with IPAH.503 The unadjusted risk\nof death for PAH-SSc compared with IPAH is 2.9, and the predictors\nof outcome are broadly similar to those for IPAH.516,517 Symptoms\nand clinical presentation are also similar to IPAH, and some patients\nthought to have IPAH can be identiﬁed as having an associated CTD\nby careful clinical examination and immunological screening tests.\nChest CT is recommended for evaluating the presence of associated\nILD or PVOD/PCH.504,513,515 An isolated reduction of DLCO is\ncommon in PAH-CTD.173,502–504\nResting echocardiography combined with other tests is recom-\nmended as a screening test in asymptomatic patients with SSc, fol-\nlowed by annual assessments. Screening/early detection is discussed\nin Section 5.3.1. In other CTDs, PH screening in the absence of sug-\ngestive symptoms is not recommended, while echocardiography\nshould be performed in the presence of symptoms. As in other forms\nof PAH, RHC is recommended in all cases of suspected PAH-CTD to\nconﬁrm diagnosis, determine severity, and rule out LHD.504\n7.2.2. Therapy\nDrugs for PAH should be prescribed in PAH-CTD according to the\nsame treatment algorithm as in IPAH (Figure 9). Patients with\nPAH-CTD have been included in most of the major RCTs for regu-\nlatory approval of PAH therapy.518 Some aspects of PAH-CTD\ntreatment\ndiffer\naccording\nto\nthe\nassociated\nCTD.506\nImmunosuppressive therapy combining glucocorticosteroids and\ncyclophosphamide may result in clinical improvement in patients\nwith SLE- or mixed CTD-associated PAH,506 while it is not recom-\nmended in PAH-SSc.519 Patients with SSc and other CTDs may have\nILD and/or HFpEF, which needs to be considered when initiating\nPAH therapy.504,515 In SSc, the long-term risk/beneﬁt ratio of oral an-\nticoagulation is unfavourable because of an increased risk of bleeding,\nwhile VKAs are recommended in PAH-CTD with a thrombophilic\npredisposition (e.g. antiphospholipid syndrome).319\nSubgroup analyses of patients with PAH-SSc enrolled in RCTs per-\nformed with monotherapy or combination therapy of ERAs, PDE5is,\nsGC stimulators, prostacyclin receptor agonists, epoprostenol, and\nprostacyclin\nanalogues\nhave\nshown\npositive\neffects\nvs.\npla-\ncebo.301,401,519,520 In some of these trials, the magnitude of the re-\nsponse in the PAH-CTD subgroup was lower than in the IPAH\nsubgroup.519,520 Continuous i.v. epoprostenol therapy improved ex-\nercise capacity, symptoms, and haemodynamics in a 3-month RCT in\nPAH-SSc.401 However, a retrospective analysis showed a better ef-\nfect of i.v. epoprostenol on survival in IPAH compared with\nPAH-SSc.521 The choice of PAH therapy in the context of SSc and\nits systemic manifestations may consider other vascular damage\nsuch as digital ulcers.522\nConnective tissue disease should not be considered as an a priori\ncontraindication for LTx.523 This has been extensively studied in SSc,\nwhere a multidisciplinary approach optimizing SSc management be-\nfore, during, and after surgery is recommended.523 Indications and\ncontraindications for transplantation have to be adapted to the spe-\nciﬁcities of CTD, with a special focus on digestive (gastro-\noesophageal reﬂux disease and intestinal disease), cardiac, renal,\nand cutaneous involvement.523\nImmediate PAH therapy should be considered in\npatients who present with intermediate-/high-risk\nPAH at diagnosis\nIIa\nC\nPatients with low-risk PAH should be re-evaluated\n3–4 months after discontinuing the suspected\ndrug or toxin, and PAH therapy may be\nconsidered when the haemodynamics have not\nnormalized\nIIb\nC\n© ESC/ERS 2022\nPAH, pulmonary arterial hypertension; PH, pulmonary hypertension.\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 15 — Recommendations for\npulmonary arterial hypertension associated with con-\nnective tissue disease\nRecommendations\nClassa\nLevelb\nIn patients with PAH associated with CTD,\ntreatment of the underlying condition according\nto current guidelines is\nrecommended166,167,419,524\nI\nA\nContinued\nESC/ERS Guidelines\n3675\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n7.3. Pulmonary arterial hypertension\nassociated with human\nimmunodeﬁciency virus infection\nThe use of highly active antiretroviral therapy (HAART), and ad-\nvances in managing opportunistic infections have contributed to in-\ncreased life expectancy in patients with HIV.525,526 Consequently,\nthe spectrum of complications has shifted towards other long-term\nconditions, including PAH. Clinical and histopathological ﬁndings in\nPAH associated with HIV infection (PAH-HIV) share many similar-\nities with IPAH.1,527 With the availability of HAART given in combin-\nation with PAH therapies, the prognosis of PAH-HIV has markedly\nimproved in recent years.526,528 In addition, the incidence of\nPAH-HIV has declined in parallel with the increasing availability of\nHAART.528 Taken together, these effects on survival and incidence\nhave resulted in a stable PAH prevalence in patients with HIV over\nrecent decades. A French population study indicated that the preva-\nlence of PAH in individuals with HIV infection was 0.46%, which is\nvery similar to the prevalence before the HAART era.177\nThe pathogenesis of PAH-HIV remains unclear. There is no evidence\nof a direct role of HIV in the pathogenesis of PAH and, although present\nin inﬂammatory cells in the lungs, the virus itself has never been found in\npulmonary vascular lesions of patients with PAH-HIV.529 This suggests\nthat an indirect action of viral infection on inﬂammation and growth fac-\ntors may act as a trigger in a predisposed patient.\n7.3.1. Diagnosis\nPulmonary arterial hypertension associated with HIV shares a clinical\npresentation with IPAH. Before the availability of HAART most pa-\ntients were in WHO-FC III or IV at diagnosis. Nowadays, patients are\ndiagnosed with much less severe symptoms and haemodynamics.\nPatients may present with other risk factors for PAH such as liver dis-\nease (chronic viral hepatitis B or C) or exposure to drugs or toxins.\nPatients with PAH-HIV are more likely to be male and i.v. drug abu-\nsers.403,526 There is no correlation between the severity of PAH and\nthe stage of HIV infection or the degree of immunodeﬁciency.403,530\nBecause of its low prevalence, asymptomatic patients with HIV\nshould not be screened for PAH. However, echocardiography\nshould be performed in patients with unexplained dyspnoea to de-\ntect HIV-related cardiovascular complications such as myocarditis,\ncardiomyopathy, or PAH. Right heart catheterization is mandatory\nto conﬁrm the diagnosis of PAH-HIV and to rule out LHD.527\nPulmonary arterial hypertension is an independent risk factor for\ndeath in patients with HIV. In the 1990s, before the availability of\nHAART, patients with PAH-HIV had poor outcomes, with a 3 year\nsurvival of ,50%.403 The overall survival has now improved and pa-\ntients with PAH-HIV have a better prognosis than most patients with\nother forms of PAH.526\n7.3.2. Therapy\nCurrent recommendations for the treatment of PAH-HIV are largely\nbased on data from IPAH.25,26\nTreatment of PAH-HIV with HAART has improved functional sta-\ntus and survival in some retrospective studies.525,526,531 The use of\nHAART in PAH-HIV is therefore recommended, irrespective of viral\nload and CD4+ cell count.\nAnticoagulation is not recommended because of an increased risk\nof bleeding and drug interactions.319,527 Patients with PAH-HIV are\nusually non-responders to acute vasoreactivity testing and therefore\nshould not receive CCBs.378\nThe prospective, open-label, BREATHE-4 study showed that bo-\nsentan markedly improved WHO-FC, exercise capacity, quality of\nlife,\nand\nhaemodynamics\nafter\n16\nweeks\nin\npatients\nwith\nPAH-HIV.532 In a long-term, retrospective series, bosentan therapy\nwas associated with haemodynamic normalization in 10/59 pa-\ntients.533 Bosentan potentially interacts with antiretroviral drugs,\nand close monitoring is required when combined with HAART.\nVery few patients with PAH-HIV have been included in RCTs with\nambrisentan and macitentan, and no deﬁnite conclusion can be\ndrawn from those studies.\nPositive effects of sildenaﬁl and tadalaﬁl in PAH-HIV have been es-\ntablished in case studies.534,535 Interactions have been reported be-\ntween PDE5is and protease inhibitors, resulting in major increases\nin PDE5i concentrations; these drugs should be introduced at low\ndosages with careful monitoring of potential side effects, including\nhypotension.536,537 There are no data on the use of the sGC stimu-\nlator riociguat in PAH-HIV.\nTreatment with i.v. epoprostenol resulted in signiﬁcant improve-\nment in WHO-FC, exercise capacity, haemodynamics, and survival\nin selected patients with PAH-HIV.403,538 There are very few data\non the use of i.v. or s.c. treprostinil or inhaled iloprost in\nPAH-HIV.539,540\nThere are no clinical trial data on the use of combination therapy\nfor PAH-HIV. Given the lack of supporting evidence and potential\nsafety concerns when PAH drugs are co-administered with anti-\nretroviral drugs, initial monotherapy with PAH medication is recom-\nmended, followed by an individualized use of combination therapy in\npatients who do not reach a low-risk proﬁle.\nIn patients with PAH associated with CTD, the\nsame treatment algorithm as for patients with\nIPAH is recommended\nI\nC\n© ESC/ERS 2022\nPAH-CTD, pulmonary arterial hypertension associated with connective tissue disease;\nIPAH, idiopathic pulmonary arterial hypertension.\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 16 — Recommendations for\npulmonary arterial hypertension associated with hu-\nman immunodeﬁciency virus infection\nRecommendations\nClassa\nLevelb\nIn patients with PAH associated with HIV\ninfection, antiretroviral treatment according to\ncurrent guidelines is recommended541,542\nI\nA\nIn patients with PAH associated with HIV\ninfection, initial monotherapy should be\nconsidered, followed by sequential combination if\nnecessary, taking into consideration comorbidities\nand drug–drug interactions\nIIa\nC\n© ESC/ERS 2022\nHIV, Human immunodeﬁciency virus; PAH, pulmonary arterial hypertension.\naClass of recommendation.\nbLevel of evidence.\n3676\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n7.4. Pulmonary arterial hypertension\nassociated with portal hypertension\nPulmonary arterial hypertension associated with portal hyperten-\nsion, commonly referred to as PoPH, develops in 2–6% of patients\nwith portal hypertension, with or without liver disease. In PAH regis-\ntries, PoPH represents 5–15% of the patients.543–545 Rarely, some\npatients with PoPH have portosystemic shunts in the absence of por-\ntal hypertension (congenital extrahepatic cavoportal shunts).546\nHowever, PoPH is distinct from hepatopulmonary syndrome\n(HPS), which is characterized by intrapulmonary vascular dilatations\nand hypoxaemia. Of note, HPS and PoPH can occur sequentially or\nconcurrently in patients with portal hypertension.547\n7.4.1. Diagnosis\nThe diagnosis of PoPH is based on the presence of otherwise unex-\nplained pre-capillary PH in patients with portal hypertension or a por-\ntosystemic shunt. The diagnostic approach is the same as in other\npatients with suspected or newly detected PH. Transthoracic echocar-\ndiography is usually the ﬁrst non-invasive assessment in patients with\nsuspected PH, and echocardiography is also recommended as a screen-\ning tool in patients evaluated for liver transplantation. As patients with\nliver disease often have an elevated CO, TRV tends to overestimate\nPAP in these patients. Hence, RHC with comprehensive haemodynamic\nassessment is essential to conﬁrm the diagnosis of PH and to distinguish\nPAH (with elevated PVR) from unclassiﬁed PH (with a normal PVR).\n7.4.2. Therapy\nPatients with unclassiﬁed PH (i.e. mPAP .20 mmHg, elevated CO,\nand PVR ≤2.0 WU) should be regularly followed-up but should\nnot be treated with drugs approved for PAH.\nIn patients with an established diagnosis of PoPH, treatment\nshould follow the same general principles as in other patients with\nPAH, taking into account the severity of underlying liver disease,\nthe indication for liver transplantation, and the potential effects of\nPAH medication on gas exchange, which may deteriorate with vaso-\ndilators in patients with PoPH.548,549 All drugs approved for PAH can\nprincipally be used to treat patients with PoPH, bearing in mind that\nthese patients are usually excluded from registration studies.\nNevertheless, various case series support the use of approved\nPAH medication in patients with PoPH. The largest series published\nso far reported on 574 patients with PoPH treated with various PAH\ndrugs, mostly PDE5is or ERAs, alone and in combination.545 Most pa-\ntients (56.8%) were in Child–Pugh class A at the time of PAH diag-\nnosis. At the ﬁrst follow-up, which took place 4.5 months after\nstarting treatment, improvements were seen in haemodynamics,\nWHO-FC, 6MWD, and BNP/NT-proBNP; survival at 5 years was\n51%. In patients presenting with mild liver disease, the main causes\nof death were PAH progression and malignancy, whereas complica-\ntions of liver disease were the most common causes of death in pa-\ntients with advanced liver disease. The 5 year survival of patients who\nunderwent liver transplantation (n = 63) was 81%.\nThe only RCT dedicated to the treatment of PoPH was PORTICO,\na 12 week study that randomized 85 patients to macitentan (n = 43)\nor placebo (n = 42).168 PORTICO met its primary endpoint, demon-\nstrating a signiﬁcant reduction in PVR from baseline (ratio of geomet-\nric mean 0.65; 95% CI, 0.59–0.72; P , 0.0001). There were, however,\nno differences between the two treatment groups in secondary out-\ncome measures, including WHO-FC, 6MWD, and NT-proBNP.\n7.4.2.1. Liver transplantation\nPorto-pulmonary hypertension is not per se an indication for liver\ntransplantation. Pulmonary arterial hypertension poses a major threat\nto patients who undergo liver transplantation when indicated for the\nseverity of liver disease. In a historical series from the Mayo Clinic, se-\nvere PAH with mPAP ≥50 mmHg was associated with a 100% peri-\noperative mortality rate. In patients with mPAP 35–50 mmHg and\nPVR .3.0 WU, mortality was still 50%.550 In liver transplantation can-\ndidates with PAH, targeted medical therapy successfully improves\nhaemodynamics and establishes eligibility for transplantation.545,551–\n554 However, haemodynamic criteria for successful liver transplant-\nation have not been ﬁrmly established. The International Liver\nTransplant Society proposed haemodynamic targets of mPAP\n,35 mmHg and PVR ,5 WU, or mPAP ≥35 mmHg and PVR ,3\nWU in patients receiving PAH therapy, while acknowledging that\nthese criteria need to be further validated.175 An mPAP ≥45 mmHg\nis regarded as an absolute contraindication to liver transplantation.175\nIn patients with PoPH who successfully underwent liver trans-\nplantation, de-escalation or discontinuation of PAH medication is of-\nten feasible, but this has to be performed on an individual basis.551,554\nRecommendation Table 17 — Recommendations for\npulmonary arterial hypertension associated with por-\ntal hypertension\nRecommendations\nClassa\nLevelb\nEchocardiography is recommended in patients\nwith liver disease or portal hypertension with\nsigns or symptoms suggestive of PH, and as a\nscreening tool in patients evaluated for liver\ntransplantation or transjugular portosystemic\nshunt\nI\nC\nIt is recommended that patients with PAH\nassociated with portal hypertension are referred\nto centres with expertise in managing both\nconditions\nI\nC\nIn patients with PAH associated with portal\nhypertension, initial monotherapy should be\nconsidered, followed by sequential combination if\nnecessary, taking into consideration the\nunderlying liver disease and indication for liver\ntransplantation\nIIa\nC\nLiver transplantation should be considered on an\nindividual basis in patients with PAH associated\nwith portal hypertension, as long as PVR is normal\nor near normal with PAH therapy\nIIa\nC\nDrugs approved for PAH are not recommended\nfor patients with portal hypertension and\nunclassiﬁed PH (i.e. elevated mPAP, high CO, and\na normal PVR)\nIII\nC\n© ESC/ERS 2022\nmPAP, mean pulmonary arterial pressure; CO, cardiac output; PAH, pulmonary arterial\nhypertension; PH, pulmonary hypertension; PVR, pulmonary vascular resistance.\naClass of recommendation.\nbLevel of evidence.\nESC/ERS Guidelines\n3677\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n7.5. Pulmonary arterial hypertension\nassociated with adult congenital heart\ndisease\nThe presence of PH in adults with CHD has a negative impact on the\nnatural course of CHD, and worsens clinical status and overall out-\ncome.555 Pulmonary arterial hypertension associated with adult CHD\nis included in group 1 of the PH clinical classiﬁcation (Table 6) and repre-\nsents a heterogeneous patient population. Post-capillary PH in adult\nCHD (e.g. systolic or diastolic, systemic, ventricular dysfunction in com-\nbination with shunt lesions or complex adult CHD, and systemic atrio-\nventricular valve dysfunction) should be excluded to determine further\nmanagement. A speciﬁc clinical classiﬁcation (Table 21) is provided to\nbetter characterize PAH associated with adult CHD. Some complex\nCHDs are associated with congenital abnormalities of the pulmonary\nvascular tree leading to segmental PH. In segmental PH, one or more,\nbut not all, segments of the lung(s) are hypertensive and each hyperten-\nsive area may present with PH of different severity, while other parts of\nthe lung vasculature may be hypoplastic. Pulmonary atresia with ven-\ntricular septal defect and systemic-to-pulmonary collaterals is the\nmost frequent condition, but other complex CHDs may also lead to\nsegmental PH.\nApproximately 3–7% of patients with adult CHD will eventually\ndevelop PAH; it is more frequently encountered in females, and\nthe incidence depends on the underlying lesion and increases with\nage and age at defect closure.556 The estimated prevalence of PAH\nin patients after correcting a simple cardiac defect is 3%.557 The epi-\ndemiology of PAH associated with adult CHD is expected to change\ndue to advances in diagnostic and therapeutic paediatric cardiology,\nresulting in fewer patients with simple adult CHD and more patients\nwith complex lesions and/or closed defects who develop PAH in\nadulthood.558\nThe clinical presentation of Eisenmenger syndrome, an advanced\nform of adult CHD-associated PAH, is characterized by the multiorgan\neffects of chronic hypoxaemia, including cyanosis, and haematological\nchanges, including secondary erythrocytosis and thrombocytopenia;\nthe main symptoms are dyspnoea, fatigue, and syncope. Eisenmenger\nsyndrome may also present with haemoptysis, chest pain, cerebrovas-\ncular accidents, brain abscesses, coagulation abnormalities, and sudden\ndeath. Patients with adult CHD and Down syndrome are at an in-\ncreased risk of developing Eisenmenger syndrome.\n7.5.1. Diagnosis and risk assessment\nThe diagnostic work-up of PAH associated with adult CHD should\nbe based on the presence of symptoms and includes medical his-\ntory, physical examination, PFTs, ABG, imaging (especially echocar-\ndiography), and exercise and laboratory testing. Of note, standard\nechocardiographic criteria for detecting PH may not be applicable\nin complex adult CHD.559 Right heart catheterization with com-\npartmental oximetry for calculating pulmonary blood ﬂow/system-\nic blood ﬂow (Qp/Qs) is required to conﬁrm PAH diagnosis and\nguide therapeutic interventions. Thermodilution should be avoided\nin the presence of intracardiac shunts, and direct Fick is the most\naccurate method. Pulmonary vascular resistance may be overesti-\nmated due to erythrocytosis.560 Interpreting invasive haemo-\ndynamics (see Section 5.1.12) should be made in the context of\nmultiparametric assessment of exercise capacity, laboratory test-\ning, and imaging.\nPredictors of worse outcomes in adult CHD-associated PAH are\nWHO-FC III–IV, exercise intolerance assessed by 6MWD or peak\nVO2, history of hospitalization for right HF, biomarkers (NT-proBNP\n.500 pg/mL, C-reactive protein .10 mg/mL, high serum creatinine,\nand low albumin levels), iron deﬁciency, and echocardiographic indices\nof RV dysfunction.559,561 When compared with patients with IPAH, pa-\ntients with Eisenmenger syndrome may have a relatively stable long-\nterm clinical course. The right ventricle is unloaded by the right-to-left\nshunt, sustaining CO at the expense of hypoxaemia and cyanosis.\nHowever, due to immortal time bias, prognosis of Eisenmenger syn-\ndrome is not as favourable as previously thought.562\nAs in other forms of PAH, risk assessment is important to guide\ntherapy, and speciﬁc risk factors have been described in Eisenmenger\nsyndrome. A large multicentre study showed that mortality in adults\nwith Eisenmenger syndrome was predicted by the presence of pre-\ntricuspid shunt, advancing age, low rest oxygen saturation, absence of\nsinus rhythm, and presence of pericardial effusion.563\nTable 21\nClinical classiﬁcation of pulmonary arterial\nhypertension associated with congenital heart disease\n(1) Eisenmenger syndrome\nIncludes all large intra- and extracardiac defects that begin as\nsystemic-to-pulmonary shunts and progress to severely elevated\nPVR and to reverse (pulmonary-to-systemic) or bidirectional\nshunting. Cyanosis, secondary erythrocytosis, and multiple organ\ninvolvement are usually present. Closing the defects is\ncontraindicated.\n(2) PAH associated with prevalent systemic-to-pulmonary shunts\n• Correctablea\n• Non-correctable\nInclude moderate-to-large defects. PVR is mildly to moderately\nincreased and systemic-to-pulmonary shunting is still prevalent,\nwhereas cyanosis at rest is not a feature.\n(3) PAH with small/coincidentalb defects\nMarkedly elevated PVR in the presence of cardiac defects considered\nhaemodynamically non-signiﬁcant (usually ventricular septal defects\n,1 cm and atrial septal defects ,2 cm of effective diameter\nassessed by echocardiography), which themselves do not account\nfor the development of elevated PVR. The clinical picture is very\nsimilar to IPAH. Closing the defects is contraindicated.\n(4) PAH after defect correction\nCongenital heart disease is repaired, but PAH either persists\nimmediately after correction or recurs/develops months or years\nafter correction in the absence of signiﬁcant, post-operative,\nhaemodynamic lesions.\n© ESC/ERS 2022\nIPAH,\nidiopathic\npulmonary\narterial\nhypertension;\nPAH,\npulmonary\narterial\nhypertension; PVR, pulmonary vascular resistance.\naWith surgery or intravascular percutaneous procedure, see also the Recommendation\nTable 18 for shunt closure.\nbThe size applies to adult patients. However, also in adults, the simple diameter may be\ninsufﬁcient for deﬁning the haemodynamic relevance of the defect, and also the pressure\ngradient, the shunt size and direction, and the pulmonary-to-systemic ﬂows ratio should\nbe considered.\n3678\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n7.5.2. Therapy\nOutcomes in adult CHD-associated PAH have improved with the\navailability of new PAH therapies, advances in surgical and peri-\noperative management, and a team-based, multidisciplinary ap-\nproach in PH centres. These patients should be managed by specia-\nlized\nhealth\nprofessionals.\nPatient\neducation,\nbehavioural\nmodiﬁcations, and social and psychological support are all important\naspects of management.\nShunt closure (surgical or interventional) may only be consid-\nered in patients with prevalent systemic-to-pulmonary shunting\nwithout signiﬁcantly increased PVR. Criteria for defect closure\nbased on Qp/Qs ratio and (baseline and/or after targeted PAH\ntreatment)\nPVR\nhave\nbeen\nproposed\nby\nthe\n2020\nESC\nGuidelines for the management of adult congenital heart dis-\nease.101 Decisions on shunt closure should not be made on\nhaemodynamic numbers alone, and a multiparametric strategy\nshould be followed. For instance, shunt closure is not indicated\nin the case of desaturation during exercise in the 6MWT or\nCPET, or when there is secondary erythrocytosis suggesting dy-\nnamic reversal of shunt. There is no evidence for a long-term\nbeneﬁt of a treat-and-repair approach in patients with adult\nCHD-associated PAH with prevalent systemic-to-pulmonary\nshunts; therefore, there is a need for future prospective stud-\nies.564 Defect closure is contraindicated in all patients with\nEisenmenger syndrome, and may also adversely affect patients\nwith small/coincidental defects that behave similarly to IPAH.565\nThere are no prospective data available on the usefulness of vasor-\neactivity testing, balloon closure testing, or lung biopsy for asses-\nsing operability and normalization of PVR after closure.566\nPatients with adult CHD-associated PAH may present with clinical\ndeterioration in different circumstances, such as arrhythmia, during\nnon-cardiac surgery requiring general anaesthesia, dehydration or\nbleeding, thrombo-embolism, and lung infections. Surgeries should\nbe limited to those deemed essential, and performed in specialized\ncentres with anaesthetists experienced in adult CHD and PAH.\nEndocarditis should be suspected in patients with sepsis, whereas a\ncerebral abscess should be excluded in those with neurological\nsymptoms or new headache, especially in those with low oxygen sa-\nturations and complex anatomies. It is recommended to avoid\nstrenuous exercise, but mild and moderate activities seem to be\nbeneﬁcial.567 Patients should receive all recommended vaccinations\nand endocarditis prophylaxis in the presence of cyanosis. Although\npregnant patients with left-to-right shunts and stable, well-controlled\nPAH have tolerated pregnancy well under specialized care, preg-\nnancy is still associated with both high maternal mortality and foetal\ncomplications in Eisenmenger syndrome and should be discouraged\nin this setting;568,569 hence, effective contraception is highly recom-\nmended. Levonorgestrel-based, long-acting, reversible contracep-\ntion implants or intrauterine devices have been recommended for\nthese patients.570\nSecondary erythrocytosis is beneﬁcial for adequate oxygen trans-\nport and delivery, and routine phlebotomy should be avoided when-\never possible. Symptoms of hyperviscosity in the presence of\nhaematocrit .65% should be approached with appropriate hydra-\ntion. Iron deﬁciency should be corrected. When i.v. iron supplemen-\ntation is administered, special care should be taken to avoid air\nemboli during administration.571 Supplemental oxygen therapy has\nnot been shown to impact survival.\nOral anticoagulant treatment with VKAs may be considered in pa-\ntients with large PA aneurysms with thrombus, atrial arrhythmias,\nand previous thrombo-embolic events, but with low bleeding risk.\nIn patients with very high Hb levels (.20 mg/dL), standard inter-\nnational\nnormalized\nratio\nmeasures\nare\nless\naccurate,\nand\ncitrate-adjusted blood bottles must be used. Regarding using novel\noral anticoagulants (NOACs), a large, nationwide, German, adult\nCHD\ndatabase\n(including\n106\nNOAC-treated\npatients\nwith\nEisenmenger syndrome) showed that NOAC users had higher long-\nterm risk of bleeding, major adverse cardiovascular events, and mor-\ntality compared with those on VKAs, suggesting that initiating\nNOACs should be reserved for experienced adult CHD centres,\ncarefully weighing potential beneﬁts and risks.572,573\nCompared with other group 1 subgroups, limited data exist on the\nuse of drugs approved for PAH in patients with adult CHD-associated\nPAH. Bosentan improved 6MWD and decreased PVR in patients with\nEisenmenger syndrome in WHO-FC III.574 Patients with more com-\nplex lesions were less likely to respond to PAH therapies compared\nwith patients with simple lesions. An RCT investigating the efﬁcacy of\nmacitentan found no effect on 6MWD in a mixed cohort of patients\nwith Eisenmenger syndrome (6MWD improved in both treatment\nand placebo arms), although decreases in NT-proBNP and PVR\nwere noted in the macitentan arm.575\nExperiences with other ERAs and PDE5is have shown favourable\nfunctional and haemodynamic results in Eisenmenger syndrome.576\nIn a small, single-centre, pilot study, adding nebulized iloprost to a\nbackground of oral PAH therapy failed to improve 6MWD in\nEisenmenger syndrome.577 In case symptoms persist or in clinical de-\nterioration, a sequential and symptom-orientated treatment strategy\nis recommended in Eisenmenger syndrome, starting with an oral\nERA (or PDE5i) and escalating therapy. Should symptoms not ad-\nequately improve with oral therapies, i.v./s.c. options should be pro-\nactively considered.578 There is a theoretical risk of paradoxical\nembolism in right-to-left shunt lesions with the presence of a central\nvenous catheter for i.v. therapy; therefore, s.c. prostacyclin analogue\ninfusion may be considered.\nThe effect of PAH therapies in patients with prevalent\nsystemic-to-pulmonary shunts is less well established. Patients with\nsmall/coincidental defects should be treated with PAH medica-\ntion.557 This is also the case for patients with PAH after defect cor-\nrection who have increased mortality compared with those with\nEisenmenger syndrome.579 These patients were included in major\nRCTs with PAH therapies and should be evaluated based on com-\nprehensive risk assessment (Table 16).580 The effect of PAH therap-\nies in patients with segmental PH remains a matter of debate.101,581\nWhile some series have reported promising results, there have been\ncases where therapies were not tolerated.581 Similarly, using PAH\ntherapies in Fontan circulation has yielded conﬂicting results, and re-\nsults of further studies are awaited.582–584\nHeart–lung transplantation or LTx with heart surgery is an option\nin highly selected cases not responsive to medical treatment; how-\never, it is limited by organ availability and lesion complexity.\nMortality is high during the ﬁrst year after surgery, especially after\nheart–lung transplantation, but remains relatively low thereafter.585\nESC/ERS Guidelines\n3679\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n7.6. Pulmonary arterial hypertension\nassociated with schistosomiasis\nSchistosomiasis is one of the most common chronic infectious dis-\neases worldwide, affecting around 200 million people.586,587\nSchistosomiasis-associated PAH is present in 5% of patients with\nthe hepatosplenic form of the disease.586 It is thus a leading cause\nof PAH, especially in some regions of South America, Africa, and\nAsia.\nCompared\nwith\npatients\nwith\nIPAH,\npatients\nwith\nschistosomiasis-associated PAH present with higher CO and lower\nPVR, and have a better survival.587 Registry data suggest that survival\nin schistosomiasis-associated PAH has improved in recent years with\nthe use of PAH drugs.588\n7.7. Pulmonary arterial hypertension\nwith signs of venous/capillary\ninvolvement\nThe common risk factors, identical genetic substrate, and indistin-\nguishable clinical presentations of PCH and PVOD necessitate their\nconsideration as a single disease belonging to the group 1 PH spec-\ntrum of diseases (PAH with signs of venous/capillary involve-\nment).1,425,589 In PVOD/PCH, post-capillary lesions affecting septal\nveins and pre-septal venules consist of loose, ﬁbrous remodelling\nof the intima that may totally occlude the lumen.1,425,589,590 These\nchanges are frequently associated with PCH consisting of capillary\nRecommendation Table 18 — Recommendations for\nshunt closure in patients with pulmonary–systemic\nﬂow ratio .1.5:1 based on calculated pulmonary vas-\ncular resistance\nRecommendations\nClassa\nLevelb\nIn patients with an ASD, VSD, or PDA and a PVR\n,3 WU, shunt closure is recommended\nI\nC\nIn patients with an ASD, VSD, or PDA and a PVR\nof 3–5 WU, shunt closure should be considered\nIIa\nC\nIn patients with an ASD and a PVR .5 WU that\ndeclines to ,5 WU with PAH treatment, shunt\nclosure may be considered\nIIb\nC\nIn patients with a VSD or PDA and a PVR .5 WU,\nshunt closure may be considered after careful\nevaluation in specialized centres\nIIb\nC\nIn patients with an ASD and a PVR .5 WU\ndespite PAH treatment, shunt closure is not\nrecommended\nIII\nC\n© ESC/ERS 2022\nASD, atrial septal defect; PAH, pulmonary arterial hypertension; PDA, patent ductus\narteriosus; PVR, pulmonary vascular resistance; VSD, ventricular septal defect; WU,\nWood units.\nDecisions on shunt closure should not be made on haemodynamic numbers alone; a\nmultiparametric strategy should be followed (see Section 7.5.2).\naClass of recommendation.\nbLevel of evidence.\nRecommendation Table 19 — Recommendations for\npulmonary arterial hypertension associated with adult\ncongenital heart disease\nRecommendations\nClassa\nLevelb\nRisk assessment\nRisk assessment is recommended for patients\nwith persistent PAH after defect closure\nI\nC\nRisk assessment should be considered in patients\nwith Eisenmenger syndrome\nIIa\nC\nTreatment\nBosentan is recommended in symptomatic\npatients with Eisenmenger syndrome to improve\nexercise capacity574\nI\nB\nIn patients with Eisenmenger syndrome, the use of\nsupplemental oxygen therapy should be\nconsidered in cases where it consistently increases\narterial oxygen saturation and reduces symptoms\nIIa\nC\nSupplemental iron treatment should be\nconsidered in patients with iron deﬁciency\nIIa\nC\nIn patients with adult CHD, including Eisenmenger\nsyndrome, other ERAs, PDE5is, riociguat,\nprostacyclin analogues, and prostacyclin receptor\nagonists should be considered\nIIa\nC\nContinued\nIn patients with PAH after corrected adult CHD,\ninitial oral combination therapy with drugs\napproved for PAH should be considered for\npatients at low and intermediate risk, while initial\ncombination therapy including i.v./s.c. prostacyclin\nanalogues should be considered for patients at\nhigh risk\nIIa\nCc\nIn patients with adult CHD, including Eisenmenger\nsyndrome, sequential combination therapy should\nbe considered if patients do not meet treatment\ngoals\nIIa\nC\nIn the absence of signiﬁcant haemoptysis, oral\nanticoagulant treatment may be considered in\npatients with Eisenmenger syndrome with\npulmonary artery thrombosis\nIIb\nC\nIn women with Eisenmenger syndrome,\npregnancy is not recommended\nIII\nC\nIn patients with Eisenmenger syndrome, routine\nphlebotomy to lower elevated haematocrit is not\nrecommended\nIII\nC\n© ESC/ERS 2022\nCHD, congenital heart disease; ERA, endothelin receptor antagonist; i.v., intravenous;\nPAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; s.c.,\nsubcutaneous.\naClass of recommendation.\nbLevel of evidence.\ncLevel of evidence differs from the 2020 ESC Guidelines for the management of adult\ncongenital heart disease because the number of patients with adult CHD included in\nthe AMBITION study was very low.\n3680\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nectasia and proliferation, with doubling and tripling of the alveolar\nseptal capillary layers that may be focally distributed within the alveo-\nlar interstitium.425,590\nThe proportion of patients with IPAH that fulﬁl the criteria for\nPVOD/PCH is ≏10%, resulting in a lowest estimate of PVOD/PCH\nincidence and prevalence of ,1 case/million.425 In contrast to\nIPAH, there is a male predominance in PVOD/PCH and its progno-\nsis is worse.425,589,591 Familial PVOD/PCH typically occurs in the\nyoung siblings of one generation, with unaffected and sometimes\nconsanguineous parents, indicating that the disease segregates as\na recessive trait.158,425,591 Biallelic mutations in the EIF2AK4 gene\ncause heritable PVOD/PCH.158 In addition, PVOD/PCH can com-\nplicate the course of associated conditions, such as SSc,425 or be\nassociated with exposure to environmental triggers, such as alkyl-\nating agents (cyclophosphamide, mitomycin C)34 and solvents\n(trichloroethylene).38\n7.7.1. Diagnosis\nMost patients complain of non-speciﬁc dyspnoea on exertion and fa-\ntigue.590 Physical examination may reveal digital clubbing and bibasal\ncrackles on lung auscultation.590 Pulmonary arterial hypertension\nand PVOD/PCH share the same haemodynamic proﬁle as pre-\ncapillary PH.590,591 The PAWP is not elevated because the pulmon-\nary vascular changes occur in small venulae and capillaries, while the\nLA ﬁlling pressure remains normal.590,591 A diagnosis of PVOD/PCH\nis based on the results of tests suggesting venous post-capillary in-\nvolvement, chronic interstitial pulmonary oedema, and capillary\nproliferation.1,590,591 These tests include PFTs (decreased DLCO,\nfrequently ,50% theoretical values), ABG (hypoxaemia), and\nnon-contrast chest CT (subpleural thickened septal lines, centrilob-\nular\nground-glass\nopacities,\nand\nmediastinal\nlymphadenop-\nathy).1,425,589,591,592 Importantly, these patients are at risk of\ndrug-induced pulmonary oedema with PAH therapy, a ﬁnding sug-\ngestive of PVOD/PCH.425,591 Detecting biallelic EIF2AK4 mutations\nis\nsufﬁcient\nto\nconﬁrm\na\ndiagnosis\nof\nheritable\nPVOD/\nPCH.158,591,592 Lung biopsy is hazardous in PH and is not recom-\nmended for diagnosing PVOD/PCH.1,425\n7.7.2. Therapy\nThere is no established medical therapy for PVOD/PCH.425\nCompared with IPAH, PVOD/PCH has a poor prognosis and limited\nresponse to PAH therapy, with a risk of pulmonary oedema due to\npulmonary venous obstruction.425,591 However, there are reports of\nincomplete and transient clinical improvement in individual patients\nwith PVOD/PCH treated with PAH therapy, which should be\nused with great caution in this setting.425,591 Diuretics, oxygen\ntherapy, and slow titration of PAH therapy can be used on an in-\ndividual basis.425 Therefore, therapy for PVOD/PCH should be\nundertaken at centres with extensive experience in managing\nPH, and patients should be fully informed about the risks.425\nAnecdotal reports suggest a potential beneﬁt of immunomodula-\ntory treatments, but this approach requires further study.593\nThe only curative therapy for PVOD/PCH is LTx, and eligible pa-\ntients should be referred to a transplant centre for evaluation\nupon diagnosis.425,591 Pathological examination of the explanted\nlungs will conﬁrm the diagnosis.590\n7.8. Paediatric pulmonary hypertension\nPulmonary hypertension may present at all ages, including in infants\nand children. Pulmonary hypertension in childhood shares many\ncommon features with PH in adulthood; however, there are also im-\nportant differences, which concern epidemiology, aetiology, genetic\nbackground, age-dependent diagnostic and treatment approaches,\nand disease monitoring. An important and conceptually distinctive\nfeature of paediatric PH is injury to developing foetal, neonatal, or\npaediatric lung circulation.\n7.8.1. Epidemiology and classiﬁcation\nThe reported annual incident rate for paediatric PH is 64/million chil-\ndren.594 The distribution of the various aetiologies of PH in child-\nhood differs from PH in adulthood.594–596 Pulmonary arterial\nhypertension is the most frequent type of PH in children, with the\nvast majority (82%) of cases being infants with transient PAH (i.e.\nPPHN or repairable cardiac shunt defects). Of the remaining children\nwith PAH, most have either IPAH, HPAH, or irreversible\nCHD-associated PAH. The reported incidences of IPAH/HPAH\nand (non-transient) CHD-associated PAH are 0.7 and 2.2/million\nchildren, respectively, with a prevalence of 4.4 and 15.6/million chil-\ndren, respectively.594 Other conditions associated with PAH\n(Table 6) do occur in children but are rare.\nAnother signiﬁcant proportion (34–49%) of children with non-\ntransient PH are neonates and infants with PH associated with re-\nspiratory disease, especially developmental lung diseases, including\nbronchopulmonary dysplasia (BPD), congenital diaphragmatic hernia\n(CDH), and congenital pulmonary vascular abnormalities.594–598\nThese children form a prominent and distinctive group in paediatric\nPH and are currently classiﬁed as PH group 3 associated with\nRecommendation Table 20 — Recommendations for\npulmonary arterial hypertension with signs of venous/\ncapillary involvement\nRecommendations\nClassa\nLevelb\nA combination of clinical and radiological ﬁndings,\nABG, PFTs, and genetic testing is recommended\nto diagnose PAH with signs of venous and/or\ncapillary involvement (PVOD/PCH)591\nI\nA\nIdentiﬁcation of biallelic EIF2AK4 mutations is\nrecommended to conﬁrm a diagnosis of heritable\nPVOD/PCH158,591\nI\nA\nReferral of eligible patients with PVOD/PCH to a\ntransplant centre for evaluation is recommended\nas soon as the diagnosis is established\nI\nC\nIn patients with PVOD/PCH, the use of drugs\napproved for PAH may be considered with careful\nmonitoring of clinical symptoms and gas exchange\nIIb\nC\nLung biopsy is not recommended to conﬁrm a\ndiagnosis of PVOD/PCH\nIII\nC\n© ESC/ERS 2022\nABG, arterial blood gas analysis; PAH, pulmonary arterial hypertension; PCH,\npulmonary capillary haemangiomatosis; PFT, pulmonary function test; PVOD,\npulmonary veno-occlusive disease.\naClass of recommendation.\nbLevel of evidence.\nESC/ERS Guidelines\n3681\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\ndevelopmental lung disease (Table 6; Table S7). A signiﬁcant and\ngrowing proportion of children with PH associated with respiratory\ndisease is made up of pre-term infants with BPD. Also, newly recog-\nnized genetic developmental lung disorders—including alveolar capil-\nlary dysplasia, TBX4-mutation-related lung disorders, and surfactant\nabnormalities—are currently classiﬁed in this category (Figure 10).599\nAnother distinctive feature of PH in children is the high burden of\ngenetic disorders. Childhood PH is often associated with chromo-\nsomal, genetic, and syndromic anomalies (11–52%). Like in adults,\ngene mutations implicated in the pathogenesis of HPAH are found\nin 20–30% of sporadic cases, where paediatric HPAH seems to be\ncharacterized\nby\nan\nenrichment\nin\nTBX4\nand\nACVRL1\nComorbidities\nRisk factors\nfor outcome\nRisk assessment tool\nRisk assessment tool\nTherapy\nTreatment algorithm\nTreatment algorithm\nEvidence\nDiabetes\nHypertension\nHeart failure\nRenal failure\nChromosomal abnormalities\nSyndromic features\n+/-\nCohort studies\n+++\nRCTs\nDiagnosis\nRHC+AVTa\nDiagnostic algorithm\nRHC+AVTa\nDiagnostic algorithm\n~\n~\n~\nChild\nAdult\nA\nInfant\nPPHN\nIPAH/HPAH\nPAH-CHD\nPAH-CTD\nPoPH\nPAH-HIV\nIPAH/HPAH\nPAH-CHD\n1\nCongenital PVS\nLeft heart failure\nCongenital MS\nCardiomyopathy\n2\nMetabolic disorders\nHaematologic diseases\nSystemic diseases\n5\nDevelopmental lung diseases\nBronchopulmonary dysplasia\nCongenital diaphragmatic hernia\nAlveolar capillary dysplasia\nTrisomy 21\nchILD\nHypoventilation syndrome\nCOPD\nILD\n3\nCongenital PS\nCongenital PS\nCTEPH\n4\nCongenital malformations\nOptimize\nrespiratory support\nNutritional support\nGORD treatment\nInhaled NO,\nPAH drugs\nRespiratory support\nSuprasystemic PH\nNecrotizing enterocolitis\nSteroids\nASD/VSD\nEchocardiography\nRHC?\nExtremely limited\nSimple CHD\nComplex CHD\nPH classification\nFigure 10 Neonatal and paediatric vs. adult pulmonary hypertension. ASD, atrial septal defect; AVT, acute vasoreactivity testing; CHD, congenital heart\ndisease; COPD, chronic obstructive pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; GORD, gastro-oesophageal reﬂux\ndisease; HPAH, heritable pulmonary arterial hypertension; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; MS, mitral sten-\nosis; NO, nitric oxide; PAH, pulmonary arterial hypertension; PAH-CHD, PAH associated with congenital heart disease; PAH-CTD, PAH associated with\nconnective tissue disease; PAH-HIV, PAH associated with HIV infection; PH, pulmonary hypertension; PoPH, porto-pulmonary hypertension; PPHN,\npersistent pulmonary hypertension of the newborn; PS, pulmonary arterial stenosis; PVS, pulmonary vein stenosis; RCT, randomized controlled trial;\nRHC, right heart catheterization; VSD, ventricular septal defect. aIn patients with idiopathic, heritable or drug-associated PAH. Pulmonary hypertension\nin neonates and infants signiﬁcantly differs in aetiology, pathophysiology, risk assessment, and treatment from older children and adults, while PH in older\nchildren has more similarities with PH in adults.\n3682\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nvariations.600,601 Additionally, 17% of children with PAH have other\ndisorders known to be associated with PAH, including trisomy 21.\nFinally, 23% of children with PAH have copy number variations not\npreviously associated with PH.600,602,603\nGiven the frequent association of paediatric PAH with chromo-\nsomal, genetic, and syndromic anomalies (for which the mechanistic\nbasis for PAH is generally uncertain), genetic testing may be consid-\nered for deﬁning aetiology and comorbidities, stratifying risk, and\nidentifying family members at risk; however, this should be after\nappropriate expert genetic counselling for the child and family (see\nSection 5.1.13).\nThe clinical PH classiﬁcation (Table 6) is also followed for paediat-\nric PH. To improve applicability of this classiﬁcation in infants and\nchildren with PH, it has been adapted to give room to PH associated\nwith various congenital cardiovascular and pulmonary diseases or\nspeciﬁc paediatric conditions (Tables S5–S8).599\n7.8.2. Diagnosis and risk assessment\nHistorically, the deﬁnition of PH in children aged .3 months has\nbeen the same as in adults. The deﬁnition for PH has now been re-\ndeﬁned to mPAP .20 mmHg in adults as well as in children. The im-\npact of an mPAP 21–24 mmHg on outcomes in children is unknown.\nHowever, in the interest of consistency and to facilitate transition\nfrom paediatric to adult PH care, it is recommended that the updated\ndeﬁnition for PH also be followed in children. No treatment recom-\nmendations currently exist for this group of children (mPAP 21–\n24 mmHg).\nRegarding the newly introduced criterion to include PVR .2 WU\nto identify pre-capillary PH in adults, PVR had previously been in-\ncluded in the deﬁnition for PAH in children. In children, blood ﬂows\nare traditionally indexed assuming that systemic and pulmonary\nblood ﬂows change proportionally with body size, while the transpul-\nmonary pressure gradient does not. Since blood ﬂow is the denom-\ninator in the equation for calculating PVR, the need for indexing of\nPVR in children is emphasized, and the criterion of pulmonary vascu-\nlar resistance index (PVRI) ≥3 WU·m2 in the deﬁnition for PAH in\nchildren remains unchanged.599\nSince the aetiology of paediatric PH is very diverse, a methodical\nand comprehensive diagnostic approach is crucial to reach an accur-\nate diagnosis and treatment plan. As in adults, IPAH is a diagnosis ‘per\nexclusion’. A diagnostic work-up, similar to that in adults but custo-\nmized for paediatric PH, is recommended.599 Pre-term infants with\nBPD should be screened for PH, since PH is prevalent in this popu-\nlation and seriously affects outcome.604\nAlso in children, RHC is the gold standard for deﬁnitively diagnosing\nand establishing the nature of PH, and provides important data for\nstratifying risk.604a,605 To identify those suitable for high-dose CCB\ntreatment, acute vasoreactivity testing is recommended in children\nwith IPAH/HPAH. The criteria used in adults for a positive acute re-\nsponse have identiﬁed children who will show sustained beneﬁt from\nCCB therapy; however, these criteria do not deﬁne reversibility of\nPAH or operability in children with CHD. Since RHC in children\nwith PH may be associated with major complications (in 1–3% of\ncases, especially in young infants and those in worse clinical condition),\nrisks and beneﬁts have to be balanced in the individual child.605 Heart\ncatheterization in children with PAH should be exclusively performed\nin experienced paediatric PH centres. Indications for repeated RHC in\nchildren with PH are currently not well deﬁned.\nTreatment of children with PAH is based on risk stratiﬁcation.599\nPredictors of worse outcome in paediatric PAH are similar to those\nin adults, and include clinical evidence of RV failure, progression of\nsymptoms, WHO-FC III–IV, certain echocardiographic parameters\n(e.g. TAPSE), and elevated serum NT-proBNP. A 6MWD ,350 m\nhas also been suggested as a predictor of worse outcome in paediat-\nric PH, but its value in young children is less established. Further prog-\nnosticators identiﬁed in paediatric PAH are failure to thrive and\nhaemodynamic variables, such as RAP .10 mmHg, the ratio of\nmean pulmonary-to-systemic blood pressure .0.75, and PVRI\n.20 WU·m2.602,606,607 Paediatric risk-assessment tools based on\nthese parameters have been retrospectively validated in observation-\nal paediatric registries.599,604a\n7.8.3. Therapy\nThe ultimate goal of treatment should be to improve survival and fa-\ncilitate normal childhood activities without limitations. In the absence\nof RCTs in paediatric PAH, recommended treatment algorithms are\nextrapolated from those in adults and enhanced with data from ob-\nservational studies in children with PAH.599\nObservational cohort studies support treatment algorithms de-\nsigned for adults to be used for children (including the superiority\nof combination therapy over monotherapy).608 Drugs investigated\nin children, with or without formal approval by the European\nMedicines Agency (EMA) for treating children with PAH, are shown\nin Table 22.\nA paediatric treatment algorithm, derived from that for adults, is\nbased on risk stratiﬁcation, recommending general measures, high-\ndose CCB therapy for responders to acute vasoreactivity testing\n(where close follow-up is mandatory, as some patients may fail long-\nterm therapy), oral or inhaled combination therapy for children at\nlow risk, and combination therapy with i.v./s.c. prostacyclin analogues\nfor those at high risk.599\nIn the case of insufﬁcient response to recommended drug therapy,\nor when drugs are unavailable, a Potts shunt (a surgical or interven-\ntional connection between the left PA and the descending aorta),\nBAS, or LTx may be considered in children with severe PH (see\nSections 6.3.6.1 and 6.3.8).599 Reported clinical experience with\nPotts shunts is limited to just over 100 patients, predominantly chil-\ndren, with a mortality of 12–25% and long-term clinical beneﬁt in a\nsubset of children with long-term follow-up.456–459\nMonitoring of treatment effect and disease course is pivotal in\nmanaging all patients with PAH (adults and in children). In children\nwith PAH, clinical risk scores including WHO-FC, TAPSE, and serum\nNT-proBNP are potential treatment targets for goal-orientated\ntreatment.604a,609\nContemporary treatment algorithms for infants with PPHN have\nbeen proposed but are outside the scope of these guidelines.610\nThe recommendations discussed above apply to children with\nPAH, whereas the speciﬁc group of infants with neonatal PVD, most-\nly classiﬁed as PH associated with developmental lung disease and\nwith heterogeneous aetiology, require a distinct and customized ap-\nproach (Figure 10).\nIn pre-term infants with BPD and PH, the underlying lung disease\nshould primarily be treated. Frequently, these infants are additionally\nESC/ERS Guidelines\n3683\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nTable 22\nUse of pulmonary arterial hypertension therapies in children\nDrug\nPaediatric study data\nEuropean Medicines Agency approval\nfor use in children with PAH\nRef.\nPhosphodiesterase 5 inhibitors (oral)\nSildenaﬁl\nRCT, open-label extension: tolerability, efﬁcacy\nYes, for ≥1 year of age\nRecommended dosing:\n,20 kg: 30 mg/day in 3 doses; ≥20 kg: 60 mg/\nday in 3 doses\nAvoid higher dosing in children (.3 mg/kg/day)\n613,614\nTadalaﬁl\nRCT, open-label: safety, tolerability, pharmacokinetics\nNo\nSuggested dosing:\n0.5–1 mg/kg/day in one dose\nMax: 40 mg/day\nEvaluated only in\nchildren aged .3 years\n615,616\nEndothelin receptor antagonists (oral)\nBosentan\nOpen-label, uncontrolled: safety, tolerability, pharmacokinetics,\nefﬁcacy\nYes, for ≥1 year of age\nPaediatric formulation\nRecommended dosing:\n4 mg/kg/day in 2 doses\nMax: 250 mg/day\n617–620\nAmbrisentan\nOpen-label, uncontrolled: safety, tolerability, pharmacokinetics\nYes, for children aged .8 years\nRecommended dosing:\n2.5–10 mg/day in one dose\n621,622\nMacitentan\nInsufﬁcient data in children\nOpen-label, ongoing: efﬁcacy, safety, pharmacokinetics in children\naged 2–18 years\nNo\nProstacyclin analogues (i.v./s.c.)\nEpoprostenol\ni.v.\nCohort studies, retrospective\nNo\nSuggested dosing:\nStarting dose: 1–2 ng/kg/min\nwithout a known maximum\nIn children, a stable dose\nis usually 40–80 ng/kg/min\nDose increases may be required\n623–626\nTreprostinil i.v./\ns.c.\nCohort studies, retrospective: pharmacokinetics\nNo\nSuggested dosing:\nStarting dose: 2 ng/kg/min\nwithout a known maximum\nIn children, a stable dose\nis usually 50–100 ng/kg/min\nDose increases may be required\n624,626,627\nOther\nIloprost\n(inhaled)\nInsufﬁcient data in children\nSmall case series, retrospective\nNo\nSelexipag (oral)\nInsufﬁcient data in children\nRandomized, placebo-controlled, add-on, ongoing: safety,\ntolerability, pharmacokinetics in children aged 2–18 years\nNo\nRiociguat (oral)\nInsufﬁcient data in children\nOpen-label, ongoing: safety, tolerability, pharmacokinetics in\nchildren aged 6–18 years\nNo\n© ESC/ERS 2022\ni.v., intravenous; PAH, pulmonary arterial hypertension; RCT, randomized controlled trial; s.c., subcutaneous.\n3684\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\ntreated with therapies for PAH, including sildenaﬁl and bosentan;\nhowever, these are not approved by the EMA for use in infants\nwith group 3 PH and developmental lung diseases (BPD, CDH).\nTheir effects on outcomes in this population are unclear, and data\nenabling robust treatment recommendations are lacking. These chil-\ndren should be treated by multidisciplinary teams involving cardiolo-\ngists, neonatologists, pulmonologists, and nutritionists. Pulmonary\nhypertension in these infants may disappear with lung healing, al-\nthough long-term cardiovascular sequelae have been reported.611,612\n8. Pulmonary hypertension\nassociated with left heart disease\n(group 2)\n8.1. Deﬁnition, prognosis, and\npathophysiology\nAmong patients with LHD, PH and RV dysfunction are frequently\npresent and associated with high mortality.47 This includes patients\nwith HF with reduced, mildly reduced, or preserved ejection fraction\n(HFrEF, HFmrEF, or HFpEF), left-sided valvular heart disease, and\ncongenital/acquired cardiovascular conditions leading to post-\ncapillary PH.13,631–635 Arguably, PH-LHD represents the most preva-\nlent form of PH, accounting for 65–80% of cases.47\nConsistent with the general deﬁnitions of PH, PH-LHD (group 2\nPH) is deﬁned by an mPAP .20 mmHg and a PAWP .15 mmHg.\nWithin this haemodynamic condition of post-capillary PH, IpcPH is\ndeﬁned by PVR ≤2 WU and CpcPH by PVR .2 WU (Table 5).\nThe diastolic pressure gradient (DPG) (calculated as the difference\nbetween dPAP and PAWP) is no longer used to distinguish between\nIpcPH and CpcPH because of conﬂicting data on prognostication in\nLHD.142\nAcross the spectrum of LHD, increases in PAP and PVR are asso-\nciated with an increased disease burden and a worse out-\ncome.13,631,633,635 In a large patient cohort—predominantly with\npost-capillary PH—a PVR ≥2.2 WU was associated with adverse\noutcomes and considered abnormal.13 However, even within this\nsubgroup of patients with LHD and CpcPH, the risk of mortality in-\ncreases with progressive elevation in PVR. In patients with advanced\nHFrEF and those with HFpEF or valvular heart disease, a PVR\n.5 WU carries additional prognostic information and is considered\nclinically meaningful by physicians.142,450,631–639 Elevated PVR also\nappears to be associated with decreased survival in special situations,\nsuch as in patients undergoing interventions for correcting valvular\nheart disease,634 heart transplantation,142,633 or LVAD implant-\nation.142,637 Based on available data, a PVR .5 WU may indicate a\nsevere pre-capillary component, the presence of which may prompt\nphysicians to refer patients to PH centres for specialized care.\nThe prevalence of PH in patients with LHD is difﬁcult to assess and\ndepends on the methodology of diagnostic testing (echocardiog-\nraphy or invasive haemodynamics), cut-off values used to deﬁne\nPH, and populations studied. Observational studies suggest an esti-\nmated prevalence of PH of 40–72% in patients with HFrEF and\n36–83% in those with HFpEF.48,639–643 When PVR is used to deﬁne\nRecommendation Table 21 — Recommendations for\npaediatric pulmonary hypertension\nRecommendations\nClassa\nLevelb\nChildren\nIt is recommended to perform the diagnostic\nwork-up, including RHC and acute vasoreactivity\ntesting, and treat children with PH at centres with\nspeciﬁc expertise in paediatric PH\nI\nC\nIn children with PH, a comprehensive work-up for\nconﬁrming diagnosis and speciﬁc aetiology is\nrecommended (similar to that in adults, but\nadapted for age)\nI\nC\nFor conﬁrming PH diagnosis, RHC is recommended,\npreferably before initiating any PAH therapy\nI\nC\nIn children with IPAH/HPAH, acute vasoreactivity\ntesting is recommended to detect those who may\nbeneﬁt from CCB therapy\nI\nC\nIt is recommended to similarly deﬁne a positive\nresponse to acute vasoreactivity testing in children\nand adults by a reduction in mPAP ≥10 mmHg to\nreach an absolute value of mPAP ≤40 mmHg,\nwith an increased or unchanged CO\nI\nC\nIn children with PAH, a therapeutic strategy based\non risk stratiﬁcation and treatment response is\nrecommended, extrapolated from that in adults\nbut adapted for age\nI\nC\nIt is recommended to monitor the treatment\nresponse in children with PAH by serially assessing\na panel of data derived from clinical assessment,\nechocardiographic evaluation, biochemical\nmarkers, and exercise tolerance tests\nI\nC\nAchieving and maintaining a low-risk proﬁle\nshould be considered as an adequate treatment\nresponse for children with PAH\nIIa\nC\nInfants\nIt is recommended to screen infants with\nbronchopulmonary dysplasia for PH628,629\nI\nB\nIn infants with (or at risk of) bronchopulmonary\ndysplasia and PH, treating lung disease—including\nhypoxia, aspiration, and structural airway disease\n—and optimizing respiratory support is\nrecommended before initiating PAH therapy630\nI\nB\nContinued\nIn neonates and infants, a diagnostic and\ntherapeutic approach to PH distinct from that in\nolder children and adults should be considered,\ngiven the frequent association with developmental\nvascular and parenchymal lung disease\nIIa\nC\n© ESC/ERS 2022\nCCB, calcium channel blocker; CO, cardiac output; HPAH, heritable pulmonary arterial\nhypertension; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean\npulmonary arterial pressure; PAH, pulmonary arterial hypertension; PH, pulmonary\nhypertension; RHC, right heart catheterization.\naClass of recommendation.\nbLevel of evidence.\nESC/ERS Guidelines\n3685\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 57",
          "page": 57,
          "content": "Recommendations | Classa | Levelb\nIt is recommended to make a diagnosis of drug- or\ntoxin-associated PAH in patients who had\nrelevant exposure and in whom other causes of\nPH have been excluded | I | C\nIn patients with suspected drug- or\ntoxin-associated PAH, it is recommended to\nimmediately discontinue the causative agent\nwhenever possible | I | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 58",
          "page": 58,
          "content": "Immediate PAH therapy should be considered in\npatients who present with intermediate-/high-risk\nPAH at diagnosis | IIa | C\nPatients with low-risk PAH should be re-evaluated\n3–4 months after discontinuing the suspected\ndrug or toxin, and PAH therapy may be\nconsidered when the haemodynamics have not\nnormalized | IIb | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 58",
          "page": 58,
          "content": "Recommendations | Classa | Levelb\nIn patients with PAH associated with CTD,\ntreatment of the underlying condition according\nto current guidelines is\nrecommended166,167,419,524 | I | A",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 59",
          "page": 59,
          "content": "Recommendations | Classa | Levelb\nIn patients with PAH associated with HIV\ninfection, antiretroviral treatment according to\ncurrent guidelines is recommended541,542 | I | A\nIn patients with PAH associated with HIV\ninfection, initial monotherapy should be\nconsidered, followed by sequential combination if\nnecessary, taking into consideration comorbidities\nand drug–drug interactions | IIa | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 60",
          "page": 60,
          "content": "Recommendations | Classa | Levelb\nEchocardiography is recommended in patients\nwith liver disease or portal hypertension with\nsigns or symptoms suggestive of PH, and as a\nscreening tool in patients evaluated for liver\ntransplantation or transjugular portosystemic\nshunt | I | C\nIt is recommended that patients with PAH\nassociated with portal hypertension are referred\nto centres with expertise in managing both\nconditions | I | C\nIn patients with PAH associated with portal\nhypertension, initial monotherapy should be\nconsidered, followed by sequential combination if\nnecessary, taking into consideration the\nunderlying liver disease and indication for liver\ntransplantation | IIa | C\nLiver transplantation should be considered on an\nindividual basis in patients with PAH associated\nwith portal hypertension, as long as PVR is normal\nor near normal with PAH therapy | IIa | C\nDrugs approved for PAH are not recommended\nfor patients with portal hypertension and\nunclassified PH (i.e. elevated mPAP, high CO, and\na normal PVR) | III | C",
          "rows": 6,
          "cols": 3
        },
        {
          "title": "Table on page 63",
          "page": 63,
          "content": "In patients with PAH after corrected adult CHD,\ninitial oral combination therapy with drugs\napproved for PAH should be considered for\npatients at low and intermediate risk, while initial\ncombination therapy including i.v./s.c. prostacyclin\nanalogues should be considered for patients at\nhigh risk | IIa | Cc\nIn patients with adult CHD, including Eisenmenger\nsyndrome, sequential combination therapy should\nbe considered if patients do not meet treatment\ngoals | IIa | C\nIn the absence of significant haemoptysis, oral\nanticoagulant treatment may be considered in\npatients with Eisenmenger syndrome with\npulmonary artery thrombosis | IIb | C\nIn women with Eisenmenger syndrome,\npregnancy is not recommended | III | C\nIn patients with Eisenmenger syndrome, routine\nphlebotomy to lower elevated haematocrit is not\nrecommended | III | C",
          "rows": 5,
          "cols": 3
        },
        {
          "title": "Table on page 63",
          "page": 63,
          "content": "Recommendations | Classa | Levelb\nIn patients with an ASD, VSD, or PDA and a PVR\n,3 WU, shunt closure is recommended | I | C\nIn patients with an ASD, VSD, or PDA and a PVR\nof 3–5 WU, shunt closure should be considered | IIa | C\nIn patients with an ASD and a PVR .5 WU that\ndeclines to ,5 WU with PAH treatment, shunt\nclosure may be considered | IIb | C\nIn patients with a VSD or PDA and a PVR .5 WU,\nshunt closure may be considered after careful\nevaluation in specialized centres | IIb | C\nIn patients with an ASD and a PVR .5 WU\ndespite PAH treatment, shunt closure is not\nrecommended | III | C",
          "rows": 6,
          "cols": 3
        },
        {
          "title": "Table on page 63",
          "page": 63,
          "content": "Recommendations |  | Classa | Levelb | \n | Risk assessment |  |  | \nRisk assessment is recommended for patients\nwith persistent PAH after defect closure |  | I | C | \nRisk assessment should be considered in patients\nwith Eisenmenger syndrome |  | IIa | C | \n | Treatment |  |  | \nBosentan is recommended in symptomatic\npatients with Eisenmenger syndrome to improve\nexercise capacity574 |  | I | B | \nIn patients with Eisenmenger syndrome, the use of\nsupplemental oxygen therapy should be\nconsidered in cases where it consistently increases\narterial oxygen saturation and reduces symptoms |  | IIa | C | \nSupplemental iron treatment should be\nconsidered in patients with iron deficiency |  | IIa | C | \nIn patients with adult CHD, including Eisenmenger\nsyndrome, other ERAs, PDE5is, riociguat,\nprostacyclin analogues, and prostacyclin receptor\nagonists should be considered |  | IIa | C | ",
          "rows": 9,
          "cols": 5
        },
        {
          "title": "Table on page 64",
          "page": 64,
          "content": "Recommendations | Classa | Levelb\nA combination of clinical and radiological findings,\nABG, PFTs, and genetic testing is recommended\nto diagnose PAH with signs of venous and/or\ncapillary involvement (PVOD/PCH)591 | I | A\nIdentification of biallelic EIF2AK4 mutations is\nrecommended to confirm a diagnosis of heritable\nPVOD/PCH158,591 | I | A\nReferral of eligible patients with PVOD/PCH to a\ntransplant centre for evaluation is recommended\nas soon as the diagnosis is established | I | C\nIn patients with PVOD/PCH, the use of drugs\napproved for PAH may be considered with careful\nmonitoring of clinical symptoms and gas exchange | IIb | C\nLung biopsy is not recommended to confirm a\ndiagnosis of PVOD/PCH | III | C",
          "rows": 6,
          "cols": 3
        },
        {
          "title": "Table on page 67",
          "page": 67,
          "content": "Drug |  | Paediatric study data | European Medicines Agency approval\nfor use in children with PAH | Ref. | \nPhosphodiesterase 5 inhibitors (oral) |  |  |  |  | \nSildenafil |  | RCT, open-label extension: tolerability, efficacy | Yes, for ≥1 year of age\nRecommended dosing:\n,20 kg: 30 mg/day in 3 doses; ≥20 kg: 60 mg/\nday in 3 doses\nAvoid higher dosing in children (.3 mg/kg/day) | 613,614 | \nTadalafil |  | RCT, open-label: safety, tolerability, pharmacokinetics | No\nSuggested dosing:\n0.5–1 mg/kg/day in one dose\nMax: 40 mg/day\nEvaluated only in\nchildren aged .3 years | 615,616 | \n | Endothelin receptor antagonists (oral) |  |  |  | \nBosentan |  | Open-label, uncontrolled: safety, tolerability, pharmacokinetics,\nefficacy | Yes, for ≥1 year of age\nPaediatric formulation\nRecommended dosing:\n4 mg/kg/day in 2 doses\nMax: 250 mg/day | 617–620 | \nAmbrisentan |  | Open-label, uncontrolled: safety, tolerability, pharmacokinetics | Yes, for children aged .8 years\nRecommended dosing:\n2.5–10 mg/day in one dose | 621,622 | \nMacitentan |  | Insufficient data in children\nOpen-label, ongoing: efficacy, safety, pharmacokinetics in children\naged 2–18 years | No |  | \n | Prostacyclin analogues (i.v./s.c.) |  |  |  | \nEpoprostenol\ni.v. |  | Cohort studies, retrospective | No\nSuggested dosing:\nStarting dose: 1–2 ng/kg/min\nwithout a known maximum\nIn children, a stable dose\nis usually 40–80 ng/kg/min\nDose increases may be required | 623–626 | \nTreprostinil i.v./\ns.c. |  | Cohort studies, retrospective: pharmacokinetics | No\nSuggested dosing:\nStarting dose: 2 ng/kg/min\nwithout a known maximum\nIn children, a stable dose\nis usually 50–100 ng/kg/min\nDose increases may be required | 624,626,627 | \n | Other |  |  |  | \nIloprost\n(inhaled) |  | Insufficient data in children\nSmall case series, retrospective | No |  | \nSelexipag (oral) |  | Insufficient data in children\nRandomized, placebo-controlled, add-on, ongoing: safety,\ntolerability, pharmacokinetics in children aged 2–18 years | No |  | \nRiociguat (oral) |  | Insufficient data in children\nOpen-label, ongoing: safety, tolerability, pharmacokinetics in\nchildren aged 6–18 years | No |  | ",
          "rows": 15,
          "cols": 6
        },
        {
          "title": "Table on page 68",
          "page": 68,
          "content": "Recommendations |  | Classa | Levelb | \n | Children |  |  | \nIt is recommended to perform the diagnostic\nwork-up, including RHC and acute vasoreactivity\ntesting, and treat children with PH at centres with\nspecific expertise in paediatric PH |  | I | C | \nIn children with PH, a comprehensive work-up for\nconfirming diagnosis and specific aetiology is\nrecommended (similar to that in adults, but\nadapted for age) |  | I | C | \nFor confirming PH diagnosis, RHC is recommended,\npreferably before initiating any PAH therapy |  | I | C | \nIn children with IPAH/HPAH, acute vasoreactivity\ntesting is recommended to detect those who may\nbenefit from CCB therapy |  | I | C | \nIt is recommended to similarly define a positive\nresponse to acute vasoreactivity testing in children\nand adults by a reduction in mPAP ≥10 mmHg to\nreach an absolute value of mPAP ≤40 mmHg,\nwith an increased or unchanged CO |  | I | C | \nIn children with PAH, a therapeutic strategy based\non risk stratification and treatment response is\nrecommended, extrapolated from that in adults\nbut adapted for age |  | I | C | \nIt is recommended to monitor the treatment\nresponse in children with PAH by serially assessing\na panel of data derived from clinical assessment,\nechocardiographic evaluation, biochemical\nmarkers, and exercise tolerance tests |  | I | C | \nAchieving and maintaining a low-risk profile\nshould be considered as an adequate treatment\nresponse for children with PAH |  | IIa | C | \n | Infants |  |  | \nIt is recommended to screen infants with\nbronchopulmonary dysplasia for PH628,629 |  | I | B | \nIn infants with (or at risk of) bronchopulmonary\ndysplasia and PH, treating lung disease—including\nhypoxia, aspiration, and structural airway disease\n—and optimizing respiratory support is\nrecommended before initiating PAH therapy630 |  | I | B | ",
          "rows": 13,
          "cols": 5
        }
      ],
      "keywords": [
        "ct",
        "intervention",
        "prognosis",
        "asymptomatic",
        "hypertension",
        "arterial",
        "specific",
        "severe",
        "symptomatic",
        "pulmonary",
        "treatment",
        "subsets",
        "diagnosis"
      ]
    },
    {
      "number": "10",
      "title": "8. Pulmonary hypertension associated with left heart disease (group 2)",
      "start_page": 68,
      "end_page": 73,
      "content": "treated with therapies for PAH, including sildenaﬁl and bosentan;\nhowever, these are not approved by the EMA for use in infants\nwith group 3 PH and developmental lung diseases (BPD, CDH).\nTheir effects on outcomes in this population are unclear, and data\nenabling robust treatment recommendations are lacking. These chil-\ndren should be treated by multidisciplinary teams involving cardiolo-\ngists, neonatologists, pulmonologists, and nutritionists. Pulmonary\nhypertension in these infants may disappear with lung healing, al-\nthough long-term cardiovascular sequelae have been reported.611,612\n8. Pulmonary hypertension\nassociated with left heart disease\n(group 2)\n8.1. Deﬁnition, prognosis, and\npathophysiology\nAmong patients with LHD, PH and RV dysfunction are frequently\npresent and associated with high mortality.47 This includes patients\nwith HF with reduced, mildly reduced, or preserved ejection fraction\n(HFrEF, HFmrEF, or HFpEF), left-sided valvular heart disease, and\ncongenital/acquired cardiovascular conditions leading to post-\ncapillary PH.13,631–635 Arguably, PH-LHD represents the most preva-\nlent form of PH, accounting for 65–80% of cases.47\nConsistent with the general deﬁnitions of PH, PH-LHD (group 2\nPH) is deﬁned by an mPAP .20 mmHg and a PAWP .15 mmHg.\nWithin this haemodynamic condition of post-capillary PH, IpcPH is\ndeﬁned by PVR ≤2 WU and CpcPH by PVR .2 WU (Table 5).\nThe diastolic pressure gradient (DPG) (calculated as the difference\nbetween dPAP and PAWP) is no longer used to distinguish between\nIpcPH and CpcPH because of conﬂicting data on prognostication in\nLHD.142\nAcross the spectrum of LHD, increases in PAP and PVR are asso-\nciated with an increased disease burden and a worse out-\ncome.13,631,633,635 In a large patient cohort—predominantly with\npost-capillary PH—a PVR ≥2.2 WU was associated with adverse\noutcomes and considered abnormal.13 However, even within this\nsubgroup of patients with LHD and CpcPH, the risk of mortality in-\ncreases with progressive elevation in PVR. In patients with advanced\nHFrEF and those with HFpEF or valvular heart disease, a PVR\n.5 WU carries additional prognostic information and is considered\nclinically meaningful by physicians.142,450,631–639 Elevated PVR also\nappears to be associated with decreased survival in special situations,\nsuch as in patients undergoing interventions for correcting valvular\nheart disease,634 heart transplantation,142,633 or LVAD implant-\nation.142,637 Based on available data, a PVR .5 WU may indicate a\nsevere pre-capillary component, the presence of which may prompt\nphysicians to refer patients to PH centres for specialized care.\nThe prevalence of PH in patients with LHD is difﬁcult to assess and\ndepends on the methodology of diagnostic testing (echocardiog-\nraphy or invasive haemodynamics), cut-off values used to deﬁne\nPH, and populations studied. Observational studies suggest an esti-\nmated prevalence of PH of 40–72% in patients with HFrEF and\n36–83% in those with HFpEF.48,639–643 When PVR is used to deﬁne\nRecommendation Table 21 — Recommendations for\npaediatric pulmonary hypertension\nRecommendations\nClassa\nLevelb\nChildren\nIt is recommended to perform the diagnostic\nwork-up, including RHC and acute vasoreactivity\ntesting, and treat children with PH at centres with\nspeciﬁc expertise in paediatric PH\nI\nC\nIn children with PH, a comprehensive work-up for\nconﬁrming diagnosis and speciﬁc aetiology is\nrecommended (similar to that in adults, but\nadapted for age)\nI\nC\nFor conﬁrming PH diagnosis, RHC is recommended,\npreferably before initiating any PAH therapy\nI\nC\nIn children with IPAH/HPAH, acute vasoreactivity\ntesting is recommended to detect those who may\nbeneﬁt from CCB therapy\nI\nC\nIt is recommended to similarly deﬁne a positive\nresponse to acute vasoreactivity testing in children\nand adults by a reduction in mPAP ≥10 mmHg to\nreach an absolute value of mPAP ≤40 mmHg,\nwith an increased or unchanged CO\nI\nC\nIn children with PAH, a therapeutic strategy based\non risk stratiﬁcation and treatment response is\nrecommended, extrapolated from that in adults\nbut adapted for age\nI\nC\nIt is recommended to monitor the treatment\nresponse in children with PAH by serially assessing\na panel of data derived from clinical assessment,\nechocardiographic evaluation, biochemical\nmarkers, and exercise tolerance tests\nI\nC\nAchieving and maintaining a low-risk proﬁle\nshould be considered as an adequate treatment\nresponse for children with PAH\nIIa\nC\nInfants\nIt is recommended to screen infants with\nbronchopulmonary dysplasia for PH628,629\nI\nB\nIn infants with (or at risk of) bronchopulmonary\ndysplasia and PH, treating lung disease—including\nhypoxia, aspiration, and structural airway disease\n—and optimizing respiratory support is\nrecommended before initiating PAH therapy630\nI\nB\nContinued\nIn neonates and infants, a diagnostic and\ntherapeutic approach to PH distinct from that in\nolder children and adults should be considered,\ngiven the frequent association with developmental\nvascular and parenchymal lung disease\nIIa\nC\n© ESC/ERS 2022\nCCB, calcium channel blocker; CO, cardiac output; HPAH, heritable pulmonary arterial\nhypertension; IPAH, idiopathic pulmonary arterial hypertension; mPAP, mean\npulmonary arterial pressure; PAH, pulmonary arterial hypertension; PH, pulmonary\nhypertension; RHC, right heart catheterization.\naClass of recommendation.\nbLevel of evidence.\nESC/ERS Guidelines\n3685\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\na pre-capillary component in patients with HF and post-capillary PH,\n≏20–30% of patients are categorized as having CpcPH.47,644,645 In\npatients with valvular heart disease, echocardiographic studies have\nshown that PH is present in up to 65% of patients with symptomatic\naortic stenosis,646–651 while virtually all patients with severe mitral\nvalve stenosis develop PH,652 which can also be found in most pa-\ntients with signiﬁcant degenerative or functional mitral regurgitation.\nThe pathophysiology of PH-LHD combines several mechanisms\n(Figure 11): (1) an initial passive increase in LV ﬁlling pressures and\nbackward transmission into the pulmonary circulation; (2) PA\nVariable degree of pulmonary congestion, vasoconstriction, vascular remodelling\nLeft ventricular phenotype\nRight ventricular phenotype\nPulmonary vascular disease\nPulmonary congestion\nNo PH\nIpcPH\nCpcPHa\nHFrEF\nAortic valve\nHFmrEF\nLA pressure\nRemodelling\nRight heart strain\nCongestion\nHFpEF\nMitral valve\nEF ≤40%\nStenosis/Regurgitation \nEF 41–49%\nEF ≥50%\nHeart failure/cardiomyopathy\nValvular heart disease\nControlled\nLHD\nLA dysfunction\nVasoconstriction\nArteriolar\nRV dysfunction\nVenous\nRV–PA \nuncoupling\nLA pressure (mmHg)\nLA volume (ml)\n20\n15\n5\n10\n20\n40\n60\n80\n100\n120\nFigure 11 Pathophysiology of pulmonary hypertension associated with left heart disease (group 2). CpcPH, combined post- and pre-capillary pulmon-\nary hypertension; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure\nwith reduced ejection fraction; IpcPH, isolated post-capillary pulmonary hypertension; LA, left atrial; LHD, left heart disease; RV, right ventricle/right ven-\ntricular; PA, pulmonary artery; PH, pulmonary hypertension. aCpcPH is deﬁned by post-capillary PH and PVR .2 WU; a PVR .5 WU may be considered\na severe pre-capillary component.\n3686\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nendothelial dysfunction (including vasoconstriction); (3) vascular re-\nmodelling (which may occur in both venules and/or arterioles); (4)\nRV dilatation/dysfunction and functional TR;653–656 and (5) altered\nRV–PA coupling.655–657 The haemodynamic proﬁle of CpcPH vs.\nIpcPH and elevated PVR reﬂects pulmonary vascular abnormalities,\nwhich contribute to an increased RV afterload. Resulting dysfunction\nof the RV is frequent and associated with a worse prognosis in pa-\ntients with PH-LHD. In HFpEF, where RV dysfunction may occur\nvia distinct mechanisms (Figure S1), deterioration of RV, but not LV\nsystolic function, has been observed over time, and both prevalent\nand incident RV dysfunction are predictors of mortality.658\nThe occurrence of PH in patients with LHD may also be due to\nother causes, including undetected CTEPH or PAH. Further, respira-\ntory comorbidities such as COPD and sleep apnoea are also com-\nmon in patients with LHD and may contribute to PH and impact\nprognosis. Patients with HFpEF and PH associated with HFpEF75,76\nmay also present with a low DLCO, which is an independent predict-\nor of outcome.75\n8.2. Diagnosis\nIn patients with LHD, symptoms (e.g. exertional dyspnoea) and phys-\nical signs of PH (e.g. peripheral oedema) frequently overlap with\nthose of the underlying left heart condition and are mostly non-\nspeciﬁc. However, while pulmonary congestion or pleural effusion\nindicate LHD as the underlying cause of PH, other features may sug-\ngest the presence of relevant PH (see Section 5.1.1).\nRoutine diagnostic tests including BNP/NT-proBNP, ECG, and\nechocardiography may show signs of underlying LHD, but may also\nindicate PH. While BNP/NT-proBNP cannot discriminate between\nleft- or right-sided HF, ECG ﬁndings such as right axis deviation or\nRV strain may suggest the presence of PH in patients with LHD.\nEchocardiography can diagnose HFrEF and HFpEF; identify speciﬁc\ncardiac conditions, including those with restrictive ﬁlling pattern;\nand diagnose additional valvular heart disease; it may also detect ele-\nvated sPAP and other features of PH (RA area, PA enlargement, RV/\nLV ratio, LV eccentricity index, RV forming the apex), leading to an\nechocardiographic probability of PH (see Section 5.1.5). A stepwise,\ncomposite echocardiographic score may discriminate pre- vs. post-\ncapillary PH and predict PVD in patients with LHD.659,660\nAdditional information may be gathered from further testing, includ-\ning biomarkers, imaging-derived markers of RV dysfunction, and\nCPET-derived variables.142\nGiven the complexity and variability of cardiopulmonary haemo-\ndynamics in patients with LHD, the distinction between post- and\npre-capillary PH and the diagnosis of PH-LHD vs. other forms of\nPH can be challenging. Diagnostic clues in the evaluation of suspected\nPH in LHD include: (1) diagnosis and control of the underlying LHD;\n(2) evaluation for PH and patient phenotyping; and (3) invasive\nhaemodynamic evaluation, when indicated.\n8.2.1. Diagnosis and control of the underlying left\nheart disease\nPatients with suspected PH-LHD will have an established diagnosis of\nLHD, such as HFrEF/HFmrEF, HFpEF, valvular heart disease, and/or\nCHD. The distinction between PH associated with HFpEF and other\nforms of PH (e.g. PAH, CTEPH) may be challenging, particularly given\nthe increased burden of cardiovascular comorbidities in real-world\nPAH populations.142,450,661 In this context, validated scores for\ndiagnosing HFpEF (HFA-PEFF, H2FPEF)16,662,663 may be helpful for\ndetecting it as an underlying condition in PH, and the presence or ab-\nsence of risk factors for PAH or CTEPH should be determined.\nPatients with signs of predominant RV strain and/or PH should be\nfurther evaluated. Patients should be assessed or reassessed when\nthey are fully recompensated and in a clinically stable condition.\n8.2.2. Evaluation of pulmonary hypertension and\npatient phenotyping\nPatients with LHD and suspected PH should be evaluated following\nthe diagnostic strategy for PH (see Section 5). This requires identify-\ning clinical features and a multimodal approach using non-invasive\ndiagnostic tests such as echocardiography, ECG, and BNP/\nNT-proBNP levels. In the presence of mild PH and predominant\nLHD, no further testing may be necessary. Otherwise, CTEPH and\nsigniﬁcant lung disease should be ruled out by V/Q scan and PFTs,\nand additional cardiac imaging including cMRI may be considered in\nselected cases. For phenotyping, a combination of variables may\nhelp to determine the likelihood of LHD, and HFpEF in particular,\nvs. other causes of PH (Table 23). Pulmonary hypertension asso-\nciated with left heart disease is likely in the presence of known car-\ndiac disease, multiple cardiovascular comorbidities/risk factors, atrial\nﬁbrillation at diagnosis, and speciﬁc imaging ﬁndings (LV hypertrophy,\nincreased LA size, and reduced LA strain). Although exercise echo-\ncardiography has been proposed to uncover HFpEF, it is unable to\ndiagnose or classify PH in this context. A combination of clinical ﬁnd-\nings and phenotyping is required to decide about the need for further\ninvasive assessment.\n8.2.3. Invasive assessment of haemodynamics\nThe decision to perform cardiac catheterization and to invasively as-\nsess cardiopulmonary haemodynamics should depend on the pres-\nence of an intermediate to high echocardiographic probability of\nPH, and should be determined by the need to obtain relevant infor-\nmation for prognostication or management. In patients with a high\nlikelihood of LHD as the main cause of PH, or with established\nunderlying LHD and mild PH (Table 23), invasive assessment for\nPH is usually not indicated. Indications for RHC in LHD include:\n(1) suspected PAH or CTEPH; (2) suspected CpcPH with a severe\npre-capillary component, where further information will aid pheno-\ntyping and treatment decisions (Figure S2); and (3) advanced HF and\nevaluation for heart transplantation. While several haemodynamic\nmeasures (mPAP, PVR, pulmonary arterial compliance [PAC], trans-\npulmonary pressure gradient, and DPG) are associated with out-\ncomes in PH-LHD,142,632,635 the most robust and consistent data\nare available for PVR. Invasive assessment should be conducted in ex-\nperienced centres, when management of the underlying LHD has\nbeen optimized and patients are in a clinically stable condition.\nWith respect to respiratory variations of intrathoracic pressures,\nall pressure readings should be taken at end-expiration.\nAdditional testing during RHC may be useful for distinguishing be-\ntween PAH and HFpEF,18,23,664–669 and to uncover LHD in patients\nwith a high likelihood of PH-LHD and normal resting PAWP;670–673\nboth exercise testing and ﬂuid challenge may be considered in special\nsituations (see Section 5.1.12). Conditions associated with reduced\nLV diastolic compliance or valvular heart disease may be associated\nESC/ERS Guidelines\n3687\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nwith a rapid increase in PAWP when challenged with increased sys-\ntemic venous return.674 While the upper limit of normal remains\ncontroversial,142,143,665,667 a PAWP cut-off of .18 mmHg has\nbeen suggested to identify HFpEF as the underlying cause of PH, des-\npite normal PAWP at baseline.143 While this may help to classify PH,\ntherapeutic consequences of such testing remain to be determined.\nAs differentiating between severe PH associated with HFpEF and\nIPAH with cardiac comorbidities is challenging, patients with an un-\nclear diagnosis, particularly those with a predominant pre-capillary\ncomponent (e.g. PVR .5 WU), should be referred to a PH centre\nfor individualized management.\n8.3. Therapy\nThe primary strategy in managing PH-LHD is optimizing treatment of\nthe underlying cardiac disease. Nevertheless, a pathophysiological se-\nquence ranging from left-sided heart disease via pulmonary circula-\ntion to chronic right heart strain (at rest or exercise) is present in\nmany patients.47 Since deterioration of RV function over time is as-\nsociated with poor outcomes in HFpEF,658 preserving RV function\nshould be considered an important treatment goal. Diuretics remain\nthe cornerstone of medical therapy in the presence of ﬂuid retention\ndue to PH-LHD.\nThere is limited and conﬂicting evidence for the use of drugs ap-\nproved for PAH in patients with group 2 PH. Some medications\nmay have variable and potentially detrimental effects in such patients\nand are therefore not indicated in PH-LHD. Management strategies\nfor PH in various left heart aetiologies are described below.\n8.3.1. Pulmonary hypertension associated with\nleft-sided heart failure\n8.3.1.1. Heart failure with reduced ejection fraction\nPatients with HFrEF or HFmrEF require guideline-directed treat-\nment including established medical and interventional therapies.27\nIn patients with advanced HFrEF, implanting an LVAD may signiﬁ-\ncantly reduce or even normalize mPAP,675 although this is not\nachieved in all patients,676 and an increased DPG emerged as a nega-\ntive prognostic factor after LVAD implantation.677 With regards to\nPAH drugs, bosentan was assessed in an RCT of patients with PH\nassociated with HFrEF,678 showing no efﬁcacy but an increase in\nadverse events compared with placebo, predominantly related to\nﬂuid\nretention.\nSmall\nstudies\nhave\nsuggested\nthat\nsildenaﬁl\nmay improve haemodynamics and exercise capacity in PH and\nHFrEF,679–681 but RCTs are lacking.\n8.3.1.2. Heart failure with preserved ejection fraction\nIn patients with HFpEF, blood pressure, volume load, and risk factors\nshould be controlled, which may lower ﬁlling pressures and PAP.27\nRecently, the SGLT-2i empagliﬂozin improved outcomes in patients\nTable 23\nPatient phenotyping and likelihood for left heart disease as cause of pulmonary hypertension\nFeature\nPH-LHD unlikely\nIntermediate\nprobability\nPH-LHD likely\nAge\n,60 years\n60–70 years\n.70 years\nObesity, hypertension, dyslipidaemia, glucose intolerance/\ndiabetes\nNo factors\n1–2 factors\n.2 factors\nPresence of known LHD\nNo\nYes\nYes\nPrevious cardiac intervention\nNo\nNo\nYes\nAtrial ﬁbrillation\nNo\nParoxysmal\nPermanent/persistent\nStructural LHD\nNo\nNo\nPresent\nECG\nNormal or signs of RV\nstrain\nMild LVH\nLBBB or LVH\nEchocardiography\nNo LA dilation\nE/e′ ,13\nNo LA dilation\nGrade ,2 mitral ﬂow\nLA dilation (LAVI .34 mL/\nm2)\nLVH\nGrade .2 mitral ﬂow\nCPET\nHigh VE/VCO2 slope\nNo EOV\nElevated VE/VCO2 slope\nEOV\nMildly elevated VE/VCO2\nslope\nEOV\ncMRI\nNo left heart abnormalities\nLVH\nLA dilation (strain or LA/RA\n.1)\n© ESC/ERS 2022\ncMRI, cardiac magnetic resonance imaging; CPET, cardiopulmonary exercise testing; E/e’, ratio between early mitral inﬂow velocity and mitral annular early diastolic velocity; ECG,\nelectrocardiogram; EOV, exercise oscillatory ventilation; LA, left atrial; LAVI, left atrial volume index; LBBB, left bundle branch block; LHD, left heart disease; LVH, left ventricular\nhypertrophy; PH, pulmonary hypertension; PH-LHD, left heart disease associated with pulmonary hypertension; RA, right atrium; RV, right ventricle; VE/VECO2, ventilatory\nequivalents for carbon dioxide.\nAssigning the likelihood of LHD as a cause of PH. This assessment may help to decide which patients should undergo a full work-up, including invasive haemodynamic assessment (see\nFigure 11 and Figure S2).\n3688\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nwith an LV ejection fraction of 40–60%.682 Endothelin receptor an-\ntagonists have not proved successful in this population, as both bo-\nsentan683 and macitentan684 failed to show efﬁcacy but rather led\nto more adverse events (ﬂuid retention) vs. placebo in patients\nwith\nHFpEF-associated\nPH\nand\nHF\nwith\nejection\nfraction\n.35%-associated CpcPH, respectively. Phosphodiesterase 5 inhibi-\ntors were assessed in two small RCTs in patients with HFpEF and\nPH with distinct haemodynamic characteristics. In patients with a\npredominantly IpcPH proﬁle, sildenaﬁl had no effect on mPAP (pri-\nmary endpoint) or other haemodynamic and clinical measures vs.\nplacebo.685 In patients with a predominantly CpcPH proﬁle, sildenaﬁl\nimproved haemodynamics, RV function, and quality of life at 6 and 12\nmonths vs. placebo.686 Furthermore, retrospective analyses and\nregistry data suggested improvements in exercise capacity with\nPDE5i therapy in patients with HFpEF-associated CpcPH and with\na severe pre-capillary component (PVR mostly .5 WU).450,687\n8.3.1.3. Interatrial shunt devices\nRecent data suggest that speciﬁc interventions may be considered in se-\nlected cases of HFpEF, such as interatrial shunt devices to unload the\nleft heart. While this was associated with short-term improvements\nin pulmonary vascular function,688 the long-term effect on the pulmon-\nary circulation remains unknown. The recent REDUCE LAP-HF II trial\nfailed to show a reduction in HF events after placement of an atrial\nshunt device in a population of HF patients with LVEF ≥40%,689 with\nworse outcomes in the presence of PVD.690 In addition, a sustained in-\ncrease in PA blood ﬂow may be a matter of concern, as this may trigger\nvascular remodelling in patients with pre-existing PH.\n8.3.1.4. Remote pulmonary arterial pressure monitoring in heart\nfailure\nThe importance of decongestion in patients with HF is underscored\nby the use of implantable pressure sensors, remotely monitoring\nPAP as a surrogate of left-sided ﬁlling pressure. Pulmonary arterial\npressure-based adjustment of HF therapy substantially reduced HF\nhospitalizations and improved outcomes in both patients with\nHFpEF and HFrEF,691–694 with adjustment of diuretic therapy being\nthe most prominent therapeutic consequence. Further strategies\nto optimize management depending on the haemodynamic pheno-\ntype in PH-LHD remain to be established. In HFrEF, novel medical\ntherapies such as ARNIs and SGLT-2is reduced remotely monitored\nPAP and diuretic use,695–698 potentially providing opportunities to\nfurther optimize PAP-guided HF therapy.\n8.3.2. Pulmonary hypertension associated with\nvalvular heart disease\nPulmonary hypertension frequently occurs as a consequence of\nvalvular heart disease. While surgical or interventional approaches\nfor valvular repair improve cardiopulmonary haemodynamics by re-\nducing PAWP and PAP and improving forward SV,699 persistent PH\nafter correcting valvular heart disease is frequent and associated with\nadverse outcomes.634,700\n8.3.2.1. Mitral valve disease\nBoth mitral stenosis and regurgitation regularly lead to post-capillary\nPH. Functional (secondary) mitral regurgitation occurs in both HFrEF\nand HFpEF, and is an important contributor to PH in LHD. Reducing\nmitral regurgitation according to the recommendations of the 2021\nESC/EACTS Guidelines for the management of valvular heart dis-\nease28 has a crucial role in improving haemodynamics in patients\nwith HFrEF, as this reduces mPAP and PAWP and improves the\nCI.699 Nevertheless, registry data have demonstrated that even mod-\nerately elevated sPAP negatively impacts post-procedural outcomes\nafter catheter-based therapy.700\n8.3.2.2. Aortic stenosis\nIn patients with aortic stenosis undergoing surgical or catheter-based\naortic valve repair, pre-interventional PH is associated with a higher\nrisk of in-hospital adverse events and adverse long-term out-\ncomes.646–651 Although post-procedural improvement in PH corre-\nlates with symptom relief and favourable outcomes, persistence of\nPH is common, and even moderate PH is associated with a higher\nall-cause mortality.646–651\nOf note, medical therapy of PH post-valvular repair may be harm-\nful. A randomized study of 231 patients with surgically corrected\nvalvular heart disease and persistent PH showed that sildenaﬁl ther-\napy vs. placebo was associated with worse outcome when compared\nwith placebo;701 however, this study did not distinguish between dif-\nferent types of PH (pre-capillary, IpcPH, and CpcPH).\n8.3.2.3. Tricuspid regurgitation\nSevere TR is associated with volume overload, increased RV work-\nload, and maladaptive remodelling, leading to symptomatic right HF\nand impaired survival.702,703 While primary TR is relatively rare, func-\ntional TR may arise from annular dilation in the presence of both PH\nand LHD. Transcatheter tricuspid valve interventions have recently\nemerged, aiming at reducing TR and RV volume overload. Of note,\ncorrecting TR in patients with PAH or PH in (non-valvular) LHD\nwith signiﬁcantly elevated PVR and/or RV dysfunction must be consid-\nered with great caution, as this may be hazardous.704 Right ventricle–\nPA coupling is an independent predictor of all-cause mortality in such\npatients.705 Patient selection appears crucial, and a comprehensive\ndiagnostic approach integrating imaging modalities and invasive\nhaemodynamic assessment is necessary in the evaluation process\nprior to tricuspid valve repair, particularly since echocardiography un-\nderestimates sPAP in the presence of severe TR.\n8.3.3. Recommendations on the use of drugs\napproved for PAH in PH-LHD\nThe recommendations on the use of drugs approved for PAH in pa-\ntients with PH-LHD have been established based on key narrative\nquestion 5 (Supplementary Data, Section 8.3).\nThe recommendations on the use of PDE5is in patients with\nCpcPH associated with HFpEF are based on PICO question II\n(Supplementary Data, Section 8.4). Two RCTs that enrolled patients\nwith HFpEF and PH were identiﬁed, but no study that speciﬁcally en-\nrolled patients with HFpEF and CpcPH. Harmful effects cannot be ex-\ncluded, even if the available data from clinical studies, case series, and\nregistries suggest that PDE5is may be safely administered to patients\nwith HFpEF-associated CpcPH. As a result, a general recommendation\nfor or against the use of PDE5is in patients with HFpEF and CpcPH can-\nnot be made. However, it is clinically relevant to make a recommenda-\ntion against their use for patients with HFpEF and IpcPH.\nESC/ERS Guidelines\n3689\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n9. Pulmonary hypertension\nassociated with lung diseases and/\nor hypoxia (group 3)\nPulmonary hypertension is frequently observed in patients with\nCOPD and/or emphysema, ILD, combined pulmonary ﬁbrosis and\nemphysema (CPFE), and hypoventilation syndromes.52,165,707,708\nPulmonary hypertension is uncommon in obstructive sleep apnoea\nunless other conditions coexist, such as COPD or daytime hypoven-\ntilation.709 At high altitude (.2500 m) hypoxia-induced PH is\nthought to affect .5% of the population, the development of PH\nbeing related to geography and genetic factors.710\nA PH screening study performed on a large cohort of .100\npatients with lymphangioleiomyomatosis conﬁrmed that PH is\nusually mild in that setting: from six patients (5.7%) present-\ning with pre-capillary PH, none had mPAP .30 mmHg and\nPH was associated with PFT alteration, suggesting that the\nrise in mPAP is associated with parenchymal involvement.711\nThus, PH in lymphangioleiomyomatosis is now classiﬁed in\ngroup 3 PH.1\nIn patients with lung disease, PH is categorized as non-severe or\nsevere, depending on haemodynamic ﬁndings (Figure 12). In the\n2015 ESC/ERS Guidelines for the diagnosis and treatment of\nPH, severe PH was deﬁned by mPAP .35 mmHg or mPAP\n≥25 mmHg with CI ,2.5 L/min/m2.25,26 However, two recent\nstudies have demonstrated that a PVR .5 WU is a better thresh-\nold for predicting worse prognosis in patients with PH associated\nwith both COPD and ILD.712,713 Based on these data, the current\nguidelines used PVR to distinguish between non-severe PH (PVR\nRecommendation Table 22 — Recommendations for pulmonary hypertension associated with left heart disease\nRecommendation Table 22A\nRecommendations\nClassa\nLevelb\nIn patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of suspected\nPH27,28\nI\nA\nRHC is recommended for suspected PH in patients with LHD, if it aids management decisions\nI\nC\nRHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair\nI\nC\nFor patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral\nto a PH centre for a complete diagnostic work-up is recommended29,47,142\nI\nC\nIn patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is\nrecommended\nI\nC\nWhen patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or\nﬂuid challenge, are treated with PAH drugs, close monitoring is recommended\nI\nC\nIn patients with PH at RHC, a borderline PAWP (13–15 mmHg) and features of HFpEF, additional testing with exercise or ﬂuid challenge\nmay be considered to uncover post-capillary PH133,143\nIIb\nC\nDrugs approved for PAH are not recommended in PH-LHDc 631,678,683,684,701,706\nIII\nA\n© ESC/ERS 2022\nRecommendation Table 22B\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nNo recommendation can be given for or against the use of PDE5is in patients\nwith HFpEF and combined post- and pre-capillary PH\nLow\nNone\n–\n–\nThe use of PDE5is in patients with HFpEF and isolated post-capillary PH is not\nrecommended\nLow\nConditional\nIII\nC\n© ESC/ERS 2022\nCpcPH, combined post- and pre-capillary PH; ERA, endothelin receptor antagonist; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with\nreduced ejection fraction; LHD, left heart disease; PAH, pulmonary arterial hypertension; PAWP, pulmonary arterial wedge pressure; PDE5is, phosphodiesterase 5 inhibitors; PH,\npulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right\nventricular; WU, Wood units.\naClass of recommendation.\nbLevel of evidence.\ncSafety concerns have been identiﬁed when ERAs are used in patients with HF (HFpEF and HFrEF, with or without PH) and when sildenaﬁl is used in patients with persistent PH after\ncorrection of valvular heart disease.\n3690\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 68",
          "page": 68,
          "content": "Recommendations |  | Classa | Levelb | \n | Children |  |  | \nIt is recommended to perform the diagnostic\nwork-up, including RHC and acute vasoreactivity\ntesting, and treat children with PH at centres with\nspecific expertise in paediatric PH |  | I | C | \nIn children with PH, a comprehensive work-up for\nconfirming diagnosis and specific aetiology is\nrecommended (similar to that in adults, but\nadapted for age) |  | I | C | \nFor confirming PH diagnosis, RHC is recommended,\npreferably before initiating any PAH therapy |  | I | C | \nIn children with IPAH/HPAH, acute vasoreactivity\ntesting is recommended to detect those who may\nbenefit from CCB therapy |  | I | C | \nIt is recommended to similarly define a positive\nresponse to acute vasoreactivity testing in children\nand adults by a reduction in mPAP ≥10 mmHg to\nreach an absolute value of mPAP ≤40 mmHg,\nwith an increased or unchanged CO |  | I | C | \nIn children with PAH, a therapeutic strategy based\non risk stratification and treatment response is\nrecommended, extrapolated from that in adults\nbut adapted for age |  | I | C | \nIt is recommended to monitor the treatment\nresponse in children with PAH by serially assessing\na panel of data derived from clinical assessment,\nechocardiographic evaluation, biochemical\nmarkers, and exercise tolerance tests |  | I | C | \nAchieving and maintaining a low-risk profile\nshould be considered as an adequate treatment\nresponse for children with PAH |  | IIa | C | \n | Infants |  |  | \nIt is recommended to screen infants with\nbronchopulmonary dysplasia for PH628,629 |  | I | B | \nIn infants with (or at risk of) bronchopulmonary\ndysplasia and PH, treating lung disease—including\nhypoxia, aspiration, and structural airway disease\n—and optimizing respiratory support is\nrecommended before initiating PAH therapy630 |  | I | B | ",
          "rows": 13,
          "cols": 5
        },
        {
          "title": "Table on page 71",
          "page": 71,
          "content": "Feature | PH-LHD unlikely | Intermediate\nprobability | PH-LHD likely\nAge | ,60 years | 60–70 years | .70 years\nObesity, hypertension, dyslipidaemia, glucose intolerance/\ndiabetes | No factors | 1–2 factors | .2 factors\nPresence of known LHD | No | Yes | Yes\nPrevious cardiac intervention | No | No | Yes\nAtrial fibrillation | No | Paroxysmal | Permanent/persistent\nStructural LHD | No | No | Present\nECG | Normal or signs of RV\nstrain | Mild LVH | LBBB or LVH\nEchocardiography | No LA dilation\nE/e′ ,13 | No LA dilation\nGrade ,2 mitral flow | LA dilation (LAVI .34 mL/\nm2)\nLVH\nGrade .2 mitral flow\nCPET | High VE/VCO slope\n2\nNo EOV | Elevated VE/VCO slope\n2\nEOV | Mildly elevated VE/VCO\n2\nslope\nEOV\ncMRI | No left heart abnormalities |  | LVH\nLA dilation (strain or LA/RA\n.1)",
          "rows": 11,
          "cols": 4
        },
        {
          "title": "Table on page 73",
          "page": 73,
          "content": "Recommendations | Classa | Levelb\nIn patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of suspected\nPH27,28 | I | A\nRHC is recommended for suspected PH in patients with LHD, if it aids management decisions | I | C\nRHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair | I | C\nFor patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral\nto a PH centre for a complete diagnostic work-up is recommended29,47,142 | I | C\nIn patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is\nrecommended | I | C\nWhen patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or\nfluid challenge, are treated with PAH drugs, close monitoring is recommended | I | C\nIn patients with PH at RHC, a borderline PAWP (13–15 mmHg) and features of HFpEF, additional testing with exercise or fluid challenge\nmay be considered to uncover post-capillary PH133,143 | IIb | C\nDrugs approved for PAH are not recommended in PH-LHDc 631,678,683,684,701,706 | III | A",
          "rows": 9,
          "cols": 3
        },
        {
          "title": "Table on page 73",
          "page": 73,
          "content": " | GRADE |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nNo recommendation can be given for or against the use of PDE5is in patients\nwith HFpEF and combined post- and pre-capillary PH | Low | None | – | –\nThe use of PDE5is in patients with HFpEF and isolated post-capillary PH is not\nrecommended | Low | Conditional | III | C",
          "rows": 4,
          "cols": 5
        }
      ],
      "keywords": [
        "left",
        "intervention",
        "prognosis",
        "echo",
        "ct",
        "group",
        "hypertension",
        "mild",
        "associated",
        "disease",
        "risk",
        "severe",
        "heart",
        "pulmonary",
        "treatment",
        "pulmonary hypertension",
        "recommendation"
      ]
    },
    {
      "number": "11",
      "title": "9. Pulmonary hypertension associated with lung diseases and/or hypoxia (group 3)",
      "start_page": 73,
      "end_page": 76,
      "content": "9. Pulmonary hypertension\nassociated with lung diseases and/\nor hypoxia (group 3)\nPulmonary hypertension is frequently observed in patients with\nCOPD and/or emphysema, ILD, combined pulmonary ﬁbrosis and\nemphysema (CPFE), and hypoventilation syndromes.52,165,707,708\nPulmonary hypertension is uncommon in obstructive sleep apnoea\nunless other conditions coexist, such as COPD or daytime hypoven-\ntilation.709 At high altitude (.2500 m) hypoxia-induced PH is\nthought to affect .5% of the population, the development of PH\nbeing related to geography and genetic factors.710\nA PH screening study performed on a large cohort of .100\npatients with lymphangioleiomyomatosis conﬁrmed that PH is\nusually mild in that setting: from six patients (5.7%) present-\ning with pre-capillary PH, none had mPAP .30 mmHg and\nPH was associated with PFT alteration, suggesting that the\nrise in mPAP is associated with parenchymal involvement.711\nThus, PH in lymphangioleiomyomatosis is now classiﬁed in\ngroup 3 PH.1\nIn patients with lung disease, PH is categorized as non-severe or\nsevere, depending on haemodynamic ﬁndings (Figure 12). In the\n2015 ESC/ERS Guidelines for the diagnosis and treatment of\nPH, severe PH was deﬁned by mPAP .35 mmHg or mPAP\n≥25 mmHg with CI ,2.5 L/min/m2.25,26 However, two recent\nstudies have demonstrated that a PVR .5 WU is a better thresh-\nold for predicting worse prognosis in patients with PH associated\nwith both COPD and ILD.712,713 Based on these data, the current\nguidelines used PVR to distinguish between non-severe PH (PVR\nRecommendation Table 22 — Recommendations for pulmonary hypertension associated with left heart disease\nRecommendation Table 22A\nRecommendations\nClassa\nLevelb\nIn patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of suspected\nPH27,28\nI\nA\nRHC is recommended for suspected PH in patients with LHD, if it aids management decisions\nI\nC\nRHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair\nI\nC\nFor patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral\nto a PH centre for a complete diagnostic work-up is recommended29,47,142\nI\nC\nIn patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is\nrecommended\nI\nC\nWhen patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or\nﬂuid challenge, are treated with PAH drugs, close monitoring is recommended\nI\nC\nIn patients with PH at RHC, a borderline PAWP (13–15 mmHg) and features of HFpEF, additional testing with exercise or ﬂuid challenge\nmay be considered to uncover post-capillary PH133,143\nIIb\nC\nDrugs approved for PAH are not recommended in PH-LHDc 631,678,683,684,701,706\nIII\nA\n© ESC/ERS 2022\nRecommendation Table 22B\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nNo recommendation can be given for or against the use of PDE5is in patients\nwith HFpEF and combined post- and pre-capillary PH\nLow\nNone\n–\n–\nThe use of PDE5is in patients with HFpEF and isolated post-capillary PH is not\nrecommended\nLow\nConditional\nIII\nC\n© ESC/ERS 2022\nCpcPH, combined post- and pre-capillary PH; ERA, endothelin receptor antagonist; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with\nreduced ejection fraction; LHD, left heart disease; PAH, pulmonary arterial hypertension; PAWP, pulmonary arterial wedge pressure; PDE5is, phosphodiesterase 5 inhibitors; PH,\npulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right\nventricular; WU, Wood units.\naClass of recommendation.\nbLevel of evidence.\ncSafety concerns have been identiﬁed when ERAs are used in patients with HF (HFpEF and HFrEF, with or without PH) and when sildenaﬁl is used in patients with persistent PH after\ncorrection of valvular heart disease.\n3690\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n≤5 WU) and severe PH (PVR .5 WU). Whereas non-severe PH\nis common in advanced COPD and ILD deﬁned by spirometric cri-\nteria, severe PH is uncommon, occurring in 1–5% of cases of\nCOPD and ,10% of patients with advanced ILD, with limited\ndata in obesity hypoventilation syndrome.714,715 Even non-severe\nPH in lung disease negatively impacts symptoms and survival, and\nis associated with increased hospitalization.715–717 Patients with\nlung disease and severe PH have a worse outcome than those\nwith non-severe PH, providing evidence that this distinction has\nclinical signiﬁcance.51,712,713,718,719 It is noteworthy that develop-\ning severe PH is largely independent of spirometry but usually ac-\ncompanied by hypoxaemia, low PaCO2, and a signiﬁcant reduction\nin DLCO.51,714,718,719\nPulmonary hypertension presenting in patients with lung disease\nmay be due to a number of causes, including undiagnosed CTEPH\nor PAH.714,720 Cardiac comorbidities are also common in patients\nwith lung disease and may contribute to PH. A number of distinct\nphenotypes of PH in patients with lung disease, including a pulmon-\nary vascular phenotype, have been proposed.51,720 The pulmonary\nvascular phenotype is characterized by better preserved spirometry,\nlow DLCO, hypoxaemia, a range of parenchymal involvement on\nlung imaging, and a circulatory limitation to exercise.51,714,718–722\nRecent studies have shown that the clinical characteristics, disease\ntrajectory, response to treatment,451,718,719 and histological corre-\nlates723,724 of patients with severe PH and minor lung disease are dif-\nferent to those in patients with IPAH, including a poorer prognosis.\nRemodelling of airways, lung parenchyma, and vessels\nPrevalence\n~70%\n~20%\n~5–10%\nMostly ventilatory\nexercise limitation\nMostly circulatory\nexercise limitation\nRemodelling of pulmonary vessels\nRemodelling of airways and parenchyma\nHypoxaemia at rest and/or during exercise\nNo PH\nNon-severe PH\nSevere PH\n(PVR >5 WU)\nCOPD\nILD\nCPFE\nR\nEmphysema\nFibrosis\nVascular pruning\nCPFE\nFigure 12 Pathophysiology of pulmonary hypertension associated with lung disease (group 3). COPD, chronic obstructive pulmonary disease; CPFE,\ncombined pulmonary ﬁbrosis and emphysema; ILD, interstitial lung disease; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; WU,\nWood units. Shown are underlying lung diseases (upper panel); contributing pathogenic pulmonary alterations of airways, parenchyma, and vessels\n(middle panel); and the relation of airway/parenchymal remodelling and vascular remodelling to the degree of PH and its consequences for exercise\nlimitation (ventilatory vs. circulatory, lower panel).\nESC/ERS Guidelines\n3691\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n9.1. Diagnosis\nIn patients with lung disease, symptoms of PH, especially exertional\ndyspnoea, overlap with those of the underlying condition. Physical\nﬁndings may also be non-speciﬁc, for example: ankle swelling is com-\nmon during episodes of ventilatory failure in COPD, where activa-\ntion of the renin–angiotensin–aldosterone system may cause ﬂuid\nretention, usually in the setting of preserved RV function.\nNon-invasive tests—such as ECG showing right axis deviation or\nRV strain, elevated levels of BNP/NT-proBNP, CPET, or features on\ncross-sectional imaging—may suggest the diagnosis of PH in patients\nwith lung disease.725,726 Echocardiography remains the most widely\nused non-invasive diagnostic tool for assessing PH; however, the ac-\ncuracy of echocardiography in patients with advanced respiratory\ndiseases is low, with a TRV unmeasurable in .50% of patients in\nsome studies, and there is a tendency to overestimate PAP and mis-\nclassify patients with PH.86,87,727 More recent data suggest that a\nstepwise, composite, echocardiographic score can identify patients\nwith severe PH, with and without an estimate of TRV, using other echo-\ncardiographic features including RA area, RV:LV ratio, and LV eccentri-\ncity index.728 Where PH is suspected, combining echocardiography\nwith a contrast-enhanced CT may aid diagnostic assessment and disease\nclassiﬁcation.108,729–731 Pulmonary artery enlargement, RV outﬂow\nhypertrophy, and increased RV:LV ratio may suggest a diagnosis of\nPH.108 Ideally, assessments should be made or repeated when the pa-\ntient is clinically stable, as exacerbations can signiﬁcantly raise PAP.\nKey parts of evaluating suspected PH in lung disease include integrat-\ning: (1) the presence or absence of risk factors for PAH, CTEPH, or\nLHD; (2) clinical features, including disease trajectory (e.g. rapid recent\ndeterioration vs. gradual change over years, and oxygen requirements);\n(3) PFTs, including DLCO and blood gas analysis; (4) NT-proBNP mea-\nsurements, ECG, and echocardiography; and (5) cross-sectional imaging\nwith contrast-enhanced CT, SPECT, or V/Q lung scan and, in selected\ncases, cMRI732 to assess the need for RHC. Cardiopulmonary exercise\ntesting may be helpful in assessing ventilatory or cardiac limitation in pa-\ntients with lung disease,121,733 although data are limited regarding its\nclinical use in identifying patients with PH in lung disease.\nIndications for RHC in lung disease include assessment for surgical\ntreatments (selected patients considered for LTx and lung volume re-\nduction surgery), suspected PAH or CTEPH, and where further infor-\nmation will aid phenotyping of disease and consideration of therapeutic\ninterventions (Figure S3).712,718,734 Such testing should ideally be con-\nducted in PH centres when patients are clinically stable and treatment\nof underlying lung disease has been optimized. Consideration should be\ngiven to how pressure measurements are made, due to the impact of\nchanging intrathoracic pressures on pulmonary haemodynamics during\nthe respiratory cycle (see Section 5.1.12).735\n9.2. Therapy\nThe therapeutic approach to group 3 PH starts with optimizing the\ntreatment of the underlying lung disease, including supplementary oxy-\ngen and non-invasive ventilation, where indicated, as well as enrolment\ninto pulmonary rehabilitation programmes.736 There is limited and con-\nﬂicting evidence for the use of medication approved for PAH in patients\nwith group 3 PH, and these drugs may have variable and sometimes\ndetrimental effects on haemodynamics, exercise capacity, gas exchange,\nand outcomes in this patient population.181,737–740\n9.2.1. Pulmonary hypertension associated with\nchronic obstructive pulmonary disease or\nemphysema\nStudies using drugs approved for PAH in patients with PH associated\nwith COPD or emphysema have yielded conﬂicting results and are\nmostly limited by small sample size, short duration, and insufﬁcient\nhaemodynamic characterization of PH.739,741,742 In a 16 week RCT\nof 28 patients with COPD and severe PH conﬁrmed by RHC, silde-\nnaﬁl therapy resulted in statistically signiﬁcant improvements in PVR\nand quality of life.743 Registry data identiﬁed that ≏30% of patients\nwith COPD and severe PH, predominantly treated with PDE5is,\nhad improved WHO-FC, 6MWD, and PVR vs. baseline, and those\nwith a treatment response had improved transplant-free sur-\nvival.51,718 However, in the absence of large randomized trials, the\nevidence is insufﬁcient to support the general use of medication ap-\nproved for PAH in patients with COPD and PH. Patients with COPD\nand suspected or conﬁrmed severe PH should be referred to PH\ncentres for individual decision-making.\n9.2.2. Pulmonary hypertension associated with\ninterstitial lung disease\nNumerous phase 2 and phase 3 studies have investigated the use of\nERAs to treat ILD, all with negative results.740,744,745 In addition, the\nPDE5i sildenaﬁl has been investigated in phase 3 trials of patients with\nILD, also with negative results.746,747 Few data from RCTs are available\nfor patients with PH associated with ILD, and many of the studies per-\nformed for this indication748,749 suffered from the same limitations as\nthe aforementioned studies in PH associated with COPD. In addition,\nthere were several adverse safety signals: ambrisentan was associated\nwith an increased risk of clinical worsening in patients with ILD with\nand without PH,740,750 while riociguat was associated with an increased\nrisk of clinical worsening events, including potential excess mortality, in\npatients with PH associated with idiopathic interstitial pneumonia.181\nIn contrast, promising results have been obtained with the use of\ninhaled treprostinil. A phase 3 RCT (INCREASE) examined inhaled\ntreprostinil at a target dose of 72 µg given four times daily in 326 pa-\ntients with PH associated with ILD.734,751 The PH diagnosis was con-\nﬁrmed by RHC within 1 year prior to enrolment. At week 16, the\nplacebo-corrected 6MWD improved by 31 m with inhaled trepros-\ntinil. There were also improvements in NT-proBNP and clinical wor-\nsening events, the latter driven by a lower proportion of patients\nwhose 6MWD declined by .15% from baseline.\nGiven the signiﬁcant impact of even non-severe PH in patients\nwith lung disease, eligible patients should be referred for LTx evalu-\nation. In patients with ILD and PH, inhaled treprostinil may be con-\nsidered based on the ﬁndings from the INCREASE study, but\nfurther data are needed, especially on long-term outcomes. The rou-\ntine use of other medication approved for PAH is not recommended\nin patients with ILD and non-severe PH. For patients with severe PH\nand/or severe RV dysfunction, or where there is uncertainty regard-\ning the treatment of PH, referral to a PH centre is recommended for\ncareful evaluation, to facilitate entry into RCTs, and consider PAH\ntherapies on an individual basis (Figure S3). Registry data show that\nsome patients with group 3 PH are being treated with PAH medica-\ntion, predominantly PDE5is,718,752,753 but it is unclear if and to what\nextent these patients beneﬁt from this treatment.\n3692\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n9.2.3. Recommendations on the use of drugs\napproved for PAH in PH associated with lung disease\nThe recommendations on the use of drugs approved for PAH in pa-\ntients with PH associated with COPD and ILD have been established\nbased on key narrative questions 6 and 7 (Supplementary Data,\nSections 9.1 and 9.2, respectively).\nThe recommendations on the use of PDE5is in patients with se-\nvere PH associated with ILD are based on PICO question III\n(Supplementary Data, Section 9.3). There are no direct data from\nRCTs on the safety, tolerability, and efﬁcacy of PDE5is in patients\nwith PH associated with ILD. The indirect data included in the\nguidelines do not enable ﬁrm conclusions to be drawn. Given the\nlack of robust evidence, the Task Force members felt unable to pro-\nvide a recommendation for or against the use of PDE5is in patients\nwith ILD and severe PH, and recommend that these patients are re-\nferred to a PH centre for individualized decision-making.\n10. Chronic thrombo-embolic\npulmonary hypertension (group 4)\nAll\npatients\nwhose\nsymptoms\ncan\nbe\nattributed\nto\npost-thrombo-embolic ﬁbrotic obstructions within the PA are\nRecommendation Table 23 — Recommendations for pulmonary hypertension associated with lung disease and/or\nhypoxia\nRecommendation Table 23A\nRecommendations\nClassa\nLevelb\nIf PH is suspected in patients with lung disease, it is recommended that echocardiographyc be performed and the results interpreted in\nconjunction with ABG, PFTs including DLCO, and CT imaging\nI\nC\nIn patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where\nindicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation\nI\nC\nIn patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH\ncentre is recommendedd\nI\nC\nIn patients with lung disease and severe PH, an individualized approach to treatment is recommended\nI\nC\nIt is recommended to refer eligible patients with lung disease and PH for LTx evaluation\nI\nC\nIn patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions\nI\nC\nInhaled treprostinil may be considered in patients with PH associated with ILD734\nIIb\nB\nThe use of ambrisentan is not recommended in patients with PH associated with IPF740\nIII\nB\nThe use of riociguat is not recommended in patients with PH associated with IIP181\nIII\nB\nThe use of PAH medication is not recommended in patients with lung disease and non-severe PHe\nIII\nC\n© ESC/ERS 2022\nRecommendation Table 23B\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nPDE5is may be considered in patients with severe PH associated with ILD\n(individual decision-making in PH centres)\nVery low\nConditional\nIIb\nC\nThe use of PDE5is in patients with ILD and non-severe PH is not recommended\nVery low\nConditional\nIII\nC\n© ESC/ERS 2022\nABG, arterial blood gas analysis; CT, computed tomography; DLCO, Lung diffusion capacity for carbon monoxide; IIP, idiopathic interstitial pneumonia; IPF, idiopathic pulmonary\nﬁbrosis; ILD, interstitial lung disease; LTx, lung transplantation; PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PFT, pulmonary function test; PH,\npulmonary hypertension; RHC, right heart catheterization.\naClass of recommendation.\nbLevel of evidence.\ncAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise pulmonary artery pressure.\ndThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.\neThis does not include inhaled treprostinil, which may be considered in patients with PH associated with ILD, irrespective of PH severity.\nESC/ERS Guidelines\n3693\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 73",
          "page": 73,
          "content": "Recommendations | Classa | Levelb\nIn patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of suspected\nPH27,28 | I | A\nRHC is recommended for suspected PH in patients with LHD, if it aids management decisions | I | C\nRHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair | I | C\nFor patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral\nto a PH centre for a complete diagnostic work-up is recommended29,47,142 | I | C\nIn patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is\nrecommended | I | C\nWhen patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or\nfluid challenge, are treated with PAH drugs, close monitoring is recommended | I | C\nIn patients with PH at RHC, a borderline PAWP (13–15 mmHg) and features of HFpEF, additional testing with exercise or fluid challenge\nmay be considered to uncover post-capillary PH133,143 | IIb | C\nDrugs approved for PAH are not recommended in PH-LHDc 631,678,683,684,701,706 | III | A",
          "rows": 9,
          "cols": 3
        },
        {
          "title": "Table on page 73",
          "page": 73,
          "content": " | GRADE |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nNo recommendation can be given for or against the use of PDE5is in patients\nwith HFpEF and combined post- and pre-capillary PH | Low | None | – | –\nThe use of PDE5is in patients with HFpEF and isolated post-capillary PH is not\nrecommended | Low | Conditional | III | C",
          "rows": 4,
          "cols": 5
        },
        {
          "title": "Table on page 76",
          "page": 76,
          "content": "Recommendations | Classa | Levelb\nIf PH is suspected in patients with lung disease, it is recommended that echocardiographyc be performed and the results interpreted in\nconjunction with ABG, PFTs including DLCO, and CT imaging | I | C\nIn patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where\nindicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation | I | C\nIn patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH\ncentre is recommendedd | I | C\nIn patients with lung disease and severe PH, an individualized approach to treatment is recommended | I | C\nIt is recommended to refer eligible patients with lung disease and PH for LTx evaluation | I | C\nIn patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions | I | C\nInhaled treprostinil may be considered in patients with PH associated with ILD734 | IIb | B\nThe use of ambrisentan is not recommended in patients with PH associated with IPF740 | III | B\nThe use of riociguat is not recommended in patients with PH associated with IIP181 | III | B\nThe use of PAH medication is not recommended in patients with lung disease and non-severe PHe | III | C",
          "rows": 11,
          "cols": 3
        },
        {
          "title": "Table on page 76",
          "page": 76,
          "content": " | GRADE |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nPDE5is may be considered in patients with severe PH associated with ILD\n(individual decision-making in PH centres) | Very low | Conditional | IIb | C\nThe use of PDE5is in patients with ILD and non-severe PH is not recommended | Very low | Conditional | III | C",
          "rows": 4,
          "cols": 5
        }
      ],
      "keywords": [
        "prognosis",
        "group",
        "hypertension",
        "associated",
        "pulmonary",
        "pulmonary hypertension",
        "tricuspid regurgitation",
        "diagnosis",
        "intervention",
        "diseases",
        "lung",
        "treatment",
        "recommendation",
        "ct",
        "monitoring",
        "mild",
        "risk",
        "severe",
        "hypoxia"
      ]
    },
    {
      "number": "12",
      "title": "10. Chronic thrombo-embolic pulmonary hypertension (group 4)",
      "start_page": 76,
      "end_page": 82,
      "content": "9.2.3. Recommendations on the use of drugs\napproved for PAH in PH associated with lung disease\nThe recommendations on the use of drugs approved for PAH in pa-\ntients with PH associated with COPD and ILD have been established\nbased on key narrative questions 6 and 7 (Supplementary Data,\nSections 9.1 and 9.2, respectively).\nThe recommendations on the use of PDE5is in patients with se-\nvere PH associated with ILD are based on PICO question III\n(Supplementary Data, Section 9.3). There are no direct data from\nRCTs on the safety, tolerability, and efﬁcacy of PDE5is in patients\nwith PH associated with ILD. The indirect data included in the\nguidelines do not enable ﬁrm conclusions to be drawn. Given the\nlack of robust evidence, the Task Force members felt unable to pro-\nvide a recommendation for or against the use of PDE5is in patients\nwith ILD and severe PH, and recommend that these patients are re-\nferred to a PH centre for individualized decision-making.\n10. Chronic thrombo-embolic\npulmonary hypertension (group 4)\nAll\npatients\nwhose\nsymptoms\ncan\nbe\nattributed\nto\npost-thrombo-embolic ﬁbrotic obstructions within the PA are\nRecommendation Table 23 — Recommendations for pulmonary hypertension associated with lung disease and/or\nhypoxia\nRecommendation Table 23A\nRecommendations\nClassa\nLevelb\nIf PH is suspected in patients with lung disease, it is recommended that echocardiographyc be performed and the results interpreted in\nconjunction with ABG, PFTs including DLCO, and CT imaging\nI\nC\nIn patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where\nindicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation\nI\nC\nIn patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH\ncentre is recommendedd\nI\nC\nIn patients with lung disease and severe PH, an individualized approach to treatment is recommended\nI\nC\nIt is recommended to refer eligible patients with lung disease and PH for LTx evaluation\nI\nC\nIn patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions\nI\nC\nInhaled treprostinil may be considered in patients with PH associated with ILD734\nIIb\nB\nThe use of ambrisentan is not recommended in patients with PH associated with IPF740\nIII\nB\nThe use of riociguat is not recommended in patients with PH associated with IIP181\nIII\nB\nThe use of PAH medication is not recommended in patients with lung disease and non-severe PHe\nIII\nC\n© ESC/ERS 2022\nRecommendation Table 23B\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nPDE5is may be considered in patients with severe PH associated with ILD\n(individual decision-making in PH centres)\nVery low\nConditional\nIIb\nC\nThe use of PDE5is in patients with ILD and non-severe PH is not recommended\nVery low\nConditional\nIII\nC\n© ESC/ERS 2022\nABG, arterial blood gas analysis; CT, computed tomography; DLCO, Lung diffusion capacity for carbon monoxide; IIP, idiopathic interstitial pneumonia; IPF, idiopathic pulmonary\nﬁbrosis; ILD, interstitial lung disease; LTx, lung transplantation; PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PFT, pulmonary function test; PH,\npulmonary hypertension; RHC, right heart catheterization.\naClass of recommendation.\nbLevel of evidence.\ncAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise pulmonary artery pressure.\ndThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.\neThis does not include inhaled treprostinil, which may be considered in patients with PH associated with ILD, irrespective of PH severity.\nESC/ERS Guidelines\n3693\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nconsidered to have CTEPD with or without PH; CTEPH remains the\npreferred term for patients with PH, as deﬁned in Section 3.1\n(Table 5).54 Chronic thrombo-embolic pulmonary disease describes\nsymptomatic patients with mismatched perfusion defects on V/Q\nscan and with signs of chronic, organized, ﬁbrotic clots on CTPA or\nDSA, such as ring-like stenoses, webs/slits, and chronic total occlusions\n(pouch lesions or tapered lesions), after at least 3 months of therapeut-\nic anticoagulation. Pulmonary hypertension in this setting is not only a\nconsequence of PA obstruction by organized ﬁbrotic clots but can also\nbe related to the associated microvasculopathy. In those patients with-\nout PH at rest, breathlessness could be due to exercise PH (see\ndeﬁnition in Section 3.1, Table 5) and/or increased dead space ventila-\ntion.54 Excluding ventilatory limitation, deconditioning and psychogenic\nhyperventilation syndrome by CPET and LV myocardial or valvular dis-\nease by echocardiography is of upmost importance when making\ntherapeutic decisions in patients with CTEPD without PH.\n10.1. Diagnosis\nChronic thrombo-embolic pulmonary hypertension is a common\nand important cause of PH, with a distinct management strategy.\nThus, the possibility of CTEPH should be carefully considered in all\npatients with PH (Figure 13). In the context of acute PE, CTEPH\nCTEPH diagnostic algorithm for symptomatic patients\nf\nPatients with confirmed CTEPH\nCTEPH suspected from history\nof PEa or risk factors for CTEPH\nf\nTr\nT eatment assessment by MDT at CTEPH centre\n(Class I)\nPH work-up\nN\nY\nPerfusion imaging\n(V/Q scan or new modalityb)\nAny mismatched\nperfusion defects\nf\nEchocardiography\nIntermediate or\nhigh probability of PH\nRefer to CTEPH/PH centre\nComprehensive work-upd\n(Table 14\nT\n, ReCo\n,\nTable 2)\nT\nAbnormal exercise tests\n(CPETc, st\n,\nress echocardiography)\nsuggestive for CTEPD\nf\nAND\nCTPA + D\nP\nSA\nwhen CTPA is inconclusi\nP\nve\nRHC\nAND\nFigure 13 Diagnostic strategy in chronic thrombo-embolic pulmonary hypertension. CPET, cardiopulmonary exercise test; CTEPD, chronic thrombo-\nembolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; CTPA, computed tomography pulmonary angiography; DECT,\ndual-energy computed tomography; DSA, digital subtraction angiography; MDT, multidisciplinary team; MRI, magnetic resonance imaging; N, no; PE, pul-\nmonary embolism; PETCO2, end-tidal partial pressure of carbon dioxide; PH, pulmonary hypertension; ReCo, recommendation; RHC, right heart cath-\neterization; sPAP, systolic pulmonary arterial pressure; V/Q, ventilation/perfusion; VE/VCO2, ventilatory equivalents for carbon dioxide; VO2/HR, oxygen\npulse; VO2, oxygen uptake; Y, yes. aCTEPH suspected from history of PE, including elevated sPAP on echocardiography and signs suggesting CTEPH on\nCTPA performed at the time of the acute PE (Section 5.1.7). bAlternative perfusion imaging techniques—such as iodine subtraction mapping, DECT, and\nMRI perfusion—are currently under evaluation. cTypical pattern, including low PETCO2, high VE/VCO2, low VO2/HR, and low peak VO2 (Section 5.1.11).\ndComprehensive work-up after 3 months of therapeutic anticoagulation or sooner in unstable or rapidly deteriorating patients. Ideally, CTPA, DSA, and\nRHC are performed in CTEPH centres, but they are sometimes performed in PH centres, depending on the country and organization.\n3694\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nshould be considered: (1) if radiological signs (detailed in Section\n5.1.7) suggest CTEPH on the CTPA performed to diagnose PE,112\nand/or if estimated sPAP is .60 mmHg112 on echocardiogram; (2)\nwhen dyspnoea or functional limitations persist in the clinical course\npost-PE;754 and (3) in asymptomatic patients with risk factors for\nCTEPH or a high CTEPH prediction score.755 Clinical conditions\nsuch as permanent intravascular devices (pacemaker, long-term cen-\ntral lines, ventriculoatrial shunts), inﬂammatory bowel diseases, es-\nsential\nthrombocythaemia,\npolycythaemia\nvera,\nsplenectomy,\nantiphospholipid syndrome, high-dose thyroid hormone replace-\nment, and malignancy are risk factors for CTEPH.54,103,756\nAlternative causes of PA obstructions (also included in group 4 of the\nPH classiﬁcation)—including PA sarcomas, other malignant tumours\n(e.g. renal carcinoma, uterine carcinoma, and germ-cell tumours of\nthe testis), non-malignant tumours (e.g. uterine leiomyoma), arteriitis\nwithout CTD, congenital or acquired PA stenoses, parasites (hydatid\ncyst), and foreign-body embolism—have to be considered in the differ-\nential diagnosis of CTEPD.757 They can be explored by speciﬁc addition-\nal imaging such as 18F-2-ﬂuoro-2-deoxy-D-glucose-positron emission\ntomography (PET) scan, which can provide additional information\nwhen PA sarcoma is suspected.758\nVentilation/perfusion scintigraphy207 remains the most effective\ntool in excluding CTEPD. Alternative perfusion imaging techniques\n—such as iodine subtraction mapping, DECT, and MRI perfusion—\nhave numerous theoretical advantages over V/Q but are more tech-\nnically challenging and expensive, have limited availability, and cur-\nrently lack multicentre validation.\nComputed tomography pulmonary angiography with bi-planar re-\nconstruction is broadly used for diagnosing CTEPD and assessing op-\nerability, but a negative CTPA, even if high quality, does not exclude\nCTEPD, as distal disease can be missed. Digital subtraction angiog-\nraphy is still used to assess treatment options when CTPA is incon-\nclusive. Selective segmental angiography, cone-beam CT, and area\ndetector CT allow for more accurate visualization of subsegmental\nvasculature and are useful for procedural guidance for BPA. The ben-\neﬁts of the new technologies require validating in prospective trials\nbefore being recommended for routine clinical use; a large,\nEuropean, multicentre study is currently ongoing.759\n10.2. Therapy\nThe CTEPH treatment algorithm includes a multimodal approach of\ncombinations of pulmonary endarterectomy (PEA), BPA, and medic-\nal therapies to target the mixed anatomical lesions: proximal, distal,\nand microvasculopathy, respectively (Figures 14 and 15).\nGeneral measures recommended for PAH also apply to CTEPH,\nincluding supervised exercise training, which is effective and safe in\ninoperable CTEPH patients,760 as well as early after PEA.761\nLifelong therapeutic anticoagulation is recommended for patients\nwith CTEPH, as recurrent pulmonary thrombo-embolism accompanied\nby insufﬁcient clot resolution are key pathophysiological features of this\ndisease. There are no RCTs in CTEPH with any of the approved anti-\ncoagulants; however, despite this lack of evidence, VKAs are recom-\nmended by experts, and are most widely used as background therapy\nfor patients with CTEPH. More recently, NOACs have more frequently\nbeen used as alternatives to VKAs, again, lacking evidence from RCTs. A\nretrospective case series from the UK and a multicentre prospective\nregistry (EXPERT) showed comparable bleeding rates for VKAs and\nNOACs in CTEPH, but recurrent venous thrombo-embolism rates\nwere higher in those receiving NOACs.762,763 In patients with antipho-\nspholipid syndrome (10% of the CTEPH population), VKAs are recom-\nmended.103,764,765 Screening for antiphospholipid syndrome should be\nperformed at CTEPH diagnosis. In the absence of any evidence in favour\nor against prolonged anticoagulation in patients with CTEPD without\nPH, long-term anticoagulant therapy is based on individual decision-\nmaking. It is recommended when the risk of PE recurrence is intermedi-\nate or high, thereby following the 2019 ESC/ERS Guidelines for the diag-\nnosis and management of acute pulmonary embolism (Table 11).103\n10.2.1. Surgical treatment\nSurgical PEA is the treatment of choice for patients with accessible\nPA lesions.102 As surgery may normalize pulmonary haemodynamics\n(65% decrease in PVR)766 and functional capacity, an expert multidis-\nciplinary team including an experienced PEA surgeon (on-site or\nclosely collaborating) is mandatory for evaluating operability and de-\nciding ﬁnal treatment.102\nOperability is based on team experience, accessibility of PA le-\nsions, correlation between severity of PH and degree of PA obstruc-\ntions, and comorbidities.767 The surgical technique is complex but\nwell standardized with .30 years of experience. It consists of a com-\nplete bilateral endarterectomy of the PAs down to segmental and\nsubsegmental levels in phases of deep hypothermic circulatory arrest\n(Figure 15).767,768 In CTEPH centres, surgical outcomes are favour-\nable, with peri-operative mortality rates ,2.5% due to improved\nmanagement of cardiac and pulmonary complications and well-\nestablished use of ECMO.768 Post-operative PH is frequently ob-\nserved (≏25%),766 but long-term outcomes after PEA surgery are\nexcellent regarding survival (averaging 90% at 3 years) and quality\nof life,769–771 even in patients with distal PA obstructions.772 On\nthe other hand, patients with proximal operable disease declining\nsurgery have a poor long-term outcome, with a 5 year survival of\n53%\ncompared\nwith\n83%\nin\npatients\nundergoing\nPEA.773\nTherefore, PEA should be offered to all operable patients with a fa-\nvourable risk:beneﬁt ratio, ideally during a personal consultation be-\ntween the patient and the PEA surgeon.102\nSelected symptomatic patients with CTEPD without PH can be\nsuccessfully treated by PEA, with clinical and haemodynamic im-\nprovements at rest and exercise.135,774 Those patients would require\ncareful discussion to balance risk and beneﬁt.\n10.2.2. Medical therapy\nTo manage the microvascular component of CTEPH (Figure 15),\nmedical therapies have been used off-label based on uncontrolled\nstudies and/or regional approvals. Meanwhile, three RCTs have suc-\ncessfully been conducted. The ﬁrst phase 3 RCT investigated the ef-\nﬁcacy of riociguat in patients with inoperable CTEPH or those with\npersistent/recurrent PH after PEA.775 Riociguat, after 16 weeks of\ntherapy, improved 6MWD and reduced PVR by 31% compared\nwith placebo, and is approved for this indication. Treprostinil s.c.\nwas investigated in a phase 3 RCT, which showed improved\n6MWD at week 24 in patients with inoperable CTEPH or those\nwith persistent/recurrent PH after PEA receiving a high dose com-\npared with a low dose;776 s.c. treprostinil is approved for this indica-\ntion. In a phase 2 study including only patients with inoperable\nCTEPH, macitentan 10 mg improved PVR and 6MWD vs. placebo\nESC/ERS Guidelines\n3695\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nat 16 and 24 weeks, respectively.777 A phase 3 RCT is ongoing to\nevaluate the safety and efﬁcacy of macitentan 75 mg in inoperable\nor persistent/recurrent CTEPH (NCT04271475).\nOther medical therapies—PDE5is (e.g. sildenaﬁl) and ERAs (e.g.\nbosentan)—have been used off-label, as their efﬁcacy in inoperable\nCTEPH has not been proven by RCTs or registry data.769,778,779\nHowever, oral combination therapy, including PDE5is and ERAs, is\ncommon practice in patients with CTEPH with severe haemodynam-\nic compromise.780\n10.2.3. Interventional treatment\nBalloon pulmonary angioplasty (Figure 15) has become an established\ntreatment for selected patients with inoperable CTEPH or persist-\nent/recurrent PH after PEA, improving haemodynamics (PVR de-\ncrease 49–66%), right heart function, and exercise capacity.781–794\nLong-term outcomes are promising, but evidence is still scarce.795\nA staged interventional procedure with a limited number of di-\nlated PA segments per session is preferred.102,788 The number of\nsessions needed and haemodynamic results are dependent on ex-\nperience.781 While BPA is effective, it is associated with serious com-\nplications, which may be fatal. Procedural and post-interventional\ncomplications include vascular injury due to wire perforation, and\nlung injury with haemoptysis and/or hypoxia.102,781,796,797 As with\nall interventional procedures, a signiﬁcant learning curve has been\nshown, with reducing complication rates over time;781 therefore,\nthis procedure should be performed in high-volume CTEPH centres.\nAs the rates of interventional complications can be reduced by med-\nical pre-treatment, patients with a PVR .4 WU should be treated\nbefore BPA (Figure 15).798\nSelected symptomatic patients with CTEPD without PH and\nsegmental/subsegmental lesions can successfully be treated by BPA,\nwith\nclinical and\nhaemodynamic improvements at\nrest and\nexercise.799\nPreliminary data on PADN point towards improved exercise cap-\nacity and pulmonary haemodynamics in patients with persistent PH\nafter PEA;800 further conﬁrmation is being awaited.\nPatients with confirmed CTEPHa\nLifelong ther\nf\napeutic anticoagulation\n(Class I)\nTr\nT eatment assessment by MDTb\n(Class I)\nPEA as treatment of choicec\n(Class I)\nLong-term foll\nf\now-up\nat a CTEPH/PH centrec\n(Class I)\nMedical therapy (ReCo\np\nTable 24)\nT\n(Class I)\nBPA\nP\nd\n(Class I)\nOperable\nPersistent/recurrent\nsymptomatic PH\nN\nN\nY\nY\nFigure 14 Management strategy in chronic thrombo-embolic pulmonary hypertension. BPA, balloon pulmonary angioplasty; CTEPD, chronic\nthrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; MDT, multidisciplinary team; N, no; PAH, pulmonary\narterial hypertension; PEA, pulmonary endarterectomy; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; ReCo, recommendation; WU,\nWood units; Y, yes. aSelected symptomatic patients with CTEPD without PH can also be treated by PEA and BPA. bMDT meeting can be virtual.\ncTreatment assessment may differ, depending on the level of expertise in PEA and BPA. dFor inoperable patients with PVR .4 WU, medical therapy\nshould be considered prior to BPA; there are limited data on BPA as ﬁrst-line therapy.\n3696\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n10.2.4. Multimodal treatment\nMultimodal therapy including surgery, medication, and intervention is\noffered to selected patients with CTEPH (Figure 15).102\nUsing medical therapy in patients with high pre-operative PVR to\nimprove pulmonary haemodynamics before PEA is common practice\nbut still controversial, as it is felt to delay timely surgical referral and\ntherefore deﬁnitive treatment.801–803\nA signiﬁcant proportion of symptomatic patients may have per-\nsistent or recurrent PH following PEA, which may also beneﬁt\nfrom medical and/or interventional therapies (Figure 15).804–806 An\nmPAP ≥30 mmHg has been associated with initiation of medical\ntherapies post-PEA, and an mPAP ≥38 mmHg and PVR ≥5 WU\nwith worse long-term survival.806\nSome patients with CTEPH may have mixed anatomical le-\nsions, with surgically accessible lesions in one lung and inoperable\nlesions in the other lung. Such patients might beneﬁt from a\ncombined approach with BPA (prior to or at the same time as\nsurgery) and PEA to decrease the surgical risk and improve\nthe ﬁnal result.807\nThe recommendations on BPA and medical therapy in patients\nwith inoperable CTEPH have been established based on key narra-\ntive question 8 (Supplementary Data, Section 10.1).\nThe recommendation on the use of medical therapy before inter-\nventional therapy in patients with CTEPH who are considered inop-\nerable but candidates for BPA is based on PICO question IV\n(Supplementary Data, Section 10.2). The included evidence suggests\nA\nB\nC\nD\nE\nPEA\nMedical therapy\nMicrovasculopathy\nProximal PA fibrotic\nobstructions\nMultimodal CTEPH treatment\nDistal PA fibrotic\nobstructions\nBPA\n1\n2\n3\nFigure 15 Overlap in treatments/multimodality approaches in chronic thrombo-embolic pulmonary hypertension. BPA, balloon pulmonary angio-\nplasty; CTEPH, chronic thrombo-embolic pulmonary hypertension; PA, pulmonary artery; PEA, pulmonary endarterectomy. Top panels: (A) Proximal\nPA ﬁbrotic obstructions (vessel diameter 10–40 mm). (B) Distal segmental and subsegmental PA ﬁbrotic obstruction potentially suitable for both\nPEA and BPA interventions (vessel diameter 2–10 mm). (C) Distal subsegmental PA ﬁbrotic obstructions form a web-lesion in a subsegmental branch\nof the PA suitable for BPA interventions (vessel diameter 0.5–5 mm). (D) Distal subsegmental PA ﬁbrotic obstructions form web-like lesions, which might\nbe accompanied by microvasculopathy (vessel diameter ,0.5 mm). (E) Microvasculopathy (vessel diameter ,0.05 mm) treated with medical therapy.\nBottom panels: (A) bottom left: PEA; vessel diameter (0.2–3 cm). The right PA is opened and the suction dissector is introduced between the artery\nwall and ﬁbrosis. Following the inside of the artery down to segmental and subsegmental levels, the ﬁbrotic material is subsequently freed from the\nwall and removed with forceps. (A) bottom right: PEA specimen with ‘tails’ to subsegmental branches of the PA; cross-section of partially organized\nand permeabilized thrombotic lesion of the large PA dissected during PEA. (B, C, D) The wire is introduced between the ﬁbrotic material (1), then\nthe balloon is inﬂated, leading to a rupture of the web (2). Fibrotic material is connected to the vessel wall (3). (E) Small muscular PA displaying eccentric\nintimal ﬁbrosis involving intimal thickening and proliferation—target for medical therapies.\nESC/ERS Guidelines\n3697\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nthat pre-treatment improves pulmonary haemodynamics and safety\nof the procedure. This is conﬁrmed by the clinical experience of Task\nForce members. However, due to the low certainty of the evidence,\nthe recommendation is conditional.\n10.2.5. Follow-up\nRegardless of the result of PEA/BPA, patients should be regularly\nfollowed-up, including invasive assessment with RHC 3–6 months\nafter intervention, allowing for consideration of a multimodal treat-\nment approach. After successful treatment, yearly non-invasive follow-\nup, including echocardiography and an evaluation of exercise capacity,\nis indicated because recurrent PH has been described (Figure 14).806\nRisk assessment with either the ESC/ERS or REVEAL risk score\ndeveloped for PAH has been validated in medically treated patients\nwith CTEPH,300,808,809 but it is unknown if its use has any therapeutic\nimplication or affects outcome.\nTherearenodataorconsensusonwhatisthetherapeutictargetafter\nPEA/BPAormedicaltherapyinCTEPH.Mostexpertsacceptachievinga\ngood functional class (WHO-FC I–II) and/or normalization or near\nnormalization of haemodynamics at rest, obtained at RHC 3–6 months\npost-procedure (PEA or last BPA), and improvement in quality of life.\n10.3. Chronic thrombo-embolic\npulmonary hypertension team and\nexperience criteria\nTo optimize patients’ outcomes, CTEPH centres should fulﬁl criteria\nfor a PH centre (Section 12) and have a CTEPH multidisciplinary team\nconsisting of a PEA surgeon, BPA interventionist, PH specialist, and\nthoracic radiologist, trained in high-volume PEA and/or BPA centres.\nThe team should meet regularly to review new referrals and post-\ntreatment follow-up cases. Ideally, CTEPH centres should have\nPEA activities (.50/year)810 and BPAs (.30 patients/year or\n.100 procedures/year),781 as these ﬁgures have been associated\nwith better outcome. The CTEPH centres should also manage med-\nically treated patients. Based on regional requirements, these num-\nbers may be adjusted for the country’s population, ideally\nconcentrating care and expertise in high-volume centres.\nRecommendation Table 24 — Recommendations for chronic thrombo-embolic pulmonary hypertension and chronic\nthrombo-embolic pulmonary disease without pulmonary hypertension\nRecommendation Table 24A\nRecommendations\nClassa\nLevelb\nCTEPH\nLifelong, therapeutic doses of anticoagulation are recommended in all patients with CTEPH762\nI\nC\nAntiphospholipid syndrome testing is recommended in patients with CTEPH\nI\nC\nIn patients with CTEPH and antiphospholipid syndrome, anticoagulation with VKAs is recommended103,764,765\nI\nC\nIt is recommended that all patients with CTEPH are reviewed by a CTEPH team for the assessment of multimodality management54\nI\nC\nPEA is recommended as the treatment of choice for patients with CTEPH and ﬁbrotic obstructions within pulmonary arteries accessible by\nsurgery54,102\nI\nB\nBPA is recommended in patients who are technically inoperable or have residual PH after PEA and distal obstructions amenable to\nBPA54,102,783,784,789,793,798,811\nI\nB\nRiociguat is recommended for symptomatic patients with inoperable CTEPH or persistent/recurrent PH after PEA775\nI\nB\nLong-term follow-up is recommended after PEA and BPA, as well as for patients with CTEPH established on medical therapy782,805,806,812\nI\nC\nA multimodality approach should be considered for patients with persistent PH after PEA and for patients with inoperable CTEPH804,805,812\nIIa\nC\nTreprostinil s.c. may be considered in patients in WHO-FC III–IV who have inoperable CTEPH or persistent/recurrent PH after PEA776\nIIb\nB\nOff-label use of drugs approved for PAH may be considered in symptomatic patients who have inoperable CTEPH55,777–779,801\nIIb\nB\nIn patients with inoperable CTEPH, a combination of sGC stimulator/PDE5i, ERA,777 or parenteral prostacyclin analogues776 may be considered\nIIb\nC\nBPA may be considered for technically operable patients with a high proportion of distal disease and an unfavourable risk:beneﬁt ratio for PEA\nIIb\nC\nCTEPD without PH\nIn patients with CTEPD without PH, long-term anticoagulant therapy should be considered on an individual basisc\nIIa\nC\nPEA or BPA should be considered in selected symptomatic patients with CTEPD without PH\nIIa\nC\n© ESC/ERS 2022\n3698\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n11. Pulmonary hypertension with\nunclear and/or multifactorial\nmechanisms (group 5)\nPulmonary hypertension with unclear and/or multifactorial mechan-\nisms (Table 24) includes several conditions that may be complicated\nby complex and sometimes overlapping pulmonary vascular\ninvolvement. Although group 5 PH represents less-studied forms\nof PH, it constitutes a signiﬁcant part of the worldwide burden\nof PH.1 Group 5 PH includes: haematological disorders, such as\nSCD and chronic myeloproliferative neoplasms; systemic disor-\nders, such as sarcoidosis; metabolic diseases, such as glycogen stor-\nage disease; and others, such as chronic renal failure, pulmonary\ntumour thrombotic microangiopathy, and ﬁbrosing mediastinitis.\nA common feature of these diseases is that the mechanisms of\nPH are poorly understood and contributing factors may include,\nalone or in combination: hypoxic pulmonary vasoconstriction, pul-\nmonary vascular remodelling, thrombosis, ﬁbrotic destruction and/\nor extrinsic compression of pulmonary vasculature, pulmonary\nvasculitis, high-output cardiac failure, and left HF. These patients\nneed careful assessment and treatment should be directed to the\nunderlying condition.\n11.1. Haematological disorders\nIn haemoglobinopathies and chronic haemolytic anaemias, including\nSCD, PH has emerged as a major cause of morbidity and mortality.\nThe prevalence of PH conﬁrmed by RHC was 6–10% in studies of\nadult patients with stable SCD.93,94,813 Patients with SCD with pre-\ncapillary PH are more commonly homozygous for haemoglobin S,\nwhile some have S-β0 thalassaemia (S-β0 thal) or haemoglobin\nSCD.814 Thrombotic lesions are a major component of PH related\nto SCD, more frequently in haemoglobin SCD.814 Patients with\nPH and SCD should be followed by multidisciplinary SCD and PH\nteams, since treatment of the anaemia is a key part of manage-\nment.814 There is a lack of data to support the use of PAH drugs\nin patients with SCD-associated PH. In a study in patients with\nSCD with TRV ≥2.7 m/s and a 6MWD of 150–500 m, sildenaﬁl\nshowed no treatment effect on 6MWD, TRV, or NT-proBNP, but\nappeared to increase hospitalization rates for pain.815 Preliminary\nevidence supports the short- and long-term beneﬁts of chronic\nblood-exchange transfusions in patients with pre-capillary PH com-\nplicating SCD.816 Pre-capillary PH complicating SCD has an import-\nant impact on survival, with an overall death rate of 2.0–5.3% in\ndifferent populations with similar follow-up (26 months and 18\nmonths, respectively).94,817 In β-thalassaemia, invasive haemodyna-\nmic evaluation conﬁrmed pre-capillary PH in 2.1% of cases, while a\npost-capillary proﬁle was found in 0.3%.818 Potential treatment strat-\negies\nare\nawaiting\nan\nenhanced\nunderstanding\nof\nthe\nRecommendation Table 24B\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nIn patients with CTEPH who are candidates for BPA, medical therapy should be\nconsidered prior to the intervention798\nVery low\nConditional\nIIa\nB\n© ESC/ERS 2022\nBPA, balloon pulmonary angioplasty; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; ERA, endothelin receptor\nantagonist; PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PEA, pulmonary endarterectomy; PE, pulmonary embolism; PH, pulmonary hypertension;\ns.c., subcutaneous; sGC, soluble guanylate cyclase; VKA, vitamin K antagonist; WHO-FC, World Health Organization functional class.\naClass of recommendation.\nbLevel of evidence.\ncLong-term anticoagulant therapy is recommended when the risk of PE recurrence is intermediate or high,103 or when there is no history of venous thrombo-embolism.\nTable 24\nPulmonary hypertension with unclear and/\nor multifactorial mechanisms\nDisorders associated with\npulmonary hypertension\n1 Haematological disorders\nInherited and acquired chronic\nhaemolytic anaemia\n• Sickle cell disease\n• β-thalassaemia\n• Spherocytosis\n• Stomatocytosis\n• Autoimmune disorders\nChronic myeloproliferative\ndisorders\n• Chronic myelogenous\nleukaemia\n• Polycythaemia vera\n• Idiopathic myeloﬁbrosis\n• Essential thrombocytopenia\n• Others\n2 Systemic disorders\nSarcoidosis\nPulmonary Langerhans’s cell\nhistiocytosis\nNeuroﬁbromatosis type 1\n3 Metabolic disorders\nGlycogen storage disease\nGaucher disease\n4 Chronic renal failure with/\nwithout haemodialysis\n5 Pulmonary tumour thrombotic\nmicroangiopathy\n6 Fibrosis mediastinitis\n© ESC/ERS 2022\nESC/ERS Guidelines\n3699\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 76",
          "page": 76,
          "content": "Recommendations | Classa | Levelb\nIf PH is suspected in patients with lung disease, it is recommended that echocardiographyc be performed and the results interpreted in\nconjunction with ABG, PFTs including DLCO, and CT imaging | I | C\nIn patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where\nindicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation | I | C\nIn patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH\ncentre is recommendedd | I | C\nIn patients with lung disease and severe PH, an individualized approach to treatment is recommended | I | C\nIt is recommended to refer eligible patients with lung disease and PH for LTx evaluation | I | C\nIn patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions | I | C\nInhaled treprostinil may be considered in patients with PH associated with ILD734 | IIb | B\nThe use of ambrisentan is not recommended in patients with PH associated with IPF740 | III | B\nThe use of riociguat is not recommended in patients with PH associated with IIP181 | III | B\nThe use of PAH medication is not recommended in patients with lung disease and non-severe PHe | III | C",
          "rows": 11,
          "cols": 3
        },
        {
          "title": "Table on page 76",
          "page": 76,
          "content": " | GRADE |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nPDE5is may be considered in patients with severe PH associated with ILD\n(individual decision-making in PH centres) | Very low | Conditional | IIb | C\nThe use of PDE5is in patients with ILD and non-severe PH is not recommended | Very low | Conditional | III | C",
          "rows": 4,
          "cols": 5
        },
        {
          "title": "Table on page 81",
          "page": 81,
          "content": "Recommendations |  | Classa | Levelb | \n | CTEPH |  |  | \nLifelong, therapeutic doses of anticoagulation are recommended in all patients with CTEPH762 |  | I | C | \nAntiphospholipid syndrome testing is recommended in patients with CTEPH |  | I | C | \nIn patients with CTEPH and antiphospholipid syndrome, anticoagulation with VKAs is recommended103,764,765 |  | I | C | \nIt is recommended that all patients with CTEPH are reviewed by a CTEPH team for the assessment of multimodality management54 |  | I | C | \nPEA is recommended as the treatment of choice for patients with CTEPH and fibrotic obstructions within pulmonary arteries accessible by\nsurgery54,102 |  | I | B | \nBPA is recommended in patients who are technically inoperable or have residual PH after PEA and distal obstructions amenable to\nBPA54,102,783,784,789,793,798,811 |  | I | B | \nRiociguat is recommended for symptomatic patients with inoperable CTEPH or persistent/recurrent PH after PEA775 |  | I | B | \nLong-term follow-up is recommended after PEA and BPA, as well as for patients with CTEPH established on medical therapy782,805,806,812 |  | I | C | \nA multimodality approach should be considered for patients with persistent PH after PEA and for patients with inoperable CTEPH804,805,812 |  | IIa | C | \nTreprostinil s.c. may be considered in patients in WHO-FC III–IV who have inoperable CTEPH or persistent/recurrent PH after PEA776 |  | IIb | B | \nOff-label use of drugs approved for PAH may be considered in symptomatic patients who have inoperable CTEPH55,777–779,801 |  | IIb | B | \nIn patients with inoperable CTEPH, a combination of sGC stimulator/PDE5i, ERA,777 or parenteral prostacyclin analogues776 may be considered |  | IIb | C | \nBPA may be considered for technically operable patients with a high proportion of distal disease and an unfavourable risk:benefit ratio for PEA |  | IIb | C | \n | CTEPD without PH |  |  | \nIn patients with CTEPD without PH, long-term anticoagulant therapy should be considered on an individual basisc |  | IIa | C | \nPEA or BPA should be considered in selected symptomatic patients with CTEPD without PH |  | IIa | C | ",
          "rows": 18,
          "cols": 5
        },
        {
          "title": "Table on page 82",
          "page": 82,
          "content": " | GRADE |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nIn patients with CTEPH who are candidates for BPA, medical therapy should be\nconsidered prior to the intervention798 | Very low | Conditional | IIa | B",
          "rows": 3,
          "cols": 5
        },
        {
          "title": "Table on page 82",
          "page": 82,
          "content": "Disorders associated with\npulmonary hypertension | \n1 Haematological disorders | Inherited and acquired chronic\nhaemolytic anaemia\n• Sickle cell disease\n• β-thalassaemia\n• Spherocytosis\n• Stomatocytosis\n• Autoimmune disorders\nChronic myeloproliferative\ndisorders\n• Chronic myelogenous\nleukaemia\n• Polycythaemia vera\n• Idiopathic myelofibrosis\n• Essential thrombocytopenia\n• Others\n2 Systemic disorders | Sarcoidosis\nPulmonary Langerhans’s cell\nhistiocytosis\nNeurofibromatosis type 1\n3 Metabolic disorders | Glycogen storage disease\nGaucher disease\n4 Chronic renal failure with/\nwithout haemodialysis | \n5 Pulmonary tumour thrombotic\nmicroangiopathy | \n6 Fibrosis mediastinitis | ",
          "rows": 7,
          "cols": 2
        }
      ],
      "keywords": [
        "echocardiography",
        "ct",
        "echo",
        "chronic",
        "group",
        "hypertension",
        "thrombo",
        "severe",
        "pulmonary",
        "embolic",
        "treatment",
        "imaging",
        "pulmonary hypertension",
        "recommendation"
      ]
    },
    {
      "number": "13",
      "title": "11. Pulmonary hypertension with unclear and/or multifactorial mechanisms (group 5)",
      "start_page": 82,
      "end_page": 84,
      "content": "11. Pulmonary hypertension with\nunclear and/or multifactorial\nmechanisms (group 5)\nPulmonary hypertension with unclear and/or multifactorial mechan-\nisms (Table 24) includes several conditions that may be complicated\nby complex and sometimes overlapping pulmonary vascular\ninvolvement. Although group 5 PH represents less-studied forms\nof PH, it constitutes a signiﬁcant part of the worldwide burden\nof PH.1 Group 5 PH includes: haematological disorders, such as\nSCD and chronic myeloproliferative neoplasms; systemic disor-\nders, such as sarcoidosis; metabolic diseases, such as glycogen stor-\nage disease; and others, such as chronic renal failure, pulmonary\ntumour thrombotic microangiopathy, and ﬁbrosing mediastinitis.\nA common feature of these diseases is that the mechanisms of\nPH are poorly understood and contributing factors may include,\nalone or in combination: hypoxic pulmonary vasoconstriction, pul-\nmonary vascular remodelling, thrombosis, ﬁbrotic destruction and/\nor extrinsic compression of pulmonary vasculature, pulmonary\nvasculitis, high-output cardiac failure, and left HF. These patients\nneed careful assessment and treatment should be directed to the\nunderlying condition.\n11.1. Haematological disorders\nIn haemoglobinopathies and chronic haemolytic anaemias, including\nSCD, PH has emerged as a major cause of morbidity and mortality.\nThe prevalence of PH conﬁrmed by RHC was 6–10% in studies of\nadult patients with stable SCD.93,94,813 Patients with SCD with pre-\ncapillary PH are more commonly homozygous for haemoglobin S,\nwhile some have S-β0 thalassaemia (S-β0 thal) or haemoglobin\nSCD.814 Thrombotic lesions are a major component of PH related\nto SCD, more frequently in haemoglobin SCD.814 Patients with\nPH and SCD should be followed by multidisciplinary SCD and PH\nteams, since treatment of the anaemia is a key part of manage-\nment.814 There is a lack of data to support the use of PAH drugs\nin patients with SCD-associated PH. In a study in patients with\nSCD with TRV ≥2.7 m/s and a 6MWD of 150–500 m, sildenaﬁl\nshowed no treatment effect on 6MWD, TRV, or NT-proBNP, but\nappeared to increase hospitalization rates for pain.815 Preliminary\nevidence supports the short- and long-term beneﬁts of chronic\nblood-exchange transfusions in patients with pre-capillary PH com-\nplicating SCD.816 Pre-capillary PH complicating SCD has an import-\nant impact on survival, with an overall death rate of 2.0–5.3% in\ndifferent populations with similar follow-up (26 months and 18\nmonths, respectively).94,817 In β-thalassaemia, invasive haemodyna-\nmic evaluation conﬁrmed pre-capillary PH in 2.1% of cases, while a\npost-capillary proﬁle was found in 0.3%.818 Potential treatment strat-\negies\nare\nawaiting\nan\nenhanced\nunderstanding\nof\nthe\nRecommendation Table 24B\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nIn patients with CTEPH who are candidates for BPA, medical therapy should be\nconsidered prior to the intervention798\nVery low\nConditional\nIIa\nB\n© ESC/ERS 2022\nBPA, balloon pulmonary angioplasty; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; ERA, endothelin receptor\nantagonist; PAH, pulmonary arterial hypertension; PDE5i, phosphodiesterase 5 inhibitor; PEA, pulmonary endarterectomy; PE, pulmonary embolism; PH, pulmonary hypertension;\ns.c., subcutaneous; sGC, soluble guanylate cyclase; VKA, vitamin K antagonist; WHO-FC, World Health Organization functional class.\naClass of recommendation.\nbLevel of evidence.\ncLong-term anticoagulant therapy is recommended when the risk of PE recurrence is intermediate or high,103 or when there is no history of venous thrombo-embolism.\nTable 24\nPulmonary hypertension with unclear and/\nor multifactorial mechanisms\nDisorders associated with\npulmonary hypertension\n1 Haematological disorders\nInherited and acquired chronic\nhaemolytic anaemia\n• Sickle cell disease\n• β-thalassaemia\n• Spherocytosis\n• Stomatocytosis\n• Autoimmune disorders\nChronic myeloproliferative\ndisorders\n• Chronic myelogenous\nleukaemia\n• Polycythaemia vera\n• Idiopathic myeloﬁbrosis\n• Essential thrombocytopenia\n• Others\n2 Systemic disorders\nSarcoidosis\nPulmonary Langerhans’s cell\nhistiocytosis\nNeuroﬁbromatosis type 1\n3 Metabolic disorders\nGlycogen storage disease\nGaucher disease\n4 Chronic renal failure with/\nwithout haemodialysis\n5 Pulmonary tumour thrombotic\nmicroangiopathy\n6 Fibrosis mediastinitis\n© ESC/ERS 2022\nESC/ERS Guidelines\n3699\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\npathophysiological mechanisms. In spherocytosis, splenectomy is a\nrisk factor for CTEPH.819\nMultiple causes of PH have been described in patients with chronic\nmyeloproliferative disorders.820 In chronic myelogenous leukaemia,\nspleen enlargement and anaemia can give rise to hyperkinetic syn-\ndrome. Hepatosplenic enlargement can also cause PoPH. Cases of\npotentially reversible DPAH have been described with dasatinib, bo-\nsutinib, and ponatinib. In polycythaemia vera and essential thrombo-\ncythaemia, there is an increased risk of venous thrombo-embolic\ndisease and CTEPH; moreover, a blood clot within the hepatic veins\ncan\nlead\nto Budd–Chiari syndrome\nand subsequent PoPH.\nPulmonary extramedullary haematopoiesis complicating idiopathic\nor secondary myeloﬁbrosis may also contribute to dyspnoea and PH.\nGroup 5 PH may be described in other haematological disorders,\nsuch as common variable immunodeﬁciency; immunoglobulin G4\n(IgG4)-related disease; Castleman disease; and polyneuropathy, or-\nganomegaly, endocrinopathy, monoclonal immunoglobulin, skin\nchanges (POEMS) syndrome.821–823\n11.2. Systemic disorders\nThe reported prevalence of PH in patients with sarcoidosis is 6–\n20%.824 The causes are multifactorial, including ﬁbrosing lung disease,\ngranulomata in the PAs and/or pulmonary veins, ﬁbrosing mediastini-\ntis and/or extrinsic compression by lymph nodes, pulmonary vascu-\nlitis, CTEPH, and PoPH.58,825 It is associated with signiﬁcant\nmorbidity and increased mortality compared with sarcoidosis with-\nout PH.58,825 In a registry, factors independently associated with out-\ncomes included physiological (forced expiratory volume in 1 s/FVC\nratio and DLCO) and functional (6MWD) parameters.58 In a large\nstudy of severe, sarcoidosis-associated PH, PAH drugs improved\nshort-term\npulmonary\nhaemodynamics\nwithout\nimproving\n6MWD.59 Small RCTs have suggested efﬁcacy of PAH drugs in these\npatients,\nwhich\nrequires\nconﬁrmation\nin\nlarger\nstudies.826\nCorticosteroids or immunosuppressive therapy may improve\nhaemodynamics in selected patients with active granulomatous dis-\nease. Of note, when pulmonary vascular compression is suspected\n(ﬁbrosing mediastinitis and/or extrinsic compression by lymph\nnodes), results from pulmonary angiography and PET scans provide\nadditional\ninformation\njustifying\nendovascular\nand/or\nanti-\ninﬂammatory approaches. Long-term survival remains poor in\nsarcoidosis-associated PH, which makes LTx a reasonable option\nfor selected severe cases.\nIn pulmonary Langerhans’s cell histiocytosis, diminished exercise\ncapacity does not appear to be due to ventilatory limitation but\nmay be related to pulmonary vascular dysfunction. In 29 patients\nwith PH associated with pulmonary Langerhans’s cell histiocytosis,\nPAH drugs improved haemodynamics without worsening oxygen\nlevels.827\nPulmonary hypertension associated with neuroﬁbromatosis type\n1 is a rare but severe complication characterized by female predom-\ninance (female/male ratio 3.9:1).828 Speciﬁc pulmonary vascular in-\nvolvement exists in these patients, and despite a potential\nshort-term beneﬁt of PAH drugs, prognosis remains poor, and\nLTx should be considered in selected patients with severe disease.\nIn the presence of dyspnoea, screening for ILD by non-contrast\nCT and for PH by echocardiography is required.828\n11.3. Metabolic disorders\nGlycogen storage diseases are caused by genetic alterations of glyco-\ngen metabolism, and PH case reports have been related to glycogen\nstorage disease type 1 and 2.829 The occurrence of PH has predom-\ninantly been described in glycogen storage disease type 1, where it\nmay partly be due to vasoconstrictive amines such as serotonin.\nDrugs for PAH have been used in some cases.830\nUntreated patients with Gaucher disease may develop PH, which\nis caused by a combination of factors, including asplenia, plugging of\nthe vasculature by abnormal macrophages, and pulmonary vascular\nremodelling. Treatment with enzyme-replacement therapy may im-\nprove PH.\n11.4. Chronic kidney failure\nAlthough commonly recognized in chronic renal failure, the patho-\ngenesis of PH remains poorly understood and PH is observed in pa-\ntients prior to and while receiving different dialysis modalities.831 A\nrecent RHC study of 3504 patients with chronic kidney disease\nfound that CpcPH was the most common phenotype, and the\nphenotype with the highest mortality.832 Post-capillary PH has\nbeen described in 65% of patients receiving haemodialysis and 71%\nof patients without kidney replacement.833\n11.5. Pulmonary tumour thrombotic\nmicroangiopathy\nPulmonary tumour thrombotic microangiopathy describes tumour-\ncell microemboli with occlusive ﬁbrointimal remodelling in small PAs,\npulmonary veins, and lymphatics. It is a rare cause of PH, which arises\ndue to multiple mechanisms, but probably remains under-diagnosed,\nas evidenced by autopsy ﬁndings.834 The disorder is associated with\ncarcinomas, notably gastric carcinoma. Progressive vessel occlusion\nultimately results in PH, which is often severe, of sudden onset, rap-\nidly progressive, and accompanied by progressive hypoxaemia. Chest\nCT may show patchy ground-glass and septal markings (masquerad-\ning as PVOD).\n11.6. Fibrosing mediastinitis\nFibrosing mediastinitis is caused by ﬁbrous tissue proliferating in the\nmediastinum, encasing mediastinal viscera and compressing mediastinal\nbronchovascular structures.835 Pre- or post-capillary PH can complicate\nthe course of ﬁbrosing mediastinitis due to extrinsic compression of the\nPAs and/or pulmonary veins. Fibrosing mediastinitis can be idiopathic or\ncaused by irradiation, infection (tuberculosis, histoplasmosis), and sys-\ntemic diseases, such as sarcoidosis and IgG4-related disease, a ﬁbroin-\nﬂammatory disease characterized by elevated serum IgG4 levels with\ninﬁltration of IgG4+ plasma cells and severe ﬁbrosis in affected tis-\nsues.821 Treatment should be directed to the underlying condition.\nNo clear clinical improvement has been described with PAH drugs.\nSurgical and endovascular procedures have been proposed to\nde-obstruct or bypass the arterial and/or venous compressions.\nIn the absence of positive RCTs studying the use of PAH drugs for\ntreating group 5 PH, treating the underlying disorder remains the\nstandard of care.836 Importantly, some of the diseases described in\nTable 24 may have a pulmonary venous component that could be\nmade worse with PAH drugs, implying that off-label use of drugs ap-\nproved for PAH should be considered with great caution, if at all.\n3700\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nPlacebo-controlled, randomized trials are currently recruiting in\nwell-phenotyped subgroups of PH with unclear and/or multifactorial\nmechanisms, such as sarcoidosis-associated PH.\n12. Deﬁnition of a pulmonary\nhypertension centre\nWhile PH is not an uncommon condition, severe forms of PH, es-\npecially PAH and CTEPH, require highly specialized management.\nSince medical centres with multidisciplinary teams and a high vol-\nume of patients generally offer best standard of care, which trans-\nlates into better clinical outcomes, establishing PH centres is\nclinically and economically highly desirable and is supported by\npatient organizations and scientiﬁc societies. The purpose of a\nPH centre is to: receive new referrals; assess and investigate the\ncause of PH; carefully phenotype and routinely manage patients\nwith medical, interventional, and surgical approaches; work closely\nwith other health care providers to achieve the best outcomes for\npatients; undertake audits (reporting patient case mix and quality\nindicators); and be involved in clinical and translational research,\nand education. The requirements—comprising deﬁnition, multi-\ndisciplinary structure, number of cases, procedures, and stafﬁng le-\nvels, as well as the skills and resources needed in a PH referral\ncentre—are described below and in Figure 16. Criteria for paediatric\nand CTEPH centres are described elsewhere (Sections 7.8.3 and 10.3,\nrespectively).\nCo-ordinated by a core MDT member responsible for the multidisciplinary approach\nCore MDT\nExtended MDT\nSocial worker\nStudy nurse\nPaediatric cardiologist\nPsychologist\nAdult CHD specialist\nLung pathologist\nHepatologist\nPhysiotherapist\nRheumatologist\nIntensive care specialist\nThoracic radiologist\nPalliative care specialist\nCardiac radiologist\nLung transplant\nphysician/surgeonc\nClinical geneticist/\nGenetic counsellorc\nAt least 2 PH nurses\nNurse specialist\nFor diagnostic pulmonary\nangiography, embolization\nInterventional\nradiologist/cardiologist\nCardiologist/Pneumologist\nAt least 2 surgeons\n(ECMO)\nCardiothoracic surgeon\nCase managerb\nResponsible for data \ncollection, analysis, and\norganization of audit meetings\nData manager\nMDT meeting\nRegular, to discuss multidisciplinary aspects of individual patient care\nPatient empowerment and advocacy\nClear verbal, and written information for patients that describes diagnostic procedures and treatment options;\nshared decision-making; collaboration with advocacy group\nInteraction with external healthcare providers and other relevant stakeholders\nGP, local specialist, social services, rehabilitation centres, national health services, labs,\ninsurers, school, work, sport club, psychologist, etc.\nQuality control/Audits\nData collection/registration; monitoring of quality indicators; regular internal audits\nResearch, training, and education\nInvolvement in clinical and translational research: teaching courses on local, national, or international basis\nPatient care pathway and clinical management protocol\nSteps from diagnosis to follow-up including advanced disease, palliative stage, and end of life\nAt least 2 PH specialists treating\na sufficient number of patientsa\nResponsible for the\nco-ordination of care\non patient level\nGynaecologist/\nObstetrician\nCardiothoracic \nanaesthetist\nProcesses\nPulmonary hypertension centre\nworking \u000250% on PH care \nFigure 16 Pulmonary hypertension centre schematic. CHD, congenital heart disease; ECMO, extracorporeal membrane oxygenation; GP, general\npractitioner; MDT, multidisciplinary team; PH, pulmonary hypertension. aNumber adapted according to speciﬁc country characteristics. bCase manager\ncan be a nurse specialist, social worker, physiotherapist, or administrative assistant in function of the centre organization. cCan be located in partner cen-\ntres. Adapted from Biganzoli et al.846\nESC/ERS Guidelines\n3701\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 82",
          "page": 82,
          "content": " | GRADE |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nIn patients with CTEPH who are candidates for BPA, medical therapy should be\nconsidered prior to the intervention798 | Very low | Conditional | IIa | B",
          "rows": 3,
          "cols": 5
        },
        {
          "title": "Table on page 82",
          "page": 82,
          "content": "Disorders associated with\npulmonary hypertension | \n1 Haematological disorders | Inherited and acquired chronic\nhaemolytic anaemia\n• Sickle cell disease\n• β-thalassaemia\n• Spherocytosis\n• Stomatocytosis\n• Autoimmune disorders\nChronic myeloproliferative\ndisorders\n• Chronic myelogenous\nleukaemia\n• Polycythaemia vera\n• Idiopathic myelofibrosis\n• Essential thrombocytopenia\n• Others\n2 Systemic disorders | Sarcoidosis\nPulmonary Langerhans’s cell\nhistiocytosis\nNeurofibromatosis type 1\n3 Metabolic disorders | Glycogen storage disease\nGaucher disease\n4 Chronic renal failure with/\nwithout haemodialysis | \n5 Pulmonary tumour thrombotic\nmicroangiopathy | \n6 Fibrosis mediastinitis | ",
          "rows": 7,
          "cols": 2
        }
      ],
      "keywords": [
        "intervention",
        "ct",
        "group",
        "follow-up",
        "hypertension",
        "unclear",
        "pulmonary",
        "mechanisms",
        "treatment",
        "multifactorial",
        "pulmonary hypertension",
        "recommendation"
      ]
    },
    {
      "number": "14",
      "title": "12. Definition of a pulmonary hypertension centre",
      "start_page": 84,
      "end_page": 86,
      "content": "Placebo-controlled, randomized trials are currently recruiting in\nwell-phenotyped subgroups of PH with unclear and/or multifactorial\nmechanisms, such as sarcoidosis-associated PH.\n12. Deﬁnition of a pulmonary\nhypertension centre\nWhile PH is not an uncommon condition, severe forms of PH, es-\npecially PAH and CTEPH, require highly specialized management.\nSince medical centres with multidisciplinary teams and a high vol-\nume of patients generally offer best standard of care, which trans-\nlates into better clinical outcomes, establishing PH centres is\nclinically and economically highly desirable and is supported by\npatient organizations and scientiﬁc societies. The purpose of a\nPH centre is to: receive new referrals; assess and investigate the\ncause of PH; carefully phenotype and routinely manage patients\nwith medical, interventional, and surgical approaches; work closely\nwith other health care providers to achieve the best outcomes for\npatients; undertake audits (reporting patient case mix and quality\nindicators); and be involved in clinical and translational research,\nand education. The requirements—comprising deﬁnition, multi-\ndisciplinary structure, number of cases, procedures, and stafﬁng le-\nvels, as well as the skills and resources needed in a PH referral\ncentre—are described below and in Figure 16. Criteria for paediatric\nand CTEPH centres are described elsewhere (Sections 7.8.3 and 10.3,\nrespectively).\nCo-ordinated by a core MDT member responsible for the multidisciplinary approach\nCore MDT\nExtended MDT\nSocial worker\nStudy nurse\nPaediatric cardiologist\nPsychologist\nAdult CHD specialist\nLung pathologist\nHepatologist\nPhysiotherapist\nRheumatologist\nIntensive care specialist\nThoracic radiologist\nPalliative care specialist\nCardiac radiologist\nLung transplant\nphysician/surgeonc\nClinical geneticist/\nGenetic counsellorc\nAt least 2 PH nurses\nNurse specialist\nFor diagnostic pulmonary\nangiography, embolization\nInterventional\nradiologist/cardiologist\nCardiologist/Pneumologist\nAt least 2 surgeons\n(ECMO)\nCardiothoracic surgeon\nCase managerb\nResponsible for data \ncollection, analysis, and\norganization of audit meetings\nData manager\nMDT meeting\nRegular, to discuss multidisciplinary aspects of individual patient care\nPatient empowerment and advocacy\nClear verbal, and written information for patients that describes diagnostic procedures and treatment options;\nshared decision-making; collaboration with advocacy group\nInteraction with external healthcare providers and other relevant stakeholders\nGP, local specialist, social services, rehabilitation centres, national health services, labs,\ninsurers, school, work, sport club, psychologist, etc.\nQuality control/Audits\nData collection/registration; monitoring of quality indicators; regular internal audits\nResearch, training, and education\nInvolvement in clinical and translational research: teaching courses on local, national, or international basis\nPatient care pathway and clinical management protocol\nSteps from diagnosis to follow-up including advanced disease, palliative stage, and end of life\nAt least 2 PH specialists treating\na sufficient number of patientsa\nResponsible for the\nco-ordination of care\non patient level\nGynaecologist/\nObstetrician\nCardiothoracic \nanaesthetist\nProcesses\nPulmonary hypertension centre\nworking \u000250% on PH care \nFigure 16 Pulmonary hypertension centre schematic. CHD, congenital heart disease; ECMO, extracorporeal membrane oxygenation; GP, general\npractitioner; MDT, multidisciplinary team; PH, pulmonary hypertension. aNumber adapted according to speciﬁc country characteristics. bCase manager\ncan be a nurse specialist, social worker, physiotherapist, or administrative assistant in function of the centre organization. cCan be located in partner cen-\ntres. Adapted from Biganzoli et al.846\nESC/ERS Guidelines\n3701\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n12.1. Facilities and skills required for a\npulmonary hypertension centre\nPulmonary hypertension centres care for a sufﬁcient number of pa-\ntients on PH therapy, as well as new referrals, to warrant this status.\nAccording to the 2015 ESC/ERS Guidelines for the diagnosis and\ntreatment of PH and the European Reference Network on rare re-\nspiratory diseases (ERN-LUNG) competency requirements, the\nideal number of patients seen by an adult centre each year is no few-\ner than 200, of which at least half have a ﬁnal diagnosis of PAH; a PH\ncentre follows at least 50 patients with PAH or CTEPH and receives\nat least two new referrals per month with documented PAH or\nCTEPH.25,26,837–839 These numbers can be adapted according to\nspeciﬁc country characteristics (small population, large geographical\narea) provided that strong working collaborations are established\nwith high-volume centres. This is currently facilitated by the availabil-\nity of secure virtual platforms (e.g. ERN clinical patient management\nsystem).840\nProper training of staff members includes core competencies, such\nas those outlined in the ERS Pulmonary Vascular Diseases Continuing\nProfessional Development framework,841 and builds on entrustable\nprofessional activities, described in the ESC Core Curriculum.842\nClinical, laboratory, and imaging facilities include: a ward where\nhealth care providers have expertise in PH; a specialist outpatient\nservice; an intermediate/ICU; 24/7 emergency care; an interventional\nradiology unit; diagnostic investigations, including echocardiography,\nCT scanning, nuclear medicine, MRI, exercise tests, and PFTs; a car-\ndiac catheterization laboratory; access to genetic counselling and\ntesting; and fast and easy access to cardiothoracic and vascular sur-\ngery. Key diagnostic procedures are performed in sufﬁcient numbers\nto guarantee expertise (e.g. ERN-LUNG requirements).837 In ana-\nlogy with the ‘advanced heart failure units’,843 PH centres offer the\nfull range of PAH therapies available in their country (including i.v./\ns.c. prostacyclin derivatives) and have early referral protocols to\nCTEPH, LTx, and rehabilitation centres. Since evaluation and early\navailability of new drugs and techniques are critical, PH centres par-\nticipate in collaborative clinical research.\nRegular multidisciplinary team meetings, including core members\nand on-demand invited members (extended multidisciplinary team)\nas needed (Figure 16), are required to establish and adapt individual\npatient care pathways. Case management (co-ordination of individ-\nual patient pathways) should include administrative, social, and care\nsupport. Remote accessibility of the PH centre by phone, mail, or\nother is a vital part of the care. Strategies have to be implemented\nin order to improve health literacy and shared decision-making,\nwith the support of dedicated patient decision tools. Transitioning\nfrom a paediatric PH centre to an adult PH centre requires adequate\nplanning to prevent gaps in care. Involving national and/or inter-\nnational patient associations helps to design patient-centric care\nand to spread medical knowledge among patients and their carers.\nPulmonary hypertension centres should record patients’ data\nusing local, national, or international patient registries, and be able\nto report process indicators (compliance with diagnostic and treat-\nment guidelines, including LTx) and outcome indicators, such as\nWHO-FC, exercise capacity, haemodynamics, quality of life, compli-\ncations, and survival. They should undergo regular audits to assess\nthe quality of delivered care.\n12.2. European Reference Network\nIn 2017, the European Commission launched European Reference\nNetworks (ERNs) for rare diseases that included the ERN-LUNG\nwith a PH core network. European Reference Networks are patient-\ncentred networks of commissioned centres offering guidance and\ncross-border best standard of care in the European Union. The\nPH network includes over 20 full members, contributing each year\n≏1500 new patients with PAH or CTEPH.844 It also includes UK\nsupporting centres, and afﬁliated partners (who do not necessarily\nhave to fulﬁl the minimum competency criteria of the ERN-LUNG\nPH network). The ERN-LUNG requires and monitors standards\nfor these centres.\n12.3. Patient associations and patient\nempowerment\nPulmonary hypertension centres should inform patients about pa-\ntient associations and encourage them to join such groups. Patient\nassociations are a valuable resource for managing patients, as they\nprovide educational and emotional support, and can have positive ef-\nfects on coping, conﬁdence, and outlook.845 It is recommended that\nPH centres collaborate with patient associations on initiatives to\nRecommendation Table 25 — Recommendations for\npulmonary hypertension centres\nRecommendations\nClassa\nLevelb\nIt is recommended that PH centres provide care\nby a multidisciplinary team (cardiologist,\npneumologist, rheumatologist, nurse specialist,\nradiologist, psychological and social work support,\nand appropriate on-call expertise)\nI\nC\nIt is recommended that PH centres have direct\nlinks and quick referral patterns to other services\n(such as genetic counselling, PEA/BPA, LTx, and\nadult congenital heart disease service)\nI\nC\nIt is recommended that PH centres maintain a\npatient registry\nI\nC\nIt is recommended that PH centres collaborate\nwith patient associations\nI\nC\nAccreditation of the PH centres should be\nconsidered (e.g. https://ec.europa.eu/health/ern/\nassessment_en)\nIIa\nC\nPH centres’ participation in collaborative clinical\nresearch should be considered\nIIa\nC\nPH centres should follow-up a sufﬁcient number\nof patients to maintain expertise (at least 50\npatients with PAH or CTEPH and at least two\nnew referrals per month with documented PAH\nor CTEPH), and consider establishing\ncollaborations with high-volume centres\nIIa\nC\n© ESC/ERS 2022\nBPA, balloon pulmonary angioplasty; CTEPH, chronic thrombo-embolic pulmonary\nhypertension; LTx, lung transplantation; PAH, pulmonary arterial hypertension; PEA,\npulmonary endarterectomy; PH, pulmonary hypertension.\naClass of recommendation.\nbLevel of evidence.\n3702\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nempower patients and improve the patient experience, addressing\nissues such as health literacy, digital skills, healthy lifestyles, mental\nhealth, and self-management. Health care can be delivered more ef-\nfectively and efﬁciently if patients are full partners in the process.\n13. Key messages\n(1) The haemodynamic deﬁnition of PH has been updated as\nmPAP .20 mmHg. The deﬁnition of PAH also implies a PVR\n.2 WU and PAWP ≤15 mmHg. These cut-off values better\nreﬂect the limits of normal ranges, but do not yet translate\ninto new therapeutic recommendations, since the efﬁcacy of\nPAH therapy in patients with PVD and an mPAP 21–\n24 mmHg and/or PVR 2–3 WU is still unknown.\n(2) The main diagnostic algorithm for PH has been simpliﬁed fol-\nlowing a three-step approach, from suspicion by ﬁrst-line phy-\nsicians, detection by echocardiography, and conﬁrmation with\nRHC in PH centres. Warning signs associated with worse out-\ncomes have been identiﬁed, which justify immediate referral\nand management in PH centres.\n(3) Screening strategies for PAH in patients with SSc and in those at\nrisk of HPAH are proposed based on the results of published\ncohort studies. Their implementation may shorten the time\nfrom symptom onset to diagnosis of PAH.\n(4) An improved recognition of CT and echocardiographic signs of\nCTEPH at the time of an acute PE event, together with a sys-\ntematic follow-up of patients with acute PE, as indicated in\nthe 2019 ESC/ERS Guidelines for the diagnosis and manage-\nment of acute pulmonary embolism, should help to remediate\nthe underdiagnosis of CTEPH.\n(5) The three-strata risk-stratiﬁcation assessment in PAH has been\nreﬁned after being validated in multiple registries. The MRI and\nechocardiographic criteria have been added to the ESC/ERS ta-\nble, reﬁning non-invasive evaluation at diagnosis.\n(6) A four-strata risk stratiﬁcation, dividing the large, intermediate-risk\ngroup into intermediate–low and intermediate–high risk, is pro-\nposed at follow-up.\n(7) The treatment algorithm for PAH has been simpliﬁed, with a\nclear focus on risk assessment, cardiopulmonary comorbidities,\nand treatment goals. Initial combination therapy and treatment\nescalation at follow-up when appropriate are current standards.\n(8) The Task Force has attempted to close the gap between paedi-\natric and adult PAH care, with therapeutic and follow-up strat-\negies based on risk stratiﬁcation and treatment response,\nextrapolated from that in adults but adapted for age.\n(9) The recommendations on sex-related issues in patients with\nPAH, including pregnancy, have been updated, with information\nand shared decision-making as key points.\n(10) The recommendations for rehabilitation and exercise pro-\ngrammes in PH have been updated following the release of add-\nitional supportive evidence.\n(11) For the ﬁrst time, there is a recommendation for PH medical\ntherapy in group 3 PH, based on a single positive RCT in pa-\ntients with ILD.\n(12) The concept of CTEPD with or without PH has been intro-\nduced, enabling further research on the natural history and\nmanagement in the absence of PH.\n(13) The treatment algorithm for CTEPH has been modiﬁed, includ-\ning multimodal therapy with surgery, PH drugs, and BPA.\n14. Gaps in evidence\n14.1. Pulmonary arterial hypertension\n(group 1)\n• The efﬁcacy and safety of PAH drugs in group 1 patients with an\nmPAP 21–24 mmHg, PVR 2–3 WU, and exercise PH has to be\nestablished.\n• The role of PAH drugs in different PAH subgroups, including\nschistosomiasis-associated PAH, needs to be explored.\n• Risk-stratiﬁcation assessment in PAH needs to be further pro-\nspectively validated through goal-orientated outcome studies,\nand optimized for patients with PAH and comorbidities.\n• New PAH phenotypes observed in patients with signiﬁcant cardio-\npulmonary comorbidities are common and should be the focus of\nmore research.\n• The importance of PAH patient phenotypes and the relevance of\ncomorbidities on treatment goals and outcomes must be further\nevaluated.\n• The impact of PAH therapies and treatment strategies on survival\nneeds to be further assessed.\n• Pulmonary arterial hypertension drugs targeting novel pathways\nare emerging and the impact of add-on use of this medication\non outcomes has to be evaluated in RCTs.\n• The role of RV imaging techniques (echocardiography, cMRI) in\ndiagnosing and stratifying risk in PAH needs to be further studied.\nThe proposed cut-off values for risk stratiﬁcation need to be prop-\nerly validated in multicentre studies.\n• The role of CPET in the early diagnosis of PAH in populations at\nrisk of developing PAH, and in assessing prognosis in PAH on\ntop of clinical and haemodynamic data, needs further investigation.\n• The role of exercise echocardiography and exercise RHC in pa-\ntients at risk of developing PAH, with abnormal CPET but normal\nrest echocardiogram, also needs further evaluation.\n• The use of mechanical circulatory support, particularly in revers-\nible PH or in patients with advanced right HF with an exit strategy\n(such as LTx), has to be further studied.\n• Differences in natural history and treatment response between\nadults and children should be further investigated.\n• Further studies are needed on the effects of PADN in PAH and in\nother PH groups.\n• The impact of centre volume, organization, and expertise on treat-\nment outcome needs further investigation.\n14.2. Pulmonary hypertension associated\nwith left heart disease (group 2)\n• The management of patients with group 2 PH needs further study\nwith RCTs.\n• Additional research is needed to facilitate non-invasive diagnosis of\nHFpEF-associated PH and distinguishing it from PAH.\n• The role of ﬂuid challenge and exercise testing to reveal left HF\nneeds further validation.\nESC/ERS Guidelines\n3703\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 85",
          "page": 85,
          "content": "Recommendations | Classa | Levelb\nIt is recommended that PH centres provide care\nby a multidisciplinary team (cardiologist,\npneumologist, rheumatologist, nurse specialist,\nradiologist, psychological and social work support,\nand appropriate on-call expertise) | I | C\nIt is recommended that PH centres have direct\nlinks and quick referral patterns to other services\n(such as genetic counselling, PEA/BPA, LTx, and\nadult congenital heart disease service) | I | C\nIt is recommended that PH centres maintain a\npatient registry | I | C\nIt is recommended that PH centres collaborate\nwith patient associations | I | C\nAccreditation of the PH centres should be\nconsidered (e.g. https://ec.europa.eu/health/ern/\nassessment en)\n_ | IIa | C\nPH centres’ participation in collaborative clinical\nresearch should be considered | IIa | C\nPH centres should follow-up a sufficient number\nof patients to maintain expertise (at least 50\npatients with PAH or CTEPH and at least two\nnew referrals per month with documented PAH\nor CTEPH), and consider establishing\ncollaborations with high-volume centres | IIa | C",
          "rows": 8,
          "cols": 3
        }
      ],
      "keywords": [
        "intervention",
        "ct",
        "definition",
        "monitoring",
        "hypertension",
        "centre",
        "severe",
        "pulmonary",
        "treatment",
        "pulmonary hypertension"
      ]
    },
    {
      "number": "15",
      "title": "13. Key messages",
      "start_page": 86,
      "end_page": 86,
      "content": "empower patients and improve the patient experience, addressing\nissues such as health literacy, digital skills, healthy lifestyles, mental\nhealth, and self-management. Health care can be delivered more ef-\nfectively and efﬁciently if patients are full partners in the process.\n13. Key messages\n(1) The haemodynamic deﬁnition of PH has been updated as\nmPAP .20 mmHg. The deﬁnition of PAH also implies a PVR\n.2 WU and PAWP ≤15 mmHg. These cut-off values better\nreﬂect the limits of normal ranges, but do not yet translate\ninto new therapeutic recommendations, since the efﬁcacy of\nPAH therapy in patients with PVD and an mPAP 21–\n24 mmHg and/or PVR 2–3 WU is still unknown.\n(2) The main diagnostic algorithm for PH has been simpliﬁed fol-\nlowing a three-step approach, from suspicion by ﬁrst-line phy-\nsicians, detection by echocardiography, and conﬁrmation with\nRHC in PH centres. Warning signs associated with worse out-\ncomes have been identiﬁed, which justify immediate referral\nand management in PH centres.\n(3) Screening strategies for PAH in patients with SSc and in those at\nrisk of HPAH are proposed based on the results of published\ncohort studies. Their implementation may shorten the time\nfrom symptom onset to diagnosis of PAH.\n(4) An improved recognition of CT and echocardiographic signs of\nCTEPH at the time of an acute PE event, together with a sys-\ntematic follow-up of patients with acute PE, as indicated in\nthe 2019 ESC/ERS Guidelines for the diagnosis and manage-\nment of acute pulmonary embolism, should help to remediate\nthe underdiagnosis of CTEPH.\n(5) The three-strata risk-stratiﬁcation assessment in PAH has been\nreﬁned after being validated in multiple registries. The MRI and\nechocardiographic criteria have been added to the ESC/ERS ta-\nble, reﬁning non-invasive evaluation at diagnosis.\n(6) A four-strata risk stratiﬁcation, dividing the large, intermediate-risk\ngroup into intermediate–low and intermediate–high risk, is pro-\nposed at follow-up.\n(7) The treatment algorithm for PAH has been simpliﬁed, with a\nclear focus on risk assessment, cardiopulmonary comorbidities,\nand treatment goals. Initial combination therapy and treatment\nescalation at follow-up when appropriate are current standards.\n(8) The Task Force has attempted to close the gap between paedi-\natric and adult PAH care, with therapeutic and follow-up strat-\negies based on risk stratiﬁcation and treatment response,\nextrapolated from that in adults but adapted for age.\n(9) The recommendations on sex-related issues in patients with\nPAH, including pregnancy, have been updated, with information\nand shared decision-making as key points.\n(10) The recommendations for rehabilitation and exercise pro-\ngrammes in PH have been updated following the release of add-\nitional supportive evidence.\n(11) For the ﬁrst time, there is a recommendation for PH medical\ntherapy in group 3 PH, based on a single positive RCT in pa-\ntients with ILD.\n(12) The concept of CTEPD with or without PH has been intro-\nduced, enabling further research on the natural history and\nmanagement in the absence of PH.\n(13) The treatment algorithm for CTEPH has been modiﬁed, includ-\ning multimodal therapy with surgery, PH drugs, and BPA.\n14. Gaps in evidence\n14.1. Pulmonary arterial hypertension\n(group 1)\n• The efﬁcacy and safety of PAH drugs in group 1 patients with an\nmPAP 21–24 mmHg, PVR 2–3 WU, and exercise PH has to be\nestablished.\n• The role of PAH drugs in different PAH subgroups, including\nschistosomiasis-associated PAH, needs to be explored.\n• Risk-stratiﬁcation assessment in PAH needs to be further pro-\nspectively validated through goal-orientated outcome studies,\nand optimized for patients with PAH and comorbidities.\n• New PAH phenotypes observed in patients with signiﬁcant cardio-\npulmonary comorbidities are common and should be the focus of\nmore research.\n• The importance of PAH patient phenotypes and the relevance of\ncomorbidities on treatment goals and outcomes must be further\nevaluated.\n• The impact of PAH therapies and treatment strategies on survival\nneeds to be further assessed.\n• Pulmonary arterial hypertension drugs targeting novel pathways\nare emerging and the impact of add-on use of this medication\non outcomes has to be evaluated in RCTs.\n• The role of RV imaging techniques (echocardiography, cMRI) in\ndiagnosing and stratifying risk in PAH needs to be further studied.\nThe proposed cut-off values for risk stratiﬁcation need to be prop-\nerly validated in multicentre studies.\n• The role of CPET in the early diagnosis of PAH in populations at\nrisk of developing PAH, and in assessing prognosis in PAH on\ntop of clinical and haemodynamic data, needs further investigation.\n• The role of exercise echocardiography and exercise RHC in pa-\ntients at risk of developing PAH, with abnormal CPET but normal\nrest echocardiogram, also needs further evaluation.\n• The use of mechanical circulatory support, particularly in revers-\nible PH or in patients with advanced right HF with an exit strategy\n(such as LTx), has to be further studied.\n• Differences in natural history and treatment response between\nadults and children should be further investigated.\n• Further studies are needed on the effects of PADN in PAH and in\nother PH groups.\n• The impact of centre volume, organization, and expertise on treat-\nment outcome needs further investigation.\n14.2. Pulmonary hypertension associated\nwith left heart disease (group 2)\n• The management of patients with group 2 PH needs further study\nwith RCTs.\n• Additional research is needed to facilitate non-invasive diagnosis of\nHFpEF-associated PH and distinguishing it from PAH.\n• The role of ﬂuid challenge and exercise testing to reveal left HF\nneeds further validation.\nESC/ERS Guidelines\n3703\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "echocardiography",
        "ct",
        "echo",
        "messages",
        "follow-up",
        "risk",
        "mri",
        "treatment",
        "diagnosis",
        "recommendation"
      ]
    },
    {
      "number": "16",
      "title": "14. Gaps in evidence",
      "start_page": 86,
      "end_page": 87,
      "content": "empower patients and improve the patient experience, addressing\nissues such as health literacy, digital skills, healthy lifestyles, mental\nhealth, and self-management. Health care can be delivered more ef-\nfectively and efﬁciently if patients are full partners in the process.\n13. Key messages\n(1) The haemodynamic deﬁnition of PH has been updated as\nmPAP .20 mmHg. The deﬁnition of PAH also implies a PVR\n.2 WU and PAWP ≤15 mmHg. These cut-off values better\nreﬂect the limits of normal ranges, but do not yet translate\ninto new therapeutic recommendations, since the efﬁcacy of\nPAH therapy in patients with PVD and an mPAP 21–\n24 mmHg and/or PVR 2–3 WU is still unknown.\n(2) The main diagnostic algorithm for PH has been simpliﬁed fol-\nlowing a three-step approach, from suspicion by ﬁrst-line phy-\nsicians, detection by echocardiography, and conﬁrmation with\nRHC in PH centres. Warning signs associated with worse out-\ncomes have been identiﬁed, which justify immediate referral\nand management in PH centres.\n(3) Screening strategies for PAH in patients with SSc and in those at\nrisk of HPAH are proposed based on the results of published\ncohort studies. Their implementation may shorten the time\nfrom symptom onset to diagnosis of PAH.\n(4) An improved recognition of CT and echocardiographic signs of\nCTEPH at the time of an acute PE event, together with a sys-\ntematic follow-up of patients with acute PE, as indicated in\nthe 2019 ESC/ERS Guidelines for the diagnosis and manage-\nment of acute pulmonary embolism, should help to remediate\nthe underdiagnosis of CTEPH.\n(5) The three-strata risk-stratiﬁcation assessment in PAH has been\nreﬁned after being validated in multiple registries. The MRI and\nechocardiographic criteria have been added to the ESC/ERS ta-\nble, reﬁning non-invasive evaluation at diagnosis.\n(6) A four-strata risk stratiﬁcation, dividing the large, intermediate-risk\ngroup into intermediate–low and intermediate–high risk, is pro-\nposed at follow-up.\n(7) The treatment algorithm for PAH has been simpliﬁed, with a\nclear focus on risk assessment, cardiopulmonary comorbidities,\nand treatment goals. Initial combination therapy and treatment\nescalation at follow-up when appropriate are current standards.\n(8) The Task Force has attempted to close the gap between paedi-\natric and adult PAH care, with therapeutic and follow-up strat-\negies based on risk stratiﬁcation and treatment response,\nextrapolated from that in adults but adapted for age.\n(9) The recommendations on sex-related issues in patients with\nPAH, including pregnancy, have been updated, with information\nand shared decision-making as key points.\n(10) The recommendations for rehabilitation and exercise pro-\ngrammes in PH have been updated following the release of add-\nitional supportive evidence.\n(11) For the ﬁrst time, there is a recommendation for PH medical\ntherapy in group 3 PH, based on a single positive RCT in pa-\ntients with ILD.\n(12) The concept of CTEPD with or without PH has been intro-\nduced, enabling further research on the natural history and\nmanagement in the absence of PH.\n(13) The treatment algorithm for CTEPH has been modiﬁed, includ-\ning multimodal therapy with surgery, PH drugs, and BPA.\n14. Gaps in evidence\n14.1. Pulmonary arterial hypertension\n(group 1)\n• The efﬁcacy and safety of PAH drugs in group 1 patients with an\nmPAP 21–24 mmHg, PVR 2–3 WU, and exercise PH has to be\nestablished.\n• The role of PAH drugs in different PAH subgroups, including\nschistosomiasis-associated PAH, needs to be explored.\n• Risk-stratiﬁcation assessment in PAH needs to be further pro-\nspectively validated through goal-orientated outcome studies,\nand optimized for patients with PAH and comorbidities.\n• New PAH phenotypes observed in patients with signiﬁcant cardio-\npulmonary comorbidities are common and should be the focus of\nmore research.\n• The importance of PAH patient phenotypes and the relevance of\ncomorbidities on treatment goals and outcomes must be further\nevaluated.\n• The impact of PAH therapies and treatment strategies on survival\nneeds to be further assessed.\n• Pulmonary arterial hypertension drugs targeting novel pathways\nare emerging and the impact of add-on use of this medication\non outcomes has to be evaluated in RCTs.\n• The role of RV imaging techniques (echocardiography, cMRI) in\ndiagnosing and stratifying risk in PAH needs to be further studied.\nThe proposed cut-off values for risk stratiﬁcation need to be prop-\nerly validated in multicentre studies.\n• The role of CPET in the early diagnosis of PAH in populations at\nrisk of developing PAH, and in assessing prognosis in PAH on\ntop of clinical and haemodynamic data, needs further investigation.\n• The role of exercise echocardiography and exercise RHC in pa-\ntients at risk of developing PAH, with abnormal CPET but normal\nrest echocardiogram, also needs further evaluation.\n• The use of mechanical circulatory support, particularly in revers-\nible PH or in patients with advanced right HF with an exit strategy\n(such as LTx), has to be further studied.\n• Differences in natural history and treatment response between\nadults and children should be further investigated.\n• Further studies are needed on the effects of PADN in PAH and in\nother PH groups.\n• The impact of centre volume, organization, and expertise on treat-\nment outcome needs further investigation.\n14.2. Pulmonary hypertension associated\nwith left heart disease (group 2)\n• The management of patients with group 2 PH needs further study\nwith RCTs.\n• Additional research is needed to facilitate non-invasive diagnosis of\nHFpEF-associated PH and distinguishing it from PAH.\n• The role of ﬂuid challenge and exercise testing to reveal left HF\nneeds further validation.\nESC/ERS Guidelines\n3703\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n• Further studies focusing on PDE5is in patients with HFpEF and a\nCpcPH phenotype are needed and currently underway.\n• The effects that new HF medication (ARNIs, SGLT-2is) has on PH,\nthrough reverse remodelling of the LV, need further investigation.\n14.3. Pulmonary hypertension associated\nwith lung diseases and/or hypoxia\n(group 3)\n• The management of patients with group 3 PH has to be further\nstudied in RCTs.\n• Reﬁning phenotypes will be crucial, as this will inform development\nof trials.\n• Clinical relevance and therapeutic implications of severe PH in lung\ndisease need to be investigated.\n• Long-term data on the effects of inhaled treprostinil (and other\nPAH drugs) in patients with PH associated with lung disease are\nneeded.\n• The impact of the hypobaric and hypoxic environment of the .150\nmillion people living at .2500 m altitude has tobe clariﬁed, and studies\nneed to be performed to assess potential treatment strategies for PH.\n14.4. Chronic thrombo-embolic\npulmonary hypertension (group 4)\n• The differentiation between acute and chronic PE in imaging\n(CTPA) has to be improved.\n• In patients with suspected CTEPH, the diagnostic role of DECT or\niodine subtraction mapping vs. V/Q lung scintigraphy has to be\nvalidated.\n• The effect of drug therapy on the outcome of patients with\nCTEPH needs to be established.\n• The treatment goals in patients with CTEPH have to be clariﬁed, as\nit is still unclear if normalizing mPAP and PVR translates into im-\nproved outcomes.\n• The role of BPA vs. PEA should be further clariﬁed: which treat-\nment in which patient? Are they equivalent for the treatment of\nsegmental/subsegmental disease?\n• In inoperable CTEPH or persistent/recurrent PH after PEA, the\npotential role of combination therapy of PH drugs must be\nassessed.\n• The role of medical treatments as bridges to interventional and op-\nerative treatments needs to be formally tested.\n• Randomized controlled trials are needed to discriminate the ef-\nfects of PEA and early follow-up rehabilitation.\n• The effect of PEA, BPA, and medical therapy on patients with\nCTEPD without PH is not established.\n14.5. Pulmonary hypertension with\nunclear and/or multifactorial\nmechanisms (group 5)\n• Further research needs to inform management of group 5 PH,\nsuch as SCD-associated PH and sarcoidosis-associated PH.\n15. ‘What to do’ and ‘What not to do’ messages from the Guidelines\nRecommendations\nClassa\nLevelb\nRecommendations for right heart catheterization and vasoreactivity testing\nRight heart catheterization\nIt is recommended that RHC is performed to conﬁrm the diagnosis of PH (especially PAH or CTEPH) and to support treatment\ndecisions\nI\nB\nIn patients with suspected or known PH, it is recommended that RHC is performed in experienced centres\nI\nC\nIt is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols\nI\nC\nVasoreactivity testing\nVasoreactivity testing is recommended in patients with I/H/DPAH to detect those who can be treated with high doses of a CCB\nI\nB\nIt is recommended that vasoreactivity testing is performed at PH centres\nI\nC\nIt is recommended to consider a positive response to vasoreactivity testing by a reduction in mPAP ≥10 mmHg to reach an absolute\nvalue of mPAP ≤40 mmHg with an increased or unchanged COc\nI\nC\nInhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol are recommended for performing vasoreactivity testing\nI\nC\nVasoreactivity testing, for identifying candidates for CCB therapy, is not recommended in patients with PAH other than I/H/DPAH and\nin PH groups 2, 3, 4, and 5\nIII\nC\nContinued\n3704\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 87",
          "page": 87,
          "content": "Recommendations |  | Classa | Levelb | \nRecommendations for right heart catheterization and vasoreactivity testing |  |  |  | \nRight heart catheterization |  |  |  | \nIt is recommended that RHC is performed to confirm the diagnosis of PH (especially PAH or CTEPH) and to support treatment\ndecisions |  | I | B | \nIn patients with suspected or known PH, it is recommended that RHC is performed in experienced centres |  | I | C | \nIt is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols |  | I | C | \n | Vasoreactivity testing |  |  | \nVasoreactivity testing is recommended in patients with I/H/DPAH to detect those who can be treated with high doses of a CCB |  | I | B | \nIt is recommended that vasoreactivity testing is performed at PH centres |  | I | C | \nIt is recommended to consider a positive response to vasoreactivity testing by a reduction in mPAP ≥10 mmHg to reach an absolute\nvalue of mPAP ≤40 mmHg with an increased or unchanged COc |  | I | C | \nInhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol are recommended for performing vasoreactivity testing |  | I | C | \nVasoreactivity testing, for identifying candidates for CCB therapy, is not recommended in patients with PAH other than I/H/DPAH and\nin PH groups 2, 3, 4, and 5 |  | III | C | ",
          "rows": 12,
          "cols": 5
        }
      ],
      "keywords": [
        "echocardiography",
        "ct",
        "echo",
        "follow-up",
        "gaps",
        "risk",
        "mri",
        "evidence",
        "treatment",
        "diagnosis",
        "recommendation"
      ]
    },
    {
      "number": "17",
      "title": "15. ‘What to do’ and ‘What not to do’ messages from the Guidelines",
      "start_page": 87,
      "end_page": 93,
      "content": "• Further studies focusing on PDE5is in patients with HFpEF and a\nCpcPH phenotype are needed and currently underway.\n• The effects that new HF medication (ARNIs, SGLT-2is) has on PH,\nthrough reverse remodelling of the LV, need further investigation.\n14.3. Pulmonary hypertension associated\nwith lung diseases and/or hypoxia\n(group 3)\n• The management of patients with group 3 PH has to be further\nstudied in RCTs.\n• Reﬁning phenotypes will be crucial, as this will inform development\nof trials.\n• Clinical relevance and therapeutic implications of severe PH in lung\ndisease need to be investigated.\n• Long-term data on the effects of inhaled treprostinil (and other\nPAH drugs) in patients with PH associated with lung disease are\nneeded.\n• The impact of the hypobaric and hypoxic environment of the .150\nmillion people living at .2500 m altitude has tobe clariﬁed, and studies\nneed to be performed to assess potential treatment strategies for PH.\n14.4. Chronic thrombo-embolic\npulmonary hypertension (group 4)\n• The differentiation between acute and chronic PE in imaging\n(CTPA) has to be improved.\n• In patients with suspected CTEPH, the diagnostic role of DECT or\niodine subtraction mapping vs. V/Q lung scintigraphy has to be\nvalidated.\n• The effect of drug therapy on the outcome of patients with\nCTEPH needs to be established.\n• The treatment goals in patients with CTEPH have to be clariﬁed, as\nit is still unclear if normalizing mPAP and PVR translates into im-\nproved outcomes.\n• The role of BPA vs. PEA should be further clariﬁed: which treat-\nment in which patient? Are they equivalent for the treatment of\nsegmental/subsegmental disease?\n• In inoperable CTEPH or persistent/recurrent PH after PEA, the\npotential role of combination therapy of PH drugs must be\nassessed.\n• The role of medical treatments as bridges to interventional and op-\nerative treatments needs to be formally tested.\n• Randomized controlled trials are needed to discriminate the ef-\nfects of PEA and early follow-up rehabilitation.\n• The effect of PEA, BPA, and medical therapy on patients with\nCTEPD without PH is not established.\n14.5. Pulmonary hypertension with\nunclear and/or multifactorial\nmechanisms (group 5)\n• Further research needs to inform management of group 5 PH,\nsuch as SCD-associated PH and sarcoidosis-associated PH.\n15. ‘What to do’ and ‘What not to do’ messages from the Guidelines\nRecommendations\nClassa\nLevelb\nRecommendations for right heart catheterization and vasoreactivity testing\nRight heart catheterization\nIt is recommended that RHC is performed to conﬁrm the diagnosis of PH (especially PAH or CTEPH) and to support treatment\ndecisions\nI\nB\nIn patients with suspected or known PH, it is recommended that RHC is performed in experienced centres\nI\nC\nIt is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols\nI\nC\nVasoreactivity testing\nVasoreactivity testing is recommended in patients with I/H/DPAH to detect those who can be treated with high doses of a CCB\nI\nB\nIt is recommended that vasoreactivity testing is performed at PH centres\nI\nC\nIt is recommended to consider a positive response to vasoreactivity testing by a reduction in mPAP ≥10 mmHg to reach an absolute\nvalue of mPAP ≤40 mmHg with an increased or unchanged COc\nI\nC\nInhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol are recommended for performing vasoreactivity testing\nI\nC\nVasoreactivity testing, for identifying candidates for CCB therapy, is not recommended in patients with PAH other than I/H/DPAH and\nin PH groups 2, 3, 4, and 5\nIII\nC\nContinued\n3704\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nRecommendations for diagnostic strategy\nEchocardiography\nEchocardiography is recommended as the ﬁrst-line, non-invasive, diagnostic investigation in suspected PH\nI\nB\nIt is recommended to assign an echocardiographic probability of PH, based on an abnormal TRV and the presence of other\nechocardiographic signs suggestive of PH (see Table 10)\nI\nB\nIt is recommended to maintain the current threshold for TRV (.2.8 m/s) for echocardiographic probability of PH according to the\nupdated haemodynamic deﬁnition\nI\nC\nImaging\nVentilation/perfusion or perfusion lung scan is recommended in patients with unexplained PH to assess for CTEPH\nI\nC\nCT pulmonary angiography is recommended in the work-up of patients with suspected CTEPH\nI\nC\nRoutine biochemistry, haematology, immunology, HIV testing, and thyroid function tests are recommended in all patients with PAH, to\nidentify associated conditions\nI\nC\nAbdominal ultrasound is recommended for the screening of portal hypertension\nI\nC\nOther diagnostic tests\nPulmonary function tests with DLCO are recommended in the initial evaluation of patients with PH\nI\nC\nOpen or thoracoscopic lung biopsy is not recommended in patients with PAH\nIII\nC\nRecommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic\npulmonary hypertension\nSystemic sclerosis\nIn patients with SSc, an annual evaluation of the risk of having PAH is recommended\nI\nB\nIn adult patients with SSc with .3 years’ disease duration, an FVC ≥40%, and a DLCO ,60%, the DETECT algorithm is recommended\nto identify asymptomatic patients with PAH\nI\nB\nIn patients with SSc, where breathlessness remains unexplained following non-invasive assessment, RHC is recommended to exclude\nPAH\nI\nC\nCTEPH/CTEPD\nIn patients with persistent or new-onset dyspnoea or exercise limitation following PE, further diagnostic evaluation to assess for\nCTEPH/CTEPD is recommended\nI\nC\nFor symptomatic patients with mismatched perfusion lung defects beyond 3 months of anticoagulation for acute PE, referral to a PH/\nCTEPH centre is recommended after considering the results of echocardiography, BNP/NT-proBNP, and/or CPET\nI\nC\nOther\nCounselling regarding the risk of PAH and annual screening are recommended in individuals who test positive for PAH-causing\nmutations and in ﬁrst-degree relatives of patients with HPAH\nI\nB\nIn patients referred for liver transplantation, echocardiography is recommended as a screening test for PH\nI\nC\nRecommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension\nIt is recommended to evaluate disease severity in patients with PAH with a panel of data derived from clinical assessment, exercise tests,\nbiochemical markers, echocardiography, and haemodynamic evaluations\nI\nB\nAchieving and maintaining a low-risk proﬁle on optimized medical therapy is recommended as a treatment goal in patients with PAH\nI\nB\nFor risk stratiﬁcation at the time of diagnosis, the use of a three-strata model (low, intermediate, and high risk) is recommended, taking\ninto account all available data including haemodynamics\nI\nB\nFor risk stratiﬁcation during follow-up, the use of a four-strata model (low, intermediate–low, intermediate–high, and high risk) based on\nWHO-FC, 6MWD, and BNP/NT-proBNP is recommended, with additional variables taken into account as necessary\nI\nB\nContinued\nESC/ERS Guidelines\n3705\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nRecommendations for general measures and special circumstances\nGeneral measures\nSupervised exercise training is recommended in patients with PAH under medical therapy\nI\nA\nPsychosocial support is recommended in patients with PAH\nI\nC\nImmunization of patients with PAH against SARS-CoV-2, inﬂuenza, and Streptococcus pneumoniae is recommended\nI\nC\nDiuretic treatment is recommended in patients with PAH with signs of RV failure and ﬂuid retention\nI\nC\nLong-term oxygen therapy is recommended in patients with PAH whose arterial blood oxygen pressure is ,8 kPa (60 mmHg)d\nI\nC\nIn the presence of iron-deﬁciency anaemia, correction of iron status is recommended in patients with PAH\nI\nC\nThe use of ACEis, ARBs, ARNIs, SGLT-2is, beta-blockers, or ivabradine is not recommended in patients with PAH unless required by\ncomorbidities (i.e. high blood pressure, coronary artery disease, left HF, or arrhythmias)\nIII\nC\nSpecial circumstances\nIn-ﬂight oxygen administration is recommended for patients using oxygen or whose arterial blood oxygen pressure is ,8 kPa\n(60 mmHg) at sea level\nI\nC\nRecommendations for women of childbearing potential\nIt is recommended that women of childbearing potential with PAH are counselled at the time of diagnosis about the risks and\nuncertainties associated with becoming pregnant; this should include advice against becoming pregnant, and referral for psychological\nsupport where needed\nI\nC\nIt is recommended to provide women of childbearing potential with PAH with clear contraceptive advice, considering the individual\nneeds of the woman but recognizing that the implications of contraceptive failure are signiﬁcant in PAH\nI\nC\nIt is recommended that women with PAH who consider pregnancy or who become pregnant receive prompt counselling in an\nexperienced PH centre, to facilitate genetic counselling and shared decision-making, and to provide psychological support to the patients\nand their families where needed\nI\nC\nFor women with PAH having termination of pregnancy, it is recommended that this be performed in PH centres, with psychological\nsupport provided to the patients and their families\nI\nC\nAs teratogenic potential has been reported in pre-clinical models for endothelin receptor antagonists and riociguat, these drugs are not\nrecommended during pregnancy\nIII\nB\nRecommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial\nhypertension\nHigh doses of CCBs are recommended in patients with IPAH, HPAH, or DPAH who are responders to acute vasoreactivity testing\nI\nC\nClose follow-up with complete reassessment after 3–4 months of therapy (including RHC) is recommended in patients with IPAH,\nHPAH, or DPAH treated with high doses of CCBs\nI\nC\nContinuing high doses of CCBs is recommended in patients with IPAH, HPAH, or DPAH in WHO-FC I or II with marked\nhaemodynamic improvement (mPAP ,30 mmHg and PVR ,4 WU)\nI\nC\nInitiating PAH therapy is recommended in patients who remain in WHO-FC III or IV or those without marked haemodynamic\nimprovement after high doses of CCBs\nI\nC\nCCBs are not recommended in patients without a vasoreactivity study or non-responders, unless prescribed for other indications (e.g.\nRaynaud’s phenomenon)\nIII\nC\nRecommendations for initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary\narterial hypertension without cardiopulmonary comorbiditiese\nInitial combination therapy with ambrisentan and tadalaﬁl is recommended\nI\nB\nInitial combination therapy with macitentan and tadalaﬁl is recommended\nI\nB\nInitial combination therapy with macitentan, tadalaﬁl, and selexipag is not recommended\nIII\nB\nContinued\n3706\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nRecommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary\narterial hypertension\nGeneral recommendation for sequential combination therapy\nIt is recommended to base treatment escalations on risk assessment and general treatment strategies (see treatment algorithm)\nI\nC\nEvidence from studies with a composite morbidity/mortality endpoint as the primary outcome measure\nThe addition of macitentan to PDE5is or oral/inhaled prostacyclin analogues is recommended to reduce the risk of morbidity/mortality\nevents\nI\nB\nThe addition of selexipag to ERAsf and/or PDE5is is recommended to reduce the risk of morbidity/mortality events\nI\nB\nThe addition of oral treprostinil to ERA or PDE5i/riociguat monotherapy is recommended to reduce the risk of morbidity/mortality\nevents\nI\nB\nThe addition of bosentan to sildenaﬁl is not recommended to reduce the risk of morbidity/mortality events\nIII\nB\nEvidence from studies with change in 6MWD as the primary outcome measure\nThe addition of sildenaﬁl to epoprostenol is recommended to improve exercise capacity\nI\nB\nEvidence from studies with safety of combination therapy as primary outcome measure\nCombining riociguat and PDE5is is not recommendedg\nIII\nB\nRecommendations for intensive care management for pulmonary arterial hypertension\nWhen managing patients with right HF in the ICU, it is recommended to involve physicians with expertise, treat causative factors, and\nuse supportive measures, including inotropes and vasopressors, ﬂuid management, and PAH drugs, as appropriate\nI\nC\nRecommendations for lung transplantation\nIt is recommended that potentially eligible candidates are referred for LTx evaluation when they have an inadequate response to oral\ncombination therapy, indicated by an intermediate–high or high risk or by a REVEAL risk score .7\nI\nC\nIt is recommended to list patients for LTx who present with a high risk of death or with a REVEAL risk score ≥10 despite receiving\noptimized medical therapy including s.c. or i.v. prostacyclin analogues\nI\nC\nRecommendations for pulmonary arterial hypertension associated with drugs or toxins\nIt is recommended to make a diagnosis of drug- or toxin-associated PAH in patients who had relevant exposure and in whom other\ncauses of PH have been excluded\nI\nC\nIn patients with suspected drug- or toxin-associated PAH, it is recommended to immediately discontinue the causative agent whenever\npossible\nI\nC\nRecommendations for pulmonary arterial hypertension associated with connective tissue disease\nIn patients with PAH associated with CTD, treatment of the underlying condition according to current guidelines is recommended\nI\nA\nIn patients with PAH associated with CTD, the same treatment algorithm as for patients with IPAH is recommended\nI\nC\nRecommendations for pulmonary arterial hypertension associated with human immunodeﬁciency virus infection\nIn patients with PAH associated with HIV infection, antiretroviral treatment according to current guidelines is recommended\nI\nA\nRecommendations for pulmonary arterial hypertension associated with portal hypertension\nEchocardiography is recommended in patients with liver disease or portal hypertension with signs or symptoms suggestive of PH, and as\na screening tool in patients evaluated for liver transplantation or transjugular portosystemic shunt\nI\nC\nIt is recommended that patients with PAH associated with portal hypertension are referred to centres with expertise in managing both\nconditions\nI\nC\nDrugs approved for PAH are not recommended for patients with portal hypertension and unclassiﬁed PH (i.e. elevated mPAP, high CO,\nand a normal PVR)\nIII\nC\nContinued\nESC/ERS Guidelines\n3707\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nRecommendations for shunt closure in patients with pulmonary-systemic ﬂow ratio .1.5:1 based on calculated pulmonary vascular\nresistance\nIn patients with an ASD, VSD, or PDA and a PVR ,3 WU, shunt closure is recommended\nI\nC\nIn patients with an ASD and a PVR .5 WU despite PAH treatment, shunt closure is not recommended\nIII\nC\nRecommendations for pulmonary arterial hypertension associated with adult congenital heart disease\nRisk assessment\nRisk assessment is recommended for patients with persistent PAH after defect closure\nI\nC\nTreatment\nBosentan is recommended in symptomatic patients with Eisenmenger syndrome to improve exercise capacity\nI\nB\nIn women with Eisenmenger syndrome, pregnancy is not recommended\nIII\nC\nIn patients with Eisenmenger syndrome, routine phlebotomy to lower elevated haematocrit is not recommended\nIII\nC\nRecommendations for pulmonary arterial hypertension with signs of venous/capillary involvement\nA combination of clinical and radiological ﬁndings, ABG, PFTs, and genetic testing is recommended to diagnose PAH with signs of venous\nand/or capillary involvement (PVOD/PCH)\nI\nA\nIdentiﬁcation of biallelic EIF2AK4 mutations is recommended to conﬁrm a diagnosis of heritable PVOD/PCH\nI\nA\nReferral of eligible patients with PVOD/PCH to a transplant centre for evaluation is recommended as soon as the diagnosis is established\nI\nC\nLung biopsy is not recommended to conﬁrm a diagnosis of PVOD/PCH\nIII\nC\nRecommendations for paediatric pulmonary hypertension\nChildren\nIt is recommended to perform the diagnostic work-up, including RHC and acute vasoreactivity testing, and treat children with PH at\ncentres with speciﬁc expertise in paediatric PH\nI\nC\nIn children with PH, a comprehensive work-up for conﬁrming diagnosis and speciﬁc aetiology is recommended (similar to that in adults,\nbut adapted for age)\nI\nC\nFor conﬁrming PH diagnosis, RHC is recommended, preferably before initiating any PAH therapy\nI\nC\nIn children with IPAH/HPAH, acute vasoreactivity testing is recommended to detect those who may beneﬁt from CCB therapy\nI\nC\nIt is recommended to similarly deﬁne a positive response to acute vasoreactivity testing in children and adults by a reduction in mPAP\n≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg, with an increased or unchanged CO\nI\nC\nIn children with PAH, a therapeutic strategy based on risk stratiﬁcation and treatment response is recommended, extrapolated from\nthat in adults, but adapted for age\nI\nC\nIt is recommended to monitor the treatment response in children with PAH by serially assessing a panel of data derived from clinical\nassessment, echocardiographic evaluation, biochemical markers, and exercise tolerance tests\nI\nC\nInfants\nIt is recommended to screen infants with bronchopulmonary dysplasia for PH\nI\nB\nIn infants with (or at risk of) bronchopulmonary dysplasia and PH, treating lung disease—including hypoxia, aspiration, and structural\nairway disease—and optimizing respiratory support is recommended before initiating PAH therapy\nI\nB\nRecommendations for pulmonary hypertension associated with left heart disease\nIn patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of\nsuspected PH\nI\nA\nRHC is recommended for suspected PH in patients with LHD, if it aids management decisions\nI\nC\nContinued\n3708\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nRHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair\nI\nC\nFor patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral\nto a PH centre for a complete diagnostic work-up is recommended\nI\nC\nIn patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is\nrecommended\nI\nC\nWhen patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or\nﬂuid challenge, are treated with PAH drugs, close monitoring is recommended\nI\nC\nDrugs approved for PAH are not recommended in PH-LHDh\nIII\nA\nRecommendations for pulmonary hypertension associated with lung disease and/or hypoxia\nIf PH is suspected in patients with lung disease, it is recommended that echocardiographyi be performed and results interpreted in\nconjunction with ABG, PFTs including DLCO, and CT imaging\nI\nC\nIn patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where\nindicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation\nI\nC\nIn patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH\ncentre is recommendedj\nI\nC\nIn patients with lung disease and severe PH, an individualized approach to treatment is recommended\nI\nC\nIt is recommended to refer eligible patients with lung disease and PH for LTx evaluation\nI\nC\nIn patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions\nI\nC\nThe use of ambrisentan is not recommended in patients with PH associated with IPF\nIII\nB\nThe use of riociguat is not recommended in patients with PH associated with IIP\nIII\nB\nThe use of PAH medication is not recommended in patients with lung disease and non-severe PHk\nIII\nC\nRecommendations for chronic thrombo-embolic pulmonary hypertension and chronic thrombo-embolic pulmonary disease without\npulmonary hypertension\nCTEPH\nLifelong, therapeutic doses of anticoagulation are recommended in all patients with CTEPH\nI\nC\nAntiphospholipid syndrome testing is recommended in patients with CTEPH\nI\nC\nIn patients with CTEPH and antiphospholipid syndrome, anticoagulation with VKAs is recommended\nI\nC\nIt is recommended that all patients with CTEPH are reviewed by a CTEPH team for the assessment of multimodality management\nI\nC\nPEA is recommended as the treatment of choice for patients with CTEPH and ﬁbrotic obstructions within pulmonary arteries accessible\nby surgery\nI\nB\nBPA is recommended in patients who are technically inoperable or have residual PH after PEA and distal obstructions amenable to BPA\nI\nB\nRiociguat is recommended for symptomatic patients with inoperable CTEPH or persistent/recurrent PH after PEA\nI\nB\nLong-term follow-up is recommended after PEA and BPA, as well as for patients with CTEPH established on medical therapy\nI\nC\nRecommendations for pulmonary hypertension centres\nIt is recommended that PH centres provide care by a multidisciplinary team (cardiologist, pneumologist, rheumatologist, nurse specialist,\nradiologist, psychological and social work support, appropriate on-call expertise)\nI\nC\nIt is recommended that PH centres have direct links and quick referral patterns to other services (such as genetic counselling, PEA/BPA,\nLTx, adult congenital heart disease service)\nI\nC\nContinued\nESC/ERS Guidelines\n3709\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n16. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.847 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations through associated quality-improvement initia-\ntives and benchmarking of care providers.848,849 As such, the role\nof QIs in improving care and outcomes for cardiovascular disease\nis increasingly being recognized by health care authorities, profes-\nsional organizations, payers, and the public.847\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established\nmethods for developing the ESC QIs for the quantiﬁcation of care\nand outcomes for cardiovascular diseases.847 To date, the ESC has\ndeveloped QI suites for a number of cardiovascular diseases850–852\nand embedded these in respective ESC Clinical Practice guide-\nlines.27,477,853,854 Furthermore, the ESC aims to integrate its QIs\nwith clinical registries such as the EurObservational Research\nProgramme and the European Uniﬁed Registries On Heart Care\nEvaluation and Randomized Trials (EuroHeart) project855 to provide\nreal-world data about the patterns and outcomes of care for cardio-\nvascular disease across Europe.\nIn parallel with the writing of this Clinical Practice Guideline, a pro-\ncess has been initiated to develop QIs for patients with PH using the\nIt is recommended that PH centres maintain a patient registry\nI\nC\nIt is recommended that PH centres collaborate with patient associations\nI\nC\n© ESC/ERS 2022\n6MWD, 6-minute walking distance; ABG, arterial blood gas analysis; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–\nneprilysin inhibitor; ASD, atrial septal defect; BNP/NT-proBNP, brain natriuretic peptide/N-terminal pro-brain natriuretic peptide; BPA, balloon pulmonary angioplasty; CCB,\ncalcium channel blocker; CpcPH, combined post- and pre-capillary pulmonary hypertension; CPET, cardiopulmonary exercise testing; CT, computed tomography; CTD, connective\ntissue disease; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon\nmonoxide; DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; FVC, forced vital capacity; HF, heart failure; HFpEF, heart failure with\npreserved ejection fraction; HIV, human immunodeﬁciency virus; HPAH, heritable pulmonary arterial hypertension; ICU, intensive care unit; I/H/DPAH, idiopathic, heritable,\ndrug-associated pulmonary arterial hypertension; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic\npulmonary ﬁbrosis; i.v., intravenous; LHD, left heart disease; LTx, lung transplantation; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PAWP,\npulmonary arterial wedge pressure; PCH, pulmonary capillary haemangiomatosis; PDA, patent ductus arteriosus; PDE5i, phosphodiesterase 5 inhibitor; PE, pulmonary embolism;\nPEA, pulmonary endarterectomy; PFTs, pulmonary function tests; PH, pulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVOD,\npulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricular; s.c., subcutaneous; SGLT-2i, sodium–glucose\ncotransporter-2 inhibitor; SSc, systemic sclerosis; TRV, tricuspid regurgitation velocity; VKA, vitamin K antagonist; VSD, ventricular septal defect; WHO-FC, World Health\nOrganization functional class; WU, Wood units.\naClass of recommendation.\nbLevel of evidence.\ncTesting should also be performed in patients with a baseline mPAP ≤40 mmHg, in whom the same responder criteria apply.\ndMeasured on at least two occasions.\neCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF such as obesity, diabetes, coronary heart disease, a history of\nhypertension, and/or a low DLCO.\nfERA used in the GRIPHON study were bosentan and ambrisentan.\ngThe PATENT plus study investigated the combination of sildenaﬁl and riociguat; however, combining riociguat with any PDE5i is contraindicated.\nhSafety concerns have been identiﬁed when ERAs are used in patients with HF (HFpEF and HFrEF, with or without PH) and when sildenaﬁl is used in patients with persistent PH after\ncorrection of valvular heart disease.\niAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise pulmonary artery pressure.\njThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.\nkThis does not include inhaled treprostinil, which may be considered in patients with PH associated with ILD irrespective of PH severity.\n‘What to do’ and ‘What not to do’ messages developed with GRADE Evidence to Decision framework\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nIn patients with IPAH/HPAH/DPAH who present at low or intermediate risk of\ndeath, initial combination therapy with a PDE5i and an ERA is recommended\nLow\nConditional\nI\nB\nThe use of PDE5i in patients with HFpEF and isolated post-capillary PH is not\nrecommended\nLow\nConditional\nIII\nC\nThe use of PDE5i in patients with ILD and non-severe PH is not recommended\nVery low\nConditional\nIII\nC\n© ESC/ERS 2022\nDPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; HPAH, heritable pulmonary arterial hypertension; HFpEF, heart failure with preserved\nejection fraction; ILD, interstitial lung disease; PDE5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension.\naClass of recommendation.\nbLevel of evidence.\n3710\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 87",
          "page": 87,
          "content": "Recommendations |  | Classa | Levelb | \nRecommendations for right heart catheterization and vasoreactivity testing |  |  |  | \nRight heart catheterization |  |  |  | \nIt is recommended that RHC is performed to confirm the diagnosis of PH (especially PAH or CTEPH) and to support treatment\ndecisions |  | I | B | \nIn patients with suspected or known PH, it is recommended that RHC is performed in experienced centres |  | I | C | \nIt is recommended that RHC comprises a complete set of haemodynamics and is performed following standardized protocols |  | I | C | \n | Vasoreactivity testing |  |  | \nVasoreactivity testing is recommended in patients with I/H/DPAH to detect those who can be treated with high doses of a CCB |  | I | B | \nIt is recommended that vasoreactivity testing is performed at PH centres |  | I | C | \nIt is recommended to consider a positive response to vasoreactivity testing by a reduction in mPAP ≥10 mmHg to reach an absolute\nvalue of mPAP ≤40 mmHg with an increased or unchanged COc |  | I | C | \nInhaled nitric oxide, inhaled iloprost, or i.v. epoprostenol are recommended for performing vasoreactivity testing |  | I | C | \nVasoreactivity testing, for identifying candidates for CCB therapy, is not recommended in patients with PAH other than I/H/DPAH and\nin PH groups 2, 3, 4, and 5 |  | III | C | ",
          "rows": 12,
          "cols": 5
        },
        {
          "title": "Table on page 88",
          "page": 88,
          "content": "Recommendations for diagnostic strategy |  |  |  | \nEchocardiography |  |  |  | \nEchocardiography is recommended as the first-line, non-invasive, diagnostic investigation in suspected PH |  | I | B | \nIt is recommended to assign an echocardiographic probability of PH, based on an abnormal TRV and the presence of other\nechocardiographic signs suggestive of PH (see Table 10) |  | I | B | \nIt is recommended to maintain the current threshold for TRV (.2.8 m/s) for echocardiographic probability of PH according to the\nupdated haemodynamic definition |  | I | C | \n | Imaging |  |  | \nVentilation/perfusion or perfusion lung scan is recommended in patients with unexplained PH to assess for CTEPH |  | I | C | \nCT pulmonary angiography is recommended in the work-up of patients with suspected CTEPH |  | I | C | \nRoutine biochemistry, haematology, immunology, HIV testing, and thyroid function tests are recommended in all patients with PAH, to\nidentify associated conditions |  | I | C | \nAbdominal ultrasound is recommended for the screening of portal hypertension |  | I | C | \n | Other diagnostic tests |  |  | \nPulmonary function tests with DLCO are recommended in the initial evaluation of patients with PH |  | I | C | \nOpen or thoracoscopic lung biopsy is not recommended in patients with PAH |  | III | C | \nRecommendations for screening and improved detection of pulmonary arterial hypertension and chronic thrombo-embolic\npulmonary hypertension |  |  |  | \n | Systemic sclerosis |  |  | \nIn patients with SSc, an annual evaluation of the risk of having PAH is recommended |  | I | B | \nIn adult patients with SSc with .3 years’ disease duration, an FVC ≥40%, and a DLCO ,60%, the DETECT algorithm is recommended\nto identify asymptomatic patients with PAH |  | I | B | \nIn patients with SSc, where breathlessness remains unexplained following non-invasive assessment, RHC is recommended to exclude\nPAH |  | I | C | \n | CTEPH/CTEPD |  |  | \nIn patients with persistent or new-onset dyspnoea or exercise limitation following PE, further diagnostic evaluation to assess for\nCTEPH/CTEPD is recommended |  | I | C | \nFor symptomatic patients with mismatched perfusion lung defects beyond 3 months of anticoagulation for acute PE, referral to a PH/\nCTEPH centre is recommended after considering the results of echocardiography, BNP/NT-proBNP, and/or CPET |  | I | C | \n | Other |  |  | \nCounselling regarding the risk of PAH and annual screening are recommended in individuals who test positive for PAH-causing\nmutations and in first-degree relatives of patients with HPAH |  | I | B | \nIn patients referred for liver transplantation, echocardiography is recommended as a screening test for PH |  | I | C | \n | Recommendations for evaluating the disease severity and risk of death in patients with pulmonary arterial hypertension |  |  | \nIt is recommended to evaluate disease severity in patients with PAH with a panel of data derived from clinical assessment, exercise tests,\nbiochemical markers, echocardiography, and haemodynamic evaluations |  | I | B | \nAchieving and maintaining a low-risk profile on optimized medical therapy is recommended as a treatment goal in patients with PAH |  | I | B | \nFor risk stratification at the time of diagnosis, the use of a three-strata model (low, intermediate, and high risk) is recommended, taking\ninto account all available data including haemodynamics |  | I | B | \nFor risk stratification during follow-up, the use of a four-strata model (low, intermediate–low, intermediate–high, and high risk) based on\nWHO-FC, 6MWD, and BNP/NT-proBNP is recommended, with additional variables taken into account as necessary |  | I | B | ",
          "rows": 29,
          "cols": 5
        },
        {
          "title": "Table on page 89",
          "page": 89,
          "content": "Recommendations for general measures and special circumstances |  |  |  | \nGeneral measures |  |  |  | \nSupervised exercise training is recommended in patients with PAH under medical therapy |  | I | A | \nPsychosocial support is recommended in patients with PAH |  | I | C | \nImmunization of patients with PAH against SARS-CoV-2, influenza, and Streptococcus pneumoniae is recommended |  | I | C | \nDiuretic treatment is recommended in patients with PAH with signs of RV failure and fluid retention |  | I | C | \nLong-term oxygen therapy is recommended in patients with PAH whose arterial blood oxygen pressure is ,8 kPa (60 mmHg)d |  | I | C | \nIn the presence of iron-deficiency anaemia, correction of iron status is recommended in patients with PAH |  | I | C | \nThe use of ACEis, ARBs, ARNIs, SGLT-2is, beta-blockers, or ivabradine is not recommended in patients with PAH unless required by\ncomorbidities (i.e. high blood pressure, coronary artery disease, left HF, or arrhythmias) |  | III | C | \n | Special circumstances |  |  | \nIn-flight oxygen administration is recommended for patients using oxygen or whose arterial blood oxygen pressure is ,8 kPa\n(60 mmHg) at sea level |  | I | C | \n | Recommendations for women of childbearing potential |  |  | \nIt is recommended that women of childbearing potential with PAH are counselled at the time of diagnosis about the risks and\nuncertainties associated with becoming pregnant; this should include advice against becoming pregnant, and referral for psychological\nsupport where needed |  | I | C | \nIt is recommended to provide women of childbearing potential with PAH with clear contraceptive advice, considering the individual\nneeds of the woman but recognizing that the implications of contraceptive failure are significant in PAH |  | I | C | \nIt is recommended that women with PAH who consider pregnancy or who become pregnant receive prompt counselling in an\nexperienced PH centre, to facilitate genetic counselling and shared decision-making, and to provide psychological support to the patients\nand their families where needed |  | I | C | \nFor women with PAH having termination of pregnancy, it is recommended that this be performed in PH centres, with psychological\nsupport provided to the patients and their families |  | I | C | \nAs teratogenic potential has been reported in pre-clinical models for endothelin receptor antagonists and riociguat, these drugs are not\nrecommended during pregnancy |  | III | B | \n | Recommendations for the treatment of vasoreactive patients with idiopathic, heritable, or drug-associated pulmonary arterial\nhypertension |  |  | \nHigh doses of CCBs are recommended in patients with IPAH, HPAH, or DPAH who are responders to acute vasoreactivity testing |  | I | C | \nClose follow-up with complete reassessment after 3–4 months of therapy (including RHC) is recommended in patients with IPAH,\nHPAH, or DPAH treated with high doses of CCBs |  | I | C | \nContinuing high doses of CCBs is recommended in patients with IPAH, HPAH, or DPAH in WHO-FC I or II with marked\nhaemodynamic improvement (mPAP ,30 mmHg and PVR ,4 WU) |  | I | C | \nInitiating PAH therapy is recommended in patients who remain in WHO-FC III or IV or those without marked haemodynamic\nimprovement after high doses of CCBs |  | I | C | \nCCBs are not recommended in patients without a vasoreactivity study or non-responders, unless prescribed for other indications (e.g.\nRaynaud’s phenomenon) |  | III | C | \n | Recommendations for initial oral drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary\narterial hypertension without cardiopulmonary comorbiditiese |  |  | \nInitial combination therapy with ambrisentan and tadalafil is recommended |  | I | B | \nInitial combination therapy with macitentan and tadalafil is recommended |  | I | B | \nInitial combination therapy with macitentan, tadalafil, and selexipag is not recommended |  | III | B | ",
          "rows": 27,
          "cols": 5
        },
        {
          "title": "Table on page 90",
          "page": 90,
          "content": "Recommendations for sequential drug combination therapy for patients with idiopathic, heritable, or drug-associated pulmonary\narterial hypertension |  |  |  | \nGeneral recommendation for sequential combination therapy |  |  |  | \nIt is recommended to base treatment escalations on risk assessment and general treatment strategies (see treatment algorithm) |  | I | C | \n | Evidence from studies with a composite morbidity/mortality endpoint as the primary outcome measure |  |  | \nThe addition of macitentan to PDE5is or oral/inhaled prostacyclin analogues is recommended to reduce the risk of morbidity/mortality\nevents |  | I | B | \nThe addition of selexipag to ERAsf and/or PDE5is is recommended to reduce the risk of morbidity/mortality events |  | I | B | \nThe addition of oral treprostinil to ERA or PDE5i/riociguat monotherapy is recommended to reduce the risk of morbidity/mortality\nevents |  | I | B | \nThe addition of bosentan to sildenafil is not recommended to reduce the risk of morbidity/mortality events |  | III | B | \n | Evidence from studies with change in 6MWD as the primary outcome measure |  |  | \nThe addition of sildenafil to epoprostenol is recommended to improve exercise capacity |  | I | B | \n | Evidence from studies with safety of combination therapy as primary outcome measure |  |  | \nCombining riociguat and PDE5is is not recommendedg |  | III | B | \n | Recommendations for intensive care management for pulmonary arterial hypertension |  |  | \nWhen managing patients with right HF in the ICU, it is recommended to involve physicians with expertise, treat causative factors, and\nuse supportive measures, including inotropes and vasopressors, fluid management, and PAH drugs, as appropriate |  | I | C | \n | Recommendations for lung transplantation |  |  | \nIt is recommended that potentially eligible candidates are referred for LTx evaluation when they have an inadequate response to oral\ncombination therapy, indicated by an intermediate–high or high risk or by a REVEAL risk score .7 |  | I | C | \nIt is recommended to list patients for LTx who present with a high risk of death or with a REVEAL risk score ≥10 despite receiving\noptimized medical therapy including s.c. or i.v. prostacyclin analogues |  | I | C | \n | Recommendations for pulmonary arterial hypertension associated with drugs or toxins |  |  | \nIt is recommended to make a diagnosis of drug- or toxin-associated PAH in patients who had relevant exposure and in whom other\ncauses of PH have been excluded |  | I | C | \nIn patients with suspected drug- or toxin-associated PAH, it is recommended to immediately discontinue the causative agent whenever\npossible |  | I | C | \n | Recommendations for pulmonary arterial hypertension associated with connective tissue disease |  |  | \nIn patients with PAH associated with CTD, treatment of the underlying condition according to current guidelines is recommended |  | I | A | \nIn patients with PAH associated with CTD, the same treatment algorithm as for patients with IPAH is recommended |  | I | C | \n | Recommendations for pulmonary arterial hypertension associated with human immunodeficiency virus infection |  |  | \nIn patients with PAH associated with HIV infection, antiretroviral treatment according to current guidelines is recommended |  | I | A | \n | Recommendations for pulmonary arterial hypertension associated with portal hypertension |  |  | \nEchocardiography is recommended in patients with liver disease or portal hypertension with signs or symptoms suggestive of PH, and as\na screening tool in patients evaluated for liver transplantation or transjugular portosystemic shunt |  | I | C | \nIt is recommended that patients with PAH associated with portal hypertension are referred to centres with expertise in managing both\nconditions |  | I | C | \nDrugs approved for PAH are not recommended for patients with portal hypertension and unclassified PH (i.e. elevated mPAP, high CO,\nand a normal PVR) |  | III | C | ",
          "rows": 29,
          "cols": 5
        },
        {
          "title": "Table on page 91",
          "page": 91,
          "content": " | Recommendations for shunt closure in patients with pulmonary-systemic flow ratio .1.5:1 based on calculated pulmonary vascular\nresistance |  |  | \nIn patients with an ASD, VSD, or PDA and a PVR ,3 WU, shunt closure is recommended |  | I | C | \nIn patients with an ASD and a PVR .5 WU despite PAH treatment, shunt closure is not recommended |  | III | C | \nRecommendations for pulmonary arterial hypertension associated with adult congenital heart disease |  |  |  | \nRisk assessment |  |  |  | \nRisk assessment is recommended for patients with persistent PAH after defect closure |  | I | C | \n | Treatment |  |  | \nBosentan is recommended in symptomatic patients with Eisenmenger syndrome to improve exercise capacity |  | I | B | \nIn women with Eisenmenger syndrome, pregnancy is not recommended |  | III | C | \nIn patients with Eisenmenger syndrome, routine phlebotomy to lower elevated haematocrit is not recommended |  | III | C | \n | Recommendations for pulmonary arterial hypertension with signs of venous/capillary involvement |  |  | \nA combination of clinical and radiological findings, ABG, PFTs, and genetic testing is recommended to diagnose PAH with signs of venous\nand/or capillary involvement (PVOD/PCH) |  | I | A | \nIdentification of biallelic EIF2AK4 mutations is recommended to confirm a diagnosis of heritable PVOD/PCH |  | I | A | \nReferral of eligible patients with PVOD/PCH to a transplant centre for evaluation is recommended as soon as the diagnosis is established |  | I | C | \nLung biopsy is not recommended to confirm a diagnosis of PVOD/PCH |  | III | C | \nRecommendations for paediatric pulmonary hypertension |  |  |  | \nChildren |  |  |  | \nIt is recommended to perform the diagnostic work-up, including RHC and acute vasoreactivity testing, and treat children with PH at\ncentres with specific expertise in paediatric PH |  | I | C | \nIn children with PH, a comprehensive work-up for confirming diagnosis and specific aetiology is recommended (similar to that in adults,\nbut adapted for age) |  | I | C | \nFor confirming PH diagnosis, RHC is recommended, preferably before initiating any PAH therapy |  | I | C | \nIn children with IPAH/HPAH, acute vasoreactivity testing is recommended to detect those who may benefit from CCB therapy |  | I | C | \nIt is recommended to similarly define a positive response to acute vasoreactivity testing in children and adults by a reduction in mPAP\n≥10 mmHg to reach an absolute value of mPAP ≤40 mmHg, with an increased or unchanged CO |  | I | C | \nIn children with PAH, a therapeutic strategy based on risk stratification and treatment response is recommended, extrapolated from\nthat in adults, but adapted for age |  | I | C | \nIt is recommended to monitor the treatment response in children with PAH by serially assessing a panel of data derived from clinical\nassessment, echocardiographic evaluation, biochemical markers, and exercise tolerance tests |  | I | C | \n | Infants |  |  | \nIt is recommended to screen infants with bronchopulmonary dysplasia for PH |  | I | B | \nIn infants with (or at risk of) bronchopulmonary dysplasia and PH, treating lung disease—including hypoxia, aspiration, and structural\nairway disease—and optimizing respiratory support is recommended before initiating PAH therapy |  | I | B | \n | Recommendations for pulmonary hypertension associated with left heart disease |  |  | \nIn patients with LHD, optimizing treatment of the underlying condition is recommended before considering assessment of\nsuspected PH |  | I | A | \nRHC is recommended for suspected PH in patients with LHD, if it aids management decisions |  | I | C | ",
          "rows": 30,
          "cols": 5
        },
        {
          "title": "Table on page 92",
          "page": 92,
          "content": "RHC is recommended in patients with severe tricuspid regurgitation with or without LHD prior to surgical or interventional valve repair |  | I | C | \nFor patients with LHD and suspected PH with features of a severe pre-capillary component and/or markers of RV dysfunction, referral\nto a PH centre for a complete diagnostic work-up is recommended |  | I | C | \nIn patients with LHD and CpcPH with a severe pre-capillary component (e.g. PVR .5 WU), an individualized approach to treatment is\nrecommended |  | I | C | \nWhen patients with PH and multiple risk factors for LHD, who have a normal PAWP at rest but an abnormal response to exercise or\nfluid challenge, are treated with PAH drugs, close monitoring is recommended |  | I | C | \nDrugs approved for PAH are not recommended in PH-LHDh |  | III | A | \n | Recommendations for pulmonary hypertension associated with lung disease and/or hypoxia |  |  | \nIf PH is suspected in patients with lung disease, it is recommended that echocardiographyi be performed and results interpreted in\nconjunction with ABG, PFTs including DLCO, and CT imaging |  | I | C | \nIn patients with lung disease and suspected PH, it is recommended to optimize treatment of the underlying lung disease and, where\nindicated, hypoxaemia, sleep-disordered breathing, and/or alveolar hypoventilation |  | I | C | \nIn patients with lung disease and suspected severe PH, or where there is uncertainty regarding the treatment of PH, referral to a PH\ncentre is recommendedj |  | I | C | \nIn patients with lung disease and severe PH, an individualized approach to treatment is recommended |  | I | C | \nIt is recommended to refer eligible patients with lung disease and PH for LTx evaluation |  | I | C | \nIn patients with lung disease and suspected PH, RHC is recommended if the results are expected to aid management decisions |  | I | C | \nThe use of ambrisentan is not recommended in patients with PH associated with IPF |  | III | B | \nThe use of riociguat is not recommended in patients with PH associated with IIP |  | III | B | \nThe use of PAH medication is not recommended in patients with lung disease and non-severe PHk |  | III | C | \n | Recommendations for chronic thrombo-embolic pulmonary hypertension and chronic thrombo-embolic pulmonary disease without\npulmonary hypertension |  |  | \nCTEPH |  |  |  | \nLifelong, therapeutic doses of anticoagulation are recommended in all patients with CTEPH |  | I | C | \nAntiphospholipid syndrome testing is recommended in patients with CTEPH |  | I | C | \nIn patients with CTEPH and antiphospholipid syndrome, anticoagulation with VKAs is recommended |  | I | C | \nIt is recommended that all patients with CTEPH are reviewed by a CTEPH team for the assessment of multimodality management |  | I | C | \nPEA is recommended as the treatment of choice for patients with CTEPH and fibrotic obstructions within pulmonary arteries accessible\nby surgery |  | I | B | \nBPA is recommended in patients who are technically inoperable or have residual PH after PEA and distal obstructions amenable to BPA |  | I | B | \nRiociguat is recommended for symptomatic patients with inoperable CTEPH or persistent/recurrent PH after PEA |  | I | B | \nLong-term follow-up is recommended after PEA and BPA, as well as for patients with CTEPH established on medical therapy |  | I | C | \n | Recommendations for pulmonary hypertension centres |  |  | \nIt is recommended that PH centres provide care by a multidisciplinary team (cardiologist, pneumologist, rheumatologist, nurse specialist,\nradiologist, psychological and social work support, appropriate on-call expertise) |  | I | C | \nIt is recommended that PH centres have direct links and quick referral patterns to other services (such as genetic counselling, PEA/BPA,\nLTx, adult congenital heart disease service) |  | I | C | ",
          "rows": 28,
          "cols": 5
        },
        {
          "title": "Table on page 93",
          "page": 93,
          "content": "It is recommended that PH centres maintain a patient registry | I | C\nIt is recommended that PH centres collaborate with patient associations | I | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 93",
          "page": 93,
          "content": "GRADE |  |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nIn patients with IPAH/HPAH/DPAH who present at low or intermediate risk of\ndeath, initial combination therapy with a PDE5i and an ERA is recommended | Low | Conditional | I | B\nThe use of PDE5i in patients with HFpEF and isolated post-capillary PH is not\nrecommended | Low | Conditional | III | C\nThe use of PDE5i in patients with ILD and non-severe PH is not recommended | Very low | Conditional | III | C",
          "rows": 5,
          "cols": 5
        }
      ],
      "keywords": [
        "intervention",
        "ct",
        "messages",
        "follow-up",
        "catheterization",
        "severe",
        "pulmonary hypertension",
        "guidelines",
        "what",
        "treatment",
        "imaging",
        "diagnosis",
        "recommendation"
      ]
    },
    {
      "number": "18",
      "title": "16. Quality indicators",
      "start_page": 93,
      "end_page": 94,
      "content": "16. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care\nquality, including structural, process, and outcomes of care.847 They\nmay also serve as a mechanism for enhancing adherence to guideline\nrecommendations through associated quality-improvement initia-\ntives and benchmarking of care providers.848,849 As such, the role\nof QIs in improving care and outcomes for cardiovascular disease\nis increasingly being recognized by health care authorities, profes-\nsional organizations, payers, and the public.847\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established\nmethods for developing the ESC QIs for the quantiﬁcation of care\nand outcomes for cardiovascular diseases.847 To date, the ESC has\ndeveloped QI suites for a number of cardiovascular diseases850–852\nand embedded these in respective ESC Clinical Practice guide-\nlines.27,477,853,854 Furthermore, the ESC aims to integrate its QIs\nwith clinical registries such as the EurObservational Research\nProgramme and the European Uniﬁed Registries On Heart Care\nEvaluation and Randomized Trials (EuroHeart) project855 to provide\nreal-world data about the patterns and outcomes of care for cardio-\nvascular disease across Europe.\nIn parallel with the writing of this Clinical Practice Guideline, a pro-\ncess has been initiated to develop QIs for patients with PH using the\nIt is recommended that PH centres maintain a patient registry\nI\nC\nIt is recommended that PH centres collaborate with patient associations\nI\nC\n© ESC/ERS 2022\n6MWD, 6-minute walking distance; ABG, arterial blood gas analysis; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–\nneprilysin inhibitor; ASD, atrial septal defect; BNP/NT-proBNP, brain natriuretic peptide/N-terminal pro-brain natriuretic peptide; BPA, balloon pulmonary angioplasty; CCB,\ncalcium channel blocker; CpcPH, combined post- and pre-capillary pulmonary hypertension; CPET, cardiopulmonary exercise testing; CT, computed tomography; CTD, connective\ntissue disease; CTEPD, chronic thrombo-embolic pulmonary disease; CTEPH, chronic thrombo-embolic pulmonary hypertension; DLCO, Lung diffusion capacity for carbon\nmonoxide; DPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; FVC, forced vital capacity; HF, heart failure; HFpEF, heart failure with\npreserved ejection fraction; HIV, human immunodeﬁciency virus; HPAH, heritable pulmonary arterial hypertension; ICU, intensive care unit; I/H/DPAH, idiopathic, heritable,\ndrug-associated pulmonary arterial hypertension; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; IPAH, idiopathic pulmonary arterial hypertension; IPF, idiopathic\npulmonary ﬁbrosis; i.v., intravenous; LHD, left heart disease; LTx, lung transplantation; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PAWP,\npulmonary arterial wedge pressure; PCH, pulmonary capillary haemangiomatosis; PDA, patent ductus arteriosus; PDE5i, phosphodiesterase 5 inhibitor; PE, pulmonary embolism;\nPEA, pulmonary endarterectomy; PFTs, pulmonary function tests; PH, pulmonary hypertension; PH-LHD, pulmonary hypertension associated with left heart disease; PVOD,\npulmonary veno-occlusive disease; PVR, pulmonary vascular resistance; RHC, right heart catheterization; RV, right ventricular; s.c., subcutaneous; SGLT-2i, sodium–glucose\ncotransporter-2 inhibitor; SSc, systemic sclerosis; TRV, tricuspid regurgitation velocity; VKA, vitamin K antagonist; VSD, ventricular septal defect; WHO-FC, World Health\nOrganization functional class; WU, Wood units.\naClass of recommendation.\nbLevel of evidence.\ncTesting should also be performed in patients with a baseline mPAP ≤40 mmHg, in whom the same responder criteria apply.\ndMeasured on at least two occasions.\neCardiopulmonary comorbidities are predominantly encountered in elderly patients and include risk factors for HFpEF such as obesity, diabetes, coronary heart disease, a history of\nhypertension, and/or a low DLCO.\nfERA used in the GRIPHON study were bosentan and ambrisentan.\ngThe PATENT plus study investigated the combination of sildenaﬁl and riociguat; however, combining riociguat with any PDE5i is contraindicated.\nhSafety concerns have been identiﬁed when ERAs are used in patients with HF (HFpEF and HFrEF, with or without PH) and when sildenaﬁl is used in patients with persistent PH after\ncorrection of valvular heart disease.\niAssessments should ideally be made when the patient is clinically stable, as exacerbations can signiﬁcantly raise pulmonary artery pressure.\njThis recommendation does not apply to patients with end-stage lung disease who are not considered candidates for LTx.\nkThis does not include inhaled treprostinil, which may be considered in patients with PH associated with ILD irrespective of PH severity.\n‘What to do’ and ‘What not to do’ messages developed with GRADE Evidence to Decision framework\nGRADE\nRecommendations\nQuality of\nevidence\nStrength of\nrecommendation\nClassa\nLevelb\nIn patients with IPAH/HPAH/DPAH who present at low or intermediate risk of\ndeath, initial combination therapy with a PDE5i and an ERA is recommended\nLow\nConditional\nI\nB\nThe use of PDE5i in patients with HFpEF and isolated post-capillary PH is not\nrecommended\nLow\nConditional\nIII\nC\nThe use of PDE5i in patients with ILD and non-severe PH is not recommended\nVery low\nConditional\nIII\nC\n© ESC/ERS 2022\nDPAH, drug-associated pulmonary arterial hypertension; ERA, endothelin receptor antagonist; HPAH, heritable pulmonary arterial hypertension; HFpEF, heart failure with preserved\nejection fraction; ILD, interstitial lung disease; PDE5i, phosphodiesterase 5 inhibitor; PH, pulmonary hypertension.\naClass of recommendation.\nbLevel of evidence.\n3710\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nESC methodology and through collaboration with domain experts\nand the Heart Failure Association of the ESC. Such QIs may be\nused for evaluating the quality of care for patients with PH, and en-\nable important aspects of care delivery to be captured. These QIs,\nalongside their speciﬁcations and development process, will be pub-\nlished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online in-\ncluding key narrative question (1-8) and PICO questions (I-IV).\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Marc Humbert*,\nFaculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre,\nFrance, Service de Pneumologie et Soins Intensifs Respiratoires,\nCentre de Référence de l’Hypertension Pulmonaire, Hôpital\nBicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre,\nFrance, INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le\nPlessis-Robinson, France; Gabor Kovacs, University Clinic of\nInternal Medicine, Division of Pulmonology, Medical University of\nGraz, Graz, Austria, Ludwig Boltzmann Institute for Lung Vascular\nResearch,\nGraz,\nAustria;\nMarius\nM.\nHoeper,\nRespiratory\nMedicine,\nHannover\nMedical\nSchool,\nHanover,\nGermany,\nBiomedical Research in End-stage and Obstructive Lung Disease\n(BREATH), member of the German Centre of Lung Research\n(DZL), Hanover, Germany; Roberto Badagliacca, Dipartimento\ndi Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari,\nSapienza\nUniversità\ndi\nRoma,\nRoma,\nItaly,\nDipartimento\nCardio-Toraco-Vascolare e\nChirurgia dei\nTrapianti\nd’Organo,\nPoliclinico Umberto I, Roma, Italy; Rolf M.F. Berger, Center for\nCongenital Heart Diseases, Beatrix Children’s Hospital, Dept of\nPaediatric\nCardiology,\nUniversity\nMedical\nCenter\nGroningen,\nUniversity of Groningen, Groningen, Netherlands; Margarita\nBrida, Department of Sports and Rehabilitation Medicine, Medical\nFaculty University of Rijeka, Rijeka, Croatia, Adult Congenital Heart\nCentre and National Centre for Pulmonary Hypertension, Royal\nBrompton & Hareﬁeld Hospitals, Guys & St Thomas’s NHS Trust,\nLondon,\nUnited\nKingdom;\nJørn\nCarlsen,\nDepartment\nof\nCardiology,\nCopenhagen\nUniversity\nHospital,\nRigshospitalet,\nCopenhagen, Denmark, Department of Clinical Medicine; Faculty of\nHealth\nand\nMedical\nSciences,\nUniversity\nof\nCopenhagen,\nCopenhagen, Denmark; Andrew J.S. Coats, Faculty of Medicine,\nUniversity of Warwick, Coventry, United Kingdom, Faculty of\nMedicine,\nMonash\nUniversity\nMelbourne,\nAustralia;\nPilar\nEscribano-Subias, Pulmonary Hypertension Unit, Cardiology\nDepartment, Hospital Universitario 12 de Octubre, Madrid, Spain,\nCIBER-CV (Centro de Investigaciones Biomédicas En Red de enfer-\nmedades CardioVasculares), Instituto de Salud Carlos III, Madrid,\nSpain, Facultad de Medicina, Universidad Complutense, Madrid,\nSpain; Pisana Ferrari (Italy), ESC Patient Forum, Sophia Antipolis,\nFrance, AIPI, Associazione Italiana Ipertensione Polmonare, Bologna,\nItaly; Diogenes S. Ferreira, Alergia e Imunologia, Hospital de\nClinicas, Universidade Federal do Parana, Curitiba, Brazil; Hossein\nArdeschir\nGhofrani,\nDepartment\nof\nInternal\nMedicine,\nUniversity\nHospital\nGiessen,\nJustus-Liebig\nUniversity,\nGiessen,\nGermany, Department of Pneumology, Kerckhoff Klinik, Bad\nNauheim, Germany, Department of Medicine, Imperial College\nLondon, London, United Kingdom; George Giannakoulas,\nCardiology\nDepartment,\nAristotle\nUniversity\nof\nThessaloniki,\nAHEPA University Hospital, Thessaloniki, Greece; David G. Kiely,\nDepartment of Infection, Immunity and Cardiovascular Disease,\nUniversity\nof\nShefﬁeld,\nShefﬁeld,\nUnited\nKingdom,\nShefﬁeld\nPulmonary Vascular Disease Unit, Shefﬁeld Teaching Hospitals NHS\nFoundation Trust, Shefﬁeld, United Kingdom, Insigneo Institute,\nUniversity of Shefﬁeld, Shefﬁeld, United Kingdom; Eckhard\nMayer,\nThoracic\nSurgery,\nKerckhoff\nClinic,\nBad\nNauheim,\nGermany; Gergely Meszaros (Hungary), ESC Patient Forum,\nSophia\nAntipolis,\nFrance,\nEuropean\nLung\nFoundation\n(ELF),\nShefﬁeld, United Kingdom; Blin Nagavci, Institute for Evidence in\nMedicine, Faculty of Medicine and Medical Center, University of\nFreiburg, Freiburg, Germany; Karen M. Olsson, Clinic of\nRespiratory Medicine, Hannover Medical School, member of the\nGerman Center of Lung Research (DZL), Hannover, Germany;\nJoanna Pepke-Zaba, Pulmonary Vascular Diseases Unit, Royal\nPapworth\nHospital,\nCambridge,\nUnited\nKingdom;\nJennifer\nK. Quint, NHLI, Imperial College London, London, United\nKingdom; Göran Rådegran, Department of Cardiology, Clinical\nSciences\nLund,\nFaculty\nof\nMedicine,\nLund,\nSweden,\nThe\nHaemodynamic Lab, The Section for Heart Failure and Valvular\nDisease, VO. Heart and Lung Medicine, Skåne University Hospital,\nLund, Sweden; Gerald Simonneau, Faculté Médecine, Université\nParis Saclay, Le Kremlin-Bicêtre, France, Centre de Référence de\nl’Hypertension\nPulmonaire,\nHopital\nMarie-Lannelongue,\nLe\nPlessis-Robinson, France; Olivier Sitbon, Faculty of Medicine,\nUniversité Paris-Saclay, Le Kremlin-Bicêtre, France, Service de\nPneumologie et Soins Intensifs Respiratoires, Centre de Référence\nde l’Hypertension Pulmonaire, Hôpital Bicêtre, Assistance Publique\nHôpitaux de Paris, Le Kremlin-Bicêtre, France, INSERM UMR_S\n999,\nHôpital Marie-Lannelongue,\nLe\nPlessis-Robinson,\nFrance;\nThomy Tonia, Institute of Social and Preventive Medicine,\nUniversity of Bern, Bern, Switzerland; Mark Toshner, Heart Lung\nResearch Institute, Dept of Medicine, University of Cambridge,\nCambridge,\nUnited\nKingdom,\nRoyal\nPapworth\nNHS\nTrust;\nJean-Luc Vachiery, Department of Cardiology, Pulmonary\nVascular Diseases and Heart Failure Clinic, HUB Hôpital Erasme,\nBrussels, Belgium; and Anton Vonk Noordegraaf, Pulmonology,\nAmsterdam UMC, Amsterdam, Netherlands.\n* Marc Humbert is supported by the Investissement d’Avenir pro-\ngramme managed by the French National Research Agency under\nthe grant contract ANR-18-RHUS-0006 (DESTINATION 2024).\n20. Appendix\nESC/ERS Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nESC/ERS Guidelines\n3711\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 93",
          "page": 93,
          "content": "It is recommended that PH centres maintain a patient registry | I | C\nIt is recommended that PH centres collaborate with patient associations | I | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 93",
          "page": 93,
          "content": "GRADE |  |  |  | \nRecommendations | Quality of\nevidence | Strength of\nrecommendation | Classa | Levelb\nIn patients with IPAH/HPAH/DPAH who present at low or intermediate risk of\ndeath, initial combination therapy with a PDE5i and an ERA is recommended | Low | Conditional | I | B\nThe use of PDE5i in patients with HFpEF and isolated post-capillary PH is not\nrecommended | Low | Conditional | III | C\nThe use of PDE5i in patients with ILD and non-severe PH is not recommended | Very low | Conditional | III | C",
          "rows": 5,
          "cols": 5
        }
      ],
      "keywords": [
        "ct",
        "indicators",
        "arb",
        "heart failure",
        "quality",
        "pulmonary hypertension",
        "recommendation"
      ]
    },
    {
      "number": "19",
      "title": "17. Supplementary data",
      "start_page": 94,
      "end_page": 94,
      "content": "ESC methodology and through collaboration with domain experts\nand the Heart Failure Association of the ESC. Such QIs may be\nused for evaluating the quality of care for patients with PH, and en-\nable important aspects of care delivery to be captured. These QIs,\nalongside their speciﬁcations and development process, will be pub-\nlished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online in-\ncluding key narrative question (1-8) and PICO questions (I-IV).\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Marc Humbert*,\nFaculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre,\nFrance, Service de Pneumologie et Soins Intensifs Respiratoires,\nCentre de Référence de l’Hypertension Pulmonaire, Hôpital\nBicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre,\nFrance, INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le\nPlessis-Robinson, France; Gabor Kovacs, University Clinic of\nInternal Medicine, Division of Pulmonology, Medical University of\nGraz, Graz, Austria, Ludwig Boltzmann Institute for Lung Vascular\nResearch,\nGraz,\nAustria;\nMarius\nM.\nHoeper,\nRespiratory\nMedicine,\nHannover\nMedical\nSchool,\nHanover,\nGermany,\nBiomedical Research in End-stage and Obstructive Lung Disease\n(BREATH), member of the German Centre of Lung Research\n(DZL), Hanover, Germany; Roberto Badagliacca, Dipartimento\ndi Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari,\nSapienza\nUniversità\ndi\nRoma,\nRoma,\nItaly,\nDipartimento\nCardio-Toraco-Vascolare e\nChirurgia dei\nTrapianti\nd’Organo,\nPoliclinico Umberto I, Roma, Italy; Rolf M.F. Berger, Center for\nCongenital Heart Diseases, Beatrix Children’s Hospital, Dept of\nPaediatric\nCardiology,\nUniversity\nMedical\nCenter\nGroningen,\nUniversity of Groningen, Groningen, Netherlands; Margarita\nBrida, Department of Sports and Rehabilitation Medicine, Medical\nFaculty University of Rijeka, Rijeka, Croatia, Adult Congenital Heart\nCentre and National Centre for Pulmonary Hypertension, Royal\nBrompton & Hareﬁeld Hospitals, Guys & St Thomas’s NHS Trust,\nLondon,\nUnited\nKingdom;\nJørn\nCarlsen,\nDepartment\nof\nCardiology,\nCopenhagen\nUniversity\nHospital,\nRigshospitalet,\nCopenhagen, Denmark, Department of Clinical Medicine; Faculty of\nHealth\nand\nMedical\nSciences,\nUniversity\nof\nCopenhagen,\nCopenhagen, Denmark; Andrew J.S. Coats, Faculty of Medicine,\nUniversity of Warwick, Coventry, United Kingdom, Faculty of\nMedicine,\nMonash\nUniversity\nMelbourne,\nAustralia;\nPilar\nEscribano-Subias, Pulmonary Hypertension Unit, Cardiology\nDepartment, Hospital Universitario 12 de Octubre, Madrid, Spain,\nCIBER-CV (Centro de Investigaciones Biomédicas En Red de enfer-\nmedades CardioVasculares), Instituto de Salud Carlos III, Madrid,\nSpain, Facultad de Medicina, Universidad Complutense, Madrid,\nSpain; Pisana Ferrari (Italy), ESC Patient Forum, Sophia Antipolis,\nFrance, AIPI, Associazione Italiana Ipertensione Polmonare, Bologna,\nItaly; Diogenes S. Ferreira, Alergia e Imunologia, Hospital de\nClinicas, Universidade Federal do Parana, Curitiba, Brazil; Hossein\nArdeschir\nGhofrani,\nDepartment\nof\nInternal\nMedicine,\nUniversity\nHospital\nGiessen,\nJustus-Liebig\nUniversity,\nGiessen,\nGermany, Department of Pneumology, Kerckhoff Klinik, Bad\nNauheim, Germany, Department of Medicine, Imperial College\nLondon, London, United Kingdom; George Giannakoulas,\nCardiology\nDepartment,\nAristotle\nUniversity\nof\nThessaloniki,\nAHEPA University Hospital, Thessaloniki, Greece; David G. Kiely,\nDepartment of Infection, Immunity and Cardiovascular Disease,\nUniversity\nof\nShefﬁeld,\nShefﬁeld,\nUnited\nKingdom,\nShefﬁeld\nPulmonary Vascular Disease Unit, Shefﬁeld Teaching Hospitals NHS\nFoundation Trust, Shefﬁeld, United Kingdom, Insigneo Institute,\nUniversity of Shefﬁeld, Shefﬁeld, United Kingdom; Eckhard\nMayer,\nThoracic\nSurgery,\nKerckhoff\nClinic,\nBad\nNauheim,\nGermany; Gergely Meszaros (Hungary), ESC Patient Forum,\nSophia\nAntipolis,\nFrance,\nEuropean\nLung\nFoundation\n(ELF),\nShefﬁeld, United Kingdom; Blin Nagavci, Institute for Evidence in\nMedicine, Faculty of Medicine and Medical Center, University of\nFreiburg, Freiburg, Germany; Karen M. Olsson, Clinic of\nRespiratory Medicine, Hannover Medical School, member of the\nGerman Center of Lung Research (DZL), Hannover, Germany;\nJoanna Pepke-Zaba, Pulmonary Vascular Diseases Unit, Royal\nPapworth\nHospital,\nCambridge,\nUnited\nKingdom;\nJennifer\nK. Quint, NHLI, Imperial College London, London, United\nKingdom; Göran Rådegran, Department of Cardiology, Clinical\nSciences\nLund,\nFaculty\nof\nMedicine,\nLund,\nSweden,\nThe\nHaemodynamic Lab, The Section for Heart Failure and Valvular\nDisease, VO. Heart and Lung Medicine, Skåne University Hospital,\nLund, Sweden; Gerald Simonneau, Faculté Médecine, Université\nParis Saclay, Le Kremlin-Bicêtre, France, Centre de Référence de\nl’Hypertension\nPulmonaire,\nHopital\nMarie-Lannelongue,\nLe\nPlessis-Robinson, France; Olivier Sitbon, Faculty of Medicine,\nUniversité Paris-Saclay, Le Kremlin-Bicêtre, France, Service de\nPneumologie et Soins Intensifs Respiratoires, Centre de Référence\nde l’Hypertension Pulmonaire, Hôpital Bicêtre, Assistance Publique\nHôpitaux de Paris, Le Kremlin-Bicêtre, France, INSERM UMR_S\n999,\nHôpital Marie-Lannelongue,\nLe\nPlessis-Robinson,\nFrance;\nThomy Tonia, Institute of Social and Preventive Medicine,\nUniversity of Bern, Bern, Switzerland; Mark Toshner, Heart Lung\nResearch Institute, Dept of Medicine, University of Cambridge,\nCambridge,\nUnited\nKingdom,\nRoyal\nPapworth\nNHS\nTrust;\nJean-Luc Vachiery, Department of Cardiology, Pulmonary\nVascular Diseases and Heart Failure Clinic, HUB Hôpital Erasme,\nBrussels, Belgium; and Anton Vonk Noordegraaf, Pulmonology,\nAmsterdam UMC, Amsterdam, Netherlands.\n* Marc Humbert is supported by the Investissement d’Avenir pro-\ngramme managed by the French National Research Agency under\nthe grant contract ANR-18-RHUS-0006 (DESTINATION 2024).\n20. Appendix\nESC/ERS Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nESC/ERS Guidelines\n3711\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "heart failure",
        "supplementary",
        "data",
        "pulmonary hypertension"
      ]
    },
    {
      "number": "20",
      "title": "18. Data availability statement",
      "start_page": 94,
      "end_page": 94,
      "content": "ESC methodology and through collaboration with domain experts\nand the Heart Failure Association of the ESC. Such QIs may be\nused for evaluating the quality of care for patients with PH, and en-\nable important aspects of care delivery to be captured. These QIs,\nalongside their speciﬁcations and development process, will be pub-\nlished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online in-\ncluding key narrative question (1-8) and PICO questions (I-IV).\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Marc Humbert*,\nFaculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre,\nFrance, Service de Pneumologie et Soins Intensifs Respiratoires,\nCentre de Référence de l’Hypertension Pulmonaire, Hôpital\nBicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre,\nFrance, INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le\nPlessis-Robinson, France; Gabor Kovacs, University Clinic of\nInternal Medicine, Division of Pulmonology, Medical University of\nGraz, Graz, Austria, Ludwig Boltzmann Institute for Lung Vascular\nResearch,\nGraz,\nAustria;\nMarius\nM.\nHoeper,\nRespiratory\nMedicine,\nHannover\nMedical\nSchool,\nHanover,\nGermany,\nBiomedical Research in End-stage and Obstructive Lung Disease\n(BREATH), member of the German Centre of Lung Research\n(DZL), Hanover, Germany; Roberto Badagliacca, Dipartimento\ndi Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari,\nSapienza\nUniversità\ndi\nRoma,\nRoma,\nItaly,\nDipartimento\nCardio-Toraco-Vascolare e\nChirurgia dei\nTrapianti\nd’Organo,\nPoliclinico Umberto I, Roma, Italy; Rolf M.F. Berger, Center for\nCongenital Heart Diseases, Beatrix Children’s Hospital, Dept of\nPaediatric\nCardiology,\nUniversity\nMedical\nCenter\nGroningen,\nUniversity of Groningen, Groningen, Netherlands; Margarita\nBrida, Department of Sports and Rehabilitation Medicine, Medical\nFaculty University of Rijeka, Rijeka, Croatia, Adult Congenital Heart\nCentre and National Centre for Pulmonary Hypertension, Royal\nBrompton & Hareﬁeld Hospitals, Guys & St Thomas’s NHS Trust,\nLondon,\nUnited\nKingdom;\nJørn\nCarlsen,\nDepartment\nof\nCardiology,\nCopenhagen\nUniversity\nHospital,\nRigshospitalet,\nCopenhagen, Denmark, Department of Clinical Medicine; Faculty of\nHealth\nand\nMedical\nSciences,\nUniversity\nof\nCopenhagen,\nCopenhagen, Denmark; Andrew J.S. Coats, Faculty of Medicine,\nUniversity of Warwick, Coventry, United Kingdom, Faculty of\nMedicine,\nMonash\nUniversity\nMelbourne,\nAustralia;\nPilar\nEscribano-Subias, Pulmonary Hypertension Unit, Cardiology\nDepartment, Hospital Universitario 12 de Octubre, Madrid, Spain,\nCIBER-CV (Centro de Investigaciones Biomédicas En Red de enfer-\nmedades CardioVasculares), Instituto de Salud Carlos III, Madrid,\nSpain, Facultad de Medicina, Universidad Complutense, Madrid,\nSpain; Pisana Ferrari (Italy), ESC Patient Forum, Sophia Antipolis,\nFrance, AIPI, Associazione Italiana Ipertensione Polmonare, Bologna,\nItaly; Diogenes S. Ferreira, Alergia e Imunologia, Hospital de\nClinicas, Universidade Federal do Parana, Curitiba, Brazil; Hossein\nArdeschir\nGhofrani,\nDepartment\nof\nInternal\nMedicine,\nUniversity\nHospital\nGiessen,\nJustus-Liebig\nUniversity,\nGiessen,\nGermany, Department of Pneumology, Kerckhoff Klinik, Bad\nNauheim, Germany, Department of Medicine, Imperial College\nLondon, London, United Kingdom; George Giannakoulas,\nCardiology\nDepartment,\nAristotle\nUniversity\nof\nThessaloniki,\nAHEPA University Hospital, Thessaloniki, Greece; David G. Kiely,\nDepartment of Infection, Immunity and Cardiovascular Disease,\nUniversity\nof\nShefﬁeld,\nShefﬁeld,\nUnited\nKingdom,\nShefﬁeld\nPulmonary Vascular Disease Unit, Shefﬁeld Teaching Hospitals NHS\nFoundation Trust, Shefﬁeld, United Kingdom, Insigneo Institute,\nUniversity of Shefﬁeld, Shefﬁeld, United Kingdom; Eckhard\nMayer,\nThoracic\nSurgery,\nKerckhoff\nClinic,\nBad\nNauheim,\nGermany; Gergely Meszaros (Hungary), ESC Patient Forum,\nSophia\nAntipolis,\nFrance,\nEuropean\nLung\nFoundation\n(ELF),\nShefﬁeld, United Kingdom; Blin Nagavci, Institute for Evidence in\nMedicine, Faculty of Medicine and Medical Center, University of\nFreiburg, Freiburg, Germany; Karen M. Olsson, Clinic of\nRespiratory Medicine, Hannover Medical School, member of the\nGerman Center of Lung Research (DZL), Hannover, Germany;\nJoanna Pepke-Zaba, Pulmonary Vascular Diseases Unit, Royal\nPapworth\nHospital,\nCambridge,\nUnited\nKingdom;\nJennifer\nK. Quint, NHLI, Imperial College London, London, United\nKingdom; Göran Rådegran, Department of Cardiology, Clinical\nSciences\nLund,\nFaculty\nof\nMedicine,\nLund,\nSweden,\nThe\nHaemodynamic Lab, The Section for Heart Failure and Valvular\nDisease, VO. Heart and Lung Medicine, Skåne University Hospital,\nLund, Sweden; Gerald Simonneau, Faculté Médecine, Université\nParis Saclay, Le Kremlin-Bicêtre, France, Centre de Référence de\nl’Hypertension\nPulmonaire,\nHopital\nMarie-Lannelongue,\nLe\nPlessis-Robinson, France; Olivier Sitbon, Faculty of Medicine,\nUniversité Paris-Saclay, Le Kremlin-Bicêtre, France, Service de\nPneumologie et Soins Intensifs Respiratoires, Centre de Référence\nde l’Hypertension Pulmonaire, Hôpital Bicêtre, Assistance Publique\nHôpitaux de Paris, Le Kremlin-Bicêtre, France, INSERM UMR_S\n999,\nHôpital Marie-Lannelongue,\nLe\nPlessis-Robinson,\nFrance;\nThomy Tonia, Institute of Social and Preventive Medicine,\nUniversity of Bern, Bern, Switzerland; Mark Toshner, Heart Lung\nResearch Institute, Dept of Medicine, University of Cambridge,\nCambridge,\nUnited\nKingdom,\nRoyal\nPapworth\nNHS\nTrust;\nJean-Luc Vachiery, Department of Cardiology, Pulmonary\nVascular Diseases and Heart Failure Clinic, HUB Hôpital Erasme,\nBrussels, Belgium; and Anton Vonk Noordegraaf, Pulmonology,\nAmsterdam UMC, Amsterdam, Netherlands.\n* Marc Humbert is supported by the Investissement d’Avenir pro-\ngramme managed by the French National Research Agency under\nthe grant contract ANR-18-RHUS-0006 (DESTINATION 2024).\n20. Appendix\nESC/ERS Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nESC/ERS Guidelines\n3711\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "statement",
        "heart failure",
        "data",
        "availability",
        "pulmonary hypertension"
      ]
    },
    {
      "number": "21",
      "title": "19. Author information",
      "start_page": 94,
      "end_page": 94,
      "content": "ESC methodology and through collaboration with domain experts\nand the Heart Failure Association of the ESC. Such QIs may be\nused for evaluating the quality of care for patients with PH, and en-\nable important aspects of care delivery to be captured. These QIs,\nalongside their speciﬁcations and development process, will be pub-\nlished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online in-\ncluding key narrative question (1-8) and PICO questions (I-IV).\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Marc Humbert*,\nFaculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre,\nFrance, Service de Pneumologie et Soins Intensifs Respiratoires,\nCentre de Référence de l’Hypertension Pulmonaire, Hôpital\nBicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre,\nFrance, INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le\nPlessis-Robinson, France; Gabor Kovacs, University Clinic of\nInternal Medicine, Division of Pulmonology, Medical University of\nGraz, Graz, Austria, Ludwig Boltzmann Institute for Lung Vascular\nResearch,\nGraz,\nAustria;\nMarius\nM.\nHoeper,\nRespiratory\nMedicine,\nHannover\nMedical\nSchool,\nHanover,\nGermany,\nBiomedical Research in End-stage and Obstructive Lung Disease\n(BREATH), member of the German Centre of Lung Research\n(DZL), Hanover, Germany; Roberto Badagliacca, Dipartimento\ndi Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari,\nSapienza\nUniversità\ndi\nRoma,\nRoma,\nItaly,\nDipartimento\nCardio-Toraco-Vascolare e\nChirurgia dei\nTrapianti\nd’Organo,\nPoliclinico Umberto I, Roma, Italy; Rolf M.F. Berger, Center for\nCongenital Heart Diseases, Beatrix Children’s Hospital, Dept of\nPaediatric\nCardiology,\nUniversity\nMedical\nCenter\nGroningen,\nUniversity of Groningen, Groningen, Netherlands; Margarita\nBrida, Department of Sports and Rehabilitation Medicine, Medical\nFaculty University of Rijeka, Rijeka, Croatia, Adult Congenital Heart\nCentre and National Centre for Pulmonary Hypertension, Royal\nBrompton & Hareﬁeld Hospitals, Guys & St Thomas’s NHS Trust,\nLondon,\nUnited\nKingdom;\nJørn\nCarlsen,\nDepartment\nof\nCardiology,\nCopenhagen\nUniversity\nHospital,\nRigshospitalet,\nCopenhagen, Denmark, Department of Clinical Medicine; Faculty of\nHealth\nand\nMedical\nSciences,\nUniversity\nof\nCopenhagen,\nCopenhagen, Denmark; Andrew J.S. Coats, Faculty of Medicine,\nUniversity of Warwick, Coventry, United Kingdom, Faculty of\nMedicine,\nMonash\nUniversity\nMelbourne,\nAustralia;\nPilar\nEscribano-Subias, Pulmonary Hypertension Unit, Cardiology\nDepartment, Hospital Universitario 12 de Octubre, Madrid, Spain,\nCIBER-CV (Centro de Investigaciones Biomédicas En Red de enfer-\nmedades CardioVasculares), Instituto de Salud Carlos III, Madrid,\nSpain, Facultad de Medicina, Universidad Complutense, Madrid,\nSpain; Pisana Ferrari (Italy), ESC Patient Forum, Sophia Antipolis,\nFrance, AIPI, Associazione Italiana Ipertensione Polmonare, Bologna,\nItaly; Diogenes S. Ferreira, Alergia e Imunologia, Hospital de\nClinicas, Universidade Federal do Parana, Curitiba, Brazil; Hossein\nArdeschir\nGhofrani,\nDepartment\nof\nInternal\nMedicine,\nUniversity\nHospital\nGiessen,\nJustus-Liebig\nUniversity,\nGiessen,\nGermany, Department of Pneumology, Kerckhoff Klinik, Bad\nNauheim, Germany, Department of Medicine, Imperial College\nLondon, London, United Kingdom; George Giannakoulas,\nCardiology\nDepartment,\nAristotle\nUniversity\nof\nThessaloniki,\nAHEPA University Hospital, Thessaloniki, Greece; David G. Kiely,\nDepartment of Infection, Immunity and Cardiovascular Disease,\nUniversity\nof\nShefﬁeld,\nShefﬁeld,\nUnited\nKingdom,\nShefﬁeld\nPulmonary Vascular Disease Unit, Shefﬁeld Teaching Hospitals NHS\nFoundation Trust, Shefﬁeld, United Kingdom, Insigneo Institute,\nUniversity of Shefﬁeld, Shefﬁeld, United Kingdom; Eckhard\nMayer,\nThoracic\nSurgery,\nKerckhoff\nClinic,\nBad\nNauheim,\nGermany; Gergely Meszaros (Hungary), ESC Patient Forum,\nSophia\nAntipolis,\nFrance,\nEuropean\nLung\nFoundation\n(ELF),\nShefﬁeld, United Kingdom; Blin Nagavci, Institute for Evidence in\nMedicine, Faculty of Medicine and Medical Center, University of\nFreiburg, Freiburg, Germany; Karen M. Olsson, Clinic of\nRespiratory Medicine, Hannover Medical School, member of the\nGerman Center of Lung Research (DZL), Hannover, Germany;\nJoanna Pepke-Zaba, Pulmonary Vascular Diseases Unit, Royal\nPapworth\nHospital,\nCambridge,\nUnited\nKingdom;\nJennifer\nK. Quint, NHLI, Imperial College London, London, United\nKingdom; Göran Rådegran, Department of Cardiology, Clinical\nSciences\nLund,\nFaculty\nof\nMedicine,\nLund,\nSweden,\nThe\nHaemodynamic Lab, The Section for Heart Failure and Valvular\nDisease, VO. Heart and Lung Medicine, Skåne University Hospital,\nLund, Sweden; Gerald Simonneau, Faculté Médecine, Université\nParis Saclay, Le Kremlin-Bicêtre, France, Centre de Référence de\nl’Hypertension\nPulmonaire,\nHopital\nMarie-Lannelongue,\nLe\nPlessis-Robinson, France; Olivier Sitbon, Faculty of Medicine,\nUniversité Paris-Saclay, Le Kremlin-Bicêtre, France, Service de\nPneumologie et Soins Intensifs Respiratoires, Centre de Référence\nde l’Hypertension Pulmonaire, Hôpital Bicêtre, Assistance Publique\nHôpitaux de Paris, Le Kremlin-Bicêtre, France, INSERM UMR_S\n999,\nHôpital Marie-Lannelongue,\nLe\nPlessis-Robinson,\nFrance;\nThomy Tonia, Institute of Social and Preventive Medicine,\nUniversity of Bern, Bern, Switzerland; Mark Toshner, Heart Lung\nResearch Institute, Dept of Medicine, University of Cambridge,\nCambridge,\nUnited\nKingdom,\nRoyal\nPapworth\nNHS\nTrust;\nJean-Luc Vachiery, Department of Cardiology, Pulmonary\nVascular Diseases and Heart Failure Clinic, HUB Hôpital Erasme,\nBrussels, Belgium; and Anton Vonk Noordegraaf, Pulmonology,\nAmsterdam UMC, Amsterdam, Netherlands.\n* Marc Humbert is supported by the Investissement d’Avenir pro-\ngramme managed by the French National Research Agency under\nthe grant contract ANR-18-RHUS-0006 (DESTINATION 2024).\n20. Appendix\nESC/ERS Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nESC/ERS Guidelines\n3711\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "information",
        "heart failure",
        "author",
        "pulmonary hypertension"
      ]
    },
    {
      "number": "22",
      "title": "20. Appendix",
      "start_page": 94,
      "end_page": 95,
      "content": "ESC methodology and through collaboration with domain experts\nand the Heart Failure Association of the ESC. Such QIs may be\nused for evaluating the quality of care for patients with PH, and en-\nable important aspects of care delivery to be captured. These QIs,\nalongside their speciﬁcations and development process, will be pub-\nlished separately.\n17. Supplementary data\nSupplementary data is available at European Heart Journal online in-\ncluding key narrative question (1-8) and PICO questions (I-IV).\n18. Data availability statement\nNo new data were generated or analysed in support of this research.\n19. Author information\nAuthor/Task Force Member Afﬁliations: Marc Humbert*,\nFaculty of Medicine, Université Paris-Saclay, Le Kremlin-Bicêtre,\nFrance, Service de Pneumologie et Soins Intensifs Respiratoires,\nCentre de Référence de l’Hypertension Pulmonaire, Hôpital\nBicêtre, Assistance Publique Hôpitaux de Paris, Le Kremlin-Bicêtre,\nFrance, INSERM UMR_S 999, Hôpital Marie-Lannelongue, Le\nPlessis-Robinson, France; Gabor Kovacs, University Clinic of\nInternal Medicine, Division of Pulmonology, Medical University of\nGraz, Graz, Austria, Ludwig Boltzmann Institute for Lung Vascular\nResearch,\nGraz,\nAustria;\nMarius\nM.\nHoeper,\nRespiratory\nMedicine,\nHannover\nMedical\nSchool,\nHanover,\nGermany,\nBiomedical Research in End-stage and Obstructive Lung Disease\n(BREATH), member of the German Centre of Lung Research\n(DZL), Hanover, Germany; Roberto Badagliacca, Dipartimento\ndi Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari,\nSapienza\nUniversità\ndi\nRoma,\nRoma,\nItaly,\nDipartimento\nCardio-Toraco-Vascolare e\nChirurgia dei\nTrapianti\nd’Organo,\nPoliclinico Umberto I, Roma, Italy; Rolf M.F. Berger, Center for\nCongenital Heart Diseases, Beatrix Children’s Hospital, Dept of\nPaediatric\nCardiology,\nUniversity\nMedical\nCenter\nGroningen,\nUniversity of Groningen, Groningen, Netherlands; Margarita\nBrida, Department of Sports and Rehabilitation Medicine, Medical\nFaculty University of Rijeka, Rijeka, Croatia, Adult Congenital Heart\nCentre and National Centre for Pulmonary Hypertension, Royal\nBrompton & Hareﬁeld Hospitals, Guys & St Thomas’s NHS Trust,\nLondon,\nUnited\nKingdom;\nJørn\nCarlsen,\nDepartment\nof\nCardiology,\nCopenhagen\nUniversity\nHospital,\nRigshospitalet,\nCopenhagen, Denmark, Department of Clinical Medicine; Faculty of\nHealth\nand\nMedical\nSciences,\nUniversity\nof\nCopenhagen,\nCopenhagen, Denmark; Andrew J.S. Coats, Faculty of Medicine,\nUniversity of Warwick, Coventry, United Kingdom, Faculty of\nMedicine,\nMonash\nUniversity\nMelbourne,\nAustralia;\nPilar\nEscribano-Subias, Pulmonary Hypertension Unit, Cardiology\nDepartment, Hospital Universitario 12 de Octubre, Madrid, Spain,\nCIBER-CV (Centro de Investigaciones Biomédicas En Red de enfer-\nmedades CardioVasculares), Instituto de Salud Carlos III, Madrid,\nSpain, Facultad de Medicina, Universidad Complutense, Madrid,\nSpain; Pisana Ferrari (Italy), ESC Patient Forum, Sophia Antipolis,\nFrance, AIPI, Associazione Italiana Ipertensione Polmonare, Bologna,\nItaly; Diogenes S. Ferreira, Alergia e Imunologia, Hospital de\nClinicas, Universidade Federal do Parana, Curitiba, Brazil; Hossein\nArdeschir\nGhofrani,\nDepartment\nof\nInternal\nMedicine,\nUniversity\nHospital\nGiessen,\nJustus-Liebig\nUniversity,\nGiessen,\nGermany, Department of Pneumology, Kerckhoff Klinik, Bad\nNauheim, Germany, Department of Medicine, Imperial College\nLondon, London, United Kingdom; George Giannakoulas,\nCardiology\nDepartment,\nAristotle\nUniversity\nof\nThessaloniki,\nAHEPA University Hospital, Thessaloniki, Greece; David G. Kiely,\nDepartment of Infection, Immunity and Cardiovascular Disease,\nUniversity\nof\nShefﬁeld,\nShefﬁeld,\nUnited\nKingdom,\nShefﬁeld\nPulmonary Vascular Disease Unit, Shefﬁeld Teaching Hospitals NHS\nFoundation Trust, Shefﬁeld, United Kingdom, Insigneo Institute,\nUniversity of Shefﬁeld, Shefﬁeld, United Kingdom; Eckhard\nMayer,\nThoracic\nSurgery,\nKerckhoff\nClinic,\nBad\nNauheim,\nGermany; Gergely Meszaros (Hungary), ESC Patient Forum,\nSophia\nAntipolis,\nFrance,\nEuropean\nLung\nFoundation\n(ELF),\nShefﬁeld, United Kingdom; Blin Nagavci, Institute for Evidence in\nMedicine, Faculty of Medicine and Medical Center, University of\nFreiburg, Freiburg, Germany; Karen M. Olsson, Clinic of\nRespiratory Medicine, Hannover Medical School, member of the\nGerman Center of Lung Research (DZL), Hannover, Germany;\nJoanna Pepke-Zaba, Pulmonary Vascular Diseases Unit, Royal\nPapworth\nHospital,\nCambridge,\nUnited\nKingdom;\nJennifer\nK. Quint, NHLI, Imperial College London, London, United\nKingdom; Göran Rådegran, Department of Cardiology, Clinical\nSciences\nLund,\nFaculty\nof\nMedicine,\nLund,\nSweden,\nThe\nHaemodynamic Lab, The Section for Heart Failure and Valvular\nDisease, VO. Heart and Lung Medicine, Skåne University Hospital,\nLund, Sweden; Gerald Simonneau, Faculté Médecine, Université\nParis Saclay, Le Kremlin-Bicêtre, France, Centre de Référence de\nl’Hypertension\nPulmonaire,\nHopital\nMarie-Lannelongue,\nLe\nPlessis-Robinson, France; Olivier Sitbon, Faculty of Medicine,\nUniversité Paris-Saclay, Le Kremlin-Bicêtre, France, Service de\nPneumologie et Soins Intensifs Respiratoires, Centre de Référence\nde l’Hypertension Pulmonaire, Hôpital Bicêtre, Assistance Publique\nHôpitaux de Paris, Le Kremlin-Bicêtre, France, INSERM UMR_S\n999,\nHôpital Marie-Lannelongue,\nLe\nPlessis-Robinson,\nFrance;\nThomy Tonia, Institute of Social and Preventive Medicine,\nUniversity of Bern, Bern, Switzerland; Mark Toshner, Heart Lung\nResearch Institute, Dept of Medicine, University of Cambridge,\nCambridge,\nUnited\nKingdom,\nRoyal\nPapworth\nNHS\nTrust;\nJean-Luc Vachiery, Department of Cardiology, Pulmonary\nVascular Diseases and Heart Failure Clinic, HUB Hôpital Erasme,\nBrussels, Belgium; and Anton Vonk Noordegraaf, Pulmonology,\nAmsterdam UMC, Amsterdam, Netherlands.\n* Marc Humbert is supported by the Investissement d’Avenir pro-\ngramme managed by the French National Research Agency under\nthe grant contract ANR-18-RHUS-0006 (DESTINATION 2024).\n20. Appendix\nESC/ERS Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac Societies.\nESC/ERS Guidelines\n3711\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nDocument Reviewers: Markus Schwerzmann (ESC Review\nCoordinator) (Switzerland), Anh-Tuan Dinh-Xuan (ERS Review\nCoordinator)\n(France),\nAndy\nBush\n(United\nKingdom),\nMagdy\nAbdelhamid (Egypt), Victor Aboyans (France), Eloisa Arbustini (Italy),\nRiccardo Asteggiano (Italy), Joan-Albert Barberà (Spain), Maurice\nBeghetti (Switzerland), Jelena Čelutkienė (Lithuania), Maja Cikes\n(Croatia), Robin Condliffe (United Kingdom), Frances de Man\n(Netherlands), Volkmar Falk (Germany), Laurent Fauchier (France),\nSean Gaine (Ireland), Nazzareno Galié (Italy), Wendy Gin-Sing\n(United\nKingdom),\nJohn\nGranton\n(Canada),\nEkkehard\nGrünig\n(Germany), Paul M. Hassoun (United States of America), Merel\nHellemons (Netherlands), Tiny Jaarsma (Sweden), Barbro Kjellström\n(Sweden), Frederikus A. Klok (Netherlands), Aleksandra Konradi\n(Russian Federation), Konstantinos C. Koskinas (Switzerland), Dipak\nKotecha (United Kingdom), Irene Lang (Austria), Basil S. Lewis\n(Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip (United\nKingdom), Maja-Lisa Løchen (Norway), Alexander G. Mathioudakis\n(United Kingdom), Richard Mindham (United Kingdom), Shahin\nMoledina (United Kingdom), Robert Naeije (Belgium), Jens Cosedis\nNielsen (Denmark), Horst Olschewski (Austria), Isabelle Opitz\n(Switzerland), Steffen E. Petersen (United Kingdom), Eva Prescott\n(Denmark), Amina Rakisheva (Kazakhstan), Abilio Reis (Portugal),\nArsen D. Ristić (Serbia), Nicolas Roche (France), Rita Rodrigues\n(Portugal), Christine Selton-Suty (France), Rogerio Souza (Brazil),\nAndrew J. Swift (United Kingdom), Rhian M. Touyz (Canada/United\nKingdom), Silvia Ulrich (Switzerland), Martin R. Wilkins (United\nKingdom), and Stephen John Wort (United Kingdom).\nESC National Cardiac Societies actively involved in the review\nprocess of the 2022 ESC/ERS Guidelines for the diagnosis and treat-\nment of pulmonary hypertension: Algeria: Algerian Society of\nCardiology,\nMessaad\nKrim;\nArmenia:\nArmenian Cardiologists\nAssociation, Hamlet Hayrapetyan; Austria: Austrian Society of\nCardiology,\nIrene\nLang;\nAzerbaijan:\nAzerbaijan\nSociety\nof\nCardiology, Oktay Musayev; Belarus: Belorussian Scientiﬁc Society\nof\nCardiologists,\nIrina\nLazareva;\nBosnia\nand Herzegovina:\nAssociation of Cardiologists of Bosnia and Herzegovina, Šekib\nSokolović; Bulgaria: Bulgarian Society of Cardiology, Vasil Velchev;\nCroatia: Croatian Cardiac Society, Maja Cikes; Cyprus: Cyprus\nSociety of Cardiology, Ioannis Michaloliakos; Czechia: Czech Society\nof Cardiology, Pavel Jansa; Denmark: Danish Society of Cardiology,\nSøren Mellemkjær; Egypt: Egyptian Society of Cardiology, Ahmed\nHassan; Estonia: Estonian Society of Cardiology, Ly Anton;\nFinland: Finnish Cardiac Society, Markku Pentikäinen; France:\nFrench Society of Cardiology, Nicolas Meneveau; Georgia: Georgian\nSociety of Cardiology, Mikheil Tsverava; Germany: German Cardiac\nSociety, Mareike Lankeit; Greece: Hellenic Society of Cardiology,\nAthanasios Manginas; Hungary: Hungarian Society of Cardiology,\nIstvan Hizoh; Ireland: Irish Cardiac Society, Vincent Maher; Israel:\nIsrael Heart Society, Rafael Hirsch; Italy: Italian Federation of\nCardiology,\nNazzareno\nGalié;\nKazakhstan:\nAssociation\nof\nCardiologists of Kazakhstan, Murat A. Mukarov; Kosovo (Republic\nof): Kosovo Society of Cardiology, Pranvera Ibrahimi; Kyrgyzstan:\nKyrgyz Society of Cardiology, Sooronbaev Talant, Latvia: Latvian\nSociety of Cardiology, Ainars Rudzitis; Lebanon: Lebanese Society\nof Cardiology, Ghassan Kiwan; Lithuania: Lithuanian Society of\nCardiology, Lina Gumbienė; Luxembourg: Luxembourg Society of\nCardiology, Andrei Codreanu; Malta: Maltese Cardiac Society, Josef\nMicallef; Moldova (Republic of): Moldavian Society of Cardiology,\nEleonora\nVataman;\nMontenegro:\nMontenegro\nSociety\nof\nCardiology, Nebojsa Bulatovic; Morocco: Moroccan Society of\nCardiology, Said Chraibi; Netherlands: Netherlands Society of\nCardiology, Marco C. Post; North Macedonia: North Macedonian\nSociety of Cardiology, Elizabeta Srbinovska Kostovska; Norway:\nNorwegian\nSociety\nof\nCardiology,\nArne\nKristian\nAndreassen;\nPoland:\nPolish\nCardiac\nSociety,\nMarcin\nKurzyna;\nPortugal:\nPortuguese Society of Cardiology, Rui Plácido; Romania: Romanian\nSociety of Cardiology, Ioan Mircea Coman; Russian Federation:\nRussian Society of Cardiology, Oksana Vasiltseva; San Marino: San\nMarino Society of Cardiology, Marco Zavatta; Serbia: Cardiology\nSociety of Serbia, Arsen D. Ristić; Slovakia: Slovak Society of\nCardiology,\nIveta\nŠimkova;\nSlovenia:\nSlovenian\nSociety\nof\nCardiology, Gregor Poglajen; Spain: Spanish Society of Cardiology,\nMaría Lázaro Salvador; Sweden: Swedish Society of Cardiology,\nStefan Söderberg; Switzerland: Swiss Society of Cardiology, Silvia\nUlrich; Syrian Arab Republic: Syrian Cardiovascular Association,\nMhd Yassin Bani Marjeh; Tunisia: Tunisian Society of Cardiology\nand Cardio-Vascular Surgery, Fatma Ouarda; Turkey: Turkish\nSociety of Cardiology, Bulent Mutlu; Ukraine: Ukrainian Association\nof Cardiology, Yuriy Sirenko; United Kingdom of Great Britain\nand Northern Ireland: British Cardiovascular Society, J. Gerry\nCoghlan;\nand\nUzbekistan:\nAssociation\nof\nCardiologists\nof\nUzbekistan, Timur Abdullaev.\nESC Clinical Practice Guidelines (CPG) Committee: Colin\nBaigent (Chairperson) (United Kingdom), Magdy Abdelhamid (Egypt),\nVictor Aboyans (France), Sotiris Antoniou (United Kingdom), Elena\nArbelo (Spain), Riccardo Asteggiano (Italy), Andreas Baumbach\n(United Kingdom), Michael A. Borger (Germany), Jelena Čelutkienė\n(Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France),\nVolkmar Falk (Germany), Laurent Fauchier (France), Chris P. Gale\n(United\nKingdom),\nSigrun\nHalvorsen\n(Norway),\nBernard\nIung\n(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian\nFederation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha\n(United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel),\nAles Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard\nMindham (United Kingdom), Jens Cosedis Nielsen (Denmark),\nSteffen E. Petersen (United Kingdom), Eva Prescott (Denmark),\nAmina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian\nM. Touyz (Canada/ United Kingdom).\nIndependent Research Methodologists: Rebecca L. Morgan\n(United States of America) and Kapeena Sivakumaran (Canada).\n21. References\n1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M,\net al. Haemodynamic deﬁnitions and updated clinical classiﬁcation of pulmonary\nhypertension. Eur Respir J 2019;53:1801913.\n2. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines:\n1. Introduction-GRADE evidence proﬁles and summary of ﬁndings tables. J Clin\nEpidemiol 2011;64:383–394.\n3. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M,\net al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transpar-\nent approach to making well informed healthcare choices. 2: Clinical practice guide-\nlines. BMJ 2016;353:i2089.\n3712\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "appendix",
        "heart failure",
        "pulmonary hypertension"
      ]
    },
    {
      "number": "23",
      "title": "21. References",
      "start_page": 95,
      "end_page": 95,
      "content": "Document Reviewers: Markus Schwerzmann (ESC Review\nCoordinator) (Switzerland), Anh-Tuan Dinh-Xuan (ERS Review\nCoordinator)\n(France),\nAndy\nBush\n(United\nKingdom),\nMagdy\nAbdelhamid (Egypt), Victor Aboyans (France), Eloisa Arbustini (Italy),\nRiccardo Asteggiano (Italy), Joan-Albert Barberà (Spain), Maurice\nBeghetti (Switzerland), Jelena Čelutkienė (Lithuania), Maja Cikes\n(Croatia), Robin Condliffe (United Kingdom), Frances de Man\n(Netherlands), Volkmar Falk (Germany), Laurent Fauchier (France),\nSean Gaine (Ireland), Nazzareno Galié (Italy), Wendy Gin-Sing\n(United\nKingdom),\nJohn\nGranton\n(Canada),\nEkkehard\nGrünig\n(Germany), Paul M. Hassoun (United States of America), Merel\nHellemons (Netherlands), Tiny Jaarsma (Sweden), Barbro Kjellström\n(Sweden), Frederikus A. Klok (Netherlands), Aleksandra Konradi\n(Russian Federation), Konstantinos C. Koskinas (Switzerland), Dipak\nKotecha (United Kingdom), Irene Lang (Austria), Basil S. Lewis\n(Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip (United\nKingdom), Maja-Lisa Løchen (Norway), Alexander G. Mathioudakis\n(United Kingdom), Richard Mindham (United Kingdom), Shahin\nMoledina (United Kingdom), Robert Naeije (Belgium), Jens Cosedis\nNielsen (Denmark), Horst Olschewski (Austria), Isabelle Opitz\n(Switzerland), Steffen E. Petersen (United Kingdom), Eva Prescott\n(Denmark), Amina Rakisheva (Kazakhstan), Abilio Reis (Portugal),\nArsen D. Ristić (Serbia), Nicolas Roche (France), Rita Rodrigues\n(Portugal), Christine Selton-Suty (France), Rogerio Souza (Brazil),\nAndrew J. Swift (United Kingdom), Rhian M. Touyz (Canada/United\nKingdom), Silvia Ulrich (Switzerland), Martin R. Wilkins (United\nKingdom), and Stephen John Wort (United Kingdom).\nESC National Cardiac Societies actively involved in the review\nprocess of the 2022 ESC/ERS Guidelines for the diagnosis and treat-\nment of pulmonary hypertension: Algeria: Algerian Society of\nCardiology,\nMessaad\nKrim;\nArmenia:\nArmenian Cardiologists\nAssociation, Hamlet Hayrapetyan; Austria: Austrian Society of\nCardiology,\nIrene\nLang;\nAzerbaijan:\nAzerbaijan\nSociety\nof\nCardiology, Oktay Musayev; Belarus: Belorussian Scientiﬁc Society\nof\nCardiologists,\nIrina\nLazareva;\nBosnia\nand Herzegovina:\nAssociation of Cardiologists of Bosnia and Herzegovina, Šekib\nSokolović; Bulgaria: Bulgarian Society of Cardiology, Vasil Velchev;\nCroatia: Croatian Cardiac Society, Maja Cikes; Cyprus: Cyprus\nSociety of Cardiology, Ioannis Michaloliakos; Czechia: Czech Society\nof Cardiology, Pavel Jansa; Denmark: Danish Society of Cardiology,\nSøren Mellemkjær; Egypt: Egyptian Society of Cardiology, Ahmed\nHassan; Estonia: Estonian Society of Cardiology, Ly Anton;\nFinland: Finnish Cardiac Society, Markku Pentikäinen; France:\nFrench Society of Cardiology, Nicolas Meneveau; Georgia: Georgian\nSociety of Cardiology, Mikheil Tsverava; Germany: German Cardiac\nSociety, Mareike Lankeit; Greece: Hellenic Society of Cardiology,\nAthanasios Manginas; Hungary: Hungarian Society of Cardiology,\nIstvan Hizoh; Ireland: Irish Cardiac Society, Vincent Maher; Israel:\nIsrael Heart Society, Rafael Hirsch; Italy: Italian Federation of\nCardiology,\nNazzareno\nGalié;\nKazakhstan:\nAssociation\nof\nCardiologists of Kazakhstan, Murat A. Mukarov; Kosovo (Republic\nof): Kosovo Society of Cardiology, Pranvera Ibrahimi; Kyrgyzstan:\nKyrgyz Society of Cardiology, Sooronbaev Talant, Latvia: Latvian\nSociety of Cardiology, Ainars Rudzitis; Lebanon: Lebanese Society\nof Cardiology, Ghassan Kiwan; Lithuania: Lithuanian Society of\nCardiology, Lina Gumbienė; Luxembourg: Luxembourg Society of\nCardiology, Andrei Codreanu; Malta: Maltese Cardiac Society, Josef\nMicallef; Moldova (Republic of): Moldavian Society of Cardiology,\nEleonora\nVataman;\nMontenegro:\nMontenegro\nSociety\nof\nCardiology, Nebojsa Bulatovic; Morocco: Moroccan Society of\nCardiology, Said Chraibi; Netherlands: Netherlands Society of\nCardiology, Marco C. Post; North Macedonia: North Macedonian\nSociety of Cardiology, Elizabeta Srbinovska Kostovska; Norway:\nNorwegian\nSociety\nof\nCardiology,\nArne\nKristian\nAndreassen;\nPoland:\nPolish\nCardiac\nSociety,\nMarcin\nKurzyna;\nPortugal:\nPortuguese Society of Cardiology, Rui Plácido; Romania: Romanian\nSociety of Cardiology, Ioan Mircea Coman; Russian Federation:\nRussian Society of Cardiology, Oksana Vasiltseva; San Marino: San\nMarino Society of Cardiology, Marco Zavatta; Serbia: Cardiology\nSociety of Serbia, Arsen D. Ristić; Slovakia: Slovak Society of\nCardiology,\nIveta\nŠimkova;\nSlovenia:\nSlovenian\nSociety\nof\nCardiology, Gregor Poglajen; Spain: Spanish Society of Cardiology,\nMaría Lázaro Salvador; Sweden: Swedish Society of Cardiology,\nStefan Söderberg; Switzerland: Swiss Society of Cardiology, Silvia\nUlrich; Syrian Arab Republic: Syrian Cardiovascular Association,\nMhd Yassin Bani Marjeh; Tunisia: Tunisian Society of Cardiology\nand Cardio-Vascular Surgery, Fatma Ouarda; Turkey: Turkish\nSociety of Cardiology, Bulent Mutlu; Ukraine: Ukrainian Association\nof Cardiology, Yuriy Sirenko; United Kingdom of Great Britain\nand Northern Ireland: British Cardiovascular Society, J. Gerry\nCoghlan;\nand\nUzbekistan:\nAssociation\nof\nCardiologists\nof\nUzbekistan, Timur Abdullaev.\nESC Clinical Practice Guidelines (CPG) Committee: Colin\nBaigent (Chairperson) (United Kingdom), Magdy Abdelhamid (Egypt),\nVictor Aboyans (France), Sotiris Antoniou (United Kingdom), Elena\nArbelo (Spain), Riccardo Asteggiano (Italy), Andreas Baumbach\n(United Kingdom), Michael A. Borger (Germany), Jelena Čelutkienė\n(Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France),\nVolkmar Falk (Germany), Laurent Fauchier (France), Chris P. Gale\n(United\nKingdom),\nSigrun\nHalvorsen\n(Norway),\nBernard\nIung\n(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian\nFederation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha\n(United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel),\nAles Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard\nMindham (United Kingdom), Jens Cosedis Nielsen (Denmark),\nSteffen E. Petersen (United Kingdom), Eva Prescott (Denmark),\nAmina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian\nM. Touyz (Canada/ United Kingdom).\nIndependent Research Methodologists: Rebecca L. Morgan\n(United States of America) and Kapeena Sivakumaran (Canada).\n21. References\n1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M,\net al. Haemodynamic deﬁnitions and updated clinical classiﬁcation of pulmonary\nhypertension. Eur Respir J 2019;53:1801913.\n2. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines:\n1. Introduction-GRADE evidence proﬁles and summary of ﬁndings tables. J Clin\nEpidemiol 2011;64:383–394.\n3. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M,\net al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transpar-\nent approach to making well informed healthcare choices. 2: Clinical practice guide-\nlines. BMJ 2016;353:i2089.\n3712\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "arb",
        "pulmonary hypertension",
        "references",
        "diagnosis"
      ]
    },
    {
      "number": "24",
      "title": "21. References",
      "start_page": 95,
      "end_page": 109,
      "content": "Document Reviewers: Markus Schwerzmann (ESC Review\nCoordinator) (Switzerland), Anh-Tuan Dinh-Xuan (ERS Review\nCoordinator)\n(France),\nAndy\nBush\n(United\nKingdom),\nMagdy\nAbdelhamid (Egypt), Victor Aboyans (France), Eloisa Arbustini (Italy),\nRiccardo Asteggiano (Italy), Joan-Albert Barberà (Spain), Maurice\nBeghetti (Switzerland), Jelena Čelutkienė (Lithuania), Maja Cikes\n(Croatia), Robin Condliffe (United Kingdom), Frances de Man\n(Netherlands), Volkmar Falk (Germany), Laurent Fauchier (France),\nSean Gaine (Ireland), Nazzareno Galié (Italy), Wendy Gin-Sing\n(United\nKingdom),\nJohn\nGranton\n(Canada),\nEkkehard\nGrünig\n(Germany), Paul M. Hassoun (United States of America), Merel\nHellemons (Netherlands), Tiny Jaarsma (Sweden), Barbro Kjellström\n(Sweden), Frederikus A. Klok (Netherlands), Aleksandra Konradi\n(Russian Federation), Konstantinos C. Koskinas (Switzerland), Dipak\nKotecha (United Kingdom), Irene Lang (Austria), Basil S. Lewis\n(Israel), Ales Linhart (Czech Republic), Gregory Y.H. Lip (United\nKingdom), Maja-Lisa Løchen (Norway), Alexander G. Mathioudakis\n(United Kingdom), Richard Mindham (United Kingdom), Shahin\nMoledina (United Kingdom), Robert Naeije (Belgium), Jens Cosedis\nNielsen (Denmark), Horst Olschewski (Austria), Isabelle Opitz\n(Switzerland), Steffen E. Petersen (United Kingdom), Eva Prescott\n(Denmark), Amina Rakisheva (Kazakhstan), Abilio Reis (Portugal),\nArsen D. Ristić (Serbia), Nicolas Roche (France), Rita Rodrigues\n(Portugal), Christine Selton-Suty (France), Rogerio Souza (Brazil),\nAndrew J. Swift (United Kingdom), Rhian M. Touyz (Canada/United\nKingdom), Silvia Ulrich (Switzerland), Martin R. Wilkins (United\nKingdom), and Stephen John Wort (United Kingdom).\nESC National Cardiac Societies actively involved in the review\nprocess of the 2022 ESC/ERS Guidelines for the diagnosis and treat-\nment of pulmonary hypertension: Algeria: Algerian Society of\nCardiology,\nMessaad\nKrim;\nArmenia:\nArmenian Cardiologists\nAssociation, Hamlet Hayrapetyan; Austria: Austrian Society of\nCardiology,\nIrene\nLang;\nAzerbaijan:\nAzerbaijan\nSociety\nof\nCardiology, Oktay Musayev; Belarus: Belorussian Scientiﬁc Society\nof\nCardiologists,\nIrina\nLazareva;\nBosnia\nand Herzegovina:\nAssociation of Cardiologists of Bosnia and Herzegovina, Šekib\nSokolović; Bulgaria: Bulgarian Society of Cardiology, Vasil Velchev;\nCroatia: Croatian Cardiac Society, Maja Cikes; Cyprus: Cyprus\nSociety of Cardiology, Ioannis Michaloliakos; Czechia: Czech Society\nof Cardiology, Pavel Jansa; Denmark: Danish Society of Cardiology,\nSøren Mellemkjær; Egypt: Egyptian Society of Cardiology, Ahmed\nHassan; Estonia: Estonian Society of Cardiology, Ly Anton;\nFinland: Finnish Cardiac Society, Markku Pentikäinen; France:\nFrench Society of Cardiology, Nicolas Meneveau; Georgia: Georgian\nSociety of Cardiology, Mikheil Tsverava; Germany: German Cardiac\nSociety, Mareike Lankeit; Greece: Hellenic Society of Cardiology,\nAthanasios Manginas; Hungary: Hungarian Society of Cardiology,\nIstvan Hizoh; Ireland: Irish Cardiac Society, Vincent Maher; Israel:\nIsrael Heart Society, Rafael Hirsch; Italy: Italian Federation of\nCardiology,\nNazzareno\nGalié;\nKazakhstan:\nAssociation\nof\nCardiologists of Kazakhstan, Murat A. Mukarov; Kosovo (Republic\nof): Kosovo Society of Cardiology, Pranvera Ibrahimi; Kyrgyzstan:\nKyrgyz Society of Cardiology, Sooronbaev Talant, Latvia: Latvian\nSociety of Cardiology, Ainars Rudzitis; Lebanon: Lebanese Society\nof Cardiology, Ghassan Kiwan; Lithuania: Lithuanian Society of\nCardiology, Lina Gumbienė; Luxembourg: Luxembourg Society of\nCardiology, Andrei Codreanu; Malta: Maltese Cardiac Society, Josef\nMicallef; Moldova (Republic of): Moldavian Society of Cardiology,\nEleonora\nVataman;\nMontenegro:\nMontenegro\nSociety\nof\nCardiology, Nebojsa Bulatovic; Morocco: Moroccan Society of\nCardiology, Said Chraibi; Netherlands: Netherlands Society of\nCardiology, Marco C. Post; North Macedonia: North Macedonian\nSociety of Cardiology, Elizabeta Srbinovska Kostovska; Norway:\nNorwegian\nSociety\nof\nCardiology,\nArne\nKristian\nAndreassen;\nPoland:\nPolish\nCardiac\nSociety,\nMarcin\nKurzyna;\nPortugal:\nPortuguese Society of Cardiology, Rui Plácido; Romania: Romanian\nSociety of Cardiology, Ioan Mircea Coman; Russian Federation:\nRussian Society of Cardiology, Oksana Vasiltseva; San Marino: San\nMarino Society of Cardiology, Marco Zavatta; Serbia: Cardiology\nSociety of Serbia, Arsen D. Ristić; Slovakia: Slovak Society of\nCardiology,\nIveta\nŠimkova;\nSlovenia:\nSlovenian\nSociety\nof\nCardiology, Gregor Poglajen; Spain: Spanish Society of Cardiology,\nMaría Lázaro Salvador; Sweden: Swedish Society of Cardiology,\nStefan Söderberg; Switzerland: Swiss Society of Cardiology, Silvia\nUlrich; Syrian Arab Republic: Syrian Cardiovascular Association,\nMhd Yassin Bani Marjeh; Tunisia: Tunisian Society of Cardiology\nand Cardio-Vascular Surgery, Fatma Ouarda; Turkey: Turkish\nSociety of Cardiology, Bulent Mutlu; Ukraine: Ukrainian Association\nof Cardiology, Yuriy Sirenko; United Kingdom of Great Britain\nand Northern Ireland: British Cardiovascular Society, J. Gerry\nCoghlan;\nand\nUzbekistan:\nAssociation\nof\nCardiologists\nof\nUzbekistan, Timur Abdullaev.\nESC Clinical Practice Guidelines (CPG) Committee: Colin\nBaigent (Chairperson) (United Kingdom), Magdy Abdelhamid (Egypt),\nVictor Aboyans (France), Sotiris Antoniou (United Kingdom), Elena\nArbelo (Spain), Riccardo Asteggiano (Italy), Andreas Baumbach\n(United Kingdom), Michael A. Borger (Germany), Jelena Čelutkienė\n(Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France),\nVolkmar Falk (Germany), Laurent Fauchier (France), Chris P. Gale\n(United\nKingdom),\nSigrun\nHalvorsen\n(Norway),\nBernard\nIung\n(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian\nFederation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha\n(United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel),\nAles Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard\nMindham (United Kingdom), Jens Cosedis Nielsen (Denmark),\nSteffen E. Petersen (United Kingdom), Eva Prescott (Denmark),\nAmina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian\nM. Touyz (Canada/ United Kingdom).\nIndependent Research Methodologists: Rebecca L. Morgan\n(United States of America) and Kapeena Sivakumaran (Canada).\n21. References\n1. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M,\net al. Haemodynamic deﬁnitions and updated clinical classiﬁcation of pulmonary\nhypertension. Eur Respir J 2019;53:1801913.\n2. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines:\n1. Introduction-GRADE evidence proﬁles and summary of ﬁndings tables. J Clin\nEpidemiol 2011;64:383–394.\n3. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M,\net al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transpar-\nent approach to making well informed healthcare choices. 2: Clinical practice guide-\nlines. BMJ 2016;353:i2089.\n3712\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n4. Nagavci B, Tonia T, Roche N, Genton C, Vaccaro V, Humbert M, et al. European\nRespiratory Society clinical practice guidelines: methodological guidance. ERJ Open\nRes 2022;8:0655–2021.\n5. Schünemann HB, Guyatt G, Oxman A. GRADE handbook for grading quality of evi-\ndence and strength of recommendations. The GRADE Working Group; 2013.\n6. Miravitlles M, Tonia T, Rigau D, Roche N, Genton C, Vaccaro V, et al. New era for\nEuropean Respiratory Society clinical practice guidelines: joining efﬁciency and high\nmethodological standards. Eur Respir J 2018;51:1800221.\n7. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary arterial pressure during\nrest and exercise in healthy subjects: a systematic review. Eur Respir J 2009;34:\n888–894.\n8. Kovacs G, Olschewski A, Berghold A, Olschewski H. Pulmonary vascular resis-\ntances during exercise in normal subjects: a systematic review. Eur Respir J 2012;\n39:319–328.\n9. Wolsk E, Bakkestrom R, Thomsen JH, Balling L, Andersen MJ, Dahl JS, et al. The in-\nﬂuence of age on hemodynamic parameters during rest and exercise in healthy in-\ndividuals. JACC Heart Fail 2017;5:337–346.\n10. Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, et al.\nAssociation of borderline pulmonary hypertension with mortality and hospitaliza-\ntion in a large patient cohort: insights from the Veterans Affairs Clinical\nAssessment, Reporting, and Tracking program. Circulation 2016;133:1240–1248.\n11. Douschan P, Kovacs G, Avian A, Foris V, Gruber F, Olschewski A, et al. Mild eleva-\ntion of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care\nMed 2018;197:509–516.\n12. Kolte D, Lakshmanan S, Jankowich MD, Brittain EL, Maron BA, Choudhary G. Mild\npulmonary hypertension is associated with increased mortality: a systematic review\nand meta-analysis. J Am Heart Assoc 2018;7:e009729.\n13. Maron BA, Brittain EL, Hess E, Waldo SW, Baron AE, Huang S, et al. Pulmonary\nvascular resistance and clinical outcomes in patients with pulmonary hypertension:\na retrospective cohort study. Lancet Respir Med 2020;8:873–884.\n14. Xanthouli P, Jordan S, Milde N, Marra A, Blank N, Egenlauf B, et al. Haemodynamic\nphenotypes and survival in patients with systemic sclerosis: the impact of the new\ndeﬁnition of pulmonary arterial hypertension. Ann Rheum Dis 2020;79:370–378.\n15. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE,\net al. How to diagnose diastolic heart failure: a consensus statement on the diagno-\nsis of heart failure with normal left ventricular ejection fraction by the Heart Failure\nand Echocardiography Associations of the European Society of Cardiology. Eur\nHeart J 2007;28:2539–2550.\n16. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to\ndiagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic al-\ngorithm: a consensus recommendation from the Heart Failure Association (HFA)\nof the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297–3317.\n17. Zeder K, BanﬁC, Steinrisser-Allex G, Maron BA, Humbert M, Lewis GD, et al.\nDiagnostic, prognostic and differential-diagnostic relevance of pulmonary hemo-\ndynamics during exercise - a systematic review. Eur Respir J 2022;2:103181.\n18. Ho JE, Zern EK, Lau ES, Wooster L, Bailey CS, Cunningham T, et al. Exercise pul-\nmonary hypertension predicts clinical outcomes in patients with dyspnea on effort.\nJ Am Coll Cardiol 2020;75:17–26.\n19. Stamm A, Saxer S, Lichtblau M, Hasler ED, Jordan S, Huber LC, et al. Exercise pul-\nmonary haemodynamics predict outcome in patients with systemic sclerosis. Eur\nRespir J 2016;48:1658–1667.\n20. Hasler ED, Muller-Mottet S, Furian M, Saxer S, Huber LC, Maggiorini M, et al.\nPressure-ﬂow during exercise catheterization predicts survival in pulmonary hyper-\ntension. Chest 2016;150:57–67.\n21. Lewis GD, Murphy RM, Shah RV, Pappagianopoulos PP, Malhotra R, Bloch KD, et al.\nPulmonary vascular response patterns during exercise in left ventricular systolic\ndysfunction predict exercise capacity and outcomes. Circ Heart Fail 2011;4:\n276–285.\n22. Zeder K, Avian A, Bachmaier G, Douschan P, Foris V, Sassmann T, et al. Exercise\npulmonary resistances predict long-term survival in systemic sclerosis. Chest\n2021;159:781–790.\n23. Eisman AS, Shah RV, Dhakal BP, Pappagianopoulos PP, Wooster L, Bailey C, et al.\nPulmonary capillary wedge pressure patterns during exercise predict exercise cap-\nacity and incident heart failure. Circ Heart Fail 2018;11:e004750.\n24. Bentley RF, Barker M, Esfandiari S, Wright SP, Valle FH, Granton JT, et al. Normal\nand abnormal relationships of pulmonary artery to wedge pressure during exercise.\nJ Am Heart Assoc 2020;9:e016339.\n25. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS\nGuidelines for the diagnosis and treatment of pulmonary hypertension: The Joint\nTask Force for the Diagnosis and Treatment of Pulmonary Hypertension of the\nEuropean Society of Cardiology (ESC) and the European Respiratory Society\n(ERS): Endorsed by: Association for European Paediatric and Congenital\nCardiology (AEPC), International Society for Heart and Lung Transplantation\n(ISHLT). Eur Respir J 2015;46:903–975.\n26. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS\nGuidelines for the diagnosis and treatment of pulmonary hypertension: The Joint\nTask Force for the Diagnosis and Treatment of Pulmonary Hypertension of the\nEuropean Society of Cardiology (ESC) and the European Respiratory Society\n(ERS): Endorsed by: Association for European Paediatric and Congenital\nCardiology (AEPC), International Society for Heart and Lung Transplantation\n(ISHLT). Eur Heart J 2016;37:67–119.\n27. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021\nESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.\nEur Heart J 2021;42:3599–3726.\n28. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021\nESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J\n2022;43:561–632.\n29. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A\nglobal view of pulmonary hypertension. Lancet Respir Med 2016;4:306–322.\n30. NHS Digital. National Audit of Pulmonary Hypertension 10th Annual Report,\nGreat Britain, 2018-19. https://digital.nhs.uk/data-and-information/publications/\nstatistical/national-pulmonary-hypertension-audit/2019# (24 March 2022, date\nlast accessed 22 July 2022).\n31. Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and\nchronic thromboembolic pulmonary hypertension: identiﬁcation of the most ac-\ncurate estimates from a systematic literature review. Pulm Circ 2021;11:\n2045894020977300.\n32. Lau EMT, Giannoulatou E, Celermajer DS, Humbert M. Epidemiology and treat-\nment of pulmonary arterial hypertension. Nat Rev Cardiol 2017;14:603–614.\n33. Montani D, Girerd B, Jais X, Laveneziana P, Lau EMT, Bouchachi A, et al. Screening\nfor pulmonary arterial hypertension in adults carrying a BMPR2 mutation. The Eur\nRespir J 2020;58:2004229.\n34. Certain MC, Chaumais MC, Jais X, Savale L, Seferian A, Parent F, et al.\nCharacteristics and long-term outcomes of pulmonary venoocclusive disease in-\nduced by mitomycin C. Chest 2021;159:1197–1207.\n35. Cornet L, Khouri C, Roustit M, Guignabert C, Chaumais MC, Humbert M, et al.\nPulmonary arterial hypertension associated with protein kinase inhibitors: a\npharmacovigilance-pharmacodynamic study. Eur Respir J 2019;53:1802472.\n36. McGee M, Whitehead N, Martin J, Collins N. Drug-associated pulmonary arterial\nhypertension. Clin Toxicol 2018;56:801–809.\n37. McGregor PC, Boosalis V, Aragam J. Carﬁlzomib-induced pulmonary hypertension\nwith associated right ventricular dysfunction: A case report. SAGE Open Med Case\nRep 2021;9:2050313X21994031.\n38. Montani D, Lau EM, Descatha A, Jais X, Savale L, Andujar P, et al. Occupational ex-\nposure to organic solvents: a risk factor for pulmonary veno-occlusive disease. Eur\nRespir J 2015;46:1721–1731.\n39. Savale L, Chaumais MC, Cottin V, Bergot E, Frachon I, Prevot G, et al. Pulmonary\nhypertension associated with benﬂuorex exposure. Eur Respir J 2012;40:\n1164–1172.\n40. Weatherald J, Bondeelle L, Chaumais MC, Guignabert C, Savale L, Jais X, et al.\nPulmonary complications of Bcr-Abl tyrosine kinase inhibitors. Eur Respir J 2020;\n56:2000279.\n41. Philen RM, Posada M. Toxic oil syndrome and eosinophilia-myalgia syndrome: May\n8–10, 1991, World Health Organization meeting report. Semin Arthritis Rheum\n1993;23:104–124.\n42. Hertzman PA, Clauw DJ, Kaufman LD, Varga J, Silver RM, Thacker HL, et al. The\neosinophilia-myalgia syndrome: status of 205 patients and results of treatment 2\nyears after onset. Ann Intern Med 1995;122:851–855.\n43. Walker AM, Langleben D, Korelitz JJ, Rich S, Rubin LJ, Strom BL, et al. Temporal\ntrends and drug exposures in pulmonary hypertension: an American experience.\nAm Heart J 2006;152:521–526.\n44. Chen SC, Dastamani A, Pintus D, Yau D, Aftab S, Bath L, et al. Diazoxide-induced\npulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations\nfrom a multicentre study in the UK. Clin Endocrinol (Oxf) 2019;91:770–775.\n45. Timlin MR, Black AB, Delaney HM, Matos RI, Percival CS. Development of pulmon-\nary hypertension during treatment with diazoxide: a case series and literature re-\nview. Pediatr Cardiol 2017;38:1247–1250.\n46. Global Burden of Disease Study Collaborators. Global, regional, and national inci-\ndence, prevalence, and years lived with disability for 301 acute and chronic diseases\nand injuries in 188 countries, 1990-2013: a systematic analysis for the Global\nBurden of Disease Study 2013. Lancet 2015;386:743–800.\n47. Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiery JL.\nLeft ventricular heart failure and pulmonary hypertension. Eur Heart J 2016;37:\n942–954.\n48. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redﬁeld MM. Pulmonary\nhypertension in heart failure with preserved ejection fraction: a community-based\nstudy. J Am Coll Cardiol 2009;53:1119–1126.\n49. Tichelbacker T, Dumitrescu D, Gerhardt F, Stern D, Wissmuller M, Adam M, et al.\nPulmonary hypertension and valvular heart disease. Herz 2019;44:491–501.\nESC/ERS Guidelines\n3713\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n50. Weber L, Rickli H, Haager PK, Joerg L, Weilenmann D, Brenner R, et al.\nHaemodynamic mechanisms and long-term prognostic impact of pulmonary\nhypertension in patients with severe aortic stenosis undergoing valve replacement.\nEur J Heart Fail 2019;21:172–181.\n51. Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C, et al. Pulmonary\nhypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013;41:\n1292–1301.\n52. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al.\nPulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019;\n53:1801914.\n53. Naeije R. Pulmonary hypertension at high altitude. Eur Respir J 2019;53:1900985.\n54. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I, et al. ERS statement\non chronic thromboembolic pulmonary hypertension. Eur Respir J 2020;57:\n2002828.\n55. Kramm T, Wilkens H, Fuge J, Schäfers H-J, Guth S, Wiedenroth CB, et al. Incidence\nand characteristics of chronic thromboembolic pulmonary hypertension in\nGermany. Clinical research in cardiology: ofﬁcial journal of the German Cardiac\nSociety 1–6 (2018) doi:10.1007/s00392-018-1215-5.\n56. Swietlik EM, Ruggiero A, Fletcher AJ, Taboada D, Knightbridge E, Harlow L, et al.\nLimitations of resting haemodynamics in chronic thromboembolic disease without\npulmonary hypertension. Eur Respir J 2019;53:1801787.\n57. Kalantari S, Gomberg-Maitland M. Group 5 pulmonary hypertension: the orphan’s\norphan disease. Cardiol Clin 2016;34:443–449.\n58. Shlobin OA, Kouranos V, Barnett SD, Alhamad EH, Culver DA, Barney J, et al.\nPhysiological predictors of survival in patients with sarcoidosis-associated pulmon-\nary hypertension: results from an international registry. Eur Respir J 2020;55:\n1901747.\n59. Boucly A, Cottin V, Nunes H, Jais X, Tazi A, Prevot G, et al. Management and long-\nterm outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J\n2017;50:1700465.\n60. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al.\nPrimary pulmonary hypertension. A national prospective study. Ann Intern Med\n1987;107:216–223.\n61. Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, et al. Registry and survival\nstudy in Chinese patients with idiopathic and familial pulmonary arterial hyperten-\nsion. Chest 2007;132:373–379.\n62. Galiè N, Saia F, Palazzini M, Manes A, Russo V, Bacchi Reggiani ML, et al. Left main\ncoronary artery compression in patients with pulmonary arterial hypertension and\nangina. J Am Coll Cardiol 2017;69:2808–2817.\n63. Kovacs G, Avian A, Foris V, Tscherner M, Kqiku X, Douschan P, et al. Use of ECG\nand other simple non-invasive tools to assess pulmonary hypertension. PLoS One\n2016;11:e0168706.\n64. Bonderman D, Wexberg P, Martischnig AM, Heinzl H, Lang MB, Sadushi R, et al. A\nnoninvasive algorithm to exclude pre-capillary pulmonary hypertension. Eur Respir J\n2011;37:1096–1103.\n65. Klok FA, Surie S, Kempf T, Eikenboom J, van Straalen JP, van Kralingen KW, et al. A\nsimple non-invasive diagnostic algorithm for ruling out chronic thromboembolic\npulmonary hypertension in patients after acute pulmonary embolism. Thromb\nRes 2011;128:21–26.\n66. Henkens IR, Mouchaers KT, Vonk-Noordegraaf A, Boonstra A, Swenne CA, Maan\nAC, et al. Improved ECG detection of presence and severity of right ventricular\npressure load validated with cardiac magnetic resonance imaging. Am J Physiol\nHeart Circ Physiol 2008;294:H2150–H2157.\n67. Rich JD, Thenappan T, Freed B, Patel AR, Thisted RA, Childers R, et al. QTc pro-\nlongation is associated with impaired right ventricular function and predicts mortal-\nity in pulmonary hypertension. Int J Cardiol 2013;167:669–676.\n68. Remy-Jardin M, Ryerson CJ, Schiebler ML, Leung ANC, Wild JM, Hoeper MM, et al.\nImaging of pulmonary hypertension in adults: a position paper from the Fleischner\nSociety. Eur Respir J 2021;57:2004455.\n69. Ascha M, Renapurkar RD, Tonelli AR. A review of imaging modalities in pulmonary\nhypertension. Ann Thorac Med 2017;12:61–73.\n70. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al.\nDeﬁnitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62:\nD42–D50.\n71. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pul-\nmonary hypertension. J Am Coll Cardiol 2003;41:1028–1035.\n72. Meyer FJ, Ewert R, Hoeper MM, Olschewski H, Behr J, Winkler J, et al. Peripheral\nairway obstruction in primary pulmonary hypertension. Thorax 2002;57:473–476.\n73. Alonso-Gonzalez R, Borgia F, Diller GP, Inuzuka R, Kempny A, Martinez-Naharro A,\net al. Abnormal lung function in adults with congenital heart disease: prevalence, rela-\ntion to cardiac anatomy, and association with survival. Circulation 2013;127:882–890.\n74. Hoeper MM, Dwivedi K, Pausch C, Lewis RA, Olsson KM, Huscher D, et al.\nPhenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet\nRespir Med 2022. Jun\n28:S2213-2600(22)00097-2. doi: 10.1016/S2213-2600(22)\n00097-2. Epub ahead of print. PMID: 35777416\n75. Hoeper MM, Meyer K, Rademacher J, Fuge J, Welte T, Olsson KM. Diffusion cap-\nacity and mortality in patients with pulmonary hypertension due to heart failure\nwith preserved ejection fraction. JACC Heart Fail 2016;4:441–449.\n76. Olson TP, Johnson BD, Borlaug BA. Impaired pulmonary diffusion in heart failure\nwith preserved ejection fraction. JACC Heart Fail 2016;4:490–498.\n77. Olsson KM, Fuge J, Meyer K, Welte T, Hoeper MM. More on idiopathic pulmonary\narterial hypertension with a low diffusing capacity. Eur Respir J 2017;50:1700354.\n78. Trip P, Nossent EJ, de Man FS, van den Berk IA, Boonstra A, Groepenhoff H, et al.\nSeverely reduced diffusion capacity in idiopathic pulmonary arterial hypertension:\npatient characteristics and treatment responses. Eur Respir J 2013;42:1575–1585.\n79. Melot C, Naeije R. Pulmonary vascular diseases. Compr Physiol 2011;1:593–619.\n80. Harbaum L, Fuge J, Kamp JC, Hennigs JK, Simon M, Sinning C, et al. Blood carbon\ndioxide tension and risk in pulmonary arterial hypertension. Int J Cardiol 2020;318:\n131–137.\n81. Jilwan FN, Escourrou P, Garcia G, Jais X, Humbert M, Roisman G. High occurrence\nof hypoxemic sleep respiratory disorders in precapillary pulmonary hypertension\nand mechanisms. Chest 2013;143:47–55.\n82. Rudski LG, Lai WW, Aﬁlalo J, Hua L, Handschumacher MD, Chandrasekaran K,\net al. Guidelines for the echocardiographic assessment of the right heart in adults:\na report from the American Society of Echocardiography endorsed by the\nEuropean Association of Echocardiography, a registered branch of the European\nSociety of Cardiology, and the Canadian Society of Echocardiography. J Am Soc\nEchocardiogr 2010;23:685–713.\n83. Lang RM, Badano LP, Mor-Avi V, Aﬁlalo J, Armstrong A, Ernande L, et al.\nRecommendations for cardiac chamber quantiﬁcation by echocardiography in adults:\nan update from the American Society of Echocardiography and the European\nAssociation of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233–270.\n84. Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al.\nStandardization of adult transthoracic echocardiography reporting in agreement\nwith recent chamber quantiﬁcation, diastolic function, and heart valve disease re-\ncommendations: an expert consensus document of the European Association of\nCardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017;18:1301–1310.\n85. Farber HW, Foreman AJ, Miller DP, McGoon MD. REVEAL Registry: correlation of\nright heart catheterization and echocardiography in patients with pulmonary arter-\nial hypertension. Congest Heart Fail 2011;17:56–64.\n86. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al.\nEchocardiographic assessment of pulmonary hypertension in patients with ad-\nvanced lung disease. Am J Respir Crit Care Med 2003;167:735–740.\n87. Fisher MR, Forﬁa PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, et al.\nAccuracy of Doppler echocardiography in the hemodynamic assessment of pul-\nmonary hypertension. Am J Respir Crit Care Med 2009;179:615–621\n88. D’Alto M, Di Maio M, Romeo E, Argiento P, Blasi E, Di Vilio A, et al.\nEchocardiographic probability of pulmonary hypertension: a validation study.\nEur Respir J. 2022;2102548. doi:10.1183/13993003.02548-2021. Epub ahead of\nprint.\n89. Jankowich M, Maron BA, Choudhary G. Mildly elevated pulmonary artery systolic\npressure on echocardiography: bridging the gap in current guidelines. Lancet\nRespir Med 2021;9:1185–1191.\n90. Huston JH, Maron BA, French J, Huang S, Thayer T, Farber-Eger EH, et al.\nAssociation of mild echocardiographic pulmonary hypertension with mortality\nand right ventricular function. JAMA Cardiol 2019;4:1112–1121.\n91. Gall H, Yogeswaran A, Fuge J, Sommer N, Grimminger F, Seeger W, et al. Validity of\nechocardiographic tricuspid regurgitation gradient to screen for new deﬁnition of\npulmonary hypertension. E Clin Med 2021;34:100822.\n92. D’Alto M, Romeo E, Argiento P, D’Andrea A, Vanderpool R, Correra A, et al.\nAccuracy and precision of echocardiography versus right heart catheterization\nfor the assessment of pulmonary hypertension. Int J Cardiol 2013;168:4058–4062.\n93. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hyperten-\nsion diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012;\n39:112–118.\n94. Parent F, Bachir D, Inamo J, Lionnet F, Driss F, Loko G, et al. A hemodynamic study\nof pulmonary hypertension in sickle cell disease. N Engl J Med 2011;365:44–53.\n95. Grunig E, Henn P, D’Andrea A, Claussen M, Ehlken N, Maier F, et al. Reference va-\nlues for and determinants of right atrial area in healthy adults by 2-dimensional\nechocardiography. Circ Cardiovasc Imaging 2013;6:117–124.\n96. Tello K, Wan J, Dalmer A, Vanderpool R, Ghofrani HA, Naeije R, et al. Validation of\nthe tricuspid annular plane systolic excursion/systolic pulmonary artery pressure\nratio for the assessment of right ventricular-arterial coupling in severe pulmonary\nhypertension. Circ Cardiovasc Imaging 2019;12:e009047.\n97. Tello K, Axmann J, Ghofrani HA, Naeije R, Narcin N, Rieth A, et al. Relevance of the\nTAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol 2018;266:\n229–235.\n98. Guazzi M, Dixon D, Labate V, Beussink-Nelson L, Bandera F, Cuttica MJ, et al. RV\ncontractile function and its coupling to pulmonary circulation in heart failure with\n3714\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\npreserved ejection fraction: stratiﬁcation of clinical phenotypes and outcomes.\nJACC Cardiovasc Imaging 2017;10:1211–1221.\n99. Arkles JS, Opotowsky AR, Ojeda J, Rogers F, Liu T, Prassana V, et al. Shape of the\nright ventricular Doppler envelope predicts hemodynamics and right heart function\nin pulmonary hypertension. Am J Respir Crit Care Med 2011;183:268–276.\n100. Takahama H, McCully RB, Frantz RP, Kane GC. Unraveling the RV ejection Doppler\nenvelope: insight into pulmonary artery hemodynamics and disease severity. JACC\nCardiovasc Imaging 2017;10:1268–1277.\n101. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, et al.\n2020 ESC Guidelines for the management of adult congenital heart disease. Eur\nHeart J 2021;42:563–645.\n102. Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, et al. Chronic\nthromboembolic pulmonary hypertension. Eur Respir J 2019;53:1801915.\n103. Konstantinides SV, Meyer G, Becattini C, Fauueno H, Bueno H, Geersing GJ, et al.\n2019 ESC Guidelines for the diagnosis and management of acute pulmonary em-\nbolism developed in collaboration with the European Respiratory Society (ERS).\nEur Heart J 2020;41:543–603.\n104. He J, Fang W, Lv B, He JG, Xiong CM, Liu ZH, et al. Diagnosis of chronic thrombo-\nembolic pulmonary hypertension: comparison of ventilation/perfusion scanning\nand multidetector computed tomography pulmonary angiography with pulmonary\nangiography. Nucl Med Commun 2012;33:459–463.\n105. Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, et al.\nVentilation-perfusion scintigraphy is more sensitive than multidetector CTPA in\ndetecting chronic thromboembolic pulmonary disease as a treatable cause of pul-\nmonary hypertension. J Nucl Med 2007;48:680–684.\n106. Giordano J, Khung S, Duhamel A, Hossein-Foucher C, Bellevre D, Lamblin N, et al.\nLung perfusion characteristics in pulmonary arterial hypertension (PAH) and per-\nipheral forms of chronic thromboembolic pulmonary hypertension (pCTEPH):\ndual-energy CT experience in 31 patients. Eur Radiol 2017;27:1631–1639.\n107. Seferian A, Helal B, Jais X, Girerd B, Price LC, Gunther S, et al. Ventilation/perfusion\nlung scan in pulmonary veno-occlusive disease. Eur Respir J 2012;40:75–83.\n108. Swift AJ, Dwivedi K, Johns C, Garg P, Chin M, Currie BJ, et al. Diagnostic accuracy of\nCT pulmonary angiography in suspected pulmonary hypertension. Eur Radiol 2020;\n30:4918–4929.\n109. Dong C, Zhou M, Liu D, Long X, Guo T, Kong X. Diagnostic accuracy of computed\ntomography for chronic thromboembolic pulmonary hypertension: a systematic\nreview and meta-analysis. PLoS One 2015;10:e0126985.\n110. Rajaram S, Swift AJ, Capener D, Telfer A, Davies C, Hill C, et al. Diagnostic accuracy\nof contrast-enhanced MR angiography and unenhanced proton MR imaging com-\npared with CT pulmonary angiography in chronic thromboembolic pulmonary\nhypertension. Eur Radiol 2012;22:310–317.\n111. Ende-Verhaar YM, Meijboom LJ, Kroft LJM, Beenen LFM, Boon GJAM, Middeldorp\nS, et al. Usefulness of standard computed tomography pulmonary angiography per-\nformed for acute pulmonary embolism for identiﬁcation of chronic thrombo-\nembolic pulmonary hypertension: results of the InShape III study. J Heart Lung\nTransplant 2019;38:731–738.\n112. Guerin L, Couturaud F, Parent F, Revel MP, Gillaizeau F, Planquette B, et al.\nPrevalence of chronic thromboembolic pulmonary hypertension after acute pul-\nmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb\nHaemost 2014;112:598–605.\n113. Tamura M, Yamada Y, Kawakami T, Kataoka M, Iwabuchi Y, Sugiura H, et al.\nDiagnostic accuracy of lung subtraction iodine mapping CT for the evaluation of\npulmonary perfusion in patients with chronic thromboembolic pulmonary hyper-\ntension: correlation with perfusion SPECT/CT. Int J Cardiol 2017;243:538–543.\n114. Masy M, Giordano J, Petyt G, Hossein-Foucher C, Duhamel A, Kyheng M, et al.\nDual-energy CT (DECT) lung perfusion in pulmonary hypertension: concordance\nrate with V/Q scintigraphy in diagnosing chronic thromboembolic pulmonary\nhypertension (CTEPH). Eur Radiol 2018;28:5100–5110.\n115. Hinrichs JB, Marquardt S, von Falck C, Hoeper MM, Olsson KM, Wacker FK, et al.\nComparison of C-arm computed tomography and digital subtraction angiography\nin patients with chronic thromboembolic pulmonary hypertension. Cardiovasc\nIntervent Radiol 2016;39:53–63.\n116. Hinrichs JB, Renne J, Hoeper MM, Olsson KM, Wacker FK, Meyer BC. Balloon pul-\nmonary angioplasty: applicability of C-Arm CT for procedure guidance. Eur Radiol\n2016;26:4064–4071.\n117. Swift AJ, Lu H, Uthoff J, Garg P, Cogliano M, Taylor J, et al. A machine learning car-\ndiac magnetic resonance approach to extract disease features and automate pul-\nmonary arterial hypertension diagnosis. Eur Heart J Cardiovasc Imaging 2021;22:\n236–245.\n118. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med 2017;\n377:2298.\n119. Rosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM. Systemic conse-\nquences of pulmonary hypertension and right-sided heart failure. Circulation\n2020;141:678–693.\n120. Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients\nwith primary pulmonary hypertension. Circulation 2001;104:429–435.\n121. Boerrigter BG, Bogaard HJ, Trip P, Groepenhoff H, Rietema H, Holverda S, et al.\nVentilatory and cardiocirculatory exercise proﬁles in COPD: the role of pulmonary\nhypertension. Chest 2012;142:1166–1174.\n122. Caravita S, Faini A, Deboeck G, Bondue A, Naeije R, Parati G, et al. Pulmonary\nhypertension and ventilation during exercise: role of the pre-capillary component.\nJ Heart Lung Transplant 2017;36:754–762.\n123. Dumitrescu D, Nagel C, Kovacs G, Bollmann T, Halank M, Winkler J, et al.\nCardiopulmonary exercise testing for detecting pulmonary arterial hypertension\nin systemic sclerosis. Heart 2017;103:774–782.\n124. Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, et al. The\n2016 International Society for Heart Lung Transplantation listing criteria for heart\ntransplantation: a 10-year update. J Heart Lung Transplant 2016;35:1–23.\n125. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al.\nComplications of right heart catheterization procedures in patients with pulmon-\nary hypertension in experienced centers. J Am Coll Cardiol 2006;48:2546–2552.\n126. Kovacs G, Avian A, Olschewski A, Olschewski H. Zero reference level for right\nheart catheterisation. Eur Respir J 2013;42:1586–1594.\n127. Opotowsky AR, Hess E, Maron BA, Brittain EL, Baron AE, Maddox TM, et al.\nThermodilution vs estimated Fick cardiac output measurement in clinical practice:\nan analysis of mortality from the Veterans Affairs Clinical Assessment, Reporting,\nand Tracking (VA CART) Program and Vanderbilt University. JAMA Cardiol 2017;\n2:1090–1099.\n128. Viray MC, Bonno EL, Gabrielle ND, Maron BA, Atkins J, Amoroso NS, et al. Role of\npulmonary artery wedge pressure saturation during right heart catheterization: a\nprospective study. Circ Heart Fail 2020;13:e007981.\n129. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, et al. Long-term\nresponse to calcium channel blockers in idiopathic pulmonary arterial hyperten-\nsion. Circulation 2005;111:3105–3111.\n130. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A\ncomparison of the acute hemodynamic effects of inhaled nitric oxide and aerosol-\nized iloprost in primary pulmonary hypertension. German PPH study group. J Am\nColl Cardiol 2000;35:176–182.\n131. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, et al.\nAssessment of the vasodilator response in primary pulmonary hypertension.\nComparing prostacyclin and iloprost administered by either infusion or inhalation.\nEur Heart J 2003;24:356–365.\n132. Jing ZC, Jiang X, Han ZY, Xu XQ, Wang Y, Wu Y, et al. Iloprost for pulmonary vaso-\ndilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 2009;33:\n1354–1360.\n133. Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, et al. An ofﬁcial\nEuropean Respiratory Society statement: pulmonary haemodynamics during exer-\ncise. Eur Respir J 2017;50:1700578.\n134. Claeys M, Claessen G, La Gerche A, Petit T, Belge C, Meyns B, et al. Impaired car-\ndiac reserve and abnormal vascular load limit exercise capacity in chronic thrombo-\nembolic disease. JACC Cardiovasc Imaging 2019;12:1444–1456.\n135. Guth S, Wiedenroth CB, Rieth A, Richter MJ, Gruenig E, Ghofrani HA, et al.\nExercise right heart catheterization before and after pulmonary endarterectomy\nin patients with chronic thromboembolic disease. Eur Respir J 2018;52:1800458.\n136. Godinas L, Lau EM, Chemla D, Lador F, Savale L, Montani D, et al. Diagnostic con-\ncordance of different criteria for exercise pulmonary hypertension in subjects with\nnormal resting pulmonary artery pressure. Eur Respir J 2016;48:254–257.\n137. Naeije R, Vanderpool R, Dhakal BP, Saggar R, Saggar R, Vachiery JL, et al.\nExercise-induced pulmonary hypertension: physiological basis and methodological\nconcerns. Am J Respir Crit Care Med 2013;187:576–583.\n138. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP III, Guyton RA, et al.\n2014 AHA/ACC guideline for the management of patients with valvular heart dis-\nease: a report of the American College of Cardiology/American Heart Association\nTask Force on Practice Guidelines. J Thorac Cardiovasc Surg 2014;148:e1–e132.\n139. Esfandiari S, Wright SP, Goodman JM, Sasson Z, Mak S. Pulmonary artery wedge\npressure relative to exercise work rate in older men and women. Med Sci Sports\nExerc 2017;49:1297–1304.\n140. Boerrigter BG, Waxman AB, Westerhof N, Vonk-Noordegraaf A, Systrom DM.\nMeasuring central pulmonary pressures during exercise in COPD: how to cope\nwith respiratory effects. Eur Respir J 2014;43:1316–1325.\n141. Andersen MJ, Wolsk E, Bakkestrom R, Thomsen JH, Balling L, Dahl JS, et al.\nHemodynamic response to rapid saline infusion compared with exercise in healthy\nparticipants aged 20–80 years. J Cardiac Failure 2019;25:902–910.\n142. Vachiery JL, Tedford RJ, Rosenkranz S, Palazzini M, Lang I, Guazzi M, et al.\nPulmonary hypertension due to left heart disease. Eur Respir J 2019;53:1801897.\n143. D’Alto M, Romeo E, Argiento P, Motoji Y, Correra A, Di Marco GM, et al. Clinical\nrelevance of ﬂuid challenge in patients evaluated for pulmonary hypertension. Chest\n2017;151:119–126.\nESC/ERS Guidelines\n3715\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n144. van de Bovenkamp AA, Wijkstra N, Oosterveer FPT, Vonk Noordegraaf A,\nBogaard HJ, van Rossum AC, et al. The value of passive leg raise during right heart\ncatheterization in diagnosing heart failure with preserved ejection fraction. Circ\nHeart Fail 2022;15:e008935.\n145. D’Alto M, Dimopoulos K, Coghlan JG, Kovacs G, Rosenkranz S, Naeije R. Right\nheart catheterization for the diagnosis of pulmonary hypertension: controversies\nand practical issues. Heart Fail Clin 2018;14:467–477.\n146. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers\non survival in primary pulmonary hypertension. N Engl J Med 1992;327:76–81.\n147. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, et al.\nDiagnosis and differential assessment of pulmonary arterial hypertension. J Am\nColl Cardiol 2004;43:40S–47S.\n148. Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F, et al.\nGenetics and genomics of pulmonary arterial hypertension. Eur Respir J 2019;53:\n1801899.\n149. Graf S, Haimel M, Bleda M, Hadinnapola C, Southgate L, Li W, et al. Identiﬁcation of\nrare sequence variation underlying heritable pulmonary arterial hypertension. Nat\nCommun 2018;9:1416.\n150. Zhu N, Swietlik EM, Welch CL, Pauciulo MW, Hagen JJ, Zhou X, et al. Rare variant\nanalysis of 4241 pulmonary arterial hypertension cases from an international con-\nsortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Med\n2021;13:80.\n151. Song J, Eichstaedt CA, Viales RR, Benjamin N, Harutyunova S, Fischer C, et al.\nIdentiﬁcation of genetic defects in pulmonary arterial hypertension by a new\ngene panel diagnostic tool. Clin Sci (Lond) 2016;130:2043–2052.\n152. International PPHC, Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA\nIII, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta recep-\ntor, cause familial primary pulmonary hypertension. Nat Genet 2000;26:81–84.\n153. Bohnen MS, Ma L, Zhu N, Qi H, McClenaghan C, Gonzaga-Jauregui C, et al.\nLoss-of-function ABCC8 mutations in pulmonary arterial hypertension. Circ\nGenom Precis Med 2018;11:e002087.\n154. Ma L, Roman-Campos D, Austin ED, Eyries M, Sampson KS, Soubrier F, et al. A no-\nvel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013;369:\n351–361.\n155. Nasim MT, Ogo T, Ahmed M, Randall R, Chowdhury HM, Snape KM, et al.\nMolecular genetic characterization of SMAD signaling molecules in pulmonary ar-\nterial hypertension. Hum Mutat 2011;32:1385–1389.\n156. Garg A, Kircher M, Del Campo M, Amato RS, Agarwal AK, University of\nWashington Center for Mendelian Genomics. Whole exome sequencing identiﬁes\nde novo heterozygous CAV1 mutations associated with a novel neonatal onset li-\npodystrophy syndrome. Am J Med Genet A 2015;167A:1796–1806.\n157. Kerstjens-Frederikse WS, Bongers EM, Roofthooft MT, Leter EM, Douwes JM, Van\nDijk A, et al. TBX4 mutations (small patella syndrome) are associated with\nchildhood-onset pulmonary arterial hypertension. J Med Genet 2013;50:500–506.\n158. Eyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C, et al. EIF2AK4 muta-\ntions cause pulmonary veno-occlusive disease, a recessive form of pulmonary\nhypertension. Nat Genet 2014;46:65–69.\n159. Swietlik EM, Greene D, Zhu N, Megy K, Cogliano M, Rajaram S, et al. Bayesian in-\nference associates rare KDR variants with speciﬁc phenotypes in pulmonary arterial\nhypertension. Circ Genom Precis Med 2020;14:e003155.\n160. Chida A, Shintani M, Yagi H, Fujiwara M, Kojima Y, Sato H, et al. Outcomes of child-\nhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers. Am J\nCardiol 2012;110:586–593.\n161. Hoeper MM, Pausch C, Grünig E, Klose H, Staehler G, Huscher D, et al. Idiopathic\npulmonary arterial hypertension phenotypes determined by cluster analysis from\nthe COMPERA registry. J Heart Lung Transpl 2020;39:1435–1444.\n162. Badagliacca R, Poscia R, Pezzuto B, Papa S, Nona A, Mancone M, et al. Pulmonary\narterial dilatation in pulmonary hypertension: prevalence and prognostic relevance.\nCardiology 2012;121:76–82.\n163. Santaniello A, Casella R, Vicenzi M, Rota I, Montanelli G, De Santis M, et al.\nCardiopulmonary exercise testing in a combined screening approach to individuate\npulmonary arterial hypertension in systemic sclerosis. Rheumatology 2020;59:\n1581–1586.\n164. Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley\nR, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an\nultrasound contrast agent. Lancet 1999;353:1579–1583.\n165. Cottin V, Le Pavec J, Prevot G, Mal H, Humbert M, Simonneau G, et al. Pulmonary\nhypertension in patients with combined pulmonary ﬁbrosis and emphysema syn-\ndrome. Eur Respir J 2010;35:105–111.\n166. Galiè N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al.\nInitial use of ambrisentan plus tadalaﬁl in pulmonary arterial hypertension. N Engl\nJ Med 2015;373:834–844.\n167. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, et al.\nMacitentan and morbidity and mortality in pulmonary arterial hypertension. N\nEngl J Med 2013;369:809–818.\n168. Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, et al.\nMacitentan for the treatment of portopulmonary hypertension (PORTICO): a\nmulticentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet\nRespir Med 2019;7:594–604.\n169. Armstrong I, Billings C, Kiely DG, Yorke J, Harries C, Clayton S, et al. The patient\nexperience of pulmonary hypertension: a large cross-sectional study of UK pa-\ntients. BMC Pulm Med 2019;19:67.\n170. Strange G, Gabbay E, Kermeen F, Williams T, Carrington M, Stewart S, et al. Time\nfrom symptoms to deﬁnitive diagnosis of idiopathic pulmonary arterial hyperten-\nsion: the delay study. Pulm Circ 2013;3:89–94.\n171. Ivarsson B, Johansson A, Kjellstrom B. The odyssey from symptom to diagnosis of\npulmonary hypertension from the patients and spouses perspective. J Prim Care\nCommunity\nHealth\n2021;12:21501327211029241.\ndoi:\n10.1177/\n21501327211029241\n172. Kiely DG, Lawrie A, Humbert M. Screening strategies for pulmonary arterial hyper-\ntension. Eur Heart J Suppl 2019;21:K9–K20.\n173. Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al.\nEvidence-based detection of pulmonary arterial hypertension in systemic sclerosis:\nthe DETECT study. Ann Rheum Dis 2014;73:1340–1349.\n174. Weatherald J, Montani D, Jevnikar M, Jais X, Savale L, Humbert M. Screening for\npulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2019;28:\n190023.\n175. Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MA, et al.\nInternational Liver Transplant Society Practice Guidelines: diagnosis and manage-\nment\nof\nhepatopulmonary\nsyndrome\nand\nportopulmonary\nhypertension.\nTransplantation 2016;100:1440–1452.\n176. Mancuso L, Scordato F, Pieri M, Valerio E, Mancuso A. Management of portopul-\nmonary\nhypertension:\nnew\nperspectives.\nWorld\nJ\nGastroenterol\n2013;19:\n8252–8257.\n177. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, RafﬁF, De Zuttere D, et al.\nPrevalence of HIV-related pulmonary arterial hypertension in the current anti-\nretroviral therapy era. Am J Respir Crit Care Med 2008;177:108–113.\n178. Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P,\nMairuhu AT, et al. Incidence of chronic thromboembolic pulmonary hypertension\nafter acute pulmonary embolism: a contemporary view of the published literature.\nEur Respir J 2017;49:1601792.\n179. Ende-Verhaar YM, Huisman MV, Klok FA. To screen or not to screen for chronic\nthromboembolic pulmonary hypertension after acute pulmonary embolism.\nThromb Res 2017;151:1–7.\n180. Kiely DG, Doyle O, Drage E, Jenner H, Salvatelli V, Daniels FA, et al. Utilising arti-\nﬁcial intelligence to determine patients at risk of a rare disease: idiopathic pulmon-\nary arterial hypertension. Pulm Circ 2019;9:2045894019890549.\n181. Nathan SD, Behr J, Collard HR, Cottin V, Hoeper MM, Martinez FJ, et al. Riociguat\nfor idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP):\na randomised, placebo-controlled phase 2b study. Lancet Respir Med 2019;7:\n780–790.\n182. Nagel C, Henn P, Ehlken N, D’Andrea A, Blank N, Bossone E, et al. Stress Doppler\nechocardiography for early detection of systemic sclerosis-associated pulmonary\narterial hypertension. Arthritis Res Ther 2015;17:165.\n183. Semalulu T, Rudski L, Huynh T, Langleben D, Wang M, Canadian Scleroderma\nResearch Group, et al. An evidence-based strategy to screen for pulmonary arterial\nhypertension in systemic sclerosis. Semin Arthritis Rheum 2020;50:1421–1427.\n184. Vandecasteele E, Drieghe B, Melsens K, Thevissen K, De Pauw M, Deschepper E,\net al. Screening for pulmonary arterial hypertension in an unselected prospective\nsystemic sclerosis cohort. Eur Respir J 2017;49:1602275.\n185. Coghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S, et al.\nIncidence of pulmonary hypertension and determining factors in patients with sys-\ntemic sclerosis. Eur Respir J 2018;51:1701197.\n186. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection\nof pulmonary arterial hypertension in systemic sclerosis: a French nationwide pro-\nspective multicenter study. Arthritis Rheum 2005;52:3792–3800.\n187. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening\nfor pulmonary arterial hypertension in patients with systemic sclerosis: clinical char-\nacteristics at diagnosis and long-term survival. Arthritis Rheum 2011;63:3522–3530.\n188. Thakkar V, Stevens W, Prior D, Youssef P, Liew D, Gabbay E, et al. The inclusion of\nN-terminal pro-brain natriuretic peptide in a sensitive screening strategy for sys-\ntemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis\nRes Ther 2013;15:R193.\n189. Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C, et al. A comparison\nof the predictive accuracy of three screening models for pulmonary arterial hyper-\ntension in systemic sclerosis. Arthritis Res Ther 2015;17:7.\n190. Morrisroe K, Stevens W, Sahhar J, Rabusa C, Nikpour M, Proudman S, et al.\nEpidemiology and disease characteristics of systemic sclerosis-related pulmonary\narterial hypertension: results from a real-life screening programme. Arthritis Res\nTher 2017;19:42.\n3716\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n191. Morrisroe K, Huq M, Stevens W, Rabusa C, Proudman SM, Nikpour M, et al. Risk\nfactors for development of pulmonary arterial hypertension in Australian systemic\nsclerosis patients: results from a large multicenter cohort study. BMC Pulm Med\n2016;16:134.\n192. Smith V, Vanhaecke A, Vandecasteele E, Guerra M, Paolino S, Melsens K, et al.\nNailfold videocapillaroscopy in systemic sclerosis-related pulmonary arterial hyper-\ntension: a systematic literature review. J Rheumatol 2020;47:888–895.\n193. Larkin EK, Newman JH, Austin ED, Hemnes AR, Wheeler L, Robbins IM, et al.\nLongitudinal analysis casts doubt on the presence of genetic anticipation in heritable\npulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:892–896.\n194. Colle IO, Moreau R, Godinho E, Belghiti J, Ettori F, Cohen-Solal A, et al. Diagnosis of\nportopulmonary hypertension in candidates for liver transplantation: a prospective\nstudy. Hepatology 2003;37:401–409.\n195. Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RP, et al. Accuracy of\nDoppler echocardiography in the assessment of pulmonary hypertension in liver\ntransplant candidates. Liver Transpl 2000;6:453–458.\n196. Raevens S, Colle I, Reyntjens K, Geerts A, Berrevoet F, Rogiers X, et al.\nEchocardiography for the detection of portopulmonary hypertension in liver trans-\nplant candidates: an analysis of cutoff values. Liver Transpl 2013;19:602–610.\n197. Golpe\nR,\nPerez-de-Llano\nLA,\nCastro-Anon\nO,\nVazquez-Caruncho\nM,\nGonzalez-Juanatey C, Veres-Racamonde A, et al. Right ventricle dysfunction and\npulmonary hypertension in hemodynamically stable pulmonary embolism. Respir\nMed 2010;104:1370–1376.\n198. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al.\nIncidence of chronic thromboembolic pulmonary hypertension after pulmonary\nembolism. N Engl J Med 2004;350:2257–2264.\n199. Simonneau G, Hoeper MM. Evaluation of the incidence of rare diseases: difﬁculties\nand uncertainties, the example of chronic thromboembolic pulmonary hyperten-\nsion. Eur Respir J 2017;49:1602522.\n200. Coquoz N, Weilenmann D, Stolz D, Popov V, Azzola A, Fellrath JM, et al.\nMulticentre observational screening survey for the detection of CTEPH following\npulmonary embolism. Eur Respir J 2018;51:1702505.\n201. Valerio LM, Mavromanoli AC, Barco S, Abele C, Becker D, Bruch L, et al.\nFOCUS Investigators. Chronic thromboembolic pulmonary hypertension and\nimpairment after pulmonary embolism: the FOCUS study. Eur Heart J 2022;43:\n3387–3398.\n202. Nijkeuter M, Hovens MM, Davidson BL, Huisman MV. Resolution of thromboem-\nboli in patients with acute pulmonary embolism: a systematic review. Chest 2006;\n129:192–197.\n203. Sanchez O, Helley D, Couchon S, Roux A, Delaval A, Trinquart L, et al. Perfusion\ndefects after pulmonary embolism: risk factors and clinical signiﬁcance. J Thromb\nHaemost 2010;8:1248–1255.\n204. Wartski M, Collignon MA. Incomplete recovery of lung perfusion after 3 months in\npatients with acute pulmonary embolism treated with antithrombotic agents.\nTHESEE Study Group. Tinzaparin ou heparin standard: evaluation dans l’Embolie\nPulmonaire study. J Nucl Med 2000;41:1043–1048.\n205. Nilsson LT, Andersson T, Larsen F, Lang IM, Liv P, Soderberg S. Dyspnea after pul-\nmonary embolism: a nation-wide population-based case-control study. Pulm Circ\n2021;11:20458940211046831.\n206. Boon G, Ende-Verhaar YM, Bavalia R, El Bouazzaoui LH, Delcroix M,\nDzikowska-Diduch O, et al. Non-invasive early exclusion of chronic thrombo-\nembolic pulmonary hypertension after acute pulmonary embolism: the InShape II\nstudy. Thorax 2021;76:1002–1009.\n207. Helmersen D, Provencher S, Hirsch AM, Van Dam A, Dennie C, de Perrot M, et al.\nDiagnosis of chronic thromboembolic pulmonary hypertension: A Canadian\nThoracic Society clinical practice guideline update. Can J Respir Crit Care Sleep\nMed 2019;3:177–198.\n208. Delcroix M, Kerr K, Fedullo P. Chronic thromboembolic pulmonary hypertension.\nEpidemiology and risk factors. Ann Am Thorac Soc 2016;13:S201–S206.\n209. Klok FA, Tesche C, Rappold L, Dellas C, Hasenfuss G, Huisman MV, et al. External val-\nidation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmon-\nary hypertension after acute pulmonary embolism. Thromb Res 2015;135:796–801.\n210. Barst RJ, Chung L, Zamanian RT, Turner M, McGoon MD. Functional class improve-\nment and 3-year survival outcomes in patients with pulmonary arterial hyperten-\nsion in the REVEAL Registry. Chest 2013;144:160–168.\n211. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The\nprognostic impact of follow-up assessments in patients with idiopathic pulmonary\narterial hypertension. Eur Respir J 2012;39:589–596.\n212. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, et al. Long-term intra-\nvenous epoprostenol infusion in primary pulmonary hypertension: prognostic fac-\ntors and survival. J Am Coll Cardiol 2002;40:780–788.\n213. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al.\nPredicting survival in pulmonary arterial hypertension: insights from the Registry to\nEvaluate Early and Long-Term Pulmonary Arterial Hypertension Disease\nManagement (REVEAL). Circulation 2010;122:164–172.\n214. Humbert M, Sitbon O, Yaici A, Montani D, O’Callaghan DS, Jais X, et al. Survival in\nincident and prevalent cohorts of patients with pulmonary arterial hypertension.\nEur Respir J 2010;36:549–555.\n215. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galiè N, et al. Survival with\nﬁrst-line bosentan in patients with primary pulmonary hypertension. Eur Respir J\n2005;25:244–249.\n216. Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The\nprognostic impact of follow-up assessments in patients with idiopathic pulmonary\narterial hypertension. Eur Respir J 2012;39:589–596.\n217. Amsallem M, Sweatt AJ, Aymami MC, Kuznetsova T, Selej M, Lu H, et al. Right heart\nend-systolic remodeling index strongly predicts outcomes in pulmonary arterial\nhypertension: comparison with validated models. Circ Cardiovasc Imaging 2017;\n10:e005771.\n218. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, et al.\nEchocardiographic predictors of adverse outcomes in primary pulmonary hyper-\ntension. J Am Coll Cardiol 2002;39:1214–1219.\n219. Badagliacca R, Papa S, Valli G, Pezzuto B, Poscia R, Manzi G, et al. Echocardiography\ncombined with cardiopulmonary exercise testing for the prediction of outcome in\nidiopathic pulmonary arterial hypertension. Chest 2016;150:1313–1322.\n220. Badagliacca R, Papa S, Manzi G, Miotti C, Luongo F, Sciomer S, et al. Usefulness of\nadding echocardiography of the right heart to risk-assessment scores in\nprostanoid-treated pulmonary arterial hypertension. JACC Cardiovasc Imaging\n2020;13:2054–2056.\n221. Ernande L, Cottin V, Leroux PY, Girerd N, Huez S, Mulliez A, et al. Right isovolumic\ncontraction velocity predicts survival in pulmonary hypertension. J Am Soc\nEchocardiogr 2013;26:297–306.\n222. Forﬁa PR, Fisher MR, Mathai SC, Housten-Harris T, Hemnes AR, Borlaug BA, et al.\nTricuspid annular displacement predicts survival in pulmonary hypertension. Am J\nRespir Crit Care Med 2006;174:1034–1041.\n223. Ghio S, Mercurio V, Fortuni F, Forﬁa PR, Gall H, Ghofrani A, et al. A comprehensive\nechocardiographic method for risk stratiﬁcation in pulmonary arterial hyperten-\nsion. Eur Respir J 2020;56:2000513.\n224. Sachdev A, Villarraga HR, Frantz RP, McGoon MD, Hsiao JF, Maalouf JF, et al. Right\nventricular strain for prediction of survival in patients with pulmonary arterial\nhypertension. Chest 2011;139:1299–1309.\n225. Vonk Noordegraaf A, Chin KM, Haddad F, Hassoun PM, Hemnes AR, Hopkins SR,\net al. Pathophysiology of the right ventricle and of the pulmonary circulation in pul-\nmonary hypertension: an update. Eur Respir J 2019;53:1801900.\n226. Batal O, Dardari Z, Costabile C, Gorcsan J, Arena VC, Mathier MA. Prognostic va-\nlue of pericardial effusion on serial echocardiograms in pulmonary arterial hyper-\ntension. Echocardiography 2015;32:1471–1476.\n227. Chen L, Larsen CM, Le RJ, Connolly HM, Pislaru SV, Murphy JG, et al. The prognos-\ntic signiﬁcance of tricuspid valve regurgitation in pulmonary arterial hypertension.\nClin Respir J 2018;12:1572–1580.\n228. Fenstad ER, Le RJ, Sinak LJ, Maradit-Kremers H, Ammash NM, Ayalew AM, et al.\nPericardial effusions in pulmonary arterial hypertension: characteristics, prognosis,\nand role of drainage. Chest 2013;144:1530–1538.\n229. Badagliacca R, Poscia R, Pezzuto B, Papa S, Reali M, Pesce F, et al. Prognostic rele-\nvance of right heart reverse remodeling in idiopathic pulmonary arterial hyperten-\nsion. J Heart Lung Transpl 2018;37:195–205.\n230. Badano LP, Addetia K, Pontone G, Torlasco C, Lang RM, Parati G, et al. Advanced\nimaging of right ventricular anatomy and function. Heart 2020;106:1469–1476.\n231. Lewis RA, Johns CS, Cogliano M, Capener D, Tubman E, Elliot CA, et al.\nIdentiﬁcation of cardiac magnetic resonance imaging thresholds for risk stratiﬁca-\ntion in pulmonary arterial hypertension. Am J Respir Crit Care Med 2020;201:\n458–466.\n232. Swift AJ, Capener D, Johns C, Hamilton N, Rothman A, Elliot C, et al. Magnetic res-\nonance imaging in the prognostic evaluation of patients with pulmonary arterial\nhypertension. Am J Respir Crit Care Med 2017;196:228–239.\n233. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ,\net al. Progressive right ventricular dysfunction in patients with pulmonary arterial\nhypertension responding to therapy. J Am Coll Cardiol 2011;58:2511–2519.\n234. van Wolferen SA, Marcus JT, Boonstra A, Marques KM, Bronzwaer JG,\nSpreeuwenberg MD, et al. Prognostic value of right ventricular mass, volume,\nand function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007;28:\n1250–1257.\n235. Alabed S, Shahin Y, Garg P, Alandejani F, Johns CS, Lewis RA, et al. Cardiac-MRI\npredicts clinical worsening and mortality in pulmonary arterial hypertension: a sys-\ntematic review and meta-analysis. JACC Cardiovasc Imaging 2021;14:931–942.\n236. Swift AJ, Wilson F, Cogliano M, Kendall L, Alandejani F, Alabed S, et al. Repeatability\nand sensitivity to change of non-invasive end points in PAH: the RESPIRE study.\nThorax 2021;76:1032–1035.\n237. van der Bruggen CE, Handoko ML, Bogaard HJ, Marcus JT, Oosterveer FPT,\nMeijboom LJ, et al. The value of hemodynamic measurements or cardiac MRI in\nESC/ERS Guidelines\n3717\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nthe follow-up of patients with idiopathic pulmonary arterial hypertension. Chest\n2021;159:1575–1585.\n238. Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, et al. Prognostic\nvalue of follow-up hemodynamic variables after initial management in pulmonary\narterial hypertension. Circulation 2018;137:693–704.\n239. van Wolferen SA, van de Veerdonk MC, Mauritz GJ, Jacobs W, Marcus JT, Marques\nKMJ, et al. Clinically signiﬁcant change in stroke volume in pulmonary hypertension.\nChest 2011;139:1003–1009.\n240. Huis In ‘t Veld AE, Van de Veerdonk MC, Spruijt O, Groeneveldt JA, Marcus JT,\nWesterhof N, et al. EXPRESS: preserving right ventricular function in patients\nwith pulmonary arterial hypertension: single centre experience with a cardiac mag-\nnetic\nresonance\nimaging-guided\ntreatment\nstrategy.\nPulm\nCirc\n2019.\ndoi:10.1177/2045894018824553. Epub ahead of print.\n241. van de Veerdonk MC, Huis In T Veld AE, Marcus JT, Westerhof N, Heymans MW,\nBogaard HJ, et al. Upfront combination therapy reduces right ventricular volumes in\npulmonary arterial hypertension. Eur Respir J 2017;49:1700007.\n242. van de Veerdonk MC, Marcus JT, Westerhof N, de Man FS, Boonstra A, Heymans\nMW, et al. Signs of right ventricular deterioration in clinically stable patients with\npulmonary arterial hypertension. Chest 2015;147:1063–1071.\n243. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al.\nSurvival in patients with primary pulmonary hypertension. Results from a national\nprospective registry. Ann Intern Med 1991;115:343–349.\n244. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in\npatients with idiopathic, familial, and anorexigen-associated pulmonary arterial\nhypertension in the modern management era. Circulation 2010;122:156–163.\n245. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension:\nthe impact of epoprostenol therapy. Circulation 2002;106:1477–1482.\n246. Provencher S, Chemla D, Herve P, Sitbon O, Humbert M, Simonneau G. Heart rate\nresponses during the 6-minute walk test in pulmonary arterial hypertension. Eur\nRespir J 2006;27:114–120.\n247. Sitbon O, Benza RL, Badesch DB, Barst RJ, Elliott CG, Gressin V, et al. Validation of\ntwo predictive models for survival in pulmonary arterial hypertension. Eur Respir J\n2015;46:152–164.\n248. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in\npulmonary arterial hypertension: a reappraisal of the NIH risk stratiﬁcation equa-\ntion. Eur Respir J 2010;35:1079–1087.\n249. Benza RL, Gomberg-Maitland M, Elliott CG, Farber HW, Foreman AJ, Frost AE,\net al. Predicting survival in patients with pulmonary arterial hypertension: the\nREVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assess-\nment strategies. Chest 2019;156:323–337.\n250. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, et al.\nThe REVEAL registry risk score calculator in patients newly diagnosed with pul-\nmonary arterial hypertension. Chest 2012;141:354–362.\n251. Savarese G, Paolillo S, Costanzo P, D’Amore C, Cecere M, Losco T, et al. Do\nchanges of 6-minute walk distance predict clinical events in patients with pulmonary\narterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol\n2012;60:1192–1201.\n252. Zelniker TA, Huscher D, Vonk-Noordegraaf A, Ewert R, Lange TJ, Klose H, et al.\nThe 6MWT as a prognostic tool in pulmonary arterial hypertension: results from\nthe COMPERA registry. Clin Res Cardiol 2018;107:460–470.\n253. Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting\noutcomes in pulmonary arterial hypertension based on the 6-minute walk distance.\nJ Heart Lung Transpl 2015;34:362–368.\n254. Heresi GA, Rao Y. Follow-up functional class and 6-minute walk distance identify\nlong-term survival in pulmonary arterial hypertension. Lung 2020;198:933–938.\n255. Souza R, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, et al. Association\nbetween six-minute walk distance and long-term outcomes in patients with pul-\nmonary arterial hypertension: data from the randomized SERAPHIN trial. PLoS\nOne 2018;13:e0193226.\n256. Halliday SJ, Wang L, Yu C, Vickers BP, Newman JH, Fremont RD, et al. Six-minute\nwalk distance in healthy young adults. Respir Med 2020;165:105933.\n257. Khirfan G, Naal T, Abuhalimeh B, Newman J, Heresi GA, Dweik RA, et al.\nHypoxemia in patients with idiopathic or heritable pulmonary arterial hyperten-\nsion. PLoS One 2018;13:e0191869.\n258. Lewis RA, Billings CG, Hurdman JA, Smith IA, Austin M, Armstrong IJ, et al. Maximal\nexercise testing using the incremental shuttle walking test can be used to risk-\nstratify patients with pulmonary arterial hypertension. Ann Am Thorac Soc 2021;\n18:34–43.\n259. Laveneziana P, Di Paolo M, Palange P. The clinical value of cardiopulmonary exer-\ncise testing in the modern era. Eur Respir Rev 2021;30:200187.\n260. Wensel R, Opitz CF, Anker SD, Winkler J, Hoffken G, Kleber FX, et al. Assessment\nof survival in patients with primary pulmonary hypertension: importance of cardio-\npulmonary exercise testing. Circulation 2002;106:319–324.\n261. Badagliacca R, Papa S, Poscia R, Valli G, Pezzuto B, Manzi G, et al. The added value of\ncardiopulmonary exercise testing in the follow-up of pulmonary arterial hyperten-\nsion. J Heart Lung Transpl 2019;38:306–314.\n262. Deboeck G, Scoditti C, Huez S, Vachiery JL, Lamotte M, Sharples L, et al. Exercise\ntesting to predict outcome in idiopathic versus associated pulmonary arterial\nhypertension. Eur Respir J 2012;40:1410–1419.\n263. Wensel R, Francis DP, Meyer FJ, Opitz CF, Bruch L, Halank M, et al. Incremental\nprognostic value of cardiopulmonary exercise testing and resting haemodynamics\nin pulmonary arterial hypertension. Int J Cardiol 2013;167:1193–1198.\n264. Badagliacca R, Rischard F, Giudice FL, Howard L, Papa S, Valli G, et al. Incremental\nvalue of cardiopulmonary exercise testing in intermediate-risk pulmonary arterial\nhypertension. J Heart Lung Transplant 2022;41:780–790.\n265. Bouzina H, Rådegran G. Low plasma stem cell factor combined with high trans-\nforming growth factor-α identiﬁes high-risk patients in pulmonary arterial hyper-\ntension. ERJ Open Res 2018;4:00035-02018.\n266. Chin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N, et al. Association of\nN-terminal pro brain natriuretic peptide and long-term outcome in patients with\npulmonary arterial hypertension: insights from the phase III GRIPHON study.\nCirculation 2019;139:2440–2450.\n267. Frantz RP, Farber HW, Badesch DB, Elliott CG, Frost AE, McGoon MD, et al.\nBaseline and serial brain natriuretic peptide level predicts 5-year overall survival\nin patients with pulmonary arterial hypertension: data from the REVEAL registry.\nChest 2018;154:126–135.\n268. Harbaum L, Ghataorhe P, Wharton J, Jimenez B, Howard LSG, Gibbs JSR, et al.\nReduced plasma levels of small HDL particles transporting ﬁbrinolytic proteins in\npulmonary arterial hypertension. Thorax 2019;74:380–389.\n269. Naal T, Abuhalimeh B, Khirfan G, Dweik RA, Tang WHW, Tonelli AR. Serum chlor-\nide levels track with survival in patients with pulmonary arterial hypertension. Chest\n2018;154:541–549.\n270. Nikolic I, Yung LM, Yang P, Malhotra R, Paskin-Flerlage S, Dinter T, et al. Bone mor-\nphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension.\nAm J Respir Crit Care Med 2019;199:891–902.\n271. Rhodes CJ, Wharton J, Ghataorhe P, Watson G, Girerd B, Howard LS, et al. Plasma\nproteome analysis in patients with pulmonary arterial hypertension: an observa-\ntional cohort study. Lancet Respir Med 2017;5:717–726.\n272. Wetzl V, Tiede SL, Faerber L, Weissmann N, Schermuly RT, Ghofrani HA, et al.\nPlasma MMP2/TIMP4 ratio at follow-up assessment predicts disease progression\nof idiopathic pulmonary arterial hypertension. Lung 2017;195:489–496.\n273. Arvidsson M, Ahmed A, Bouzina H, Rådegran G. Matrix metalloproteinase 7 in diag-\nnosis and differentiation of pulmonary arterial hypertension. Pulm Circ 2019;9:\n2045894019895414.\n274. Kylhammar D, Hesselstrand R, Nielsen S, Scheele C, Radegran G. Angiogenic and\ninﬂammatory biomarkers for screening and follow-up in patients with pulmonary\narterial hypertension. Scand J Rheumatol 2018;47:319–324.\n275. Saleby J, Bouzina H, Ahmed S, Lundgren J, Radegran G. Plasma receptor tyrosine\nkinase RET in pulmonary arterial hypertension diagnosis and differentiation. ERJ\nOpen Res 2019;5:00037–02019.\n276. van Bon L, Affandi AJ, Broen J, Christmann RB, Marijnissen RJ, Stawski L, et al.\nProteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl\nJ Med 2014;370:433–443.\n277. Ferrer E, Dunmore BJ, Hassan D, Ormiston ML, Moore S, Deighton J, et al. A po-\ntential role for exosomal translationally controlled tumor protein export in vascu-\nlar remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2018;59:\n467–478.\n278. Lavoie JR, Ormiston ML, Perez-Iratxeta C, Courtman DW, Jiang B, Ferrer E, et al.\nProteomic analysis implicates translationally controlled tumor protein as a novel\nmediator of occlusive vascular remodeling in pulmonary arterial hypertension.\nCirculation 2014;129:2125–2135.\n279. Warwick G, Thomas PS, Yates DH. Biomarkers in pulmonary hypertension. Eur\nRespir J 2008;32:503–512.\n280. Hoeper M, Pausch C, Olsson K, Huscher D, Pittrow D, Grünig E, et al. COMPERA\n2.0: a reﬁned 4-strata risk assessment model for pulmonary arterial hypertension.\nEur Respir J 2022;60:2102311.\n281. Delcroix M, Howard L. Pulmonary arterial hypertension: the burden of disease and\nimpact on quality of life. Eur Respir Rev 2015;24:621–629.\n282. Yorke J, Corris P, Gaine S, Gibbs JS, Kiely DG, Harries C, et al. emPHasis-10: devel-\nopment of a health-related quality of life measure in pulmonary hypertension. Eur\nRespir J 2014;43:1106–1113.\n283. McGoon MD, Ferrari P, Armstrong I, Denis M, Howard LS, Lowe G, et al. The im-\nportance of patient perspectives in pulmonary hypertension. Eur Respir J 2019;53:\n1801919.\n284. Twiss J, McKenna S, Ganderton L, Jenkins S, Ben-L’amri M, Gain K, et al.\nPsychometric performance of the CAMPHOR and SF-36 in pulmonary hyperten-\nsion. BMC Pulm Med 2013;13:45.\n3718\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n285. Chen H, De Marco T, Kobashigawa EA, Katz PP, Chang VW, Blanc PD.\nComparison of cardiac and pulmonary-speciﬁc quality-of-life measures in pulmon-\nary arterial hypertension. Eur Respir J 2011;38:608–616.\n286. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge\nPulmonary\nHypertension\nOutcome\nReview\n(CAMPHOR):\na\nmeasure\nof\nhealth-related quality of life and quality of life for patients with pulmonary hyper-\ntension. Qual Life Res 2006;15:103–115.\n287. Lewis RA, Armstrong I, Bergbaum C, Brewis MJ, Cannon J, Charalampopoulos A,\net al. EmPHasis-10 health-related quality of life score predicts outcomes in patients\nwith idiopathic and connective tissue disease-associated pulmonary arterial hyper-\ntension: results from a UK multicentre study. Eur Respir J 2021;57:2000124.\n288. Bonner N, Abetz L, Meunier J, Sikirica M, Mathai SC. Development and validation of\nthe living with pulmonary hypertension questionnaire in pulmonary arterial hyper-\ntension patients. Health Qual Life Outcomes 2013;11:161.\n289. McCollister D, Shaffer S, Badesch DB, Filusch A, Hunsche E, Schuler R, et al.\nDevelopment of the Pulmonary Arterial Hypertension-Symptoms and Impact\n(PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument\nfor PAH. Respir Res 2016;17:72.\n290. McCabe C, Bennett M, Doughty N, MacKenzie Ross R, Sharples L, Pepke-Zaba J.\nPatient-reported outcomes assessed by the CAMPHOR questionnaire predict clin-\nical deterioration in idiopathic pulmonary arterial hypertension and chronic\nthromboembolic pulmonary hypertension. Chest 2013;144:522–530.\n291. Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, et al. Prediction of\nhealth-related quality of life and hospitalization in pulmonary arterial hypertension:\nthe Pulmonary Hypertension Association Registry. Am J Respir Crit Care Med 2021;\n203:761–764.\n292. Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S, et al.\nA comprehensive risk stratiﬁcation at early follow-up determines prognosis in pul-\nmonary arterial hypertension. Eur Heart J 2018;39:4175–4181.\n293. Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N, et al.\nMortality in pulmonary arterial hypertension: prediction by the 2015 European pul-\nmonary hypertension guidelines risk stratiﬁcation model. Eur Respir J 2017;50:\n1700740.\n294. Hjalmarsson C, Kjellström B, Jansson K, Nisell M, Kylhammar D, Kavianipour M,\net al. Early risk prediction in patients with idiopathic versus connective tissue\ndisease-associated pulmonary arterial hypertension: call for a reﬁned assessment.\nERJ Open Res 2021;7:00854-02020.\n295. Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G, et al. Risk assessment,\nprognosis and guideline implementation in pulmonary arterial hypertension. Eur\nRespir J 2017;50:1700889.\n296. Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, et al. Development and\nvalidation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL\nLite 2, for use in patients with pulmonary arterial hypertension. Chest 2021;159:\n337–346.\n297. Bouzina H, Rådegran G, Butler O, Hesselstrand R, Hjalmarsson C, Holl K, et al.\nLongitudinal changes in risk status in pulmonary arterial hypertension. ESC Heart\nFail 2021;8:680–690.\n298. D’Alto M, Badagliacca R, Lo Giudice F, Argiento P, Casu G, Corda M, et al.\nHemodynamics and risk assessment 2 years after the initiation of upfront\nambrisentan–tadalaﬁl in pulmonary arterial hypertension. J Heart Lung\nTranspl 2020;39:1389–1397.\n299. Hjalmarsson C, Rådegran G, Kylhammar D, Rundqvist B, Multing J, Nisell MD, et al.\nImpact of age and comorbidity on risk stratiﬁcation in idiopathic pulmonary arterial\nhypertension. Eur Respir J 2018;51:1702310.\n300. Humbert M, Farber HW, Ghofrani HA, Benza RL, Busse D, Meier C, et al. Risk as-\nsessment in pulmonary arterial hypertension and chronic thromboembolic pul-\nmonary hypertension. Eur Respir J 2019;53:1802004.\n301. Kuwana M, Blair C, Takahashi T, Langley J, Coghlan JG. Initial combination therapy\nof ambrisentan and tadalaﬁl in connective tissue disease-associated pulmonary ar-\nterial hypertension (CTD-PAH) in the modiﬁed intention-to-treat population of\nthe AMBITION study: post hoc analysis. Ann Rheum Dis 2020;79:626–634.\n302. Kylhammar D, Hjalmarsson C, Hesselstrand R, Jansson K, Kavianipour M,\nKjellstrom B, et al. Predicting mortality during long-term follow-up in pulmonary\narterial hypertension. ERJ Open Res 2021;7:00837-02020.\n303. Sitbon O, Chin KM, Channick RN, Benza RL, Di Scala L, Gaine S, et al. Risk assess-\nment in pulmonary arterial hypertension: insights from the GRIPHON study. J\nHeart Lung Transpl 2020;39:300–309.\n304. Rhodes CJ, Wharton J, Swietlik EM, Harbaum L, Girerd B, Coghlan JG, et al. Using\nthe plasma proteome for risk stratifying patients with pulmonary arterial hyperten-\nsion. Am J Respir Crit Care Med 2022;205:1102–1111.\n305. Benza RL, Lohmueller LC, Kraisangka J, Kanwar M. Risk assessment in pulmonary\narterial hypertension patients: the long and short of it. Adv Pulm Hypertens 2018;\n16:125–135.\n306. Yogeswaran A, Richter MJ, Sommer N, Ghofrani HA, Seeger W, Tello K, et al.\nAdvanced risk stratiﬁcation of intermediate risk group in pulmonary arterial hyper-\ntension. Pulm Circ 2020;10:2045894020961739.\n307. Zelt JGE, Hossain A, Sun LY, Mehta S, Chandy G, Davies RA, et al. Incorporation of\nrenal function in mortality risk assessment for pulmonary arterial hypertension. J\nHeart Lung Transplant 2020;39:675–685.\n308. Boucly A, Weatherald J, Savale L, de Groote P, Cottin V, Prévot G, et al. External\nvalidation of a reﬁned 4-strata risk assessment score from the French pulmonary\nhypertension registry. Eur Respir J 2022;59:2102419.\n309. Olsson KM, Richter MJ, Kamp JC, Gall H, Heine A, Ghofrani HA, et al. Intravenous\ntreprostinil as an add-on therapy in patients with pulmonary arterial hypertension. J\nHeart Lung Transplant 2019;38:748–756.\n310. Tonelli AR, Sahay S, Gordon KW, Edwards LD, Allmon AG, Broderick M, et al.\nImpact of inhaled treprostinil on risk stratiﬁcation with noninvasive parameters: a\npost hoc analysis of the TRIUMPH and BEAT studies. Pulm Circ 2020;10:\n2045894020977025.\n311. Weatherald J, Boucly A, Launay D, Cottin V, Prévot G, Bourlier D, et al.\nHaemodynamics and serial risk assessment in systemic sclerosis associated pulmon-\nary arterial hypertension. Eur Respir J 2018;52:1800678.\n312. Chan L, Chin LMK, Kennedy M, Woolstenhulme JG, Nathan SD, Weinstein AA,\net al. Beneﬁts of intensive treadmill exercise training on cardiorespiratory function\nand quality of life in patients with pulmonary hypertension. Chest 2013;143:\n333–343.\n313. de Man FS, Handoko ML, Groepenhoff H, van ‘t Hul AJ, Abbink J, Koppers RJ, et al.\nEffects of exercise training in patients with idiopathic pulmonary arterial hyperten-\nsion. Eur Respir J 2009;34:669–675.\n314. Ehlken N, Lichtblau M, Klose H, Weidenhammer J, Fischer C, Nechwatal R, et al.\nExercise training improves peak oxygen consumption and haemodynamics in pa-\ntients with severe pulmonary arterial hypertension and inoperable chronic\nthrombo-embolic pulmonary hypertension: a prospective, randomized, controlled\ntrial. Eur Heart J 2016;37:35–44.\n315. Grunig E, MacKenzie A, Peacock AJ, Eichstaedt CA, Benjamin N, Nechwatal R, et al.\nStandardized exercise training is feasible, safe, and effective in pulmonary arterial\nand chronic thromboembolic pulmonary hypertension: results from a large\nEuropean multicentre randomized controlled trial. Eur Heart J 2021;42:2284–2295.\n316. Mereles D, Ehlken N, Kreuscher S, Ghofrani S, Hoeper MM, Halank M, et al.\nExercise and respiratory training improve exercise capacity and quality of life in pa-\ntients with severe chronic pulmonary hypertension. Circulation 2006;114:\n1482–1489.\n317. Grunig E, Eichstaedt C, Barbera JA, Benjamin N, Blanco I, Bossone E, et al. ERS\nstatement on exercise training and rehabilitation in patients with severe chronic\npulmonary hypertension. Eur Respir J 2019;53:1800332.\n318. Johnson SR, Granton JT, Mehta S. Thrombotic arteriopathy and anticoagulation in\npulmonary hypertension. Chest 2006;130:545–552.\n319. Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al.\nAnticoagulation and survival in pulmonary arterial hypertension: results from the\nComparative, Prospective Registry of Newly Initiated Therapies for Pulmonary\nHypertension (COMPERA). Circulation 2014;129:57–65.\n320. Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, et al. Effect of\nwarfarin treatment on survival of patients with pulmonary arterial hypertension\n(PAH) in the Registry to Evaluate Early and Long-term PAH Disease\nManagement (REVEAL). Circulation 2015;132:2403–2411.\n321. Khan MS, Usman MS, Siddiqi TJ, Khan SU, Murad MH, Mookadam F, et al. Is antic-\noagulation beneﬁcial in pulmonary arterial hypertension? Circ Cardiovasc Qual\nOutcomes 2018;11:e004757.\n322. Wang P, Hu L, Yin Y, Yan D, Zheng H, Zhang J, et al. Can anticoagulants improve the\nsurvival rate for patients with idiopathic pulmonary arterial hypertension? A sys-\ntematic review and meta-analysis. Thromb Res 2020;196:251–256.\n323. Stickel S, Gin-Sing W, Wagenaar M, Gibbs JSR. The practical management of ﬂuid\nretention in adults with right heart failure due to pulmonary arterial hypertension.\nEur Heart J Suppl 2019;21:K46–K53.\n324. Sandoval J, Aguirre JS, Pulido T, Martinez-Guerra ML, Santos E, Alvarado P, et al.\nNocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J\nRespir Crit Care Med 2001;164:1682–1687.\n325. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term\noxygen therapy can reverse the progression of pulmonary hypertension in patients\nwith chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;131:493–498.\n326. Ulrich S, Saxer S, Hasler ED, Schwarz EI, Schneider SR, Furian M, et al. Effect of\ndomiciliary oxygen therapy on exercise capacity and quality of life in patients\nwith pulmonary arterial or chronic thromboembolic pulmonary hypertension: a\nrandomised, placebo-controlled trial. Eur Respir J 2019;54:1900276.\n327. Ulrich S, Hasler ED, Saxer S, Furian M, Muller-Mottet S, Keusch S, et al. Effect of\nbreathing oxygen-enriched air on exercise performance in patients with precapil-\nlary pulmonary hypertension: randomized, sham-controlled cross-over trial. Eur\nHeart J 2017;38:1159–1168.\nESC/ERS Guidelines\n3719\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n328. Adir Y, Humbert M, Chaouat A. Sleep-related breathing disorders and pulmonary\nhypertension. Eur Respir J 2021;57:2002258.\n329. McDonagh T, Damy T, Doehner W, Lam CSP, Sindone A, van der Meer P, et al.\nScreening, diagnosis and treatment of iron deﬁciency in chronic heart failure: put-\nting the 2016 European Society of Cardiology heart failure guidelines into clinical\npractice. Eur J Heart Fail 2018;20:1664–1672.\n330. Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS, et al. Iron deﬁ-\nciency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical\nprevalence, outcomes, and mechanistic insights. J Am Coll Cardiol 2011;58:300–309.\n331. Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, et al.\nIron deﬁciency is common in idiopathic pulmonary arterial hypertension. Eur Respir\nJ 2011;37:1386–1391.\n332. Ruiter G, Lanser IJ, de Man FS, van der Laarse WJ, Wharton J, Wilkins MR, et al. Iron\ndeﬁciency in systemic sclerosis patients with and without pulmonary hypertension.\nRheumatology 2014;53:285–292.\n333. Van De Bruaene A, Delcroix M, Pasquet A, De Backer J, De Pauw M, Naeije R, et al.\nIron deﬁciency is associated with adverse outcome in Eisenmenger patients. Eur\nHeart J 2011;32:2790–2799.\n334. Sonnweber T, Nairz M, Theurl I, Petzer V, Tymoszuk P, Haschka D, et al. The cru-\ncial impact of iron deﬁciency deﬁnition for the course of precapillary pulmonary\nhypertension. PLoS One 2018;13:e0203396.\n335. Ruiter G, Manders E, Happe CM, Schalij I, Groepenhoff H, Howard LS, et al.\nIntravenous iron therapy in patients with idiopathic pulmonary arterial hyperten-\nsion and iron deﬁciency. Pulm Circ 2015;5:466–472.\n336. Viethen T, Gerhardt F, Dumitrescu D, Knoop-Busch S, Ten Freyhaus H, Rudolph\nTK, et al. Ferric carboxymaltose improves exercise capacity and quality of life in pa-\ntients with pulmonary arterial hypertension and iron deﬁciency: a pilot study. Int J\nCardiol 2014;175:233–239.\n337. Kramer T, Wissmuller M, Natsina K, Gerhardt F, Ten Freyhaus H, Dumitrescu D,\net al. Ferric carboxymaltose in patients with pulmonary arterial hypertension and\niron deﬁciency: a long-term study. J Cachexia Sarcopenia Muscle 2021;12:\n1501–1512.\n338. Olsson KM, Fuge J, Brod T, Kamp JC, Schmitto J, Kempf T, et al. Oral iron supple-\nmentation with ferric maltol in patients with pulmonary hypertension. Eur Respir J\n2020;56:2000616.\n339. Howard LSGE, He J, Watson GMJ, Huang L, Wharton J, Luo Q, et al.\nSupplementation with iron in pulmonary arterial hypertension. Two randomized\ncrossover trials. Ann Am Thorac Soc 2021;18:981–988.\n340. Larisch A, Neeb C, de Zwaan M, Pabst C, Tiede H, Ghofrani A, et al. Mental distress\nand wish for psychosomatic treatment of patients with pulmonary hypertension.\nPsychother Psychosom Med Psychol 2014;64:384–389.\n341. Olsson KM, Meltendorf T, Fuge J, Kamp JC, Park DH, Richter MJ, et al. Prevalence of\nmental disorders and impact on quality of life in patients with pulmonary arterial\nhypertension. Front Psychiatry 2021;31:667602.\n342. Pfeuffer E, Krannich H, Halank M, Wilkens H, Kolb P, Jany B, et al. Anxiety, depres-\nsion, and health-related QOL in patients diagnosed with PAH or CTEPH. Lung\n2017;195:759–768.\n343. Zhou X, Shi H, Yang Y, Zhang Z, Zhai Z, Wang C. Anxiety and depression in pa-\ntients with pulmonary arterial hypertension and chronic thromboembolic pulmon-\nary hypertension: results from a Chinese survey. Exp Ther Med 2020;19:\n3124–3132.\n344. Kingman M, Hinzmann B, Sweet O, Vachiery JL. Living with pulmonary hyperten-\nsion: unique insights from an international ethnographic study. BMJ Open 2014;4:\ne004735.\n345. Harzheim D, Klose H, Pinado FP, Ehlken N, Nagel C, Fischer C, et al. Anxiety and\ndepression disorders in patients with pulmonary arterial hypertension and chronic\nthromboembolic pulmonary hypertension. Respir Res 2013;14:104.\n346. Anand V, Vallabhajosyula S, Cheungpasitporn W, Frantz RP, Cajigas HR, Strand JJ,\net al. Inpatient palliative care use in patients with pulmonary arterial hypertension:\ntemporal trends, predictors, and outcomes. Chest 2020;158:2568–2578.\n347. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:\n487–497.\n348. Kjellstrom B, Sandqvist A, Hjalmarsson C, Nisell M, Nasman P, Ivarsson B.\nAdherence to disease-speciﬁc drug treatment among patients with pulmonary ar-\nterial hypertension or chronic thromboembolic pulmonary hypertension. ERJ Open\nRes 2020;6:00299-02020.\n349. Shah NB, Mitchell RE, Proctor ST, Choi L, DeClercq J, Jolly JA, et al. High rates of\nmedication adherence in patients with pulmonary arterial hypertension: an inte-\ngrated specialty pharmacy approach. PLoS One 2019;14:e0217798.\n350. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in\npregnancy: a systematic overview from 1978 through 1996. J Am Coll Cardiol 1998;\n31:1650–1657.\n351. Bedard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on\npregnancy outcomes among women with pulmonary arterial hypertension? Eur\nHeart J 2009;30:256–265.\n352. Duarte AG, Thomas S, Safdar Z, Torres F, Pacheco LD, Feldman J, et al.\nManagement of pulmonary arterial hypertension during pregnancy: a retrospective,\nmulticenter experience. Chest 2013;143:1330–1336.\n353. Jais X, Olsson KM, Barbera JA, Blanco I, Torbicki A, Peacock A, et al. Pregnancy out-\ncomes in pulmonary arterial hypertension in the modern management era. Eur\nRespir J 2012;40:881–885.\n354. Kiely DG, Condliffe R, Webster V, Mills GH, Wrench I, Gandhi SV, et al. Improved\nsurvival in pregnancy and pulmonary hypertension using a multiprofessional ap-\nproach. BJOG 2010;117:565–574.\n355. Luo J, Shi H, Xu L, Su W, Li J. Pregnancy outcomes in patients with pulmonary ar-\nterial hypertension: a retrospective study. Medicine 2020;99:e20285.\n356. Kamp JC, von Kaisenberg C, Greve S, Winter L, Park DH, Fuge J, et al. Pregnancy in\npulmonary arterial hypertension: midterm outcomes of mothers and offspring. J\nHeart Lung Transplant 2021;40:229–233.\n357. Corbach N, Berlier C, Lichtblau M, Schwarz EI, Gautschi F, Groth A, et al. Favorable\npregnancy outcomes in women with well-controlled pulmonary arterial hyperten-\nsion. Front Med (Lausanne) 2021;8:689764.\n358. Bostock S, Sheares K, Cannon J, Taboada D, Pepke-Zaba J, Toshner M. The poten-\ntial effects of pregnancy in a patient with idiopathic pulmonary arterial hypertension\nresponding to calcium channel blockade. Eur Respir J 2017;50:1701141.\n359. de Raaf MA, Beekhuijzen M, Guignabert C, Vonk Noordegraaf A, Bogaard HJ.\nEndothelin-1 receptor antagonists in fetal development and pulmonary arterial\nhypertension. Reprod Toxicol 2015;56:45–51.\n360. Dunn L, Greer R, Flenady V, Kumar S. Sildenaﬁl in pregnancy: a systematic review of\nmaternal tolerance and obstetric and perinatal outcomes. Fetal Diagn Ther 2017;41:\n81–88.\n361. van Giersbergen PL, Halabi A, Dingemanse J. Pharmacokinetic interaction between\nbosentan and the oral contraceptives norethisterone and ethinyl estradiol. Int J Clin\nPharmacol Ther 2006;44:113–118.\n362. Meyer S, McLaughlin VV, Seyfarth HJ, Bull TM, Vizza CD, Gomberg-Maitland M,\net al. Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an inter-\nnational prospective survey. Eur Respir J 2013;41:1302–1307.\n363. Hassan HJ, Housten T, Balasubramanian A, Simpson CE, Damico RL, Mathai SC,\net al. A novel approach to perioperative risk assessment for patients with pulmon-\nary hypertension. ERJ Open Res 2021;7:00257-02021.\n364. Non-cardiac surgery: Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M,\nBarbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and manage-\nment of patients undergoing non-cardiac surgery. Eur Heart J 2022. https://doi.\norg/10.1093/eurheartj/ehac270.\n365. Burns RM, Peacock AJ, Johnson MK, Church AC. Hypoxaemia in patients with pul-\nmonary arterial hypertension during simulated air travel. Respir Med 2013;107:\n298–304.\n366. Kylhammar D, Rådegran G. The principal pathways involved in the in vivo modula-\ntion of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and\npulmonary hypertension. Acta Physiol 2017;219:728–756.\n367. Code of Federal Regulations. Chapter I, Subchapter C, Part 25, Subpart D, Subjgrp -\nPressurization. Section 25.841 - Pressurized cabins. Washington, DC: US\nGovernment Printing Ofﬁce; 2012.\n368. Groth A, Saxer S, Bader PR, Lichtblau M, Furian M, Schneider SR, et al. Acute hemo-\ndynamic changes by breathing hypoxic and hyperoxic gas mixtures in pulmonary\narterial and chronic thromboembolic pulmonary hypertension. Int J Cardiol 2018;\n270:262–267.\n369. Roubinian N, Elliott CG, Barnett CF, Blanc PD, Chen J, De Marco T, et al. Effects of\ncommercial air travel on patients with pulmonary hypertension air travel and pul-\nmonary hypertension. Chest 2012;142:885–892.\n370. Schneider SR, Mayer LC, Lichtblau M, Berlier C, Schwarz EI, Saxer S, et al. Effect of\nnormobaric hypoxia on exercise performance in pulmonary hypertension: rando-\nmized trial. Chest 2021;159:757–771.\n371. Seccombe LM, Chow V, Zhao W, Lau EMT, Rogers PG, Ng ACC, et al. Right heart\nfunction during simulated altitude in patients with pulmonary arterial hypertension.\nOpen Heart 2017;4:e000532.\n372. Thamm M, Voswinckel R, Tiede H, Lendeckel F, Grimminger F, Seeger W, et al. Air\ntravel can be safe and well tolerated in patients with clinically stable pulmonary\nhypertension. Pulm Circ 2011;1:239–243.\n373. Cramer D, Ward S, Geddes D. Assessment of oxygen supplementation during air\ntravel. Thorax 1996;51:202–203.\n374. Dubroff J, Melendres L, Lin Y, Beene DR, Ketai L. High geographic prevalence of\npulmonary artery hypertension: associations with ethnicity, drug use, and altitude.\nPulm Circ 2020;10:2045894019894534.\n375. Fakhri S, Hannon K, Moulden K, Peterson R, Hountras P, Bull T, et al. Residence at\nmoderately high altitude and its relationship with WHO Group 1 pulmonary arter-\nial hypertension symptom severity and clinical characteristics: the Pulmonary\nHypertension Association Registry. Pulm Circ 2020;10:2045894020964342.\n3720\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n376. Schneider SR, Mayer LC, Lichtblau M, Berlier C, Schwarz EI, Saxer S, et al. Effect of a\nday-trip to altitude (2500 m) on exercise performance in pulmonary hypertension:\nrandomised crossover trial. ERJ Open Res 2021;7:00314-02021.\n377. Makowski CT, Rissmiller RW, Bullington WM. Riociguat: a novel new drug for\ntreatment of pulmonary hypertension. Pharmacotherapy 2015;35:502–519.\n378. Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G, et al. Long-term response\nto calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur\nHeart J 2010;31:1898–1907.\n379. Galiè N, Ussia G, Passarelli P, Parlangeli R, Branzi A, Magnani B. Role of pharmaco-\nlogic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 1995;\n75:55A–62A.\n380. Clozel M, Maresta A, Humbert M. Endothelin receptor antagonists. Handb Exp\nPharmacol 2013;218:199–227.\n381. Xing J, Cao Y, Yu Y, Li H, Song Z, Yu H. In vitro micropatterned human pluripotent\nstem cell test (microP-hPST) for morphometric-based teratogen screening. Sci Rep\n2017;7:8491.\n382. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al.\nAmbrisentan for the treatment of pulmonary arterial hypertension: results of the\nambrisentan in pulmonary arterial hypertension, randomized, double-blind,\nplacebo-controlled, multicenter, efﬁcacy (ARIES) study 1 and 2. Circulation 2008;\n117:3010–3019.\n383. Rubin LJ, Badesch DB, Barst RJ, Galiè N, Black CM, Keogh A, et al. Bosentan therapy\nfor pulmonary arterial hypertension. N Engl J Med 2002;346:896–903.\n384. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of\nEuropean post-marketing surveillance of bosentan in pulmonary hypertension.\nEur Respir J 2007;30:338–344.\n385. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma\nconcentration of sildenaﬁl when coprescribed in pulmonary hypertension. Br J Clin\nPharmacol 2005;60:107–112.\n386. Weber C, Banken L, Birnboeck H, Schulz R. Effect of the endothelin-receptor an-\ntagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J\nClin Pharmacol 1999;39:847–854.\n387. Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI.\nPharmacokinetic interaction between tadalaﬁl and bosentan in healthy male sub-\njects. J Clin Pharmacol 2008;48:610–618.\n388. Ghofrani HA, Osterloh IH, Grimminger F. Sildenaﬁl: from angina to erectile dys-\nfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006;5:\n689–702.\n389. Galiè N, Muller K, Scalise AV, Grunig E. PATENT PLUS: a blinded, randomised and\nextension study of riociguat plus sildenaﬁl in pulmonary arterial hypertension. Eur\nRespir J 2015;45:1314–1322.\n390. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenaﬁl cit-\nrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:\n2148–2157.\n391. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efﬁcacy of sildenaﬁl in pri-\nmary pulmonary hypertension: a randomized, placebo-controlled, double-blind,\ncrossover study. J Am Coll Cardiol 2004;43:1149–1153.\n392. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, et al. Addition of\nsildenaﬁl to long-term intravenous epoprostenol therapy in patients with pulmon-\nary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521–530.\n393. Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al.\nTadalaﬁl therapy for pulmonary arterial hypertension. Circulation 2009;119:\n2894–2903.\n394. Schermuly RT, Janssen W, Weissmann N, Stasch JP, Grimminger F, Ghofrani HA.\nRiociguat for the treatment of pulmonary hypertension. Expert Opin Investig\nDrugs 2011;20:567–576.\n395. Ghofrani HA, Galiè N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat\nfor the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:\n330–340.\n396. Galiè N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J\nRespir Med 2003;2:123–137.\n397. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyc-\nlin receptors elicits opposing effects on vascular smooth muscle cell growth and\nmitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995;48:\n890–896.\n398. Sitbon O, Delcroix M, Bergot E, Boonstra AB, Granton J, Langleben D, et al.\nEPITOME-2: An open-label study assessing the transition to a new formulation\nof intravenous epoprostenol in patients with pulmonary arterial hypertension.\nAm Heart J 2014;167:210–217.\n399. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison\nof continuous intravenous epoprostenol (prostacyclin) with conventional therapy\nfor primary pulmonary hypertension. The Primary Pulmonary Hypertension Study\nGroup. N Engl J Med 1996;334:296–302.\n400. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, et al. Treatment\nof primary pulmonary hypertension with continuous intravenous prostacyclin\n(epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112:485–491.\n401. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, et al.\nContinuous intravenous epoprostenol for pulmonary hypertension due to the\nscleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med\n2000;132:425–434.\n402. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH.\nImprovement in pulmonary hemodynamics during intravenous epoprostenol\n(prostacyclin): a study of 15 patients with moderate to severe portopulmonary\nhypertension. Hepatology 1999;30:641–648.\n403. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, et al. Prognostic\nfactors for survival in human immunodeﬁciency virus-associated pulmonary arterial\nhypertension. Am J Respir Crit Care Med 2003;167:1433–1439.\n404. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hyper-\ntension with associated congenital heart defects. Circulation 1999;99:1858–1865.\n405. Boucly A, O’Connell C, Savale L, O’Callaghan DS, Jais X, Montani D, et al. Tunnelled\ncentral venous line-associated infections in patients with pulmonary arterial hyper-\ntension treated with intravenous prostacyclin. Presse Med 2016;45:20–28.\n406. Doran AK, Ivy DD, Barst RJ, Hill N, Murali S, Benza RL, et al. Guidelines for the pre-\nvention of central venous catheter-related blood stream infections with prostanoid\ntherapy for pulmonary arterial hypertension. Int J Clin Pract Suppl 2008;(160):5–9.\n407. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled\niloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322–329.\n408. Simonneau G, Barst RJ, Galiè N, Naeije R, Rich S, Bourge RC, et al. Continuous sub-\ncutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmon-\nary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J\nRespir Crit Care Med 2002;165:800–804.\n409. Bourge RC, Waxman AB, Gomberg-Maitland M, Shapiro SM, Tarver JH III, Zwicke\nDL, et al. Treprostinil administered to treat pulmonary arterial hypertension using a\nfully implantable programmable intravascular delivery system: results of the\nDelIVery for PAH trial. Chest 2016;150:27–34.\n410. Richter MJ, Harutyunova S, Bollmann T, Classen S, Gall H, Gerhardt Md F, et al.\nLong-term safety and outcome of intravenous treprostinil via an implanted\npump in pulmonary hypertension. J Heart Lung Transplant 2018;37:1235–1244.\n411. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al.\nAddition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension:\na randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915–1922.\n412. Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, et al. Oral treprostinil for the\ntreatment of pulmonary arterial hypertension in patients receiving background en-\ndothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the\nFREEDOM-C2 study): a randomized controlled trial. Chest 2013;144:952–958.\n413. Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral tre-\nprostinil for the treatment of pulmonary arterial hypertension in patients on back-\nground endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor\ntherapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012;142:\n1383–1390.\n414. Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, et al. Efﬁcacy and\nsafety of oral treprostinil monotherapy for the treatment of pulmonary arterial\nhypertension: a randomized, controlled trial. Circulation 2013;127:624–633.\n415. White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY,\net al. Combination therapy with oral treprostinil for pulmonary arterial hyperten-\nsion. A double-blind placebo-controlled clinical trial. Am J Respir Crit Care Med 2020;\n201:707–717.\n416. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al. Beraprost ther-\napy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119–2125.\n417. Galiè N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, et al. Effects of\nberaprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial\nhypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol\n2002;39:1496–1502.\n418. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galiè N, et al.\nSelexipag: an oral, selective prostacyclin receptor agonist for the treatment of pul-\nmonary arterial hypertension. Eur Respir J 2012;40:874–880.\n419. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag for the\ntreatment of pulmonary arterial hypertension. N Engl J Med 2015;373:2522–2533.\n419a. McLaughlin V, Channick RN, Ghofrani H-A, Lemarié J-C, Naeije R, Packer M, et al.\nBosentan added to sildenaﬁl therapy in patients with pulmonary arterial hyperten-\nsion. Eur Respir J 2015;46:405–413.\n420. Hoeper MM, McLaughlin VV, Barbera JA, Frost AE, Ghofrani HA, Peacock AJ, et al.\nInitial combination therapy with ambrisentan and tadalaﬁl and mortality in patients\nwith pulmonary arterial hypertension: a secondary analysis of the results from the\nrandomised, controlled AMBITION study. Lancet Respir Med 2016;4:894–901.\n421. Chin KM, Sitbon O, Doelberg M, Feldman J, Gibbs JSR, Grunig E, et al. Three- versus\ntwo-drug therapy for patients with newly diagnosed pulmonary arterial hyperten-\nsion. J Am Coll Cardiol 2021;78:1393–1403.\nESC/ERS Guidelines\n3721\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n422. Badagliacca R, D’Alto M, Ghio S, Argiento P, Bellomo V, Brunetti ND, et al. Risk\nreduction and hemodynamics with initial combination therapy in pulmonary arter-\nial hypertension. Am J Respir Crit Care Med 2021;203:484–492.\n423. Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, et al.\nAmbrisentan and tadalaﬁl up-front combination therapy in scleroderma-associated\npulmonary arterial hypertension. Am J Respir Crit Care Med 2015;192:1102–1110.\n424. Kirtania L, Maiti R, Srinivasan A, Mishra A. Effect of combination therapy of en-\ndothelin receptor antagonist and phosphodiesterase-5 inhibitor on clinical out-\ncome and pulmonary haemodynamics in patients with pulmonary arterial\nhypertension: a meta-analysis. Clin Drug Investig 2019;39:1031–1044.\n425. Montani D, Lau EM, Dorfmuller P, Girerd B, Jais X, Savale L, et al. Pulmonary\nveno-occlusive disease. Eur Respir J 2016;47:1518–1534.\n426. Sitbon O, Jais X, Savale L, Cottin V, Bergot E, Macari EA, et al. Upfront triple com-\nbination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J 2014;\n43:1691–1697.\n427. D’Alto M, Badagliacca R, Argiento P, Romeo E, Farro A, Papa S, et al. Risk reduction\nand right heart reverse remodeling by upfront triple combination therapy in pul-\nmonary arterial hypertension. Chest 2020;157:376–383.\n428. Boucly A, Savale L, Jais X, Bauer F, Bergot E, Bertoletti L, et al. Association between\ninitial treatment strategy and long-term survival in pulmonary arterial hypertension.\nAm J Respir Crit Care Med 2021;204:842–854.\n429. Hoeper MM, Al-Hiti H, Benza RL, Chang SA, Corris PA, Gibbs JSR, et al. Switching\nto riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in pa-\ntients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label,\nrandomised controlled trial. Lancet Respir Med 2021;9:573–584.\n430. Sitbon O, Cottin V, Canuet M, Clerson P, Gressin V, Perchenet L, et al. Initial com-\nbination therapy of macitentan and tadalaﬁl in pulmonary arterial hypertension. Eur\nRespir J 2020;56:2000673. doi:10.1183/13993003.00673-2020.\n431. Coghlan JG, Channick R, Chin K, Di Scala L, Galiè N, Ghofrani HA, et al. Targeting\nthe prostacyclin pathway with selexipag in patients with pulmonary arterial hyper-\ntension receiving double combination therapy: insights from the randomized con-\ntrolled GRIPHON study. Am J Cardiovasc Drugs 2018;18:37–47.\n432. Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, et al. Combination\ntherapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis.\nLancet Respir Med 2016;4:291–305.\n433. Hoeper MM, Pausch C, Grunig E, Staehler G, Huscher D, Pittrow D, et al. Temporal\ntrends in pulmonary arterial hypertension: results from the COMPERA registry.\nEur Respir J 2022;59:2102024. doi:10.1183/13993003.02024-2021.\n434. Zelt JGE, Sugarman J, Weatherald J, Partridge ACR, Liang JC, Swiston J, et al.\nMortality trends in pulmonary arterial hypertension in Canada: a temporal analysis\nof survival per ESC/ERS Guideline Era. Eur Respir J 2022;59:2101552. doi:\n10.1183/13993003.01552-2021.\n435. Hoeper MM, Simonneau G, Corris PA, Ghofrani HA, Klinger JR, Langleben D, et al.\nRESPITE: switching to riociguat in pulmonary arterial hypertension patients with\ninadequate response to phosphodiesterase-5 inhibitors. Eur Respir J 2017;50:\n1602425.\n436. Bartolome SD, Sood N, Shah TG, Styrvoky K, Torres F, Chin KM. Mortality in pa-\ntients with pulmonary arterial hypertension treated with continuous prostanoids.\nChest 2018;154:532–540.\n437. Galiè N, Jansa P, Pulido T, Channick RN, Delcroix M, Ghofrani HA, et al. SERAPHIN\nhaemodynamic substudy: the effect of the dual endothelin receptor antagonist ma-\ncitentan on haemodynamic parameters and NT-proBNP levels and their associ-\nation with disease progression in patients with pulmonary arterial hypertension.\nEur Heart J 2017;38:1147–1155.\n438. Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost A, et al. Long-term sil-\ndenaﬁl added to intravenous epoprostenol in patients with pulmonary arterial\nhypertension. J Heart Lung Transplant 2014;33:689–697.\n439. Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, et al.\nLong-term effects of inhaled treprostinil in patients with pulmonary arterial hyper-\ntension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary\nArterial Hypertension (TRIUMPH) study open-label extension. J Heart Lung\nTransplant 2011;30:1327–1333.\n440. Rubin LJ, Galiè N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for\nthe treatment of pulmonary arterial hypertension: a long-term extension study\n(PATENT-2). Eur Respir J 2015;45:1303–1313.\n441. Hoeper MM, Leuchte H, Halank M, Wilkens H, Meyer FJ, Seyfarth HJ, et al.\nCombining inhaled iloprost with bosentan in patients with idiopathic pulmonary ar-\nterial hypertension. Eur Respir J 2006;28:691–694.\n442. McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, et al.\nRandomized study of adding inhaled iloprost to existing bosentan in pulmonary ar-\nterial hypertension. Am J Respir Crit Care Med 2006;174:1257–1263.\n443. Badesch DB, Feldman J, Keogh A, Mathier MA, Oudiz RJ, Shapiro S, et al. ARIES-3:\nambrisentan therapy in a diverse population of patients with pulmonary hyperten-\nsion. Cardiovasc Ther 2012;30:93–99.\n444. Dardi F, Manes A, Palazzini M, Bachetti C, Mazzanti G, Rinaldi A, et al. Combining\nbosentan and sildenaﬁl in pulmonary arterial hypertension patients failing mono-\ntherapy: real-world insights. Eur Respir J 2015;46:414–421.\n445. Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination ther-\napy with bosentan and sildenaﬁl in Eisenmenger syndrome: a randomized, placebo-\ncontrolled, double-blinded trial. Eur Heart J 2010;31:1124–1131.\n446. Vizza CD, Jansa P, Teal S, Dombi T, Zhou D. Sildenaﬁl dosed concomitantly with\nbosentan for adult pulmonary arterial hypertension in a randomized controlled\ntrial. BMC Cardiovasc Disord 2017;17:239.\n447. Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al.\nElderly patients diagnosed with idiopathic pulmonary arterial hypertension: results\nfrom the COMPERA registry. Int J Cardiol 2013;168:871–880.\n448. Khou V, Anderson JJ, Strange G, Corrigan C, Collins N, Celermajer DS, et al.\nDiagnostic delay in pulmonary arterial hypertension: insights from the Australian\nand New Zealand pulmonary hypertension registry. Respirology 2020;25:863–871.\n449. McLaughlin VV, Vachiery JL, Oudiz RJ, Rosenkranz S, Galiè N, Barbera JA, et al.\nPatients with pulmonary arterial hypertension with and without cardiovascular\nrisk factors: results from the AMBITION trial. J Heart Lung Transplant 2019;38:\n1286–1295.\n450. Opitz CF, Hoeper MM, Gibbs JS, Kaemmerer H, Pepke-Zaba J, Coghlan JG, et al.\nPre-capillary, combined, and post-capillary pulmonary hypertension: a patho-\nphysiological continuum. J Am Coll Cardiol 2016;68:368–378.\n451. Lewis RA, Thompson AAR, Billings CG, Charalampopoulos A, Elliot CA, Hamilton\nN, et al. Mild parenchymal lung disease and/or low diffusion capacity impacts sur-\nvival and treatment response in patients diagnosed with idiopathic pulmonary ar-\nterial hypertension. Eur Respir J 2020;55:2000041.\n452. Valentin S, Maurac A, Sitbon O, Beurnier A, Gomez E, Guillaumot A, et al.\nOutcomes of patients with decreased arterial oxyhaemoglobin saturation on pul-\nmonary arterial hypertension drugs. Eur Respir J 2021;58:2004066.\n453. Rosenkranz S, Channick R, Chin KM, Jenner B, Gaine S, Galiè N, et al. The impact of\ncomorbidities on selexipag treatment effect in patients with pulmonary arterial\nhypertension: insights from the GRIPHON study. Eur J Heart Fail 2022;24:205–214.\n454. Khan MS, Memon MM, Amin E, Yamani N, Khan SU, Figueredo VM, et al. Use of\nballoon atrial septostomy in patients with advanced pulmonary arterial hyperten-\nsion: a systematic review and meta-analysis. Chest 2019;156:53–63.\n455. Sandoval J, Gaspar J, Pulido T, Bautista E, Martinez-Guerra ML, Zeballos M, et al.\nGraded balloon dilation atrial septostomy in severe primary pulmonary hyperten-\nsion. A therapeutic alternative for patients nonresponsive to vasodilator treatment.\nJ Am Coll Cardiol 1998;32:297–304.\n456. Aggarwal M, Grady RM, Choudhry S, Anwar S, Eghtesady P, Singh GK. Potts shunt\nimproves right ventricular function and coupling with pulmonary circulation in chil-\ndren with suprasystemic pulmonary arterial hypertension. Circ Cardiovasc Imaging\n2018;11:e007964.\n457. Baruteau AE, Belli E, Boudjemline Y, Laux D, Levy M, Simonneau G, et al. Palliative\nPotts shunt for the treatment of children with drug-refractory pulmonary arterial\nhypertension: updated data from the ﬁrst 24 patients. Eur J Cardiothorac Surg 2015;\n47:e105–e110.\n458. Grady RM, Canter M, Shmalts A, Coleman R, Beghetti M, Berger RM, et al.\nPulmonary-to-systemic arterial shunt in children with severe pulmonary hyperten-\nsion. J Am Coll Cardiol 2021;78:468–477.\n459. Rosenzweig EB, Ankola A, Krishnan U, Middlesworth W, Bacha E, Bacchetta M. A\nnovel unidirectional-valved shunt approach for end-stage pulmonary arterial hyper-\ntension: early experience in adolescents and adults. J Thorac Cardiovasc Surg 2021;\n161:1438–1446.e1432.\n460. Ciarka A, Doan V, Velez-Roa S, Naeije R, van de Borne P. Prognostic signiﬁcance of\nsympathetic nervous system activation in pulmonary arterial hypertension. Am J\nRespir Crit Care Med 2010;181:1269–1275.\n461. Velez-Roa S, Ciarka A, Najem B, Vachiery JL, Naeije R, van de Borne P. Increased\nsympathetic nerve activity in pulmonary artery hypertension. Circulation 2004;\n110:1308–1312.\n462. Juratsch CE, Jengo JA, Castagna J, Laks MM. Experimental pulmonary hypertension\nproduced by surgical and chemical denervation of the pulmonary vasculature. Chest\n1980;77:525–530.\n463. Rothman A, Jonas M, Castel D, Tzafriri AR, Traxler H, Shav D, et al. Pulmonary ar-\ntery denervation using catheter-based ultrasonic energy. EuroIntervention 2019;15:\n722–730.\n464. Chen SL, Zhang FF, Xu J, Xie DJ, Zhou L, Nguyen T, et al. Pulmonary artery denerv-\nation to treat pulmonary arterial hypertension: the single-center, prospective,\nﬁrst-in-man PADN-1 study (ﬁrst-in-man pulmonary artery denervation for treat-\nment of pulmonary artery hypertension). J Am Coll Cardiol 2013;62:1092–1100.\n465. Rothman AMK, Vachiery JL, Howard LS, Mikhail GW, Lang IM, Jonas M, et al.\nIntravascular ultrasound pulmonary artery denervation to treat pulmonary arterial\nhypertension (TROPHY1): multicenter, early feasibility study. JACC Cardiovasc Interv\n2020;13:989–999.\n3722\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n466. Sztrymf B, Souza R, Bertoletti L, Jais X, Sitbon O, Price LC, et al. Prognostic factors\nof acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J\n2010;35:1286–1293.\n467. Campo A, Mathai SC, Le Pavec J, Zaiman AL, Hummers LK, Boyce D, et al.\nOutcomes of hospitalisation for right heart failure in pulmonary arterial hyperten-\nsion. Eur Respir J 2011;38:359–367.\n468. Hoeper MM, Benza RL, Corris P, de Perrot M, Fadel E, Keogh AM, et al. Intensive\ncare, right ventricular support and lung transplantation in patients with pulmonary\nhypertension. Eur Respir J 2019;53:1801906.\n469. Kapur NK, Esposito ML, Bader Y, Morine KJ, Kiernan MS, Pham DT, et al.\nMechanical circulatory support devices for acute right ventricular failure.\nCirculation 2017;136:314–326.\n470. Konstam MA, Kiernan MS, Bernstein D, Bozkurt B, Jacob M, Kapur NK, et al.\nEvaluation and management of right-sided heart failure: a scientiﬁc statement\nfrom the American Heart Association. Circulation 2018;137:e578–e622.\n471. Olsson KM, Richter MJ, Kamp JC, Gall H, Ghofrani HA, Fuge J, et al. Reﬁned risk\nstratiﬁcation in pulmonary arterial hypertension and timing of lung transplantation.\nEur Respir J 2022. doi:10.1183/13993003.03087-2021. Epub ahead of print.\n472. Moser B, Jaksch P, Taghavi S, Murakozy G, Lang G, Hager H, et al. Lung transplant-\nation for idiopathic pulmonary arterial hypertension on intraoperative and post-\noperatively prolonged extracorporeal membrane oxygenation provides optimally\ncontrolled reperfusion and excellent outcome. Eur J Cardiothorac Surg 2018;53:\n178–185.\n473. Christie JD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F,\net\nal.\nThe\nRegistry\nof\nthe\nInternational\nSociety\nfor\nHeart\nand\nLung\nTransplantation: 29th adult lung and heart-lung transplant report-2012. J Heart\nLung Transplant 2012;31:1073–1086.\n474. Egan TM, Edwards LB. Effect of the lung allocation score on lung transplantation in\nthe United States. J Heart Lung Transplant 2016;35:433–439.\n475. Savale L, Le Pavec J, Mercier O, Mussot S, Jais X, Fabre D, et al. Impact of high-\npriority allocation on lung and heart-lung transplantation for pulmonary hyperten-\nsion. Ann Thorac Surg 2017;104:404–411.\n476. Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB,\net\nal.\nThe\nRegistry\nof\nthe\nInternational\nSociety\nfor\nHeart\nand\nLung\nTransplantation:\nThirty-second\nOfﬁcial\nAdult\nLung\nand\nHeart-Lung\nTransplantation Report–2015; Focus Theme: Early Graft Failure. J Heart Lung\nTransplant 2015;34:1264–1277.\n477. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al.\n2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation devel-\noped in collaboration with the European Association for Cardio-Thoracic Surgery\n(EACTS): the Task Force for the diagnosis and management of atrial ﬁbrillation of\nthe European Society of Cardiology (ESC) developed with the special contribution\nof the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;\n42:373–498.\n478. Wanamaker B, Cascino T, McLaughlin V, Oral H, Latchamsetty R, Siontis KC. Atrial\narrhythmias in pulmonary hypertension: pathogenesis, prognosis and management.\nArrhythm Electrophysiol Rev 2018;7:43–48.\n479. Andersen MO, Diederichsen SZ, Svendsen JH, Carlsen J. Assessment of cardiac ar-\nrhythmias using long-term continuous monitoring in patients with pulmonary\nhypertension. Int J Cardiol 2021;334:110–115.\n480. Olsson KM, Nickel NP, Tongers J, Hoeper MM. Atrial ﬂutter and ﬁbrillation in pa-\ntients with pulmonary hypertension. Int J Cardiol 2013;167:2300–2305.\n481. Wen L, Sun ML, An P, Jiang X, Sun K, Zheng L, et al. Frequency of supraventricular\narrhythmias in patients with idiopathic pulmonary arterial hypertension. Am J\nCardiol 2014;114:1420–1425.\n482. Luesebrink U, Fischer D, Gezgin F, Duncker D, Koenig T, Oswald H, et al. Ablation\nof typical right atrial ﬂutter in patients with pulmonary hypertension. Heart Lung\nCirc 2012;21:695–699.\n483. Santangeli P, Zado ES, Hutchinson MD, Riley MP, Lin D, Frankel DS, et al.\nPrevalence and distribution of focal triggers in persistent and long-standing persist-\nent atrial ﬁbrillation. Heart Rhythm 2016;13:374–382.\n484. Ghigna MR, Guignabert C, Montani D, Girerd B, Jais X, Savale L, et al. BMPR2 mu-\ntation status inﬂuences bronchial vascular changes in pulmonary arterial hyperten-\nsion. Eur Respir J 2016;48:1668–1681.\n485. Rasciti E, Sverzellati N, Silva M, Casadei A, Attina D, Palazzini M, et al. Bronchial ar-\ntery embolization for the treatment of haemoptysis in pulmonary hypertension.\nRadiol Med 2017;122:257–264.\n486. Yang S, Wang J, Kuang T, Gong J, Ma Z, Shen YH, et al. Efﬁcacy and safety of bron-\nchial artery embolization on hemoptysis in chronic thromboembolic pulmonary\nhypertension: a pilot prospective cohort study. Crit Care Med 2019;47:e182–e189.\n487. Demerouti\nEA,\nManginas\nAN,\nAthanassopoulos\nGD,\nKaratasakis\nGT.\nComplications leading to sudden cardiac death in pulmonary arterial hypertension.\nRespir Care 2013;58:1246–1254.\n488. Kreibich M, Siepe M, Kroll J, Hohn R, Grohmann J, Beyersdorf F. Aneurysms of the\npulmonary artery. Circulation 2015;131:310–316.\n489. Mak SM, Strickland N, Gopalan D. Complications of pulmonary hypertension: a pic-\ntorial review. Br J Radiol 2017;90:20160745.\n490. Nuche J, Montero Cabezas JM, Alonso Charterina S, Escribano Subias P.\nManagement of incidentally diagnosed pulmonary artery dissection in patients\nwith pulmonary arterial hypertension. Eur J Cardiothorac Surg 2019;56:210–212.\n491. Russo V, Zompatori M, Galiè N. Extensive right pulmonary artery dissection in a\nyoung patient with chronic pulmonary hypertension. Heart 2012;98:265–266.\n492. Zylkowska J, Kurzyna M, Florczyk M, Burakowska B, Grzegorczyk F, Burakowski J,\net al. Pulmonary artery dilatation correlates with the risk of unexpected death in\nchronic arterial or thromboembolic pulmonary hypertension. Chest 2012;142:\n1406–1416.\n493. Florczyk M, Wieteska M, Kurzyna M, Gosciniak P, Pepke-Zaba J, Biederman A, et al.\nAcute and chronic dissection of pulmonary artery: new challenges in pulmonary ar-\nterial hypertension? Pulm Circ 2018;8:2045893217749114.\n494. Velazquez Martin M, Montero Cabezas JM, Huertas S, Nuche J, Albarran A, Delgado\nJF, et al. Clinical relevance of adding intravascular ultrasound to coronary angiog-\nraphy for the diagnosis of extrinsic left main coronary artery compression by a pul-\nmonary artery aneurysm in pulmonary hypertension. Catheter Cardiovasc Interv\n2021;98:691–700.\n495. Torres F, Farber H, Ristic A, McLaughlin V, Adams J, Zhang J, et al. Efﬁcacy and safety\nof ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background\ntherapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.\nEur Respir J 2019;54:1901030.\n496. Humbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston\nIR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J\nMed 2021;384:1204–1215.\n497. Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idio-\npathic pulmonary arterial hypertension? Chest 2006;130:1657–1663.\n498. Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, et al.\nFeatures and outcomes of methamphetamine-associated pulmonary arterial\nhypertension. Am J Respir Crit Care Med 2018;197:788–800.\n499. Savale L, Sattler C, Gunther S, Montani D, Chaumais MC, Perrin S, et al. Pulmonary\narterial hypertension in patients treated with interferon. Eur Respir J 2014;44:\n1627–1634.\n500. Weatherald J, Chaumais MC, Savale L, Jais X, Seferian A, Canuet M, et al. Long-term\noutcomes of dasatinib-induced pulmonary arterial hypertension: a population-\nbased study. Eur Respir J 2017;50:1700217.\n501. Cardio-Oncology: Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar\nMC, Bergler-Klein J, et al. Guidelines on cardio-oncology. Eur Heart J 2022.\nhttps://doi.org/10.1093/eurheartj/ehac244.\n502. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of\npulmonary hypertension in systemic sclerosis in European Caucasians and metaa-\nnalysis of 5 studies. J Rheumatol 2010;37:2290–2298.\n503. Launay D, Montani D, Hassoun PM, Cottin V, Le Pavec J, Clerson P, et al. Clinical\nphenotypes and survival of pre-capillary pulmonary hypertension in systemic scler-\nosis. PLoS One 2018;13:e0197112.\n504. Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic\nsclerosis: different phenotypes. Eur Respir Rev 2017;26:170056.\n505. Hachulla E, Jais X, Cinquetti G, Clerson P, Rottat L, Launay D, et al. Pulmonary ar-\nterial hypertension associated with systemic lupus erythematosus: results from the\nFrench Pulmonary Hypertension Registry. Chest 2018;153:143–151.\n506. Jais X, Launay D, Yaici A, Le Pavec J, Tcherakian C, Sitbon O, et al.\nImmunosuppressive\ntherapy\nin\nlupus-\nand\nmixed\nconnective\ntissue\ndisease-associated pulmonary arterial hypertension: a retrospective analysis of\ntwenty-three cases. Arthritis Rheum 2008;58:521–531.\n507. Qian J, Li M, Zhang X, Wang Q, Zhao J, Tian Z, et al. Long-term prognosis of pa-\ntients with systemic lupus erythematosus-associated pulmonary arterial hyperten-\nsion: CSTAR-PAH cohort study. Eur Respir J 2019;53:1800081.\n508. Sanges S, Yelnik CM, Sitbon O, Benveniste O, Mariampillai K, Phillips-Houlbracq M,\net al. Pulmonary arterial hypertension in idiopathic inﬂammatory myopathies: data\nfrom the French pulmonary hypertension registry and review of the literature.\nMedicine (Baltimore) 2016;95:e4911.\n509. Wang J, Li M, Wang Q, Zhang X, Qian J, Zhao J, et al. Pulmonary arterial hyperten-\nsion associated with primary Sjogren’s syndrome: a multicentre cohort study from\nChina. Eur Respir J 2020;56:1902157.\n510. Montani D, Henry J, O’Connell C, Jais X, Cottin V, Launay D, et al. Association be-\ntween rheumatoid arthritis and pulmonary hypertension: data from the French\nPulmonary Hypertension Registry. Respiration 2018;95:244–250.\n511. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al.\nPulmonary arterial hypertension in France: results from a national registry. Am J\nRespir Crit Care Med 2006;173:1023–1030.\n512. Humbert M, Khaltaev N, Bousquet J, Souza R. Pulmonary hypertension: from an\norphan disease to a public health problem. Chest 2007;132:365–367.\n513. Gunther S, Jais X, Maitre S, Berezne A, Dorfmuller P, Seferian A, et al. Computed\ntomography ﬁndings of pulmonary venoocclusive disease in scleroderma patients\nESC/ERS Guidelines\n3723\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\npresenting with precapillary pulmonary hypertension. Arthritis Rheum 2012;64:\n2995–3005.\n514. Hsu S, Kokkonen-Simon KM, Kirk JA, Kolb TM, Damico RL, Mathai SC, et al. Right\nventricular\nmyoﬁlament\nfunctional\ndifferences\nin\nhumans\nwith\nsystemic\nsclerosis-associated versus idiopathic pulmonary arterial hypertension. Circulation\n2018;137:2360–2370.\n515. Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella-Chatron J, et al.\nHemodynamic response to treatment and outcomes in pulmonary hypertension\nassociated with interstitial lung disease versus pulmonary arterial hypertension in\nsystemic sclerosis: data from a study identifying prognostic factors in pulmonary\nhypertension associated with interstitial lung disease. Arthritis Rheum 2021;73:\n295–304.\n516. Launay D, Sitbon O, Hachulla E, Mouthon L, Gressin V, Rottat L, et al. Survival in\nsystemic sclerosis-associated pulmonary arterial hypertension in the modern man-\nagement era. Ann Rheum Dis 2013;72:1940–1946.\n517. Ramjug S, Hussain N, Hurdman J, Billings C, Charalampopoulos A, Elliot CA, et al.\nIdiopathic and systemic sclerosis-associated pulmonary arterial hypertension: a\ncomparison of demographic, hemodynamic, and MRI characteristics and outcomes.\nChest 2017;152:92–102.\n518. Pan J, Lei L, Zhao C. Comparison between the efﬁcacy of combination therapy and\nmonotherapy in connective tissue disease associated pulmonary arterial hyperten-\nsion: a systematic review and meta-analysis. Clin Exp Rheumatol 2018;36:\n1095–1102.\n519. Sanchez O, Sitbon O, Jais X, Simonneau G, Humbert M. Immunosuppressive ther-\napy in connective tissue diseases-associated pulmonary arterial hypertension. Chest\n2006;130:182–189.\n520. Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, et al.\nRiociguat for the treatment of pulmonary arterial hypertension associated with\nconnective tissue disease: results from PATENT-1 and PATENT-2. Ann Rheum\nDis 2017;76:422–426.\n521. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE.\nHemodynamics and survival in patients with pulmonary arterial hypertension re-\nlated to systemic sclerosis. Chest 2003;123:344–350.\n522. Trombetta AC, Pizzorni C, Ruaro B, Paolino S, Sulli A, Smith V, et al. Effects of long-\nterm treatment with bosentan and iloprost on nailfold absolute capillary number,\nﬁngertip blood perfusion, and clinical status in systemic sclerosis. J Rheumatol 2016;\n43:2033–2041.\n523. Pradere P, Tudorache I, Magnusson J, Savale L, Brugiere O, Douvry B, et al. Lung\ntransplantation for scleroderma lung disease: An international, multicenter, obser-\nvational cohort study. J Heart Lung Transplant 2018;37:903–911.\n524. Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, et al. Selexipag for the\ntreatment of connective tissue disease-associated pulmonary arterial hypertension.\nEur Respir J 2017;50:1602493.\n525. Barbaro G, Lucchini A, Pellicelli AM, Grisorio B, Giancaspro G, Fauarbarini G, et al.\nHighly active antiretroviral therapy compared with HAART and bosentan in com-\nbination in patients with HIV-associated pulmonary hypertension. Heart 2006;92:\n1164–1166.\n526. Degano B, Guillaume M, Savale L, Montani D, Jais X, Yaici A, et al. HIV-associated\npulmonary arterial hypertension: survival and prognostic factors in the modern\ntherapeutic era. AIDS 2010;24:67–75.\n527. Sitbon O. HIV-related pulmonary arterial hypertension: clinical presentation and\nmanagement. AIDS 2008;22:S55–S62.\n528. Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hyper-\ntension: trends in the HAART era. AIDS (London, England) 2008;22:S35–S40.\n529. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, et al.\nPlatelet-derived growth factor expression in primary pulmonary hypertension:\ncomparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;\n11:554–559.\n530. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-related pulmonary hyperten-\nsion: analytic review of 131 cases. Chest 2000;118:1133–1141.\n531. Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, et al. Pulmonary ar-\nterial hypertension related to HIV infection: improved hemodynamics and survival\nassociated with antiretroviral therapy. Clin Infect Dis 2004;38:1178–1185.\n532. Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, et al.\nBosentan for the treatment of human immunodeﬁciency virus-associated pulmon-\nary arterial hypertension. Am J Respir Crit Care Med 2004;170:1212–1217.\n533. Degano B, Yaici A, Le Pavec J, Savale L, Jais X, Camara B, et al. Long-term effects of\nbosentan in patients with HIV-associated pulmonary arterial hypertension. Eur\nRespir J 2009;33:92–98.\n534. Carlsen J, Kjeldsen K, Gerstoft J. Sildenaﬁl as a successful treatment of otherwise\nfatal HIV-related pulmonary hypertension. AIDS 2002;16:1568–1569.\n535. Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenaﬁl in HIV-related pul-\nmonary hypertension. AIDS 2001;15:1747–1748.\n536. Muirhead GJ, Wulff MB, Fielding A, Kleinermans D, Buss N. Pharmacokinetic inter-\nactions between sildenaﬁl and saquinavir/ritonavir. Br J Clin Pharmacol 2000;50:\n99–107.\n537. Garraffo R, Lavrut T, Ferrando S, Durant J, Rouyrre N, MacGregor TR, et al. Effect\nof tipranavir/ritonavir combination on the pharmacokinetics of tadalaﬁl in healthy\nvolunteers. J Clin Pharmacol 2011;51:1071–1078.\n538. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pul-\nmonary hypertension. Am J Respir Crit Care Med 2000;162:1846–1850.\n539. Cea-Calvo L, Escribano Subias P, Tello de Menesses R, Lazaro Salvador M, Gomez\nSanchez MA, Delgado Jimenez JF, et al. Treatment of HIV-associated pulmonary\nhypertension with treprostinil. Rev Esp Cardiol 2003;56:421–425.\n540. Ghofrani HA, Friese G, Discher T, Olschewski H, Schermuly RT, Weissmann N,\net al. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe\npulmonary hypertension. Eur Respir J 2004;23:321–326.\n541. Bigna JJ, Sime PS, Koulla-Shiro S. HIV related pulmonary arterial hypertension: epi-\ndemiology in Africa, physiopathology, and role of antiretroviral treatment. AIDS Res\nTher 2015;12:36.\n542. Ryom L, Cotter A, De Miguel R, Beguelin C, Podlekareva D, Arribas JR, et al. 2019\nupdate of the European AIDS Clinical Society Guidelines for treatment of people\nliving with HIV version 10.0. HIV Med 2020;21:617–624.\n543. Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, et al.\nPortopulmonary hypertension: a report from the US-based REVEAL Registry.\nChest 2012;141:906–915.\n544. Lazaro Salvador M, Quezada Loaiza CA, Rodriguez Padial L, Barbera JA,\nLopez-Meseguer M, Lopez-Reyes R, et al. Portopulmonary hypertension: prognosis\nand management in the current treatment era - results from the REHAP registry.\nIntern Med J 2021;51:355–365.\n545. Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, et al.\nPortopulmonary hypertension in the current era of pulmonary hypertension man-\nagement. J Hepatol 2020;73:130–139.\n546. Baiges A, Turon F, Simon-Talero M, Tasayco S, Bueno J, Zekrini K, et al. Congenital\nextrahepatic portosystemic shunts (Abernethy malformation): an international ob-\nservational study. Hepatology 2020;71:658–669.\n547. Fussner LA, Iyer VN, Cartin-Ceba R, Lin G, Watt KD, Krowka MJ. Intrapulmonary\nvascular dilatations are common in portopulmonary hypertension and may be as-\nsociated with decreased survival. Liver Transpl 2015;21:1355–1364.\n548. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan\ntherapy for portopulmonary hypertension. Eur Respir J 2005;25:502–508.\n549. Olsson KM, Meyer K, Berliner D, Hoeper MM. Development of hepatopulmonary\nsyndrome during combination therapy for portopulmonary hypertension. Eur\nRespir J 2019;53:1801880.\n550. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary\nhemodynamics and perioperative cardiopulmonary-related mortality in patients\nwith portopulmonary hypertension undergoing liver transplantation. Liver Transpl\n2000;6:443–450.\n551. Cartin-Ceba R, Burger C, Swanson K, Vargas H, Aqel B, Keaveny AP, et al. Clinical\noutcomes after liver transplantation in patients with portopulmonary hyperten-\nsion. Transplantation 2021;105:2283–2290.\n552. Deroo R, Trepo E, Holvoet T, De Pauw M, Geerts A, Verhelst X, et al.\nVasomodulators and liver transplantation for portopulmonary hypertension: evi-\ndence from a systematic review and meta-analysis. Hepatology 2020;72:\n1701–1716.\n553. Sadd CJ, Osman F, Li Z, Chybowski A, Decker C, Henderson B, et al. Long-term\noutcomes and survival in moderate-severe portopulmonary hypertension after li-\nver transplant. Transplantation 2021;105:346–353.\n554. Savale L, Sattler C, Coilly A, Conti F, Renard S, Francoz C, et al. Long-term outcome\nin liver transplantation candidates with portopulmonary hypertension. Hepatology\n2017;65:1683–1692.\n555. Diller GP, Kempny A, Alonso-Gonzalez R, Swan L, Uebing A, Li W, et al. Survival\nprospects and circumstances of death in contemporary adult congenital heart dis-\nease patients under follow-up at a large tertiary centre. Circulation 2015;132:\n2118–2125.\n556. van Riel AC, Schuuring MJ, van Hessen ID, Zwinderman AH, Cozijnsen L, Reichert\nCL, et al. Contemporary prevalence of pulmonary arterial hypertension in adult\ncongenital heart disease following the updated clinical classiﬁcation. Int J Cardiol\n2014;174:299–305.\n557. Lammers AE, Bauer LJ, Diller GP, Helm PC, Abdul-Khaliq H, Bauer UMM, et al.\nPulmonary hypertension after shunt closure in patients with simple congenital\nheart defects. Int J Cardiol 2020;308:28–32.\n558. Ntiloudi D, Zanos S, Gatzoulis MA, Karvounis H, Giannakoulas G. How to evaluate\npatients with congenital heart disease-related pulmonary arterial hypertension.\nExpert Rev Cardiovasc Ther 2019;17:11–18.\n559. Dimopoulos K, Condliffe R, Tulloh RMR, Clift P, Alonso-Gonzalez R, Bedair R, et al.\nEchocardiographic screening for pulmonary hypertension in congenital heart dis-\nease: JACC review topic of the week. J Am Coll Cardiol 2018;72:2778–2788.\n3724\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\n560. Kempny A, Dimopoulos K, Fraisse A, Diller GP, Price LC, Raﬁq I, et al. Blood vis-\ncosity and its relevance to the diagnosis and management of pulmonary hyperten-\nsion. J Am Coll Cardiol 2019;73:2640–2642.\n561. Arvanitaki A, Giannakoulas G, Baumgartner H, Lammers AE. Eisenmenger syn-\ndrome: diagnosis, prognosis and clinical management. Heart 2020;106:1638–1645.\n562. Diller GP, Korten MA, Bauer UM, Miera O, Tutarel O, Kaemmerer H, et al. Current\ntherapy and outcome of Eisenmenger syndrome: data of the German National\nRegister for congenital heart defects. Eur Heart J 2016;37:1449–1455.\n563. Kempny A, Hjortshoj CS, Gu H, Li W, Opotowsky AR, Landzberg MJ, et al.\nPredictors of death in contemporary adult patients with Eisenmenger syndrome:\na multicenter study. Circulation 2017;135:1432–1440.\n564. Arvind B, Relan J, Kothari SS. “Treat and repair” strategy for shunt lesions: a critical\nreview. Pulm Circ 2020;10:2045894020917885.\n565. Brida M, Nashat H, Gatzoulis MA. Pulmonary arterial hypertension: closing the gap\nin congenital heart disease. Curr Opin Pulm Med 2020;26:422–428.\n566. van der Feen DE, Bartelds B, de Boer RA, Berger RMF. Assessment of reversibility in\npulmonary arterial hypertension and congenital heart disease. Heart 2019;105:\n276–282.\n567. Becker-Grunig T, Klose H, Ehlken N, Lichtblau M, Nagel C, Fischer C, et al. Efﬁcacy\nof exercise training in pulmonary arterial hypertension associated with congenital\nheart disease. Int J Cardiol 2013;168:375–381.\n568. Hartopo AB, Anggrahini DW, Nurdiati DS, Emoto N, Dinarti LK. Severe pulmon-\nary hypertension and reduced right ventricle systolic function associated with ma-\nternal mortality in pregnant uncorrected congenital heart diseases. Pulm Circ 2019;\n9:2045894019884516.\n569. Li Q, Dimopoulos K, Liu T, Xu Z, Liu Q, Li Y, et al. Peripartum outcomes in a large\npopulation of women with pulmonary arterial hypertension associated with con-\ngenital heart disease. Eur J Prev Cardiol 2019;26:1067–1076.\n570. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomstrom-Lundqvist C,\nCifkova R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardio-\nvascular diseases during pregnancy. Eur Heart J 2018;39:3165–3241.\n571. Blanche C, Alonso-Gonzalez R, Uribarri A, Kempny A, Swan L, Price L, et al. Use of\nintravenous iron in cyanotic patients with congenital heart disease and/or pulmon-\nary hypertension. Int J Cardiol 2018;267:79–83.\n572. Bertoletti L, Mismetti V, Giannakoulas G. Use of anticoagulants in patients with pul-\nmonary hypertension. Hamostaseologie 2020;40:348–355.\n573. Freisinger E, Gerss J, Makowski L, Marschall U, Reinecke H, Baumgartner H, et al.\nCurrent use and safety of novel oral anticoagulants in adults with congenital heart\ndisease: results of a nationwide analysis including more than 44 000 patients. Eur\nHeart J 2020;41:4168–4177.\n574. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan\ntherapy in patients with Eisenmenger syndrome: a multicenter, double-blind, ran-\ndomized, placebo-controlled study. Circulation 2006;114:48–54.\n575. Gatzoulis MA, Landzberg M, Beghetti M, Berger RM, Efﬁcace M, Gesang S, et al.\nEvaluation of Macitentan in patients with Eisenmenger syndrome. Circulation\n2019;139:51–63.\n576. Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenzweig EB.\nAmbrisentan for pulmonary arterial hypertension due to congenital heart disease.\nAm J Cardiol 2011;107:1381–1385.\n577. Nashat H, Kempny A, Harries C, Dormand N, Alonso-Gonzalez R, Price LC, et al. A\nsingle-centre, placebo-controlled, double-blind randomised cross-over study of\nnebulised iloprost in patients with Eisenmenger syndrome: A pilot study. Int J\nCardiol 2020;299:131–135.\n578. D’Alto M, Constantine A, Balint OH, Romeo E, Argiento P, Ablonczy L, et al. The\neffects of parenteral prostacyclin therapy as add-on treatment to oral compounds\nin Eisenmenger syndrome. Eur Respir J 2019;54:1901401.\n579. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N. Current era\nsurvival of patients with pulmonary arterial hypertension associated with congenital\nheart disease: a comparison between clinical subgroups. Eur Heart J 2014;35:\n716–724.\n580. Savale L, Manes A. Pulmonary arterial hypertension populations of special interest:\nportopulmonary hypertension and pulmonary arterial hypertension associated\nwith congenital heart disease. Eur Heart J Suppl 2019;21:K37–K45.\n581. Dimopoulos K, Diller GP, Opotowsky AR, D’Alto M, Gu H, Giannakoulas G, et al.\nDeﬁnition and management of segmental pulmonary hypertension. J Am Heart\nAssoc 2018;7:e008587.\n582. Amedro P, Gavotto A, Abassi H, Picot MC, Matecki S, Malekzadeh-Milani S, et al.\nEfﬁcacy of phosphodiesterase type 5 inhibitors in univentricular congenital heart\ndisease: the SV-INHIBITION study design. ESC Heart Fail 2020;7:747–756.\n583. Goldberg DJ, Zak V, Goldstein BH, Schumacher KR, Rhodes J, Penny DJ, et al.\nResults of the FUEL Trial. Circulation 2020;141:641–651.\n584. Ridderbos FS, Hagdorn QAJ, Berger RMF. Pulmonary vasodilator therapy as treat-\nment for patients with a Fontan circulation: the Emperor’s new clothes? Pulm Circ\n2018;8:2045894018811148.\n585. Dimopoulos K, Muthiah K, Alonso-Gonzalez R, Banner NR, Wort SJ, Swan L, et al.\nHeart or heart-lung transplantation for patients with congenital heart disease in\nEngland. Heart 2019;105:596–602.\n586. Lapa M, Dias B, Jardim C, Fernandes CJ, Dourado PM, Figueiredo M, et al.\nCardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation\n2009;119:1518–1523.\n587. KnaﬂD, Gerges C, King CH, Humbert M, Bustinduy AL. Schistosomiasis-associated\npulmonary arterial hypertension: a systematic review. Eur Respir Rev 2020;29:190089.\n588. Fernandes CJC, Piloto B, Castro M, Gavilanes Oleas F, Alves JL Jr, Lopes Prada LF,\net al. Survival of patients with schistosomiasis-associated pulmonary arterial hyper-\ntension in the modern management era. Eur Respir J 2018;51:1800307.\n589. Weatherald J, Dorfmuller P, Perros F, Ghigna MR, Girerd B, Humbert M, et al.\nPulmonarycapillaryhaemangiomatosis: a distinct entity?Eur Respir Rev 2020;29:190168.\n590. Humbert M, Guignabert C, Bonnet S, Dorfmuller P, Klinger JR, Nicolls MR, et al.\nPathology and pathobiology of pulmonary hypertension: state of the art and re-\nsearch perspectives. Eur Respir J 2019;53:1801887.\n591. Montani D, Girerd B, Jais X, Levy M, Amar D, Savale L, et al. Clinical phenotypes and\noutcomes of heritable and sporadic pulmonary veno-occlusive disease: a\npopulation-based study. Lancet Respir Med 2017;5:125–134.\n592. Perez-Olivares C, Segura de la Cal T, Flox-Camacho A, Nuche J, Tenorio J, Martinez\nMenaca A, et al. The role of cardiopulmonary exercise test in identifying pulmonary\nveno-occlusive disease. Eur Respir J 2021;57:2100115.\n593. Bergbaum C, Samaranayake CB, Pitcher A, Weingart E, Semple T, Kokosi M, et al. A\ncase series on the use of steroids and mycophenolate mofetil in idiopathic and her-\nitable pulmonary veno-occlusive disease: is there a role for immunosuppression?\nEur Respir J 2021;57:2004354.\n594. vanLoonRL,RoofthooftMT,HillegeHL,tenHarkelAD,vanOsch-GeversM,Delhaas\nT, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and char-\nacterization during the period 1991 to 2005. Circulation 2011;124:1755–1764.\n595. del Cerro Marin MJ, Sabate Rotes A, Rodriguez Ogando A, Mendoza Soto A,\nQuero Jimenez M, Gavilan Camacho JL, et al. Assessing pulmonary hypertensive\nvascular disease in childhood. Data from the Spanish registry. Am J Respir Crit\nCare Med 2014;190:1421–1429.\n596. Li L, Jick S, Breitenstein S, Hernandez G, Michel A, Vizcaya D. Pulmonary arterial\nhypertension in the USA: an epidemiological study in a large insured pediatric popu-\nlation. Pulm Circ 2017;7:126–136.\n597. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, et al. Clinical features\nof paediatric pulmonary hypertension: a registry study. Lancet 2012;379:537–546.\n598. Abman SH, Mullen MP, Sleeper LA, Austin ED, Rosenzweig EB, Kinsella JP, et al.\nCharacterisation of paediatric pulmonary hypertensive vascular disease from the\nPPHNet Registry. Eur Respir J 2021;59:2003337.\n599. Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, et al.\nPaediatric pulmonary arterial hypertension: updates on deﬁnition, classiﬁcation,\ndiagnostics and management. Eur Respir J 2019;53:1801916.\n600. Haarman MG, Kerstjens-Frederikse WS, Vissia-Kazemier TR, Breeman KTN,\nTimens W, Vos YJ, et al. The genetic epidemiology of pediatric pulmonary arterial\nhypertension. J Pediatr 2020;225:65–73.e65.\n601. Levy M, Eyries M, Szezepanski I, Ladouceur M, Nadaud S, Bonnet D, et al. Genetic\nanalyses in a cohort of children with pulmonary hypertension. Eur Respir J 2016;48:\n1118–1126.\n602. Mourani PM, Abman SH. Pulmonary hypertension and vascular abnormalities in\nbronchopulmonary dysplasia. Clin Perinatol 2015;42:839–855.\n603. van Loon RL, Roofthooft MT, van Osch-Gevers M, Delhaas T, Strengers JL, Blom\nNA, et al. Clinical characterization of pediatric pulmonary hypertension: complex\npresentation and diagnosis. J Pediatr 2009;155:176–182.e171.\n604. Arjaans S, Zwart EAH, Ploegstra MJ, Bos AF, Kooi EMW, Hillege HL, et al.\nIdentiﬁcation of gaps in the current knowledge on pulmonary hypertension in ex-\ntremely preterm infants: a systematic review and meta-analysis. Paediatr Perinatal\nEpidemiol 2018;32:258–267.\n604a. Haarman MG, Do JM, Ploegstra MJ, Roofthooft MTR, Vissia-Kazemier TR, Hillege\nHL, et al. The clinical value of proposed risk stratiﬁcation tools in pediatric pul-\nmonary arterial hypertension. Am J Respir Crit Care Med 2019;200:1312–1315.\n605. Beghetti M, Schulze-Neick I, Berger RM, Ivy DD, Bonnet D, Weintraub RG, et al.\nHaemodynamic characterisation and heart catheterisation complications in children\nwith pulmonary hypertension: insights from the Global TOPP Registry (tracking out-\ncomes and practice in paediatric pulmonary hypertension). Int J Cardiol 2016;203:\n325–330.\n606. Ploegstra MJ, Zijlstra WMH, Douwes JM, Hillege HL, Berger RMF. Prognostic fac-\ntors in pediatric pulmonary arterial hypertension: a systematic review and\nmeta-analysis. Int J Cardiol 2015;184:198–207.\n607. Ivy DD, Rosenzweig EB, Lemarie JC, Brand M, Rosenberg D, Barst RJ. Long-term\noutcomes in children with pulmonary arterial hypertension treated with bosentan\nin real-world clinical settings. Am J Cardiol 2010;106:1332–1338.\n608. Zijlstra WMH, Douwes JM, Rosenzweig EB, Schokker S, Krishnan U, Roofthooft\nMTR, et al. Survival differences in pediatric pulmonary arterial hypertension: clues\nESC/ERS Guidelines\n3725\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026\n\n\nto a better understanding of outcome and optimal treatment strategies. J Am Coll\nCardiol 2014;63:2159–2169.\n609. Ploegstra MJ, Douwes JM, Roofthooft MT, Zijlstra WM, Hillege HL, Berger RM.\nIdentiﬁcation of treatment goals in paediatric pulmonary arterial hypertension.\nEur Respir J 2014;44:1616–1626.\n610. Singh Y, Lakshminrusimha S. Pathophysiology and management of persistent pul-\nmonary hypertension of the newborn. Clin Perinatol 2021;48:595–618.\n611. Arjaans S, Haarman MG, Roofthooft MTR, Fries MWF, Kooi EMW, Bos AF, et al.\nFate of pulmonary hypertension associated with bronchopulmonary dysplasia be-\nyond 36 weeks postmenstrual age. Arch Dis Child Fetal Neonatal Ed 2021;106:\n45–50.\n612. Goss KN, Beshish AG, Barton GP, Haraldsdottir K, Levin TS, Tetri LH, et al. Early\npulmonary vascular disease in young adults born preterm. Am J Respir Crit Care Med\n2018;198:1549–1558.\n613. Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, et al. STARTS-2:\nlong-term survival with oral sildenaﬁl monotherapy in treatment-naive pediatric\npulmonary arterial hypertension. Circulation 2014;129:1914–1923.\n614. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized,\ndouble-blind, placebo-controlled, dose-ranging study of oral sildenaﬁl citrate in\ntreatment-naive children with pulmonary arterial hypertension. Circulation 2012;\n125:324–334.\n615. Ivy D, Bonnet D, Berger R, Meyer G, Baygani S, Li B. Efﬁcacy and safety of tadalaﬁl in\na pediatric population with pulmonary arterial hypertension: phase 3 randomized,\ndouble-blind placebo-controlled study. Pulm Circ 2021;11:20458940211024955.\n616. Small D, Ferguson-Sells L, Dahdah N, Bonnet D, Landry J, Li B. Pharmacokinetics\nand safety of tadalaﬁl in a paediatric population with pulmonary arterial hyperten-\nsion: a multiple ascending-dose study. Br J Clin Pharmacol 2019;85:2302–2309.\n617. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al.\nPharmacokinetics, safety, and efﬁcacy of bosentan in pediatric patients with pul-\nmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372–382.\n618. Beghetti M, Haworth SG, Bonnet D, Barst RJ, Acar P, Fraisse A, et al.\nPharmacokinetic and clinical proﬁle of a novel formulation of bosentan in children\nwith pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol\n2009;68:948–955.\n619. Berger RM, Haworth SG, Bonnet D, Dulac Y, Fraisse A, Galiè N, et al. FUTURE-2:\nresults from an open-label, long-term safety and tolerability extension study using\nthe pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. Int J\nCardiol 2016;202:52–58.\n620. Berger RMF, Gehin M, Beghetti M, Ivy D, Kusic-Pajic A, Cornelisse P, et al. A bosen-\ntan pharmacokinetic study to investigate dosing regimens in paediatric patients with\npulmonary arterial hypertension: FUTURE-3. Br J Clin Pharmacol 2017;83:\n1734–1744.\n621. Ivy D, Beghetti M, Juaneda-Simian E, Miller D, Lukas M, Ioannou C, et al. A rando-\nmized study of safety and efﬁcacy of two doses of ambrisentan to treat pulmonary\narterial hypertension in pediatric patients aged 8 years up to 18 years. J Pediatr\n2020;5:100055.\n622. Takatsuki S, Rosenzweig EB, Zuckerman W, Brady D, Calderbank M, Ivy DD.\nClinical safety, pharmacokinetics, and efﬁcacy of ambrisentan therapy in children\nwith pulmonary arterial hypertension. Pediatr Pulmonol 2013;48:27–34.\n623. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hyper-\ntension in children. Circulation 1999;99:1197–1208.\n624. Hopper RK, Wang Y, DeMatteo V, Santo A, Kawut SM, Elci OU, et al. Right ven-\ntricular function mirrors clinical improvement with use of prostacyclin analogues\nin pediatric pulmonary hypertension. Pulm Circ 2018;8:2045894018759247.\n625. Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children\nwith severe pulmonary hypertension. Heart 2007;93:739–743.\n626. Douwes JM, Zijlstra WM, Rosenzweig EB, Ploegstra MJ, Krishnan US, Haarman MG,\net al. Parenteral prostanoids in pediatric pulmonary arterial hypertension: start\nearly, dose high, combine. Ann Am Thorac Soc 2022;19:227–237.\n627. Tella JB, Kulik TJ, McSweeney JE, Sleeper LA, Lu M, Mullen MP. Prostanoids in pedi-\natric pulmonary hypertension: clinical response, time-to-effect, and dose-response.\nPulm Circ 2020;10:2045894020944858.\n628. Krishnan U, Feinstein JA, Adatia I, Austin ED, Mullen MP, Hopper RK, et al.\nEvaluation and management of pulmonary hypertension in children with broncho-\npulmonary dysplasia. J Pediatr 2017;188:24–34.e21.\n629. Vayalthrikkovil S, Vorhies E, Stritzke A, Bashir RA, Mohammad K, Kamaluddeen M,\net al. Prospective study of pulmonary hypertension in preterm infants with bronch-\nopulmonary dysplasia. Pediatr Pulmonol 2019;54:171–178.\n630. Abman SH, Collaco JM, Shepherd EG, Keszler M, Cuevas-Guaman M, Welty SE,\net al. Interdisciplinary care of children with severe bronchopulmonary dysplasia. J\nPediatr 2017;181:12–28.e11.\n631. Bermejo J, Gonzalez-Mansilla A, Mombiela T, Fernandez AI, Martinez-Legazpi P,\nYotti R, et al. Persistent pulmonary hypertension in corrected valvular heart dis-\nease: hemodynamic insights and long-term survival. J Am Heart Assoc 2021;10:\ne019949.\n632. Caravita S, Dewachter C, Soranna D, D’Araujo SC, Khaldi A, Zambon A, et al.\nHaemodynamics to predict outcome in pulmonary hypertension due to left heart\ndisease: a meta-analysis. Eur Respir J 2018;51:1702427.\n633. Crawford TC, Leary PJ, Fraser CD III, Suarez-Pierre A, Magruder JT, Baumgartner\nWA, et al. Impact of the new pulmonary hypertension deﬁnition on heart trans-\nplant outcomes: expanding the hemodynamic risk proﬁle. Chest 2020;157:\n151–161.\n634. O’Sullivan CJ, Wenaweser P, Ceylan O, Rat-Wirtzler J, Stortecky S, Heg D, et al.\nEffect of pulmonary hypertension hemodynamic presentation on clinical outcomes\nin patients with severe symptomatic aortic valve stenosis undergoing transcatheter\naortic valve implantation: insights from the new proposed pulmonary hypertension\nclassiﬁcation. Circ Cardiovasc Interv 2015;8:e002358.\n635. Vanderpool RR, Saul M, Nouraie M, Gladwin MT, Simon MA. Association between\nhemodynamic markers of pulmonary hypertension and outcomes in heart failure\nwith preserved ejection fraction. JAMA Cardiol 2018;3:298–306.\n636. Murali S, Kormos RL, Uretsky BF, Schechter D, Reddy PS, Denys BG, et al.\nPreoperative pulmonary hemodynamics and early mortality after orthotopic car-\ndiac transplantation: the Pittsburgh experience. Am Heart J 1993;126:896–904.\n637. Zimpfer D, Zrunek P, Roethy W, Czerny M, Schima H, Huber L, et al. Left ventricu-\nlar assist devices decrease ﬁxed pulmonary hypertension in cardiac transplant can-\ndidates. J Thorac Cardiovasc Surg 2007;133:689–695.\n638. Al-Naamani N, Preston IR, Paulus JK, Hill NS, Roberts KE. Pulmonary arterial cap-\nacitance is an important predictor of mortality in heart failure with a preserved\nejection fraction. JACC Heart Fail 2015;3:467–474.\n639. Miller WL, Grill DE, Borlaug BA. Clinical features, hemodynamics, and outcomes of\npulmonary hypertension due to chronic heart failure with reduced ejection frac-\ntion: pulmonary hypertension and heart failure. JACC Heart Fail 2013;1:290–299.\n640. Leung CC, Moondra V, Catherwood E, Andrus BW. Prevalence and risk factors of\npulmonary hypertension in patients with elevated pulmonary venous pressure and\npreserved ejection fraction. Am J Cardiol 2010;106:284–286.\n641. Shah AM, Shah SJ, Anand IS, Sweitzer NK, O’Meara E, Heitner JF, et al. Cardiac\nstructure and function in heart failure with preserved ejection fraction: baseline\nﬁndings from the echocardiographic study of the Treatment of Preserved\nCardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart\nFail 2014;7:104–115.\n642. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, et al. Independent\nand additive prognostic value of right ventricular systolic function and pulmonary\nartery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001;37:\n183–188.\n643. Tampakakis E, Leary PJ, Selby VN, De Marco T, Cappola TP, Felker GM, et al. The\ndiastolic pulmonary gradient does not predict survival in patients with pulmonary\nhypertension due to left heart disease. JACC Heart Fail 2015;3:9–16.\n644. Naeije R, Gerges M, Vachiery JL, Caravita S, Gerges C, Lang IM. Hemodynamic phe-\nnotyping of pulmonary hypertension in left heart failure. Circ Heart Fail 2017;10:\ne004082.\n645. Guazzi M, Naeije R. Pulmonary hypertension in heart failure: pathophysiology,\npathobiology, and emerging clinical perspectives. J Am Coll Cardiol 2017;69:\n1718–1734.\n646. Zlotnick DM, Ouellette ML, Malenka DJ, DeSimone JP, Leavitt BJ, Helm RE, et al.\nEffect of preoperative pulmonary hypertension on outcomes in patients with se-\nvere aortic stenosis following surgical aortic valve replacement. Am J Cardiol\n2013;112:1635–1640.\n647. Melby SJ, Moon MR, Lindman BR, Bailey MS, Hill LL, Damiano RJ Jr. Impact of pul-\nmonary hypertension on outcomes after aortic valve replacement for aortic valve\nstenosis. J Thorac Cardiovasc Surg 2011;141:1424–1430.\n648. Lucon A, Oger E, Bedossa M, Boulmier D, Verhoye JP, Eltchaninoff H, et al.\nPrognostic implications of pulmonary hypertension in patients with severe aortic\nstenosis undergoing transcatheter aortic valve implantation: study from the\nFRANCE 2 Registry. Circ Cardiovasc Interv 2014;7:240–247.\n649. Faggiano P, Antonini-Canterin F, Ribichini F, D’Aloia A, Ferrero V, Cervesato E,\net al. Pulmonary artery hypertension in adult patients with symptomatic valvular\naortic stenosis. Am J Cardiol 2000;85:204–208.\n650. Zuern CS, Eick C, Rizas K, Stoleriu C, Woernle B, Wildhirt S, et al. Prognostic value\nof mild-to-moderate pulmonary hypertension in patients with severe aortic valve\nstenosis undergoing aortic valve replacement. Clin Res Cardiol 2012;101:81–88.\n651. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, et al. Risk\nfactors and outcome in European cardiac surgery: analysis of the EuroSCORE\nmultinational database of 19030 patients. Eur J Cardiothorac Surg 1999;15:\n816–822; discussion 822–813.\n652. Chandrashekhar Y, Westaby S, Narula J. Mitral stenosis. Lancet 2009;374:\n1271–1283.\n653. Dreyfus GD, Martin RP, Chan KM, Dulguerov F, Alexandrescu C. Functional tricus-\npid regurgitation: a need to revise our understanding. J Am Coll Cardiol 2015;65:\n2331–2336.\n3726\nESC/ERS Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/38/3618/6673929 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "ct",
        "arb",
        "pulmonary hypertension",
        "references",
        "diagnosis"
      ]
    }
  ]
}